PMID- 42905886 OWN - NLM STAT- Publisher LR - 20261022 IS - 1809-452X (Electronic) IS - 1516-4446 (Linking) DP - 2026 Oct 21 TI - Protective Effect of COVID-19 Vaccination on Post-Infection Visuospatial Deficits. LID - 10.47626/1516-4446-2026-4853 [doi] AB - OBJECTIVE: COVID-19 has been associated with persistent cognitive deficits months after SARS-CoV-2 infection. Vaccination reduces severe disease, but its effect on post-infection cognition remains uncertain. We evaluated whether COVID-19 vaccination attenuates cognitive deficits after SARS-CoV-2. METHODS: We assessed 237 adults with COVID-19 and 105 controls. Patients were grouped by vaccination status at infection (vaccinated n=87; unvaccinated n=150). The neuropsychological assessment covered language, visuospatial ability, visual memory, verbal memory, attention, executive functions, and working memory. Group differences were tested with Aligned Rank Transform ANOVA with Holm-corrected post hoc comparisons, adjusting for education. RESULTS: Significant group differences were observed in visuospatial ability and visual memory, assessed with the Rey-Osterrieth Complex Figure Test (Copy, Immediate and Delayed Recall) (all p < 0.001). The vaccinated group outperformed the unvaccinated group (p = 0.022) on visuospatial performance. The Rey-Osterrieth Complex Figure Test Copy did not differ significantly among participants vaccinated with CoronaVac, AstraZeneca, or Pfizer. CONCLUSIONS: The findings suggest that COVID-19 vaccination may mitigate post-infection visuospatial deficits, reinforcing the importance of immunization in preventing cognitive sequelae associated with the disease. FAU - da Silva, Lucas Gomes AU - da Silva LG AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Rosa, Daniela Valadao AU - Rosa DV AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Pediatrics, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. LA - eng GR - CNPq/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Brazil GR - FAPEMIG/Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Brazil GR - Decit/SECTICS/MS/Departamento de Ciencia e Tecnologia do Ministerio da Saude/Brazil GR - CAPES/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Brazil PT - Journal Article DEP - 20261021 PL - Brazil TA - Braz J Psychiatry JT - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JID - 100895975 SB - IM OTO - NOTNLM OT - SARS-CoV-2 OT - cognitive dysfunction OT - neuropsychological tests OT - post-acute COVID-19 Syndrome OT - spatial processing COIS- The authors declare no conflict of interest. EDAT- 2026/10/22 23:29 MHDA- 2026/10/22 23:29 CRDT- 2026/10/22 18:44 PHST- 2026/04/30 00:00 [received] PHST- 2026/10/05 00:00 [accepted] PHST- 2026/10/22 23:29 [medline] PHST- 2026/10/22 23:29 [pubmed] PHST- 2026/10/22 18:44 [entrez] AID - 10.47626/1516-4446-2026-4853 [doi] PST - aheadofprint SO - Braz J Psychiatry. 2026 Oct 21. doi: 10.47626/1516-4446-2026-4853. PMID- 42900956 OWN - NLM STAT- Publisher LR - 20261020 IS - 1809-452X (Electronic) IS - 1516-4446 (Linking) DP - 2026 Oct 20 TI - Protective Effect of COVID-19 Vaccination on Post-Infection Visuospatial Deficits. LID - 0.47626/1516-4446-2026-4853 [doi] AB - OBJECTIVE: COVID-19 has been associated with persistent cognitive deficits months after SARS-CoV-2 infection. Vaccination reduces severe disease, but its effect on post-infection cognition remains uncertain. We evaluated whether COVID-19 vaccination attenuates cognitive deficits after SARS-CoV-2. METHODS: We assessed 237 adults with COVID-19 and 105 controls. Patients were grouped by vaccination status at infection (vaccinated n=87; unvaccinated n=150). The neuropsychological assessment covered language, visuospatial ability, visual memory, verbal memory, attention, executive functions, and working memory. Group differences were tested with Aligned Rank Transform ANOVA with Holm-corrected post hoc comparisons, adjusting for education. RESULTS: Significant group differences were observed in visuospatial ability and visual memory, assessed with the Rey-Osterrieth Complex Figure Test (Copy, Immediate and Delayed Recall) (all p < 0.001). The vaccinated group outperformed the unvaccinated group (p = 0.022) on visuospatial performance. The Rey-Osterrieth Complex Figure Test Copy did not differ significantly among participants vaccinated with CoronaVac, AstraZeneca, or Pfizer. CONCLUSIONS: The findings suggest that COVID-19 vaccination may mitigate post-infection visuospatial deficits, reinforcing the importance of immunization in preventing cognitive sequelae associated with the disease. FAU - da Silva, Lucas Gomes AU - da Silva LG AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Rosa, Daniela Valadao AU - Rosa DV AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AD - National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Pediatrics, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AD - Graduate Program in Molecular Medicine, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. National Institute of Science and Technology for Responsible Neurotechnology (INCT-NeurotecR), School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Department of Psychiatry, School of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, MG, Brazil. LA - eng GR - CNPq/Conselho Nacional de Desenvolvimento Cientifico e Tecnologico/Brazil GR - FAPEMIG/Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Brazil GR - Decit/SECTICS/MS/Departamento de Ciencia e Tecnologia do Ministerio da Saude/Brazil GR - CAPES/Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior/Brazil PT - Journal Article DEP - 20261020 PL - Brazil TA - Braz J Psychiatry JT - Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) JID - 100895975 SB - IM OTO - NOTNLM OT - SARS-CoV-2 OT - cognitive dysfunction OT - neuropsychological tests OT - post-acute COVID-19 Syndrome OT - spatial processing COIS- The authors declare no conflict of interest. EDAT- 2026/10/20 23:29 MHDA- 2026/10/20 23:29 CRDT- 2026/10/20 17:14 PHST- 2026/04/30 00:00 [received] PHST- 2026/10/05 00:00 [accepted] PHST- 2026/10/20 23:29 [medline] PHST- 2026/10/20 23:29 [pubmed] PHST- 2026/10/20 17:14 [entrez] PST - aheadofprint SO - Braz J Psychiatry. 2026 Oct 20. PMID- 42841133 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20261007 LR - 20261008 IS - 1980-5764 (Print) IS - 2764-4863 (Electronic) IS - 1980-5764 (Linking) VI - 20 DP - 2026 TI - Prior COVID-19 vaccination and cognitive outcomes after SARS-CoV-2 infection: a mini-review. PG - e20260494 LID - 10.1590/1980-5764-DN-2026-0494 [doi] LID - e20260494 AB - COVID-19 infection has been frequently associated with cognitive deficits that persist for months after the acute phase, but the impact of vaccination on preventing these deficits remains uncertain. Evidence suggests that immunization reduces the incidence and severity of post-COVID symptoms, yet few studies have evaluated its influence on cognition using objective measures. To address this gap, a mini-review was conducted using a systematic search strategy, following PRISMA recommendations where applicable, with a protocol registered in PROSPERO (CRD42025636772). Searches were carried out in the PubMed/MEDLINE and Scopus databases, and eligible studies were those that assessed cognition using objective measures and compared vaccinated and unvaccinated individuals at the time of infection. A total of 1,796 records were identified, of which only five met the inclusion criteria. The included studies varied considerably in cognitive assessment tools, study designs, and sample sizes. Four of the five studies found no association between prior vaccination and cognitive deficits, whereas the only study that identified a subtle difference among individuals who had received at least two doses of the vaccine had a substantially larger sample than all the others combined. Methodological inconsistencies in cognitive assessment, variability in the definitions of vaccination status, and the lack of stratification by specific cognitive domains limit the interpretation of the current findings. Although vaccination may play a role in protecting against cognitive deficits following COVID-19 infection, the evidence remains limited and inconclusive. Further studies with standardized definitions of vaccination status and comprehensive objective assessments are needed to clarify this relationship. FAU - da Silva, Lucas Gomes AU - da Silva LG AUID- ORCID: 0000-0002-7314-1977 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Oliveira, Jordano Cesar Milagres AU - Oliveira JCM AUID- ORCID: 0000-0001-8723-7251 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Fini, Bruna Carmeni Di AU - Fini BCD AUID- ORCID: 0000-0002-3382-5186 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Porto, Aline Arantes AU - Porto AA AUID- ORCID: 0000-0002-8281-6729 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - Costa, Danielle de Souza AU - Costa DS AUID- ORCID: 0000-0001-6883-5133 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. FAU - de Miranda, Debora Marques AU - de Miranda DM AUID- ORCID: 0000-0002-7081-8401 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Pediatria, Belo Horizonte MG, Brazil. FAU - Romano-Silva, Marco Aurelio AU - Romano-Silva MA AUID- ORCID: 0000-0002-6558-4639 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Psiquiatria, Belo Horizonte MG, Brazil. FAU - de Paula, Jonas Jardim AU - de Paula JJ AUID- ORCID: 0000-0001-5530-2346 AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Programa de Pos-Graduacao em Medicina Molecular, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Instituto Nacional de Ciencia e Tecnologia em Neurotecnologia Responsavel, Belo Horizonte MG, Brazil. AD - Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Psiquiatria, Belo Horizonte MG, Brazil. LA - eng PT - Journal Article PT - Review DEP - 20261002 PL - Brazil TA - Dement Neuropsychol JT - Dementia & neuropsychologia JID - 101506587 PMC - PMC13641761 OTO - NOTNLM OT - COVID-19 OT - Cognition OT - Memory Disorders OT - Post-Acute COVID-19 Syndrome OT - Vaccination. COIS- Disclosure: There is no conflict of interest to declare. EDAT- 2026/10/07 11:32 MHDA- 2026/10/07 11:33 PMCR- 2026/10/02 CRDT- 2026/10/07 11:00 PHST- 2026/02/25 00:00 [received] PHST- 2026/06/07 00:00 [revised] PHST- 2026/07/15 00:00 [accepted] PHST- 2026/10/07 11:33 [medline] PHST- 2026/10/07 11:32 [pubmed] PHST- 2026/10/07 11:00 [entrez] PHST- 2026/10/02 00:00 [pmc-release] AID - 10.1590/1980-5764-DN-2026-0494 [doi] PST - epublish SO - Dement Neuropsychol. 2026 Oct 2;20:e20260494. doi: 10.1590/1980-5764-DN-2026-0494. eCollection 2026. PMID- 42797547 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260926 LR - 20260929 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 14 IP - 9 DP - 2026 Aug 22 TI - Association Between Respiratory Vaccines and Risk of Cognitive Impairment, Dementia and Alzheimer's Disease: A Scoping Review. LID - 10.3390/vaccines14090726 [doi] LID - 726 AB - Background/Objectives: Neurocognitive disorders represent a growing burden among older adults. Although respiratory vaccines have demonstrated efficacy and safety in preventing acute respiratory events, their potential impact on the development of chronic neurocognitive disorders, such as cognitive impairment, dementia, and Alzheimer's disease (AD), has not been extensively explored. The objective of this scoping review was to synthesize and analyze the available evidence on the association between respiratory vaccination and the risk of developing cognitive impairment, dementia, and Alzheimer's disease. Methods: A scoping review was conducted in accordance with the PRISMA-ScR guidelines. A literature search was performed in the PubMed, Scopus, and Web of Science databases through 15 June 2026. Studies involving older adults (>/=60 years), irrespective of their baseline neurocognitive status, were included. Observational studies (cohort and case-control studies) were considered. Editorials, narrative reviews, and other non-original articles were excluded. Results: Eighteen studies were included, with cohort studies being the predominant design. Four main categories of respiratory vaccines were evaluated: influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal vaccines, in relation to the risk of cognitive impairment, dementia, and AD. Influenza vaccination was associated with a lower risk of dementia and AD, with a potential dose-response relationship observed, whereby a greater number of vaccinations was associated with a greater reduction in risk. Pneumococcal vaccination was also associated with a lower risk of dementia and AD, particularly among individuals who received a greater number of vaccine doses. In contrast, the evidence regarding COVID-19 and RSV vaccines was limited and yielded heterogeneous findings. Conclusions: Influenza and pneumococcal vaccination maybe associated with a lower risk of Alzheimer's disease and dementia. However, the evidence regarding COVID-19 and RSV vaccines remains limited, and additional studies are needed to clarify their impact on the risk of developing neurocognitive disorders. FAU - Runzer-Colmenares, Fernando M AU - Runzer-Colmenares FM AUID- ORCID: 0000-0003-4045-0260 AD - CHANGE Research Working Group, Universidad Cientifica del Sur, Lima 15067, Peru. FAU - Cahuapaza-Gutierrez, Nelson Luis AU - Cahuapaza-Gutierrez NL AUID- ORCID: 0000-0002-1228-1941 AD - CHANGE Research Working Group, Universidad Cientifica del Sur, Lima 15067, Peru. AD - Research Department, N y C-Center of Research and Medical Excellence (CRME), Lima 15067, Peru. FAU - Calderon-Hernandez, Cielo Cinthya AU - Calderon-Hernandez CC AD - CHANGE Research Working Group, Universidad Cientifica del Sur, Lima 15067, Peru. AD - Research Department, N y C-Center of Research and Medical Excellence (CRME), Lima 15067, Peru. FAU - Hilares-Jorge, Camila Marjory AU - Hilares-Jorge CM AD - Research Department, N y C-Center of Research and Medical Excellence (CRME), Lima 15067, Peru. AD - Faculty of Health Sciences, Psychology School, Universidad Cientifica del Sur, Lima 15067, Peru. LA - eng PT - Journal Article PT - Review DEP - 20260822 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC13611525 OTO - NOTNLM OT - Alzheimer's disease OT - COVID-19 vaccine OT - cognitive impairment OT - dementia OT - influenza vaccine OT - pneumococcal vaccine OT - respiratory vaccines OT - scoping review (source: MeSH NLM) COIS- The authors declare no conflicts of interest. EDAT- 2026/09/26 05:35 MHDA- 2026/09/26 05:36 PMCR- 2026/08/22 CRDT- 2026/09/26 01:16 PHST- 2026/07/01 00:00 [received] PHST- 2026/07/31 00:00 [revised] PHST- 2026/08/18 00:00 [accepted] PHST- 2026/09/26 05:36 [medline] PHST- 2026/09/26 05:35 [pubmed] PHST- 2026/09/26 01:16 [entrez] PHST- 2026/08/22 00:00 [pmc-release] AID - vaccines14090726 [pii] AID - vaccines-14-00726 [pii] AID - 10.3390/vaccines14090726 [doi] PST - epublish SO - Vaccines (Basel). 2026 Aug 22;14(9):726. doi: 10.3390/vaccines14090726. PMID- 42675735 OWN - NLM STAT- MEDLINE DCOM- 20260901 LR - 20261014 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 105 IP - 35 DP - 2026 Aug 28 TI - Long-term adverse effects following COVID-19 vaccination: A comparative analysis of Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. PG - e50282 LID - 10.1097/MD.0000000000050282 [doi] LID - e50282 AB - During the COVID-19 pandemic, vaccinations were highly beneficial to public health, preventing disease and reducing mortality. This study aimed to investigate long-term adverse clinical symptoms following COVID-19 vaccination with the Oxford AstraZeneca (ChAdOx1 nCoV-19, Oxford), Pfizer-BioNTech (BNT162b2), and Moderna (mRNA-1273) vaccines. In this cross-sectional study, the total number of participants was 429; among them, 243 (56.6%) were male, and 186 (43.4%) were female. An online Google Form was prepared in both Arabic and English and distributed to participants who received the Oxford AstraZeneca, Pfizer-BioNTech, and Moderna vaccines. The most common long-term adverse effects reported after COVID-19 vaccination were chronic fatigue, impaired cognitive function, and menstrual irregularity. The Moderna vaccine had a higher self-reported symptom rate among male participants (50-61.5%) than among female participants (33.3-28%). Chronic fatigue was more frequent among Oxford AstraZeneca recipients (34.7%) than among Moderna (22.2%) and Pfizer-BioNTech (27.7%) recipients. The second dose was associated with slightly higher rates of chronic fatigue among Oxford AstraZeneca recipients (38.9%) than among Moderna (25%) and Pfizer-BioNTech recipients (27.3%). For cognitive problems, the prevalence was similar across all brands (25%). Menstrual irregularity was slightly higher among females who received Pfizer-BioNTech (14.8%) than among Oxford AstraZeneca recipients (18.9%). The highest proportion of recipients who were infected after vaccination was among those who received the Oxford AstraZeneca vaccine (46.3%). In conclusion, the most commonly reported long-term adverse effects after COVID-19 vaccination were chronic fatigue, cognitive impairment, and menstrual irregularity. Further large-scale studies are required to provide more conclusive evidence. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, LLC. FAU - Aldali, Jehad A AU - Aldali JA AD - Department of Pathology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia. FAU - Meo, Sultan Ayoub AU - Meo SA AUID- ORCID: 0000-0001-9820-1852 AD - Department of Physiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (BNT162 Vaccine) RN - EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273) SB - IM MH - Humans MH - Female MH - Male MH - Cross-Sectional Studies MH - *COVID-19 Vaccines/adverse effects MH - ChAdOx1 nCoV-19/adverse effects MH - *COVID-19/prevention & control MH - BNT162 Vaccine/adverse effects MH - Adult MH - Middle Aged MH - 2019-nCoV Vaccine mRNA-1273/adverse effects MH - Vaccination/adverse effects MH - Fatigue/epidemiology PMC - PMC13529125 OTO - NOTNLM OT - COVID-19 vaccination OT - Moderna OT - Oxford AstraZeneca OT - Pfizer-BioNTech OT - adverse symptoms COIS- The authors have no funding and conflicts of interest to declare. EDAT- 2026/09/01 05:41 MHDA- 2026/09/01 05:42 PMCR- 2026/08/28 CRDT- 2026/09/01 01:01 PHST- 2026/06/03 00:00 [received] PHST- 2026/08/03 00:00 [accepted] PHST- 2026/09/01 05:42 [medline] PHST- 2026/09/01 05:41 [pubmed] PHST- 2026/09/01 01:01 [entrez] PHST- 2026/08/28 00:00 [pmc-release] AID - 00005792-202608280-00067 [pii] AID - MD-D-26-08262 [pii] AID - 10.1097/MD.0000000000050282 [doi] PST - ppublish SO - Medicine (Baltimore). 2026 Aug 28;105(35):e50282. doi: 10.1097/MD.0000000000050282. PMID- 42599142 OWN - NLM STAT- Publisher LR - 20260814 IS - 1758-2032 (Electronic) IS - 1758-2024 (Linking) DP - 2026 Aug 14 TI - Incidence and clinical characteristics of amyotrophic lateral sclerosis during the post-COVID-19 Period: a population-based study from Isfahan, Iran. PG - 1-8 LID - 10.1080/17582024.2026.2718409 [doi] AB - AIMS: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. Understanding the underlying causes would help further studies on the pathogenesis and treatments. Recent interest has emerged in evaluating whether the COVID-19 pandemic and vaccination have any influence on the epidemiological patterns of ALS. MATERIALS & METHODS: To assess this association in Isfahan, Iran, during the post-COVID-19 era, we conducted this retrospective study. Newly diagnosed ALS cases were identified, and demographic data, environmental exposures, comorbidities, vaccination history, and other aspects were collected. RESULTS: A total of 63 patients were diagnosed with definite ALS, yielding an incidence rate of 0.74 per 100,000 person-years (95% CI: 0.57-0.94). The mean age was 59.7 +/- 11.6 years, and cases were predominantly male (73%). Of the 63 new ALS-diagnosed cases, 45% of patients reported probable prior COVID-19 infection, and 95.3% mentioned at least one dose of COVID-19 vaccination. Bulbar signs, including facial muscle weakness, tongue atrophy, and fasciculation, were present in 46% of cases, and emotional lability and cognitive decline were observed in 20.6%. CONCLUSION: We showed a probable relation between COVID-19 infection and the epidemiology of ALS in post-COVID era. However, our results and symptom alterations require further investigation. FAU - Etemadifar, Masoud AU - Etemadifar M AD - Neurology Department, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Salari, Mehri AU - Salari M AD - Men's Health and Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Kashefi, Mohammadamin AU - Kashefi M AD - School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Shams, Yalda AU - Shams Y AD - Neurology Department, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Heydari Sichani, Mohammadamin AU - Heydari Sichani M AD - Medical Student, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Hojjatipour, Fatemeh AU - Hojjatipour F AUID- ORCID: 0000-0002-1861-7063 AD - Neurology Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article DEP - 20260814 PL - England TA - Neurodegener Dis Manag JT - Neurodegenerative disease management JID - 101517977 SB - IM OAB - Amyotrophic lateral sclerosis (ALS) is a rare and serious disease that causes the nerve cells controlling movement to gradually stop working. Because ALS has no cure, understanding when and how it appears in the community is important for improving care and planning future research.Since the COVID-19 pandemic affected many body systems, including the brain and immune system, some people have wondered whether COVID-19 infection or vaccination might influence the development of ALS. To explore this question, we studied all new ALS cases diagnosed in Isfahan Province, Iran, between May 2023 and December 2024. This is the first study to examine ALS patterns in this region after the pandemic.We identified 63 new patients with definite ALS. The number of new cases was higher than the rate reported in Isfahan before the pandemic, suggesting that COVID-19 changed how often ALS occurs in this population. Almost half of the patients reported a previous COVID-19 infection, and most had received at least one COVID-19 vaccine dose, which reflects the high vaccination rate in the general population. We did not find evidence that infection or vaccination affected the type or severity of ALS symptoms.However, many patients showed bulbar symptoms (such as speech or swallowing problems) and some had cognitive changes at diagnosis, which highlights the need for early evaluation and support.Overall, our findings show that ALS patterns in Isfahan have changed after the COVID-19 pandemic, and continued monitoring is important. OABL- eng OTO - NOTNLM OT - Amyotrophic lateral sclerosis OT - COVID-19 OT - Iran OT - epidemiology OT - vaccination EDAT- 2026/08/14 12:16 MHDA- 2026/08/14 12:16 CRDT- 2026/08/14 09:42 PHST- 2026/08/14 12:16 [medline] PHST- 2026/08/14 12:16 [pubmed] PHST- 2026/08/14 09:42 [entrez] AID - 10.1080/17582024.2026.2718409 [doi] PST - aheadofprint SO - Neurodegener Dis Manag. 2026 Aug 14:1-8. doi: 10.1080/17582024.2026.2718409. PMID- 42543573 OWN - NLM STAT- Publisher LR - 20260803 IS - 1884-2836 (Electronic) IS - 1344-6304 (Linking) DP - 2026 Jul 31 TI - Long COVID symptom trajectories according to post-COVID-19 vaccination status: a prospective longitudinal study. LID - 10.7883/yoken.JJID.2026.021 [doi] AB - Long COVID remains a substantial public health challenge, and the relationship between post-COVID-19 vaccination and symptom persistence remains uncertain. This prospective longitudinal study evaluated long COVID symptom trajectories according to post-COVID-19 vaccination status. Adult patients who were unvaccinated at the time of COVID-19 diagnosis were followed at 1, 3, 6, and 9 months and categorized according to vaccination status. Symptom Tool (ST) and Impact Tool (IT) scores and SARS-CoV-2 IgG antibody levels were assessed longitudinally. A total of 59 patients (mean age 43.1+/-14.1 years; 45.8% male) were included, of whom eight were vaccinated. The most frequently reported symptoms were memory problems, fatigue, brain fog, word-finding difficulties, and excessive sweating. Baseline characteristics were broadly comparable between groups. ST and IT scores decreased significantly over time in the overall cohort; however, no statistically significant association between vaccination status and symptom trajectories was identified. SARS-CoV-2 IgG antibody levels were higher among vaccinated participants but were not associated with symptom burden. Given the small sample size and substantial group imbalance, the study is underpowered and the findings should be interpreted cautiously. Larger prospective studies are needed to better clarify the relationship between post-COVID-19 vaccination and long COVID outcomes. FAU - Benli, Aysun AU - Benli A AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Ala Selek, Selva AU - Ala Selek S AD - Department of Infectious Diseases and Clinical Microbiology, Bagcilar Training and Education Hospital, Turkey. FAU - Basaran, Seniha AU - Basaran S AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Simsek Yavuz, Serap AU - Simsek Yavuz S AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Mese, Sevim AU - Mese S AD - Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Cagatay, Atahan AU - Cagatay A AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Oncul, Oral AU - Oncul O AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Ozsut, Halit AU - Ozsut H AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Onel, Mustafa AU - Onel M AD - Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Agacfidan, Ali AU - Agacfidan A AD - Department of Medical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. FAU - Eraksoy, Haluk AU - Eraksoy H AD - Department of Infectious Diseases and Clinical Microbiology, Istanbul Faculty of Medicine, Istanbul University, Turkey. LA - eng PT - Journal Article DEP - 20260731 PL - Japan TA - Jpn J Infect Dis JT - Japanese journal of infectious diseases JID - 100893704 SB - IM OTO - NOTNLM OT - Antibody OT - COVID-19 OT - Long COVID OT - SARS-CoV-2 IgG OT - SARS-CoV-2 vaccine EDAT- 2026/08/03 06:36 MHDA- 2026/08/03 06:36 CRDT- 2026/08/03 00:53 PHST- 2026/08/03 06:36 [medline] PHST- 2026/08/03 06:36 [pubmed] PHST- 2026/08/03 00:53 [entrez] AID - 10.7883/yoken.JJID.2026.021 [doi] PST - aheadofprint SO - Jpn J Infect Dis. 2026 Jul 31. doi: 10.7883/yoken.JJID.2026.021. PMID- 42543244 OWN - NLM STAT- Publisher LR - 20260802 IS - 1476-8321 (Electronic) IS - 0887-0446 (Linking) DP - 2026 Aug 2 TI - Predicting parents' COVID-19 vaccination intentions and behavior for their children: application of an integrated social cognition model. PG - 1-34 LID - 10.1080/08870446.2026.2707302 [doi] AB - OBJECTIVE: Identifying modifiable determinants of parent-for-child vaccination may inform interventions for ongoing management of infectious diseases including COVID-19. We tested an integrated theoretical model in which social cognition constructs (coping appraisals, anticipated regret, moral norms) mediated effects of dispositional constructs (political orientation, conspiracy beliefs, vaccine hesitancy) on parent-for-child COVID-19 vaccination intention and behaviour. METHODS AND MEASURES: In a prospective correlational study, US parents (N = 497) with an unvaccinated child completed political orientation, conspiracy beliefs, vaccine hesitancy, and social cognition construct measures referring to COVID-19 vaccination for their child. Parents reported their vaccination behaviour for their child five weeks later. RESULTS: Consistent with predictions, we observed indirect effects of political orientation and vaccination hesitancy on intentions mediated by coping efficacy, anticipated regret, and moral norms, and sums of indirect effects of political orientation, conspiracy beliefs, and vaccine hesitancy on intention mediated by social cognition constructs. We also observed a sum of indirect effects of vaccine hesitancy on behaviour. CONCLUSION: Findings contribute to an evidence base for the effects of dispositional and social cognition constructs of parent-for-child COVID-19 vaccination intentions and behaviour and signal a candidate mechanism. Findings may provide formative evidence for developing interventions to manage childhood COVID-19 infection rates. FAU - Griffith, Zoe M AU - Griffith ZM AD - Department of Psychological Sciences, University of California, Merced, California, USA. FAU - Royer, Zoe AU - Royer Z AD - Department of Psychology, Cal Poly Humboldt, Arcata, California, USA. FAU - Gaffney, Amber M AU - Gaffney AM AD - Department of Psychology, Cal Poly Humboldt, Arcata, California, USA. FAU - Hagger, Martin S AU - Hagger MS AD - Department of Psychological Sciences, University of California, Merced, California, USA. AD - Health Sciences Research Institute, University of California, Merced, California, USA. AD - Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla, Finland. AD - School of Applied Psychology, Griffith University. LA - eng PT - Journal Article DEP - 20260802 PL - England TA - Psychol Health JT - Psychology & health JID - 8807983 SB - IM OTO - NOTNLM OT - COVID-19 vaccination OT - Social cognition theory OT - dispositional-belief-motivation model OT - psychological determinants OT - theory integration EDAT- 2026/08/03 00:35 MHDA- 2026/08/03 00:35 CRDT- 2026/08/02 22:22 PHST- 2026/08/03 00:35 [medline] PHST- 2026/08/03 00:35 [pubmed] PHST- 2026/08/02 22:22 [entrez] AID - 10.1080/08870446.2026.2707302 [doi] PST - aheadofprint SO - Psychol Health. 2026 Aug 2:1-34. doi: 10.1080/08870446.2026.2707302. PMID- 42513402 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260729 LR - 20260824 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 15 IP - 14 DP - 2026 Jul 13 TI - Posterior Circulation Ischemic Stroke Occurring After ChAdOx1 nCoV-19/AZD1222 Vaccination Without Evidence of Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Case Report and Focused Narrative Review. LID - 10.3390/jcm15145487 [doi] LID - 5487 AB - Background: Ischemic stroke has been reported rarely after coronavirus disease 2019 (COVID-19) vaccination, most clearly in association with vaccine-induced immune thrombotic thrombocytopenia (VITT). Nevertheless, temporal proximity alone cannot establish causality, particularly when conventional vascular risk factors are present. We report a case of posterior circulation ischemic stroke occurring 36-48 h after first-dose ChAdOx1 nCoV-19/AZD1222 vaccination without VITT and provide a focused narrative review of the clinical, epidemiological, and mechanistic evidence regarding post-vaccination stroke. Methods: Clinical, laboratory, and neuroimaging data were reviewed retrospectively. A focused narrative literature review was performed to contextualize VITT-related and non-VITT ischemic stroke after COVID-19 vaccination, pharmacovigilance signals, population-based evidence, and proposed biological mechanisms. Results: A 63-year-old man with well-controlled hypertension and a remote history of smoking developed systemic symptoms within 24 h of first-dose ChAdOx1 nCoV-19/AZD1222 vaccination, followed by severe hypertension and acute posterior circulation neurological symptoms 36-48 h after vaccination. Neuroimaging showed an acute left cerebellar infarct extending into the middle cerebellar peduncle, with approximately 50% stenosis of the intradural left vertebral artery. Platelet counts remained normal, D-dimer and anti-PF4 antibody testing were normal, SARS-CoV-2 polymerase chain reaction (PCR) testing was negative, and routine cardiac evaluation did not identify a definite cardioembolic source. Conclusions: This case highlights an early posterior circulation ischemic stroke temporally associated with ChAdOx1 nCoV-19/AZD1222 vaccination in the absence of VITT. Although individual causality cannot be established from a single case, careful reporting of such presentations may improve clinical recognition, etiological evaluation, and pharmacovigilance. FAU - Bermejo-Pareja, Felix AU - Bermejo-Pareja F AD - Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (Imas12), 28041 Madrid, Spain. FAU - Ramo-Tello, Cristina AU - Ramo-Tello C AD - Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain. AD - Department of Medicine, Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. FAU - Benito-Leon, Julian AU - Benito-Leon J AUID- ORCID: 0000-0002-1769-4809 AD - Group of Neurodegenerative Diseases, Hospital Universitario 12 de Octubre Research Institute (Imas12), 28041 Madrid, Spain. AD - Department of Neurology, 12 de Octubre University Hospital, 28041 Madrid, Spain. AD - Department of Medicine, Faculty of Medicine, Complutense University of Madrid, 28040 Madrid, Spain. AD - Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), 28031 Madrid, Spain. LA - eng GR - R01 NS039422/NS/NINDS NIH HHS/United States GR - R01 NS094607/NS/NINDS NIH HHS/United States PT - Journal Article PT - Review DEP - 20260713 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC13412417 OTO - NOTNLM OT - AZD1222 OT - COVID-19 vaccination OT - ChAdOx1 nCoV-19 OT - TOAST classification OT - VITT OT - cerebellar infarction OT - ischemic stroke OT - narrative review OT - pharmacovigilance OT - posterior circulation OT - temporal association COIS- F.B.-P. may provide expert testimony related to the clinical case discussed in this manuscript under Spanish law. This role did not influence the selection, interpretation, or drafting of the manuscript. C.R.T. and J.B.-L. declare no competing interests. EDAT- 2026/07/28 06:37 MHDA- 2026/07/28 06:38 PMCR- 2026/07/13 CRDT- 2026/07/28 01:14 PHST- 2026/06/16 00:00 [received] PHST- 2026/07/07 00:00 [revised] PHST- 2026/07/10 00:00 [accepted] PHST- 2026/07/28 06:38 [medline] PHST- 2026/07/28 06:37 [pubmed] PHST- 2026/07/28 01:14 [entrez] PHST- 2026/07/13 00:00 [pmc-release] AID - jcm15145487 [pii] AID - jcm-15-05487 [pii] AID - 10.3390/jcm15145487 [doi] PST - epublish SO - J Clin Med. 2026 Jul 13;15(14):5487. doi: 10.3390/jcm15145487. PMID- 42426643 OWN - NLM STAT- MEDLINE DCOM- 20261006 LR - 20261008 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 26 IP - 1 DP - 2026 Jul 9 TI - Strict long COVID, symptom persistence, and functional decline among community-dwelling older adults in Quito, Ecuador: a cross-sectional study. LID - 10.1186/s12877-026-07976-9 [doi] LID - 1256 AB - BACKGROUND: Long COVID is an increasingly recognized health concern in older adults, yet data from Latin America remain limited. Older adults may be particularly vulnerable to post-COVID sequelae because of frailty, multimorbidity, and reduced physiological reserve. This study aimed to estimate the prevalence of strict long COVID among older Ecuadorian adults and to characterize persistent post-COVID symptoms, clinical correlates, and functional/cognitive worsening. METHODS: We conducted a cross-sectional study of 1,050 community-dwelling adults aged 65 years or older with PCR-confirmed SARS-CoV-2 infection in Quito, Ecuador. Data were collected through structured face-to-face interviews and cognitive screening. Strict long COVID was defined as symptoms persisting for more than 12 weeks after SARS-CoV-2 infection. Symptoms lasting 4-12 weeks were classified as persistent post-COVID symptoms but were not considered strict long COVID. Multivariable logistic regression was used to evaluate factors associated with strict long COVID. RESULTS: The mean age was 74.2 +/- 7.5 years, and 565 participants (53.8%) were women. Overall, 191 participants met criteria for strict long COVID, corresponding to a prevalence of 18.2% (95% CI, 16.0-20.6). Persistent post-COVID symptoms lasting 4-6 weeks and 7-12 weeks were reported by 401 (38.2%) and 458 (43.6%) participants, respectively. Participants with strict long COVID had higher frequencies of dyspnea, cognitive impairment, sleep disturbance, myalgia, depression, anxiety, and difficulty sleeping. Functional/cognitive worsening was more frequent among participants with strict long COVID than among those without strict long COVID (53.4% vs. 36.6%; p < 0.001), particularly for walking or climbing stairs. In multivariable analysis, severe or critical acute COVID-19 was independently associated with strict long COVID (adjusted OR, 2.36; 95% CI, 1.62-3.41; p < 0.001). Female sex, age >/= 81 years, incomplete vaccination, diabetes with organ involvement, hospitalization, and care dependence were not independently associated with strict long COVID. CONCLUSION: Strict long COVID affected nearly one in five older adults with PCR-confirmed SARS-CoV-2 infection in Quito, Ecuador. Severe or critical acute COVID-19 was the main factor independently associated with strict long COVID, and affected participants had greater functional/cognitive worsening. These findings support integrating post-COVID screening, functional assessment, and geriatric rehabilitation into primary care for older adults in Latin America. CI - (c) 2026. The Author(s). FAU - Gonzalez-Andrade, Fabricio AU - Gonzalez-Andrade F AUID- ORCID: 0000-0002-2091-9095 AD - Faculty of Health Sciences, Dean's Office of Postgraduate Studies in Health, Indoamerica Technological University, Machala and Sabanilla Street, Quito, 170301, Ecuador. fabriciogonzaleza@gmail.com. LA - eng PT - Journal Article DEP - 20260709 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 SB - IM MH - Humans MH - Ecuador/epidemiology MH - Cross-Sectional Studies MH - Female MH - Aged MH - Post-Acute COVID-19 Syndrome MH - Male MH - *Independent Living MH - *COVID-19/epidemiology/diagnosis/psychology/complications MH - Aged, 80 and over MH - *Cognitive Dysfunction/epidemiology PMC - PMC13640318 OTO - NOTNLM OT - Cognitive impairment OT - Ecuador OT - Functional decline OT - Long COVID OT - Older adults OT - Persistent post-COVID symptoms OT - Post-COVID condition OT - Strict long COVID OT - Sustainable development goal 3 OT - Vaccination COIS- Declarations. Ethics approval and consent to participate: The study received approval from the Committee on Ethics in Human Research (CEISH) from Carlos Andrade Marin Specialty Hospital (HCAM) on July 6, 2020, under protocol code IESS-HCAM-CEISH-2020-200-DF, in compliance with national and international research regulations. Consent for publication: Not applicable. This manuscript does not contain identifying images or personal clinical details that could compromise participant anonymity. Competing interests: The authors declare no competing interests. EDAT- 2026/07/10 06:35 MHDA- 2026/10/06 05:29 PMCR- 2026/07/09 CRDT- 2026/07/10 00:06 PHST- 2026/04/13 00:00 [received] PHST- 2026/07/07 00:00 [accepted] PHST- 2026/10/06 05:29 [medline] PHST- 2026/07/10 06:35 [pubmed] PHST- 2026/07/10 00:06 [entrez] PHST- 2026/07/09 00:00 [pmc-release] AID - 10.1186/s12877-026-07976-9 [pii] AID - 7976 [pii] AID - 10.1186/s12877-026-07976-9 [doi] PST - epublish SO - BMC Geriatr. 2026 Jul 9;26(1):1256. doi: 10.1186/s12877-026-07976-9. PMID- 42404887 OWN - NLM STAT- MEDLINE DCOM- 20260706 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Mechanisms and impact of long COVID: pathophysiology, neuropsychiatric effects and vaccination. PG - 1710777 LID - 10.3389/fimmu.2026.1710777 [doi] LID - 1710777 AB - Long COVID or post-acute sequelae of COVID-19 is defined as an after-effect of acute COVID-19 infection. Its broad clinical symptoms include brain fog, shortness of breath, fatigue, joint, chest, or muscle pain, dysautonomia and neuropsychiatric symptoms such as anxiety, depression and post-traumatic stress disorder. It is estimated that 1 in every 5 COVID-19 survivors exhibit symptoms within the Long COVID bracket. An array of risk factors such as smoking habit, age, obesity, female sex, and prior hospitalization may increase the probability of a person developing Long COVID. While the underlying mechanisms of Long COVID remain elusive, we examine the various possible pathophysiologies involved in Long COVID. We take up impactful neuropsychiatric issues as another spectrum of Long COVID symptoms and the likely effect of various forms of COVID-19 vaccines. In this review, the focus will be on the main mechanisms associated with the development of long COVID, which include latent Epstein-Barr virus reactivation, molecular mimicry, virus persistence, autoantibodies, and mitochondrial dysfunction. Understanding these mechanisms shed light on the continued persistence of COVID-19 related symptoms long after the resolution of acute infection. For instance, the reactivation of Epstein-Barr virus in the immunocompromised context seen post-acute SARS-CoV-2 infection could lead to the symptoms commonly observed in Long COVID such as fatigue and brain fog. The Epstein-Barr virus could possibly disrupt mitochondrial function, explaining the fatigue commonly observed in Long COVID patients. Other factors such as continued presence of viral particles in specific areas such as the gut may result in continued inflammation, leading to manifestations such as fatigue, cognitive impairment and gastrointestinal dysfunction. Additionally, heightened and persistent presence of autoantibodies post-acute infection results in persistent symptoms and could potentially trigger the onset of autoimmune disorders. We also aim to revisit the diverse and prolonged effects of the COVID-19 pandemic that continue to affect the well-being and quality of human life. CI - Copyright (c) 2026 Ponnachan, Dhawlarker, Yasmin, Shah, Malhotra, Shastri, Al-Ramadi and Kishore. FAU - Ponnachan, Pretty AU - Ponnachan P AD - Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates. AD - Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. FAU - Dhawlarker, Anam AU - Dhawlarker A AD - National Institute of Virology (NIV), Indian Council of Medical Research (ICMR), Pune, India. FAU - Yasmin, Hadida AU - Yasmin H AD - Institute of Health Sciences, Presidency University, Kolkata, West Bengal, India. FAU - Shah, Akash AU - Shah A AD - Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom. AD - Ashford and St Peter's NHS Foundation Trust, Ashford, United Kingdom. FAU - Malhotra, Aastha AU - Malhotra A AD - Department of Zoology, Hans Raj College, University of Delhi, Delhi, India. FAU - Shastri, Abhishek AU - Shastri A AD - Central and North West London National Health Service (NHS) Foundation Trust, London, United Kingdom. FAU - Al-Ramadi, Basel K AU - Al-Ramadi BK AD - Department of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. AD - Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. AD - ASPIRE Precision Medicine Research Institute Abu Dhabi, United Arab Emirates University, Al Ain, United Arab Emirates. FAU - Kishore, Uday AU - Kishore U AD - Department of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates. AD - Zayed Centre for Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates. LA - eng PT - Journal Article PT - Review DEP - 20260619 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/immunology/physiopathology/psychology/complications/prevention & control MH - Post-Acute COVID-19 Syndrome MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology MH - Vaccination MH - Mental Disorders/etiology PMC - PMC13328189 OTO - NOTNLM OT - Epstein-Barr virus OT - SARS-CoV-2 OT - autoimmunity OT - complement system OT - immune dysregulation OT - long COVID OT - neuropsychiatric effects COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/07/06 10:10 MHDA- 2026/07/06 12:42 PMCR- 2026/06/19 CRDT- 2026/07/06 05:40 PHST- 2025/09/22 00:00 [received] PHST- 2026/04/23 00:00 [revised] PHST- 2026/05/12 00:00 [accepted] PHST- 2026/07/06 12:42 [medline] PHST- 2026/07/06 10:10 [pubmed] PHST- 2026/07/06 05:40 [entrez] PHST- 2026/06/19 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1710777 [doi] PST - epublish SO - Front Immunol. 2026 Jun 19;17:1710777. doi: 10.3389/fimmu.2026.1710777. eCollection 2026. PMID- 42396417 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260703 LR - 20260813 IS - 0019-5545 (Print) IS - 1998-3794 (Electronic) IS - 0019-5545 (Linking) VI - 68 IP - 6 DP - 2026 Jun TI - Post-COVID neuropsychiatric symptoms in India: Prevalence, risk factors, and persistence. PG - 552-559 LID - 10.4103/indianjpsychiatry_946_25 [doi] AB - BACKGROUND: The global research has actively investigated the post-COVID neuropsychiatric symptoms (PCNS). There is a paucity of studies from India that explore long-term PCNS. AIM: This study aims to estimate prevalence, types of PCNS, associated factors (sociodemographic factors, life events, COVID-19-related variables, and vaccination status) and persistence of PCNS after two years. METHODS: A cross-sectional study was conducted from October 2022 to October 2023 in a tertiary care hospital. A total of 2,281 randomly selected individuals with reverse transcription polymerase chain reaction-positive for COVID-19 were screened for PCNS. Among 927 participants consented to and completed the telephonic screening for PCNS. Structured clinical interviews for DSM-5-Research Version and World Health Organization-Post-COVID Case Report Form were applied. Descriptive statistics and binary logistic regression analysis were used for data analysis. RESULTS: Median age of individuals was 34 years, and 51.3% being female. Only 21.6% had lifetime PCNS, and 7.3% had persistent PCNS at two years of COVID-19. The common lifetime PCNS were persistent fatigue (15.6%), reduced smell (5.9%), reduced taste (4.8%), anxiety (4.3%), insomnia (3.6%), depressed mood (2.6%), cognitive symptoms (2.6%), and persistent muscle pain (2.6%). The logistic regression analysis revealed a positive association of lifetime PCNS with female gender, preexisting medical comorbidities, symptomatic COVID-19, oxygen supplementation, repeated infections, and life events. Full or partially vaccinated against COVID-19 appeared to be protective against PCNS. CONCLUSION: About one in five individuals developed lifetime PCNS following COVID. Among them, one in three had persistent PCNS after two years of COVID. Female gender, life events, severity of COVID-19, repeated infection, and Vaccine-naive status were associated with the development of PCNS. CI - Copyright: (c) 2026 Indian Journal of Psychiatry. FAU - Laha, Poulami AU - Laha P AD - Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Gowda, Guru S AU - Gowda GS AD - Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Moirangthem, Sydney AU - Moirangthem S AD - Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Veenakumari, H B AU - Veenakumari HB AD - Department of Neuro-Microbiology, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Binukumar, Bhaskarapillai AU - Binukumar B AD - Department of Biostatistics, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Reddi, Venkata Senthil Kumar AU - Reddi VSK AD - Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. FAU - Thippeswamy, Harish AU - Thippeswamy H AD - Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, Karnataka, India. LA - eng PT - Journal Article DEP - 20260620 PL - India TA - Indian J Psychiatry JT - Indian journal of psychiatry JID - 0013255 PMC - PMC13327406 OTO - NOTNLM OT - COVID-19 OT - neuropsychiatry OT - persistent post-COVID neuropsychiatric symptoms OT - post-COVID COIS- There are no conflicts of interest. EDAT- 2026/07/03 06:31 MHDA- 2026/07/03 06:32 PMCR- 2026/06/01 CRDT- 2026/07/03 05:31 PHST- 2025/09/08 00:00 [received] PHST- 2026/05/30 00:00 [revised] PHST- 2026/05/31 00:00 [accepted] PHST- 2026/07/03 06:32 [medline] PHST- 2026/07/03 06:31 [pubmed] PHST- 2026/07/03 05:31 [entrez] PHST- 2026/06/01 00:00 [pmc-release] AID - IJPsy-68-552 [pii] AID - 10.4103/indianjpsychiatry_946_25 [doi] PST - ppublish SO - Indian J Psychiatry. 2026 Jun;68(6):552-559. doi: 10.4103/indianjpsychiatry_946_25. Epub 2026 Jun 20. PMID- 42392028 OWN - NLM STAT- MEDLINE DCOM- 20260828 LR - 20260828 IS - 1873-5347 (Electronic) IS - 0277-9536 (Linking) VI - 404 DP - 2026 Sep TI - Does education shield against vaccine hesitancy? Evidence from the East-West divide. PG - 119464 LID - S0277-9536(26)00540-X [pii] LID - 10.1016/j.socscimed.2026.119464 [doi] AB - Education is among the strongest correlates of health behavior, yet its relationship with vaccine acceptance varies sharply across European contexts. Using the SHARE COVID-19 Survey 2 (summer 2021) linked to rich pre-pandemic data from SHARE and SHARELIFE - a longitudinal survey of adults aged 50 and above across 27 European countries - we document a striking East-West asymmetry: schooling is strongly and positively associated with COVID-19 vaccine take-up in Central and Eastern Europe (CEE) but only weakly related in Western and Central Europe (WCE). We argue that this contrast is consistent with the institutional legacies of communist rule, which generated persistent deficits in institutional trust and social capital that education may help bridge. To investigate which pre-pandemic domains account for the steeper CEE gradient, we add conceptually motivated blocks of covariates capturing cognitive resources, social capital, social networks, health, and early-life circumstances. Cognitive functioning accounts for the largest observable share of the gradient, but a sizable residual remains after extensive adjustment and is robust to sensitivity analysis for unobserved confounding. A within-Germany comparison by birthplace (East vs West) confirms that the education gradient is steeper among those raised in the former GDR, reinforcing the interpretation that institutional context shapes how education translates into vaccine acceptance. CI - Copyright (c) 2026 The Author. Published by Elsevier Ltd.. All rights reserved. FAU - Fawaz, Yarine AU - Fawaz Y AD - CEMFI and UAM (Universidad Autonoma de Madrid), Spain. Electronic address: yarine.fawaz@uam.es. LA - eng PT - Journal Article DEP - 20260629 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Vaccination Hesitancy/statistics & numerical data/psychology MH - *COVID-19 Vaccines/administration & dosage MH - *COVID-19/prevention & control MH - Europe/epidemiology MH - *Educational Status MH - Middle Aged MH - Longitudinal Studies MH - Male MH - Female MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - Eastern Europe OT - Education OT - Health behaviors OT - Health inequalities OT - Vaccination COIS- Declaration of competing interest The authors declare no competing interest. EDAT- 2026/07/03 00:30 MHDA- 2026/08/28 23:34 CRDT- 2026/07/02 18:13 PHST- 2025/12/02 00:00 [received] PHST- 2026/05/06 00:00 [revised] PHST- 2026/05/27 00:00 [accepted] PHST- 2026/08/28 23:34 [medline] PHST- 2026/07/03 00:30 [pubmed] PHST- 2026/07/02 18:13 [entrez] AID - S0277-9536(26)00540-X [pii] AID - 10.1016/j.socscimed.2026.119464 [doi] PST - ppublish SO - Soc Sci Med. 2026 Sep;404:119464. doi: 10.1016/j.socscimed.2026.119464. Epub 2026 Jun 29. PMID- 42382104 OWN - NLM STAT- Publisher LR - 20260813 IS - 0972-7531 (Print) IS - 0976-3260 (Electronic) IS - 0972-7531 (Linking) DP - 2026 Jun 29 TI - COVID-19 Vaccine-triggered Relapsing Immune Dysregulation: An Observational Study with Four-year Follow-up. PG - 09727531261434290 LID - 10.1177/09727531261434290 [doi] LID - 09727531261434290 AB - BACKGROUND: Vaccination against COVID-19 infection became mandatory because of the field situation during the pandemic. PURPOSE: Vaccine efficacy and safety need many field years of study; time constraints due to the pandemic limited the same. A hospital-based study was done in South India among patients who presented with immune-mediated disorders in temporal correlation with COVID-19 vaccination. METHODS: The study period was 20 months, from March 2020 to November 2021. There were a total of 3,235 patients with neurological issues seen in two tertiary institutions, catering predominantly to patients from lower socio-economic strata in South India. A total of 1,007 (31.12%) patients had received COVID-19 vaccination (single dose in 511 [50.7%] and both doses in 496 [49.3%]). The general prevalence of primary demyelinating disease was compared with the background of vaccine-induced demyelination. Chi-square test was utilised for determining the association between neurological sequelae and the type of vaccine administered. RESULTS: Eighteen patients had neurological sequelae, and 16 had a monophasic pattern. Recurrent autoimmunity was seen in two patients who took the Sputnik vaccine. Comparing the prevalence of primary multiple sclerosis (MS) versus vaccine-induced demyelination, there was a statistically significant difference (chi (2) = 572.38; p < .001), which indicates a definite role of vaccination in these patients. The association between neurological manifestations of Covishield and Covaxin showed no statistically significant difference in neurological sequelae (chi (2) = 0.0466; p = .8). The Sputnik vaccine was not considered, as the number was less than five. Anti-myelin oligodendrocyte glycoprotein-associated recurrent optic neuritis was seen in one patient, and tongue atrophy, pyramidal signs, ulcerative colitis and arthritis after 3 months, and C-ANCA positivity were seen following the Sputnik vaccine in one patient. CONCLUSION: Vaccination is an effective public health intervention. However, in susceptible individuals, it can probably trigger a recurrent and multisystem event by immune dysregulation. The association is an observation-based postulate that needs a longer, larger follow-up. As per this study, it is non-fatal and remits permanently. CI - (c) The Author(s) 2026. FAU - Annapoorni, C S Vidhya AU - Annapoorni CSV AUID- ORCID: 0000-0003-3789-5082 AD - SAT Hospital Medical College, Thiruvananthapuram, Kerala, India. FAU - Chandra, S R AU - Chandra SR AUID- ORCID: 0000-0002-6756-9475 AD - S. K. Hospital, Thiruvananthapuram, Kerala, India. FAU - Isaac, Thomas Gregor AU - Isaac TG AUID- ORCID: 0000-0003-3148-3466 AD - Centre for Brain Research (CBR), Indian Institute of Science (IISc), Bengaluru, Karnataka, India. LA - eng PT - Journal Article DEP - 20260629 PL - United States TA - Ann Neurosci JT - Annals of neurosciences JID - 101523367 PMC - PMC13314644 OTO - NOTNLM OT - COVID-19 OT - immune dysregulation OT - sequelae OT - vaccination COIS- The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2026/07/01 10:11 MHDA- 2026/07/01 10:11 PMCR- 2026/06/29 CRDT- 2026/07/01 05:08 PHST- 2025/08/20 00:00 [received] PHST- 2025/09/26 00:00 [revised] PHST- 2025/09/30 00:00 [accepted] PHST- 2026/07/01 10:11 [medline] PHST- 2026/07/01 10:11 [pubmed] PHST- 2026/07/01 05:08 [entrez] PHST- 2026/06/29 00:00 [pmc-release] AID - 10.1177_09727531261434290 [pii] AID - 10.1177/09727531261434290 [doi] PST - aheadofprint SO - Ann Neurosci. 2026 Jun 29:09727531261434290. doi: 10.1177/09727531261434290. PMID- 42336872 OWN - NLM STAT- MEDLINE DCOM- 20260915 LR - 20261002 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Jun 23 TI - Risk of new-onset obstructive sleep apnea up to 4.5 years after COVID-19 in the urban population. LID - 10.1038/s41598-026-56469-7 [doi] LID - 28670 AB - Obstructive sleep apnea (OSA) is linked to cardiovascular, metabolic, and cognitive morbidity. Although COVID-19 has been associated with long-term respiratory and neurological sequelae, its role in precipitating new-onset OSA remains unclear. We evaluated whether SARS-CoV-2 infection increases risk of developing OSA up to 4.5 years post-infection and how risk varies by hospitalization status, demographics, comorbidities, and vaccination status. This retrospective cohort study used electronic health records from the Montefiore Health System in the Bronx. Adults tested for SARS-CoV-2 between March 1, 2020, and August 17, 2024, were classified as hospitalized COVID+ , non-hospitalized COVID+ , or COVID- . Patients with prior OSA or loss to follow-up were excluded. Inverse probability weighting adjusted for demographic, clinical, socioeconomic, and vaccination covariates. New-onset OSA was assessed using weighted Cox proportional hazards models. Secondary outcomes including hypertension, myocardial infarction, heart failure, stroke, arrhythmia, pulmonary hypertension, type 2 diabetes, and obesity of individuals who developed new-onset OSA were evaluated with Poisson regression. Sensitivity analysis used a pre-pandemic control cohort. Among 910,393 eligible patients, hospitalized [HR 1.41 (95% CI 1.14-1.73)] and non-hospitalized [HR 1.33 (95% CI 1.22-1.46)] COVID+ patients had higher adjusted risk of new-onset OSA versus COVID- controls. Similar findings were observed when compared to the historical controls (n = 621,046). After OSA onset, hospitalized COVID+ patients had higher risks of heart failure and pulmonary hypertension, while non-hospitalized COVID+ patients had higher risk of obesity vs COVID- patients. SARS-CoV-2 infection is independently associated with increased risk of new-onset OSA. These findings support targeted screening post-COVID in high-risk populations. CI - (c) 2026. The Author(s). FAU - Changela, Sagar AU - Changela S AD - Department of Radiology, Albert Einstein College of Medicine and Montefiore Health System, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. FAU - Katz, Rachel AU - Katz R AD - Department of Radiology, Albert Einstein College of Medicine and Montefiore Health System, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. FAU - Shah, Jainam AU - Shah J AD - Department of Radiology, Albert Einstein College of Medicine and Montefiore Health System, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. FAU - Henry, Sonya S AU - Henry SS AD - Department of Radiology, Albert Einstein College of Medicine and Montefiore Health System, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. FAU - Duong, Tim Q AU - Duong TQ AD - Department of Radiology, Albert Einstein College of Medicine and Montefiore Health System, Albert Einstein College of Medicine and Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY, 10461, USA. tim.duong@einsteinmed.edu. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20260623 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM MH - Humans MH - *Sleep Apnea, Obstructive/epidemiology/etiology MH - *COVID-19/complications/epidemiology MH - Female MH - Middle Aged MH - Male MH - Retrospective Studies MH - Risk Factors MH - Urban Population MH - SARS-CoV-2/isolation & purification MH - Aged MH - Hospitalization MH - Comorbidity MH - Post-Acute COVID-19 Syndrome MH - Adult MH - Proportional Hazards Models PMC - PMC13575142 OTO - NOTNLM OT - Health disparities OT - Long COVID OT - Post-acute sequelae OT - Sleep-disordered breathing, socioeconomic status COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/06/24 00:43 MHDA- 2026/09/15 05:36 PMCR- 2026/06/23 CRDT- 2026/06/23 23:15 PHST- 2025/09/02 00:00 [received] PHST- 2026/06/01 00:00 [accepted] PHST- 2026/09/15 05:36 [medline] PHST- 2026/06/24 00:43 [pubmed] PHST- 2026/06/23 23:15 [entrez] PHST- 2026/06/23 00:00 [pmc-release] AID - 10.1038/s41598-026-56469-7 [pii] AID - 56469 [pii] AID - 10.1038/s41598-026-56469-7 [doi] PST - epublish SO - Sci Rep. 2026 Jun 23;16(1):28670. doi: 10.1038/s41598-026-56469-7. PMID- 42333961 OWN - NLM STAT- Publisher LR - 20260623 IS - 1461-7277 (Electronic) IS - 1359-1053 (Linking) DP - 2026 Jun 23 TI - An integrated model of the emotional, cognitive, and community-related dimensions affecting vaccine hesitancy during COVID-19 pandemic. PG - 13591053261460718 LID - 10.1177/13591053261460718 [doi] AB - This paper proposes an integrated model of cognitive, emotional, and community-related predictors of vaccine hesitancy. A multiple mediation model was run using Structural Equation Modeling to test the role of perceived job and economic insecurities, pandemic-related emotions, and Sense of Community (SoC) as to respondents' vaccine hesitancy, through the mediation of safeguarding one's own and others' health and re-accessing pre-pandemic public and social life as motivations toward vaccination. Data was gathered from 432 Italian citizens through an online questionnaire. Results suggest that while emotional and community-related dimensions were effective in motivating individuals to protect their and others' health up to reducing their vaccine hesitancy, the perception of material hardships and re-accessing pre-pandemic public and social life were not. The theoretical and practical implications of these results are discussed, paying also attention to the contextual constraints stemming from the specific policies and approaches adopted in Italy to face COVID-19 outbreak. FAU - Gatti, Flora AU - Gatti F AUID- ORCID: 0000-0003-2149-6570 AD - University of Naples Federico II, Napoli, Italy. FAU - Procentese, Fortuna AU - Procentese F AD - University of Naples Federico II, Napoli, Italy. FAU - Compare, Christian AU - Compare C AD - University of Bologna, Cesena, Italy. FAU - Albanesi, Cinzia AU - Albanesi C AD - University of Bologna, Cesena, Italy. FAU - Rizzo, Marco AU - Rizzo M AD - eCampus University, Novedrate, Italy. FAU - Fedi, Angela AU - Fedi A AD - University of Torino, Italy. FAU - Gattino, Silvia AU - Gattino S AD - University of Torino, Italy. FAU - Aresi, Giovanni AU - Aresi G AD - Universita Cattolica del Sacro Cuore, Milano, Italy. AD - CERISVICO Research Centre on Community Development and Organisational Quality of Life, Brescia, Italy. FAU - Rochira, Alessia AU - Rochira A AUID- ORCID: 0000-0003-4240-5076 AD - University of Salento, Lecce, Italy. LA - eng PT - Journal Article DEP - 20260623 PL - England TA - J Health Psychol JT - Journal of health psychology JID - 9703616 SB - IM OTO - NOTNLM OT - COVID-19 OT - anxiety OT - green pass OT - pandemic OT - scarcity theory OT - sense of community OT - vaccine hesitancy OT - worry EDAT- 2026/06/23 12:34 MHDA- 2026/06/23 12:34 CRDT- 2026/06/23 08:03 PHST- 2026/06/23 12:34 [medline] PHST- 2026/06/23 12:34 [pubmed] PHST- 2026/06/23 08:03 [entrez] AID - 10.1177/13591053261460718 [doi] PST - aheadofprint SO - J Health Psychol. 2026 Jun 23:13591053261460718. doi: 10.1177/13591053261460718. PMID- 42272704 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260611 LR - 20260813 IS - 2055-2076 (Print) IS - 2055-2076 (Electronic) IS - 2055-2076 (Linking) VI - 12 DP - 2026 Jan-Dec TI - Specialist care at a distance: Patient-reported experience with telemedicine video consultations for neurological symptoms associated with post-COVID-19 condition or in temporal association with COVID-19 vaccination in a single-center retrospective cross-sectional study. PG - 20552076261451372 LID - 10.1177/20552076261451372 [doi] LID - 20552076261451372 AB - OBJECTIVES: To describe patient-reported experience with a structured telemedicine video consultation (TVC) pathway in routine neurological care among adults with persistent neurological symptoms with onset after SARS-CoV-2 infection or in temporal association with COVID-19 vaccination. METHODS: This single-center retrospective cross-sectional study examined TVC delivered in routine clinical care at the Department of Neurology, Charite-Universitatsmedizin Berlin (11/2022-12/2023). Patients with neurological symptoms persisting >/=3 months after SARS-CoV-2 infection or occurring in temporal association with COVID-19 vaccination were included. Data included demographics, symptom assessments, validated questionnaires on mood, fatigue, and subjective memory, audiovisual cognitive screening, and a post-consultation survey of patient-reported telemedicine experience. RESULTS: Forty-one patients (mean age 41.3+/-12.8 years; 61% female) were included. The median home-to-clinic distance was 356 km; and 39% reported mobility limitations affecting in-person attendance. Patients reported positive immediate experiences: most found scheduling easy, reported good audio/video quality, and considered the consultation relevant and time-saving. A minority reported technical difficulties or required assistance. Patients reported high fatigue levels (Fatigue Severity Scale 5.3+/-1.8), frequent subjective cognitive symptoms, moderate subjective memory satisfaction (Multifactorial Memory Questionnaire-Satisfaction Domain, 47.7+/-17.3), and mean Montreal Cognitive Assessment score of 27.3+/-2.3. DISCUSSION: These exploratory findings indicate positive patient-reported experience with a structured TVC pathway in routine neurological care. Fatigue and subjective cognitive difficulties were common across the selected cohort. This study describes a tele-neurology workflow integrating document pre-review, digital symptom assessment, remote history taking, and cognitive screening. Further controlled longitudinal studies are needed to determine the clinical role, safety, and equitable implementation of such approaches. CI - (c) The Author(s) 2026. FAU - Raeder, Vanessa AU - Raeder V AUID- ORCID: 0000-0002-5969-7581 AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Bremer, Benno AU - Bremer B AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Breuer, Ameli AU - Breuer A AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Audebert, Heinrich J AU - Audebert HJ AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AD - Charite - Universitatsmedizin Berlin, corporate member of Freie Universitat Berlin and Humboldt Universitat zu Berlin, Department of Neurology and Experimental Neurology, Hindenburgdamm, Berlin, Germany. LA - eng PT - Journal Article DEP - 20260608 PL - United States TA - Digit Health JT - Digital health JID - 101690863 PMC - PMC13247382 OTO - NOTNLM OT - cognitive dysfunction OT - fatigue OT - patient satisfaction OT - post-COVID-19 condition OT - telemedicine OT - vaccination OT - video conferencing COIS- The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2026/06/11 06:36 MHDA- 2026/06/11 06:37 PMCR- 2026/06/08 CRDT- 2026/06/11 04:46 PHST- 2025/11/05 00:00 [received] PHST- 2026/04/14 00:00 [revised] PHST- 2026/04/25 00:00 [accepted] PHST- 2026/06/11 06:37 [medline] PHST- 2026/06/11 06:36 [pubmed] PHST- 2026/06/11 04:46 [entrez] PHST- 2026/06/08 00:00 [pmc-release] AID - 10.1177_20552076261451372 [pii] AID - 10.1177/20552076261451372 [doi] PST - epublish SO - Digit Health. 2026 Jun 8;12:20552076261451372. doi: 10.1177/20552076261451372. eCollection 2026 Jan-Dec. PMID- 42236640 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260618 LR - 20260926 IS - 2193-8229 (Print) IS - 2193-6382 (Electronic) IS - 2193-6382 (Linking) VI - 15 IP - 7 DP - 2026 Jul TI - Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study. PG - 1955-1976 LID - 10.1007/s40121-026-01362-z [doi] AB - INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. METHODS: We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. RESULTS: Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45-0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41-0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77-0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68-0.96]) and post-acute symptoms (aHR = 0.77 [0.63-0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71-0.93]) and composite symptoms (aHR 0.87 [0.76-0.99]). CONCLUSION: SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently. CI - (c) 2026. The Author(s). FAU - Ngiam, Jinghao Nicholas AU - Ngiam JN AUID- ORCID: 0000-0002-3339-7281 AD - Division of Infectious Diseases, Department of Medicine, National University Health System Singapore, 1E Kent Ridge Rd, NUHS Tower Block, Level 10, Singapore, 119228, Singapore. nicholas_ngiam@nuhs.edu.sg. AD - Communicable Diseases Agency, Singapore, Singapore. nicholas_ngiam@nuhs.edu.sg. FAU - Loy, Enoch Xueheng AU - Loy EX AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Koh, Matthew Chung Yi AU - Koh MCY AD - Division of Infectious Diseases, Department of Medicine, National University Health System Singapore, 1E Kent Ridge Rd, NUHS Tower Block, Level 10, Singapore, 119228, Singapore. FAU - Chiew, Calvin J AU - Chiew CJ AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Li, Russell Jingxian AU - Li RJ AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Lim, Su Chi AU - Lim SC AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. AD - Clinical Research Unit, Khoo Teck Puat Hospital, Singapore, Singapore. AD - Diabetes Centre, Admiralty Medical Centre, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Tai, E Shyong AU - Tai ES AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Bee, Yong Mong AU - Bee YM AD - Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. AD - Department of Endocrinology, Singapore General Hospital, Singapore, Singapore. FAU - Chow, Wai Leng AU - Chow WL AD - Ministry of Health, Singapore, Singapore. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. FAU - Lye, David Chien Boon AU - Lye DCB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Chia, Yew Woon AU - Chia YW AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore. FAU - Chan, Mark Yan Yee AU - Chan MYY AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Department of Cardiology, National University Heart Centre, Singapore, Singapore. FAU - Hausenloy, Derek J AU - Hausenloy DJ AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. AD - National Heart Research Institute Singapore, National Heart Centre, Singapore, Singapore. AD - The Hatter Cardiovascular Institute, University College London, London, UK. FAU - Tan, Kelvin Bryan AU - Tan KB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. AD - Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Wee, Liang En AU - Wee LE AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Duke-NUS Medical School, National University of Singapore, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. AD - Communicable Diseases Agency, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20260603 PL - New Zealand TA - Infect Dis Ther JT - Infectious diseases and therapy JID - 101634499 PMC - PMC13280275 OTO - NOTNLM OT - COVID-19 OT - Long COVID OT - Metformin OT - SARS-CoV-2 OT - SGLT-2 inhibitors COIS- Declarations. Conflict of Interest: All authors [Jinghao Nicholas Ngiam, Enoch Xueheng Loy, Matthew Chung Yi Koh, Calvin J Chiew, Russell Jingxian Li, Su Chi Lim, E Shyong Tai, Yong Mong Bee, Wai Leng Chow, David Chien Boon Lye, Yew Woon Chia, Mark Yan Yee Chan, Derek J Hausenloy, Kelvin Bryan Tan, Liang En Wee] report no conflicts of interest. Ethical Approval: This study was conducted as part of national public health surveillance under the Singapore Infectious Diseases Act, and separate ethics approval by an Institutional Review Board (IRB) was not required. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. EDAT- 2026/06/04 00:39 MHDA- 2026/06/04 00:40 PMCR- 2026/06/03 CRDT- 2026/06/03 23:20 PHST- 2026/04/06 00:00 [received] PHST- 2026/05/04 00:00 [accepted] PHST- 2026/06/04 00:40 [medline] PHST- 2026/06/04 00:39 [pubmed] PHST- 2026/06/03 23:20 [entrez] PHST- 2026/06/03 00:00 [pmc-release] AID - 10.1007/s40121-026-01362-z [pii] AID - 1362 [pii] AID - 10.1007/s40121-026-01362-z [doi] PST - ppublish SO - Infect Dis Ther. 2026 Jul;15(7):1955-1976. doi: 10.1007/s40121-026-01362-z. Epub 2026 Jun 3. PMID- 42216347 OWN - NLM STAT- MEDLINE DCOM- 20260717 LR - 20260922 IS - 1536-5964 (Electronic) IS - 0025-7974 (Print) IS - 0025-7974 (Linking) VI - 105 IP - 22 DP - 2026 May 29 TI - Prevalence and long-term outcomes of brain fog and cognitive impairment in individuals with long COVID: A systematic review. PG - e49022 LID - 10.1097/MD.0000000000049022 [doi] LID - e49022 AB - BACKGROUND: Long COVID is increasingly recognized as a complex multisystem condition, with brain fog and cognitive impairment emerging as some of its manifestations. Despite growing literature, the pooled prevalence, subgroup differences, and underlying mechanisms remain incompletely understood. METHODS: We systematically reviewed 47 studies (2000-2025) encompassing over 25,000 patients to evaluate the prevalence of brain fog and cognitive impairment among long COVID populations. Data were extracted on study design, patient demographics, follow-up duration, and subgroup variables including gender, hospitalization, vaccination, and geographic region. Risk of bias was assessed using the Newcastle-Ottawa Scale (NOS v9.0) and JBI checklists. Quantitative synthesis was performed with subgroup and temporal analyses, presented in forest plots and summary figures. RESULTS: The pooled prevalence of brain fog was 30% (95% CI: 28-32), while cognitive impairment was 25% (95% CI: 23-27). Female patients consistently showed higher rates compared to males (34% vs 23% for brain fog; 29% vs 21% for cognitive impairment). Community-managed patients demonstrated higher prevalence compared to hospitalized cohorts, and unvaccinated individuals had a greater burden than vaccinated ones. Temporal analyses indicated that prevalence increased with longer follow-up, suggesting symptom persistence or late manifestation. Pathophysiological explanations include neuroinflammation, microvascular injury, immune dysregulation, and psychosocial stressors. CONCLUSION: Brain fog and cognitive impairment are common, persistent, and clinically significant features of long COVID. Gender differences, vaccination status, and follow-up duration influence prevalence. Future studies should focus on mechanisms, preventive strategies, and targeted interventions to mitigate long-term cognitive sequelae. CI - Copyright (c) 2026 the Author(s). Published by Wolters Kluwer Health, Inc. FAU - Faseeh, Ahmar AU - Faseeh A AD - Department of Dentistry, Islamic International Dental College, Islamabad, Pakistan. FAU - Rida, Maryam AU - Rida M AD - Department of Medicine, NUMS Hitec Institute of Medical Sciences, Taxila, Pakistan. FAU - Karim, Noor E AU - Karim NE AD - Department of Medicine, NUMS Hitec Institute of Medical Sciences, Taxila, Pakistan. FAU - Zafar, Ayesha AU - Zafar A AD - Department of Medicine, NUMS Hitec Institute of Medical Sciences, Taxila, Pakistan. FAU - Shah, Arif AU - Shah A AD - Department of Medicine, Saidu Group of Teaching Hospital, Swat, Pakistan. FAU - Perveen, Abida AU - Perveen A AUID- ORCID: 0009-0009-7548-8833 AD - Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan. LA - eng PT - Journal Article PT - Systematic Review PL - United States TA - Medicine (Baltimore) JT - Medicine JID - 2985248R SB - IM MH - Humans MH - *Cognitive Dysfunction/epidemiology/etiology MH - Prevalence MH - *COVID-19/complications/epidemiology MH - Post-Acute COVID-19 Syndrome MH - Female MH - Male MH - SARS-CoV-2 PMC - PMC13225561 OTO - NOTNLM OT - Long COVID OT - brain fog OT - cognitive impairment OT - neuroinflammation OT - post-acute sequelae COIS- The authors have no funding and conflicts of interest to disclose. EDAT- 2026/05/30 06:36 MHDA- 2026/05/30 06:37 PMCR- 2026/05/29 CRDT- 2026/05/30 01:01 PHST- 2025/12/23 00:00 [received] PHST- 2026/05/08 00:00 [accepted] PHST- 2026/05/30 06:37 [medline] PHST- 2026/05/30 06:36 [pubmed] PHST- 2026/05/30 01:01 [entrez] PHST- 2026/05/29 00:00 [pmc-release] AID - 00005792-202605290-00033 [pii] AID - MD-D-25-18536 [pii] AID - 10.1097/MD.0000000000049022 [doi] PST - ppublish SO - Medicine (Baltimore). 2026 May 29;105(22):e49022. doi: 10.1097/MD.0000000000049022. PMID- 41939860 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260813 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 17 DP - 2026 TI - Immune correlates underlying small fiber neuropathy presenting as vaccine-associated post-acute SARS- coronavirus syndrome. PG - 1752120 LID - 10.3389/fimmu.2026.1752120 [doi] LID - 1752120 AB - BACKGROUND: A spectrum of adverse events overlapping with Post-acute Sequelae of SARS-CoV-2 infection (PASC) occurs in some patients following SARS-CoV-2 vaccination including small fiber neuropathy (SFN) and cognitive symptoms. AIMS: Accruing information regarding disease course and immune response imbalances in these patients. METHODS: We studied 71 previously healthy patients with neurological symptoms following SARS-CoV-vaccination. All had negative neurological workup for central/peripheral involvement (MR, EMG/EN). Cutaneous biopsy (21pts.) and peripheral blood sampling (20pts) were performed for anti-idiotype Ab analysis (ACE-2,NRP-1) (ELISA, IF) and for Flowcytometric analysis. RESULTS: Paresthesia, cognitive impairment and autonomic symptoms agreed with SFN international definition. Comparative differences included abrupt onset, presence of simultaneous diverse paresthesia across multiple body regions frequently affecting the facial and cervical regions (44%) and the trunk (26%), associated to dysautonomia. Median time from vaccination to symptom manifestation was 3 days (mean +/- SD: 8.76 +/- 17.4 days). Symptom severity was still high (5.9 +/- 1.9 mean+SD) at the time of evaluation and sampling, (382 +/- 133 days from onset. Reduced small fiber density was observed in 19/21 biopsies. Anti-ACE-2 antibodies in 9/71pts. (12%) and 4/19 (21%) vaccinated HD sera and NRP-1 reactivity in 14/71 (20%) patient and 1/19 (5%) HD sera were not significantly increased. Peripheral NKG2D+CD8+ and NKG2D+DNAM-1+CD4+ T-cells were increased. Circulating inflammatory CD34+ cells were increased and generated in vitro a prevalence of NKG2D+DNAM-1+ T-cells. CONCLUSION: PASC-vac SFN is associated with persistent immune imbalances common to other immune-mediated diseases. Additional effort to identify immune mechanisms unleashing PASC-vac SFN will contribute to modulate future early interventions for these patients and refine vaccine design. CI - Copyright (c) 2026 Limongelli, Bozzano, Hajabbas Farshchi, Bellucci, Bavastro, Castellano, Pesce, Antonini, Incensi, Giannoccaro, Uccelli, Del Zotto, Moretta, Donadio, Benedetti and De Maria. FAU - Limongelli, Alessandro AU - Limongelli A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Bozzano, Federica AU - Bozzano F AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Hajabbas Farshchi, Alireza AU - Hajabbas Farshchi A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Bellucci, Margherita AU - Bellucci M AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - Bavastro, Martina AU - Bavastro M AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. FAU - Castellano, Chiara AU - Castellano C AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Pesce, Giampaola AU - Pesce G AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. FAU - Antonini, Francesca AU - Antonini F AD - Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Incensi, Alex AU - Incensi A AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Giannoccaro, Maria Pia AU - Giannoccaro MP AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Uccelli, Antonio AU - Uccelli A AD - Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy. AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - Del Zotto, Genny AU - Del Zotto G AD - Integrated Department of Services and Laboratories, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Moretta, Lorenzo AU - Moretta L AD - Tumor Immunology Unit, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy. FAU - Donadio, Vincenzo AU - Donadio V AD - IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, Bologna, Italy. FAU - Benedetti, Luana AU - Benedetti L AD - Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, Genoa, Italy. FAU - De Maria, Andrea AU - De Maria A AD - Universita degli Studi di Genova, Department of Health Sciences, Genoa, Italy. AD - S.C. Malattie Infettive, Azienda Sociosanitaria Ligure n.5, La Spezia, Italy. LA - eng PT - Journal Article DEP - 20260319 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - *Small Fiber Neuropathy/immunology/etiology/pathology MH - Male MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - Middle Aged MH - Post-Acute COVID-19 Syndrome MH - Adult MH - *COVID-19 Vaccines/adverse effects/immunology MH - Vaccination/adverse effects MH - Aged PMC - PMC13043346 OTO - NOTNLM OT - Long-COVID OT - NKG2D OT - PASC OT - SARS-CoV-2 OT - innate-like T cells OT - post-acute sequelae of SARS-CoV-2 infection OT - small fiber neuropathy OT - vaccine COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/04/06 12:36 MHDA- 2026/04/06 12:37 PMCR- 2026/03/19 CRDT- 2026/04/06 06:21 PHST- 2025/11/22 00:00 [received] PHST- 2026/01/25 00:00 [revised] PHST- 2026/02/03 00:00 [accepted] PHST- 2026/04/06 12:37 [medline] PHST- 2026/04/06 12:36 [pubmed] PHST- 2026/04/06 06:21 [entrez] PHST- 2026/03/19 00:00 [pmc-release] AID - 10.3389/fimmu.2026.1752120 [doi] PST - epublish SO - Front Immunol. 2026 Mar 19;17:1752120. doi: 10.3389/fimmu.2026.1752120. eCollection 2026. PMID- 41906364 OWN - NLM STAT- MEDLINE DCOM- 20260714 LR - 20260813 IS - 1529-8027 (Electronic) IS - 1085-9489 (Print) IS - 1085-9489 (Linking) VI - 31 IP - 2 DP - 2026 Jun TI - A Next-Generation ELISA for the Detection of Anti-(Para)Nodal Antibodies in Autoimmune Nodopathy and COVID-19 Vaccinated Individuals. PG - e70117 LID - 10.1111/jns.70117 [doi] LID - e70117 AB - BACKGROUND AND AIMS: Autoimmune nodopathy (AN) is a subtype of antibody-mediated inflammatory neuropathy targeting the node of Ranvier (NoR). Diagnosis requires detection of anti-(para)nodal autoantibodies like contactin-1 and neurofascin-155 via ELISA or cell-based assays, but protocols are inconsistent. Causes of node autoimmunity are unknown, and respiratory infections, including SARS-CoV-2 infection or COVID-19 vaccination as triggers, have not been thoroughly investigated. We aim to establish and validate a next-generation automated ELISA for anti-(para)nodal antibodies and investigate whether low-titer antibodies occur in recently COVID-19-vaccinated healthy individuals. METHODS: We used the Ella platform to customize an automated ELISA for anti-contactin-1, -neurofascin-155, and -Caspr-1 serum IgG. Patients with known AN (23 anti-neurofascin, 13 anti-contactin-1, and 8 anti-Caspr-1), 64 patients with seronegative (sub) acute inflammatory neuropathies, and 30 healthy controls served for validation, including quality analysis versus standard ELISA. Thirty-seven diagnostic samples of patients with suspected AN and 280 sera of healthcare workers included in the CoVacSer study, collected 3 weeks after COVID-19 vaccination or infection, were tested for anti-contactin-1 and anti-neurofascin-155. RESULTS: The automated ELISA showed high sensitivity (87.5%-100%) and specificity (98.4%-100%) for identifying AN, with reduced hands-on time, high automation, and similar quality and titer characteristics as standard ELISA. Low-titer anti-neurofascin-155, but no anti-contactin-1 autoantibodies, were detected in 1/280 post-SARS-CoV-2-vaccination or infection sera (0.36%). Longitudinal testing and clinical assessment did not indicate SARS-CoV-2-related neurological symptoms. INTERPRETATION: We provide a highly automated, rapid, universally applicable test platform for anti-(para)nodal antibodies. The low frequency of anti-(para)nodal antibodies and absence of clinical AN manifestations in COVID-19-vaccinated individuals support vaccination safety regarding AN development. CI - (c) 2026 The Author(s). Journal of the Peripheral Nervous System published by Wiley Periodicals LLC on behalf of Peripheral Nerve Society. FAU - Appeltshauser, Luise AU - Appeltshauser L AUID- ORCID: 0000-0001-5248-4009 AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Ruprecht, Chiara AU - Ruprecht C AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Reusch, Julia AU - Reusch J AD - Department of General, Visceral, Transplantation, Vascular and Pediatric Surgery, University Hospital Wurzburg, Wurzburg, Germany. FAU - Mees, Juliane AU - Mees J AUID- ORCID: 0009-0000-4383-3107 AD - Central Laboratory Unit, University Hospital Wurzburg, Wurzburg, Germany. FAU - Glenewinkel, Helena AU - Glenewinkel H AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Sommer, Claudia AU - Sommer C AD - Department of Anesthesiology, Intensive Care, Emergency Medicine and Pain Medicine, Centre for Interdisciplinary Pain Medicine, University Hospital Wurzburg, Wurzburg, Germany. FAU - Krone, Manuel AU - Krone M AD - Central Laboratory Unit, University Hospital Wurzburg, Wurzburg, Germany. FAU - Wagenhauser, Isabell AU - Wagenhauser I AD - Department of Pediatrics, University Hospital Wurzburg, Wurzburg, Germany. FAU - Doppler, Kathrin AU - Doppler K AD - Department of Neurology, University Hospital Wurzburg, Wurzburg, Germany. FAU - Petri, Nils AU - Petri N AD - Department of Internal Medicine I, University Hospital Wurzburg, Wurzburg, Germany. LA - eng GR - AP1/1/Deutsche Gesellschaft fur Muskelkranke/ GR - 01KX2021/German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)/ GR - 01KX2121/German Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, BMBF)/ GR - Julius-Maximilians-Universitat Wurzburg/ PT - Journal Article PL - United States TA - J Peripher Nerv Syst JT - Journal of the peripheral nervous system : JPNS JID - 9704532 RN - 0 (Autoantibodies) RN - 0 (COVID-19 Vaccines) RN - 0 (Contactin 1) RN - 0 (Nerve Growth Factors) RN - 0 (Cell Adhesion Molecules) RN - 0 (NFASC protein, human) SB - IM MH - Humans MH - Enzyme-Linked Immunosorbent Assay/methods MH - Female MH - *Autoantibodies/blood MH - Adult MH - Middle Aged MH - *COVID-19/prevention & control/immunology MH - *COVID-19 Vaccines MH - Male MH - Contactin 1/immunology MH - Nerve Growth Factors/immunology MH - Aged MH - Cell Adhesion Molecules/immunology MH - SARS-CoV-2 PMC - PMC13033911 OTO - NOTNLM OT - COVID-19 OT - ELISA OT - SARS-CoV-2 OT - autoimmune nodopathy OT - contactin-1 OT - neurofascin EDAT- 2026/03/30 06:29 MHDA- 2026/03/30 06:30 PMCR- 2026/03/30 CRDT- 2026/03/30 01:23 PHST- 2026/01/30 00:00 [revised] PHST- 2025/09/10 00:00 [received] PHST- 2026/02/24 00:00 [accepted] PHST- 2026/03/30 06:30 [medline] PHST- 2026/03/30 06:29 [pubmed] PHST- 2026/03/30 01:23 [entrez] PHST- 2026/03/30 00:00 [pmc-release] AID - JNS70117 [pii] AID - 10.1111/jns.70117 [doi] PST - ppublish SO - J Peripher Nerv Syst. 2026 Jun;31(2):e70117. doi: 10.1111/jns.70117. PMID- 41832317 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20260813 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 16 IP - 1 DP - 2026 Mar 14 TI - Characterizing persistent Post-COVID-19 vaccination symptoms using MedDRA system organ class and preferred term classifications. LID - 10.1038/s41598-026-43949-z [doi] LID - 12366 AB - Post-COVID-19 Vaccination Syndrome (PCVS) refers to persistent, multisystemic symptoms developing after SARS-CoV-2 immunization. We established a nationwide registry across 14 Japanese outpatient clinics and analyzed 179 "clinically definitive" cases from 279 enrollees (December 2020-August 2023). All adverse events (AEs) were coded using MedDRA/J Preferred Terms and System Organ Classes; severity followed NCI-CTCAE V5.0. The cohort (66.5% female; mean age 59 years) experienced 493 AEs (median 2 per patient, range 1-29). Three System Organ Classes-General Disorders (29.2%), Nervous System Disorders (22.3%), and Musculoskeletal Disorders (10.1%)-accounted for 61.7% of events; fatigue, brain fog, dizziness, and extremity pain predominated. While 69.4% of AEs arose within 90 days post-vaccination, 12.4% appeared >/= 360 days later. Severe AEs (>/= Grade 3) occurred in 14.6% of patients; overall improvement was 65.1%, leaving 29.4% unresolved. A provisional phenotype classification combining symptom patterns, onset timing, and severity identified high-risk subgroups with > 60% non-recovery rates. These findings underscore the need for enhanced post-vaccination surveillance systems and comprehensive care frameworks specifically tailored to address the protean manifestations and persistent nature of PCVS. FAU - Fujisawa, Akinori AU - Fujisawa A AD - Kokoro Medical Corporation, Honbetsu Cardiovascular Medicine Clinic, Hokkaido, Japan. FAU - Kodama, Shinichiro AU - Kodama S AD - Kodama Hospital & Kodama Medical Office, Hyogo, Japan. FAU - Konishi, Nafuko AU - Konishi N AD - Viola Clinic, Osaka, Japan. FAU - Ueda, Jun AU - Ueda J AD - Department of Advanced Medical Science, Asahikawa Medical University, Hokkaido, Japan. FAU - Kitagawa, Akiko AU - Kitagawa A AD - Kitaris Co., Ltd, Aichi, Japan. FAU - Okada, Eri AU - Okada E AD - Kitaris Co., Ltd, Aichi, Japan. FAU - Miyokawa, Mariko AU - Miyokawa M AD - Kitaris Co., Ltd, Aichi, Japan. FAU - Hirai, Yuriko AU - Hirai Y AD - MCL Corporation, Kyoto, Japan. FAU - Nakatani, Eiji AU - Nakatani E AD - Department of Biostatistics and Health Data Science, Graduate School of Medical Science, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan. nakatani.eiji.int@gmail.com. FAU - Fukushima, Masanori AU - Fukushima M AD - Learning Health Society Institute, Nagoya, Japan. LA - eng PT - Journal Article DEP - 20260314 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Middle Aged MH - Male MH - *COVID-19 Vaccines/adverse effects MH - *Vaccination/adverse effects MH - Aged MH - *COVID-19/prevention & control MH - Japan/epidemiology MH - Adult MH - Adverse Drug Reaction Reporting Systems MH - SARS-CoV-2/immunology MH - Post-Acute COVID-19 Syndrome MH - Registries PMC - PMC13079843 OTO - NOTNLM OT - Adverse drug reaction reporting systems OT - COVID-19 Vaccines/adverse effects OT - Chronic OT - Fatigue syndrome OT - Nervous system diseases/etiology OT - Pharmacovigilance OT - Post-Acute COVID-19 Syndrome COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2026/03/15 06:49 MHDA- 2026/06/27 12:36 PMCR- 2026/03/14 CRDT- 2026/03/15 00:17 PHST- 2025/08/11 00:00 [received] PHST- 2026/03/09 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/15 06:49 [pubmed] PHST- 2026/03/15 00:17 [entrez] PHST- 2026/03/14 00:00 [pmc-release] AID - 10.1038/s41598-026-43949-z [pii] AID - 43949 [pii] AID - 10.1038/s41598-026-43949-z [doi] PST - epublish SO - Sci Rep. 2026 Mar 14;16(1):12366. doi: 10.1038/s41598-026-43949-z. PMID- 41824149 OWN - NLM STAT- MEDLINE DCOM- 20260627 LR - 20261009 IS - 1534-6293 (Electronic) IS - 1528-4042 (Linking) VI - 26 IP - 1 DP - 2026 Mar 13 TI - Cognition and Long COVID: a Review. LID - 15 [pii] LID - 10.1007/s11910-026-01485-3 [doi] AB - PURPOSE OF REVIEW: Provide an overview of current knowledge regarding cognitive issues in patients with long COVID, also termed brain fog or cognitive COVID. RECENT FINDINGS: Subjective cognitive symptoms in long COVID patients are common but often go undetected by traditional standardised cognitive test batteries. This discrepancy poses a major clinical and societal problem, given the prevalence, protracted course and impact of cognitive COVID on work functioning. New, online assessment methods for cognitive function are feasible and corroborate subjective self-report symptoms, finding executive function impairments in cognitive COVID. As vaccination protects against brain fog and not against anxiety and depression in long COVID, brain fog can be seen as a core symptom of long COVID, concerning executive functioning, and a direct effect of neurotropic viral brain infiltration. Depression and anxiety are comorbid conditions due to indirect factors associated with the pandemic, such as increased social isolation and loss of work. Ongoing vaccination programs should not only target the elderly, but also working-age people. Online cognitive assessment batteries are recommended for assessment and treatment monitoring in long COVID. Integrated care is recommended given the high rate of multimorbidity. Future research might explore the effects of antiviral medication, modulation of the immune response, and GLP-1 agonists in long COVID. FAU - van der Feltz-Cornelis, Christina M AU - van der Feltz-Cornelis CM AUID- ORCID: 0000-0001-6925-8956 AD - Department of Health Sciences, University of York, ARRC Building, MHARG, Heslington York, York, YO10 5DD, UK. christina.vanderfeltz-cornelis@york.ac.uk. LA - eng PT - Journal Article PT - Review DEP - 20260313 PL - United States TA - Curr Neurol Neurosci Rep JT - Current neurology and neuroscience reports JID - 100931790 SB - IM MH - Humans MH - *COVID-19/complications/psychology MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - Pandemics MH - *Cognition Disorders/etiology MH - *Cognition/physiology MH - *Cognitive Dysfunction/etiology MH - Neuropsychological Tests OTO - NOTNLM OT - Brain fog OT - Cognitive function OT - Diagnostic assessment OT - Integrated care OT - Long COVID OT - Review OT - Vaccination COIS- Declarations. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors. Competing interests: The authors declare no competing interests. EDAT- 2026/03/13 19:31 MHDA- 2026/06/27 12:36 CRDT- 2026/03/13 12:18 PHST- 2026/02/12 00:00 [received] PHST- 2026/02/16 00:00 [accepted] PHST- 2026/06/27 12:36 [medline] PHST- 2026/03/13 19:31 [pubmed] PHST- 2026/03/13 12:18 [entrez] AID - 10.1007/s11910-026-01485-3 [pii] AID - 10.1007/s11910-026-01485-3 [doi] PST - epublish SO - Curr Neurol Neurosci Rep. 2026 Mar 13;26(1):15. doi: 10.1007/s11910-026-01485-3. PMID- 41762950 OWN - NLM STAT- MEDLINE DCOM- 20260709 LR - 20260804 IS - 2211-0356 (Electronic) IS - 2211-0348 (Linking) VI - 109 DP - 2026 May TI - Machine learning model predicts prognosis in SARS-CoV-2-infected autoimmune encephalitis patients. PG - 107028 LID - S2211-0348(26)00064-7 [pii] LID - 10.1016/j.msard.2026.107028 [doi] AB - OBJECTIVE: To assess the neurological prognosis of patients with autoimmune encephalitis (AE) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and construct risk prediction models for a worse prognosis. METHODS: This was a prospective, multicenter, observational cohort study. Patients with AE, with or without SARS-CoV-2, were followed up every 3 months. Multivariate logistic regression was used to identify factors influencing neurological prognosis. Prediction models were created using nine machine-learning strategies. RESULTS: SARS-CoV-2 infection was noted in 241 of 308 patients. Multivariate logistic regression showed inactivated immunizations plus recombinant or adenovirus vector vaccines protected against SARS-CoV-2 infection (odds ratio [OR] 0.05, 95% confidence interval [CI] 0.01-0.52, p = 0.01). Three months after infection, 12.4% of patients with stable AE had a worse neurological prognosis, 6.2% failed to recover their working conditions. Pre-infection modified Rankin Scale (mRS) = 1 (OR 4.06, 95% CI 1.11-14.91, p = 0.04) and mRS > 1 (OR 13.4, 95% CI 3.31-54.02, p < 0.01), immunotherapy during infection (OR 5.1, 95% CI 1.65-15.79, p = 0.01), and SARS-CoV-2-related drowsiness (OR 19.5, 95% CI 5.42-70.34, p < 0.01) and gastrointestinal symptoms (OR 4.4, 95% CI 1.58-11.96, p < 0.01) were identified as risk factors for worse prognosis. The ranger model(https://xingjieli1999.shinyapps.io/clinical_prediction_app/) using these four parameters showed a discrimination accuracy of 0.96 (95% CI 0.94-0.99). CONCLUSIONS: Patients with AE could experience exacerbated neurological symptoms following SARS-CoV-2 infection. Machine-learning algorithms showed feasibility of predicting prognoses based on clinical information in patients with AE. CI - Copyright (c) 2026 Elsevier B.V. All rights reserved. FAU - Li, Xingjie AU - Li X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Kong, Xueying AU - Kong X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Li, Aiqing AU - Li A AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Gong, Xue AU - Gong X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Guo, Kundian AU - Guo K AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Xu AU - Liu X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Liu, Yue AU - Liu Y AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Zhang, Tianyu AU - Zhang T AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Deng, Xiaolin AU - Deng X AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China. FAU - Li, Jinmei AU - Li J AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. FAU - Zhou, Dong AU - Zhou D AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. FAU - Hong, Zhen AU - Hong Z AD - Department of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Institute of Brain science and Brain-inspired technology of West China Hospital, of Sichuan University, Chengdu, Sichuan, China; Department of Neurology, Chengdu Shangjin Nanfu Hospital, Chengdu, Sichuan 611730, China. Electronic address: hongzhengoog@aliyun.com. LA - eng PT - Journal Article PT - Multicenter Study PT - Observational Study DEP - 20260206 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - Hashimoto's encephalitis SB - IM MH - Humans MH - Female MH - Prognosis MH - Predictive Learning Models MH - *COVID-19/complications/diagnosis MH - *Hashimoto Disease/diagnosis/complications MH - Male MH - *Machine Learning MH - Adult MH - Middle Aged MH - Prospective Studies MH - *Encephalitis/diagnosis MH - SARS-CoV-2 OTO - NOTNLM OT - Autoimmune encephalitis OT - Machine learning prediction model OT - Prognosis OT - SARS-CoV-2 infection and vaccination COIS- Declaration of competing interest None of the authors have any conflicts of interest to disclose. Funding sources were not involved in the study design, data collection, analysis, interpretation, writing of the report, or decision to submit the article for publication. EDAT- 2026/03/01 00:35 MHDA- 2026/04/11 00:32 CRDT- 2026/02/28 18:07 PHST- 2024/08/15 00:00 [received] PHST- 2025/06/06 00:00 [revised] PHST- 2026/01/24 00:00 [accepted] PHST- 2026/04/11 00:32 [medline] PHST- 2026/03/01 00:35 [pubmed] PHST- 2026/02/28 18:07 [entrez] AID - S2211-0348(26)00064-7 [pii] AID - 10.1016/j.msard.2026.107028 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2026 May;109:107028. doi: 10.1016/j.msard.2026.107028. Epub 2026 Feb 6. PMID- 41737426 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260225 LR - 20260813 IS - 2398-8835 (Electronic) IS - 2398-8835 (Linking) VI - 9 IP - 2 DP - 2026 Feb TI - The Impact of COVID-19 on Obstructive Pulmonary Diseases: A Narrative Review of Long-Term Consequences and Vaccination Strategies. PG - e71882 LID - 10.1002/hsr2.71882 [doi] LID - e71882 AB - BACKGROUND AND AIMS: The COVID-19 pandemic has posed significant challenges for individuals with obstructive pulmonary diseases (OPDs), such as asthma and chronic obstructive pulmonary disease (COPD). Emerging evidence highlights the complex interplay between SARS-CoV-2 infection and OPDs, including increased risks of severe disease, long-term sequelae, and potential new-onset respiratory conditions. This narrative review synthesizes current knowledge on the pathophysiological mechanisms, clinical outcomes, and management strategies for COVID-19 in OPD patients, with a focus on long-term consequences and vaccination efficacy. METHODS: A comprehensive literature search was conducted using PubMed, Embase, and Scopus (January 2020-June 2025). Inclusion criteria encompassed original studies, reviews, and meta-analyses examining COVID-19's impact on asthma or COPD, while non-English publications, animal studies, and case reports were excluded. Data were extracted and thematically synthesized to address acute outcomes, long COVID, vaccination, and therapeutic considerations. RESULTS: Risk and Severity: COPD patients faced higher risks of severe COVID-19 (hospitalization, ICU admission, and mortality), while asthma phenotypes influenced outcomes (eosinophilic asthma conferred milder disease).Long COVID: Persistent respiratory symptoms (dyspnea and cough), fatigue, and cognitive dysfunction were prevalent in OPD patients, with new-onset asthma reported post-infection.Vaccination: mRNA vaccines significantly reduced severe outcomes in OPDs, though biologic therapies in asthma may attenuate immune responses.Treatment: Antivirals (e.g., nirmatrelvir-ritonavir) and corticosteroids were effective, but drug interactions (e.g., CYP3A4 inhibitors) required careful management. CONCLUSION: COVID-19 exacerbates OPD-related morbidity, underscoring the need for tailored prevention (vaccination and early diagnosis) and multidisciplinary management. Future research should prioritize phenotype-specific therapeutic strategies and long-term surveillance to mitigate post-COVID sequelae in this vulnerable population. CI - (c) 2026 The Author(s). Health Science Reports published by Wiley Periodicals LLC. FAU - Dalfardi, Behnam AU - Dalfardi B AD - Clinical Research Development Unit, Afzalipour Hospital Kerman University of Medical Sciences Kerman Iran. FAU - Abtahi, Hamidreza AU - Abtahi H AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Edalatifard, Maryam AU - Edalatifard M AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Mozaffari, Sedigheh AU - Mozaffari S AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Rahimi, Besharat AU - Rahimi B AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. FAU - Roostaei, Ghazal AU - Roostaei G AD - Rasool Akram Hospital Clinical Research Development Center, School of Medicine, Rasool Akram Medical Complex Iran University of Medical Sciences Tehran Iran. FAU - Khoshnam Rad, Niloofar AU - Khoshnam Rad N AUID- ORCID: 0000-0001-6700-3570 AD - Thoracic Research Center, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran. LA - eng PT - Journal Article DEP - 20260220 PL - United States TA - Health Sci Rep JT - Health science reports JID - 101728855 PMC - PMC12927929 OTO - NOTNLM OT - COPD OT - COVID-19 OT - asthma OT - long COVID OT - obstructive pulmonary diseases OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2026/02/25 10:21 MHDA- 2026/02/25 10:22 PMCR- 2026/02/20 CRDT- 2026/02/25 04:50 PHST- 2025/03/30 00:00 [received] PHST- 2025/08/04 00:00 [revised] PHST- 2026/02/12 00:00 [accepted] PHST- 2026/02/25 10:22 [medline] PHST- 2026/02/25 10:21 [pubmed] PHST- 2026/02/25 04:50 [entrez] PHST- 2026/02/20 00:00 [pmc-release] AID - HSR271882 [pii] AID - 10.1002/hsr2.71882 [doi] PST - epublish SO - Health Sci Rep. 2026 Feb 20;9(2):e71882. doi: 10.1002/hsr2.71882. eCollection 2026 Feb. PMID- 41709791 OWN - NLM STAT- MEDLINE DCOM- 20260708 LR - 20260813 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 22 IP - 1 DP - 2026 Dec TI - Understanding the practices and perceptions of Chinese older adults towards vaccination in the context of COVID-19: A qualitative study in Anhui Province. PG - 2622184 LID - 10.1080/21645515.2026.2622184 [doi] LID - 2622184 AB - This study examines vaccination perceptions and practices among rural older adults in China during the COVID-19 pandemic to inform strategies for promoting vaccination among older adults. Qualitative research was employed, involving 13 rural older adults aged 60 and above in Anhui Province. Two rounds of in-depth interviews were conducted in May 2022 (during the severe pandemic period) and May 2024 (post-pandemic era), with data analyzed using grounded theory. Rural older adults exhibited dual perceptions of COVID-19 characterized by "seriousness" and "relative reassurance," maintaining trust, understanding, and acknowledgment of government prevention policies. They generally recognized the necessity of COVID-19 vaccination as a key means to alleviate infection fears and reduce risk exposure. However, they exhibited self-marginalization, believing vaccine resources should be prioritized for younger individuals and those deemed more deserving. And, collectivist values motivated active compliance with epidemic control policies but also led to attention bias, causing them to overlook routine vaccines such as influenza and pneumonia vaccines that received less government promotion. As the pandemic progressed, individual awareness gradually awakened. Professional authority and family opinions emerged as new drivers for vaccination, though health belief biases also surfaced, with some seniors refusing shots citing "good physical constitution." The government should intensify vaccination outreach, optimize community services, guide seniors toward accurate self-perception, and leverage the roles of family members and medical professionals in vaccination efforts. These measures will enhance vaccination rates among rural seniors and safeguard the health of the population. FAU - He, Aiping AU - He A AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Zixin AU - Wang Z AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Yang, Yang AU - Yang Y AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Zhang, Xinyi AU - Zhang X AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Yao, Lili AU - Yao L AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Li AU - Wang L AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. FAU - Chen, Ren AU - Chen R AD - Department of Health Services Management, School of Health Services Management, Anhui Medical University, Hefei, China. FAU - Wang, Peizhong Peter AU - Wang PP AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. AD - Division of Population Health and Applied Health Sciences, Faculty of Medicine, Memorial University, St. John's, NL, Canada. AD - Centre for New Immigrant Well-Being (CNIW), Toronto, ON, Canada. FAU - Wei, Xiaolin AU - Wei X AD - Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada. LA - eng PT - Journal Article DEP - 20260219 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) RN - Chinese people SB - IM MH - Humans MH - Aged MH - China/epidemiology MH - *COVID-19/prevention & control/psychology/epidemiology MH - Male MH - Female MH - *Vaccination/psychology MH - *COVID-19 Vaccines/administration & dosage MH - Qualitative Research MH - *Health Knowledge, Attitudes, Practice MH - Middle Aged MH - Rural Population MH - Aged, 80 and over MH - SARS-CoV-2/immunology MH - East Asian People PMC - PMC12928655 OTO - NOTNLM OT - COVID-19 OT - cognition OT - older adults OT - qualitative research OT - rural OT - vaccination COIS- No potential conflict of interest was reported by the author(s). EDAT- 2026/02/19 07:03 MHDA- 2026/02/19 07:04 PMCR- 2026/02/19 CRDT- 2026/02/19 03:53 PHST- 2026/02/19 07:04 [medline] PHST- 2026/02/19 07:03 [pubmed] PHST- 2026/02/19 03:53 [entrez] PHST- 2026/02/19 00:00 [pmc-release] AID - 2622184 [pii] AID - 10.1080/21645515.2026.2622184 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2026 Dec;22(1):2622184. doi: 10.1080/21645515.2026.2622184. Epub 2026 Feb 19. PMID- 41695180 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260216 LR - 20260218 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 13 DP - 2026 TI - Long-term health effects of COVID-19 among patients in Croatian primary care settings. PG - 1740432 LID - 10.3389/fmed.2026.1740432 [doi] LID - 1740432 AB - INTRODUCTION: The COVID-19 pandemic has left lasting effects that extend beyond the acute phase of infection, with increasing evidence of long-term health consequences. This study aimed to assess the prevalence of post-COVID symptoms and conditions and to identify associated risk factors, including pre-existing chronic diseases, COVID-19 vaccination status, and severity of acute infection. METHODS: This retrospective cross-sectional study was conducted in 10 family medicine practices in Croatia. The data collected from medical records included demographics, COVID-19 vaccination status, SARS-CoV-2 infection history and severity, and documented health conditions before and after infection. Descriptive statistics were used to summarize the data. Group differences were analyzed using the independent samples t-test or chi(2) test. Variables significant in univariate analyses (p < 0.05) were included into multivariate regression models. Multiple linear regression was used to identify predictors of COVID-19 severity, and binary logistic regression was applied to determine factors associated with post-COVID conditions. Results are presented as regression coefficients (beta) or odds ratios (OR) with 95% confidence intervals (CI). A p-value < 0.05 was considered statistically significant. RESULTS: The study included 1,423 participants (58.0% female; mean age 52.6 +/- 17.2 years), of whom 82.4% had confirmed SARS-CoV-2 infection and 32.3% were unvaccinated. At least one chronic disease was present in 28.1% of participants. The most frequently reported post-COVID conditions were brain fog (4.9%), neurological disorders (4.7%), cardiovascular diseases (2.9%), shortness of breath (2.8%), obesity (2.7%) and mental health disorders (2.6%). Greater COVID-19 severity was independently associated with pulmonary disease (beta = 0.22; p = 0.031) and older age, particularly 51-65 years (beta = 0.31; p < 0.001) and >/=66 years (beta = 0.50; p < 0.001). COVID-19 vaccination was associated with milder disease (beta = -0.21; p < 0.001). Previous cardiovascular and musculoskeletal diseases significantly increased the risk of thromboembolism. Diabetes, obesity, and number of vaccine doses were predictors of brain fog, while neurological comorbidities predicted post-COVID mental health disorders. CONCLUSION: Post-COVID symptoms and conditions represent an important long-term public health challenge. Family medicine physicians play a key role in early recognition, monitoring, and management of post-COVID sequelae, contributing to improved long-term patient outcomes. CI - Copyright (c) 2026 Popovic, Lesac Brizic, Ljubotina, Zavidic, Tudor Spalj, Markovic Stimac, Fisic Jurkovic, Basic Markovic, Diminic Lisica, Vucak and Radosevic Quadranti. FAU - Popovic, Branislava AU - Popovic B AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Family Medicine Practice Branislava Popovic, Rijeka, Croatia. FAU - Lesac Brizic, Ana AU - Lesac Brizic A AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Community Health Centre Primorsko Goranska County, Rijeka, Croatia. FAU - Ljubotina, Aleksandar AU - Ljubotina A AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Family Medicine Practice Aleksandar Ljubotina, Rijeka, Croatia. FAU - Zavidic, Tina AU - Zavidic T AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Istrian Health Centres, Pazin, Croatia. FAU - Tudor Spalj, Vedrana AU - Tudor Spalj V AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Community Health Centre Primorsko Goranska County, Rijeka, Croatia. FAU - Markovic Stimac, Roberta AU - Markovic Stimac R AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Primary Health Care Institution Srdoci, Rijeka, Croatia. FAU - Fisic Jurkovic, Martina AU - Fisic Jurkovic M AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Community Health Centre Primorsko Goranska County, Rijeka, Croatia. FAU - Basic Markovic, Nina AU - Basic Markovic N AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Primary Health Care Institution Srdoci, Rijeka, Croatia. FAU - Diminic Lisica, Ines AU - Diminic Lisica I AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Health Institution dr. Ines Diminic Lisica, Rijeka, Croatia. FAU - Vucak, Jasna AU - Vucak J AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Family Medicine Practice Jasna Vucak, Sukosan, Croatia. FAU - Radosevic Quadranti, Nives AU - Radosevic Quadranti N AD - Department of Family Medicine, Faculty of Medicine, University of Rijeka, Rijeka, Croatia. AD - Community Health Centre Primorsko Goranska County, Rijeka, Croatia. LA - eng PT - Journal Article DEP - 20260129 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC12893981 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - chronic diseases OT - long COVID OT - post-COVID syndrome OT - primary care COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/16 12:32 MHDA- 2026/02/16 12:33 PMCR- 2026/01/29 CRDT- 2026/02/16 06:47 PHST- 2025/11/06 00:00 [received] PHST- 2026/01/09 00:00 [revised] PHST- 2026/01/14 00:00 [accepted] PHST- 2026/02/16 12:33 [medline] PHST- 2026/02/16 12:32 [pubmed] PHST- 2026/02/16 06:47 [entrez] PHST- 2026/01/29 00:00 [pmc-release] AID - 10.3389/fmed.2026.1740432 [doi] PST - epublish SO - Front Med (Lausanne). 2026 Jan 29;13:1740432. doi: 10.3389/fmed.2026.1740432. eCollection 2026. PMID- 41685877 OWN - NLM STAT- MEDLINE DCOM- 20260707 LR - 20260813 IS - 1600-0412 (Electronic) IS - 0001-6349 (Print) IS - 0001-6349 (Linking) VI - 105 IP - 4 DP - 2026 Apr TI - Long COVID following SARS-CoV-2 infection during pregnancy: An observational study in a large Italian hospital during the COVID-19 pandemic. PG - 604-612 LID - 10.1111/aogs.70127 [doi] AB - INTRODUCTION: Despite mounting evidence on Long COVID, data regarding its impact on women infected during pregnancy remains scarce. This study aimed to assess the development of Long COVID in women who had been infected with SARS-CoV-2 during pregnancy, focusing on possible risk factors and potential protective elements associated with its development. MATERIAL AND METHODS: We analyzed a cohort of 348 pregnant women with laboratory-confirmed SARS-CoV-2 infection admitted to ASST-Spedali Civili (Brescia, Italy) between March 2020 and May 2022. Data collection included demographics, comorbidities, COVID-19 severity markers, and vaccination status. To assess the possible association between the analyzed risk factors and Long Covid, beyond standard multivariable models, we employed inverse probability weighting techniques (IPTW) and calculated e-values to assess unmeasured confounding. RESULTS: Among study participants, 27.0% (94/348) developed Long COVID. Risk factors included preexisting respiratory comorbidities (adjusted OR = 3.171, 95% CI 0.99-10.1), pneumonia at admission (adjusted OR = 4.48, 95% CI 2.16-9.28), and earlier pregnancy stage at infection (adjusted OR = 0.96 per week, 95% CI 0.93-0.99). COVID-19 vaccination was associated with a significantly lower risk of Long COVID (15.5% in vaccinated vs. 31.8% in unvaccinated women; IPTW-adjusted OR = 0.38, 95% CI: 0.20-0.71, p-value: 0.003). The most common symptoms were fatigue (46.8%) and memory impairment (38.3%), with unvaccinated patients exhibiting a higher prevalence of neuropsychiatric symptoms. CONCLUSIONS: Our data suggest that one in four pregnant women hospitalized with COVID-19 develop persistent symptoms. The most frequently affected women had preexisting respiratory disease, pneumonia at admission, and infection earlier in pregnancy. COVID-19 vaccination appears to reduce risk and alter symptom presentation. These findings underscore the importance of vaccination throughout pregnancy and highlight the need for targeted surveillance in high-risk subgroups. CI - (c) 2026 The Author(s). Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG). FAU - Fichera, Anna AU - Fichera A AUID- ORCID: 0000-0002-7368-0823 AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. AD - Obstetrics and Gynecology Unit, ASST-Spedali Civili, Brescia, Italy. FAU - Biancareddu, Eleonora AU - Biancareddu E AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Bozzo, Marco AU - Bozzo M AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Ezenwa, Mirabella AU - Ezenwa M AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Ongarini, Emma Paola AU - Ongarini EP AUID- ORCID: 0009-0004-7089-4035 AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. FAU - Ferrari, Federico Giorgio AU - Ferrari FG AUID- ORCID: 0000-0001-7065-2432 AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. AD - Obstetrics and Gynecology Unit, ASST-Spedali Civili, Brescia, Italy. FAU - Prefumo, Federico AU - Prefumo F AUID- ORCID: 0000-0001-7793-714X AD - Obstetrics and Gynecology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy. FAU - Odicino, Franco Edoardo AU - Odicino FE AUID- ORCID: 0000-0001-8870-4739 AD - Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. AD - Obstetrics and Gynecology Unit, ASST-Spedali Civili, Brescia, Italy. LA - eng PT - Journal Article PT - Observational Study DEP - 20260213 PL - United States TA - Acta Obstet Gynecol Scand JT - Acta obstetricia et gynecologica Scandinavica JID - 0370343 SB - IM MH - Humans MH - Female MH - Pregnancy MH - *COVID-19/epidemiology/complications MH - Italy/epidemiology MH - Adult MH - *Pregnancy Complications, Infectious/epidemiology MH - Post-Acute COVID-19 Syndrome MH - Risk Factors MH - SARS-CoV-2 MH - Comorbidity PMC - PMC13140548 OTO - NOTNLM OT - PASC OT - SARS-CoV-2 infection OT - long COVID OT - pandemic OT - pregnancy COIS- The authors declare no conflicts of interest. EDAT- 2026/02/13 12:48 MHDA- 2026/03/30 12:49 PMCR- 2026/02/13 CRDT- 2026/02/13 08:52 PHST- 2025/11/23 00:00 [revised] PHST- 2025/07/20 00:00 [received] PHST- 2025/12/08 00:00 [accepted] PHST- 2026/03/30 12:49 [medline] PHST- 2026/02/13 12:48 [pubmed] PHST- 2026/02/13 08:52 [entrez] PHST- 2026/02/13 00:00 [pmc-release] AID - AOGS70127 [pii] AID - 10.1111/aogs.70127 [doi] PST - ppublish SO - Acta Obstet Gynecol Scand. 2026 Apr;105(4):604-612. doi: 10.1111/aogs.70127. Epub 2026 Feb 13. PMID- 41635700 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260204 LR - 20260206 IS - 1662-4548 (Print) IS - 1662-453X (Electronic) IS - 1662-453X (Linking) VI - 19 DP - 2025 TI - Neural mechanisms of cognitive conflict: processing COVID-19 vaccine misinformation. PG - 1661523 LID - 10.3389/fnins.2025.1661523 [doi] LID - 1661523 AB - INTRODUCTION: The rapid spread of misinformation during the COVID-19 pandemic has raised important questions about how individuals evaluate false information, particularly when it conflicts with strongly held prior attitudes. Understanding the neural mechanisms underlying the processing of vaccine-related misinformation may clarify why such beliefs persist despite corrective information. METHODS: Using functional magnetic resonance imaging (fMRI), we examined neural responses to COVID-19 vaccine misinformation and factual information in vaccine-receptive participants (N = 29). During scanning, participants were presented with a series of vaccine-related statements-both accurate and false-and indicated their level of agreement. Analyses focused on the influence of prior beliefs and attitude congruence on neural activation. RESULTS: Contrary to our hypotheses, exposure to attitude-incongruent misinformation did not elicit significant activation in emotional processing regions such as the amygdala or precuneus. However, when participants made attitude-incongruent responses-endorsing misinformation or rejecting accurate information-we observed increased activation in the left dorsolateral prefrontal cortex (DLPFC), dorsomedial prefrontal cortex (DMPFC), intraparietal sulcus (IPS), and middle frontal gyrus (MFG), regions associated with decision-making, moral reasoning, memory integration, and cognitive control. DISCUSSION: These findings suggest that conflicts between incoming information and prior attitudes engage effortful, higher-order cognitive systems rather than affective processing. Resolving such conflicts appears to rely on decision-making and control mechanisms that manage uncertainty and cognitive dissonance. Due to recruitment limitations, the present study focused exclusively on vaccine-receptive individuals. Future research should investigate whether vaccine-resistant individuals exhibit similar or distinct neural patterns, which may provide further insight into the persistence of misinformation in the context of negative prior attitudes. CI - Copyright (c) 2026 McClellan, Kirwan and Ashby. FAU - McClellan, Morgan Chase AU - McClellan MC AD - Center for Neuroscience, Brigham Young University, Provo, UT, United States. FAU - Kirwan, C Brock AU - Kirwan CB AD - MindCORE, University of Pennsylvania, Philadelphia, PA, United States. FAU - Ashby, Stefania R AU - Ashby SR AD - Center for Neuroscience, Brigham Young University, Provo, UT, United States. AD - Department of Psychology, Brigham Young University, Provo, UT, United States. LA - eng PT - Journal Article DEP - 20260119 PL - Switzerland TA - Front Neurosci JT - Frontiers in neuroscience JID - 101478481 PMC - PMC12862833 OTO - NOTNLM OT - decision-making OT - functional MRI (fMRI) OT - misinformation OT - prior attitudes OT - semantic memory OT - vaccine hesitancy COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/02/04 11:32 MHDA- 2026/02/04 11:33 PMCR- 2026/01/19 CRDT- 2026/02/04 04:09 PHST- 2025/07/07 00:00 [received] PHST- 2025/12/18 00:00 [revised] PHST- 2025/12/22 00:00 [accepted] PHST- 2026/02/04 11:33 [medline] PHST- 2026/02/04 11:32 [pubmed] PHST- 2026/02/04 04:09 [entrez] PHST- 2026/01/19 00:00 [pmc-release] AID - 10.3389/fnins.2025.1661523 [doi] PST - epublish SO - Front Neurosci. 2026 Jan 19;19:1661523. doi: 10.3389/fnins.2025.1661523. eCollection 2025. PMID- 41630534 OWN - NLM STAT- Publisher LR - 20260203 IS - 1744-4144 (Electronic) IS - 1385-4046 (Linking) DP - 2026 Feb 2 TI - Impact of serologically confirmed SARS-CoV-2 infection on cognitive test performance in a vaccinated HIV+ adult cohort relative to pre-pandemic levels. PG - 1-17 LID - 10.1080/13854046.2026.2623824 [doi] AB - Objectives: Cognitive abnormalities have been documented following COVID-19 infection. Using pre-pandemic levels of cognitive functioning, we examined the impact of detectable serologic response to COVID-19 infection on cognitive domain performance in a cohort of people with HIV (PWH). We also evaluated the additional impact of potential risk factors for cognitive deficits in the context of SARS-CoV-2 serostatus, including psychiatric variables, number of medical comorbidities, and HIV biomarkers. Methods: 118 ethnically and racially diverse PWH (mean age 63.6; 50% women) completed comprehensive, in-person neuropsychological and medical assessments before the pandemic (March 2018 to March 2020) and at follow-up (August 2020 to June 2024). All but 4 study participants had been vaccinated against SARS-CoV-2 prior to follow-up assessment. 54 participants had anti-SARS-CoV-2 nucleoprotein antibodies. Mixed design repeated-measures ANOVAs were used to compare longitudinal performance among serological groups (anti-N positive, anti-N negative) on global cognitive function and 7 cognitive domains. Subsequently, multivariate regression models were used to examine the role of risk factors on cognitive functioning stratified by SARS-CoV-2 serostatus. Results: Positive anti-N serostatus did not influence cognitive test performance, self-perceived stress and depressive mood when compared to pre-pandemic levels. When stratified by serostatus, only greater number of medical comorbidities predicted worse motor domain functioning in the anti-N negative group. Conclusion: Serological response to COVID-19 infection had no deleterious cognitive or psychological impact relative to pre-pandemic levels. Number of medical comorbidities and HIV biomarkers may play a more central role on cognitive outcomes. FAU - Gonzalez, Jairo AU - Gonzalez J AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Byrd, Desiree AU - Byrd D AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. AD - Department of Psychology, Queens College and the Graduate Center, City University of New York, New York, NY, USA. FAU - Lissinna, Hanna AU - Lissinna H AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Kumkowski, Nicolette AU - Kumkowski N AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. FAU - Lopez, Johnny A AU - Lopez JA AD - Department of Psychology, Queens College and the Graduate Center, City University of New York, New York, NY, USA. FAU - Morgello, Susan AU - Morgello S AD - Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. AD - Departments of Neuroscience and Pathology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. LA - eng PT - Journal Article DEP - 20260202 PL - England TA - Clin Neuropsychol JT - The Clinical neuropsychologist JID - 8806548 SB - IM OTO - NOTNLM OT - HIV OT - SARS-CoV-2 infection OT - neuropsychological assessment EDAT- 2026/02/03 07:41 MHDA- 2026/02/03 07:41 CRDT- 2026/02/03 02:34 PHST- 2026/02/03 07:41 [medline] PHST- 2026/02/03 07:41 [pubmed] PHST- 2026/02/03 02:34 [entrez] AID - 10.1080/13854046.2026.2623824 [doi] PST - aheadofprint SO - Clin Neuropsychol. 2026 Feb 2:1-17. doi: 10.1080/13854046.2026.2623824. PMID- 41595843 OWN - NLM STAT- MEDLINE DCOM- 20260701 LR - 20260827 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 23 IP - 1 DP - 2025 Dec 30 TI - Long-Term Health Effects of COVID-19 in Tunisia, 2020-2021. LID - 10.3390/ijerph23010049 [doi] LID - 49 AB - Background: Some patients suffer from persistent symptoms following a COVID-19 infection, referred to as long COVID. The aims of the study were to estimate the prevalence of long COVID and study its determinants in Tunisia. Methods: We conducted a nationwide cross-sectional study among a representative sample of COVID-19 survivors residing in Tunisia between June and August 2022. We selected a random sample, stratified by age and region, among residents registered in the national surveillance database with a SARS-CoV-2 positive test taken from September 2020 to September 2021 (n = 479,743). The expected sample size was 384. We defined a patient with long COVID as having at least one self-reported symptom persisting for more than four weeks after the first confirmation of SARS-CoV-2 infection (RT-PCR or Ag-RDT) and not explained by an alternative diagnosis. Trained healthcare workers interviewed consenting respondents by phone using a structured questionnaire. We described continuous variables using median and interquartile range (IQR). We measured the prevalence of long COVID and its 95% confidence interval (95% CI). We estimated the association between explanatory variables (socio-demographic, lifestyle and comorbidities, SARS-CoV-2 history infection, COVID-19 vaccination status) and long COVID using a log-binomial model, reporting adjusted prevalence ratios (a-PR) and its 95% CI. Results: Of 1094 persons contacted, 416 were enrolled (response rate: 38%). Long-COVID prevalence was 64% (267/416); 95% CI [59-69%]. The sex ratio (M:F) was 0.72. Age ranged from 1 to 101 years, with a median of 41 years (IQR:31-55 years). The most common symptoms were fatigue (63%), myalgia/arthralgia (33%), and cognitive symptoms (52%). Median duration of long-COVID symptoms was 11 months (IQR: 3-14 months). In multivariate analysis, experiencing acute COVID-19 (a-PR = 1.5; 95% CI [1.0-2.1]), being a woman of childbearing age (a-PR = 1.2; 95% CI [1.0-1.4]) and residing in the central region (a-PR = 1.5; 95% CI [1.1-2.0]) were significantly associated with a higher prevalence of long COVID. Conclusions: Long COVID is prevalent in Tunisia affecting patients with multiple symptoms initially, those residing in the central region and young women. We recommend to enhance healthcare access and medical follow-up both during and after the infection, focusing on identified risk groups. We also recommend to conduct further research to optimize management of long-COVID patients. FAU - Dhaouadi, Sonia AU - Dhaouadi S AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. AD - Mediterranean and Black Sea Programme in Intervention Epidemiology Training (MediPIET), European Centre for Disease Prevention and Control (ECDC), Solna, 16973 Stockholm, Sweden. FAU - Bouguerra, Hind AU - Bouguerra H AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. FAU - Hechaichi, Aicha AU - Hechaichi A AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. FAU - Letaief, Hejer AU - Letaief H AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. FAU - Safer, Mouna AU - Safer M AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. FAU - Aichouch, Chaima AU - Aichouch C AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - Zouayti, Amenallah AU - Zouayti A AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - Bougatef, Myriam AU - Bougatef M AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - Neffati, Arwa AU - Neffati A AUID- ORCID: 0000-0003-0067-274X AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - El Mili, Nawel AU - El Mili N AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - Mhadhbi, Rim AU - Mhadhbi R AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. FAU - Bouafif Ep Ben Alaya, Nissaf AU - Bouafif Ep Ben Alaya N AUID- ORCID: 0000-0002-3326-9861 AD - National Observatory of New and Emerging Diseases, Tunis 1002, Tunisia. AD - LR01ES04 Epidemiologie et Prevention des Maladies Cardiovasculaires en Tunisie, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis 1007, Tunisia. LA - eng PT - Journal Article DEP - 20251230 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 SB - IM MH - Humans MH - Tunisia/epidemiology MH - Female MH - *COVID-19/epidemiology/complications MH - Male MH - Cross-Sectional Studies MH - Post-Acute COVID-19 Syndrome MH - Middle Aged MH - Adult MH - Prevalence MH - Aged MH - SARS-CoV-2 MH - Young Adult MH - Adolescent PMC - PMC12840641 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - Tunisia OT - determinants OT - epidemiology OT - long COVID OT - prevalence COIS- The authors declare no conflicts of interest. EDAT- 2026/01/28 07:47 MHDA- 2026/01/28 19:21 PMCR- 2025/12/30 CRDT- 2026/01/28 01:08 PHST- 2025/10/16 00:00 [received] PHST- 2025/12/18 00:00 [revised] PHST- 2025/12/24 00:00 [accepted] PHST- 2026/01/28 19:21 [medline] PHST- 2026/01/28 07:47 [pubmed] PHST- 2026/01/28 01:08 [entrez] PHST- 2025/12/30 00:00 [pmc-release] AID - ijerph23010049 [pii] AID - ijerph-23-00049 [pii] AID - 10.3390/ijerph23010049 [doi] PST - epublish SO - Int J Environ Res Public Health. 2025 Dec 30;23(1):49. doi: 10.3390/ijerph23010049. PMID- 41487610 OWN - NLM STAT- MEDLINE DCOM- 20260105 LR - 20260107 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - Integrating sociocultural theories to inform public health response: unique relationships between moral foundations, cultural cognition worldviews, and COVID-19 attitudes and behaviors. PG - 1606229 LID - 10.3389/fpubh.2025.1606229 [doi] LID - 1606229 AB - Key variables from Moral Foundations Theory and the Cultural Theory of Risk were examined in relationship to COVID-19 attitudes and behaviors. Two surveys were conducted with unvaccinated U. S. adults (n = 1,025) that assessed five moral foundations (care, fairness, authority, loyalty, and purity), two dimensions of Cultural Cognition Worldviews (individualism-communitarianism and hierarchy-egalitarianism), COVID-19 vaccination likelihood and related attitudes (including measures of perceived risk, protective behavior, and trust), political orientation, and demographic characteristics. The individualism-communitarianism scale, derived from the Cultural Theory of Risk, was the most impactful predictor across surveys. When controlling for responses to all other measures, participants who placed greater emphasis on individualism tended to report a lower likelihood of getting a COVID-19 vaccination, to perceive a lower level of risk from COVID-19, and to express greater distrust in the safety of vaccines developed by the government. Many other moral and cultural worldview dimensions were uniquely predictive of COVID-19 attitudes as well, while political orientation and demographic characteristics were generally weak or non-significant in multiple regression models. Findings underscore the sociocultural foundations of health behavior. CI - Copyright (c) 2025 Wolsko and Marino. FAU - Wolsko, Christopher AU - Wolsko C AD - Laboratory for the American Conversation, Oregon State University - Cascades, Bend, OR, United States. FAU - Marino, Elizabeth AU - Marino E AD - Laboratory for the American Conversation, Oregon State University - Cascades, Bend, OR, United States. LA - eng PT - Journal Article DEP - 20251219 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Humans MH - *COVID-19/prevention & control/psychology MH - Female MH - Male MH - *Morals MH - Adult MH - Middle Aged MH - *Public Health MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - United States MH - *Health Knowledge, Attitudes, Practice MH - Young Adult MH - Adolescent MH - Aged MH - Health Behavior PMC - PMC12757365 OTO - NOTNLM OT - COVID-19 OT - Moral Foundations Theory OT - cultural worldview OT - individualism OT - vaccine attitudes COIS- The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2026/01/05 06:47 MHDA- 2026/01/05 06:48 PMCR- 2025/12/19 CRDT- 2026/01/05 05:22 PHST- 2025/04/07 00:00 [received] PHST- 2025/10/24 00:00 [revised] PHST- 2025/11/25 00:00 [accepted] PHST- 2026/01/05 06:48 [medline] PHST- 2026/01/05 06:47 [pubmed] PHST- 2026/01/05 05:22 [entrez] PHST- 2025/12/19 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1606229 [doi] PST - epublish SO - Front Public Health. 2025 Dec 19;13:1606229. doi: 10.3389/fpubh.2025.1606229. eCollection 2025. PMID- 41481757 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20260102 LR - 20260106 IS - 2767-3375 (Electronic) IS - 2767-3375 (Linking) VI - 6 IP - 1 DP - 2026 TI - Beyond emotions: Social cognitive predictors of COVID-19 vaccination intentions before and after vaccine roll-out. PG - e0005668 LID - 10.1371/journal.pgph.0005668 [doi] LID - e0005668 AB - Understanding the drivers of COVID-19 vaccination intentions remains relevant as public health systems prepare for future pandemics. This study examined how emotional and social-cognitive factors influence COVID-19 vaccination intentions during two key phases of the COVID-19 pandemic: before (April-June 2020) and after (January-February 2021) vaccination rollout. A total of 586 adults completed an online survey assessing beliefs about COVID-19, self-efficacy to adhere to protective behaviours, perceived stress, affect, psychological flexibility, and prosociality. Self-efficacy, prosociality, psychological flexibility and positive affect significantly declined after vaccination rollout. Higher self-efficacy and perceived severity of the disease consistently predicted stronger vaccination intentions across time points. Perceived susceptibility was negatively associated with vaccination intention before, but not after rollout. The psychological variables were not significant predictors of intentions. These findings underscore the importance of social-cognitive factors, especially self-efficacy and perceived severity, in shaping vaccination-related decisions, with implications for designing effective communication strategies in future health emergencies. CI - Copyright: (c) 2026 Manoli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Manoli, Athina AU - Manoli A AUID- ORCID: 0000-0001-8500-7006 AD - Department of Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. AD - Centre for Psychiatry & Mental Health, Wolfson Institute of Population Health, Barts & The London School of Medicine & Dentistry, Queen Mary, University of London, United Kingdom. FAU - Kyprianidou, Maria AU - Kyprianidou M AD - Department of Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. AD - Department of Psychology, University of Cyprus, Nicosia, Cyprus. AD - Department of Social and Political Sciences, University of Cyprus, Nicosia, Cyprus. FAU - Lamnisos, Demetris AU - Lamnisos D AD - Department of Health Sciences, School of Sciences, European University Cyprus, Nicosia, Cyprus. FAU - Lubenko, Jelena AU - Lubenko J AD - Psychological Laboratory, Faculty of Public Health and Social Welfare, Riga Stradins University, Riga, Latvia. FAU - Presti, Giovambattista AU - Presti G AD - Kore University Behavioral Lab (KUBeLab), Department of Human and Social Sciences, University of Enna "Kore", Enna, Italy. FAU - Squatrito, Valeria AU - Squatrito V AD - Kore University Behavioral Lab (KUBeLab), Department of Human and Social Sciences, University of Enna "Kore", Enna, Italy. FAU - Constantinou, Marios AU - Constantinou M AUID- ORCID: 0000-0002-6646-5877 AD - Department of Social Sciences, School of Humanities and Social Sciences, University of Nicosia, Nicosia, Cyprus. FAU - Nicolaou, Christiana AU - Nicolaou C AD - Department of Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. FAU - Papacostas, Savvas AU - Papacostas S AUID- ORCID: 0000-0003-3845-7439 AD - Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus. FAU - Aydin, Gokcen AU - Aydin G AD - Department of Guidance and Psychological Counseling, TED University, Ankara, Turkiye. FAU - Chong, Yuen Yu AU - Chong YY AD - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Chien, Wai Tong AU - Chien WT AUID- ORCID: 0000-0001-5321-5791 AD - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Cheng, Ho Yu AU - Cheng HY AD - The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Ruiz, Francisco AU - Ruiz F AUID- ORCID: 0000-0001-8863-1111 AD - Department of Psychology, Fundacion Universitaria Konrad Lorenz, Bogota, Colombia. FAU - Garcia-Martin, Maria Belen AU - Garcia-Martin MB AD - Department of Psychology and Education, Universidad de Loyola, Sevilla, Spain. FAU - Obando-Posada, Diana P AU - Obando-Posada DP AD - Department of Psychology, University of La Sabana, Chia, Colombia. FAU - Segura-Vargas, Miguel AU - Segura-Vargas M AD - Department of Psychology, Fundacion Universitaria Konrad Lorenz, Bogota, Colombia. FAU - Vasiliou, Vasilis S AU - Vasiliou VS AUID- ORCID: 0000-0003-3501-4093 AD - Department of Psychology, Royal Holloway, University of London, United Kingdom. FAU - McHugh, Louise AU - McHugh L AD - School of Psychology, University College Dublin, Dublin, Ireland. FAU - Hofer, Stefan AU - Hofer S AD - Department of Psychiatry II, Medical University Innsbruck, Innsbruck, Austria. FAU - Baban, Adriana AU - Baban A AD - Department of Psychology, Babes-Bolyai University, Cluj-Napoca, Romania. FAU - Neto, David Dias AU - Neto DD AUID- ORCID: 0000-0002-3129-262X AD - APPsyCI-Applied Psychology Research Center Capabilities & Inclusion, ISPA-Instituto Universitario, Lisbon, Portugal. FAU - Da Silva, Ana Nunes AU - Da Silva AN AUID- ORCID: 0000-0001-7125-716X AD - CICPSI, Faculdade de Psicologia, Universidade de Lisboa, Lisbon, Portugal. FAU - Monestes, Jean-Louis AU - Monestes JL AD - LIP/PC2S, Universite Grenoble Alpes, Grenoble, France. FAU - Alvarez-Galvez, Javier AU - Alvarez-Galvez J AUID- ORCID: 0000-0001-9512-7853 AD - CS2 DataLab, University Research Institute for Sustainable Social Development, University of Cadiz, Jerez, Spain. AD - Department of General Economy (Sociology area), Faculty of Health Sciences, University of Cadiz, Cadiz, Spain. FAU - Paez-Blarrina, Marisa AU - Paez-Blarrina M AD - Instituto ACT, Madrid, Spain. FAU - Montesinos, Francisco AU - Montesinos F AUID- ORCID: 0000-0002-7472-7734 AD - Department of Psychology, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain. FAU - Valdivia-Salas, Sonsoles AU - Valdivia-Salas S AD - Department of Psychology and Sociology, Universidad de Zaragoza, Zaragoza, Spain. FAU - Ori, Dorottya AU - Ori D AUID- ORCID: 0000-0003-0878-165X AD - Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary. AD - Department of Mental Health, Heim Pal National Pediatric Institute, Budapest, Hungary. FAU - Kleszcz, Bartosz AU - Kleszcz B AD - Behawioralnie, Poland. FAU - Lappalainen, Raimo AU - Lappalainen R AD - Department of Psychology, University of Jyvaskyla, Jyvaskyla, Finland. FAU - Ivanovic, Iva AU - Ivanovic I AUID- ORCID: 0000-0001-6939-7489 AD - Department of Child Psychiatry, Institute for Children's Diseases, Clinical Centre of Montenegro, Podgorica, Montenegro. AD - Centre for early development, Clinical Centre of Montenegro, Podgorica, Montenegro. FAU - Gosar, David AU - Gosar D AUID- ORCID: 0000-0002-5289-3459 AD - Department of Child, Adolescent and Developmental Neurology, Children's University Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia. AD - Department of Psychology, Univerisity of Ljubljana, Ljubljana, Slovenia. FAU - Dionne, Frederick AU - Dionne F AD - Departement de Psychologie, Universite du Quebec a Trois-Rivieres, Trois-Rivieres, Canada. FAU - Merwin, Rhonda AU - Merwin R AUID- ORCID: 0000-0002-3729-0297 AD - Department of Psychiatry and Behavioral Science, Duke University, Durham, United States of America. FAU - Karekla, Maria AU - Karekla M AUID- ORCID: 0000-0001-7021-7908 AD - Department of Psychology, University of Cyprus, Nicosia, Cyprus. FAU - Gloster, Andrew AU - Gloster A AD - Division of Clinical Psychology, Faculty of Behavioural Sciences and Psychology, University of Lucerne, Lucerne, Switzerland. FAU - Kassianos, Angelos AU - Kassianos A AUID- ORCID: 0000-0001-6428-2623 AD - Department of Nursing, Faculty of Health Sciences, Cyprus University of Technology, Limassol, Cyprus. LA - eng PT - Journal Article DEP - 20260102 PL - United States TA - PLOS Glob Public Health JT - PLOS global public health JID - 9918283779606676 PMC - PMC12758815 COIS- The authors have declared that no competing interests exist. EDAT- 2026/01/02 19:38 MHDA- 2026/01/02 19:39 PMCR- 2026/01/02 CRDT- 2026/01/02 14:04 PHST- 2025/09/19 00:00 [received] PHST- 2025/12/01 00:00 [accepted] PHST- 2026/01/02 19:39 [medline] PHST- 2026/01/02 19:38 [pubmed] PHST- 2026/01/02 14:04 [entrez] PHST- 2026/01/02 00:00 [pmc-release] AID - PGPH-D-25-02717 [pii] AID - 10.1371/journal.pgph.0005668 [doi] PST - epublish SO - PLOS Glob Public Health. 2026 Jan 2;6(1):e0005668. doi: 10.1371/journal.pgph.0005668. eCollection 2026. PMID- 41466718 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260101 IS - 2042-0986 (Print) IS - 2042-0994 (Electronic) IS - 2042-0986 (Linking) VI - 16 DP - 2025 TI - Complex chronic adverse events following immunization: a systemic critique and reform proposal for vaccine pharmacovigilance. PG - 20420986251395925 LID - 10.1177/20420986251395925 [doi] LID - 20420986251395925 AB - The COVID-19 pandemic has renewed attention to complex chronic health conditions that challenge conventional biomedical paradigms. Syndromes such as postural orthostatic tachycardia syndrome and myalgic encephalomyelitis/chronic fatigue syndrome have gained broader visibility through the lens of Long COVID. As global vaccination campaigns expanded, a subset of individuals began reporting similarly persistent, multisystem symptoms following COVID-19 immunization-informally referred to as post-COVID-19 vaccination syndrome. These presentations, which include dysautonomia, neuropathic pain, post-exertional malaise, and cognitive dysfunction, resemble post-infectious syndromes and may involve shared immune-related mechanisms. Although no causal relationship to vaccination has been established, these cases-together with comparable reports following other vaccines-highlight limitations in current vaccine safety systems for detecting and evaluating complex chronic outcomes. This article introduces the concept of complex chronic adverse events following immunization (CC-AEFIs) as a pragmatic, surveillance-oriented framework to support the systematic identification and investigation of such cases. CC-AEFIs are not syndromic diagnoses but a higher-order category encompassing persistent, multifactorial conditions that may follow immunization yet challenge existing pharmacovigilance definitions and tools. These conditions often involve multiple organ systems, delayed onset, fluctuating trajectories, diagnostic ambiguity, and symptom heterogeneity. Drawing on the author's lived experience as an affected patient and integrating clinical, regulatory, and experiential evidence, the analysis examines structural and epistemic limitations across the pharmacovigilance continuum-from underrecognition in clinical settings to analytic exclusion and constrained governance. It concludes by proposing reforms to strengthen safety-system responsiveness, including enhanced diagnostic training, longitudinal surveillance, patient-reported outcome integration, and analytic transparency. Addressing these limitations is essential to sustain public trust, ensure equitable care, and uphold the scientific integrity of immunization programs. CI - (c) The Author(s), 2025. FAU - Kenny, Tiff-Annie AU - Kenny TA AUID- ORCID: 0000-0001-9688-6149 AD - Faculte de medecine, Universite de Montreal, Montreal, QC, Canada. AD - CRCHU de Quebec Universite Laval, Quebec, QC, Canada. LA - eng PT - Journal Article DEP - 20251224 PL - England TA - Ther Adv Drug Saf JT - Therapeutic advances in drug safety JID - 101549074 PMC - PMC12743803 OAB - Improving vaccine safety systems to better detect and respond to chronic health problems after vaccination - Though vaccines are exceptionally safe and critical for public health, a small number of individuals develop long-lasting and complex health problems after vaccination that are difficult to diagnose and poorly understood. - These problems often involve symptoms such as fatigue, nerve pain, dizziness, heart rhythm issues, or brain fog. They may begin days or weeks after vaccination, affect multiple body systems, and change over time. Because they don't fit standard medical categories, many people are dismissed or misdiagnosed. - Similar symptoms have also been observed after infections like COVID-19 (known as Long COVID), suggesting that shared immune-related processes may be involved. While a direct causal link to vaccination is not always clear, emerging evidence shows the importance of systematically studying these cases. - Current vaccine safety systems work well to detect short-term or clearly defined side effects like fever or allergic reactions. However, they often miss longer-term, more complex, or delayed conditions that do not follow expected patterns. - This paper introduces a new framework-Complex Chronic Adverse Events Following Immunization (CC-AEFIs)-to help describe, investigate, and monitor these cases more effectively. - It also identifies challenges across the vaccine safety system-from diagnosis to reporting, data analysis, and governance: - Recognition: These conditions are often dismissed due to lack of clear tests (biomarkers) and a tendency to label symptoms as psychological. - Reporting: There are widespread underreporting issues, especially for complex or delayed symptoms. - Analysis: Current systems lack the long-term tracking and comparison data needed to detect rare or complex patterns. - Governance: Oversight processes are often opaque, influenced by vaccine manufacturers, and rarely include affected individuals. - The paper proposes concrete reforms to make vaccine safety systems more transparent, inclusive, and responsive. OABL- eng OTO - NOTNLM OT - adverse events following immunization (AEFI) OT - long COVID OT - myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) OT - patient-reported outcomes OT - pharmacovigilance OT - post-vaccination syndrome OT - postural orthostatic tachycardia syndrome (POTS) OT - vaccine safety COIS- The author is an affected patient and has lived experience of a serious adverse event following immunization. This dual role-as both researcher and patient-informs the perspective and analysis offered in this article. The author declares no financial or other non-financial conflicts of interest. EDAT- 2025/12/30 07:40 MHDA- 2025/12/30 07:41 PMCR- 2025/12/24 CRDT- 2025/12/30 04:14 PHST- 2025/04/17 00:00 [received] PHST- 2025/10/27 00:00 [accepted] PHST- 2025/12/30 07:41 [medline] PHST- 2025/12/30 07:40 [pubmed] PHST- 2025/12/30 04:14 [entrez] PHST- 2025/12/24 00:00 [pmc-release] AID - 10.1177_20420986251395925 [pii] AID - 10.1177/20420986251395925 [doi] PST - epublish SO - Ther Adv Drug Saf. 2025 Dec 24;16:20420986251395925. doi: 10.1177/20420986251395925. eCollection 2025. PMID- 41432873 OWN - NLM STAT- MEDLINE DCOM- 20251223 LR - 20261009 IS - 1573-2649 (Electronic) IS - 0962-9343 (Linking) VI - 35 IP - 1 DP - 2025 Dec 23 TI - How do fatigue, cognitive dysfunction, activity and role functioning, and mental health inter-relate in adults with post-COVID-19 syndrome? A structural equation model analysis. PG - 3 LID - 10.1007/s11136-025-04122-7 [doi] AB - PURPOSE: Post-COVID-19 Syndrome (PCS) is associated with persistent fatigue and cognitive symptoms that may disrupt daily functioning and mental health. This study examined interrelationships among fatigue, cognitive function, activity and role functioning, and mental health in individuals with PCS. METHODS: We analyzed cross-sectional data from 535 adults in the Quebec Action for Post-COVID (QAPC) cohort who self-identified as experiencing PCS symptoms. Structural Equation Modelling was used to estimate associations among fatigue, self-reported cognitive concerns, cognitive performance, and two latent constructs: activity and role functioning and mental health. Models were adjusted for age, sex, education, race, alcohol use, prior mental health history, and vaccination status. RESULTS: Fatigue showed association with mental health (standardized regression coefficient, beta_std = 0.44, p < 0.001), primarily through a direct path (beta_std = 0.42) and a smaller indirect path via self-reported cognitive concerns (beta_std = 0.10). Fatigue was also associated with reduced activity and role functioning (beta_std = - 0.79), which did not mediate its link to mental health. Self-reported cognitive concerns were independently associated with poorer mental health (beta_std = 0.19). Cognitive performance was positively associated with activity and role functioning (beta_std = 0.11) but not with mental health. Covariates, including older age, Caucasian ethnicity, and vaccination, were linked to more favourable outcomes. CONCLUSION: Fatigue and self-reported cognitive concerns were associated with mental health symptoms in PCS. These findings highlight the value of symptom cluster-based screening to inform referral pathways for cognitive, psychological, and functional support. Longitudinal research is needed to clarify temporal ordering. CI - (c) 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG. FAU - Michael, Henry Ukachukwu AU - Michael HU AUID- ORCID: 0000-0002-1944-0650 AD - Division of Clinical and Translational Research, McGill University, Montreal, QC, Canada. henry.michael@mail.mcgill.ca. AD - Center for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre (RI-MUHC), 5252 de Maisonneuve, 2B:43, Montreal, QC, H4A 3S5, Canada. henry.michael@mail.mcgill.ca. FAU - Aste, Fernando Gonzales AU - Aste FG AD - Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada. FAU - Brouillette, Marie-Josee AU - Brouillette MJ AD - Center for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre (RI-MUHC), 5252 de Maisonneuve, 2B:43, Montreal, QC, H4A 3S5, Canada. AD - Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada. AD - Chronic Viral Illness Service, McGill University Health Centre (MUHC), Montreal, QC, Canada. FAU - Fellows, Lesley K AU - Fellows LK AD - Department of Neurology & Neurosurgery, Montreal Neurological Institute, McGill University, Montreal, QC, Canada. FAU - Mayo, Nancy E AU - Mayo NE AD - Division of Clinical and Translational Research, McGill University, Montreal, QC, Canada. AD - Center for Outcomes Research and Evaluation (CORE), Research Institute of McGill University Health Centre (RI-MUHC), 5252 de Maisonneuve, 2B:43, Montreal, QC, H4A 3S5, Canada. AD - Division of Geriatrics, Division of Clinical Epidemiology, Department of Medicine, McGill University, Montreal, Canada. AD - School of Physical and Occupational Therapy, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. LA - eng PT - Journal Article DEP - 20251223 PL - Netherlands TA - Qual Life Res JT - Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation JID - 9210257 SB - IM MH - Humans MH - Male MH - Female MH - *COVID-19/psychology/complications MH - *Fatigue/psychology/etiology MH - Cross-Sectional Studies MH - Middle Aged MH - Adult MH - *Cognitive Dysfunction/psychology/etiology MH - *Mental Health MH - Quebec/epidemiology MH - SARS-CoV-2 MH - Latent Class Analysis MH - Aged MH - *Activities of Daily Living/psychology MH - Post-Acute COVID-19 Syndrome OAB - Some people continue to experience symptoms like extreme tiredness, memory problems, and emotional distress long after having COVID-19. This ongoing condition is often referred to as post-COVID syndrome (PCS). Our study aimed to understand how these symptoms are related and whether staying involved in everyday activities like work or household tasks can help protect mental health. We surveyed people living with PCS to explore the links between fatigue, thinking difficulties, and emotional well-being. We also looked at whether being active in daily roles helped reduce emotional distress. The results showed that people who felt more tired or had more difficulty thinking clearly also reported worse mental health. However, being engaged in regular activities did not appear to reduce this emotional impact. We found that how people rated their thinking abilities mattered more for mental health than how they scored on formal thinking tests. This suggests that feeling unable to think clearly can be very upsetting, even if test results do not show problems. Our findings highlight the importance of supporting people's concerns about fatigue and cognitive symptoms and suggest that the way we measure activity and role functioning in daily life may need to be broadened to fully understand its role in recovery. OABL- eng OTO - NOTNLM OT - Cognition OT - Fatigue OT - Long Covid OT - Mental health OT - Role functioning OT - Structural equation modelling COIS- Declarations. Conflict of interest: The authors have no conflicts of interest to declare. Ethical approval: This study was performed in line with the principles of the Declaration of Helsinki. Ethical approval for the QAPC study was obtained from the McGill University Health Centre Research Ethics Board (Project ID: 2022-8066). Consent to participate: Informed consent was obtained from all individual participants included in the study. EDAT- 2025/12/23 12:48 MHDA- 2025/12/23 12:49 CRDT- 2025/12/23 11:20 PHST- 2025/06/18 00:00 [received] PHST- 2025/10/29 00:00 [accepted] PHST- 2025/12/23 12:49 [medline] PHST- 2025/12/23 12:48 [pubmed] PHST- 2025/12/23 11:20 [entrez] AID - 10.1007/s11136-025-04122-7 [pii] AID - 10.1007/s11136-025-04122-7 [doi] PST - epublish SO - Qual Life Res. 2025 Dec 23;35(1):3. doi: 10.1007/s11136-025-04122-7. PMID- 41349247 OWN - NLM STAT- MEDLINE DCOM- 20251219 LR - 20251219 IS - 1950-6007 (Electronic) IS - 0753-3322 (Linking) VI - 193 DP - 2025 Dec TI - Metabolic modulation as a therapeutic strategy for post-acute vaccination syndrome (PACVS): A review of pathomechanisms and existing therapeutic components. PG - 118864 LID - S0753-3322(25)01058-3 [pii] LID - 10.1016/j.biopha.2025.118864 [doi] AB - Post-Acute Vaccination Syndrome (PACVS) is a post-vaccination disorder marked by persistent fatigue, cognitive impairment, and exercise intolerance. Current research identifies interconnected pathophysiological processes, including persisting spike protein, mitochondrial dysfunction, decreased tissue oxygenation, and impaired metabolism. Emerging treatments rely on metabolic regulation and therapeutic agents promoting mitochondrial and vascular function. These therapies stimulate cellular energy generation, reduce oxidative stress, and regulate inflammatory pathways. This review examines metabolic and mitochondrial mechanisms underlying PACVS, evaluates existing therapeutic strategies targeting these pathways, and synthesizes current evidence for future research and clinical management. CI - Copyright (c) 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved. FAU - Halma, Matthew AU - Halma M AD - Open Source Medicine Foundation, Harju maakond, Kesklinna linnaosa, Parnu mnt 139c, Tallinn 11317, Estonia; Independent Medical Alliance, 2001 L St. NW Suite 500, Washington DC 20036, USA. Electronic address: mhalma@imahealth.org. FAU - Varon, Joseph AU - Varon J AD - Independent Medical Alliance, 2001 L St. NW Suite 500, Washington DC 20036, USA. LA - eng PT - Journal Article PT - Review DEP - 20251204 PL - France TA - Biomed Pharmacother JT - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JID - 8213295 SB - IM MH - Humans MH - *Vaccination/adverse effects MH - Oxidative Stress/drug effects MH - Mitochondria/metabolism/drug effects MH - Animals MH - *Energy Metabolism/drug effects OTO - NOTNLM OT - Long COVID OT - Metabolic modulation OT - Post-Acute COVID Syndrome OT - Post-Acute COVID-19 Vaccination Syndrome OT - Post-viral fatigue COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/06 00:32 MHDA- 2025/12/19 06:30 CRDT- 2025/12/05 18:04 PHST- 2025/10/09 00:00 [received] PHST- 2025/11/28 00:00 [revised] PHST- 2025/11/30 00:00 [accepted] PHST- 2025/12/19 06:30 [medline] PHST- 2025/12/06 00:32 [pubmed] PHST- 2025/12/05 18:04 [entrez] AID - S0753-3322(25)01058-3 [pii] AID - 10.1016/j.biopha.2025.118864 [doi] PST - ppublish SO - Biomed Pharmacother. 2025 Dec;193:118864. doi: 10.1016/j.biopha.2025.118864. Epub 2025 Dec 4. PMID- 41344606 OWN - NLM STAT- MEDLINE DCOM- 20260521 LR - 20260521 IS - 1600-6143 (Electronic) IS - 1600-6135 (Linking) VI - 26 IP - 5 DP - 2026 May TI - Postacute sequelae following Omicron SARS-CoV-2 infection in transplant recipients: A population -based cohort study. PG - 1176-1189 LID - S1600-6135(25)03131-4 [pii] LID - 10.1016/j.ajt.2025.11.025 [doi] AB - Population-based studies evaluating prevalence of postacute sequelae following coronavirus diseases 2019 (COVID-19), or long-COVID-19, in transplant recipients are limited. We examined the risk of long-COVID-19 following severe-acute-respiratory-syndrome-coronavirus-2 (SARS-CoV-2) infection with the Omicron variant, in a retrospective population-based cohort of transplant recipients vs test-negatives. National COVID-19/health care claims databases were used to construct cohorts of all Singaporean adult transplant recipients infected during Omicron predominance (January 1-December 31, 2022) and contemporaneous test-negatives. Competing-risks regression (death as a competing risk), with overlap weights applied, was used to estimate risks of new-incident diagnoses/symptoms 31 to 300 days post-SARS-CoV-2 infection in transplant recipients vs test-negatives. A total of 1890 SARS-CoV-2-infected transplant recipients and 1482 test-negatives were included. In total, 88.7% were boosted. Overall risks of postacute sequelae were not significantly increased in SARS-CoV-2-infected transplant recipients vs test-negatives (any postacute diagnosis: adjusted hazard ratio [aHR] = 1.35 [95% confidence interval CI, = 0.74-2.45]; any postacute symptom: aHR = 1.06 [95% CI = 0.52-2.17]). However, increased risk of postacute autoimmune (aHR = 5.34 [95% CI = 1.03-27.62])/neurologic sequelae (aHR = 3.06 [95% CI = 1.23-7.61]) was observed in SARS-CoV-2-infected transplant recipients vs test-negatives, though excess burden was modest (autoimmune: excess burden per 1000 individuals = 5.58 [95% CI = -4.49 to 15.65]; neurologic: excess burden per 1000 individuals = 19.82 [95% CI = -4.33 to 43.96]). Risks of postacute neurologic/autoimmune sequelae remained elevated in untreated COVID-19 cases vs test-negatives but did not significantly differ in treated COVID-19 cases vs test-negatives. We concluded that the overall risk of postacute sequelae was not significantly elevated in a highly vaccinated/boosted cohort of Omicron SARS-CoV-2-infected transplant recipients vs test-negatives. COVID-19 vaccination/boosting remains important during endemicity. CI - Copyright (c) 2025 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. FAU - Wee, Liang En AU - Wee LE AD - Communicable Diseases Agency, Singapore, Singapore; Duke NUS Medical School, National University of Singapore, Singapore, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. Electronic address: ian.wee.l.e@singhealth.com.sg. FAU - Tan, Yong Yi AU - Tan YY AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Bin Abdul Malek, Muhammad Ismail AU - Bin Abdul Malek MI AD - Communicable Diseases Agency, Singapore, Singapore; National Centre for Infectious Diseases, Singapore, Singapore. FAU - Lim, Jue Tao AU - Lim JT AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Chiew, Calvin J AU - Chiew CJ AD - Communicable Diseases Agency, Singapore, Singapore. FAU - Lye, David Chien AU - Lye DC AD - Communicable Diseases Agency, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; National Centre for Infectious Diseases, Singapore, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Tan, Kelvin Bryan AU - Tan KB AD - Communicable Diseases Agency, Singapore, Singapore; Duke NUS Medical School, National University of Singapore, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Ministry of Health, Government of Singapore, Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20251202 PL - United States TA - Am J Transplant JT - American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons JID - 100968638 SB - IM MH - Humans MH - *COVID-19/epidemiology/complications MH - Male MH - Female MH - Middle Aged MH - Retrospective Studies MH - Adult MH - *SARS-CoV-2 MH - *Transplant Recipients/statistics & numerical data MH - Aged MH - *Organ Transplantation MH - Risk Factors MH - Post-Acute COVID-19 Syndrome OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - long COVID-19 OT - postacute sequelae of SARS-CoV-2 (PASC) OT - transplant OT - vaccination COIS- Declaration of competing interest The authors of this manuscript have no conflicts of interest to disclose as described by American Journal of Transplantation. EDAT- 2025/12/05 01:02 MHDA- 2026/05/22 00:33 CRDT- 2025/12/04 19:33 PHST- 2025/06/25 00:00 [received] PHST- 2025/11/25 00:00 [revised] PHST- 2025/11/25 00:00 [accepted] PHST- 2026/05/22 00:33 [medline] PHST- 2025/12/05 01:02 [pubmed] PHST- 2025/12/04 19:33 [entrez] AID - S1600-6135(25)03131-4 [pii] AID - 10.1016/j.ajt.2025.11.025 [doi] PST - ppublish SO - Am J Transplant. 2026 May;26(5):1176-1189. doi: 10.1016/j.ajt.2025.11.025. Epub 2025 Dec 2. PMID- 41319437 OWN - NLM STAT- MEDLINE DCOM- 20251211 LR - 20251211 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 70 DP - 2026 Jan 5 TI - Examining the independent and interactive roles of intolerance of uncertainty in vaccination intent. PG - 128008 LID - S0264-410X(25)01306-4 [pii] LID - 10.1016/j.vaccine.2025.128008 [doi] AB - Vaccine hesitancy remains common and sociopolitical anti-vaccine movements continue to gain ground in the United States and beyond. To inform more effective public health campaigns and increase vaccination intent, research is needed on how cognitive and emotional variables interact to influence vaccination intent. Intolerance of uncertainty (IU), defined as experiencing distress or discomfort in response to uncertain situations, is known to influence both approach and avoidance behaviors. IU may interact with other decision-making factors that impact vaccination intent, including people's actual knowledge about disease, perception of disease risk, and worry about vaccine safety. We recruited a community sample of Florida residents (N = 2152) for a longitudinal study spanning the first eight months of the COVID-19 pandemic and tested how COVID-specific IU (i.e., IU pertaining specifically to the disease) independently and interactively influenced vaccination intent. We found that higher COVID-IU early in the pandemic (May/June 2020) significantly predicted greater vaccination intent measured months later (December 2020/January 2021), even after controlling for relevant demographic variables, depression and anxiety symptoms, subjective risk, perceived vaccine safety, and disease knowledge. There was also a significant interaction between IU and knowledge, such that the effect of COVID-IU on vaccination intent was stronger for those with less disease knowledge. These findings suggest that disease specific IU can shape vaccination intent, independently and in interaction with disease knowledge. Our findings suggest that public health messaging seeking to increase vaccine uptake could benefit from emphasizing the distressing nature of the uncertainty inherent in contracting major diseases. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Dev, Amelia S AU - Dev AS AD - Department of Psychology, University of Miami, United States. Electronic address: ameliadev@miami.edu. FAU - Broos, Hannah C AU - Broos HC AD - Department of Psychology, University of Miami, United States. FAU - Llabre, Maria M AU - Llabre MM AD - Department of Psychology, University of Miami, United States. FAU - Saab, Patrice G AU - Saab PG AD - Department of Psychology, University of Miami, United States. FAU - Timpano, Kiara R AU - Timpano KR AD - Department of Psychology, University of Miami, United States. LA - eng PT - Journal Article DEP - 20251129 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Uncertainty MH - Female MH - Male MH - *COVID-19/prevention & control/psychology/epidemiology MH - Adult MH - Middle Aged MH - *Vaccination/psychology MH - *Vaccination Hesitancy/psychology MH - Longitudinal Studies MH - Florida/epidemiology MH - Health Knowledge, Attitudes, Practice MH - *COVID-19 Vaccines/administration & dosage MH - SARS-CoV-2/immunology MH - Young Adult MH - Aged MH - Intention MH - Decision Making MH - Adolescent OTO - NOTNLM OT - Cognition OT - Disease knowledge OT - Intolerance of uncertainty OT - Vaccine hesitancy OT - Vaccine intent COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/12/01 00:29 MHDA- 2025/12/12 01:38 CRDT- 2025/11/30 18:03 PHST- 2025/08/27 00:00 [received] PHST- 2025/11/17 00:00 [revised] PHST- 2025/11/17 00:00 [accepted] PHST- 2025/12/12 01:38 [medline] PHST- 2025/12/01 00:29 [pubmed] PHST- 2025/11/30 18:03 [entrez] AID - S0264-410X(25)01306-4 [pii] AID - 10.1016/j.vaccine.2025.128008 [doi] PST - ppublish SO - Vaccine. 2026 Jan 5;70:128008. doi: 10.1016/j.vaccine.2025.128008. Epub 2025 Nov 29. PMID- 41306864 OWN - NLM STAT- MEDLINE DCOM- 20251127 LR - 20251129 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - A systematic review on the psychological factors behind vaccine hesitancy in the COVID-19 era. PG - 1711428 LID - 10.3389/fpubh.2025.1711428 [doi] LID - 1711428 AB - BACKGROUND: Vaccine hesitancy may represent a global threat because of its inherent consequences for health, social and economic systems. Understanding the factors associated with vaccine hesitancy is fundamental to developing effective healthcare policies. While previous studies have mainly focused on sociological and cultural variables and transient illness-specific fears and beliefs, the present systematic review focuses on the psychological factors (such as emotional dispositions, cognitive functioning and expectations, and stable personality traits) associated with vaccine hesitancy during the COVID-19 era. METHODS: A systematic review using a systematic search of PubMed, PsychINFO and Web of Science databases was performed with a time frame ranging between 1 January 2020 to 31 January 2025 focusing on psychological factors and vaccine hesitancy. Studies targeting the general population and employing validated instruments to assess emotional, cognitive and personality factors and vaccine hesitancy were selected, while investigations on context-specific, psycho-social, cultural and political factors were excluded. Quality and risk of bias in the selected studies was assessed using an adapted version of the Newcastle-Ottawa Scale, and main studies' characteristics, variables and outcomes were synthesised using a narrative approach and table. RESULTS: Fourteen studies were finally included in the qualitative synthesis. The results showed that some variables such as depressive and anxiety levels, as well as emotion regulation strategies may affect vaccination behaviour, although some cultural and generational differences were also observed. Differences in cognitive flexibility, decision-making, and personal expectations may influence vaccine hesitancy. Notably, some personality factors, like extraversion, openness, conscientiousness and dark personality traits, may influence hesitancy to vaccinate. CONCLUSION: This review highlights emotional, cognitive, and personality factors associated with vaccine hesitancy, providing evidence for personalised, evidence-based interventions aimed at promoting adherence to national vaccination policies. CI - Copyright (c) 2025 Panico, De Biase, Catalano, Zappullo, D'Olimpio, Trojano and Sagliano. FAU - Panico, Francesco AU - Panico F AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - De Biase, Rosalia AU - De Biase R AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Catalano, Laura AU - Catalano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Zappullo, Isa AU - Zappullo I AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - D'Olimpio, Francesca AU - D'Olimpio F AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Trojano, Luigi AU - Trojano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. FAU - Sagliano, Laura AU - Sagliano L AD - Department of Psychology, University of Campania "Luigi Vanvitelli", Caserta, Italy. LA - eng PT - Journal Article PT - Systematic Review DEP - 20251111 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/psychology MH - *Vaccination Hesitancy/psychology MH - *COVID-19 Vaccines/administration & dosage MH - SARS-CoV-2 MH - *Vaccination/psychology MH - Personality PMC - PMC12644076 OTO - NOTNLM OT - COVID-19 OT - cognition OT - emotion OT - health OT - intervention OT - personality OT - vaccine hesitancy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. EDAT- 2025/11/27 06:28 MHDA- 2025/11/27 12:28 PMCR- 2025/11/11 CRDT- 2025/11/27 04:34 PHST- 2025/09/23 00:00 [received] PHST- 2025/10/24 00:00 [accepted] PHST- 2025/11/27 12:28 [medline] PHST- 2025/11/27 06:28 [pubmed] PHST- 2025/11/27 04:34 [entrez] PHST- 2025/11/11 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1711428 [doi] PST - epublish SO - Front Public Health. 2025 Nov 11;13:1711428. doi: 10.3389/fpubh.2025.1711428. eCollection 2025. PMID- 41258118 OWN - NLM STAT- MEDLINE DCOM- 20260213 LR - 20260216 IS - 1433-8491 (Electronic) IS - 0940-1334 (Print) IS - 0940-1334 (Linking) VI - 276 IP - 1 DP - 2026 Feb TI - Cognitive impairment, depression, and fatigue in post-COVID and post-vaccination syndrome: a large-scale cross-sectional study. PG - 221-234 LID - 10.1007/s00406-025-02144-3 [doi] AB - BACKGROUND: Persistent cognitive difficulties are among the most prevalent symptoms observed after COVID-19. This study examined the neuropsychological characteristics, mental health and risk factors associated with cognitive impairment in patients with Post-Acute Sequelae of COVID-19 (PASC). In addition, differences regarding the cognitive dysfunctions between individuals with PASC and Post-Vaccination Syndrome (PVS) were explored. METHODS: Participants were consecutively recruited at the Post-COVID Center of the University Hospital Erlangen in Germany (12/2022-02/2025). Assessments included a broad neuropsychological assessment: d2 Test of Attention, digit span backwards from the Wechsler Memory Scale-Revised (WMS-R) and module 1 (formal lexical fluency) of the Regensburger Verbal Fluency Test (RWT), along with assessments of depression, fatigue, and inflammatory markers (C-reactive protein). RESULTS: The sample (N = 793, mean age: 46.1 +/- 12.4 years; 66.8% women) included n = 723 PASC patients and n = 70 PVS patients. In the total sample, deficits were most frequent in working speed (61.7%), attention (54.7%) and verbal fluency (48.8%); 30.3% showed multidomain impairment. Clinically significant depressive symptoms (64.5%) and fatigue (92.4%) were common. Cognitive patterns, depressive symptoms and fatigue in the PVS group closely resembled those observed in PASC. In PASC, lower education, older age, depressive symptoms, and elevated CRP were associated with cognitive impairment. CONCLUSION: Cognitive impairment is highly prevalent in PASC and PVS and appears to be influenced by both psychological and biological factors. Similar patterns identified in PVS suggest possible shared mechanisms. Further research is needed to clarify trajectories and optimize treatment strategies. CI - (c) 2025. The Author(s). FAU - Hanc, Evelyne AU - Hanc E AUID- ORCID: 0009-0009-6008-9573 AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. evelyne.hanc@uk-erlangen.de. FAU - Koller, Katharina AU - Koller K AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. FAU - Herold, Regina AU - Herold R AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. FAU - Erim, Yesim AU - Erim Y AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. AD - Post-COVID Center of the University Hospital of Erlangen, Erlangen, Germany. FAU - Morawa, Eva AU - Morawa E AD - Department of Psychosomatic Medicine and Psychotherapy, University Hospital of Erlangen, Friedrich-Alexander University Erlangen-Nurnberg (FAU), Schwabachanlage 6, 91054, Erlangen, Germany. LA - eng PT - Journal Article DEP - 20251119 PL - Germany TA - Eur Arch Psychiatry Clin Neurosci JT - European archives of psychiatry and clinical neuroscience JID - 9103030 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Adult MH - Cross-Sectional Studies MH - *Fatigue/epidemiology/etiology/physiopathology MH - *COVID-19/complications/epidemiology MH - *Cognitive Dysfunction/epidemiology/etiology/physiopathology MH - *Depression/epidemiology/etiology MH - Germany/epidemiology MH - Post-Acute COVID-19 Syndrome MH - Neuropsychological Tests MH - *COVID-19 Vaccines/adverse effects MH - *Vaccination/adverse effects PMC - PMC12904920 OTO - NOTNLM OT - Cognitive impairments OT - Depression OT - Fatigue OT - Neuropsychological assessment OT - Post-COVID syndrome OT - Post-Vaccination syndrome COIS- Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Avaliability of data and materials: The datasets analyzed during the current study contain sensitive patient information and are therefore not publicly avaliable due to ethical and legal restrictions. Aggregate statistical results relevant to the study are provided within the article. EDAT- 2025/11/19 12:28 MHDA- 2026/02/13 12:50 PMCR- 2025/11/19 CRDT- 2025/11/19 09:12 PHST- 2025/07/14 00:00 [received] PHST- 2025/10/27 00:00 [accepted] PHST- 2026/02/13 12:50 [medline] PHST- 2025/11/19 12:28 [pubmed] PHST- 2025/11/19 09:12 [entrez] PHST- 2025/11/19 00:00 [pmc-release] AID - 10.1007/s00406-025-02144-3 [pii] AID - 2144 [pii] AID - 10.1007/s00406-025-02144-3 [doi] PST - ppublish SO - Eur Arch Psychiatry Clin Neurosci. 2026 Feb;276(1):221-234. doi: 10.1007/s00406-025-02144-3. Epub 2025 Nov 19. PMID- 41254536 OWN - NLM STAT- MEDLINE DCOM- 20251119 LR - 20251123 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 25 IP - 1 DP - 2025 Nov 18 TI - Risk factors for severe disease in children hospitalized with SARS-CoV-2 infection in China: a retrospective cohort study. PG - 1611 LID - 10.1186/s12879-025-12024-9 [doi] LID - 1611 AB - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread rapidly worldwide since its emergence in 2019. While infections in children are generally mild, severe disease can occur in some rare cases. Herein, we aim to identify risk factors for severe disease in children hospitalized with SARS-CoV-2 infection during the post-Omicron period. METHODS: This retrospective cohort study was based on a review of the records of children aged under 15 years hospitalized with SARS-CoV-2 infection at a university hospital in Xi'an, China between December 8, 2022, and January 17, 2023. Multivariable logistic regression was applied to identify factors associated with severe disease. RESULTS: Of 164 children included in the analysis, 33 had severe disease and 131 had non-severe disease. Disease severity did not differ significantly according to sex or SARS-CoV-2 vaccination status. The prevalence of comorbidities was significantly higher in children with severe disease than in those with non-severe disease (30% [10/33] vs. 10.7% [14/131], p = 0.04). The prevalence of neurological manifestations and multisystem disease were also significantly higher in children with severe disease than in those with non-severe disease (91% [30/33] vs. 27.5% [36/131], p = 0.001; and 64% [21/33] vs. 43.5% [57/131], p = 0.039, respectively). Multivariable logistic regression analysis identified younger age (odds ratio [OR]: 0.702, 95% confidence interval [CI]: 0.551-0.893; p = 0.004), the presence of comorbidities (OR: 9.042, 95% CI: 2.505X-32.645; p = 0.001), and neurological signs (OR: 217.21, 95% CI: 34.988-1348.469; p < 0.001) as independent risk factors for severe disease. CONCLUSION: This single-center retrospective cohort study reveals that younger children with comorbidities and neurological manifestations are at higher risk of developing severe SARS-CoV-2 infection. These findings should be interpreted considering limitations including short study timeframe, homogeneous vaccine types, and lack of variant-specific analyses. CI - (c) 2025. The Author(s). FAU - Wang, Yan AU - Wang Y AD - Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P.R. China. FAU - Song, Ye AU - Song Y AD - Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P.R. China. AD - International Peace Maternity and Child Health Hospital of China Welfare Institution, School of Medicine, Shanghai Jiao Tong University, Shanghai, 20030, China. FAU - Zhu, Binhui AU - Zhu B AD - Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P.R. China. FAU - Feng, You AU - Feng Y AD - Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P.R. China. FAU - Lou, Dandan AU - Lou D AD - Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, P.R. China. DanielleLOU@xjtu.edu.cn. FAU - Zhang, Yueping AU - Zhang Y AD - Department of Pediatrics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P.R. China. ypzhang@fmmu.edu.cn. LA - eng GR - 2023-YBSF-640/Shaanxi Provincial Key R&D Programs/ PT - Journal Article DEP - 20251118 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 SB - IM MH - Humans MH - *COVID-19/epidemiology/pathology MH - Retrospective Studies MH - Male MH - Female MH - China/epidemiology MH - Child MH - Risk Factors MH - Child, Preschool MH - Adolescent MH - SARS-CoV-2 MH - Hospitalization/statistics & numerical data MH - Severity of Illness Index MH - Infant MH - Comorbidity MH - Logistic Models PMC - PMC12624980 OTO - NOTNLM OT - COVID-19 OT - Comorbidities OT - Neurological signs OT - SARS-CoV-2 vaccination COIS- Declarations. Ethical approval: This study was conducted in accordance with principles of the Declaration of Helsinki, and was approved by the Ethics Committee of the First Affiliated Hospital of Air Force Medical University (Number:KY20252368-C-1). The requirement for informed consent was waived due to the retrospective study design. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/11/19 06:32 MHDA- 2025/11/19 06:33 PMCR- 2025/11/18 CRDT- 2025/11/19 00:04 PHST- 2024/09/10 00:00 [received] PHST- 2025/10/23 00:00 [accepted] PHST- 2025/11/19 06:33 [medline] PHST- 2025/11/19 06:32 [pubmed] PHST- 2025/11/19 00:04 [entrez] PHST- 2025/11/18 00:00 [pmc-release] AID - 10.1186/s12879-025-12024-9 [pii] AID - 12024 [pii] AID - 10.1186/s12879-025-12024-9 [doi] PST - epublish SO - BMC Infect Dis. 2025 Nov 18;25(1):1611. doi: 10.1186/s12879-025-12024-9. PMID- 41180683 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251230 LR - 20260917 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 87 IP - 11 DP - 2025 Nov TI - Neurological manifestations of COVID-19 and its vaccines: an updated comprehensive review with an insight into pathophysiology. PG - 7390-7399 LID - 10.1097/MS9.0000000000003931 [doi] AB - The COVID-19 pandemic caused by SARS-CoV-2 has had a significant global impact on the respiratory system and multiple organ systems, including the nervous system. Neurological manifestations associated with COVID-19 infection and its vaccines have been increasingly recognized, ranging from problems with smell and taste to more severe conditions such as encephalitis, stroke, and Guillain-Barre syndrome. This narrative review critically evaluates the neurological manifestations of COVID-19 infection and its vaccines, providing insights into potential pathophysiological mechanisms. A comprehensive literature search was conducted, and data were retrieved from various databases. The prevalence, types, and severity of neurological symptoms in COVID-19 patients were discussed. The possible mechanisms of neurological injury in COVID-19 were explored, including direct viral invasion, hypoxic brain injury, immune-mediated damage, and cerebrovascular injury. Furthermore, the review addressed the neurological complications associated with COVID-19 vaccination. While severe vaccine-related adverse effects remain rare, understanding their occurrence is essential for risk assessment and public health interventions. In conclusion, COVID-19 can affect the nervous system in various ways, leading to various neurological symptoms. Further research is necessary to enhance our understanding of these manifestations and develop effective preventive and treatment strategies to manage this global health crisis. CI - Copyright (c) 2025 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Abbasher Hussien Mohamed Ahmed, Khabab AU - Abbasher Hussien Mohamed Ahmed K AUID- ORCID: 0000-0003-4608-5321 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Kalool Fadlalla Ahmad, Tagwa AU - Kalool Fadlalla Ahmad T AD - Faculty of Medicine, Ahfad University for Women, Omdurman, Sudan. FAU - Ismail Abdu Ismail, Mohamed AU - Ismail Abdu Ismail M AD - Faculty of Medicine, Sudan International University, Khartoum, Sudan. FAU - Elgadi, Ammar T AU - Elgadi AT AUID- ORCID: 0000-0003-1730-9023 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Hassan Salih Elhaj, Esraa AU - Hassan Salih Elhaj E AUID- ORCID: 0000-0001-9363-9230 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Mustafa Ahmed, Ghassan E AU - Mustafa Ahmed GE AUID- ORCID: 0000-0002-0258-6282 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Khan, Faheemullah AU - Khan F AD - Cardiovascular Imaging Fellow, Diagnostic Institute, Cleveland Clinic, Main Campus, Ohio, USA. FAU - Mohammed, Mohammed Babiker Habbiballah AU - Mohammed MBH AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Manhal, Gaffar Alemam A AU - Manhal GAA AUID- ORCID: 0000-0001-7939-0117 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Daffalla Mussaad Mohammed, Ahmed AU - Daffalla Mussaad Mohammed A AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Ali, Mustafa Mohamed Ibrahim AU - Ali MMI AUID- ORCID: 0009-0001-3870-2791 AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Abdullah Mohammed, Mohammed Elmustafa Adil AU - Abdullah Mohammed MEA AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. FAU - Meshref, Mostafa AU - Meshref M AD - Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt. FAU - Hussien, Abbasher AU - Hussien A AD - Faculty of Medicine, University of Khartoum, Khartoum, Sudan. LA - eng PT - Journal Article PT - Review DEP - 20250918 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC12577873 OTO - NOTNLM OT - COVID-19 OT - COVID-19 pathophysiology OT - SARS-coV-2 OT - neurological manifestations OT - vaccination COIS- Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. The authors have no conflict of interest to declare. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/09/18 CRDT- 2025/11/03 07:12 PHST- 2024/12/24 00:00 [received] PHST- 2025/09/09 00:00 [accepted] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 07:12 [entrez] PHST- 2025/09/18 00:00 [pmc-release] AID - AMSU-D-24-02716 [pii] AID - 10.1097/MS9.0000000000003931 [doi] PST - epublish SO - Ann Med Surg (Lond). 2025 Sep 18;87(11):7390-7399. doi: 10.1097/MS9.0000000000003931. eCollection 2025 Nov. PMID- 41179613 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251103 LR - 20260925 IS - 2050-0904 (Print) IS - 2050-0904 (Electronic) IS - 2050-0904 (Linking) VI - 13 IP - 11 DP - 2025 Nov TI - Parsonage-Turner Syndrome and Vocal Fold Paresis Following Soberana 2 FINLAY-FR-2 COVID-19 Vaccination: A Case Report. PG - e71348 LID - 10.1002/ccr3.71348 [doi] LID - e71348 AB - This case report presents a 58-year-old male who developed Parsonage-Turner syndrome (PTS) and vocal cord paresis after receiving the Soberana 2 FINLAY-FR-2 COVID-19 vaccine. The patient experienced escalating pain and weakness in both shoulders and upper limbs after each vaccine dose, with subsequent neurological symptoms including headaches, dysphagia, hoarseness, numbness, dyspnea, and chest discomfort. Neurological examinations and electrodiagnostic studies confirmed upper trunk brachial plexopathy along with vocal fold paresis. This patient was treated with intravenous methylprednisolone. Despite therapeutic intervention, the patient exhibited persistent neurological deficits during follow-up. CI - (c) 2025 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. FAU - Bordbari, Amir-Hassan AU - Bordbari AH AD - Student Research Committee, School of Medicine Mazandaran University of Medical Sciences Sari Iran. FAU - Heidari, Negar AU - Heidari N AD - Department of Neurology, Clinical Research Development Unit of Bou Ali Sina Hospital Mazandaran University of Medical Sciences Sari Iran. FAU - Karimi, Narges AU - Karimi N AUID- ORCID: 0000-0001-5912-3732 AD - Department of Neurology, School of Medicine, Immunogenetics Research Center, Clinical Research Development Unit of Bou Ali Sina Hospital Mazandaran University of Medical Sciences Sari Iran. LA - eng PT - Journal Article DEP - 20251031 PL - England TA - Clin Case Rep JT - Clinical case reports JID - 101620385 PMC - PMC12578595 OTO - NOTNLM OT - COVID-19 vaccines OT - Parsonage-Turner syndrome OT - brachial plexus neuritis OT - vocal fold paralysis COIS- The authors declare no conflicts of interest. EDAT- 2025/11/03 13:42 MHDA- 2025/11/03 13:43 PMCR- 2025/10/31 CRDT- 2025/11/03 06:59 PHST- 2024/09/23 00:00 [received] PHST- 2025/10/03 00:00 [revised] PHST- 2025/10/14 00:00 [accepted] PHST- 2025/11/03 13:43 [medline] PHST- 2025/11/03 13:42 [pubmed] PHST- 2025/11/03 06:59 [entrez] PHST- 2025/10/31 00:00 [pmc-release] AID - CCR371348 [pii] AID - 10.1002/ccr3.71348 [doi] PST - epublish SO - Clin Case Rep. 2025 Oct 31;13(11):e71348. doi: 10.1002/ccr3.71348. eCollection 2025 Nov. PMID- 41169891 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251031 LR - 20251102 IS - 2296-2360 (Print) IS - 2296-2360 (Electronic) IS - 2296-2360 (Linking) VI - 13 DP - 2025 TI - Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic. PG - 1640747 LID - 10.3389/fped.2025.1640747 [doi] LID - 1640747 AB - BACKGROUND: Long COVID describes the persistence or recurrence of symptoms beyond the acute phase of SARS-CoV-2 infection and is increasingly recognized in children and adolescents. Despite its prevalence, understanding of symptom patterns and the influence of vaccination on disease trajectory in pediatric populations remains limited. METHODS: We conducted a retrospective study of patients aged 0-21 years evaluated at the Long COVID Clinic at Children's Hospital Los Angeles between August 2021 and November 2023. Patients were included if they reported persistent or new symptoms >/=4 weeks after SARS-CoV-2 infection. RESULTS: A total of 123 patients were enrolled. The mean age was 13.1 years, and 51% were male. Symptom onset occurred a mean of 5 weeks after infection. At presentation, 56% of patients reported symptoms lasting 0-24 weeks, 28% for 25-52 weeks, and 16% for >52 weeks. Fatigue (93%) and headache (70%) were the most prevalent symptoms in both younger (<12 years) and older (>12 years) cohorts. Female patients more frequently reported brain fog, dizziness, palpitations, and postural orthostatic tachycardia syndrome. Overall symptom burden decreased significantly over time (p < 0.001). Vaccination status at baseline was not associated with difference in symptom duration on initial presentation (p = 0.4). However, among those vaccinated after developing long COVID, 41% reported subjective improvement in the following weeks. CONCLUSION: Pediatric long COVID is marked by prolonged, multisystem symptoms. Vaccination may offer symptomatic benefit for some patients, though larger prospective studies are necessary to better define its role. CI - (c) 2025 Kamel, Vu, Bender, Warburton, Wood and Mohandas. FAU - Kamel, Dina AU - Kamel D AD - Division of Infectious Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. AD - Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. FAU - Vu, My H AU - Vu MH AD - Biostatistics and Data Management Core, The Saban Research Institute, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. FAU - Bender, Jeffery AU - Bender J AD - Division of Infectious Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. AD - Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. FAU - Warburton, David AU - Warburton D AD - Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. FAU - Wood, John C AU - Wood JC AD - Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. AD - Department of Radiology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. FAU - Mohandas, Sindhu AU - Mohandas S AD - Division of Infectious Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. AD - Department of Pediatrics, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States. LA - eng PT - Journal Article DEP - 20251015 PL - Switzerland TA - Front Pediatr JT - Frontiers in pediatrics JID - 101615492 PMC - PMC12568432 OTO - NOTNLM OT - COVID 19 vaccine OT - COVID-19 OT - PASC OT - long COVID OT - post COVID COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/10/31 06:26 MHDA- 2025/10/31 06:27 PMCR- 2025/10/15 CRDT- 2025/10/31 04:51 PHST- 2025/06/04 00:00 [received] PHST- 2025/09/29 00:00 [accepted] PHST- 2025/10/31 06:27 [medline] PHST- 2025/10/31 06:26 [pubmed] PHST- 2025/10/31 04:51 [entrez] PHST- 2025/10/15 00:00 [pmc-release] AID - 10.3389/fped.2025.1640747 [doi] PST - epublish SO - Front Pediatr. 2025 Oct 15;13:1640747. doi: 10.3389/fped.2025.1640747. eCollection 2025. PMID- 41161981 OWN - NLM STAT- MEDLINE DCOM- 20251029 LR - 20251029 IS - 1557-9832 (Electronic) IS - 0272-2712 (Linking) VI - 45 IP - 4 DP - 2025 Dec TI - Hemostatic Disorders Following Severe Acute Respiratory Syndrome Coronavirus 2 Infection, COVID-19 Vaccination, and Long-COVID Syndrome: Current Evidence and Controversies in Clinical Practice. PG - 643-655 LID - S0272-2712(25)00062-9 [pii] LID - 10.1016/j.cll.2025.07.008 [doi] AB - The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented profound global health challenges. Beyond acute illness, a substantial proportion of individuals experience persistent symptoms including fatigue, brain fog, and post-exertional malaise, collectively known as Long-COVID. Among the complications associated with SARS-CoV-2 infection and vaccination, hemostatic disorders ranging from mild platelet dysfunction to severe thromboembolic events, and rare but serious coagulation-related adverse effects, such as vaccine-induced immune thrombotic thrombocytopenia, have emerged as a significant concern. Herein we provide an overview of current information and controversies surrounding hemostatic complications in SARS-CoV-2 infection and COVID-19 vaccination. CI - Copyright (c) 2025 Elsevier Inc. All rights reserved. FAU - Vishnu, Prakash AU - Vishnu P AD - Fred Hutch Cancer Center, 825 Eastlake Avenue E (LG7-710), Seattle, WA 98109, USA; University of Washington, Seattle, WA, USA. Electronic address: pvishnu1@uw.edu. FAU - Aboulafia, David M AU - Aboulafia DM AD - University of Washington, Seattle, WA, USA; Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, WA, USA. LA - eng PT - Journal Article PT - Review DEP - 20250811 PL - United States TA - Clin Lab Med JT - Clinics in laboratory medicine JID - 8100174 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/complications/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Hemostatic Disorders/etiology MH - SARS-CoV-2 MH - *Vaccination/adverse effects OTO - NOTNLM OT - COVID-19 vaccine OT - Severe acute respiratory syndrome coronavirus 2 infection OT - Thrombosis OT - Vaccine-induced thrombotic thrombocytopenia COIS- Disclosures The authors have no commercial or financial conflicts of interest to disclose. Dr Aboulafia receives funding from a National Institutes of Health, United States grant as a member of the AIDS Malignancy Consortium. EDAT- 2025/10/30 00:27 MHDA- 2025/10/30 00:28 CRDT- 2025/10/29 21:54 PHST- 2025/10/30 00:28 [medline] PHST- 2025/10/30 00:27 [pubmed] PHST- 2025/10/29 21:54 [entrez] AID - S0272-2712(25)00062-9 [pii] AID - 10.1016/j.cll.2025.07.008 [doi] PST - ppublish SO - Clin Lab Med. 2025 Dec;45(4):643-655. doi: 10.1016/j.cll.2025.07.008. Epub 2025 Aug 11. PMID- 41084072 OWN - NLM STAT- MEDLINE DCOM- 20251014 LR - 20251016 IS - 2050-7283 (Electronic) IS - 2050-7283 (Linking) VI - 13 IP - 1 DP - 2025 Oct 13 TI - Sensitivity to change of the COVID-19 anxiety syndrome scale among Canadian dentists. PG - 1133 LID - 10.1186/s40359-025-03491-5 [doi] LID - 1133 AB - INTRODUCTION: The COVID-19 Anxiety Syndrome Scale (C-19ASS) is valid and reliable instrument to measure COVID-19 related anxiety in Canadian dentists. There is a need to further validate the C-19ASS by evaluating its sensitivity to change over time. AIM: To estimate the sensitivity to change over time of the C-19ASS in a sample of Canadian dentists. To estimate the effect of age, sex, practice type and vaccination on the anxiety levels of dentists in Canada. METHODS: Longitudinal data were used from a prospective cohort study conducted to estimate the incidence of COVID-19 among dentists practising in Canada. Mixed effects ordinal logistic regression models were used to estimate the association between total C-19ASS scores and follow-up time in the study and COVID-19 case counts in the province of practice of the participants during the 14 days prior to completing the C-19ASS questionnaire. Mixed effects models were utilized to identify the factors associated with COVID-19 related anxiety. RESULTS: The odds of being in a more severe category of anxiety were reduced by 26% (OR 0.74, 95% C.I. 0.72-0.76) with every 30-day increase in the follow-up time. The odds of being in a more severe category of anxiety increased by 20% (Odds Ratio = 1.20, 95% C.I. = 1.12-1.27) with each 10,000 COVID-19 case increase in the dentists' work province during the 14 days prior to data collection. Age, sex and practice type were significantly associated with COVID-19 related anxiety in dentists. CONCLUSION: The C-19ASS is sensitive to change over time and with external anxiety stimuli. COVID-19 related anxiety among dentists was associated with age, sex and practice type. CLINICAL TRIAL NUMBER: Not applicable. CI - (c) 2025. The Author(s). FAU - Seth, Rachita AU - Seth R AD - Faculty of Dental Medicine and Oral Health Sciences, McGill University, 2001 McGill College Avenue, Montreal, QC, H3A 1G1, Canada. FAU - Madathil, Sreenath A AU - Madathil SA AD - Faculty of Dental Medicine and Oral Health Sciences, McGill University, 2001 McGill College Avenue, Montreal, QC, H3A 1G1, Canada. FAU - Siqueira, Walter L AU - Siqueira WL AD - College of Dentistry, University of Saskatchewan, Saskatoon, Canada. FAU - McNally, Mary AU - McNally M AD - Faculty of Dentistry, Dalhousie University, Halifax, Canada. FAU - Quinonez, Carlos R AU - Quinonez CR AD - Schulich School of Medicine and Dentistry, Western University, London, Canada. FAU - Glogauer, Michael AU - Glogauer M AD - Faculty of Dentistry, University of Toronto, Toronto, Canada. FAU - Allison, Paul J AU - Allison PJ AD - Faculty of Dental Medicine and Oral Health Sciences, McGill University, 2001 McGill College Avenue, Montreal, QC, H3A 1G1, Canada. paul.allison@mcgill.ca. LA - eng GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada GR - VR4-172757/CAPMC/CIHR/Canada PT - Journal Article DEP - 20251013 PL - England TA - BMC Psychol JT - BMC psychology JID - 101627676 SB - IM MH - Humans MH - *COVID-19/psychology/epidemiology MH - Male MH - Female MH - Canada/epidemiology MH - *Dentists/psychology/statistics & numerical data MH - Middle Aged MH - Adult MH - Prospective Studies MH - Longitudinal Studies MH - *Anxiety/diagnosis/epidemiology MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - *Psychiatric Status Rating Scales PMC - PMC12519770 OTO - NOTNLM OT - Anxiety OT - C-19ASS OT - Dentists OT - Longitudinal OT - Responsiveness OT - Vaccination COIS- Declarations. Ethics approval and consent to participate: This study protocol was approved by the Institutional Review Board of McGill University, Montreal- IRB Review Number A06-M49-20 A (20-06-018). All participants provided their written informed consent to participate in the study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/10/14 06:28 MHDA- 2025/10/14 06:29 PMCR- 2025/10/13 CRDT- 2025/10/14 00:30 PHST- 2024/06/19 00:00 [received] PHST- 2025/09/19 00:00 [accepted] PHST- 2025/10/14 06:29 [medline] PHST- 2025/10/14 06:28 [pubmed] PHST- 2025/10/14 00:30 [entrez] PHST- 2025/10/13 00:00 [pmc-release] AID - 10.1186/s40359-025-03491-5 [pii] AID - 3491 [pii] AID - 10.1186/s40359-025-03491-5 [doi] PST - epublish SO - BMC Psychol. 2025 Oct 13;13(1):1133. doi: 10.1186/s40359-025-03491-5. PMID- 41082015 OWN - NLM STAT- MEDLINE DCOM- 20251013 LR - 20261010 IS - 1557-1904 (Electronic) IS - 1557-1890 (Linking) VI - 20 IP - 1 DP - 2025 Oct 13 TI - Neurological Adverse Events from COVID-19 Vaccination and It's Associated Factors in Burkina Faso: Analysis of Spontaneous Reports from the National Database of Pharmacovigilance from 2021 to 2023. PG - 89 LID - 10.1007/s11481-025-10249-8 [doi] AB - INTRODUCTION: Neurological adverse effects are frequent, primarily non-serious, due to the tropism of COVID 19 adverse effects for neuronal structures and tissues. To our knowledge, there are no studies on neurological adverse effects of COVID-19 vaccines in Burkina Faso. The purpose of this study was to determine the prevalence of neurological side effects of COVID-19 vaccines, to catalogue neurological adverse effects, to describe these manifestations, and to identify factors associated. MATERIALS AND METHODS: This was a cross-sectional study of people who had experienced adverse events of COVID-19 vaccines during the period from 1 December 2021 to 31 December 2023. Individuals who had experienced at least one adverse event after immunisation (AEFI) of the COVID-19 vaccine registered in the Vigibase Burkina database were included. The data was gathered through a questionnaire. RESULTS: The study included 1,060 people who experienced adverse events. Of them, 614 (57.9%) had neurological adverse effects. Their mean age was 44.08 +/- 18 years. Most of the participants were men (56.8%) and healthcare workers (61.2%). Most of the participants (65.8%) had their side effects occur within 24 h. The AstraZeneca vaccine was reported in 51.8% of participants. The prevalence of side effects after the first dose was 83%.The most common symptoms were headaches (49.7%), myalgia (21.7%) and radiculopathies (9%). There was a significant association between the AstraZeneca vaccine and adverse neurological events (p = 0.000000). Factors associated with the appearance of serious neurological symptoms were age >/= 60 years (p = 0.02744) and comorbidities (p = 0.000002). CONCLUSION: Neurological adverse events after COVID-19 immunisation were frequent and benign among spontaneous notifications. Headache was the most common neurological adverse effect of COVID-19 vaccines. Serious side effects were more frequent in the elderly and people with comorbidities. CI - (c) 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Dabilgou, Alfred Anselme AU - Dabilgou AA AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. dabilgouanselm@yahoo.fr. FAU - Ouedraogo, Emile Wendni AU - Ouedraogo EW AD - Laboratory for Medical Development, University Joseph KI-ZERBO, Ouagadougou, Burkina Faso. FAU - Kyelem, Julie Marie Adeline Wendlamita AU - Kyelem JMAW AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. FAU - Drave, Alassane AU - Drave A AD - Department of Neurology, Regional University Hospital of Ouahigouya, Ouahigouya, Burkina Faso. FAU - Wanre, Ousmane AU - Wanre O AD - Department of Neurology, Yalgado Ouedraogo University Hospital, Ouagadougou, Burkina Faso. FAU - Napon, Christain AU - Napon C AD - Department of Neurology, University Hospital of Bogodogo, Ouagadougou, Burkina Faso. FAU - Millogo, Athanase AU - Millogo A AD - Department of Neurology, University Hospital Sourou Sanou, Bobo-Dioulasso, Burkina Faso. LA - eng PT - Journal Article DEP - 20251013 PL - United States TA - J Neuroimmune Pharmacol JT - Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology JID - 101256586 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Cross-Sectional Studies MH - Adult MH - Middle Aged MH - *Pharmacovigilance MH - *COVID-19 Vaccines/adverse effects MH - Burkina Faso/epidemiology MH - Young Adult MH - *Nervous System Diseases/epidemiology/chemically induced MH - *COVID-19/prevention & control/epidemiology MH - Aged MH - Databases, Factual/trends MH - Adolescent MH - *Vaccination/adverse effects MH - Child OTO - NOTNLM OT - Burkina Faso OT - Covid-19 vaccines OT - Headaches OT - Neurological manifestations OT - Pharmacovigilance COIS- Declarations. Ethical Approval: We had the permission of the Ethics Board of the School of the University Joseph KI-ZERBO and of the Director of the National Department of Pharmacovigilance in Burkina Faso. The study was conducted in accordance with the Declaration of Helsinki. Human Ethics and Consent to Participate: Not applicable. Consent to Participate: Not applicable. Publication Consent of the Participants: Not applicable. Consent for Publication: All authors of the manuscript have read and agreed on its content and are responsible for all aspects of the accuracy and integrity of the manuscript in accordance with the ICMJE criteria. Conflict of interest: The authors declare no competing interests. Conflicts of interest/Competing interests: All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript. EDAT- 2025/10/13 12:30 MHDA- 2025/10/13 12:31 CRDT- 2025/10/13 11:22 PHST- 2024/07/24 00:00 [received] PHST- 2025/09/03 00:00 [accepted] PHST- 2025/10/13 12:31 [medline] PHST- 2025/10/13 12:30 [pubmed] PHST- 2025/10/13 11:22 [entrez] AID - 10.1007/s11481-025-10249-8 [pii] AID - 10.1007/s11481-025-10249-8 [doi] PST - epublish SO - J Neuroimmune Pharmacol. 2025 Oct 13;20(1):89. doi: 10.1007/s11481-025-10249-8. PMID- 41076807 OWN - NLM STAT- MEDLINE DCOM- 20251101 LR - 20251101 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 66 DP - 2025 Nov 14 TI - Differentiating COVID-19 vaccine-related adverse events from long COVID: A comprehensive review of clinical manifestations, pathophysiology, and diagnostic approaches. PG - 127842 LID - S0264-410X(25)01139-9 [pii] LID - 10.1016/j.vaccine.2025.127842 [doi] AB - The global deployment of COVID-19 vaccines has introduced diagnostic challenges due to overlapping symptoms with long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC), prompting a comprehensive review of vaccine safety profiles, long COVID manifestations, and evidence-based differentiation strategies. Through a literature search (PubMed, Scopus, Web of Science) from December 2020 to June 2025, including peer-reviewed studies, clinical trials, and cohort studies, the present review reports that COVID-19 vaccines maintain robust safety, with rare adverse events like myocarditis and thrombosis with thrombocytopenia syndrome, while long COVID affects 10-40 % of SARS-CoV-2 survivors, presenting symptoms such as fatigue, cognitive dysfunction, and dyspnea. Differentiation between these conditions relies on careful analysis of the timing of symptom onset, detailed symptom characterization, and the use of advanced diagnostic tools. Systematic clinical assessment is essential for accurate diagnosis, which is critical for appropriate patient management, maintaining public confidence in vaccination, and guiding future research. Further studies are needed to validate diagnostic biomarkers, develop targeted therapies, and monitor long-term outcomes, with standardized global registries and interdisciplinary collaboration identified as key priorities for improving care and advancing the field. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Domingo, Jose L AU - Domingo JL AD - Universitat Rovira i Virgili, School of Medicine, Laboratory of Toxicology and Environmental Health, San Llorens 21, 43201 Reus, Catalonia, Spain.. Electronic address: joseluis.domingo@urv.cat. LA - eng PT - Journal Article PT - Review DEP - 20251011 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - *COVID-19/prevention & control/diagnosis/immunology MH - SARS-CoV-2/immunology MH - Post-Acute COVID-19 Syndrome MH - Vaccination/adverse effects OTO - NOTNLM OT - COVID-19 vaccines OT - adverse events OT - differential diagnosis OT - long COVID OT - vaccine safety COIS- Declaration of competing interest The author declares that he has no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/10/13 00:27 MHDA- 2025/11/02 00:33 CRDT- 2025/10/12 18:04 PHST- 2025/07/02 00:00 [received] PHST- 2025/08/10 00:00 [revised] PHST- 2025/10/04 00:00 [accepted] PHST- 2025/11/02 00:33 [medline] PHST- 2025/10/13 00:27 [pubmed] PHST- 2025/10/12 18:04 [entrez] AID - S0264-410X(25)01139-9 [pii] AID - 10.1016/j.vaccine.2025.127842 [doi] PST - ppublish SO - Vaccine. 2025 Nov 14;66:127842. doi: 10.1016/j.vaccine.2025.127842. Epub 2025 Oct 11. PMID- 40977400 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250922 LR - 20250926 IS - 2056-4724 (Print) IS - 2056-4724 (Electronic) IS - 2056-4724 (Linking) VI - 11 IP - 5 DP - 2025 Sep 22 TI - Short-term risk of psychiatric adverse events following COVID-19 vaccination: nationwide self-controlled case series study. PG - e218 LID - 10.1192/bjo.2025.10803 [doi] LID - e218 AB - BACKGROUND: To date, little is known about the evidence of a potential risk of psychiatric adverse events following COVID-19 vaccination in large populations with adequate study design. AIMS: To investigate whether COVID-19 vaccination is associated with increased risk of psychiatric adverse events. METHOD: We used South Korea's linkage database to obtain registry data and claims data from 2019 to 2021, and conducted a population-based self-controlled case series study including 11 751 806 individuals. Primary outcomes included anxiety/nervousness, mood disorders, perceptual disturbances/psychoses, aggression/behavioural disturbances, cognitive impairments and sleep disorders within 21 days of COVID-19 vaccination. Secondary outcomes were the stratified primary outcomes according to each individual's psychiatric history. Conditional Poisson regression was used to estimate incidence rate ratios (IRR) and 95% confidence intervals. RESULTS: COVID-19 vaccination did not increase the rate of anxiety and nervousness (adjusted IRR 0.95, 95% CI 0.95-0.96), mood disorders (adjusted IRR 0.75, 95% CI 0.75-0.76), perceptual disturbances and psychoses (adjusted IRR 0.72, 95% CI 0.70-0.74), aggression and behavioural disturbances (adjusted IRR 0.93, 95% CI 0.89-0.97), cognitive impairment (adjusted IRR 0.68, 95% CI 0.67-0.69) or sleep disorders (adjusted IRR 0.90, 95% CI 0.89-0.91). Secondary outcomes were consistent with the primary outcome, although the adjusted IRRs for anxiety and nervousness (adjusted IRR 1.17, 95% CI 1.15-1.18) and sleep disorders (adjusted IRR 1.07, 95% CI 1.06-1.09) were statistically significant in individuals with no history of psychiatric disorders. Sensitivity analyses showed consistent results with our main findings. CONCLUSIONS: Our findings provide short-term safety profiles for COVID-19 vaccines regarding psychiatric adverse events. Continuous monitoring of anxiety/nervousness or sleep disorders after COVID-19 vaccination is required regardless of history of psychiatric comorbidities. FAU - Lee, Hyesung AU - Lee H AD - Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea. AD - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. FAU - Hong, Bin AU - Hong B AD - School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. FAU - Lee, Eun AU - Lee E AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. FAU - Park, Jin Young AU - Park JY AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. AD - Center for Digital Health, Yongin Severance Hospital, Yonsei University Health System, Yongin, Republic of Korea. FAU - Jung, Jaehun AU - Jung J AD - Department of Preventive Medicine, Korea University College of Medicine, Seoul, Republic of Korea. AD - Institute on Aging, Korea University, Seoul, Republic of Korea. FAU - Kim, Woo Jung AU - Kim WJ AUID- ORCID: 0000-0002-4963-4819 AD - Department of Psychiatry, Institute of Behavioral Science in Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea. AD - Department of Psychiatry, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea. AD - Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea. FAU - Shin, Ju-Young AU - Shin JY AUID- ORCID: 0000-0003-1010-7525 AD - Department of Medical Informatics, Kangwon National University College of Medicine, Chuncheon, Republic of Korea. AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Republic of Korea. AD - Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea. LA - eng PT - Journal Article DEP - 20250922 PL - England TA - BJPsych Open JT - BJPsych open JID - 101667931 PMC - PMC12458088 OTO - NOTNLM OT - COVID-19 vaccine OT - psychiatric adverse events OT - self-controlled case series COIS- J.-Y.S. received grants from the Ministry of Food and Drug Safety, the National Research Foundation of Korea and pharmaceutical companies, including Pfizer, Yuhan Corporation and the UCB Korea. No other relationships or activities have influenced the submitted work. EDAT- 2025/09/22 06:31 MHDA- 2025/09/22 06:32 PMCR- 2025/09/22 CRDT- 2025/09/22 05:05 PHST- 2025/09/22 06:32 [medline] PHST- 2025/09/22 06:31 [pubmed] PHST- 2025/09/22 05:05 [entrez] PHST- 2025/09/22 00:00 [pmc-release] AID - S205647242510803X [pii] AID - 10.1192/bjo.2025.10803 [doi] PST - epublish SO - BJPsych Open. 2025 Sep 22;11(5):e218. doi: 10.1192/bjo.2025.10803. PMID- 40944962 OWN - NLM STAT- MEDLINE DCOM- 20250916 LR - 20260325 IS - 1099-1654 (Electronic) IS - 1052-9276 (Linking) VI - 35 IP - 5 DP - 2025 Sep TI - Post-COVID-19 Vaccination (or Long Vax) Syndrome: Putative Manifestation, Pathophysiology, and Therapeutic Options. PG - e70070 LID - 10.1002/rmv.70070 [doi] AB - With the global rollout of COVID-19 vaccines, vaccine safety remains a priority. Emerging concerns have raised the potential risk of a long COVID-like syndrome following vaccination, informally called long Vax and provisionally termed post-COVID-19 vaccination syndrome (PCVS). Our narrative review describes the putative manifestation, pathophysiology, and therapeutic approaches of PCVS based on the available evidence, mostly from case reports/series and observational studies. Our review noted that PCVS typically manifests within days to weeks post-vaccination, with symptoms lasting months to years. PCVS may present as recognized diagnoses such as postural orthostatic tachycardia syndrome (POTS), small-fibre neuropathy (SFN), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), or as long-term sequelae of myocarditis, vaccine-induced thrombotic thrombocytopaenia (VITT), or immune thrombocytopaenia purpura (ITP). Symptomatically, PCVS overlaps with long COVID, such as fatigue and brain fog, but PCVS may involve more frequent paraesthesia and less dyspnoea. We also review pathophysiological hypotheses of PCVS, focussing on the vaccine-derived spike protein and related immune responses. Finally, we discuss potential therapies used to treat patients with PCVS or related conditions, primarily documented in case reports/series, which could guide future clinical research. Overall, PCVS remains a poorly understood condition that requires more research to elucidate its prevalence, prognosis, risk factors, and treatments. CI - (c) 2025 John Wiley & Sons Ltd. FAU - Yong, Shin Jie AU - Yong SJ AUID- ORCID: 0000-0001-9752-8386 AD - School of Medical and Life Sciences, Sunway University, Sunway City, Malaysia. FAU - Kenny, Tiff-Annie AU - Kenny TA AD - Departement de medecine sociale et preventive, Faculte de medecine de l'universite Laval, Quebec City, Quebec, Canada. AD - Centre de recherche du CHU de Quebec-Universite Laval, Quebec City, Quebec, Canada. FAU - Halim, Alice AU - Halim A AD - Royal Bolton Hospital, Bolton NHS Foundation Trust, Bolton, UK. FAU - Munipalli, Bala AU - Munipalli B AD - Division of General Internal Medicine, Mayo Clinic Florida, Jacksonville, Florida, USA. FAU - Alhashem, Yousef N AU - Alhashem YN AUID- ORCID: 0000-0003-4435-3003 AD - Clinical Laboratory Science Department, Mohammed Al-Mana College for Medical Sciences, Dammam, Saudi Arabia. FAU - AlSaihati, Hajir AU - AlSaihati H AD - Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia. FAU - Al-Subaie, Maha F AU - Al-Subaie MF AD - Research Center, Dr. Sulaiman Alhabib Medical Group, Riyadh, Saudi Arabia. AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. FAU - Al Kaabi, Nawal A AU - Al Kaabi NA AD - College of Medicine and Health Science, Khalifa University, Abu Dhabi, UAE. AD - Sheikh Khalifa Medical City, Abu Dhabi Health Services Company, Abu Dhabi, UAE. FAU - Al Fares, Mona A AU - Al Fares MA AD - Department of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia. FAU - Garout, Mohammed AU - Garout M AD - Department of Community Medicine and Health Care for Pilgrims, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia. FAU - Sabour, Amal A AU - Sabour AA AD - Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia. FAU - Alshiekheid, Maha A AU - Alshiekheid MA AD - Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia. FAU - Almansour, Zainab H AU - Almansour ZH AUID- ORCID: 0000-0003-0227-6863 AD - Biological Science Department, College of Science, King Faisal University, Hofuf, Saudi Arabia. FAU - Alotaibi, Jawaher AU - Alotaibi J AD - Infectious Diseases Unit, Department of Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. FAU - Alrasheed, Hayam A AU - Alrasheed HA AUID- ORCID: 0009-0002-6186-848X AD - Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. FAU - Alamri, Aref A AU - Alamri AA AD - Molecular Microbiology and Cytogenetics Department, Riyadh Regional Laboratory, Riyadh, Saudi Arabia. FAU - Albayat, Hawra AU - Albayat H AD - Infectious Disease Department, King Saud Medical City, Riyadh, Saudi Arabia. FAU - Alamodi, Ameera Saeed AU - Alamodi AS AD - Department of Pharmacy, Mental Health Hospital, Taif, Saudi Arabia. FAU - Tombuloglu, Huseyin AU - Tombuloglu H AD - Department of Genetics Research, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia. FAU - Mohapatra, Ranjan K AU - Mohapatra RK AUID- ORCID: 0000-0001-7623-3343 AD - Department of Chemistry, Government College of Engineering, Keonjhar, India. FAU - Hazazi, Ali AU - Hazazi A AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. AD - Department of Pathology and Laboratory Medicine, Security Forces Hospital Program, Riyadh, Saudi Arabia. FAU - Rabaan, Ali A AU - Rabaan AA AUID- ORCID: 0000-0002-6774-9847 AD - College of Medicine, Alfaisal University, Riyadh, Saudi Arabia. AD - Molecular Diagnostic Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia. AD - Department of Public Health and Nutrition, The University of Haripur, Haripur, Pakistan. LA - eng PT - Journal Article PT - Review PL - England TA - Rev Med Virol JT - Reviews in medical virology JID - 9112448 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control/immunology MH - *Vaccination/adverse effects MH - SARS-CoV-2/immunology MH - Fatigue Syndrome, Chronic MH - Syndrome OTO - NOTNLM OT - COVID-19 vaccines OT - mRNA vaccine OT - post-COVID-19 vaccination syndrome OT - spike protein OT - vaccine safety EDAT- 2025/09/13 18:29 MHDA- 2025/09/16 06:36 CRDT- 2025/09/13 14:52 PHST- 2025/07/24 00:00 [revised] PHST- 2025/05/08 00:00 [received] PHST- 2025/08/19 00:00 [accepted] PHST- 2025/09/16 06:36 [medline] PHST- 2025/09/13 18:29 [pubmed] PHST- 2025/09/13 14:52 [entrez] AID - 10.1002/rmv.70070 [doi] PST - ppublish SO - Rev Med Virol. 2025 Sep;35(5):e70070. doi: 10.1002/rmv.70070. PMID- 40885518 OWN - NLM STAT- MEDLINE DCOM- 20251002 LR - 20251005 IS - 1878-3511 (Electronic) IS - 1201-9712 (Linking) VI - 159 DP - 2025 Oct TI - Classic pathway persistent complement activation is associated with specific symptoms in individuals with post-COVID-19 condition: A case-control study. PG - 108032 LID - S1201-9712(25)00254-1 [pii] LID - 10.1016/j.ijid.2025.108032 [doi] AB - OBJECTIVES: The complement system is a crucial part of the immune system. The role of complement activation in post-COVID-19 condition is still not conclusive. We present a case-control study investigating long-lasting complement hyperactivation in COVID-19 survivors with/without post-COVID-19 condition. METHODS: A case-control (2:1 design) study was performed. Concentration levels of four proteins from classic complement pathway (C3, C4, C5, C7) and total hemolytic complement (CH50) activity were obtained from blood samples in group of survivors with post-COVID-19 condition and in a comparison group of survivors without post-COVID-19 condition, matched by age, sex, and vaccination status. Post-COVID-19 condition was defined when individuals self-reported at least one of these post-COVID-19 symptoms: fatigue, arthralgia, myalgia, memory problems, new-onset headache, or palpitations. RESULTS: A total of 57 (56.1% women, age: 46.5 years, SD: 9.0 years) survivors with post-COVID-19 condition and 27 (55.5% women, age: 46.5 years, SD: 11.5 years) survivors without post-COVID-19 condition were evaluated 1.7 (SD 1.2) and 2.0 (SD 1.7) years after SARS-CoV-2 infection, respectively. Overall, the results did not reveal differences in complement protein levels and CH50 activity between survivors with or without post-COVID-19 condition. Patients reporting post-COVID fatigue exhibited lower C3 levels (P = 0.025) than those without post-COVID fatigue, whereas survivors with post-COVID dyspnea reported lower levels of C3 (P = 0.001), C5 (P = 0.015), and C7 (P = 0.030) proteins than those without post-COVID dyspnea. CONCLUSIONS: This explorative case-control study did not observe overall complement activation from classic pathway in survivors with post-COVID-19 condition up to 2 years after. Some complement proteins were elevated in individuals with specific post-COVID symptoms, such as fatigue or dyspnea. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Fernandez-de-Las-Penas, Cesar AU - Fernandez-de-Las-Penas C AD - Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos (URJC), Madrid, Spain; Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark. Electronic address: cesar.fernandez@urjc.es. FAU - Ruiz-Ruigomez, Maria AU - Ruiz-Ruigomez M AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain. FAU - Esparcia-Pinedo, Laura AU - Esparcia-Pinedo L AD - F.E.A Inmunologia, SYNLAB Diagnosticos Globales S.A.U, Barcelona, Spain. FAU - Colom-Fernandez, Beatriz AU - Colom-Fernandez B AD - F.E.A Inmunologia, SYNLAB Diagnosticos Globales S.A.U, Barcelona, Spain. FAU - Cava-Valenciano, Fernando AU - Cava-Valenciano F AD - F.E.A Inmunologia, SYNLAB Diagnosticos Globales S.A.U, Barcelona, Spain. FAU - Torres-Macho, Juan AU - Torres-Macho J AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. FAU - Arrieta-Ortubay, Estibaliz AU - Arrieta-Ortubay E AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain. FAU - Akasbi-Moltalvo, Miriam AU - Akasbi-Moltalvo M AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain. FAU - Lumbreras-Bermejo, Carlos AU - Lumbreras-Bermejo C AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, Madrid, Spain. FAU - Arendt-Nielsen, Lars AU - Arendt-Nielsen L AD - Center for Neuroplasticity and Pain (CNAP), SMI, Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark; Department of Gastroenterology & Hepatology, Mech-Sense, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark; Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, Aalborg, Denmark. FAU - Franco-Moreno, Anabel AU - Franco-Moreno A AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, Madrid, Spain. LA - eng PT - Journal Article DEP - 20250828 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 SB - IM MH - Humans MH - *COVID-19/immunology/complications MH - Female MH - Male MH - Case-Control Studies MH - Middle Aged MH - Adult MH - SARS-CoV-2 MH - *Complement Pathway, Classical/immunology MH - *Complement Activation MH - Survivors OTO - NOTNLM OT - Complement OT - Dyspnea OT - Fatigue OT - Long-COVID OT - Plasma OT - post-COVID-19 COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2025/08/31 04:45 MHDA- 2025/10/03 00:29 CRDT- 2025/08/30 19:16 PHST- 2025/08/05 00:00 [received] PHST- 2025/08/24 00:00 [revised] PHST- 2025/08/26 00:00 [accepted] PHST- 2025/10/03 00:29 [medline] PHST- 2025/08/31 04:45 [pubmed] PHST- 2025/08/30 19:16 [entrez] AID - S1201-9712(25)00254-1 [pii] AID - 10.1016/j.ijid.2025.108032 [doi] PST - ppublish SO - Int J Infect Dis. 2025 Oct;159:108032. doi: 10.1016/j.ijid.2025.108032. Epub 2025 Aug 28. PMID- 40883541 OWN - NLM STAT- MEDLINE DCOM- 20250829 LR - 20250901 IS - 2399-3642 (Electronic) IS - 2399-3642 (Linking) VI - 8 IP - 1 DP - 2025 Aug 29 TI - SARS-CoV-2 vaccination during pregnancy enhances offspring hippocampal neurogenesis and working memory via IFN-gamma-responsive microglia. PG - 1307 LID - 10.1038/s42003-025-08691-8 [doi] LID - 1307 AB - In the face of severe outcomes from COVID-19, vaccines have proven immunogenic and safe and are strongly recommended during pregnancy. This study examines the effects of maternal COVID-19 vaccination on physical development, behavior, and neurogenesis in mouse offspring. After inoculation with inactivated SARS-CoV-2 vaccine (Vero Cell) at gestational day 14.5, antibodies were detected in the serum of dams and pups. At one month of age, offspring of vaccinated dams-but not controls-showed enhanced working memory, increased neural proliferation, neuroblast formation, stem cell activity, and more mature neurons in the dentate gyrus (DG). Luminex assay showed elevated hippocampal IFN-gamma and CX3CL1, both linked to neurogenesis and memory. Conditional knockout experiments identified microglial IFNgammaR1 and CX3CR1 as key mediators of neuronal development through regulating microglial activation and chemotaxis. These findings suggest maternal SARS-CoV-2 vaccination transiently enhances hippocampal neurogenesis and working memory in offspring, without causing neurodevelopmental risk. CI - (c) 2025. The Author(s). FAU - Tang, Jiaoling AU - Tang J AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Qi, Fangfang AU - Qi F AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. qi.fangfang@mayo.edu. AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. qi.fangfang@mayo.edu. FAU - Zou, Juntao AU - Zou J AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Liu, Hao AU - Liu H AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Zuo, Zejie AU - Zuo Z AD - Department of Rehabilitation Medicine, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. FAU - Wang, Lingxiao AU - Wang L AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. AD - Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, USA. FAU - Wang, Na AU - Wang N AD - Department of Neurology, Mayo Clinic, Rochester, MN, USA. FAU - Li, Zhihui AU - Li Z AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. FAU - Kumar, Ashutosh AU - Kumar A AD - Department of Anatomy, All India Institute of Medical Sciences (AIIMS), Patna, India. AD - Etiologically Elusive Disorders Research Network (EEDRN), New Delhi, India. FAU - Guo, Kaihua AU - Guo K AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. guokh@mail.sysu.edu.cn. FAU - Hu, Dandan AU - Hu D AD - Children's Health Section, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China. guohdd@126.com. FAU - Yao, Zhibin AU - Yao Z AUID- ORCID: 0000-0003-1613-9157 AD - Department of Anatomy and Physiology, Guangdong Province Key Laboratory of Brain Function and Disease, Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China. yao.zb@163.com. LA - eng GR - 82271473;81971021/National Natural Science Foundation of China (National Science Foundation of China)/ PT - Journal Article DEP - 20250829 PL - England TA - Commun Biol JT - Communications biology JID - 101719179 RN - 82115-62-6 (Interferon-gamma) RN - 0 (COVID-19 Vaccines) RN - 0 (Interferon gamma Receptor) RN - 0 (Receptors, Interferon) RN - 0 (CX3C Chemokine Receptor 1) RN - 0 (Cx3cr1 protein, mouse) SB - IM MH - Animals MH - *Neurogenesis/drug effects MH - Female MH - *Microglia/immunology/metabolism MH - Pregnancy MH - *Hippocampus/immunology MH - Mice MH - *Memory, Short-Term/drug effects MH - *COVID-19/prevention & control/immunology MH - *Interferon-gamma/metabolism MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Vaccination MH - Interferon gamma Receptor MH - Receptors, Interferon/genetics/metabolism MH - CX3C Chemokine Receptor 1/genetics/metabolism MH - Mice, Inbred C57BL MH - Male MH - Mice, Knockout PMC - PMC12397237 COIS- Competing interests: The authors declare no competing interests. EDAT- 2025/08/31 04:45 MHDA- 2025/08/31 04:46 PMCR- 2025/08/29 CRDT- 2025/08/29 23:34 PHST- 2024/12/21 00:00 [received] PHST- 2025/08/07 00:00 [accepted] PHST- 2025/08/31 04:46 [medline] PHST- 2025/08/31 04:45 [pubmed] PHST- 2025/08/29 23:34 [entrez] PHST- 2025/08/29 00:00 [pmc-release] AID - 10.1038/s42003-025-08691-8 [pii] AID - 8691 [pii] AID - 10.1038/s42003-025-08691-8 [doi] PST - epublish SO - Commun Biol. 2025 Aug 29;8(1):1307. doi: 10.1038/s42003-025-08691-8. PMID- 40881041 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250915 LR - 20250915 IS - 2632-6140 (Electronic) IS - 2632-6140 (Linking) VI - 7 IP - 2 DP - 2025 TI - Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination. PG - e001013 LID - 10.1136/bmjno-2024-001013 [doi] LID - e001013 AB - BACKGROUND AND OBJECTIVES: Persistent headache has emerged as a symptom following acute COVID-19 and, to a lesser extent, after SARS-CoV-2 vaccination. However, the underlying mechanisms remain poorly understood. This study aimed to evaluate plasma levels of amyloid-related biomarkers in patients experiencing persistent headaches after COVID-19 or SARS-CoV-2 vaccination. METHODS: In this prospective observational cohort, patients presenting with severe headache as the dominating symptom after COVID-19 (n=29) or SARS-CoV-2 vaccination (n=31) had neurological assessments with reassessments after 6 months. Plasma levels of amyloid precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum Amyloid A (SAA1) were measured using ELISA and compared with levels in healthy controls (n=16). RESULTS: We found a strong and persistent upregulation of APP in patients with headache after COVID-19 as compared with the two other groups. Notably, APP levels remained elevated at both inclusion and after 6 months in individuals with accompanying cognitive symptoms. In contrast, PZP levels were increased in patients with headache after SARS-CoV-2 vaccination at both time points relative to healthy controls. CTSL was only elevated in the post-COVID-19 at baseline, whereas SAA1 showed levels comparable across all groups. CONCLUSION: Altered plasma levels of soluble markers, potentially reflecting changes in amyloid processing, were found in patients with persistent headache following SARS-CoV-2 vaccine, particularly in those with persistent headache after COVID-19. In the latter group, we also found some association with cognitive symptoms. TRIAL REGISTRATION NUMBERS: NCT04576351 and NCT05235776. CI - Copyright (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Aamodt, Anne Hege AU - Aamodt AH AUID- ORCID: 0000-0002-2824-2760 AD - Neurology, Oslo University Hospital, Oslo, Norway. AD - Neuroscience and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway. FAU - Ueland, Thor AU - Ueland T AD - Research Institute of Internal Medicine and Institute of Clinical Medicine, University of Oslo and Oslo University Hospital, Oslo, Norway. AD - Thrombosis Research Center (TREC), Division of internal medicine, University Hospital of North Norway, Tromso, Norway. FAU - Boldingh, Marion AU - Boldingh M AD - Neurology, Oslo University Hospital, Oslo, Norway. FAU - Bezgal, Burcu Ella AU - Bezgal BE AD - Neurology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. FAU - Argren, Maria Bengtson AU - Argren MB AD - Neurology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. FAU - Dunne, Cecilia Adele AU - Dunne CA AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. FAU - Otterdal, Kari AU - Otterdal K AD - Neurology, Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Gregersen, Ida AU - Gregersen I AD - Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Bjerkeli, Vigdis AU - Bjerkeli V AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Michelsen, Annika Elisabet AU - Michelsen AE AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Neurology, Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Husoy, Andreas AU - Husoy A AD - Neuroscience and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Neurology, St Olavs Hospital Trondheim University Hospital Neurology Clinic, Trondheim, Norway. FAU - Morsund, Ase Hagen AU - Morsund AH AUID- ORCID: 0000-0003-4890-9654 AD - Department of Neurology, Helse More og Romsdal HF, Alesund, Norway. FAU - Devik, Kristina AU - Devik K AD - Neurology, Namsos Hospital, Namsos, Norway. AD - Department of Neuromedicine and Movement Science, Norges teknisk-naturvitenskapelige universitet, Trondheim, Norway. FAU - Poole, Anne Christine AU - Poole AC AD - Oslo Headache Centre, Oslo, Norway. FAU - Gjendemsjo, Kristine Bodding AU - Gjendemsjo KB AD - Sandvika Neuro Centre, Oslo, Norway. FAU - Schluter, Katrin AU - Schluter K AD - Stavanger University Hospital, Stavanger, Norway. FAU - Mathisen, Sara Maria AU - Mathisen SM AD - Stavanger University Hospital, Stavanger, Norway. FAU - Aalstad-Johansen, Mari AU - Aalstad-Johansen M AD - Neurology, Sykehuset Innlandet HF Divisjon Lillehammer, Lillehammer, Norway. FAU - Skattor, Thor Hakon AU - Skattor TH AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Radiology, Oslo University Hospital, Oslo, Norway. FAU - Sonnervik, Julie AU - Sonnervik J AD - Hodeverket, Sandnes, Norway. FAU - Boye, Turid Birgitte AU - Boye TB AD - Institute of Basic Medical Sciences, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Unit Psychosomatic Medicine and CL Psychiatry, Oslo universitetssykehus, Oslo, Norway. FAU - Popperud, Trine Haug AU - Popperud TH AD - Neurology, Oslo University Hospital, Oslo, Norway. FAU - Hogestol, Einar August AU - Hogestol EA AD - Neurology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. FAU - Harbo, Hanne Flinstad AU - Harbo HF AD - Neurology, Oslo University Hospital, Oslo, Norway. AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. FAU - Lund-Johansen, Fridtjof AU - Lund-Johansen F AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Immunology, Oslo University Hospital, Oslo, Norway. FAU - Aukrust, Pal AU - Aukrust P AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Tronvik, Erling AU - Tronvik E AD - Neuroscience and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway. AD - Department of Neurology, St Olavs Hospital Trondheim University Hospital Neurology Clinic, Trondheim, Norway. FAU - Dahl, Tuva Borresdatter AU - Dahl TB AD - Neurology, Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. FAU - Halvorsen, Bente Evy AU - Halvorsen BE AD - Institute of Clinical Medicine, University of Oslo Faculty of Medicine, Oslo, Norway. AD - Research Institute for Internal Medicine, Oslo University Hospital and University of Oslo, Oslo, Norway. AD - Department of Medicine, Division of Cardiovascular Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA. LA - eng SI - ClinicalTrials.gov/NCT05235776 SI - ClinicalTrials.gov/NCT04576351 PT - Journal Article DEP - 20250826 PL - England TA - BMJ Neurol Open JT - BMJ neurology open JID - 101775450 PMC - PMC12382501 OTO - NOTNLM OT - AMYLOID OT - COVID-19 OT - HEADACHE OT - MIGRAINE COIS- The authors report no disclosures relevant to this study. AHA has received honoraria for advice or lecturing from Pfizer Allergan, Teva, Novartis, Roche, Lundbeck and Teva and research grant from Boehringer Ingelheim. ACP: lecturing, advisory boards and/or clinical studies: AbbVie, Lundbeck, Pfizer, Novartis, Teva, Eli Lilly. EDAT- 2025/08/30 04:46 MHDA- 2025/08/30 04:47 PMCR- 2025/08/26 CRDT- 2025/08/29 14:20 PHST- 2024/12/21 00:00 [received] PHST- 2025/08/10 00:00 [accepted] PHST- 2025/08/30 04:47 [medline] PHST- 2025/08/30 04:46 [pubmed] PHST- 2025/08/29 14:20 [entrez] PHST- 2025/08/26 00:00 [pmc-release] AID - bmjno-2024-001013 [pii] AID - 10.1136/bmjno-2024-001013 [doi] PST - epublish SO - BMJ Neurol Open. 2025 Aug 26;7(2):e001013. doi: 10.1136/bmjno-2024-001013. eCollection 2025. PMID- 40867400 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20250914 LR - 20250914 IS - 2076-328X (Print) IS - 2076-328X (Electronic) IS - 2076-328X (Linking) VI - 15 IP - 8 DP - 2025 Aug 1 TI - Cognitive-Affective Dynamics of Political Attitude Polarization: EEG-Based Behavioral Evidence from a COVID-19 Vaccine Mandate Task. LID - 10.3390/bs15081043 [doi] LID - 1043 AB - Political polarization in policy evaluations arises from identity-driven cognitive-affective dynamics, yet the neural mechanisms underlying the real-time processing of policy texts remain unexplored. This study bridges this gap by employing EEG to capture neurobehavioral responses during a COVID-19 vaccine mandate judgment task. The analysis of 70 politically stratified participants revealed significantly elevated gamma1 (30-50 Hz) activity in the right prefrontal cortex among policy supporters, reflecting enhanced attentional engagement and value integration. These topographically specific neural dissociations demonstrate how ideological alignment modulates cognitive-affective processing. Our findings establish EEG as a robust tool for quantifying implicit identity-driven evaluations, offering new pathways to decode polarization in contested policy contexts. FAU - Li, Jing AU - Li J AUID- ORCID: 0009-0006-9132-2700 AD - School of Political Science and Public Administration, Wuhan University, Wuhan 430072, China. FAU - Xu, Zhiwei AU - Xu Z AUID- ORCID: 0009-0002-8480-1739 AD - School of Business, Hubei University, Wuhan 430062, China. LA - eng GR - 71872062/National Natural Science Foundation of China/ PT - Journal Article DEP - 20250801 PL - Switzerland TA - Behav Sci (Basel) JT - Behavioral sciences (Basel, Switzerland) JID - 101576826 PMC - PMC12383215 OTO - NOTNLM OT - EEG OT - behavioral neuroscience OT - cognitive engagement OT - political polarization OT - right prefrontal cortex COIS- The authors declare no conflicts of interest. EDAT- 2025/08/30 04:49 MHDA- 2025/08/30 04:50 PMCR- 2025/08/01 CRDT- 2025/08/28 01:03 PHST- 2025/05/16 00:00 [received] PHST- 2025/06/23 00:00 [revised] PHST- 2025/07/29 00:00 [accepted] PHST- 2025/08/30 04:50 [medline] PHST- 2025/08/30 04:49 [pubmed] PHST- 2025/08/28 01:03 [entrez] PHST- 2025/08/01 00:00 [pmc-release] AID - bs15081043 [pii] AID - behavsci-15-01043 [pii] AID - 10.3390/bs15081043 [doi] PST - epublish SO - Behav Sci (Basel). 2025 Aug 1;15(8):1043. doi: 10.3390/bs15081043. PMID- 40832032 OWN - NLM STAT- MEDLINE DCOM- 20250820 LR - 20250822 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - Mental symptoms in post-COVID syndrome and post-COVID-19 vaccination syndrome: results of a representative population survey. PG - 1623757 LID - 10.3389/fpubh.2025.1623757 [doi] LID - 1623757 AB - BACKGROUND: Mental symptoms such as fatigue, concentration difficulties, and sleep disorders are frequently reported in both Post-COVID Syndrome (PCS) and Post-COVID-19 Vaccination Syndrome (PCVS). Although symptom profiles may overlap, comparative epidemiological data from the general population are limited. METHODS: We conducted a representative online survey of 4,632 adults in Germany and investigated mental symptoms associated with PCS and PCVS, including fatigue, cognitive problems, sleep disturbances, impaired performance and depressed mood. Socio-demographic factors, vaccination status, vaccine type and number of vaccinations were analysed. RESULTS: The prevalence of self-reported mental symptoms of PCS was 12.1% among respondents, with women and younger individuals more commonly affected. The prevalence of self-reported PCVS was 12.6% among vaccinated individuals, with no significant gender differences, but fewer cognitive symptoms in older adults. Respondents with only one vaccination reported the highest rate of PCVS symptoms (20.8%), which decreased to 8.9% for those with four or more vaccinations. Differences between vaccine types were small overall, but non-mRNA vaccines were associated with a slightly higher rate of sleep and concentration problems. CONCLUSION: Mental symptoms are relatively common after both SARS-CoV-2 infection and vaccination and show overlap, especially fatigue. These findings highlight how difficult it is to distinguish PCS from PCVS and emphasize the need to consider alternative explanations, such as undiagnosed depressive disorders, in clinical assessments. CI - Copyright (c) 2025 Czaplicki, Hipper and Hegerl. FAU - Czaplicki, Andreas AU - Czaplicki A AD - German Foundation for Depression and Suicide Prevention, Leipzig, Germany. FAU - Hipper, Leonie AU - Hipper L AD - German Foundation for Depression and Suicide Prevention, Leipzig, Germany. FAU - Hegerl, Ulrich AU - Hegerl U AD - German Foundation for Depression and Suicide Prevention, Leipzig, Germany. AD - Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Goethe University Frankfurt (Goethe Research Professorship), Frankfurt am Main, Germany. LA - eng PT - Journal Article DEP - 20250804 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Germany/epidemiology MH - Adult MH - Middle Aged MH - *COVID-19/prevention & control/psychology/epidemiology MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - Aged MH - Fatigue/epidemiology/etiology MH - *Vaccination/adverse effects/psychology MH - Surveys and Questionnaires MH - Young Adult MH - Sleep Wake Disorders/epidemiology/etiology MH - SARS-CoV-2 MH - *Mental Disorders/epidemiology/etiology MH - Adolescent MH - Prevalence MH - Post-Acute COVID-19 Syndrome PMC - PMC12358428 OTO - NOTNLM OT - COVID 19 OT - COVID-vaccine OT - depression OT - differential diagnosis OT - mental health OT - mental symptoms OT - population survey OT - post-COVID COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/20 06:33 MHDA- 2025/08/20 06:34 PMCR- 2025/08/04 CRDT- 2025/08/20 05:06 PHST- 2025/05/06 00:00 [received] PHST- 2025/07/20 00:00 [accepted] PHST- 2025/08/20 06:34 [medline] PHST- 2025/08/20 06:33 [pubmed] PHST- 2025/08/20 05:06 [entrez] PHST- 2025/08/04 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1623757 [doi] PST - epublish SO - Front Public Health. 2025 Aug 4;13:1623757. doi: 10.3389/fpubh.2025.1623757. eCollection 2025. PMID- 40802282 OWN - NLM STAT- MEDLINE DCOM- 20250910 LR - 20260709 IS - 2150-7511 (Electronic) VI - 16 IP - 9 DP - 2025 Sep 10 TI - COVID-19-associated neuroinflammation and astrocyte death in the brain linked to ORF3a-induced activation of Sur1-mediated ion channels. PG - e0201225 LID - 10.1128/mbio.02012-25 [doi] LID - e02012-25 AB - The coronavirus disease 2019 (COVID-19) pandemic has disproportionately affected individuals with pre-existing medical conditions, such as neurocognitive disorders. Premorbid neurocognitive conditions compounded by COVID-19 can escalate into COVID-associated neurological complications, leading to severe illness or even death. As COVID-19 continues to persist and vaccines lose efficacy against emerging variants, individuals with neurocognitive disorders often experience prolonged symptoms that are further exacerbated by repeated breakthrough infections of highly diversified viral variants due to emergence of new viral mutations. Despite the significance of neurocognitive disorders as risk factors for COVID-19-related mortality and long COVID, the underlying causes remain largely unknown. In this study, we report a link between ORF3a expression and COVID-associated neuroinflammation and neurocytotoxicity in postmortem brain tissues from COVID-19 patients. These findings were further verified through neural cell-based in vitro and in vivo animal studies introducing ORF3a either alone or in the context of viral infection. As a membrane-associated protein, ORF3a induces upregulation of Sur1-regulated ion channels, resulting in intracellular Ca(2+) influx, apoptosis, and necrosis through both NF-kB-dependent and independent proinflammatory responses in astrocytes. These findings reveal a novel clinical and mechanistic link between ORF3a and Sur1-regulated ion channels, which are highly responsive to neuroinflammatory conditions causing neurodegeneration. Additionally, we have identified a Food and Drug Administration-approved drug, glibenclamide, and a natural antiviral compound glycyrrhizin that effectively mitigates the neuropathological effects of ORF3a, underscoring the therapeutic potential and clinical significance of these findings.IMPORTANCECoronavirus disease 2019 (COVID-19) disproportionately affects individuals with pre-existing neurocognitive conditions primarily due to COVID-19-associated neuroinflammation and neurotoxicity (CNN), which can progress to COVID-associated neurological disorders (CANDs), leading to severe illness and mortality. Despite CNN's significant contribution to CANDs and related morbidity and mortality, its underlying causes remain poorly understood. Our study identifies ORF3a as a key driver of CNN, establishing a direct clinical and functional link between ORF3a and CNN linking to CANDs. Mechanistically, ORF3a disrupts ion homeostasis in astrocytes by promoting Ca(2)(+) influx through Sur1-regulated ion channels, contributing to CNN. Notably, the Food and Drug Administration-approved drug glibenclamide, a Sur1-specific inhibitor, and the natural compound glycyrrhizin effectively mitigate ORF3a-induced neuropathology, highlighting ORF3a as a promising therapeutic target. These findings present a potential strategy to eliminate CNN and prevent CANDs. FAU - Gerzanich, Volodymyr AU - Gerzanich V AD - Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. FAU - Zhang, Chenyu AU - Zhang C AD - Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. FAU - Zhang, Jiantao AU - Zhang J AD - Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA. FAU - Sallapalli, Bhargava Teja AU - Sallapalli BT AD - Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA. FAU - Pei, Shaokai AU - Pei S AD - Department of Microbiology, Howard University College of Medicine, Washington, DC, USA. FAU - Nasr, Mohamed AU - Nasr M AD - Drug Development and Preclinical Research Branch, Division of AIDS, NIAID, NIH, Bethesda, Maryland, USA. FAU - Tosun, Cigdem AU - Tosun C AD - Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. FAU - Zhang, Yanjin AU - Zhang Y AUID- ORCID: 0000-0002-5847-3260 AD - Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA. FAU - Tang, Qiyi AU - Tang Q AUID- ORCID: 0000-0002-6487-2356 AD - Department of Microbiology, Howard University College of Medicine, Washington, DC, USA. FAU - Simard, J Marc AU - Simard JM AUID- ORCID: 0000-0002-5373-1988 AD - Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. AD - Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA. AD - Drug Development and Preclinical Research Branch, Division of AIDS, NIAID, NIH, Bethesda, Maryland, USA. FAU - Zhao, Richard Y AU - Zhao RY AUID- ORCID: 0000-0003-3424-2852 AD - Department of Pathology, University of Maryland School of Medicine, Baltimore, Maryland, USA. AD - Research & Development Service, VA Maryland Health Care System, Baltimore, Maryland, USA. AD - Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA. AD - Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA. AD - Institute of Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA. LA - eng GR - G12MD007597/MD/NIMHD NIH HHS/United States GR - R01NS102589, R01NS105633/NS/NINDS NIH HHS/United States GR - R01 NS105633/NS/NINDS NIH HHS/United States GR - I01 BX004652/BX/BLRD VA/United States GR - I01BX004652/U.S. Department of Veterans Affairs/ GR - R01NS107262/NS/NINDS NIH HHS/United States GR - R01 NS107262/NS/NINDS NIH HHS/United States GR - R01 NS102589/NS/NINDS NIH HHS/United States GR - R21 AI175931/AI/NIAID NIH HHS/United States GR - G12 MD007597/MD/NIMHD NIH HHS/United States GR - R01 HL082517/HL/NHLBI NIH HHS/United States GR - SC1 AI112785/AI/NIAID NIH HHS/United States GR - R21AI175931/National Institute of Allergy and Infectious Diseases/ GR - SC1AI112785/National Institute of Allergy and Infectious Diseases/ GR - I01RX003060, I01BX004652/U.S. Department of Veterans Affairs/ GR - I01 RX003060/RX/RRD VA/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20250813 PL - United States TA - mBio JT - mBio JID - 101519231 RN - 0 (Viroporin Proteins) RN - 0 (Sulfonylurea Receptors) RN - 0 (ORF3a protein, SARS-CoV-2) RN - 0 (ABCC8 protein, human) RN - 0 (Ion Channels) SB - IM MH - Humans MH - *Astrocytes/pathology/metabolism/virology MH - *COVID-19/pathology/complications/metabolism/virology MH - Animals MH - SARS-CoV-2 MH - *Viroporin Proteins/metabolism/genetics MH - *Brain/pathology/virology/metabolism MH - *Sulfonylurea Receptors/metabolism/genetics MH - *Neuroinflammatory Diseases/virology/metabolism/pathology MH - Mice MH - Male MH - *Ion Channels/metabolism MH - Female PMC - PMC12421821 OTO - NOTNLM OT - COVID-19 OT - ORF3a OT - SARS-CoV-2 OT - Sur1-regulated ion channels OT - glibenclamide OT - glycyrrhizin OT - neuroinflammation and neurotoxicity OT - reactive astrocytes COIS- The authors declare no conflict of interest. EDAT- 2025/08/13 12:31 MHDA- 2025/09/10 12:32 PMCR- 2025/08/13 CRDT- 2025/08/13 11:47 PHST- 2025/09/10 12:32 [medline] PHST- 2025/08/13 12:31 [pubmed] PHST- 2025/08/13 11:47 [entrez] PHST- 2025/08/13 00:00 [pmc-release] AID - mbio02012-25 [pii] AID - mbio.02012-25 [pii] AID - 10.1128/mbio.02012-25 [doi] PST - ppublish SO - mBio. 2025 Sep 10;16(9):e0201225. doi: 10.1128/mbio.02012-25. Epub 2025 Aug 13. PMID- 40761637 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20261011 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 16 DP - 2025 TI - Neurologic symptoms following COVID-19 in Lima, Peru: a prospective longitudinal observational study. PG - 1524613 LID - 10.3389/fneur.2025.1524613 [doi] LID - 1524613 AB - INTRODUCTION: There is limited research on long-term neurologic symptoms following SARS-CoV-2 infection in Peru. This study aimed to describe the longitudinal experience of survivors of mild to moderate COVID-19 in Lima, Peru. METHODS: This prospective, longitudinal observational study included neurologic follow-up data between 3- and 12-months following SARS-CoV-2 infection. Recruitment to a parent study: "Natural History of SARS-CoV-2 in Comparison to Influenza Virus: A Multi-site Study Focused on the Southern Hemisphere and Equatorial Regions" (COFLU Peru), occurred between February 2021 and February 2022 in a Callao, Peru public hospital emergency department. In-person visits for this sub-study, "Neuro COFLU," included neurologic history and symptom questionnaire. RESULTS: Fifty-four patients were seen for at least one visit, two of whom required hospitalization for COVID-19. Forty-one (76%) reported at least one pre-existing neurologic diagnosis (59% headaches; 24% migraines). At follow-up visits, patients reported at least one new neurologic symptom since COVID-19: 24/29 (83%) at 90 days, 31/42 (74%) at 180 days, 41/46 (89%) at 270 days, and 20/21 (95%) at 365 days. The median number of new symptoms was 3 at 90 days, 3 at 180, 4 at 270 and 3 at 365 days. Days 90-180 frequent symptoms included: muscular pain, neck stiffness, headache, loss of appetite, numbness, insomnia, and weakness (24-31%). Days 181-365 frequent symptoms included: fatigue, weakness, memory problems, irritability, changes in hearing, muscular pain, joint pain, and insomnia (28-33%). Pre-existing anxiety was associated with post-COVID-19 hearing changes, muscular pain, numbness and weakness and pre-existing depression with neck stiffness and numbness. No significant association was found with age, sex, vaccination status, or pre-existing headaches. Full recovery was reported for 6/29 (21%) at day 90, 13/42 (31%) at day 180, 17/46 (37%) at day 270, and 9/20 (45%) at day 365. By day 365, patients reported median recovery of 85-90%. DISCUSSION: Persistent neurological symptoms are common in COVID-19 survivors in Lima. Many new neurologic symptoms persisted and increased in prevalence over 3-12 months. Limitations include lack of control group and small sample size. Longitudinal studies of outcomes are needed to predict and mitigate the long-term physical, social and economic effects of SARS-CoV-2 infection. CI - Copyright (c) 2025 Huff, Villanueva-Colina, Diaz, Tovar, Davila Luna, Wu, Hamer, Koralnik, Solomon, Caniza and Garcia. FAU - Huff, Hanalise V AU - Huff HV AD - Department of Global Health and Population, Harvard T. H. Chan School of Public Health, Boston, MA, United States. AD - Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States. FAU - Villanueva-Colina, Carla AU - Villanueva-Colina C AD - School of Public Health, Cayetano Heredia University, Lima, Peru. FAU - Diaz, Monica M AU - Diaz MM AD - Department of Neurology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, United States. FAU - Tovar, Sofia AU - Tovar S AD - School of Public Health, Cayetano Heredia University, Lima, Peru. FAU - Davila Luna, Andrea AU - Davila Luna A AD - School of Public Health, Cayetano Heredia University, Lima, Peru. FAU - Wu, Tianxia AU - Wu T AD - Clinical Trials Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, United States. FAU - Hamer, Davidson H AU - Hamer DH AD - Department of Global Health, Boston University School of Public Health, Boston, MA, United States. AD - Section of Infectious Diseases, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, United States. AD - Boston University Center on Emerging Infectious Diseases, Boston, MA, United States. FAU - Koralnik, Igor J AU - Koralnik IJ AD - Ken and Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. FAU - Solomon, Tom AU - Solomon T AD - The Pandemic Institute and The National Institute for Health and Care Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, United Kingdom. AD - The Walton Centre, NHS Foundation Trust, Liverpool, United Kingdom. FAU - Caniza, Miguela A AU - Caniza MA AD - Department of Global Pediatric Medicine and Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States. FAU - Garcia, Patricia J AU - Garcia PJ AD - School of Public Health, Cayetano Heredia University, Lima, Peru. LA - eng GR - D43 TW010540/TW/FIC NIH HHS/United States GR - D43 TW010543/TW/FIC NIH HHS/United States GR - HHSN272201400006C/AI/NIAID NIH HHS/United States GR - K23 MH131466/MH/NIMH NIH HHS/United States PT - Journal Article DEP - 20250721 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 EIN - Front Neurol. 2025 Oct 10;16:1676667. doi: 10.3389/fneur.2025.1676667. PMID: 41159191 PMC - PMC12320530 OTO - NOTNLM OT - COVID-19 OT - Latin America OT - Long-COVID OT - Peru OT - global health OT - neuroinfectious disease OT - neurologic COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/08/05 06:28 MHDA- 2025/08/05 06:29 PMCR- 2025/07/21 CRDT- 2025/08/05 04:51 PHST- 2024/11/12 00:00 [received] PHST- 2025/06/11 00:00 [accepted] PHST- 2025/08/05 06:29 [medline] PHST- 2025/08/05 06:28 [pubmed] PHST- 2025/08/05 04:51 [entrez] PHST- 2025/07/21 00:00 [pmc-release] AID - 10.3389/fneur.2025.1524613 [doi] PST - epublish SO - Front Neurol. 2025 Jul 21;16:1524613. doi: 10.3389/fneur.2025.1524613. eCollection 2025. PMID- 40727493 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250731 IS - 0974-777X (Print) IS - 0974-8245 (Electronic) IS - 0974-777X (Linking) VI - 17 IP - 2 DP - 2025 Apr-Jun TI - Impact, Trends, and Visibility of Scientific Publications on Neurological Effects of COVID-19 Vaccine: A Scientometric Analysis. PG - 98-103 LID - 10.4103/jgid.jgid_159_24 [doi] AB - INTRODUCTION: Neurological complications associated with the COVID-19 vaccine can include different neurological diseases. Although these cases are rare, it is crucial for healthcare professionals to recognize them for timely diagnosis and treatment. The aim of this study was to analyze the impact, trend, and visibility of scientific publications on the neurological effects of the COVID-19 vaccine during 2020-2023 in Scopus. METHODS: A bibliometric, descriptive, and retrospective study was conducted. Through Scopus (SciVal), variables were measured objectively. Data were sought from December 2018 to August 2023. All papers on neurological effects associated with the COVID-19 vaccine were published between January 2020 and August 2023 in the Scopus database. On August 18, 2023, 65 articles were identified, of which 59 met the inclusion criteria. They were downloaded and exported in.csv format and subsequently analyzed in Microsoft Excel(R) 2019 using tables. RESULTS: The United States was the country with the highest number of authors (six) publishing on the subject in Scopus, followed by India with two authors. In addition, it was observed that the United States was the country with the highest production, with 30 publications and 411 countable citations. However, India, being the second in scientific production, was the country with the highest impact. Of the most productive institutions, six were from the United States, with Harvard University being the institution with the highest scientific production. With respect to the journals, six obtained two publications on the subject under study, where "Journal of Neurology" and "Journal of Clinical Medicine" stand out with 100 and 80 publications, respectively. CONCLUSIONS: The bibliometric analysis reveals that the USA leads in publications on adverse neurological effects of COVID-19 vaccine. India stands out for its impact, especially through institutions such as Ahmedabad Civil Hospital and B. J. Medical College. It is suggested to expand the research to other databases. CI - Copyright: (c) 2025 Journal of Global Infectious Diseases. FAU - Ramirez, Ana Paula Sangama AU - Ramirez APS AD - Department of Academic, Faculty of Human Medicine, Universidad Cientifica del Sur, Lima, Peru. FAU - Cavero, Raul Sebastian Tello AU - Cavero RST AD - Department of Academic, Faculty of Human Medicine, Universidad Cientifica del Sur, Lima, Peru. FAU - Mayta-Tovalino, Frank AU - Mayta-Tovalino F AD - Department of Academic, Bibliometrics, Evidence Evaluation and Systematic Reviews Group, Human Medicine Faculty, Universidad Cientifica del Sur, Lima, Peru. LA - eng PT - Journal Article DEP - 20250626 PL - India TA - J Glob Infect Dis JT - Journal of global infectious diseases JID - 101521436 PMC - PMC12294153 OTO - NOTNLM OT - Bibliometrics OT - COVID-19 OT - neurological manifestations OT - vaccines COIS- There are no conflicts of interest. EDAT- 2025/07/29 06:30 MHDA- 2025/07/29 06:31 PMCR- 2025/06/26 CRDT- 2025/07/29 05:57 PHST- 2024/08/07 00:00 [received] PHST- 2024/10/15 00:00 [revised] PHST- 2025/02/10 00:00 [accepted] PHST- 2025/07/29 06:31 [medline] PHST- 2025/07/29 06:30 [pubmed] PHST- 2025/07/29 05:57 [entrez] PHST- 2025/06/26 00:00 [pmc-release] AID - JGID-17-98 [pii] AID - 10.4103/jgid.jgid_159_24 [doi] PST - epublish SO - J Glob Infect Dis. 2025 Jun 26;17(2):98-103. doi: 10.4103/jgid.jgid_159_24. eCollection 2025 Apr-Jun. PMID- 40708533 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260228 IS - 2056-4724 (Print) IS - 2056-4724 (Electronic) IS - 2056-4724 (Linking) VI - 11 IP - 4 DP - 2025 Jul 25 TI - Chronic post-COVID neuropsychiatric symptoms persisting more than 1 year after infection during the 'Omicron wave'. PG - e160 LID - 10.1192/bjo.2025.10078 [doi] LID - e160 AB - BACKGROUND: The heterogeneity of chronic post-COVID neuropsychiatric symptoms (PCNPS), especially after infection by the Omicron strain, has not been adequately explored. AIMS: To explore the clustering pattern of chronic PCNPS in a cohort of patients having their first COVID infection during the 'Omicron wave' and discover phenotypes of patients based on their symptoms' patterns using a pre-registered protocol. METHOD: We assessed 1205 eligible subjects in Hong Kong using app-based questionnaires and cognitive tasks. RESULTS: Partial network analysis of chronic PCNPS in this cohort produced two major symptom clusters (cognitive complaint-fatigue and anxiety-depression) and a minor headache-dizziness cluster, like our pre-Omicron cohort. Participants with high numbers of symptoms could be further grouped into two distinct phenotypes: a cognitive complaint-fatigue predominant phenotype and another with symptoms across multiple clusters. Multiple logistic regression showed that both phenotypes were predicted by the level of pre-infection deprivation (adjusted P-values of 0.025 and 0.0054, respectively). The severity of acute COVID (adjusted P = 0.023) and the number of pre-existing medical conditions predicted only the cognitive complaint-fatigue predominant phenotype (adjusted P = 0.003), and past suicidal ideas predicted only the symptoms across multiple clusters phenotype (adjusted P < 0.001). Pre-infection vaccination status did not predict either phenotype. CONCLUSIONS: Our findings suggest that we should pursue a phenotype-driven approach with holistic biopsychosocial perspectives in disentangling the heterogeneity under the umbrella of chronic PCNPS. Management of patients complaining of chronic PCNPS should be stratified according to their phenotypes. Clinicians should recognise that depression and anxiety cannot explain all chronic post-COVID cognitive symptoms. FAU - Chau, Steven Wai Ho AU - Chau SWH AUID- ORCID: 0000-0002-2986-8677 AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Chue, Timothy Mitchell AU - Chue TM AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Lam, Tsz Ching AU - Lam TC AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Lai, Yee Lok AU - Lai YL AUID- ORCID: 0009-0004-1002-8805 AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Chan, Rachel Ngan Yin AU - Chan RNY AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Wong, Paul W C AU - Wong PWC AUID- ORCID: 0000-0003-3388-6285 AD - Department of Social Work and Social Administration, Faculty of Social Sciences, The University of Hong Kong, Hong Kong SAR. FAU - Li, Shirley Xin AU - Li SX AD - Department of Psychology, Faculty of Social Science, The University of Hong Kong, Hong Kong SAR. FAU - Liu, Yaping AU - Liu Y AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. FAU - Chan, Joey Wing Yan AU - Chan JWY AUID- ORCID: 0000-0002-2692-2666 AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Chan, Paul Kay-Sheung AU - Chan PK AD - Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Lai, Christopher Koon-Chi AU - Lai CK AD - Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - S.H. Ho Research Centre for Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Leung, Thomas W H AU - Leung TWH AD - Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. FAU - Wing, Yun Kwok AU - Wing YK AUID- ORCID: 0000-0002-5745-5474 AD - Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR. AD - Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR. LA - eng PT - Journal Article DEP - 20250725 PL - England TA - BJPsych Open JT - BJPsych open JID - 101667931 PMC - PMC12260592 OTO - NOTNLM OT - Infection OT - long-COVID OT - network analysis OT - neuropsychiatry COIS- J.W.Y.C. has received personal fees from Eisai Co., Ltd and travel support from Lundbeck HK Ltd for overseas conferences. C.K.-C.L. has received honoraria for lectures from GSK and support for attending meetings from Pfizer. Y.K.W. has received personal fees from Eisai Co., Ltd for delivering a lecture and sponsorship from Lundbeck HK Ltd and Aculys Pharma, Inc. EDAT- 2025/07/25 06:38 MHDA- 2025/07/25 06:39 PMCR- 2025/07/25 CRDT- 2025/07/25 04:02 PHST- 2025/07/25 06:39 [medline] PHST- 2025/07/25 06:38 [pubmed] PHST- 2025/07/25 04:02 [entrez] PHST- 2025/07/25 00:00 [pmc-release] AID - S2056472425100781 [pii] AID - 10.1192/bjo.2025.10078 [doi] PST - epublish SO - BJPsych Open. 2025 Jul 25;11(4):e160. doi: 10.1192/bjo.2025.10078. PMID- 40655221 OWN - NLM STAT- MEDLINE DCOM- 20250714 LR - 20260925 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 13 DP - 2025 TI - Understanding the social and cognitive influences on the adoption of COVID-19 non-pharmaceutical interventions: a survey of a Saudi Arabian sample. PG - 1588931 LID - 10.3389/fpubh.2025.1588931 [doi] LID - 1588931 AB - INTRODUCTION: COVID-19 vaccines prevent death and severe illness, but not infection. Public health leaders continue to stress the importance of non-pharmaceutical intervention behaviors (NPIs). However, little is known about how social, environmental, and cognitive factors influence the adoption of NPIs. METHODS: A theory-informed survey was distributed to adults living in Al-Ahsa, Saudi Arabia. The primary focus is self-reported adherence with NPIs. Socio-environmental factors included observational learning, social norms, and media. Personal cognitive factors included self-efficacy, outcome expectancies, and knowledge. RESULTS: The mean age was 31 years (n = 368), most participants were males (62%), and the study sample were significantly more vaccinated (40%) than the Saudi public (5.3%). NPIs were strongly correlated with social norms (r = 0.73, p < 0.001), and positively correlated with self-efficacy (r = 0.25, p < 0.001). Females reported higher NPIs adherence rates (M = 17.04, SD = 3.86) than males (M = 16.29, SD = 4.12). The hierarchical multiple regression model revealed that socio-environmental factors explained a significant proportion of variance in NPIs (R (2) = 0.52, p < 0.001). DISCUSSION: The findings highlight the usefulness of a social cognitive model in predicting NPIs. The study shows that social factors, especially social norms, significantly influence the adoption of NPIs. Hence, health organizations should consider social factors when developing campaigns against current and future infectious diseases. CI - Copyright (c) 2025 Alobaydullah, LaJoie, Thomas, Fumey and Alsaleem. FAU - Alobaydullah, Ahmed AU - Alobaydullah A AD - Emergency Medical Services Program, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Al Ahsa, Saudi Arabia. AD - King Abdullah International Medical Research Center, Al Ahsa, Saudi Arabia. FAU - LaJoie, Andrew Scott AU - LaJoie AS AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Thomas, Susann Denise AU - Thomas SD AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Fumey, Raphael AU - Fumey R AD - Department of Health Promotion and Behavioral Sciences, University of Louisville, Louisville, KY, United States. FAU - Alsaleem, Abdulrahman AU - Alsaleem A AD - Emergency Medical Services Program, College of Applied Medical Sciences, King Saud bin Abdulaziz University for Health Sciences, Al Ahsa, Saudi Arabia. AD - King Abdullah International Medical Research Center, Al Ahsa, Saudi Arabia. LA - eng PT - Journal Article DEP - 20250627 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Saudi Arabia MH - Male MH - Female MH - Adult MH - *COVID-19/prevention & control MH - Self Efficacy MH - Middle Aged MH - Surveys and Questionnaires MH - SARS-CoV-2 MH - *COVID-19 Vaccines/administration & dosage MH - Young Adult MH - *Health Knowledge, Attitudes, Practice MH - *Cognition MH - Adolescent MH - Social Norms PMC - PMC12245856 OTO - NOTNLM OT - COVID-19 OT - Saudi Arabia OT - non-pharmaceutical interventions OT - preventive behaviors OT - social cognitive theory OT - social norms COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/07/14 12:29 MHDA- 2025/07/14 12:30 PMCR- 2025/06/27 CRDT- 2025/07/14 07:36 PHST- 2025/03/06 00:00 [received] PHST- 2025/05/31 00:00 [accepted] PHST- 2025/07/14 12:30 [medline] PHST- 2025/07/14 12:29 [pubmed] PHST- 2025/07/14 07:36 [entrez] PHST- 2025/06/27 00:00 [pmc-release] AID - 10.3389/fpubh.2025.1588931 [doi] PST - epublish SO - Front Public Health. 2025 Jun 27;13:1588931. doi: 10.3389/fpubh.2025.1588931. eCollection 2025. PMID- 40645616 OWN - NLM STAT- MEDLINE DCOM- 20250711 LR - 20250714 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 15 IP - 7 DP - 2025 Jul 10 TI - Basel Long COVID Cohort Study (BALCoS): protocol of a prospective cohort study. PG - e093981 LID - 10.1136/bmjopen-2024-093981 [doi] LID - e093981 AB - INTRODUCTION: The recent pandemic caused by SARS-CoV-2 had a profound global impact. While many individuals recovered from COVID-19, some developed long-lasting symptoms that significantly disrupted daily life. The WHO defines this condition as post-COVID-19 condition (PCC). Common symptoms include fatigue, dyspnoea, sleep disturbances and cognitive difficulties. Increasing evidence suggests that PCC is a multifactorial condition, shaped not only by biomedical but also psychological and social factors. This article presents the protocol of the Basel Long COVID Cohort Study (BALCoS), which aims to improve understanding of PCC by capturing clinical, functional and psychosocial aspects through repeated assessments over the course of 1 year. METHODS AND ANALYSIS: BALCoS is a prospective, single-site cohort study. Inclusion criteria include either a probable or confirmed history of SARS-CoV-2 infection with persistent symptoms consistent with the WHO definition of PCC, sufficient German language skills and age >/=18 years. At baseline, we collected detailed information on previous SARS-CoV-2 infections, symptom history, reinfections, COVID-19 vaccination status and pre-existing medical conditions. The study includes standardised psychometric assessments, physical performance tests, ecological momentary assessments (EMAs), neurocognitive testing and blood sample collection. Assessments are scheduled at baseline and at 3-month, 6-month and 12-month follow-up. All participants complete psychometric assessments at each time point. Blood samples are only collected at baseline. Neurocognitive testing and physical performance measures are collected at baseline and 12-month follow-up for in-person participants only. Participants who are unable to attend in person complete a remote version of the study, excluding these in-clinic assessments. EMAs are initiated the day after each time point and consist of eight questions over 10 consecutive days. The study is exploratory in nature, with a target sample size of 120 participants. BALCoS is part of the Horizon Europe Long COVID project, a multinational interdisciplinary research consortium integrating mechanistic, clinical and interventional studies. ETHICS AND DISSEMINATION: The study was approved by the Ethics Commission of Northwest and Central Switzerland (BASEC-ID: 2023-00359) and is registered at ClinicalTrials.gov (ID: NCT05781893). All participants provide written informed consent. Study findings will be disseminated through peer-reviewed publications. TRIAL REGISTERATION NUMBER: NCT05781893. CI - (c) Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group. FAU - Rohner, Stefan AU - Rohner S AUID- ORCID: 0000-0002-4812-6433 AD - Faculty of Medicine, University of Basel, Basel, Switzerland. AD - Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland. FAU - Schnepper, Rebekka AU - Schnepper R AD - Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland. AD - Digital and Blended Psychosomatics and Psychotherapy, University of Basel, Basel, Switzerland. FAU - Meinlschmidt, Gunther AU - Meinlschmidt G AUID- ORCID: 0000-0002-3488-193X AD - Faculty of Medicine, University of Basel, Basel, Switzerland. AD - Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland. AD - Department of Digital and Blended Psychosomatics and Psychotherapy, University Hospital Basel, Basel, Switzerland. AD - Department of Clinical Psychology and Psychotherapy - Methods and Approaches, University of Trier, Trier, Germany. FAU - Schaefert, Rainer AU - Schaefert R AD - Faculty of Medicine, University of Basel, Basel, Switzerland. AD - Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland. FAU - Mayr, Michael AU - Mayr M AUID- ORCID: 0000-0002-1962-8186 AD - Faculty of Medicine, University of Basel, Basel, Switzerland. AD - Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland. FAU - Bopp, Katrin AU - Bopp K AD - Faculty of Medicine, University of Basel, Basel, Switzerland. AD - Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland. FAU - Meienberg, Andrea AU - Meienberg A AUID- ORCID: 0000-0002-0751-2469 AD - Faculty of Medicine, University of Basel, Basel, Switzerland andrea.meienberg@usb.ch. AD - Medical Outpatient Clinic, University Hospital Basel, Basel, Switzerland. LA - eng SI - ClinicalTrials.gov/NCT05781893 PT - Clinical Trial Protocol PT - Journal Article DEP - 20250710 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 SB - IM MH - Female MH - Humans MH - Male MH - *COVID-19/complications/psychology/epidemiology MH - Post-Acute COVID-19 Syndrome MH - Prospective Studies MH - Psychometrics MH - Research Design MH - Switzerland/epidemiology MH - Observational Studies as Topic PMC - PMC12248209 OTO - NOTNLM OT - COVID-19 OT - EPIDEMIOLOGY OT - Observational Study OT - Post-Acute COVID-19 Syndrome OT - Public health OT - SARS-CoV-2 Infection COIS- Competing interests: GM received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia Bangerter-Rhyner-Stiftung under projects no. PC 28/17 and PC 05/18, from Health Promotion Switzerland (Gesundheitsforderung Schweiz) under project no. 18.191/K50001, from the Swiss Heart Foundation under project no. FF21101, from the Research Foundation of the International Psychoanalytic University (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation (SNSF) under project no. 100014_135328, from the German Federal Ministry of Education and Research under budget item 68606, from the Hasler Foundation under project No. 23004, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium "Long COVID" (funding number: 101057553) and from Wings Health in the context of a proof-of-concept study. GM is a co-founder and shareholder of Therayou AG, active in digital and blended mental healthcare. GM receives royalties from publishing companies as author, including a book published by Springer, and an honourarium from Lundbeck for speaking at a symposium. Furthermore, GM is compensated for providing psychotherapy to patients, acting as a supervisor, serving as a self-experience facilitator ('Selbsterfahrungsleiter'), and for postgraduate training of psychotherapists, psychosomatic specialists and supervisors. RaS received funding from Health Promotion Switzerland (Gesundheitsforderung Schweiz) under contract no. 18.191/ K50001, from the Health Department Basel-City, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium "Long COVID" (funding number: 101057553), and from Wings Health in the context of a proof of concept study. RaS is co-editor of the German AWMF S3-Guidelines on Functional Complaints and contributed to the German guidelines on irritable bowel syndrome and on Lyme Borreliosis. RaS is chairman of the Basel Institute for Psychosomatic Medicine (BIPM), and founder and managing director of the Psychosomatic and Psychosocial Services GmbH, which develops and implements psychosomatic and psychosocial training and continuing education programmes. RaS is a member of the Swiss Academy of Psychosomatic and Psychosocial Medicine (SAPPM) - where he is a member of the Scientific Advisory Board, of the Societe Medicale Suisse d'Hypnose (SMSH), of the Dt. Kollegium fur Psychosomatische Medizin (DKPM), of the Dt. Gesellschaft fur Psychosomatische Medizin und Arztliche Psychotherapie (DGPM) and of the German Balint Society (DBG). RaS serves as spokesman of DKPM and DGPM for Consultation and Liaison Psychosomatics. He is a member of the board of trustees of the Foundation Psychosomatic and Social Medicine (Ascona Foundation). MM served as a consultant for AstraZeneca, Boehringer Ingelheim and Bayer and received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis and Viatris to support the organisation of independent medical education events. ReS received funding from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium "Long COVID" (funding number: 101057553). AM received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi-Aventis and Viatris to support the organisation of independent medical education events. All other authors have no competing interest to declare. EDAT- 2025/07/12 16:44 MHDA- 2025/07/12 16:45 PMCR- 2025/07/10 CRDT- 2025/07/11 20:33 PHST- 2025/07/12 16:45 [medline] PHST- 2025/07/12 16:44 [pubmed] PHST- 2025/07/11 20:33 [entrez] PHST- 2025/07/10 00:00 [pmc-release] AID - bmjopen-2024-093981 [pii] AID - 10.1136/bmjopen-2024-093981 [doi] PST - epublish SO - BMJ Open. 2025 Jul 10;15(7):e093981. doi: 10.1136/bmjopen-2024-093981. PMID- 40616705 OWN - NLM STAT- MEDLINE DCOM- 20250705 LR - 20250710 IS - 2509-9280 (Electronic) IS - 2509-9280 (Linking) VI - 9 IP - 1 DP - 2025 Jul 5 TI - Impact on the microstructure of deep gray matter in unvaccinated patients after moderate-to-severe COVID-19: insights from MRI T1 mapping. PG - 63 LID - 10.1186/s41747-025-00598-7 [doi] LID - 63 AB - BACKGROUND: To determine changes in quantitative T1 relaxation times (qT1) in deep gray matter in patients recovered from coronavirus disease 2019 (COVID-19). METHODS: Unvaccinated COVID-19 participants >/= 3 months after seropositivity and age- and sex-matched controls were examined using 3-T magnetic resonance imaging. Bilateral measures of thalamus, pallidum, putamen, caudate and accumbens nuclei, and hippocampus were extracted from qT1 maps after automated segmentation. Baseline characteristics and results of tests assessing neurological functions (standardized exam), ability to smell (4-Item Pocket Smell Test), depression (Beck Depression Inventory-II), sleepiness (Epworth Sleepiness Scale), sleep quality (Pittsburgh Sleep Quality Index), health-related quality of life (EQ-5D), and cognitive performance (Montreal Cognitive Assessment) were evaluated. RESULTS: One hundred forty-five subjects (median age, 46 years; 73 females) were included (11/2020-12/2021): 69 recovered after COVID-19 and 76 controls (age, p = 0.532; sex, p = 0.799), without significant differences in qT1 values overall (all p-values > 0.050). Subgroup analysis of participants aged >/= 40 (age, p = 0.675; sex, p = 0.447) revealed higher qT1 values in previously hospitalized COVID-19 subjects (23/69) compared to controls (47/76) in left and right caudate nuclei (p = 0.009; p = 0.027), left accumbens nucleus (p = 0.017), right putamen (p = 0.041), and right hippocampus (p = 0.020). No correlations were found with macroscopic imaging findings, pre-existing conditions, time since COVID-19 diagnosis, inpatient treatment duration, or test results. CONCLUSION: T1 mapping revealed microstructural changes in striatal and hippocampal regions of unvaccinated individuals aged >/= 40 who recovered from moderate-to-severe COVID-19 during the pre-Omicron era. RELEVANCE STATEMENT: This study elucidates brain involvement following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, underscoring the need for further longitudinal analyses to assess the potential reversibility, stability or deterioration of these findings. KEY POINTS: We hypothesized altered T1 relaxation times in deep gray matter after COVID-19. Unvaccinated participants >/= 40 years exhibited higher striatal, hippocampal qT1 after moderate-to-severe COVID-19. No qT1 correlations were found with hospitalization duration, pre-existing conditions, or neuro-(psycho)logical tests. CI - (c) 2025. The Author(s). FAU - Fahim, Masia AU - Fahim M AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Hattingen, Elke AU - Hattingen E AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. hattingen@med.uni-frankfurt.de. FAU - Jurcoane, Alina AU - Jurcoane A AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Schure, Jan R AU - Schure JR AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Klinsing, Svenja AU - Klinsing S AD - Department of Neurology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Koepsell, Julia AU - Koepsell J AD - Department of Internal Medicine, Infectious Diseases, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Jahnke, Kolja AU - Jahnke K AD - Department of Neurology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Ronellenfitsch, Michael W AU - Ronellenfitsch MW AD - Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Pilatus, Ulrich AU - Pilatus U AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Vehreschild, Maria J G T AU - Vehreschild MJGT AD - Department of Internal Medicine, Infectious Diseases, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Deichmann, Ralf AU - Deichmann R AD - Brain Imaging Center, Goethe University Frankfurt, Frankfurt am Main, Germany. FAU - Arendt, Christophe T AU - Arendt CT AUID- ORCID: 0000-0003-3300-3729 AD - Institute of Neuroradiology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany. arendt@med.uni-frankfurt.de. LA - eng PT - Journal Article DEP - 20250705 PL - England TA - Eur Radiol Exp JT - European radiology experimental JID - 101721752 SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - Middle Aged MH - Case-Control Studies MH - *COVID-19/diagnostic imaging/pathology MH - *Gray Matter/diagnostic imaging/pathology MH - *Magnetic Resonance Imaging/methods MH - Severity of Illness Index MH - Unvaccinated Persons PMC - PMC12228859 OTO - NOTNLM OT - Brain mapping OT - COVID-19 OT - Gray matter OT - Magnetic resonance imaging OT - SARS-CoV-2 COIS- Declarations. Ethics approval and consent to participate: The study was approved by the Ethics Committee of the Faculty of Medicine at Goethe University Frankfurt, Germany (20-838) and registered at the German Clinical Trials Register (DRKS00023880). The study was conducted in accordance with the ethical guidelines for research involving human subjects, according to the Declaration of Helsinki. Guarantor: The scientific guarantor of this publication is Prof Dr Elke Hattingen. Consent for publication: Each participant signed an informed consent form for research. Competing interests: The authors declare that they have no competing interests. EDAT- 2025/07/05 20:44 MHDA- 2025/07/05 20:45 PMCR- 2025/07/05 CRDT- 2025/07/05 11:15 PHST- 2024/06/17 00:00 [received] PHST- 2025/06/04 00:00 [accepted] PHST- 2025/07/05 20:45 [medline] PHST- 2025/07/05 20:44 [pubmed] PHST- 2025/07/05 11:15 [entrez] PHST- 2025/07/05 00:00 [pmc-release] AID - 10.1186/s41747-025-00598-7 [pii] AID - 598 [pii] AID - 10.1186/s41747-025-00598-7 [doi] PST - epublish SO - Eur Radiol Exp. 2025 Jul 5;9(1):63. doi: 10.1186/s41747-025-00598-7. PMID- 40604014 OWN - NLM STAT- MEDLINE DCOM- 20250703 LR - 20250705 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 15 IP - 1 DP - 2025 Jul 2 TI - Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients. PG - 23437 LID - 10.1038/s41598-025-07017-2 [doi] LID - 23437 AB - Previous studies suggest that butyrylcholinesterase (BChE), an enzyme involved in the cholinergic anti-inflammatory pathway, may be linked to inflammation, disease severity, and risk of death in COVID-19 patients. Extending earlier work on BChE and COVID-19 severity, this study investigates additional factors such as age, sex, vaccination status, and symptom profiles. We analyzed 462 patients with polymerase chain reaction (PCR)-confirmed COVID-19 from the first epidemic wave in Spain, examining the association between BChE activity, clinical outcomes, demographic factors, and symptoms. The cohort consisted of 78 asymptomatic patients, 200 patients with mild symptoms, 122 patients with severe symptoms, and 62 critically ill patients. Of the patients in the severe symptoms group and critically ill patients, 26 died within 30 days of diagnosis. Our results showed that BChE activity was not affected by sex but decreased significantly with age (P < 0.0001). Patients with severe COVID-19 symptoms and critically ill patients exhibited lower BChE activity than asymptomatic or mildly symptomatic individuals (P < 0.0001). Furthermore, lower BChE activity was observed in patients with respiratory symptoms, such as pneumonia (P = 0.0027) and dyspnea (P = 0.0120), while higher BChE activity was seen in patients with neurological symptoms, such as anosmia (P < 0.0001), ageusia (P = 0.0012), and headache (P = 0.0005). No significant association was found between BChE activity and gastrointestinal, algesic, musculoskeletal, or systemic inflammatory symptoms. Additionally, vaccinated patients, particularly those who received two doses, had lower BChE activity compared to unvaccinated individuals (P = 0.0465). In conclusion, serum BChE activity is significantly associated with the severity, mortality, and specific symptoms of COVID-19, and is influenced by age and vaccination status. These findings imply that BChE may be a potential biomarker to support prognosis and risk stratification in COVID-19 patients. However, further research is needed to understand the underlying mechanisms and to validate the role of BChE in clinical practice. CI - (c) 2025. The Author(s). FAU - Fazekas, Tomas AU - Fazekas T AD - Department of Physical Chemistry of Drugs, Faculty of Pharmacy, Comenius University Bratislava, Odbojarov 10, Bratislava, 832 32, Slovakia. FAU - Kovacik, Lucia AU - Kovacik L AD - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Odbojarov 10, Bratislava, 832 32, Slovakia. FAU - Rad, Morteza Motahari AU - Rad MM AD - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Odbojarov 10, Bratislava, 832 32, Slovakia. FAU - Barrios, Xavier Gabaldo AU - Barrios XG AD - Microbiology Laboratory, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Reus, 43204, Spain. FAU - Iftimie, Simona Mihaela AU - Iftimie SM AD - Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Reus, 43204, Spain. FAU - Camps, Jordi AU - Camps J AD - Biochemical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Reus, 43204, Spain. FAU - Hrabovska, Anna AU - Hrabovska A AD - Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University Bratislava, Odbojarov 10, Bratislava, 832 32, Slovakia. anna.paul.hrabovska@uniba.sk. AD - Toxicological and Antidoping Center, Faculty of Pharmacy, Comenius University Bratislava, Odbojarov 10, 832 32, Bratislava, Slovakia. anna.paul.hrabovska@uniba.sk. LA - eng GR - VEGA 1/0293/25/Ministerstvo skolstva, vedy, vyskumu a sportu Slovenskej republiky/ GR - VEGA 1/0283/22/Ministerstvo skolstva, vedy, vyskumu a sportu Slovenskej republiky/ GR - VEGA 1/0283/22/Ministerstvo skolstva, vedy, vyskumu a sportu Slovenskej republiky/ GR - APVV-22-0541/Agentura Ministerstva Skolstva, Vedy, Vyskumu a Sportu SR/ GR - APVV-22-0541/Agentura Ministerstva Skolstva, Vedy, Vyskumu a Sportu SR/ GR - 201807-10/Fundacio la Marato de TV3/ PT - Journal Article DEP - 20250702 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - EC 3.1.1.8 (Butyrylcholinesterase) RN - 0 (Biomarkers) SB - IM MH - Humans MH - *COVID-19/mortality/blood/diagnosis/enzymology/pathology MH - *Butyrylcholinesterase/blood MH - Male MH - Female MH - Middle Aged MH - Aged MH - Severity of Illness Index MH - SARS-CoV-2 MH - Adult MH - Spain/epidemiology MH - Aged, 80 and over MH - Prognosis MH - Biomarkers/blood PMC - PMC12222779 OTO - NOTNLM OT - Butyrylcholinesterase OT - COVID-19 OT - Ellman's assay OT - Mortality OT - Severity OT - Symptoms COIS- Declarations. Competing interests: The authors declare no competing interests. EDAT- 2025/07/03 00:27 MHDA- 2025/07/03 06:27 PMCR- 2025/07/02 CRDT- 2025/07/02 23:57 PHST- 2025/04/08 00:00 [received] PHST- 2025/06/12 00:00 [accepted] PHST- 2025/07/03 06:27 [medline] PHST- 2025/07/03 00:27 [pubmed] PHST- 2025/07/02 23:57 [entrez] PHST- 2025/07/02 00:00 [pmc-release] AID - 10.1038/s41598-025-07017-2 [pii] AID - 7017 [pii] AID - 10.1038/s41598-025-07017-2 [doi] PST - epublish SO - Sci Rep. 2025 Jul 2;15(1):23437. doi: 10.1038/s41598-025-07017-2. PMID- 40579261 OWN - NLM STAT- MEDLINE DCOM- 20251213 LR - 20251213 IS - 1995-9133 (Electronic) IS - 1684-1182 (Linking) VI - 58 IP - 6 DP - 2025 Dec TI - Neurological and psychiatric aspects of long COVID among vaccinated healthcare workers: An assessment of prevalence and reporting biases. PG - 670-677 LID - S1684-1182(25)00125-2 [pii] LID - 10.1016/j.jmii.2025.06.002 [doi] AB - BACKGROUND: This study assessed the prevalence and severity of neurological and psychiatric long COVID symptoms among healthcare workers (HCWs) based on their COVID-19 status, aiming to unravel the complexities associated with post-acute sequelae of SARS-CoV-2 infection. METHODS: A cohort of 467 HCWs from a teaching hospital in northern Taiwan, who received at least three doses of COVID-19 vaccines, were surveyed for long COVID symptoms. Participants were categorized into symptomatic (n = 224), asymptomatic (n = 21), and absence of COVID-19 (n = 222) groups based on diagnostic criteria involving questionnaire responses, medical records, and anti-nucleoprotein antibody data. Through a comprehensive set of questionnaires, symptoms, memory dysfunction, anxiety, and depression were rigorously evaluated and statistically analyzed for group comparisons. RESULTS: Despite meticulous data collection, the study revealed no statistically significant differences in the severity of neurological and psychiatric long COVID symptoms across the COVID-19 status groups. Noteworthy trends were observed, including higher instances of memory problems worsening over time, elevated anxiety levels in symptomatic cases, and subtle indicators of increased depression severity in this subgroup. The findings underscored the multifactorial nature of long COVID manifestations and the impact of COVID-19 history on reported symptoms. CONCLUSION: The study highlighted potential biases in symptom reporting that may inflate long COVID prevalence estimates. While the robust methodology shed light on diverse health profiles among HCWs, future research should focus on longitudinal designs and objective diagnostic measures to provide more accurate assessments of long COVID's burden. CI - Copyright (c) 2025. Published by Elsevier B.V. FAU - Chen, Yi-Chun AU - Chen YC AD - Department of Neurology, Chang Gung Memorial Hospital Linkou Medical Center and College of Medicine, Chang Gung University, 333, Taoyuan, Taiwan; Dementia Center, Taoyuan Chang Gung Memorial Hospital, 333, Taoyuan, Taiwan. FAU - Chiu, Cheng-Hsun AU - Chiu CH AD - Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, 333, Taoyuan, Taiwan; School of Medicine, College of Medicine, Chang Gung University, 333, Taoyuan, Taiwan; Molecular Infectious Diseases Research Center, Chang Gung Memorial Hospital, 333, Taoyuan, Taiwan. FAU - Chen, Chih-Jung AU - Chen CJ AD - Division of Pediatric Infectious Diseases, Departments of Pediatrics, Chang Gung Memorial Hospital, 333, Taoyuan, Taiwan; School of Medicine, College of Medicine, Chang Gung University, 333, Taoyuan, Taiwan; Molecular Infectious Diseases Research Center, Chang Gung Memorial Hospital, 333, Taoyuan, Taiwan. Electronic address: chinjung@cgmh.org.tw. LA - eng PT - Journal Article DEP - 20250623 PL - England TA - J Microbiol Immunol Infect JT - Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi JID - 100956211 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Health Personnel/psychology/statistics & numerical data MH - *COVID-19/epidemiology/psychology/prevention & control/complications MH - Male MH - Female MH - Adult MH - Taiwan/epidemiology MH - Prevalence MH - Middle Aged MH - *COVID-19 Vaccines/administration & dosage MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - Depression/epidemiology MH - Anxiety/epidemiology MH - Vaccination MH - Post-Acute COVID-19 Syndrome MH - Cohort Studies OTO - NOTNLM OT - Healthcare workers OT - Long COVID OT - Omicron variant OT - Symptomatology OT - Vaccination impact COIS- Declaration of competing interest The authors declare no competing interests. EDAT- 2025/06/28 00:39 MHDA- 2025/12/14 00:39 CRDT- 2025/06/27 21:52 PHST- 2024/12/03 00:00 [received] PHST- 2025/06/01 00:00 [revised] PHST- 2025/06/20 00:00 [accepted] PHST- 2025/12/14 00:39 [medline] PHST- 2025/06/28 00:39 [pubmed] PHST- 2025/06/27 21:52 [entrez] AID - S1684-1182(25)00125-2 [pii] AID - 10.1016/j.jmii.2025.06.002 [doi] PST - ppublish SO - J Microbiol Immunol Infect. 2025 Dec;58(6):670-677. doi: 10.1016/j.jmii.2025.06.002. Epub 2025 Jun 23. PMID- 40554922 OWN - NLM STAT- MEDLINE DCOM- 20250810 LR - 20250810 IS - 1973-8102 (Electronic) IS - 0010-9452 (Linking) VI - 189 DP - 2025 Aug TI - Changes in memory function in adults following SARS-CoV-2 infection: Findings from the Covid and Cognition online study. PG - 205-225 LID - S0010-9452(25)00158-3 [pii] LID - 10.1016/j.cortex.2025.05.019 [doi] AB - SARS-CoV-2, the virus responsible for the Covid-19 pandemic, has been shown to have an impact on cognitive function, but the specific aspects of cognition that are affected remain unclear. In this Registered Report, we analysed cognitive data collected online from 296 participants (209 who had experienced Covid-19 infection and 87 who did not). We have found previously reported effect of Covid status on accuracy in 2 long-term memory tasks (verbal item memory task and nonverbal associative memory task), but did not replicate previously reported effect on reaction times. Further, across 4 long-term memory tasks, we found consistent effect of Covid status on memory accuracy but not reaction times. Contrary to our predictions, we did not find an interaction with memory type (associative versus item) or stimulus type (verbal versus nonverbal). Moreover, we compared cognitive functioning amongst vaccinated and unvaccinated individuals to explore the role of vaccination status in cognitive symptoms associated with Covid-19. Using Bayesian analysis, we did not find conclusive evidence for either the null or alternative hypothesis. Overall, the study replicates and extends previously reported findings, thereby providing valuable insights into the effects of SARS-CoV-2 infection on cognitive functions. CI - Copyright (c) 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Weinerova, Josefina AU - Weinerova J AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. FAU - Yeung, Sabine AU - Yeung S AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Guo, Panyuan AU - Guo P AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Yau, Alice AU - Yau A AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Horne, Connor AU - Horne C AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Ghinn, Molly AU - Ghinn M AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Curtis, Lyn AU - Curtis L AD - School of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, United Kingdom. FAU - Adlard, Francess AU - Adlard F AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Bhagat, Vidita AU - Bhagat V AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Zhang, Seraphina AU - Zhang S AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Kaser, Muzaffer AU - Kaser M AD - Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom; Cambridgeshire and Peterborough NHS Trust, Cambridge, United Kingdom. FAU - Bozic, Mirjana AU - Bozic M AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. FAU - Schluppeck, Denis AU - Schluppeck D AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. FAU - Reid, Andrew AU - Reid A AD - School of Social and Behavioural Sciences, Tilburg University, Tilburg, Netherlands. FAU - Tibon, Roni AU - Tibon R AD - School of Psychology, University of Nottingham, Nottingham, United Kingdom. Electronic address: roni.tibon@nottingham.ac.uk. FAU - Cheke, Lucy AU - Cheke L AD - Department of Psychology, University of Cambridge, Cambridge, United Kingdom. LA - eng PT - Journal Article DEP - 20250611 PL - Italy TA - Cortex JT - Cortex; a journal devoted to the study of the nervous system and behavior JID - 0100725 SB - IM MH - Humans MH - *COVID-19/psychology/complications MH - Male MH - Female MH - Adult MH - *Cognition/physiology MH - Middle Aged MH - Reaction Time/physiology MH - SARS-CoV-2 MH - Neuropsychological Tests MH - Aged MH - Young Adult MH - *Memory/physiology MH - *Memory, Long-Term/physiology OTO - NOTNLM OT - Associative memory OT - Cognition OT - Covid-19 OT - Item memory OT - Long Covid OT - Long-term memory OT - SARS-CoV-2 OT - Vaccination COIS- Declaration of competing interest No conflict of interest is declared. EDAT- 2025/06/25 00:28 MHDA- 2025/08/11 00:26 CRDT- 2025/06/24 18:04 PHST- 2025/05/20 00:00 [received] PHST- 2025/05/29 00:00 [revised] PHST- 2025/05/29 00:00 [accepted] PHST- 2025/08/11 00:26 [medline] PHST- 2025/06/25 00:28 [pubmed] PHST- 2025/06/24 18:04 [entrez] AID - S0010-9452(25)00158-3 [pii] AID - 10.1016/j.cortex.2025.05.019 [doi] PST - ppublish SO - Cortex. 2025 Aug;189:205-225. doi: 10.1016/j.cortex.2025.05.019. Epub 2025 Jun 11. PMID- 40512699 OWN - NLM STAT- MEDLINE DCOM- 20250613 LR - 20261016 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 20 IP - 6 DP - 2025 TI - Severity, mortality, long COVID-19, and quality of life: Insights from a cohort study of hospitalized COVID-19 patients during the delta variant predominance period in Thailand. PG - e0324061 LID - 10.1371/journal.pone.0324061 [doi] LID - e0324061 AB - BACKGROUND: The COVID-19 pandemic, declared in March 2020, has had significant global impacts, with Thailand reporting over 4.6 million cases and 32,000 fatalities by September 2022. Long COVID, or Post-COVID Conditions (PCC), affects 10-30% of COVID-19 patients globally, with symptoms lasting beyond three months. Common issues include fatigue, brain fog, respiratory problems, and psychological effects such as anxiety and depression. Symptoms can persist regardless of the initial infection severity, and ongoing research continues to refine understanding and management strategies. To address residual symptoms of COVID-19 during the Delta variant predominance period, a study was conducted from July to December 2021 at a tertiary care hospital in Chiang Mai, Thailand. The study aimed to describe the characteristics of COVID-19 patients, explore the Long COVID symptoms experienced by patients after discharge, and assess their quality of life. METHODS: The study characterized 604 are moderate to severe COVID-19 patients at Tertiary Care Hospital during the Delta wave in Thailand (July-December 2021), using secondary data from medical records. Confirmed cases were cohort monitored using a Long COVID questionnaire for symptoms, chronic conditions, and social impact a year after discharge. Quality of life was evaluated using the SF-12 questionnaire (SF-12: 12-Item Short Form Survey). Long COVID, in this study, is defined as the persistence or emergence of one or more physical, psychological, or cognitive symptoms that last for more than 12 weeks after the initial onset of COVID-19 and cannot be explained by alternative diagnoses. This includes, but is not limited to, symptoms such as fatigue, dyspnea, chest pain, cough, cognitive dysfunction ("brain fog"), insomnia, anxiety, or depression. FINDINGS: Most patients were Thai (85.9%) and female (57.3%), with obesity common among those aged 18-60 (48.3%). Severe cases and mortality were higher in patients over 60 (30.2%) and unvaccinated patients (60.4%). Severity was related with male gender, older age, lack of antiviral use, and being unvaccinated; overweight status, comorbidities, and abnormal chest x-rays were not significant. Deaths were influenced by gender, age, and antiviral use, but not hospital stay duration, overweight status, comorbidities, or vaccination status. At one-year follow-up, Long COVID symptoms were reported in a small proportion of patients (4.2% shortness of breath, 1.5% chronic cough), mostly in adults and older adults. Other symptoms were rare (<1%) and limited to the 18-60 age group. No severe neurological or systemic symptoms were reported. One-year post-hospitalization, 79.15% had no Long COVID symptoms. Quality of life scores were high (Physical Component Summary: PCS = 48.62, Mental Component Summary: MCS = 50.65). INTERPRETATION: This study found a very low prevalence of Long COVID symptoms, which may be due to the severity of the Delta variant leading to higher mortality among patients with severe illness. Those who survived and recovered mostly had moderate symptoms and were predominantly under 60 years of age, which may explain the lower occurrence of Long COVID in this group. The majority of COVID-19 patients in Chiang Mai experienced moderate symptoms and had a high survival rate. Despite varied long COVID symptoms, most reported good physical and mental health one year after recovery. These findings highlight the resilience of patients and the importance of monitoring long-term health outcomes. CI - Copyright: (c) 2025 Khammawan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Khammawan, Pimpinan AU - Khammawan P AUID- ORCID: 0009-0007-4309-1802 AD - Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand. AD - Nakornping Hospital, Ministry of Public Health, Chiang Mai, Thailand. FAU - Thongprachum, Aksara AU - Thongprachum A AD - Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand. FAU - Intawong, Kannikar AU - Intawong K AD - Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand. FAU - Chariyalertsak, Suwat AU - Chariyalertsak S AD - Faculty of Public Health, Chiang Mai University, Chiang Mai, Thailand. LA - eng PT - Journal Article DEP - 20250613 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Humans MH - *COVID-19/mortality/epidemiology/virology/pathology MH - Thailand/epidemiology MH - *Quality of Life MH - Male MH - Female MH - Middle Aged MH - Adult MH - Aged MH - SARS-CoV-2/isolation & purification MH - Hospitalization MH - Severity of Illness Index MH - Cohort Studies MH - Anxiety MH - Fatigue PMC - PMC12165381 COIS- The authors have declared that no competing interests exist. EDAT- 2025/06/13 18:27 MHDA- 2025/06/13 18:28 PMCR- 2025/06/13 CRDT- 2025/06/13 13:33 PHST- 2024/08/21 00:00 [received] PHST- 2025/04/20 00:00 [accepted] PHST- 2025/06/13 18:28 [medline] PHST- 2025/06/13 18:27 [pubmed] PHST- 2025/06/13 13:33 [entrez] PHST- 2025/06/13 00:00 [pmc-release] AID - PONE-D-24-33832 [pii] AID - 10.1371/journal.pone.0324061 [doi] PST - epublish SO - PLoS One. 2025 Jun 13;20(6):e0324061. doi: 10.1371/journal.pone.0324061. eCollection 2025. PMID- 40482741 OWN - NLM STAT- MEDLINE DCOM- 20250719 LR - 20250719 IS - 1879-0003 (Electronic) IS - 0141-8130 (Linking) VI - 318 IP - Pt 1 DP - 2025 Jul TI - [Illuminating the shadows - perspectives on mRNA vaccine adverse events - mechanisms, risks and management]: A review. PG - 145010 LID - S0141-8130(25)05563-1 [pii] LID - 10.1016/j.ijbiomac.2025.145010 [doi] AB - Apparently, mRNA vaccines have played a pivotal role in curbing the further spread of COVID-19. However, their deployment has been accompanied by reports of adverse events (AEs), including cardiovascular and neurological symptoms. The comprehensive review proposes a conceptual framework to better characterize AEs, elucidate the underlying mechanisms, and outline therapeutic strategies. It also profiles AEs into a three-axe mechanism classification: host susceptibility, delivery system interactions, and mRNA component immunogenicity, thereby advancing current understanding of their etiology. Finally, the analysis integrates these axes with critical perspectives - mRNA molecular design, platform-specific toxicity, and human nature - to provide a comprehensive roadmap for addressing above issues. CI - Copyright (c) 2025 Elsevier B.V. All rights reserved. FAU - Kang, Haobo AU - Kang H AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Sun, Yubo AU - Sun Y AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China. FAU - Fang, Zhenchi AU - Fang Z AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Ding, Weijie AU - Ding W AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Bai, Tianyuan AU - Bai T AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. FAU - Yang, Kun AU - Yang K AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China. Electronic address: yangkunkun@fmmu.edu.cn. FAU - Jiang, Dongbo AU - Jiang D AD - Department of Immunology, Basic Medicine School, Air Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China; The Key Laboratory of Bio-Hazard Damage and Prevention Medicine, Basic Medicine School, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710032, China; Department of Rehabilitation, Tangdu Hospital, Air-Force Medical University (The Fourth Military Medical University), Xi'an 710038, Shaanxi, China; Department of Microbiology, Basic Medicine School, Air-Force Medical University (the Fourth Military Medical University), Xi'an 710032, Shaanxi, China. Electronic address: superjames1991@fmmu.edu.cn. LA - eng PT - Journal Article PT - Review DEP - 20250605 PL - Netherlands TA - Int J Biol Macromol JT - International journal of biological macromolecules JID - 7909578 RN - 0 (COVID-19 Vaccines) RN - 0 (mRNA Vaccines) RN - 0 (RNA, Messenger) RN - 0 (Vaccines, Synthetic) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects/immunology MH - *COVID-19/prevention & control/immunology MH - SARS-CoV-2/immunology MH - *mRNA Vaccines/adverse effects MH - *RNA, Messenger/immunology MH - *Vaccines, Synthetic/adverse effects/immunology MH - *Drug-Related Side Effects and Adverse Reactions OTO - NOTNLM OT - Adverse event OT - Mechanism OT - mRNA vaccine COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/06/08 03:37 MHDA- 2025/07/19 16:45 CRDT- 2025/06/07 19:36 PHST- 2025/03/11 00:00 [received] PHST- 2025/06/03 00:00 [revised] PHST- 2025/06/04 00:00 [accepted] PHST- 2025/07/19 16:45 [medline] PHST- 2025/06/08 03:37 [pubmed] PHST- 2025/06/07 19:36 [entrez] AID - S0141-8130(25)05563-1 [pii] AID - 10.1016/j.ijbiomac.2025.145010 [doi] PST - ppublish SO - Int J Biol Macromol. 2025 Jul;318(Pt 1):145010. doi: 10.1016/j.ijbiomac.2025.145010. Epub 2025 Jun 5. PMID- 40411153 OWN - NLM STAT- MEDLINE DCOM- 20251104 LR - 20260814 IS - 1708-8267 (Electronic) IS - 1081-5589 (Linking) VI - 73 IP - 8 DP - 2025 Dec TI - Protective effects of booster dose of SARS-COV-2 vaccination against post-acute COVID-19 syndrome: A systematic review. PG - 606-613 LID - 10.1177/10815589251346963 [doi] AB - The global impact of COVID-19, caused by SARS-CoV-2, has extended beyond acute infection, with post-acute COVID-19 syndrome (PACS) affecting an estimated 10% of recovered individuals. PACS manifests a range of debilitating symptoms, including fatigue, cognitive impairment, and gastrointestinal issues. While vaccination has proven effective in mitigating severe COVID-19 outcomes, the role of booster doses in preventing PACS remains unclear. This study aimed to evaluate whether COVID-19 booster vaccinations reduce the incidence and severity of PACS in individuals with prior SARS-CoV-2 infection. A systematic review and meta-analysis were conducted, adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Databases PubMed, Embase, and Cochrane were searched for peer-reviewed studies published in English from January 2020 to August 2023. Inclusion criteria encompassed randomized controlled trials, prospective cohort studies, and case-control studies comparing PACS prevalence between booster recipients and non-recipients. The risk of bias was assessed using the Joanna Briggs Institute appraisal tool. Data synthesis included pooled prevalence estimates and narrative analyses. Of 849 identified studies, 22 met inclusion criteria, with 12 providing complete data for meta-analysis. Among 38,718 participants, a trend toward lower PACS prevalence was observed in booster recipients (RR: 0.66; 95% CI: 0.41-1.09), though heterogeneity (I(2) = 98%) limited statistical significance. Risk of bias analysis classified most studies as low or moderate risk, with two high-risk studies reporting higher PACS rates in boosted individuals. This study suggests a potential protective effect of booster vaccinations against PACS, though findings were not statistically significant. Further research with larger, standardized cohorts is essential to validate these observations and guide vaccination strategies.Prospero Record Number: CRD42023461326. FAU - Patel, Ved AU - Patel V AUID- ORCID: 0009-0008-7764-3844 AD - Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, Hempstead, NY, USA. FAU - Korsun, Maximilian AU - Korsun M AUID- ORCID: 0000-0001-7289-7564 AD - Hospital for Special Surgery, New York, NY, USA. FAU - Cervia, Joseph AU - Cervia J AUID- ORCID: 0000-0002-8286-0009 AD - Donald and Barbara Zucker School of Medicine at Hofstra, Northwell, Hempstead, NY, USA. AD - HealthCare Partners, IPA, & MSO, Manhasset, NY, USA. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20250523 PL - England TA - J Investig Med JT - Journal of investigative medicine : the official publication of the American Federation for Clinical Research JID - 9501229 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control/immunology/epidemiology/complications MH - *COVID-19 Vaccines/administration & dosage/immunology MH - *Immunization, Secondary MH - *Post-Acute COVID-19 Syndrome/epidemiology/immunology/prevention & control/virology MH - *SARS-CoV-2/immunology MH - Vaccination OTO - NOTNLM OT - COVID-19 OT - Vaccination OT - booster vaccination OT - post-acute COVID-19 syndrome COIS- Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2025/05/25 00:45 MHDA- 2025/11/04 06:29 CRDT- 2025/05/24 01:43 PHST- 2025/11/04 06:29 [medline] PHST- 2025/05/25 00:45 [pubmed] PHST- 2025/05/24 01:43 [entrez] AID - 10.1177/10815589251346963 [doi] PST - ppublish SO - J Investig Med. 2025 Dec;73(8):606-613. doi: 10.1177/10815589251346963. Epub 2025 May 23. PMID- 40267596 OWN - NLM STAT- MEDLINE DCOM- 20250516 LR - 20250925 IS - 1532-2653 (Electronic) IS - 0967-5868 (Linking) VI - 136 DP - 2025 Jun TI - Critical appraisal of: "expression of SARS-CoV-2 spike protein in cerebral arteries: implications for hemorrhagic stroke post-mRNA vaccination". PG - 111270 LID - S0967-5868(25)00242-5 [pii] LID - 10.1016/j.jocn.2025.111270 [doi] AB - This correspondence offers a critical appraisal of the study by Ota et al. on the expression of SARS-CoV-2 spike protein in cerebral arteries following mRNA vaccination. While the original study contributes to understanding potential neurological sequelae post-vaccination, we identify several methodological limitations. Chief concerns include the absence of a control group, reliance on negative nucleocapsid staining to exclude prior infection, a small and unbalanced sample size, lack of lesionspecific tissue analysis, and unconfirmed RNA detection techniques. These issues collectively undermine causal inferences regarding vaccine-related spike protein persistence. We recommend methodological refinements for future studies, including matched controls, serial serological testing, tissue validation protocols, and robust subgroup stratification. CI - Copyright (c) 2025 Elsevier Ltd. All rights reserved. FAU - Mueed, Ahmed AU - Mueed A AD - Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan. Electronic address: drahmedmueed@gmail.com. FAU - Shariq, Abia AU - Shariq A AD - Dow Medical College, Karachi, Pakistan. FAU - Ashar, Manaal AU - Ashar M AD - Dow Medical College, Karachi, Pakistan. LA - eng PT - Letter DEP - 20250422 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Spike Glycoprotein, Coronavirus/metabolism/biosynthesis MH - *COVID-19 Vaccines/adverse effects MH - *Cerebral Arteries/metabolism/virology MH - *COVID-19/prevention & control MH - *SARS-CoV-2/metabolism MH - *Stroke/etiology/metabolism OTO - NOTNLM OT - Cerebral arteries OT - Hemorrhagic stroke OT - SARS-CoV-2 spike protein OT - Vaccine safety OT - mRNA vaccination COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/04/24 00:27 MHDA- 2025/05/16 11:44 CRDT- 2025/04/23 18:02 PHST- 2025/04/16 00:00 [received] PHST- 2025/04/16 00:00 [accepted] PHST- 2025/05/16 11:44 [medline] PHST- 2025/04/24 00:27 [pubmed] PHST- 2025/04/23 18:02 [entrez] AID - S0967-5868(25)00242-5 [pii] AID - 10.1016/j.jocn.2025.111270 [doi] PST - ppublish SO - J Clin Neurosci. 2025 Jun;136:111270. doi: 10.1016/j.jocn.2025.111270. Epub 2025 Apr 22. PMID- 40254264 OWN - NLM STAT- MEDLINE DCOM- 20250616 LR - 20250616 IS - 1618-0402 (Electronic) IS - 0940-9602 (Linking) VI - 260 DP - 2025 Jun TI - Spike protein-related proteinopathies: A focus on the neurological side of spikeopathies. PG - 152662 LID - S0940-9602(25)00289-4 [pii] LID - 10.1016/j.aanat.2025.152662 [doi] AB - BACKGROUND: The spike protein (SP) is an outward-projecting transmembrane glycoprotein on viral surfaces. SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2), responsible for COVID-19 (Coronavirus Disease 2019), uses SP to infect cells that express angiotensin converting enzyme 2 (ACE2) on their membrane. Remarkably, SP has the ability to cross the blood-brain barrier (BBB) into the brain and cause cerebral damage through various pathomechanisms. To combat the COVID-19 pandemic, novel gene-based products have been used worldwide to induce human body cells to produce SP to stimulate the immune system. This artificial SP also has a harmful effect on the human nervous system. STUDY DESIGN: Narrative review. OBJECTIVE: This narrative review presents the crucial role of SP in neurological complaints after SARS-CoV-2 infection, but also of SP derived from novel gene-based anti-SARS-CoV-2 products (ASP). METHODS: Literature searches using broad terms such as "SARS-CoV-2", "spike protein", "COVID-19", "COVID-19 pandemic", "vaccines", "COVID-19 vaccines", "post-vaccination syndrome", "post-COVID-19 vaccination syndrome" and "proteinopathy" were performed using PubMed. Google Scholar was used to search for topic-specific full-text keywords. CONCLUSIONS: The toxic properties of SP presented in this review provide a good explanation for many of the neurological symptoms following SARS-CoV-2 infection and after injection of SP-producing ASP. Both SP entities (from infection and injection) interfere, among others, with ACE2 and act on different cells, tissues and organs. Both SPs are able to cross the BBB and can trigger acute and chronic neurological complaints. Such SP-associated pathologies (spikeopathies) are further neurological proteinopathies with thrombogenic, neurotoxic, neuroinflammatory and neurodegenerative potential for the human nervous system, particularly the central nervous system. The potential neurotoxicity of SP from ASP needs to be critically examined, as ASPs have been administered to millions of people worldwide. CI - Copyright (c) 2025 The Authors. Published by Elsevier GmbH.. All rights reserved. FAU - Posa, Andreas AU - Posa A AD - University Clinics and Outpatient Clinics for Radiology, Neuroradiology and Neurology, Martin Luther University Halle-Wittenberg, Ernst-Grube-Strasse 40, Halle 06120, Germany. Electronic address: andreas.posa@medizin.uni-halle.de. LA - eng PT - Journal Article PT - Review DEP - 20250418 PL - Germany TA - Ann Anat JT - Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft JID - 100963897 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) RN - EC 3.4.17.23 (Angiotensin-Converting Enzyme 2) RN - EC 3.4.17.23 (ACE2 protein, human) SB - IM MH - Humans MH - *Spike Glycoprotein, Coronavirus/metabolism MH - COVID-19 MH - SARS-CoV-2 MH - *Nervous System Diseases/etiology MH - Angiotensin-Converting Enzyme 2/metabolism MH - Pandemics MH - Blood-Brain Barrier/metabolism OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccines OT - Proteinopathy OT - SARS-CoV-2 OT - Spike protein COIS- Declaration of Competing Interest The corresponding author states that there is no conflict of interest. EDAT- 2025/04/21 00:25 MHDA- 2025/06/16 11:11 CRDT- 2025/04/20 19:34 PHST- 2025/02/24 00:00 [received] PHST- 2025/04/07 00:00 [revised] PHST- 2025/04/09 00:00 [accepted] PHST- 2025/06/16 11:11 [medline] PHST- 2025/04/21 00:25 [pubmed] PHST- 2025/04/20 19:34 [entrez] AID - S0940-9602(25)00289-4 [pii] AID - 10.1016/j.aanat.2025.152662 [doi] PST - ppublish SO - Ann Anat. 2025 Jun;260:152662. doi: 10.1016/j.aanat.2025.152662. Epub 2025 Apr 18. PMID- 40217186 OWN - NLM STAT- MEDLINE DCOM- 20250412 LR - 20250414 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 25 IP - 1 DP - 2025 Apr 11 TI - Association between infant feeding practices, COVID-19 related cognitive factors, and postpartum depression during the COVID-19 pandemic: a cross-sectional online study in Thailand. PG - 1366 LID - 10.1186/s12889-025-22672-w [doi] LID - 1366 AB - BACKGROUND: Maternal beliefs towards COVID-19 vaccine safety may be associated with infant feeding practice and postpartum depression (PPD). Since there is a paucity of studies, this study aims to identify associations of COVID-19-related cognitive factors (e.g., COVID-19-vaccination-related belief and COVID-19-related knowledge and attitude) with infant feeding practices and their associations with PPD during the COVID-19 pandemic in Thai postpartum mothers. METHODS: A cross-sectional online survey was conducted among 840 postpartum mothers whose infants were less than or equal to 6 months old. Mothers with a score >/= 13 using the Edinburgh Postnatal Depression Scale (EPDS) were considered to have PPD. Student t-tests were used to measure the association between infant feeding practices and COVID-19-related cognitive factors, and Chi-square tests were used to assess their associations with PPD. Significant variables (p < 0.05) from the chi-square test were included in the logistic regression analysis. Multivariable logistic regression analyses were performed to identify factors associated with PPD. The associations were reported in adjusted odds ratio at 95% confidence interval. RESULTS: This study showed one-third of the participants (32.4%) were at risk of having PPD. Mothers who fed expressed breastmilk had positive beliefs towards COVID-19 vaccination and higher scores on COVID-19 knowledge and attitude, while mothers who fed infant formula or solid, semi-solid, or soft food had negative beliefs towards the vaccination compared to their counterparts. Multivariable logistic regression showed women who fed their infant with solid, semi-solid, and soft foods (AOR = 3.28; 95% CI = 1.35-10.92) had significantly higher odds of PPD. Among COVID-19-related cognitive factors, negative or moderate COVID-19-related attitudes were associated with higher odds of PPD (1.91; 1.19-3.07 and 1.85; 1.20-2.86, respectively). Socio-demographic factors associated with PPD included living in urban areas, residing outside the Southern region, having food insecurity during the pandemic, having unintended pregnancy, and having health problems during the perinatal period. CONCLUSIONS: The association of COVID-19-related cognitive factors and feeding practices with PPD may suggest that proper education on prevention, control, and vaccination of emerging infectious diseases such as COVID-19, as well as support for appropriate infant feeding practices, should be provided to postpartum mothers, which ultimately contributes to improving their mental health. CI - (c) 2025. The Author(s). FAU - Suriyawongpaisal, Wichukorn AU - Suriyawongpaisal W AD - ASEAN Institute for Health Development, Mahidol University, Nakhon Pathom, 73170, Thailand. FAU - Kittikul, Punpawee AU - Kittikul P AD - Breastfeeding Clinic Nakhon Pathom Hospital, Nakhon Pathom, Thailand. FAU - Lee, Eun Young AU - Lee EY AD - Department of Nursing, Catholic Kkottongnae University, Chungcheongbuk-do, Republic of Korea. FAU - Chien, Li-Yin AU - Chien LY AD - Institute of Community Health Care, College of Nursing, National Yang Ming Chiao Tung University, Hsinchu City, Taiwan. FAU - Chang, Yan-Shing AU - Chang YS AD - Florence Nightingale Faculty of Nursing, Midwifery & Palliative Care, King's College London, SE1 8WA, London, UK. FAU - Coca, Kelly Pereira AU - Coca KP AD - Escola Paulista de Enfermagem, Universidade Federal de Sao Paulo, Sao Paulo, Brazil. FAU - Buntup, Doungjai AU - Buntup D AD - Department of Community Health, Faculty of Public Health, Mahidol University, Bangkok, Thailand. FAU - Hong, Seo Ah AU - Hong SA AUID- ORCID: 0000-0002-6702-8038 AD - Department of Public Health Administration, Faculty of Public Health, Mahidol University, 420/1 Ratchawithi RD., Ratchathewi District, Bangkok, 10400, Bangkok, Thailand. seoah.hon@mahidol.ac.th. LA - eng PT - Journal Article DEP - 20250411 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Cross-Sectional Studies MH - Female MH - *COVID-19/psychology/epidemiology/prevention & control MH - *Depression, Postpartum/epidemiology/psychology MH - Thailand/epidemiology MH - Adult MH - *Health Knowledge, Attitudes, Practice MH - *Breast Feeding/psychology/statistics & numerical data MH - Infant MH - *Mothers/psychology/statistics & numerical data MH - Young Adult MH - Surveys and Questionnaires MH - COVID-19 Vaccines MH - SARS-CoV-2 PMC - PMC11987166 OTO - NOTNLM OT - COVID-19 knowledge and attitude OT - COVID-19 vaccination OT - Infant feeding practices OT - Postpartum depression OT - Postpartum mothers COIS- Declarations. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. Conflict of interest: The authors declared no conflict of interests. Ethical approval and informed consent: An ethical committee at Mahidol University in Thailand approved the study protocol (No.: 2021/03-042). The study was in accordance with relevant institutional guidelines in accordance with the declaration of Helsinki. All participants provided an online informed consent prior to survey initiation after explanation of the study objectives, assurance of the confidentiality of their identity and assurance that choosing not to participate would not disadvantage them in any way. EDAT- 2025/04/12 00:43 MHDA- 2025/04/12 00:44 PMCR- 2025/04/11 CRDT- 2025/04/11 23:44 PHST- 2023/10/06 00:00 [received] PHST- 2025/04/07 00:00 [accepted] PHST- 2025/04/12 00:44 [medline] PHST- 2025/04/12 00:43 [pubmed] PHST- 2025/04/11 23:44 [entrez] PHST- 2025/04/11 00:00 [pmc-release] AID - 10.1186/s12889-025-22672-w [pii] AID - 22672 [pii] AID - 10.1186/s12889-025-22672-w [doi] PST - epublish SO - BMC Public Health. 2025 Apr 11;25(1):1366. doi: 10.1186/s12889-025-22672-w. PMID- 40206472 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260924 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 12 DP - 2025 TI - Impact of QazVac vaccination on clinical manifestations and immune responses in post-COVID syndrome: a cross-sectional study. PG - 1556623 LID - 10.3389/fmed.2025.1556623 [doi] LID - 1556623 AB - INTRODUCTION: Post-COVID syndrome, also known as long COVID, has emerged as a major public health concern, affecting a substantial proportion of individuals recovering from SARS-CoV-2 infection. This condition is characterized by persistent symptoms lasting at least 2 months after acute infection, significantly impacting quality of life and increasing healthcare burdens. In Kazakhstan, the recognition of post- COVID syndrome in national clinical protocols highlights the need for effective prevention and management strategies. Vaccination has been suggested as a key intervention to reduce the severity and prevalence of long COVID symptoms, yet data on its effectiveness, particularly for the domestic QazVac vaccine, remain limited. The aim of this study is to investigate the impact of vaccination with the domestic QazVac vaccine on the features of humoral and cellular immunity in patients with post-COVID conditions and to identify the leading clinical variants of the course. METHODS: We analyzed data from 90 vaccinated and 217 non-vaccinated patients, examining sex, age, smoking status, BMI, comorbidities, and clinical manifestations. RESULTS: There were no significant differences between the groups with regard to sex, age, and smoking status. However, the characteristics of the subjects indicated that vaccination was correlated with a lower prevalence of diabetes mellitus (2.2% vs. 11.1%, p = 0.011) and cardiovascular diseases (0.0% vs. 10.1%, p = 0.047), and a higher prevalence of hypertension among non-vaccinated subjects. With regard to clinical symptoms, vaccinated individuals presented a significantly decreased frequency of neurological (51.1% vs. 74.2%, p = 0.001), gastrointestinal (4.4% vs. 15.2%, p = 0.008), respiratory (21.1% vs. 36.4%, p = 0.009), rheumatological symptoms (26.7% vs. 38.7%, p = 0.044), and kidney symptoms (2.2% vs. 9.7%, p = 0.024). In contrast, unvaccinated participants had more memory loss (49.8% vs. 22.2%, p < 0.001), depression (31.3% vs. 6.7%, p < 0.001), joint pain (33.2% vs. 14.4%, p = 0.001), and other psychopathological symptoms. DISCUSSION: A sharp decrease in the frequency of neurological, gastrointestinal, respiratory, and rheumatological symptoms was recorded in vaccinated patients, advocating for the protective role of vaccination against long COVID-19 sequelae. These findings highlight the potential for vaccination to mitigate the burden of post-COVID complications across various organ systems. CI - Copyright (c) 2025 Madenbayeva, Kurmangaliyeva, Urazayeva, Kurmangaliyev, Bazargaliyev and Kudabayeva. FAU - Madenbayeva, Akzhan M AU - Madenbayeva AM AD - Department of Internal Diseases No 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Kurmangaliyeva, Saulesh S AU - Kurmangaliyeva SS AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Urazayeva, Saltanat T AU - Urazayeva ST AD - Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Kurmangaliyev, Kairat B AU - Kurmangaliyev KB AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Bazargaliyev, Yerlan Sh AU - Bazargaliyev YS AD - Department of Internal Diseases No 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. FAU - Kudabayeva, Khatimya I AU - Kudabayeva KI AD - Department of Internal Diseases No 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan. LA - eng PT - Journal Article DEP - 20250326 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC11978623 OTO - NOTNLM OT - QazVac vaccine OT - cellular immune response OT - flow cytometry OT - immunoglobulin G OT - post-COVID-19 condition COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2025/04/10 11:24 MHDA- 2025/04/10 11:25 PMCR- 2025/03/26 CRDT- 2025/04/10 05:00 PHST- 2025/01/07 00:00 [received] PHST- 2025/03/12 00:00 [accepted] PHST- 2025/04/10 11:25 [medline] PHST- 2025/04/10 11:24 [pubmed] PHST- 2025/04/10 05:00 [entrez] PHST- 2025/03/26 00:00 [pmc-release] AID - 10.3389/fmed.2025.1556623 [doi] PST - epublish SO - Front Med (Lausanne). 2025 Mar 26;12:1556623. doi: 10.3389/fmed.2025.1556623. eCollection 2025. PMID- 40144475 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250328 IS - 0253-8253 (Print) IS - 2227-0426 (Electronic) IS - 0253-8253 (Linking) VI - 2025 IP - 1 DP - 2025 TI - A comparison of Gam-COVID-Vac vaccination and non-vaccination on neurological symptoms and immune response in post-COVID-19 syndrome. PG - 6 LID - 10.5339/qmj.2025.6 [doi] LID - 6 AB - The post-COVID-19 syndrome may present with a range of neurological symptoms such as headaches, sleep disorders, and dizziness. The objective of this study was to examine the effectiveness of the Gam-COVID-Vac vaccine in mitigating the neurological symptoms of post-COVID-19 syndrome. The study involved 95 patients diagnosed with the neurological form of long COVID-19, who were divided into two groups according to their vaccination status. The immunological parameters of humoral immunity were evaluated by enzyme-linked immunosorbent assay (ELISA), while the parameters of cellular immunity were evaluated using flow cytometry. Administration of the vaccination resulted in a reduction in clinical symptoms of the neurological form of long COVID-19. Statistically significant differences (p = 0.035) were found in symptoms such as headaches, sleep disturbances, and dizziness, especially in central nervous system (CNS) disorders, between the groups that received the vaccination and those that did not. More than 90% of patients had elevated levels of Receptor Binding Domain (RBD) immunoglobulin G against the viral S-protein (>2,500 BAU/ml), indicating strong humoral immunity regardless of vaccination status. An increase in B-lymphocyte (CD3(-)CD19(+)) counts was noted in both groups, with levels significantly higher in the group that received the vaccination (p < 0.03). Analysis of T-cell profiles and NK (natural killer) cell levels showed no changes. The study suggests that administration of Gam-COVID-Vac vaccination could reduce the occurrence of CNS symptoms in individuals with post-COVID-19 syndrome. Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters. CI - (c) 2025 Kurmangaliyeva, Madenbayeva, Urazayeva, Baktikulova, Kurmangaliyev, licensee HBKU Press. FAU - Kurmangaliyeva, Saulesh AU - Kurmangaliyeva S AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Madenbayeva, Akzhan AU - Madenbayeva A AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Urazayeva, Saltanat AU - Urazayeva S AD - Department of Epidemiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. FAU - Baktikulova, Kristina AU - Baktikulova K AD - Department of Transfusiology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan*Correspondence: Saltanat Urazayeva. Email: sal.urazayeva@gmail.com. FAU - Kurmangaliyev, Kairat AU - Kurmangaliyev K AD - Department of Microbiology, Virology and Immunology, West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan. LA - eng PT - Journal Article DEP - 20250223 PL - Qatar TA - Qatar Med J JT - Qatar medical journal JID - 8101648 PMC - PMC11938678 OTO - NOTNLM OT - Post-COVID-19 OT - cellular and humoral immunity OT - coronavirus OT - damage to the nervous system OT - hybrid immunity OT - long COVID-19 COIS- The authors have no conflicts of interest to declare. EDAT- 2025/03/27 06:29 MHDA- 2025/03/27 06:30 PMCR- 2025/02/23 CRDT- 2025/03/27 05:11 PHST- 2024/05/16 00:00 [received] PHST- 2024/10/13 00:00 [accepted] PHST- 2025/03/27 06:30 [medline] PHST- 2025/03/27 06:29 [pubmed] PHST- 2025/03/27 05:11 [entrez] PHST- 2025/02/23 00:00 [pmc-release] AID - qmj.2025.6 [pii] AID - 10.5339/qmj.2025.6 [doi] PST - epublish SO - Qatar Med J. 2025 Feb 23;2025(1):6. doi: 10.5339/qmj.2025.6. eCollection 2025. PMID- 40127994 OWN - NLM STAT- MEDLINE DCOM- 20250529 LR - 20260916 IS - 1557-8992 (Electronic) IS - 1044-5463 (Linking) VI - 35 IP - 5 DP - 2025 Jun TI - Pediatric Neuropsychiatric Syndromes: Updates on COVID-19 Infection and Vaccination. PG - 294-303 LID - 10.1089/cap.2024.0129 [doi] AB - Introduction: SARS-CoV-2 (COVID-19) infection has been implicated in the onset of neuropsychiatric symptoms in adults and children. While outcomes of COVID-19 infection and vaccination have been tracked in the general pediatric population, little is known of their impact on children with preexisting neuropsychiatric syndromes, including pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). The aim of this study is to understand the prevalence and severity of COVID-19 symptoms and PANS/PANDAS symptoms following COVID-19 infection or vaccination in children with PANS/PANDAS. Methods: We analyzed retrospective COVID-19 survey data from caregivers of youth with PANS/PANDAS at Massachusetts General Hospital (MGH; n = 57) and the International PANS Registry (IPR; n = 478). Surveys were conducted online between late 2021 and early 2022 to collect COVID-19 infection and vaccination histories, side effects, and changes in PANS/PANDAS symptoms. Descriptive results are reported, stratified by case and sibling groups within the IPR sample. Results: Among patients with test-confirmed COVID-19 (MGH: n = 20, IPR: n = 65 cases, n = 16 siblings), mild/minor COVID-19 symptoms were common (62-75%). All patients with preexisting PANS/PANDAS-related symptoms at the time of COVID-19 infection experienced an exacerbation of PANS/PANDAS symptoms, while remitted patients did not report any PANS/PANDAS symptoms. Following the first COVID-19 vaccine dose (MGH: n = 45, IPR: n = 150 cases, n = 44 siblings), fatigue was the predominant side effect (30-56%). Most patients did not report new (59-81%) or worsened (71-82%) PANS symptoms post-vaccination, irrespective of symptomatic status at vaccination. Vaccine hesitancy often stemmed from concerns that the vaccination would cause an exacerbation of PANS/PANDAS symptoms. Conclusions: In two samples of children with PANS/PANDAS, symptoms of COVID-19 following infection and vaccination were common and generally mild to moderate. Children experiencing PANS/PANDAS symptoms at the time of COVID-19 infection experienced an increase in PANS/PANDAS symptom severity. FAU - O'Dor, Sarah AU - O'Dor S AUID- ORCID: 0000-0001-6141-1266 AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA, USA. FAU - Adams, Celia AU - Adams C AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. FAU - Gavin, Jessica AU - Gavin J AD - Pediatric Research and Advocacy Initiative, Richmond, Virginia, USA. FAU - Zagaroli, Julia S AU - Zagaroli JS AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. FAU - Carlisle, Elliott AU - Carlisle E AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. FAU - Downer, Olivia M AU - Downer OM AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. FAU - Williams, Kyle A AU - Williams KA AD - Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA, USA. FAU - Masterson, Erin E AU - Masterson EE AD - Department of Environmental & Occupational Health Sciences, University of Washington, Seattle, WA, USA. LA - eng PT - Journal Article DEP - 20250324 PL - United States TA - J Child Adolesc Psychopharmacol JT - Journal of child and adolescent psychopharmacology JID - 9105358 RN - 0 (COVID-19 Vaccines) RN - Pediatric acute-onset neuropsychiatric syndrome RN - Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology/psychology MH - Child MH - Male MH - Retrospective Studies MH - Female MH - Adolescent MH - *Vaccination/adverse effects MH - *COVID-19 Vaccines/administration & dosage/adverse effects MH - *Streptococcal Infections/epidemiology/complications MH - *Autoimmune Diseases/epidemiology MH - Child, Preschool MH - Severity of Illness Index MH - Obsessive-Compulsive Disorder OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - neuropsychiatric conditions OT - observational study OT - pediatric acute-onset neuropsychiatric syndrome OT - pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections EDAT- 2025/03/25 00:38 MHDA- 2025/05/29 12:54 CRDT- 2025/03/24 21:53 PHST- 2025/05/29 12:54 [medline] PHST- 2025/03/25 00:38 [pubmed] PHST- 2025/03/24 21:53 [entrez] AID - 10.1089/cap.2024.0129 [doi] PST - ppublish SO - J Child Adolesc Psychopharmacol. 2025 Jun;35(5):294-303. doi: 10.1089/cap.2024.0129. Epub 2025 Mar 24. PMID- 40115993 OWN - NLM STAT- MEDLINE DCOM- 20250514 LR - 20260703 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 32 IP - 3 DP - 2025 Mar TI - Neurological long COVID in the outpatient clinic: Is it so long? PG - e16510 LID - 10.1111/ene.16510 [doi] LID - e16510 AB - BACKGROUND AND PURPOSE: Neurological involvement in long COVID (coronavirus disease 2019) is well known. In a previous study we identified two subtypes of neurological long COVID, one characterized by memory disturbances, psychological impairment, headache, anosmia and ageusia, and the other characterized by peripheral nervous system involvement, each of which present a different risk factor profile. In this study, we aimed to clarify the persistence of neurological long COVID symptoms with a significantly longer term follow-up. METHODS: We prospectively collected data from patients with prior COVID-19 infection who showed symptoms of neurological long COVID. We conducted a descriptive analysis to investigate the progression of neurological symptoms over time at 3-, 6-, 12-, and 18-month follow-ups. We performed a k-means clustering analysis on the temporal evolution of the symptoms at 6, 12, and 18 months. Finally, we assessed the difference between the recovery course of vaccinated and non-vaccinated patients by computing the cumulative recovery rate of symptoms in the two groups. RESULTS: The study confirmed the presence of two subtypes of neurological long COVID. Further, 50% of patients presented a complete resolution of symptoms at 18 months of follow-up, regardless of which subtype of neurological long COVID they had. Vaccination against SARS-Cov-2 appeared to imply a higher overall recovery rate for all neurological symptoms, although the statistical reliability of this finding is hampered by the limited sample size of the unvaccinated patients included in this study. CONCLUSIONS: Neurological long COVID can undergo complete resolution after 18 months of follow-up in 50% of patients and vaccination can accelerate the recovery. CI - (c) 2025 The Author(s). European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Grisanti, Stefano Giuseppe AU - Grisanti SG AUID- ORCID: 0000-0002-6293-9756 AD - Struttura Complessa Neurologia P.O. Ponente, Dipartimento Testa-Collo, Ospedale Santa Corona, Pietra Ligure, Italy. FAU - Garbarino, Sara AU - Garbarino S AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FAU - Bellucci, Margherita AU - Bellucci M AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Schenone, Cristina AU - Schenone C AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Candiani, Valentina AU - Candiani V AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Di Lillo, Simmaco AU - Di Lillo S AD - Dipartimento di Matematica, Universita di Roma Tor Vergata, Rome, Italy. FAU - Campi, Cristina AU - Campi C AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Barisione, Emanuela AU - Barisione E AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Aloe, Teresita AU - Aloe T AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Tagliabue, Elena AU - Tagliabue E AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Serventi, Alberto AU - Serventi A AD - Chirurgia presidio ospedaliero Mons. Giovanni Galliano, Acqui Terme, Italy. FAU - Pesce, Giampaola AU - Pesce G AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Massucco, Sara AU - Massucco S AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. FAU - Cabona, Corrado AU - Cabona C AUID- ORCID: 0000-0002-4282-8805 AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Lechiara, Anastasia AU - Lechiara A AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Uccelli, Antonio AU - Uccelli A AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Schenone, Angelo AU - Schenone A AD - Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica E Scienze Materno-Infantili, Universita di Genova, Genoa, Italy. AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. FAU - Piana, Michele AU - Piana M AD - Life Science Computational Laboratory, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. AD - MIDA group, Dipartimento di Matematica, Universita di Genova, Genoa, Italy. FAU - Benedetti, Luana AU - Benedetti L AUID- ORCID: 0000-0002-9540-9727 AD - IRCCS, Ospedale Policlinico San Martino, Genoa, Italy. LA - eng GR - NET-2018-12366666/Ministero della Salute/ GR - PE0000006/NEXTGENERATIONEU (NGEU)/ GR - ECS00000035/NEXTGENERATIONEU (NGEU)/ PT - Journal Article PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 SB - IM MH - Humans MH - *COVID-19/complications/epidemiology MH - Male MH - Female MH - Middle Aged MH - Adult MH - *Nervous System Diseases/epidemiology MH - Aged MH - Ambulatory Care Facilities MH - Prospective Studies MH - Follow-Up Studies MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - Disease Progression MH - Anosmia/etiology PMC - PMC11926444 OTO - NOTNLM OT - COVID-19 OT - clustering OT - neurological long COVID OT - recovery rate OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2025/03/21 11:17 MHDA- 2025/03/21 11:18 PMCR- 2025/03/21 CRDT- 2025/03/21 05:11 PHST- 2024/09/20 00:00 [revised] PHST- 2024/03/07 00:00 [received] PHST- 2024/09/21 00:00 [accepted] PHST- 2025/03/21 11:18 [medline] PHST- 2025/03/21 11:17 [pubmed] PHST- 2025/03/21 05:11 [entrez] PHST- 2025/03/21 00:00 [pmc-release] AID - ENE16510 [pii] AID - 10.1111/ene.16510 [doi] PST - ppublish SO - Eur J Neurol. 2025 Mar;32(3):e16510. doi: 10.1111/ene.16510. PMID- 40074874 OWN - NLM STAT- MEDLINE DCOM- 20250416 LR - 20250419 IS - 1432-1440 (Electronic) IS - 0946-2716 (Print) IS - 0946-2716 (Linking) VI - 103 IP - 4 DP - 2025 Apr TI - Longitudinal study on immunologic, lipoproteomic, and inflammatory responses indicates the safety of sequential COVID-19 vaccination. PG - 421-433 LID - 10.1007/s00109-025-02527-y [doi] AB - COVID-19 vaccines are crucial in reducing SARS-CoV-2 transmission and severe health outcomes. Despite widespread administration, their long-term systemic effects on human metabolism remain inadequately understood. This longitudinal study aims to evaluate IgG responses, 34 cytokines, 112 lipoproteins, and 21 low-molecular-weight metabolites in 33 individuals receiving two to four COVID-19 vaccine doses. Changes in metabolic profiles for the first 16 days post each dose of vaccine, and up to 480 days post-initial dose, were compared to baseline (before vaccination). Additionally, metabolic profiles of vaccinated participants were compared to a reference cohort of unvaccinated individuals without prior exposure to SARS-CoV-2 infection (controls) and SARS-CoV-2 cases. Positive IgG responses were observed in 78.8% (N = 26) of participants after the first dose, reaching 100% with subsequent doses. The most common side effects were localized pain at the injection site and "flu-like" symptoms, reported by > 50% of participants. Systemic side effects, e.g., sore lymph nodes, fatigue, and brain fog, were reported but showed no significant correlations to IgG responses. Transient temporal changes were observed for cytokine IP10 (CXCL10) and glutamic acid around the third vaccine dose. Compared to the reference cohort, 497 vaccinated samples (95.0%) had profiles similar to the controls, while the remaining 26 samples with prior infection exposures were similar to mild cases of SARS-CooV-2 infection. In conclusion, COVID-19 vaccination did not induce lasting changes in inflammatory and metabolic responses, nor did it induce changes similar to mild cases of SARS-CoV-2 infection. This supports the metabolic safety of the vaccine and contributes to increased vaccine confidence. KEY MESSAGES: Minimal changes in inflammatory/metabolic markers up to 480 days post-vaccination. Transient increase in IP10 (CXCL10) and glutamic acid around the third dose. Post-vaccination IgG response did not alter metabolic profiles like SARS-CoV-2 cases. Our findings provide insights into the safety of repeated COVID-19 vaccinations. CI - (c) 2025. The Author(s). FAU - Lang, Jurissa AU - Lang J AUID- ORCID: 0009-0005-3959-0946 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Bernal, Andres AU - Bernal A AUID- ORCID: 0000-0003-1668-7225 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Wist, Julien AU - Wist J AUID- ORCID: 0000-0002-3416-2572 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. AD - Chemistry Department, Universidad del Valle, Cali, 76001, Colombia. AD - Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington, London, SW7 2AZ, UK. FAU - Egan, Siobhon AU - Egan S AUID- ORCID: 0000-0003-4395-4069 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Bong, Sze How AU - Bong SH AUID- ORCID: 0000-0002-3313-5097 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Millet, Oscar AU - Millet O AUID- ORCID: 0000-0001-8748-4105 AD - Centro de Investigacion Cooperativa en Biociencias -CIC bioGUNE, Precision Medicine and Metabolism Laboratory, Basque Research and Technology Alliance, Bizkaia Science and Technology Park, 48160, Derio, Spain. FAU - Ryan, Monique AU - Ryan M AUID- ORCID: 0000-0001-9188-7097 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Lee, Aude-Claire AU - Lee AC AUID- ORCID: 0000-0002-9692-9396 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Hall, Drew AU - Hall D AUID- ORCID: 0000-0001-6562-2335 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Nitschke, Philipp AU - Nitschke P AUID- ORCID: 0000-0002-5814-7529 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Masuda, Reika AU - Masuda R AUID- ORCID: 0000-0003-4891-7830 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. FAU - Imrie, Allison AU - Imrie A AUID- ORCID: 0000-0003-4715-6662 AD - School of Biomedical Sciences, University of Western Australia, Nedlands, WA, 6009, Australia. FAU - Holmes, Elaine AU - Holmes E AUID- ORCID: 0000-0002-0556-8389 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. AD - Nutrition Research, Department of Metabolism, Nutrition and Reproduction, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, London, SW7 2AZ, UK. FAU - Nicholson, Jeremy AU - Nicholson J AUID- ORCID: 0000-0002-8123-8349 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. Jeremy.Nicholson@murdoch.edu.au. AD - Nutrition Research, Department of Metabolism, Nutrition and Reproduction, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, London, SW7 2AZ, UK. Jeremy.Nicholson@murdoch.edu.au. AD - Institute of Global Health and Innovation, Imperial College London, Faculty Building South Kensington Campus, London, SW7 2AZ, UK. Jeremy.Nicholson@murdoch.edu.au. FAU - Loo, Ruey Leng AU - Loo RL AUID- ORCID: 0000-0001-5307-5709 AD - Australian National Phenome Centre and Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, 5 Robin Warren Drive, Perth, WA, 6150, Australia. rueyleng.loo@murdoch.edu.au. LA - eng GR - 2014349/Western Australian State Government, and the MRFF/ GR - PID2021-124171OB-I00/Agencia Estatal de Investigacion/ PT - Journal Article DEP - 20250312 PL - Germany TA - J Mol Med (Berl) JT - Journal of molecular medicine (Berlin, Germany) JID - 9504370 RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin G) RN - 0 (Cytokines) RN - 0 (Antibodies, Viral) SB - IM MH - Humans MH - Female MH - Male MH - Longitudinal Studies MH - *COVID-19/prevention & control/immunology MH - *COVID-19 Vaccines/adverse effects/immunology/administration & dosage MH - Middle Aged MH - Adult MH - *SARS-CoV-2/immunology MH - Immunoglobulin G/blood/immunology MH - Cytokines/blood MH - Vaccination/adverse effects MH - Antibodies, Viral/blood/immunology MH - Inflammation/immunology MH - Proteomics/methods MH - Aged PMC - PMC12003606 OTO - NOTNLM OT - COVID-19 vaccine OT - IgG responses OT - Inflammation OT - Longitudinal study OT - Metabolomics OT - SARS-CoV-2 infection COIS- Declarations. Ethics approval and consent to participate: All participants used in the current study provided informed consent, and ethical approvals were obtained from the Murdoch University Human Research Ethics Committee (project numbers 2021/49, 2020/052, and 2020/053). Competing interests: The authors declare no competing interests. EDAT- 2025/03/13 06:28 MHDA- 2025/04/16 14:34 PMCR- 2025/03/12 CRDT- 2025/03/13 00:20 PHST- 2024/09/25 00:00 [received] PHST- 2025/02/24 00:00 [accepted] PHST- 2025/02/18 00:00 [revised] PHST- 2025/04/16 14:34 [medline] PHST- 2025/03/13 06:28 [pubmed] PHST- 2025/03/13 00:20 [entrez] PHST- 2025/03/12 00:00 [pmc-release] AID - 10.1007/s00109-025-02527-y [pii] AID - 2527 [pii] AID - 10.1007/s00109-025-02527-y [doi] PST - ppublish SO - J Mol Med (Berl). 2025 Apr;103(4):421-433. doi: 10.1007/s00109-025-02527-y. Epub 2025 Mar 12. PMID- 39966881 OWN - NLM STAT- MEDLINE DCOM- 20250508 LR - 20250508 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 25 IP - 1 DP - 2025 Feb 18 TI - Perceived social support and self-stigma as factors of COVID-19 booster vaccination behavior and intention via cognitive coping and emotion regulation among people infected with COVID-19 in Hong Kong. PG - 659 LID - 10.1186/s12889-025-21899-x [doi] LID - 659 AB - BACKGROUND: It is imperative to promote behavior/intention of taking up booster COVID-19 vaccination (BI-BV) among people who have ever contracted COVID-19 (PECC). The aims were to investigate the prevalence of BI-BV and its associations with perceived social support. Guided by the stress coping theory, we tested mediators between perceived social support and BI-BV via self-stigma, active coping, and maladaptive emotion regulation (rumination and catastrophizing). METHODS: A random population-based telephone survey was conducted among adult PECC having completed the primary series of COVID-19 vaccination prior to the diagnosis; 230 participants were interviewed from June to August 2022 during the fifth (last) major outbreak in Hong Kong. The associations between the independent variables and BI-BV were tested by logistic regression analysis. A structural equation model (SEM) tested the indirect effects of the latent variables of self-stigma, active coping, and maladaptive emotion regulation between the latent variable of perceived social support and BI-BV. RESULTS: The prevalence of BI-BV was 62.2%. It was associated with age, marital status, full-time employment, and chronic disease status. The logistic regression analysis found that BI-BV was positively associated with perceived social support (ORc = 1.31, 95% CI: 1.12- 1.54), active coping (ORc = 1.40, 95% CI: 1.10- 1.79), rumination (ORc = 1.75, 95% CI: 1.13- 2.70), and catastrophizing (ORc = 3.12, 95% CI: 1.49- 6.51) and negatively associated with self-stigma (ORc = 0.80, 95% CI: 0.72- 0.88). In the SEM analysis, the positive association between perceived social support and BI-BV was fully mediated: 1) via self-stigma (beta = 0.07, 95% CI: 0.03- 0.14), 2) via active coping (beta = 0.06, 95% CI: 0.02- 0.12), and 3) via self-stigma and then active coping (beta = 0.01, 95% CI: 0.002- 0.04). Two of these indirect paths involved active coping. The indirect paths involving maladaptive emotion regulation were all non-significant. CONCLUSIONS: Perceived social support was associated with BI-BV, and was mediated via self-stigma, active coping, and serially self-stigma then active coping but not emotion maladaptation. The data supported the stress cognitive coping model in explaining the association between perceived social support and BI-BV. Interventions promoting BI-BV may consider modifying the observed significant factors. Future longitudinal studies are warranted to confirm the findings. CI - (c) 2025. The Author(s). FAU - Zhang, Xiaoying AU - Zhang X AD - College of Public Health, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. FAU - Luan, Yiming AU - Luan Y AD - Meilong Community Health Center of Minhang District, Shanghai, 201100, China. FAU - Tang, Yihan AU - Tang Y AD - School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, China. FAU - Lau, Mason M C AU - Lau MMC AD - Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. FAU - Yu, Yanqiu AU - Yu Y AD - School of Public Health, Fudan University, Shanghai, 200032, China. yuyanqiu@fudan.edu.cn. FAU - Gu, Jing AU - Gu J AD - School of Public Health, Sun Yat-Sen University, Guangzhou, 510080, China. gujing5@mail.sysu.edu.cn. FAU - Lau, Joseph T F AU - Lau JTF AD - Public Mental Health Center, School of Mental Health, Wenzhou Medical University, Wenzhou, 325000, China. jlau@cuhk.edu.hk. AD - Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, 325000, China. jlau@cuhk.edu.hk. AD - Center for Health Behaviors Research, The Chinese University of Hong Kong, Hong Kong, China. jlau@cuhk.edu.hk. LA - eng PT - Journal Article DEP - 20250218 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Hong Kong/epidemiology MH - Female MH - Male MH - *Social Support MH - *Adaptation, Psychological MH - Adult MH - *COVID-19/prevention & control/psychology MH - Middle Aged MH - *Social Stigma MH - *COVID-19 Vaccines/administration & dosage MH - *Emotional Regulation MH - *Intention MH - Young Adult MH - Surveys and Questionnaires MH - Aged MH - SARS-CoV-2 MH - Coping Skills PMC - PMC11834225 OTO - NOTNLM OT - Active coping OT - Booster COVID-19 vaccines OT - Catastrophizing OT - Emotion regulation OT - Mediation OT - Perceived social support OT - Rumination OT - Self-stigma OT - Stress coping model COIS- Declarations. Ethics approval and consent to participate: The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Survey and Behavioral Research Ethics Committee of the Chinese University of Hong Kong (No. SBRE-21-0778). Informed consent was obtained from all subjects involved in this study. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. EDAT- 2025/02/19 06:22 MHDA- 2025/02/19 06:23 PMCR- 2025/02/18 CRDT- 2025/02/19 00:00 PHST- 2024/02/09 00:00 [received] PHST- 2025/02/11 00:00 [accepted] PHST- 2025/02/19 06:23 [medline] PHST- 2025/02/19 06:22 [pubmed] PHST- 2025/02/19 00:00 [entrez] PHST- 2025/02/18 00:00 [pmc-release] AID - 10.1186/s12889-025-21899-x [pii] AID - 21899 [pii] AID - 10.1186/s12889-025-21899-x [doi] PST - epublish SO - BMC Public Health. 2025 Feb 18;25(1):659. doi: 10.1186/s12889-025-21899-x. PMID- 39881668 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250131 IS - 2666-6065 (Electronic) IS - 2666-6065 (Linking) VI - 52 DP - 2024 Nov TI - Long COVID facts and findings: a large-scale online survey in 74,075 Chinese participants. PG - 101218 LID - 10.1016/j.lanwpc.2024.101218 [doi] LID - 101218 AB - BACKGROUND: Research on long COVID in China is limited, particularly in terms of large-sample epidemiological data and the effects of recent SARS-CoV-2 sub-variants. China provides an ideal study environment owing to its large infection base, high vaccine coverage, and stringent pre-pandemic measures. METHODS: This retrospective study used an online questionnaire to investigate SARS-CoV-2 infection status and long COVID symptoms among 74,075 Chinese residents over one year. The relationships between baseline characteristics, vaccination status, pathogenic infection, and long COVID were analyzed using multinomial logistic regression, and propensity matching. FINDINGS: Analysis of 68,200 valid responses revealed that the most frequent long COVID symptoms include fatigue (30.53%), memory decline (27.93%), decreased exercise ability (18.29%), and brain fog (16.87%). These symptoms were less prevalent among those infected only once: fatigue (24.85%), memory decline (18.11%), and decreased exercise ability (12.52%), etc. Women were more likely to experience long COVID, with symptoms varying by age group, except for sleep disorders and muscle/joint pain, which were more common in older individuals. Northern China exhibits a higher prevalence of long COVID, potentially linked to temperature gradients. Risk factors included underlying diseases, alcohol consumption, smoking, and the severity of acute infection (OR > 1, FDR < 0.05). Reinfection was associated with milder symptoms but led to a higher incidence and severity of long COVID (OR > 1, FDR < 0.05). Vaccination, particularly multiple boosters, significantly reduced long-term symptoms by 30%-70% (OR < 1, FDR < 0.05). COVID-19 participants also self-reported more bacterial, influenza and mycoplasma infections, and 8%-10% of patients felt SARS-CoV-2-induced chronic diseases. INTERPRETATION: This survey provides valuable insights into long COVID situation among Chinese residents, with 10%-30% (including repeated infection) reporting symptoms. Monitoring at-risk individuals based on identified risk factors is essential for public health efforts. FUNDING: This study was funded by the China Postdoctoral Science Foundation (2022M723344, 2023M743729), Guangdong Basic and Applied Basic Research Foundation (2023A1515110489), and the Bill & Melinda Gates Foundation (INV-027420). CI - (c) 2024 The Author(s). FAU - Qin, Shijie AU - Qin S AD - Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518038, China. AD - Innovative Vaccine and Immunotherapy Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310009, China. AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Zhang, Yanan AU - Zhang Y AD - Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518038, China. AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Li, Yanhua AU - Li Y AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Huang, Ling AU - Huang L AD - Department of Critical Medicine, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital, The First Affiliated Hospital, Southern University of Science and Technology, Shenzhen, 518020, Guangdong, China. FAU - Yang, Ting AU - Yang T AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Si, Jiahui AU - Si J AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Wang, Likui AU - Wang L AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences (CAS), Beijing, 100101, China. AD - International Institute of Vaccine Research and Innovation, University of Chinese Academy of Sciences (UCAS), Beijing, 101408, China. FAU - Zhao, Xin AU - Zhao X AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. FAU - Ma, Xiaopeng AU - Ma X AD - Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518038, China. FAU - Gao, George F AU - Gao GF AD - Department of Infectious Diseases, Shenzhen Children's Hospital, Shenzhen, 518038, China. AD - Innovative Vaccine and Immunotherapy Research Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, 310009, China. AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences (CAS), Beijing, 100101, China. AD - CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, CAS-TWAS Center of Excellence for Emerging Infectious Diseases (CEEID), Chinese Academy of Sciences (CAS), Beijing, 100101, China. LA - eng PT - Journal Article DEP - 20241011 PL - England TA - Lancet Reg Health West Pac JT - The Lancet regional health. Western Pacific JID - 101774968 PMC - PMC11776084 OTO - NOTNLM OT - COVID-19 OT - Epidemiology OT - Long COVID OT - Questionnaire survey OT - SARS-CoV-2 OT - Vaccine background COIS- All authors declare that there are no conflicts of interest. EDAT- 2025/01/30 11:07 MHDA- 2025/01/30 11:08 PMCR- 2024/10/11 CRDT- 2025/01/30 04:23 PHST- 2024/07/29 00:00 [received] PHST- 2024/08/24 00:00 [revised] PHST- 2024/09/23 00:00 [accepted] PHST- 2025/01/30 11:08 [medline] PHST- 2025/01/30 11:07 [pubmed] PHST- 2025/01/30 04:23 [entrez] PHST- 2024/10/11 00:00 [pmc-release] AID - S2666-6065(24)00212-8 [pii] AID - 101218 [pii] AID - 10.1016/j.lanwpc.2024.101218 [doi] PST - epublish SO - Lancet Reg Health West Pac. 2024 Oct 11;52:101218. doi: 10.1016/j.lanwpc.2024.101218. eCollection 2024 Nov. PMID- 39857653 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260923 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 13 IP - 1 DP - 2024 Dec 30 TI - Persistent Health and Cognitive Impairments up to Four Years Post-COVID-19 in Young Students: The Impact of Virus Variants and Vaccination Timing. LID - 10.3390/biomedicines13010069 [doi] LID - 69 AB - Background: The long-term consequences of COVID-19 infection are becoming increasingly evident in recent studies. This repeated cross-sectional study aimed to explore the long-term health and cognitive effects of COVID-19, focusing on how virus variants, vaccination, illness severity, and time since infection impact post-COVID-19 outcomes. Methods: We examined three cohorts of university students (N = 584) and used non-parametric methods to assess correlations of various health and cognitive variables with SARS-CoV-2 infection, COVID-19 severity, vaccination status, time since infection, time since vaccination, and virus variants. Results: Our results suggest that some health and cognitive impairments may persist, with some even appearing to progressively worsen-particularly fatigue in women and memory in men-up to four years post-infection. The data further indicate that the ancestral SARS-CoV-2 variant may have the most significant long-term impact, while the Omicron variant appears to have the least. Interestingly, the severity of the acute illness was not correlated with the variant of SARS-CoV-2. The analysis also revealed that individuals who contracted COVID-19 after vaccination had better health and cognitive outcomes compared to those infected before vaccination. Conclusions: Overall, our results indicate that even in young individuals who predominantly experienced only mild forms of the infection, a gradual decline in health and fitness can occur over a span of four years post-infection. Notably, some negative trends-at least in men-only began to stabilize or even reverse during the fourth year, whereas in women, these trends showed no such improvement. These findings suggest that the long-term public health impacts of COVID-19 may be more severe and affect a much broader population than is commonly assumed. FAU - Latifi, Ashkan AU - Latifi A AUID- ORCID: 0000-0001-8725-2910 AD - Laboratory of Evolutionary Biology, Department of Philosophy and History of Sciences, Faculty of Science, Charles University, Vinicna 7, 128 00 Prague, Czech Republic. FAU - Flegr, Jaroslav AU - Flegr J AUID- ORCID: 0000-0002-0822-0126 AD - Laboratory of Evolutionary Biology, Department of Philosophy and History of Sciences, Faculty of Science, Charles University, Vinicna 7, 128 00 Prague, Czech Republic. LA - eng GR - 22-20785S/Czech Science Foundation/ PT - Journal Article DEP - 20241230 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11760454 OTO - NOTNLM OT - SARS-CoV-2 OT - cognition OT - long COVID OT - long-term effects OT - mental health COIS- The authors declare no conflicts of interest. EDAT- 2025/01/25 13:52 MHDA- 2025/01/25 13:53 PMCR- 2024/12/30 CRDT- 2025/01/25 01:06 PHST- 2024/11/09 00:00 [received] PHST- 2024/12/27 00:00 [revised] PHST- 2024/12/28 00:00 [accepted] PHST- 2025/01/25 13:53 [medline] PHST- 2025/01/25 13:52 [pubmed] PHST- 2025/01/25 01:06 [entrez] PHST- 2024/12/30 00:00 [pmc-release] AID - biomedicines13010069 [pii] AID - biomedicines-13-00069 [pii] AID - 10.3390/biomedicines13010069 [doi] PST - epublish SO - Biomedicines. 2024 Dec 30;13(1):69. doi: 10.3390/biomedicines13010069. PMID- 39787799 OWN - NLM STAT- MEDLINE DCOM- 20250430 LR - 20250905 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 47 DP - 2025 Feb 15 TI - Post-COVID symptoms after SARS-CoV-2 omicron infection and the effect of booster vaccination: A population-based cohort study. PG - 126664 LID - S0264-410X(24)01346-X [pii] LID - 10.1016/j.vaccine.2024.126664 [doi] AB - BACKGROUND: The impact of vaccination on the type and risk of specific post-COVID symptoms after Omicron infection is not clear. We aimed to investigate the excess risk and patterns of 22 symptoms 3-5 months after Omicron infection, comparing uninfected and infected subjects with and without recent booster vaccination. METHODS: We conducted a population-based prospective study based on four questionnaire-based cohorts linked to national health registries. Our study includes female and male participants aged 11-80 years from The Norwegian Mother, Father, and Child Cohort Study, The Norwegian Influenza Pregnancy Cohort, The Senior Cohort, and The Young Adult Cohort. All participants registered presence of 22 COVID-related symptoms irrespective of infection and vaccination status. RESULTS: The study sample includes more than 31,000 uninfected and 26,000 Omicron infected subjects. Among infected subjects, 12 % were vaccinated with two doses >130 days before the primary infection (median 154 days) but had not received a third dose, while 76 % had received a third (booster) dose (median 40 days before infection). Among those with two doses only, the excess risk for new symptoms after infection (vs. no infection) were up to 15 % for women and 9 % for men. Among infected subjects with recent booster dose, the corresponding excess risks were 7 % among women and up to 5 % among men. The largest risk differences after recent booster vaccination were seen for poor memory, brain fog, and fatigue. Post-COVID symptoms were more often detected among young and middle-aged adults than among adolescents and older age groups. CONCLUSION: Recent booster vaccination before infection substantially reduced both neurocognitive and cardiorespiratory symptoms occurring at least 3 months after Omicron infection. CI - Copyright (c) 2025 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Caspersen, Ida Henriette AU - Caspersen IH AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. Electronic address: ida.henriette.caspersen@fhi.no. FAU - Skodvin, Siri N AU - Skodvin SN AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. FAU - Blix, Kristine AU - Blix K AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Robertson, Anna Hayman AU - Robertson AH AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Laake, Ida AU - Laake I AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Feiring, Berit AU - Feiring B AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Magnus, Per AU - Magnus P AD - Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway. FAU - Mjaaland, Siri AU - Mjaaland S AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. FAU - Trogstad, Lill AU - Trogstad L AD - Department of Method Development and Analysis, Norwegian Institute of Public Health, Oslo, Norway. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20250108 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - Middle Aged MH - Adult MH - *Immunization, Secondary MH - Adolescent MH - Aged MH - *COVID-19/prevention & control/epidemiology/immunology/complications MH - Child MH - Young Adult MH - Aged, 80 and over MH - Prospective Studies MH - *COVID-19 Vaccines/administration & dosage/immunology MH - *SARS-CoV-2/immunology MH - Norway/epidemiology MH - Vaccination OTO - NOTNLM OT - COVID-19 OT - MoBa OT - Post-acute sequelae OT - SARS-CoV-2 OT - The Norwegian Mother, Father and Child Cohort Study COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2025/01/10 00:21 MHDA- 2025/01/31 00:21 CRDT- 2025/01/09 18:06 PHST- 2024/09/06 00:00 [received] PHST- 2024/12/19 00:00 [revised] PHST- 2024/12/19 00:00 [accepted] PHST- 2025/01/31 00:21 [medline] PHST- 2025/01/10 00:21 [pubmed] PHST- 2025/01/09 18:06 [entrez] AID - S0264-410X(24)01346-X [pii] AID - 10.1016/j.vaccine.2024.126664 [doi] PST - ppublish SO - Vaccine. 2025 Feb 15;47:126664. doi: 10.1016/j.vaccine.2024.126664. Epub 2025 Jan 8. PMID- 39777257 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260925 IS - 2632-1297 (Electronic) IS - 2632-1297 (Linking) VI - 7 IP - 1 DP - 2025 TI - Vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID. PG - fcae448 LID - 10.1093/braincomms/fcae448 [doi] LID - fcae448 AB - Persistent symptoms after COVID-19 constitute the long COVID syndrome, also called post-acute sequelae of SARS-CoV-2 infection (PASC). COVID-19 vaccines reduce the gravity of ensuing SARS-CoV-2 infections. However, whether vaccines also have an impact on PASC remain unknown. We investigated whether vaccination prior to infection alters the subsequent neurologic post-acute sequelae of SARS-CoV-2 infection (Neuro-PASC). We studied prospectively the first consecutive 200 post-hospitalization Neuro-PASC (PNP) and 1100 non-hospitalized Neuro-PASC (NNP) patients evaluated at our neuro-COVID-19 clinic between May 2020 and January 2023. Among PNP patients, 87% had a pre-vaccination infection and 13% had a breakthrough infection post-vaccination. Among the NNP patients, 70.7% had a pre-vaccination infection and 29.3% had a breakthrough infection. Both PNP and NNP breakthrough infection patients had more frequent pre-existing depression/anxiety than their respective pre-vaccination infection groups, and NNP breakthrough infection patients also had more frequent comorbidities of headache, lung and gastrointestinal diseases than the NNP pre-vaccination infection group. An average of 10 months after symptom onset, the three most common neurological symptoms for PNP patients were brain fog (86.5%), numbness/tingling (56.5%) and headache (56.5%). Of all Neuro-PASC symptoms, PNP breakthrough infection more frequently reported anosmia compared to PNP pre-vaccination infection patients (69.2 versus 37.9%; P = 0.005). For NNP patients, the three most common neurological symptoms were brain fog (83.9%), headache (70.9%) and dizziness (53.8%). NNP pre-vaccination infection reported anosmia (56.6 versus 39.1%; P < 0.0001) and dysgeusia (53.3 versus 37.3%; P < 0.0001) more frequently than breakthrough infection patients. NNP breakthrough infection more frequently reported dizziness compared to NNP pre-vaccination infection patients (61.5 versus 50.6%; P = 0.001). Both PNP and NNP patients had impaired quality-of-life in cognitive, fatigue, sleep, anxiety and depression domains with no differences between pre-vaccination infection and breakthrough infection groups. PNP patients performed worse on National Institutes of Health Toolbox tests of processing speed, attention, executive function and working memory than a US normative population whereas NNP patients had lower results in processing, speed, attention and working memory, without differences between pre-vaccination infection and breakthrough infection groups. These results indicate that vaccination prior to SARS-CoV-2 infection does not affect the neurologic manifestations of long COVID in either PNP or NNP patients. Minor differences in neurologic symptoms between pre-vaccination infection and breakthrough infection groups may be caused by SARS-CoV-2 strains evolution. Patients developing Neuro-PASC after breakthrough infection have a higher burden of comorbidities, highlighting different risk factors warranting targeted management. CI - (c) The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain. FAU - Mukherjee, Shreya AU - Mukherjee S AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Singer, Tracey AU - Singer T AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Venkatesh, Aditi AU - Venkatesh A AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Choudhury, Natasha A AU - Choudhury NA AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Perez Giraldo, Gina S AU - Perez Giraldo GS AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Jimenez, Millenia AU - Jimenez M AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Miller, Janet AU - Miller J AD - Northwestern Medicine, Chicago, IL 60611, USA. FAU - Lopez, Melissa AU - Lopez M AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Hanson, Barbara A AU - Hanson BA AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Bawa, Aasheeta P AU - Bawa AP AD - Northwestern Medicine, Chicago, IL 60611, USA. FAU - Batra, Ayush AU - Batra A AUID- ORCID: 0000-0002-4783-5801 AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Liotta, Eric M AU - Liotta EM AUID- ORCID: 0000-0003-3182-585X AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Koralnik, Igor J AU - Koralnik IJ AUID- ORCID: 0000-0001-6836-1468 AD - Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. LA - eng GR - K23 AG078705/AG/NIA NIH HHS/United States GR - R21 AG086751/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20250107 PL - England TA - Brain Commun JT - Brain communications JID - 101755125 PMC - PMC11703551 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 infection OT - long COVID OT - neurology OT - post-acute sequelae of SARS-CoV-2 infection COIS- The authors report no competing interests. EDAT- 2025/01/09 00:23 MHDA- 2025/01/09 00:24 PMCR- 2025/01/07 CRDT- 2025/01/08 18:04 PHST- 2024/07/29 00:00 [received] PHST- 2024/11/18 00:00 [revised] PHST- 2024/12/09 00:00 [accepted] PHST- 2025/01/09 00:24 [medline] PHST- 2025/01/09 00:23 [pubmed] PHST- 2025/01/08 18:04 [entrez] PHST- 2025/01/07 00:00 [pmc-release] AID - fcae448 [pii] AID - 10.1093/braincomms/fcae448 [doi] PST - epublish SO - Brain Commun. 2025 Jan 7;7(1):fcae448. doi: 10.1093/braincomms/fcae448. eCollection 2025. PMID- 39767757 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250108 IS - 2227-9059 (Print) IS - 2227-9059 (Electronic) IS - 2227-9059 (Linking) VI - 12 IP - 12 DP - 2024 Dec 15 TI - Autoantibodies Targeting G-Protein-Coupled Receptors and RAS-Related Molecules in Post-Acute COVID Vaccination Syndrome: A Retrospective Case Series Study. LID - 10.3390/biomedicines12122852 [doi] LID - 2852 AB - Background/Objectives: While post-acute COVID-19 syndrome is well known and extensively studied, the post-acute COVID vaccination syndrome (PACVS) is a more recent nosological entity that is poorly defined at the immunopathological level, although it shares many symptoms with the sequelae of viral infections. Methods: This single-center retrospective study reports a case series of 17 subjects vaccinated with mRNA or adenoviral vector vaccines who were healthy before vaccination and had never been infected with SARS-CoV-2 but who presented with symptoms similar to PACVS for a median time of 20 months (min 4, max 32). The medical records of all patients referred to our outpatient clinic over a one-year period were retrospectively analyzed. Results: In this group, serological tests showed that, in addition to positivity for anti-spike protein antibodies, a high percentage of subjects were positive for antibodies against G protein-coupled receptors and molecules involved in the response to SARS-CoV-2. In a panel of 16 autoantibodies tested, a few were positively associated with some of the symptoms reported by patients: anti-ATR1 with lymphadenopathy and/or tonsillitis; anti-ACE2 with skin symptoms such as ecchymosis, skin oedema, and rash; anti-MAS1 with widespread burning sensation; and anti-STAB1 with skin oedema and rash. Anti-ADRA2A were negatively associated with memory loss and/or mental fog. ACE2 correlated with the serum levels of anti-S antibodies, supporting the hypothesis of an anti-idiotype mechanism in the immunopathogenesis of PACVS. Conclusions: This exploratory analysis suggests that the levels of autoantibodies directed against ACE2, and probably also MAS1 and STAB1, may serve as biomarkers for PACVS. FAU - Mantovani, Mauro AU - Mantovani M AD - Istituto di Medicina Biologica, 20129 Milano, Italy. FAU - Bellavite, Paolo AU - Bellavite P AUID- ORCID: 0000-0002-5086-3504 AD - Independent Researcher, 37121 Verona, Italy. FAU - Fazio, Serafino AU - Fazio S AUID- ORCID: 0000-0002-2743-9836 AD - School of Medicine, Federico II University, 80100 Napoli, Italy. FAU - Di Fede, Giuseppe AU - Di Fede G AD - Istituto di Medicina Biologica, 20129 Milano, Italy. FAU - Tomasi, Marco AU - Tomasi M AD - Istituto di Medicina Biologica, 20129 Milano, Italy. FAU - Belli, Daniele AU - Belli D AD - Istituto di Medicina Biologica, 20129 Milano, Italy. FAU - Zanolin, Elisabetta AU - Zanolin E AD - Unit of Epidemiology & Statistical Medicine, Department of Diagnostics and Public Health, University of Verona, 37134 Verona, Italy. LA - eng PT - Journal Article DEP - 20241215 PL - Switzerland TA - Biomedicines JT - Biomedicines JID - 101691304 PMC - PMC11673082 OTO - NOTNLM OT - ACE2 OT - COVID-19 vaccine OT - G protein-coupled receptors OT - PACVS OT - adverse events OT - autoantibodies OT - autoimmunity OT - post-acute COVID vaccination syndrome OT - spike protein COIS- The authors declare no conflicts of interest. EDAT- 2025/01/08 06:21 MHDA- 2025/01/08 06:22 PMCR- 2024/12/15 CRDT- 2025/01/08 01:14 PHST- 2024/11/19 00:00 [received] PHST- 2024/12/06 00:00 [revised] PHST- 2024/12/13 00:00 [accepted] PHST- 2025/01/08 06:22 [medline] PHST- 2025/01/08 06:21 [pubmed] PHST- 2025/01/08 01:14 [entrez] PHST- 2024/12/15 00:00 [pmc-release] AID - biomedicines12122852 [pii] AID - biomedicines-12-02852 [pii] AID - 10.3390/biomedicines12122852 [doi] PST - epublish SO - Biomedicines. 2024 Dec 15;12(12):2852. doi: 10.3390/biomedicines12122852. PMID- 39720104 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250318 IS - 2405-6502 (Electronic) IS - 2405-6502 (Linking) VI - 38 DP - 2025 Mar TI - Oral minocycline therapy as first-line treatment in patients with Myalgic encephalomyelitis and long COVID: A pilot study. PG - 100537 LID - 10.1016/j.ensci.2024.100537 [doi] LID - 100537 AB - BACKGROUND: Myalgic encephalomyelitis (ME) is associated with long COVID and also untoward sequelae after anti-coronavirus vaccination. Recently, oral minocycline therapy has been reported to ameliorate symptoms in patients with ME, particularly at the initial stage of the disease. METHODS: Oral minocycline (100 mg x 2 on the first day, followed by 100 mg/day for 41 days) was administered to 55 patients with ME that emerged during the "Corona era," including 19 patients with long COVID and 5 patients diagnosed with untoward sequalae following coronavirus vaccination. RESULTS: Acute adverse effects including nausea and/or dizziness caused four (7 %) patients to discontinue treatment in the first few days. Among the other 51 patients who completed therapy, favorable effects were observed, including a decrease in performance status score or index for restricted activities of daily living >/=2 points in 41 (80 %) patients. Disease duration was inversely associated with the favorable therapeutic effects (p = 0.02) and the disease duration within 6 months was significantly associated with the favorable therapeutic effects (27/30, 90 %, p = 0.02, hazard ratio: 3.6, 95 % confidence interval, 1.2-10.6). The favorable effects were observed in 16 (89 %) of 18 patients with long COVID. Significant amelioration of subjective symptoms of fatigue, post-exertional malaise, unrefreshing sleep, brain fog, disequilibrium, orthostatic intolerance, and neuropathic pain were observed. CONCLUSIONS: Oral minocycline was effective at ameliorating symptoms in patients with ME including long COVID and post-coronavirus vaccination sequalae. It represents an effective first-line therapeutic option for these patients in the initial stage. CI - (c) 2024 The Author(s). FAU - Miwa, Kunihisa AU - Miwa K AD - Department of Internal Medicine, Miwa Naika Clinic, Toyama, Japan. LA - eng PT - Journal Article DEP - 20241202 PL - Netherlands TA - eNeurologicalSci JT - eNeurologicalSci JID - 101667077 EIN - eNeurologicalSci. 2025 Jan 24;38:100557. doi: 10.1016/j.ensci.2025.100557. PMID: 40099157 PMC - PMC11665601 OTO - NOTNLM OT - Chronic fatigue syndrome OT - Disequilibrium OT - Long COVID OT - Minocycline OT - Myalgic encephalomyelitis OT - Post-coronavirus vaccination sequalae COIS- None. EDAT- 2024/12/25 06:19 MHDA- 2024/12/25 06:20 PMCR- 2024/12/02 CRDT- 2024/12/25 04:18 PHST- 2024/06/06 00:00 [received] PHST- 2024/09/11 00:00 [revised] PHST- 2024/11/13 00:00 [accepted] PHST- 2024/12/25 06:20 [medline] PHST- 2024/12/25 06:19 [pubmed] PHST- 2024/12/25 04:18 [entrez] PHST- 2024/12/02 00:00 [pmc-release] AID - S2405-6502(24)00044-3 [pii] AID - 100537 [pii] AID - 10.1016/j.ensci.2024.100537 [doi] PST - epublish SO - eNeurologicalSci. 2024 Dec 2;38:100537. doi: 10.1016/j.ensci.2024.100537. eCollection 2025 Mar. PMID- 39675123 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 2211-0356 (Electronic) IS - 2211-0348 (Linking) VI - 93 DP - 2025 Jan TI - COVID-19 in patients with multiple sclerosis-A narrative review. PG - 106221 LID - S2211-0348(24)00797-1 [pii] LID - 10.1016/j.msard.2024.106221 [doi] AB - BACKGROUND: Multiple sclerosis (MS) is a complex neurodegenerative disease characterized by immune dysregulation, affecting over 2.5 million people worldwide. Interestingly, COVID-19 infection can cause neurodegeneration through demyelination similar to that of MS, and COVID-19 infection can lead to long-term neurological sequelae, post-COVID-19 neurological syndrome. These overlapping neurological mechanisms suggest that patients with MS (PwMS) may have a unique and potentially more complex relationship with COVID-19. DISCUSSION AND CONCLUSION: The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can enter the central nervous system via the olfactory nerve or through interactions with angiotensin-converting enzyme-2 receptors in the blood-brain barrier, potentially initiating or enhancing neurodegenerative processes through demyelination. The risk of SARS-CoV-2 infection among PwMS is similar to that of the general population; however, PwMS with higher Expanded Disability Status Scale scores, longer MS duration, or progressive forms of MS are at an increased risk for developing severe COVID-19 outcomes. Most disease-modifying therapies (DMT), such as interferon, glatiramer, teriflunomide, and cladribine, do not appear to affect the risk of COVID-19 infection, the severity of COVID-19 illness, or the response to COVID-19 vaccines. As a result, these therapies should be continued during COVID-19 infection in PwMS. Rituximab, however, has been shown to increase the risk of severe COVID-19 outcomes. For managing symptomatic COVID-19 infection in PwMS, remdesivir and neutralizing monoclonal antibodies are shown to be effective. COVID-19-associated cytokine release syndrome can be managed with corticosteroids. Importantly, COVID-19 infection does not increase susceptibility to MS relapses or exacerbate the progression of MS symptoms. Furthermore, COVID-19 vaccination is encouraged for all MS patients, particularly those at greater risk of severe outcomes, as it does not trigger relapses, exacerbate MS symptoms, or diminish the efficacy of DMT. Despite these findings, high-quality evidence remains lacking to fully establish the relationship between COVID-19 and MS, highlighting the need for further research in this area. CI - Copyright (c) 2024 Elsevier B.V. All rights reserved. FAU - Shrestha, Bijay Kumar AU - Shrestha BK AD - University of South Alabama Children's and Women's Hospital, Mobile, AL, United States. Electronic address: dr.bijay.kumar.shrestha@gmail.com. FAU - Sujakhu, Eru AU - Sujakhu E AD - University of South Alabama Children's and Women's Hospital, Mobile, AL, United States. FAU - Karale, Smruti AU - Karale S AD - Government Medical College, Kolhapur, Maharashtra, India. FAU - Telagarapu, Venkata Madhavi Latha AU - Telagarapu VML AD - University of Miami Miller School of Medicine, Miami, FL, United States. LA - eng PT - Journal Article PT - Review DEP - 20241208 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 SB - IM MH - Humans MH - *COVID-19/complications/immunology/epidemiology MH - *Multiple Sclerosis/complications/drug therapy/epidemiology/immunology MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccination OT - Disease-modifying therapies OT - Multiple sclerosis OT - Patients with MS OT - SARS-CoV-2 COIS- Declaration of competing interest None. EDAT- 2024/12/16 11:30 MHDA- 2025/01/30 00:19 CRDT- 2024/12/15 18:02 PHST- 2024/05/27 00:00 [received] PHST- 2024/10/02 00:00 [revised] PHST- 2024/12/07 00:00 [accepted] PHST- 2025/01/30 00:19 [medline] PHST- 2024/12/16 11:30 [pubmed] PHST- 2024/12/15 18:02 [entrez] AID - S2211-0348(24)00797-1 [pii] AID - 10.1016/j.msard.2024.106221 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2025 Jan;93:106221. doi: 10.1016/j.msard.2024.106221. Epub 2024 Dec 8. PMID- 39657038 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1537-6591 (Electronic) IS - 1058-4838 (Linking) VI - 80 IP - 3 DP - 2025 Mar 17 TI - Bivalent Boosters and Risk of Postacute Sequelae Following Vaccine-Breakthrough SARS-CoV-2 Omicron Infection: A Cohort Study. PG - 520-528 LID - 10.1093/cid/ciae598 [doi] AB - BACKGROUND: Vaccination has been shown to attenuate the risk of postacute sequelae following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, no prior population-based studies have evaluated if updated bivalent boosters reduce risk of postacute sequelae following Omicron variant infection, versus ancestral vaccines. METHODS: National databases were utilized to construct a population-based cohort of adult individuals infected during Omicron-predominant transmission. Risk and excess burden (EB) of prespecified multiorgan new-incident diagnoses at 31-365 days post-SARS-CoV-2 infection were compared between individuals who received prior bivalent boosters and those boosted with ancestral messenger RNA (mRNA) vaccines, using competing-risks regression. RESULTS: A total of 1 080 348 vaccine-breakthrough infections after an ancestral mRNA booster were contrasted against 9824 vaccine-breakthrough infections following a bivalent mRNA booster. There was an estimated 37.8% (hazard ratio [HR], 0.62 [95 confidence interval CI, .53-.73]) decrease in risk and lower overall EB per 1000 (-28.73 [95% CI, -40.47 to -16.99]) of any postacute sequelae, as well as a 39.9% (HR, 0.62 [95% CI, .52-.73]) decrease in risk and lower EB (-22.95 [95% CI, -32.71 to -13.19]) of any postacute neurological sequelae, among individuals who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. Specifically, there was reduced risk of thrombotic disorders (HR, 0.54 [95% CI, .29-.99]), episodic neurological disorders (HR, 0.55 [95% CI, .43-.72]), movement disorders (HR, 0.57 [95% CI, .47-.70]), and autoimmune vasculitis (HR, 0.54 [95% CI, .29-.99]) 31-365 days postinfection among those who received prior bivalent boosters, versus those boosted with ancestral mRNA vaccines. CONCLUSIONS: Boosting with updated bivalent mRNA vaccines was associated with greater attenuation of risk for postacute sequelae following Omicron variant infection, compared with ancestral mRNA boosters. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact journals.permissions@oup.com. FAU - Wee, Liang En AU - Wee LE AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Duke-National University of Singapore Graduate Medical School, National University of Singapore, Singapore, Singapore. AD - Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. FAU - Lim, Jue Tao AU - Lim JT AUID- ORCID: 0000-0002-2245-0331 AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Goel, Mayank AU - Goel M AD - National Centre for Infectious Diseases, Singapore, Singapore. FAU - Malek, Muhammad Ismail Abdul AU - Malek MIA AD - National Centre for Infectious Diseases, Singapore, Singapore. FAU - Chiew, Calvin J AU - Chiew CJ AUID- ORCID: 0000-0002-8217-7971 AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. FAU - Ong, Benjamin AU - Ong B AD - Ministry of Health, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Lye, David Chien Boon AU - Lye DCB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. AD - Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. AD - Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. FAU - Tan, Kelvin Bryan AU - Tan KB AD - National Centre for Infectious Diseases, Singapore, Singapore. AD - Ministry of Health, Singapore, Singapore. AD - Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. LA - eng GR - Singhealth Regional Health Systems PULSES Fellowship/ GR - Ministry of Education/ PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Infect Dis JT - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JID - 9203213 RN - 0 (COVID-19 Vaccines) RN - COVID-19 breakthrough infections RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/prevention & control/complications/epidemiology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Male MH - Middle Aged MH - Female MH - Adult MH - *SARS-CoV-2/immunology MH - *Immunization, Secondary MH - Cohort Studies MH - Aged MH - Young Adult MH - Breakthrough Infections OTO - NOTNLM OT - COVID-19 OT - Delta OT - Omicron OT - bivalent vaccines OT - multiorgan sequelae COIS- Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. EDAT- 2024/12/15 19:30 MHDA- 2025/03/17 18:30 CRDT- 2024/12/10 15:43 PHST- 2024/08/09 00:00 [received] PHST- 2025/03/17 18:30 [medline] PHST- 2024/12/15 19:30 [pubmed] PHST- 2024/12/10 15:43 [entrez] AID - 7917536 [pii] AID - 10.1093/cid/ciae598 [doi] PST - ppublish SO - Clin Infect Dis. 2025 Mar 17;80(3):520-528. doi: 10.1093/cid/ciae598. PMID- 39662823 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20250518 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 4 DP - 2025 Apr TI - Booster vaccination and post-COVID-19 condition during the Omicron variant-dominant wave: a large population-based study. PG - 630-635 LID - S1198-743X(24)00588-3 [pii] LID - 10.1016/j.cmi.2024.12.002 [doi] AB - OBJECTIVES: The effect of the COVID-19 booster vaccination and the long-term consequences concerning preventing post-COVID-19 condition (PCC) remains unclear. We aimed to investigate the association of COVID-19 booster vaccination dose and vaccination timing before infection with the risk of PCC during the Omicron variant-dominant wave. METHODS: This population-based study included patients confirmed with COVID-19 (extracted from the Health Center Real-time Information-sharing System) aged 20-69 years, who were infected between 1 July and 31 August 2022. We used a self-report questionnaire to evaluate PCC and extracted information on vaccination from the municipal vaccine registry system. We calculated multiple propensity scores for COVID-19 vaccination status (unvaccinated, 1-2 doses and >/=3 doses) to control for baseline population differences. We then used a logistic regression model with inverse probability weighting to analyse the associations between the number of vaccine doses and the risk of PCC. Additionally, we conducted stratified analysis by gender and subgroup analysis for respiratory and neurological symptoms. Multivariable logistic regression was used to analyse the association between vaccination timing and PCC risk, adjusting for vaccination doses. RESULTS: Of the 7936 participants with COVID-19 (mean age 42.9 years, 4553 women), 940 (11.8%) had at least 1 PCC. Compared with people unvaccinated, those vaccinated >/=3 times before the infection had a lower probability of PCC with the OR of 0.69 (95% CI: 0.53-0.90), although we detected no association with one or two doses. This association was present in women (>/=3 doses vs. unvaccinated OR: 0.70, 95% CI: 0.51-0.95) but not in men. Those vaccinated >/=3 times had fewer neurological symptoms compared with those unvaccinated (OR: 0.61, 95% CI: 0.45-0.83); however, no significant association was found for respiratory symptoms. DISCUSSION: This study suggests that booster vaccination could lower the risk of PCC. CI - Copyright (c) 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Iba, Arisa AU - Iba A AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. Electronic address: aiba@it.ncgm.go.jp. FAU - Hosozawa, Mariko AU - Hosozawa M AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Hori, Miyuki AU - Hori M AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Muto, Yoko AU - Muto Y AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. FAU - Kihara, Tomomi AU - Kihara T AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan; Department of Public Health Medicine, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan; Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Muraki, Isao AU - Muraki I AD - Public Health, Department of Social and Environmental Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. FAU - Masuda, Rie AU - Masuda R AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Tamiya, Nanako AU - Tamiya N AD - Health Services Research and Development Center, University of Tsukuba, Tsukuba, Ibaraki, Japan; Department of Health Services Research, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan. FAU - Iso, Hiroyasu AU - Iso H AD - Institute of Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan. LA - eng PT - Journal Article DEP - 20241209 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Middle Aged MH - Male MH - Female MH - *COVID-19/prevention & control/epidemiology/virology/complications MH - Adult MH - *Immunization, Secondary/statistics & numerical data MH - Aged MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/administration & dosage/immunology MH - Young Adult MH - Vaccination OTO - NOTNLM OT - Booster vaccine OT - Japan OT - Population study OT - Post-COVID-19 condition OT - Vaccination effect EDAT- 2024/12/12 00:24 MHDA- 2025/03/18 00:26 CRDT- 2024/12/11 19:32 PHST- 2024/05/09 00:00 [received] PHST- 2024/11/19 00:00 [revised] PHST- 2024/12/03 00:00 [accepted] PHST- 2025/03/18 00:26 [medline] PHST- 2024/12/12 00:24 [pubmed] PHST- 2024/12/11 19:32 [entrez] AID - S1198-743X(24)00588-3 [pii] AID - 10.1016/j.cmi.2024.12.002 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Apr;31(4):630-635. doi: 10.1016/j.cmi.2024.12.002. Epub 2024 Dec 9. PMID- 39644590 OWN - NLM STAT- MEDLINE DCOM- 20250427 LR - 20260821 IS - 1872-7123 (Electronic) IS - 0165-1781 (Linking) VI - 344 DP - 2025 Feb TI - Insight into potential long COVID effects: Antidepressant use in post SARS-CoV-2 Infection scenarios. A multiregional nested case-control study. PG - 116290 LID - S0165-1781(24)00575-4 [pii] LID - 10.1016/j.psychres.2024.116290 [doi] AB - This study aimed to investigate the impact of previous SARS-CoV-2 infection and the role of vaccination in the onset of neuropsychiatric conditions, evaluated through antidepressant prescriptions. This case-control study evaluated the risk of new antidepressant prescriptions in relation to previous exposure to SARS-CoV-2 infection and vaccination. It was conducted in three Italian Regions on adults who did not receive antidepressant prescriptions in the year preceding the study period. Individuals with newly prescribed antidepressants (cases) were matched by sex and age to non-users of antidepressants (controls). Pooled estimates of regional Odds Ratios (ORs) were obtained through a meta-analysis. Findings showed that individuals previously infected with SARS-CoV-2 had a higher risk of receiving a new prescription of antidepressants. Moreover, this association was stronger among subjects hospitalized due to infection, and SARS-CoV-2 vaccination may have acted as an effect modifier by reducing that risk. In fact, the pooled OR for receiving a new antidepressant prescription was higher for unvaccinated individuals than for those vaccinated. The results of this study confirm the role of SARS-CoV-2 infection as a risk factor for the onset of neuropsychiatric symptoms. Antidepressant treatment initiation was much more likely after severe COVID-19 infection but vaccination reduced such a risk. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Rosolen, Valentina AU - Rosolen V AD - Central Directorate for Health, Social Policies and Disability, Friuli Venezia Giulia Region, Trieste, Italy. FAU - Beorchia, Yvonne AU - Beorchia Y AD - Institute of Hygiene and Evaluative Epidemiology, Friuli Centrale University Health Authority, Udine, Italy. FAU - Castriotta, Luigi AU - Castriotta L AD - Central Directorate for Health, Social Policies and Disability, Friuli Venezia Giulia Region, Trieste, Italy; Institute of Hygiene and Evaluative Epidemiology, Friuli Centrale University Health Authority, Udine, Italy. Electronic address: luigi.castriotta@asufc.sanita.fvg.it. FAU - Fanizza, Caterina AU - Fanizza C AD - Strategic Regional Agency for Health and Social Affairs, Apulia Region, Bari, Italy. FAU - Profili, Francesco AU - Profili F AD - Tuscany Regional Health Agency, Tuscany Region, Florence, Italy. FAU - Floridia, Marco AU - Floridia M AD - Italian National Institute of Health, Rome, Italy. FAU - Giuliano, Marina AU - Giuliano M AD - Italian National Institute of Health, Rome, Italy. FAU - Pricci, Flavia AU - Pricci F AD - Italian National Institute of Health, Rome, Italy. FAU - Villa, Marika AU - Villa M AD - Italian National Institute of Health, Rome, Italy. FAU - Grisetti, Tiziana AU - Grisetti T AD - Italian National Institute of Health, Rome, Italy. FAU - Grassi, Tiziana AU - Grassi T AD - Italian National Institute of Health, Rome, Italy. FAU - Tiple, Dorina AU - Tiple D AD - Italian National Institute of Health, Rome, Italy. FAU - Silenzi, Andrea AU - Silenzi A AD - Italian Ministry of Health, Rome, Italy. FAU - Francesconi, Paolo AU - Francesconi P AD - Tuscany Regional Health Agency, Tuscany Region, Florence, Italy. FAU - Bisceglia, Lucia AU - Bisceglia L AD - Strategic Regional Agency for Health and Social Affairs, Apulia Region, Bari, Italy. FAU - Barbone, Fabio AU - Barbone F AD - Central Directorate for Health, Social Policies and Disability, Friuli Venezia Giulia Region, Trieste, Italy; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy. FAU - Brusaferro, Silvio AU - Brusaferro S AD - Accreditation, Clinical Risk Management, and Health Care Performance Evaluation Udine, Friuli Centrale University Health Authority, Udine, Italy. FAU - Onder, Graziano AU - Onder G AD - Universita Cattolica del Sacro Cuore, Rome, Italy; Fondazione Policlinico Gemelli IRCCS, Rome, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241128 PL - Ireland TA - Psychiatry Res JT - Psychiatry research JID - 7911385 RN - 0 (Antidepressive Agents) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/complications/prevention & control/psychology/epidemiology MH - *Antidepressive Agents/therapeutic use MH - Case-Control Studies MH - Male MH - Female MH - Middle Aged MH - Adult MH - Italy/epidemiology MH - Aged MH - COVID-19 Vaccines MH - Vaccination/statistics & numerical data MH - Risk Factors MH - SARS-CoV-2 MH - *Depression/drug therapy/epidemiology OTO - NOTNLM OT - Administrative database OT - Drug utilization OT - Mental health OT - Post-covid conditions OT - Public health OT - Vaccination COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/12/08 01:11 MHDA- 2025/01/20 22:53 CRDT- 2024/12/07 18:02 PHST- 2024/05/28 00:00 [received] PHST- 2024/11/08 00:00 [revised] PHST- 2024/11/25 00:00 [accepted] PHST- 2025/01/20 22:53 [medline] PHST- 2024/12/08 01:11 [pubmed] PHST- 2024/12/07 18:02 [entrez] AID - S0165-1781(24)00575-4 [pii] AID - 10.1016/j.psychres.2024.116290 [doi] PST - ppublish SO - Psychiatry Res. 2025 Feb;344:116290. doi: 10.1016/j.psychres.2024.116290. Epub 2024 Nov 28. PMID- 39615487 OWN - NLM STAT- MEDLINE DCOM- 20241212 LR - 20260818 IS - 1934-6069 (Electronic) IS - 1931-3128 (Linking) VI - 32 IP - 12 DP - 2024 Dec 11 TI - Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19. PG - 2112-2130.e10 LID - S1931-3128(24)00438-4 [pii] LID - 10.1016/j.chom.2024.11.007 [doi] AB - SARS-CoV-2 infection is associated with long-lasting neurological symptoms, although the underlying mechanisms remain unclear. Using optical clearing and imaging, we observed the accumulation of SARS-CoV-2 spike protein in the skull-meninges-brain axis of human COVID-19 patients, persisting long after viral clearance. Further, biomarkers of neurodegeneration were elevated in the cerebrospinal fluid from long COVID patients, and proteomic analysis of human skull, meninges, and brain samples revealed dysregulated inflammatory pathways and neurodegeneration-associated changes. Similar distribution patterns of the spike protein were observed in SARS-CoV-2-infected mice. Injection of spike protein alone was sufficient to induce neuroinflammation, proteome changes in the skull-meninges-brain axis, anxiety-like behavior, and exacerbated outcomes in mouse models of stroke and traumatic brain injury. Vaccination reduced but did not eliminate spike protein accumulation after infection in mice. Our findings suggest persistent spike protein at the brain borders may contribute to lasting neurological sequelae of COVID-19. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Rong, Zhouyi AU - Rong Z AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Medical Research School (MMRS), Munich, Germany. FAU - Mai, Hongcheng AU - Mai H AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China; Munich Medical Research School (MMRS), Munich, Germany. FAU - Ebert, Gregor AU - Ebert G AD - Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. FAU - Kapoor, Saketh AU - Kapoor S AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Department of Immunobiology, Yale School of Medicine, New Haven, CT, USA. FAU - Puelles, Victor G AU - Puelles VG AD - III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark. FAU - Czogalla, Jan AU - Czogalla J AD - III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Hu, Senbin AU - Hu S AD - Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Su, Jinpeng AU - Su J AD - Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany. FAU - Prtvar, Danilo AU - Prtvar D AD - German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. FAU - Singh, Inderjeet AU - Singh I AD - Research Unit Adipocytes & Metabolism (ADM), Helmholtz Diabetes Center, Helmholtz Munich, 85764 Neuherberg, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany. FAU - Schadler, Julia AU - Schadler J AD - Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Delbridge, Claire AU - Delbridge C AD - Institute of Pathology, Division of Neuropathology, School of Medicine, Technical University of Munich, Munich, Germany. FAU - Steinke, Hanno AU - Steinke H AD - Institute of Anatomy, University of Leipzig, Leipzig, Germany. FAU - Frenzel, Hannah AU - Frenzel H AD - Institute of Anatomy, University of Leipzig, Leipzig, Germany. FAU - Schmidt, Katja AU - Schmidt K AD - Institute of Anatomy, University of Leipzig, Leipzig, Germany. FAU - Braun, Christian AU - Braun C AD - Institute of Legal Medicine, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Bruch, Gina AU - Bruch G AD - Institute of Legal Medicine, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Ruf, Viktoria AU - Ruf V AD - Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. FAU - Ali, Mayar AU - Ali M AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Graduate School of Neuroscience (GSN), Munich, Germany. FAU - Suhs, Kurt-Wolfram AU - Suhs KW AD - Department of Neurology, Medical School Hannover, Hannover, Germany. FAU - Nemati, Mojtaba AU - Nemati M AD - Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Hopfner, Franziska AU - Hopfner F AD - Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Ulukaya, Selin AU - Ulukaya S AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany. FAU - Jeridi, Denise AU - Jeridi D AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany. FAU - Mistretta, Daniele AU - Mistretta D AD - Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany. FAU - Caliskan, Ozum Sehnaz AU - Caliskan OS AD - Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany. FAU - Wettengel, Jochen Martin AU - Wettengel JM AD - Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany. FAU - Cherif, Fatma AU - Cherif F AD - German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. FAU - Kolabas, Zeynep Ilgin AU - Kolabas ZI AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Graduate School of Neuroscience (GSN), Munich, Germany. FAU - Molbay, Muge AU - Molbay M AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Medical Research School (MMRS), Munich, Germany. FAU - Horvath, Izabela AU - Horvath I AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Center of Doctoral Studies in Informatics and its Applications (CEDOSIA), Technical University of Munich, Munich, Germany. FAU - Zhao, Shan AU - Zhao S AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Krahmer, Natalie AU - Krahmer N AD - Institute for Diabetes and Obesity, Helmholtz Munich, Neuherberg, Germany. FAU - Yildirim, Ali Onder AU - Yildirim AO AD - Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. FAU - Ussar, Siegfried AU - Ussar S AD - Research Unit Adipocytes & Metabolism (ADM), Helmholtz Diabetes Center, Helmholtz Munich, 85764 Neuherberg, Germany; German Center for Diabetes Research (DZD), 85764 Neuherberg, Germany. FAU - Herms, Jochen AU - Herms J AD - Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. FAU - Huber, Tobias B AU - Huber TB AD - III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Hamburg Center for Kidney Health (HCKH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Tahirovic, Sabina AU - Tahirovic S AD - German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany. FAU - Schwarzmaier, Susanne M AU - Schwarzmaier SM AD - Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Plesnila, Nikolaus AU - Plesnila N AD - Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Hoglinger, Gunter AU - Hoglinger G AD - German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany; Department of Neurology, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany. FAU - Ondruschka, Benjamin AU - Ondruschka B AD - III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Legal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. FAU - Bechmann, Ingo AU - Bechmann I AD - Institute of Anatomy, University of Leipzig, Leipzig, Germany. FAU - Protzer, Ulrike AU - Protzer U AD - Institute of Virology, Technical University of Munich/Helmholtz Munich, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany. FAU - Elsner, Markus AU - Elsner M AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany. FAU - Bhatia, Harsharan Singh AU - Bhatia HS AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Hellal, Farida AU - Hellal F AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany. FAU - Erturk, Ali AU - Erturk A AD - Institute for Tissue Engineering and Regenerative Medicine (iTERM), Helmholtz Munich, Neuherberg, Germany; Institute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-University Munich, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Koc University, School of Medicine, Istanbul, Turkey. Electronic address: ali.erturk@helmholtz-munich.de. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241129 PL - United States TA - Cell Host Microbe JT - Cell host & microbe JID - 101302316 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - *COVID-19/metabolism/virology MH - Animals MH - *Spike Glycoprotein, Coronavirus/metabolism MH - Humans MH - Mice MH - *SARS-CoV-2 MH - *Brain/virology/metabolism MH - *Disease Models, Animal MH - *Meninges/virology/metabolism MH - *Skull/virology MH - Male MH - Female MH - Proteomics MH - Stroke/metabolism/virology MH - Neuroinflammatory Diseases/metabolism/virology MH - Mice, Inbred C57BL MH - Brain Injuries, Traumatic/metabolism/virology OTO - NOTNLM OT - SARS-CoV-2 OT - brain OT - long COVID OT - mRNA vaccine OT - meninges OT - neurodegeneration OT - neuroinflammation OT - skull OT - spike protein OT - tissue clearing COIS- Declaration of interests The authors declare no competing interests. EDAT- 2024/12/01 15:22 MHDA- 2024/12/13 00:22 CRDT- 2024/11/30 18:42 PHST- 2024/08/26 00:00 [received] PHST- 2024/10/10 00:00 [revised] PHST- 2024/11/08 00:00 [accepted] PHST- 2024/12/13 00:22 [medline] PHST- 2024/12/01 15:22 [pubmed] PHST- 2024/11/30 18:42 [entrez] AID - S1931-3128(24)00438-4 [pii] AID - 10.1016/j.chom.2024.11.007 [doi] PST - ppublish SO - Cell Host Microbe. 2024 Dec 11;32(12):2112-2130.e10. doi: 10.1016/j.chom.2024.11.007. Epub 2024 Nov 29. PMID- 39601170 OWN - NLM STAT- MEDLINE DCOM- 20250106 LR - 20250110 IS - 1875-5828 (Electronic) IS - 1567-2050 (Linking) VI - 21 IP - 7 DP - 2024 TI - Impact of the COVID-19 Pandemic on People with Dementia and their Caregivers: A Multiphase Observational Study from India. PG - 470-478 LID - 10.2174/0115672050346469241112115052 [doi] AB - INTRODUCTION: The COVID-19 pandemic has had multifaceted and enduring impacts on people with dementia and their caregivers; however, our understanding of the long-term outcomes remains limited. We aimed to explore the long-term effects of the COVID-19 pandemic on cognitive symptoms and vaccination rates in people living with dementia. METHODS: This study was conducted as a part of a longitudinal study design in two specialized hospitals in South India. In this study, patients with dementia and their caregivers assessed in earlier phases ('period of lockdown with phased relaxations - phase-I' and 'cluster of cases transmission phase - phase-II') were telephonically interviewed. We adopted a quantitative approach to understand disease progression during the three-year course of the pandemic. Changes in cognition and disease severity were measured using the Clinical Dementia Rating (CDR) scale. In brief, semistructured interviews were carried out with caregivers of people with dementia to gain insights into vaccination rates. Data obtained from the current study (phase III) were compared against phase I data, which served as the baseline. Among the 72 participants contacted in the current phase, 59 (81.9%) could be reevaluated for dementia severity and vaccination status, whereas 13 (18.0%) had died. Among the 59 participants, 33 (55.9%) had severe dementia (CDR 3). This is in contrast to phases I and II, when 17.6% and 19.2% of the participants, respectively, were classified as CDR 3. RESULTS: A significant difference in dementia severity between the two phases (phases I and III) was observed. In addition, we observed vaccination hesitancy among caregivers of patients with dementia. This study would provide valuable insights into the long-term impact of the COVID-19 pandemic on the cognitive outcomes and vaccination status of patients with dementia. CONCLUSION: This overall longitudinal study has compared dementia severity between different phases throughout the pandemic, with implications for future studies to tailor home-based support and healthcare interventions in order to meet these evolving needs. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Arshad, Faheem AU - Arshad F AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Hurzuk, Saadiya AU - Hurzuk S AD - Strengthening Responses to Dementia in Developing Countries (STRiDE), Psychology, India, Alzheimer's and Related Disorders Society of India, Hyderabad, India. FAU - Tiwari, Megha AU - Tiwari M AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Varghese, Feba AU - Varghese F AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Hoskeri, Rakshith Maneshwar AU - Hoskeri RM AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Paplikar, Avanthi AU - Paplikar A AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Goyal, Sheetal AU - Goyal S AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Dhiren, Shah Rutul AU - Dhiren SR AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Ganeshbhai, Patel Vishal AU - Ganeshbhai PV AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. FAU - Ansari, Mohammed Farhan AU - Ansari MF AD - Hosur Road, Bangalore, Karnataka, Bangalore. FAU - Komaravolu, Shashidhar AU - Komaravolu S AD - Alzheimer's and Related Disorders Society of India Hyderabad Deccan Chapter, Psychiatry, Hyderabad, India. FAU - Kammammettu, Chandrashekar AU - Kammammettu C AD - Department of Neuropsychiatry and Geriatric Psychiatry, Asha Hospital, Psychiatry, Hyderabad, India. FAU - Thomas, Priya Treesa AU - Thomas PT AD - Department of Psychiatric Social Work, National Institute of Mental Health and Neurosciences, Bangalore, India. FAU - Rao, Girish Nagaraja AU - Rao GN AD - Department of Epidemiology, National Institute of Mental Health and Neurosciences, Bangalore, India. FAU - Alladi, Suvarna AU - Alladi S AD - Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka, Bangalore, India. LA - eng PT - Journal Article PT - Observational Study PL - United Arab Emirates TA - Curr Alzheimer Res JT - Current Alzheimer research JID - 101208441 SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Caregivers/psychology MH - *COVID-19/psychology/epidemiology MH - *Dementia/psychology/epidemiology MH - Disease Progression MH - India/epidemiology MH - Longitudinal Studies MH - SARS-CoV-2 MH - Vaccination/psychology MH - *Pandemics OTO - NOTNLM OT - COVID-19 OT - Dementia OT - LMICs OT - cognition OT - pandemic. OT - vaccination EDAT- 2024/11/27 06:19 MHDA- 2025/01/07 00:21 CRDT- 2024/11/27 05:13 PHST- 2024/08/01 00:00 [received] PHST- 2024/10/27 00:00 [revised] PHST- 2024/10/30 00:00 [accepted] PHST- 2025/01/07 00:21 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 05:13 [entrez] AID - CAR-EPUB-144621 [pii] AID - 10.2174/0115672050346469241112115052 [doi] PST - ppublish SO - Curr Alzheimer Res. 2024;21(7):470-478. doi: 10.2174/0115672050346469241112115052. PMID- 39598316 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 14 IP - 11 DP - 2024 Nov 20 TI - Insights into the Risk Factors and Outcomes of Post-COVID-19 Syndrome-Results from a Retrospective, Cross-Sectional Study in Romania. LID - 10.3390/life14111519 [doi] LID - 1519 AB - Post-Coronavirus Disease 2019 (post-COVID-19) syndrome represents a cluster of persistent symptoms following Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection that can severely affect quality of life. The pathogenic mechanisms and epidemiology in different regions are still under evaluation. To assess the outcomes of post-COVID-19 syndrome, we performed a questionnaire-based, cross-sectional study in previously infected individuals. Out of 549 respondents, (male:female ratio: 0.32), 29.5% had persistent symptoms at 3 months, 23.5% had persistent symptoms at 6 months, and 18.3% had persistent symptoms at 12 months after the initial infection. The most common symptoms included fatigue (8.7%), sleep disturbances (7.1%), and cognitive impairment (6.4%). The risk of developing post-COVID-19 syndrome increased for those with more symptoms in the acute phase (OR 4.24, p < 0.001) and those experiencing reinfections (OR 2.405, p < 0.001), while SARS-CoV-2 vaccination halved the risk (OR = 0.489, p = 0.004). Individuals with post-COVID-19 syndrome had a 5.7-fold higher risk of being diagnosed with a new chronic condition, with 44% reporting cardiovascular disease, and a 6.8-fold higher likelihood of needing medical care or leave. Affected individuals reported significant impairments in mobility, pain/discomfort, and anxiety/depression, with 20.7% needing to adjust their work schedules. Overall, patients with post-COVID-19 syndrome require ongoing monitoring and rehabilitation, and further socio-economic impact studies are needed. FAU - Bejan, Ioana AU - Bejan I AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. FAU - Popescu, Corneliu Petru AU - Popescu CP AUID- ORCID: 0000-0001-6316-0333 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. AD - Victor Babes Hospital for Infectious and Tropical Diseases, 030303 Bucharest, Romania. FAU - Ruta, Simona Maria AU - Ruta SM AUID- ORCID: 0000-0002-2492-6073 AD - Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania. AD - Stefan S Nicolau Institute of Virology, 030304 Bucharest, Romania. LA - eng PT - Journal Article DEP - 20241120 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC11596014 OTO - NOTNLM OT - COVID-19 sequelae OT - SARS-CoV-2 vaccination OT - long COVID OT - post-COVID-19 syndrome COIS- The authors declare no conflicts of interest. EDAT- 2024/11/27 06:19 MHDA- 2024/11/27 06:20 PMCR- 2024/11/20 CRDT- 2024/11/27 01:34 PHST- 2024/10/16 00:00 [received] PHST- 2024/11/16 00:00 [revised] PHST- 2024/11/17 00:00 [accepted] PHST- 2024/11/27 06:20 [medline] PHST- 2024/11/27 06:19 [pubmed] PHST- 2024/11/27 01:34 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - life14111519 [pii] AID - life-14-01519 [pii] AID - 10.3390/life14111519 [doi] PST - epublish SO - Life (Basel). 2024 Nov 20;14(11):1519. doi: 10.3390/life14111519. PMID- 39595924 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241130 IS - 2076-3425 (Print) IS - 2076-3425 (Electronic) IS - 2076-3425 (Linking) VI - 14 IP - 11 DP - 2024 Nov 20 TI - Cross-Section of Neurological Manifestations Among SARS-CoV-2 Omicron Subvariants-Single-Center Study. LID - 10.3390/brainsci14111161 [doi] LID - 1161 AB - Background/Objectives: The Omicron variant of SARS-CoV-2 is undergoing constant mutation. New strains vary in neuropathogenicity and the neurological spectrum of disease. The aim of this study was to assess the frequency and clinical characteristics of neurological manifestations during the Omicron dominance among hospitalized patients, including the differences between three subsequent periods. Methods: This retrospective single-center study included 426 hospitalized adults with confirmed COVID-19 divided into three periods (O1, O2, and O3) dependent on the dominance of Omicron subvariants in Poland. Demographic and clinical data, in particular neurological manifestations, were collected and compared. Results: The median age of the group was 74, older in subsequent (later) periods. The number of patients with a history of previous SARS-CoV-2 infection or vaccination increased with the duration of the pandemic. The severity of COVID-19 became lower in successive periods. Neurological manifestations were observed in 55.4% of patients, and the most frequent were delirium, headache, myalgia, dizziness, cerebrovascular diseases, and encephalopathy. In subsequent periods of Omicron dominance, a higher frequency of neurological manifestations such as delirium, transient ischemic attack (TIA), and encephalopathy was observed. Headache or myalgia was related to a shorter hospitalization while delirium, cerebrovascular diseases, and ischemic stroke were linked with an increased risk of death. Conclusions: The Omicron variant of SARS-CoV-2 presents a wide spectrum of neurological manifestations. Although there is an improvement in the survival rate of patients with COVID-19, the frequency of neurological manifestations increases. The occurrence of delirium, cerebrovascular diseases, and ischemic stroke results in higher mortality. FAU - Jachman-Kapulka, Justyna AU - Jachman-Kapulka J AD - 6th Department of Internal Medicine, J. Gromkowski Specialist Regional Hospital, 51-149 Wroclaw, Poland. FAU - Zinczuk, Aleksander AU - Zinczuk A AUID- ORCID: 0000-0003-4725-123X AD - 1st Department of Infectious Diseases, J. Gromkowski Specialist Regional Hospital, 51-149 Wroclaw, Poland. FAU - Simon, Krzysztof AU - Simon K AD - 1st Department of Infectious Diseases, J. Gromkowski Specialist Regional Hospital, 51-149 Wroclaw, Poland. AD - Clinical Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 50-369 Wroclaw, Poland. FAU - Rorat, Marta AU - Rorat M AUID- ORCID: 0000-0002-5318-4945 AD - Department of Social Sciences and Infectious Diseases, Medical Faculty, Wroclaw University of Science and Technology, 50-370 Wroclaw, Poland. LA - eng PT - Journal Article DEP - 20241120 PL - Switzerland TA - Brain Sci JT - Brain sciences JID - 101598646 PMC - PMC11591697 OTO - NOTNLM OT - COVID-19 vaccine OT - SARS-CoV-2 variants OT - elderly OT - neurologic manifestations COIS- The authors declare no conflicts of interest. EDAT- 2024/11/27 06:20 MHDA- 2024/11/27 06:21 PMCR- 2024/11/20 CRDT- 2024/11/27 01:20 PHST- 2024/11/06 00:00 [received] PHST- 2024/11/17 00:00 [revised] PHST- 2024/11/19 00:00 [accepted] PHST- 2024/11/27 06:21 [medline] PHST- 2024/11/27 06:20 [pubmed] PHST- 2024/11/27 01:20 [entrez] PHST- 2024/11/20 00:00 [pmc-release] AID - brainsci14111161 [pii] AID - brainsci-14-01161 [pii] AID - 10.3390/brainsci14111161 [doi] PST - epublish SO - Brain Sci. 2024 Nov 20;14(11):1161. doi: 10.3390/brainsci14111161. PMID- 39558292 OWN - NLM STAT- MEDLINE DCOM- 20241119 LR - 20241212 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 24 IP - 1 DP - 2024 Nov 18 TI - Protective role of vaccination on the development of long COVID: data from a large, multicenter, prospective cohort study. PG - 1313 LID - 10.1186/s12879-024-10226-1 [doi] LID - 1313 AB - BACKGROUND: Long COVID, a highly heterogeneous syndrome affecting millions of people worldwide, is emerging as an urgent public health threat, but data on the predictors of specific clinical manifestations over long follow-up periods are limited. The aim of this study is to investigate the role of viral variants and other predictors in long COVID incidence and clinical manifestations. METHODS: All COVID-19 patients aged > 18 years and hospitalized from March 1 2020 to April 2022 in two Italian University Hospitals were enrolled. Incidence and clinical presentation of long COVID were assessed through structured questionnaires delivered by phone calls. The association between possible risk factors collected during hospitalization and long COVID was reported using an adjusted logistic regression and reported as odds ratios (ORs) with their 95% confidence intervals (CIs). RESULTS: Among 1,012 recruited patients, over a median follow-up of 19 months (IQR: 15-24 months), the cumulative incidence of long COVID was 91.7%, with the most common clinical manifestations involving the respiratory system (80.5%) and the neurological system (77.3%). Among 1,012 recruited patients, over a median follow-up of 19 months (IQR: 15-24 months), the cumulative incidence of long COVID was 91.7%, with the most common clinical manifestations involving the respiratory system (80.5%) and the neurological system (77.3%). Overall, 54% reported long COVID symptomatology between 18 and 24 months. Multivariate analysis suggested that being vaccinated against SARS-CoV-2 was associated with reduced odds of reporting any long COVID symptomatology (OR: 0.34; 95% CI: 0.21-0.58), while infection with the Delta variant was a strong predictor (OR: 9.61, p < 0.0001) for the development of post-COVID conditions characterized by neuropsychiatric symptoms. CONCLUSIONS: In this study long COVID symptoms were still highly prevalent after 18-24 months of follow-up and, when compared to wild-type virus, infection with the Delta variant was associated with a higher risk of developing a neurological post-COVID condition. CI - (c) 2024. The Author(s). FAU - Gennaro, Francesco Di AU - Gennaro FD AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Veronese, Nicola AU - Veronese N AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Segala, Francesco Vladimiro AU - Segala FV AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Frallonardo, Luisa AU - Frallonardo L AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. luisana.frallonardo@gmail.com. FAU - Guido, Giacomo AU - Guido G AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Cormio, Mariangela AU - Cormio M AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Romita, Greta AU - Romita G AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Parisi, Angela AU - Parisi A AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Marrone, Eliana AU - Marrone E AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Ciuppa, Maria Elena AU - Ciuppa ME AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Carrubba, Anna La AU - Carrubba A AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Carruba, Luca AU - Carruba L AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Licata, Anna AU - Licata A AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Cavallaro, Giada AU - Cavallaro G AD - Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Pagliuso, Vittorio AU - Pagliuso V AD - Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Maino, Teresa AU - Maino T AD - Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Lollo, Silvia AU - Lollo S AD - Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Latino, Lorenzo AU - Latino L AD - Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Solimeo, Lidia Tina AU - Solimeo LT AD - Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Ianniello, Antonia AU - Ianniello A AD - Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Montalbo, Domenico AU - Montalbo D AD - Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Bavaro, Davide Fiore AU - Bavaro DF AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Fiorella, Maria Luisa AU - Fiorella ML AD - Otolaryngology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari "Aldo Moro", Bari, 70124, Italy. FAU - Barbagallo, Mario AU - Barbagallo M AD - Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, 90127, Italy. FAU - Saracino, Annalisa AU - Saracino A AD - Department of Precision and Regenerative Medicine and Ionian Area - (DiMePRe-J) - Clinic of Infectious Diseases, University of Bari "Aldo Moro", Bari, 70124, Italy. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20241118 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/prevention & control/epidemiology MH - Male MH - Female MH - Prospective Studies MH - Middle Aged MH - Aged MH - Italy/epidemiology MH - *SARS-CoV-2/immunology MH - Incidence MH - Risk Factors MH - Vaccination/statistics & numerical data MH - COVID-19 Vaccines/administration & dosage MH - Post-Acute COVID-19 Syndrome MH - Adult MH - Hospitalization/statistics & numerical data PMC - PMC11572516 OTO - NOTNLM OT - COVID-19 vaccination OT - Delta variant OT - Long COVID OT - Omicron variant OT - Post-acute sequelae of COVID-19 COIS- Declarations Ethics approval and consent to participate The study was approved by the Ethical Committee of the University of Palermo during the session of the 28th of April 2021 (number 04/2021). The study is in accordance with the declaration of Helsinki relevant institutional guidelines. Informed consent was obtained from each participant and/or their legal guardian(s) who received information verbally and read the information letter. Consent for publication Not applicable. Competing interests The authors declare no competing interests. EDAT- 2024/11/19 00:21 MHDA- 2024/11/19 15:15 PMCR- 2024/11/18 CRDT- 2024/11/18 23:59 PHST- 2023/06/06 00:00 [received] PHST- 2024/11/14 00:00 [accepted] PHST- 2024/11/19 15:15 [medline] PHST- 2024/11/19 00:21 [pubmed] PHST- 2024/11/18 23:59 [entrez] PHST- 2024/11/18 00:00 [pmc-release] AID - 10.1186/s12879-024-10226-1 [pii] AID - 10226 [pii] AID - 10.1186/s12879-024-10226-1 [doi] PST - epublish SO - BMC Infect Dis. 2024 Nov 18;24(1):1313. doi: 10.1186/s12879-024-10226-1. PMID- 39552582 OWN - NLM STAT- MEDLINE DCOM- 20241209 LR - 20260402 IS - 1461-7471 (Electronic) IS - 1363-4615 (Print) IS - 1363-4615 (Linking) VI - 61 IP - 5 DP - 2024 Oct TI - The protective power of dissent? A longitudinal study on cognitive and socio-emotional determinants of COVID-19 vaccine hesitancy among young people in Canada. PG - 734-748 LID - 10.1177/13634615241296293 [doi] AB - COVID-19 has elicited polarized reactions to public health measures, fueling anti-vaccination movements worldwide which indicate that vaccine hesitancy represents a common expression of dissent. We investigate changes in cognitive (i.e., trust in government, conspiracy beliefs, vaccine attitudes, and other COVID-19-related factors) and socio-emotional factors (i.e., psychological distress and social support) over time, and examine if these factors are associated with COVID-19 vaccine hesitancy. A sample of Canadian young adults (N = 2,695; 18 to 40 years old) responded to an online survey in May/June 2021 (after the first vaccination campaign) and then in November 2021 (after vaccine mandates were introduced). Based on survey answers, participants were categorized as "not hesitant", "hesitant", and "do not intend to get vaccinated" at each time point. Results from generalized estimating equation models indicate that vaccination hesitancy decreased over time. The importance attributed to specific COVID-19-related factors (e.g., research and science about COVID-19 vaccines, opinions of friends and family) decreased whereas psychological distress increased over time. Cognitive and socio-emotional factors were associated with vaccine hesitancy, with participants who did not intend to get vaccinated reporting the lowest psychological distress scores. We argue that dissent may be an empowering way for young people to restore a sense of personal agency via the opposition to a system perceived as illegitimate and/or unfair. These results raise important questions about potential collateral effects of top-down government and public health interventions in times of crisis. FAU - Miconi, Diana AU - Miconi D AUID- ORCID: 0000-0002-7088-1646 AD - Department of Educational Psychology and Adult Education, Universite de Montreal, Montreal, QC, Canada. FAU - Levinsson, Anna AU - Levinsson A AD - Centre de Recherche du Centre Hospitalier de l'Universite de Montreal - CRCHUM, Montreal, QC, Canada. AD - Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada. AD - Department of Social Medicine and Public Health, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden. FAU - Kafi, Mohammed Abdullah Heel AU - Kafi MAH AD - McGill International TB Centre, RI-MUHC, Montreal, QC, Canada. FAU - Ngov, Cindy AU - Ngov C AD - Research and Action on Social Polarisations (RAPS), Montreal, QC, Canada. FAU - Santavicca, Tara AU - Santavicca T AD - Research and Action on Social Polarisations (RAPS), Montreal, QC, Canada. FAU - Rousseau, Cecile AU - Rousseau C AD - Division of Social and Cultural Psychiatry, McGill University, Montreal, QC, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20241118 PL - England TA - Transcult Psychiatry JT - Transcultural psychiatry JID - 9708119 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Canada MH - *Vaccination Hesitancy/psychology MH - Adult MH - *COVID-19 Vaccines MH - *COVID-19/prevention & control/psychology MH - Young Adult MH - Longitudinal Studies MH - Adolescent MH - Surveys and Questionnaires MH - SARS-CoV-2 MH - Health Knowledge, Attitudes, Practice MH - Trust MH - Social Support PMC - PMC11629591 OTO - NOTNLM OT - COVID-19 OT - conspiracy beliefs OT - dissent OT - psychological distress OT - vaccine hesitancy COIS- Declaration of conflicting interestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/11/18 06:22 MHDA- 2024/12/09 17:34 PMCR- 2024/12/10 CRDT- 2024/11/18 05:43 PHST- 2024/12/09 17:34 [medline] PHST- 2024/11/18 06:22 [pubmed] PHST- 2024/11/18 05:43 [entrez] PHST- 2024/12/10 00:00 [pmc-release] AID - 10.1177_13634615241296293 [pii] AID - 10.1177/13634615241296293 [doi] PST - ppublish SO - Transcult Psychiatry. 2024 Oct;61(5):734-748. doi: 10.1177/13634615241296293. Epub 2024 Nov 18. PMID- 39543596 OWN - NLM STAT- MEDLINE DCOM- 20241115 LR - 20260518 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 22 IP - 1 DP - 2024 Nov 14 TI - Symptom profile, case and symptom clustering, clinical and demographic characteristics of a multicentre cohort of 1297 patients evaluated for Long-COVID. PG - 532 LID - 10.1186/s12916-024-03746-9 [doi] LID - 532 AB - BACKGROUND: Long-COVID symptoms remain incompletely defined due to a large heterogeneity in the populations studied, case definitions, and settings of care. The aim of this study was to assess, in patients accessing care for Long-COVID, the profile of symptoms reported, the possible clustering of symptoms and cases, the functional status compared to pre-infection, and the impact on working activity. METHODS: Multicentre cohort study with a collection of both retrospective and prospective data. Demographics, comorbidities, severity and timing of acute COVID, subjective functional status, working activity and presence of 30 different symptoms were collected using a shortened version of the WHO Post COVID-19 Case Report Form. The impact on working activity was assessed in multivariable logistic regression models. Clustering of symptoms was analysed by hierarchical clustering and the clustering of cases by two-step automatic clustering. RESULTS: The study evaluated 1297 individuals (51.5% women) from 30 clinical centres. Men and women had different profiles in terms of comorbidities, vaccination status, severity and timing of acute SARS-CoV-2 infection. Fatigue (55.9%) and dyspnea (47.2%) were the most frequent symptoms. Women reported more symptoms (3.6 vs. 3.1, p < 0.001), with a significantly higher prevalence of memory loss, difficult concentration, cough, palpitation or tachycardia, dermatological abnormalities, brain fog, headache and visual disturbances. Dyspnea was more common in men. In the cluster analysis of the 19 more common symptoms, five aggregations were found: four two-symptom clusters (smell and taste reduction; anxiety and depressed mood; joint pain or swelling and muscle pain; difficult concentration and memory loss) and one six-symptom cluster (brain fog, equilibrium/gait disturbances, headache, paresthesia, thoracic pain, and palpitations/tachycardia). In a multivariable analysis, headache, dyspnea, difficult concentration, disturbances of equilibrium or gait, visual disturbances and muscular pain were associated with reduced or interrupted working activity. Clustering of cases defined two clusters, with distinct characteristics in terms of phase and severity of acute infection, age, sex, number of comorbidities and symptom profile. CONCLUSIONS: The findings provide further evidence that Long-COVID is a heterogeneous disease with manifestations that differ by sex, phase of the pandemic and severity of acute disease, and support the possibility that multiple pathways lead to different clinical manifestations. CI - (c) 2024. The Author(s). FAU - Floridia, Marco AU - Floridia M AUID- ORCID: 0000-0003-3971-0141 AD - National Center for Global Health, Istituto Superiore Di Sanita, Rome, Italy. marco.floridia@iss.it. FAU - Giuliano, Marina AU - Giuliano M AD - National Center for Global Health, Istituto Superiore Di Sanita, Rome, Italy. FAU - Weimer, Liliana Elena AU - Weimer LE AD - National Center for Global Health, Istituto Superiore Di Sanita, Rome, Italy. FAU - Ciardi, Maria Rosa AU - Ciardi MR AD - Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. FAU - Agostoni, Piergiuseppe AU - Agostoni P AD - Centro Cardiologico Monzino, IRCCS, Milan, Italy. AD - Department of Clinical Science and Community Medicine, University of Milan, Milan, Italy. FAU - Palange, Paolo AU - Palange P AD - Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy. FAU - Rovere Querini, Patrizia AU - Rovere Querini P AD - IRCCS Ospedale S. Raffaele, Milan, Italy. FAU - Zucco, Silvia AU - Zucco S AD - Infectious Disaese Unit, Ospedale Amedeo Di Savoia, Turin, Italy. FAU - Tosato, Matteo AU - Tosato M AD - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. FAU - Lo Forte, Aldo AU - Lo Forte A AD - Department of Multidimensional Medicine, Internal Medicine Unit, San Giovanni Di Dio Hospital, Florence, Italy. FAU - Bonfanti, Paolo AU - Bonfanti P AD - Infectious Diseases Unit, Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy. AD - University of Milano-Bicocca, Monza, Italy. FAU - Lacedonia, Donato AU - Lacedonia D AD - Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Barisione, Emanuela AU - Barisione E AD - IRCCS Ospedale Policlinico San Martino, Genoa, Italy. FAU - Figliozzi, Stefano AU - Figliozzi S AD - IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. FAU - Andreozzi, Paola AU - Andreozzi P AD - Predictive Medicine Unit, Department of Internal Medicine, Endocrine-Metabolic Sciences and Infectious Diseases, Azienda Ospedaliero Universitaria Policlinico Umberto I, Rome, Italy. FAU - Damiano, Cecilia AU - Damiano C AD - Department of Cardiovascular, Endocrine-Metabolic Diseases and Ageing, Istituto Superiore Di Sanita, Rome, Italy. FAU - Pricci, Flavia AU - Pricci F AD - Department of Cardiovascular, Endocrine-Metabolic Diseases and Ageing, Istituto Superiore Di Sanita, Rome, Italy. FAU - Onder, Graziano AU - Onder G AD - Fondazione Policlinico Universitario A. Gemelli IRCCS, Universita Cattolica del Sacro Cuore, Rome, Italy. AD - Office of the President, Istituto Superiore Di Sanita, Rome, Italy. CN - I. S. S. Long-COVID Study Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20241114 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 SB - IM MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - Cluster Analysis MH - Cohort Studies MH - COVID-19/epidemiology/diagnosis MH - *Demography MH - Dyspnea/epidemiology/physiopathology MH - Fatigue/epidemiology MH - *Post-Acute COVID-19 Syndrome/epidemiology/pathology MH - Prospective Studies MH - Retrospective Studies MH - Severity of Illness Index MH - *Symptom Assessment PMC - PMC11566432 OTO - NOTNLM OT - COVID-19 OT - Dyspnea OT - Fatigue OT - Long-COVID OT - Post-COVID OT - Symptom clusters OT - Symptoms COIS- Declarations Ethics approval and consent to participate The Italian National Ethics Committee approved the project (AOO-ISS-19/04/2022-0015066 Class: PRE BIO CE 01.00). Written informed consent was required for patient inclusion, using a patient information and consent form also approved by the Italian National Ethics Committee. Consent for publication Not applicable. Competing interests The authors declare no competing interests. FIR - Grisetti, Tiziana IR - Grisetti T FIR - Grassi, Tiziana IR - Grassi T FIR - Tiple, Dorina IR - Tiple D FIR - Villa, Marika IR - Villa M FIR - Polizzi, Cosimo IR - Polizzi C FIR - Galati, Fabio IR - Galati F FIR - Pasculli, Patrizia IR - Pasculli P FIR - Colazzo, Francesca IR - Colazzo F FIR - Mattavelli, Irene IR - Mattavelli I FIR - Salvioni, Elisabetta IR - Salvioni E FIR - Pellegrino, Daniela IR - Pellegrino D FIR - Bezzio, Marco IR - Bezzio M FIR - Olmati, Federica IR - Olmati F FIR - Sanna, Arianna IR - Sanna A FIR - Schifano, Arianna IR - Schifano A FIR - Angelone, Dario IR - Angelone D FIR - Fabozzi, Antonio IR - Fabozzi A FIR - Santoro, Simona IR - Santoro S FIR - Fumagalli, Anna IR - Fumagalli A FIR - Merolla, Aurora IR - Merolla A FIR - Canti, Valentina IR - Canti V FIR - Ruggiero, Maria Pia IR - Ruggiero MP FIR - Messina, Marco IR - Messina M FIR - Biganzoli, Marina IR - Biganzoli M FIR - Buonsenso, Danilo IR - Buonsenso D FIR - Ianniello, Alice IR - Ianniello A FIR - Galluzzo, Vincenzo IR - Galluzzo V FIR - Macculi, Laura IR - Macculi L FIR - Bottaro, Valeria Maria IR - Bottaro VM FIR - Bonaffini, Luca IR - Bonaffini L FIR - Spolti, Anna IR - Spolti A FIR - Squillace, Nicola IR - Squillace N FIR - Campanino, Terence IR - Campanino T FIR - Aloe, Teresita IR - Aloe T FIR - Tagliabue, Elena IR - Tagliabue E FIR - Testerini, Federica IR - Testerini F FIR - Miglionico, Marzia IR - Miglionico M FIR - Barbitta, Antonia IR - Barbitta A FIR - Cenciarelli, Chiara IR - Cenciarelli C FIR - Pagnanelli, Gianluca IR - Pagnanelli G FIR - Piccinni, Giuseppe IR - Piccinni G FIR - Gnerre, Paola IR - Gnerre P FIR - Parodi, Lionello IR - Parodi L FIR - Monaco, Eugenia IR - Monaco E FIR - Buscaglia, Sandra IR - Buscaglia S FIR - Visconti, Antonella IR - Visconti A FIR - Loso, Kwelusukila IR - Loso K FIR - Martino, Giuseppe Pio IR - Martino GP FIR - Bitti, Giuseppina IR - Bitti G FIR - Postacchini, Laura IR - Postacchini L FIR - Cognigni, Antonella IR - Cognigni A FIR - di Rosolini, Maria Antonietta IR - di Rosolini MA FIR - Mavilla, Sergio IR - Mavilla S FIR - Toraldo, Domenico Maurizio IR - Toraldo DM FIR - Vagheggini, Guido IR - Vagheggini G FIR - Bardi, Giulio IR - Bardi G FIR - Levantino, Giuseppa IR - Levantino G FIR - Stefan, Cristina IR - Stefan C FIR - Parati, Gianfranco IR - Parati G FIR - Perger, Elisa IR - Perger E FIR - Gianfranceschi, Enrico IR - Gianfranceschi E FIR - Pozzoli, Francesca IR - Pozzoli F FIR - De Leo, Pasqualina IR - De Leo P FIR - Grignolo, Sara IR - Grignolo S FIR - Monari, Caterina IR - Monari C FIR - Bianchi, Leila IR - Bianchi L FIR - Galli, Luisa IR - Galli L FIR - Surace, Lorenzo IR - Surace L FIR - Falbo, Elisabetta IR - Falbo E FIR - Boni, Silvia IR - Boni S FIR - Battello, Claudia IR - Battello C FIR - Baghiris, Caterina IR - Baghiris C FIR - Serviddio, Gaetano IR - Serviddio G EDAT- 2024/11/15 06:25 MHDA- 2024/11/16 09:58 PMCR- 2024/11/14 CRDT- 2024/11/15 00:10 PHST- 2024/09/18 00:00 [received] PHST- 2024/10/31 00:00 [accepted] PHST- 2024/11/16 09:58 [medline] PHST- 2024/11/15 06:25 [pubmed] PHST- 2024/11/15 00:10 [entrez] PHST- 2024/11/14 00:00 [pmc-release] AID - 10.1186/s12916-024-03746-9 [pii] AID - 3746 [pii] AID - 10.1186/s12916-024-03746-9 [doi] PST - epublish SO - BMC Med. 2024 Nov 14;22(1):532. doi: 10.1186/s12916-024-03746-9. PMID- 39498382 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241106 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 42 DP - 2024 Dec TI - Clinical features and predictive nomogram for fatigue sequelae in non-severe patients infected with SARS-CoV-2 Omicron variant in Shanghai, China. PG - 100889 LID - 10.1016/j.bbih.2024.100889 [doi] LID - 100889 AB - BACKGROUND: Patients with coronavirus disease 2019(COVID-2019) infections may still experience long-term effects, with fatigue being one of the most frequent ones. Clinical research on the long COVID in the Chinese population after infection is comparatively lacking. OBJECTIVE: To collect and analyze the long-term effects of non-severe COVID-19 infection patients and to develop a model for the prediction of fatigue symptoms. METHODS: 223 non-severe COVID-19 patients admitted to one designated hospital were enrolled after finish all the self-designed clinical information registration form and nine-month follow-up. We explored the frequency and symptom types of long COVID. Correlation analysis was done on the neuropsychological scale results. After cluster analysis, lasoo regression and logistic regressions, a nomogram prediction model was produced as a result of investigating the risk factors for fatigue. RESULTS: A total of 108 (48.4%) of the 223 non-severe COVID-19 patients reported sequelae for more than 4 weeks, and of these, 35 (15.7%) had fatigue sequelae that were scale-confirmed. Other sequelae of more than 10% were brain fog (n = 37,16.6%), cough (n = 26,11.7%) and insomnia (n = 23,10.3%). A correlation between depression and fatigue was discovered following the completion of neuropsychological scale. The duration of hospitalization, the non-use of antiviral medications in treatment, IL-6 and CD16+CD56(+) cell levels in blood are the main independent risk factors and predictors of fatigue sequelae in long COVID. Additionally, the neurology diseases and vaccination status may also influence the fatigue sequelae. CONCLUSION: Nearly half of the patients infected with COVID-19 Omicron variant complained of sequelae, and fatigue was the most common symptom, which was correlated with depression. Significant predictors of fatigue sequelae included length of hospitalization, non-use of antiviral drug, and immune-related serum markers of IL-6 and CD16+CD56(+) NK cell levels. The presence of neurology diseases and a lack of vaccination could also predict the occurrence of fatigue sequelae. CI - (c) 2024 The Authors. Published by Elsevier Inc. FAU - Shen, Xiao-Lei AU - Shen XL AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Jiang, Yu-Han AU - Jiang YH AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Li, Shen-Jie AU - Li SJ AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Xie, Xin-Yi AU - Xie XY AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Cheng, Yu AU - Cheng Y AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Wu, Li AU - Wu L AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Shen, Jun AU - Shen J AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Chen, Wei AU - Chen W AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. FAU - Liu, Jian-Ren AU - Liu JR AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200011, China. LA - eng PT - Journal Article DEP - 20241018 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC11532739 OTO - NOTNLM OT - COVID-19 OT - Fatigue OT - Long COVID syndrome OT - Omicron OT - SARS-CoV-2 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/11/05 10:54 MHDA- 2024/11/05 10:55 PMCR- 2024/10/18 CRDT- 2024/11/05 04:39 PHST- 2024/03/26 00:00 [received] PHST- 2024/08/31 00:00 [revised] PHST- 2024/10/05 00:00 [accepted] PHST- 2024/11/05 10:55 [medline] PHST- 2024/11/05 10:54 [pubmed] PHST- 2024/11/05 04:39 [entrez] PHST- 2024/10/18 00:00 [pmc-release] AID - S2666-3546(24)00167-4 [pii] AID - 100889 [pii] AID - 10.1016/j.bbih.2024.100889 [doi] PST - epublish SO - Brain Behav Immun Health. 2024 Oct 18;42:100889. doi: 10.1016/j.bbih.2024.100889. eCollection 2024 Dec. PMID- 39364271 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241005 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 76 DP - 2024 Oct TI - Changes in memory and cognition during the SARS-CoV-2 human challenge study. PG - 102842 LID - 10.1016/j.eclinm.2024.102842 [doi] LID - 102842 AB - BACKGROUND: Patient-reported outcomes and cross-sectional evidence show an association between COVID-19 and persistent cognitive problems. The causal basis, longevity and domain specificity of this association is unclear due to population variability in baseline cognitive abilities, vulnerabilities, virus variants, vaccination status and treatment. METHODS: Thirty-four young, healthy, seronegative volunteers were inoculated with Wildtype SARS-CoV-2 under prospectively controlled conditions. Volunteers completed daily physiological measurements and computerised cognitive tasks during quarantine and follow-up at 30, 90, 180, 270, and 360 days. Linear modelling examined differences between 'infected' and 'inoculated but uninfected' individuals. The main cognitive endpoint was the baseline corrected global cognitive composite score across the battery of tasks administered to the volunteers. Exploratory cognitive endpoints included baseline corrected scores from individual tasks. The study was registered on ClinicalTrials.gov with the identifier NCT04865237 and took place between March 2021 and July 2022. FINDINGS: Eighteen volunteers developed infection by qPCR criteria of sustained viral load, one without symptoms and the remainder with mild illness. Infected volunteers showed statistically lower baseline-corrected global composite cognitive scores than uninfected volunteers, both acutely and during follow up (mean difference over all time points = -0.8631, 95% CI = -1.3613, -0.3766) with significant main effect of group in repeated measures ANOVA (F (1,34) = 7.58, p = 0.009). Sensitivity analysis replicated this cross-group difference after controlling for community upper respiratory tract infection, task-learning, remdesivir treatment, baseline reference and model structure. Memory and executive function tasks showed the largest between-group differences. No volunteers reported persistent subjective cognitive symptoms. INTERPRETATION: These results support larger cross sectional findings indicating that mild Wildtype SARS-CoV-2 infection can be followed by small changes in cognition and memory that persist for at least a year. The mechanistic basis and clinical implications of these small changes remain unclear. FUNDING: This study was funded through the UK Vaccine Taskforce of the Department for Business, Energy and Industrial Strategy (BEIS) of Her Majesty's Government. WT was funded by the EPSRC through the CDT for Neurotechnology Imperial College London. CI - (c) 2024 The Authors. FAU - Trender, William AU - Trender W AD - Department of Brain Sciences, Imperial College London, UK. FAU - Hellyer, Peter J AU - Hellyer PJ AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. FAU - Killingley, Ben AU - Killingley B AD - Department of Infectious Diseases, University College London Hospital, London, UK. FAU - Kalinova, Mariya AU - Kalinova M AD - HVIVO Services Ltd., London, UK. FAU - Mann, Alex J AU - Mann AJ AD - HVIVO Services Ltd., London, UK. FAU - Catchpole, Andrew P AU - Catchpole AP AD - HVIVO Services Ltd., London, UK. FAU - Menon, David AU - Menon D AD - Cambridge University Hospitals National Health Service Foundation Trust, UK. FAU - Needham, Edward AU - Needham E AD - Cambridge University Hospitals National Health Service Foundation Trust, UK. FAU - Thwaites, Ryan AU - Thwaites R AD - National Heart and Lung Institute, Imperial College London, London, UK. FAU - Chiu, Christopher AU - Chiu C AD - Department of Infectious Disease, Imperial College London, London, UK. FAU - Scott, Gregory AU - Scott G AD - Department of Brain Sciences, Imperial College London, UK. FAU - Hampshire, Adam AU - Hampshire A AD - Department of Brain Sciences, Imperial College London, UK. AD - Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. LA - eng SI - ClinicalTrials.gov/NCT04865237 PT - Journal Article DEP - 20240921 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC11447363 OTO - NOTNLM OT - Baseline corrected OT - COVID-19 OT - Cognition OT - Human challenge study OT - SARS-CoV-2 COIS- AH is founder and director of Future Cognition Ltd and H2 Cognitive Designs, which develop custom cognitive assessment tasks and provide online assessment services respectively, primarily within the academic research sector. CC had funding to institution from the UK Vaccine Task Force and Wellcome Trust. DM had support for the present manuscript in the form of payments to the institution from the UKRI (UKRI, The COVID-19: Clinical Neuroscience Study (COVID-CNS) (Co-I) and UKRI. Convalescent plasma for COVID-19 patients (Co-I)), the Addenbrooke's Charitable Trust (COVID-19: understanding its long-term respiratory, cardiac and neuro-psychiatric sequelae and the determinants of adverse outcomes), the NIHR (NIHR Cambridge Biomedical Research Centre). They also received support unrelated to the current manuscript in the form of consultancy fees and research support from: Neurotrauma Sciences, Lantmannen AB, GlaxoSmithKline Ltd and PressuraNeuro Ltd. EN received a portion of their salary from Brain Research UK during the periods in question. PJH is Co-founder and director of H2 Cognitive Designs LTD, which markets online cognitive testing platforms for healthcare and research. In this role he receives Remuneration. RT received support for the present manuscript from UK Vaccine Taskforce of the Department of Business, Energy and Industrial Strategy of Her Majesty's Government (BEIS) and the Wellcome Trust (grant no. 224530/Z/21/Z). Also payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca. WT is employed by H2 Cognitive Designs LTD, which markets online cognitive testing platforms for healthcare and research. AJM is a holder of shares in hVIVO Ltd and an employee of hVivo Ltd. MK, GS, BK and APC have no declarations of interest. EDAT- 2024/10/04 08:43 MHDA- 2024/10/04 08:44 PMCR- 2024/09/21 CRDT- 2024/10/04 04:23 PHST- 2024/05/07 00:00 [received] PHST- 2024/09/05 00:00 [revised] PHST- 2024/09/05 00:00 [accepted] PHST- 2024/10/04 08:44 [medline] PHST- 2024/10/04 08:43 [pubmed] PHST- 2024/10/04 04:23 [entrez] PHST- 2024/09/21 00:00 [pmc-release] AID - S2589-5370(24)00421-8 [pii] AID - 102842 [pii] AID - 10.1016/j.eclinm.2024.102842 [doi] PST - epublish SO - EClinicalMedicine. 2024 Sep 21;76:102842. doi: 10.1016/j.eclinm.2024.102842. eCollection 2024 Oct. PMID- 39334235 OWN - NLM STAT- MEDLINE DCOM- 20240928 LR - 20260519 IS - 1750-1172 (Electronic) IS - 1750-1172 (Linking) VI - 19 IP - 1 DP - 2024 Sep 27 TI - COVID-19 risk factors and outcomes in individuals with stiff person syndrome spectrum disorders before and after omicron. PG - 356 LID - 10.1186/s13023-024-03357-w [doi] LID - 356 AB - BACKGROUND: Stiff person syndrome spectrum disorders (SPSD) are rare, disabling disorders of the nervous system that are associated with risk factors for Coronavirus disease 2019 (COVID-19). However, limited data exist on the overall impact of COVID-19 on SPSD. METHODS: Patients with SPSD and COVID-19 who are followed at Johns Hopkins SPS Center were included. Demographics and SPSD characteristics along with COVID-19-specific data were recorded. RESULTS: Thirty-five cases of SPSD with COVID-19 cases were reported during the study time period. Mean age of the cohort was 56 (SD +/- 10) and most were female (66.7%). Eighty percent of the COVID-19 cases were confirmed with testing, and the rest were highly suggestive of COVID-19. COVID-19 comorbidities among patients were hypertension (n = 6), diabetes (n = 6), obesity (n = 5), and cardiovascular disease (n = 4). The majority of participants were on immune therapies and/or benzodiazepines. Out of the cases reported, only 2 required hospitalization, both of whom had diabetes, and one was on immunosuppressive therapy. The majority of cases were post-full-vaccination cases. Fever was the most common COVID-19-associated symptom. Transient neurological symptoms were also reported. CONCLUSION: Risk factors for developing severe COVID-19 in SPSD appear to be the same as historical data in the general population. Importantly, COVID-19 did not appear to be associated with worsening SPSD post-COVID-19. Vaccination may have played a role in preventing severe cases of COVID-19. CI - (c) 2024. The Author(s). FAU - Afshar, Hanyeh AU - Afshar H AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Simpson, Alexandra AU - Simpson A AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Taylor, Elena AU - Taylor E AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Miles, Ashley AU - Miles A AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Chen, Herbert R AU - Chen HR AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. FAU - Newsome, Scott D AU - Newsome SD AUID- ORCID: 0000-0002-5284-4681 AD - Johns Hopkins University School of Medicine, Baltimore, MD, USA. snewsom2@jhmi.edu. LA - eng PT - Journal Article DEP - 20240927 PL - England TA - Orphanet J Rare Dis JT - Orphanet journal of rare diseases JID - 101266602 SB - IM MH - Humans MH - *COVID-19/epidemiology/complications MH - Female MH - Male MH - Risk Factors MH - Middle Aged MH - *Stiff-Person Syndrome/epidemiology MH - *SARS-CoV-2 MH - Aged MH - Adult MH - Comorbidity PMC - PMC11428925 OTO - NOTNLM OT - COVID-19 OT - Neurology OT - SPSD OT - Stiff person syndrome OT - Vaccination COIS- The authors declare that they have no competing interests. EDAT- 2024/09/28 22:44 MHDA- 2024/09/28 22:45 PMCR- 2024/09/27 CRDT- 2024/09/28 00:23 PHST- 2024/01/03 00:00 [received] PHST- 2024/09/11 00:00 [accepted] PHST- 2024/09/28 22:45 [medline] PHST- 2024/09/28 22:44 [pubmed] PHST- 2024/09/28 00:23 [entrez] PHST- 2024/09/27 00:00 [pmc-release] AID - 10.1186/s13023-024-03357-w [pii] AID - 3357 [pii] AID - 10.1186/s13023-024-03357-w [doi] PST - epublish SO - Orphanet J Rare Dis. 2024 Sep 27;19(1):356. doi: 10.1186/s13023-024-03357-w. PMID- 39314761 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240925 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 41 DP - 2024 Nov TI - Executive deficits after SARS-CoV-2 infection: A cross-sectional population study. PG - 100857 LID - 10.1016/j.bbih.2024.100857 [doi] LID - 100857 AB - IMPORTANCE: Despite the major implications of executive deficits in day-to-day functioning, few studies have investigated this in post-acute sequelae of SARS-CoV-2 infection using standardized measures that differentiate between aspects of executive function. OBJECTIVE: Examine whether SARS-CoV-2 infection is associated with deficits in executive functions and if so, investigate the duration of this association. DESIGN SETTING AND PARTICIPANTS: The present research has a cross-sectional design and uses data from the Norwegian Covid-19 Cohort study. The current cohort (n = 8102) completed the Behavior Rating Inventory of Executive Function- Adult Version (BRIEF-A) electronically between April 2021 and September 2021. During the assessment, 4183 of the included participants had a prior positive polymerase chain reaction test (PCR) for SARS-CoV-2 and 3919 were untested or had a confirmed negative PCR test. EXPOSURE: Laboratory-confirmed SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: Executive functions were measured using the BRIEF-A, a self-report questionnaire comprising 75 items within nine theoretically and empirically distinct clinical scales. All participants self-reported on demographical variables and comorbidity. Information on sex and age was derived from the personal identification number, and vaccination status was obtained from the Norwegian Immunization Registry (SYSVAK). RESULTS: Participants with a positive SARS-CoV-2 status reported executive deficits in everyday life above the clinical threshold (T-score >/=65) more often than non-infected controls (383 vs. 225). Specifically, the SARS-CoV-2 positive status group indicated significantly more deficits related to metacognition, with the greatest difference demonstrated for working memory. This difference remained when adjusting for various demographic factors and comorbidities, with significantly greater odds of reporting above the clinical threshold following SARS-CoV-2 infection, as observed on the global executive composite score 6-12 months after infection (OR 1.97; 95% CI 1.51 to 2.55). CONCLUSIONS: Our study confirms more perceived executive deficits following SARS-CoV-2 infection compared to non-infected controls, with metacognitive aspects being the most affected. These findings shed light on the potential functional difficulties that individuals may encounter during the post-acute phase of SARS-CoV-2 infection and may guide further development of targeted interventions addressing metacognitive domains of executive functioning. CI - (c) 2024 The Authors. FAU - Buer, S AU - Buer S AD - Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway. AD - Department of Psychology, University of Oslo, Oslo, Norway. FAU - Hagen, B I AU - Hagen BI AD - Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway. FAU - Soraas, A AU - Soraas A AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - White, R A AU - White RA AD - Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway. FAU - Bo, R AU - Bo R AD - Department of Psychology, University of Oslo, Oslo, Norway. FAU - Ellingjord-Dale, M AU - Ellingjord-Dale M AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - Istre, M S AU - Istre MS AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - Brunvoll, S H AU - Brunvoll SH AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - Lerdal, A AU - Lerdal A AD - Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway. AD - Faculty of Medicine, University of Oslo, Oslo, Norway. FAU - Landro, N I AU - Landro NI AD - Department of Psychology, University of Oslo, Oslo, Norway. FAU - Nygaard, A B AU - Nygaard AB AD - Department of Microbiology, Oslo University Hospital, Oslo, Norway. FAU - Stubberud, J AU - Stubberud J AD - Department of Research, Lovisenberg Diaconal Hospital, Oslo, Norway. AD - Department of Psychology, University of Oslo, Oslo, Norway. LA - eng PT - Journal Article DEP - 20240910 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC11418142 OTO - NOTNLM OT - COVID-19 OT - Executive functioning OT - Neuropsychology OT - Post-COVID-19 condition COIS- Dr. Soraas reported being an employee and shareholder at Age Labs outside of the submitted work. No other disclosures were reported. EDAT- 2024/09/24 10:19 MHDA- 2024/09/24 10:20 PMCR- 2024/09/10 CRDT- 2024/09/24 04:42 PHST- 2024/05/16 00:00 [received] PHST- 2024/08/20 00:00 [revised] PHST- 2024/09/07 00:00 [accepted] PHST- 2024/09/24 10:20 [medline] PHST- 2024/09/24 10:19 [pubmed] PHST- 2024/09/24 04:42 [entrez] PHST- 2024/09/10 00:00 [pmc-release] AID - S2666-3546(24)00135-2 [pii] AID - 100857 [pii] AID - 10.1016/j.bbih.2024.100857 [doi] PST - epublish SO - Brain Behav Immun Health. 2024 Sep 10;41:100857. doi: 10.1016/j.bbih.2024.100857. eCollection 2024 Nov. PMID- 39291099 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240919 IS - 1664-2295 (Print) IS - 1664-2295 (Electronic) IS - 1664-2295 (Linking) VI - 15 DP - 2024 TI - Exploring cognitive impairments and the efficacy of phosphatidylcholine and computer-assisted cognitive training in post-acute COVID-19 and post-acute COVID-19 Vaccination Syndrome. PG - 1419134 LID - 10.3389/fneur.2024.1419134 [doi] LID - 1419134 AB - PURPOSE: The COVID-19 pandemic has led to millions of confirmed cases worldwide, resulting in numerous deaths and hospitalizations. Long-term symptoms after infection or vaccination, known as Post-acute COVID-19 Syndrome (PACS) or Post-acute COVID-19 Vaccination Syndrome (PACVS), present a challenge for the healthcare system. Among the various neurological symptoms, cognitive impairments are frequently observed in PACS/PACVS patients. This study aimed to understand cognitive deficits in PACS/PACVS patients and evaluated potential treatment options, including phosphatidylcholine and computer-assisted cognitive training (CCT). METHODS: The Neuro-COVID Outpatient Clinic at Evangelic Hospital Vienna evaluated n = 29 PACS/PACVS patients from May 2023 to October 2023. Enrolled patients were divided into three therapy schemes: Group A received phosphatidylcholine, B received phosphatidylcholine plus access to a computer-assisted cognitive training program, and C (divided into two subgroups) served as a control group. Cognitive impairments were evaluated in multiple assessments (initial and during therapy) using the COGBAT test. Simultaneously, an assessment of the quality of life was conducted using the WHOQOL-BREF. RESULTS: Primary cognitive impairments, especially attentional deficits were notably evident compared to the general population. While all treatment groups showed cognitive improvement (significant or with a positive trend, but without reaching the level of statistical significance) after therapy, no significant interaction was found between assessment time points and treatment schemes for overall cognitive performance, attention, memory, and executive functions, suggesting consistency across the groups. The WHOQOL-BREF primarily demonstrated deficits in the domains of physical health and psychological well-being. CONCLUSION: This study examined the impact of PACS/PACVS on cognitive performance and evaluated phosphatidylcholine and CCT as potential treatment options. Patients with PACS/PACVS showed notable cognitive deficits, especially in the domain attention. While the effectiveness of phosphatidylcholine and CCT in treating cognitive deficits was inconclusive, the study indicated the possibility of spontaneous remission of cognitive deficits in PACS/PACVS. CI - Copyright (c) 2024 Hotz, Kellerberger, Elea Jochlinger, Danielova, Temizsoy, Otsch, Goller, Yacob and Zifko. FAU - Hotz, Julian Frederic AU - Hotz JF AD - Department of Neurology, Evangelic Hospital Vienna, Vienna, Austria. AD - Department of Neurology, Hospital St. John's of God, Vienna, Austria. AD - Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria. FAU - Kellerberger, Sophie AU - Kellerberger S AD - Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Elea Jochlinger, Sara AU - Elea Jochlinger S AD - Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Danielova, Iren AU - Danielova I AD - Department of Neurology, Evangelic Hospital Vienna, Vienna, Austria. AD - Department of Neurology, Rudolfinerhaus Private Clinic and Campus, Vienna, Austria. FAU - Temizsoy, Hanife AU - Temizsoy H AD - Department of Neurology, Evangelic Hospital Vienna, Vienna, Austria. FAU - Otsch, Sandra AU - Otsch S AD - Department of Clinical Psychology, Rudolfinerhaus Private Clinic and Campus, Vienna, Austria. FAU - Goller, Jurgen AU - Goller J AD - Karl Landsteiner University of Health Sciences, Krems, Austria. FAU - Yacob, Muhammad AU - Yacob M AD - Department of Neurology, Accident Hospital Meidling, Vienna, Austria. FAU - Zifko, Udo AU - Zifko U AD - Department of Neurology, Rudolfinerhaus Private Clinic and Campus, Vienna, Austria. LA - eng PT - Journal Article DEP - 20240903 PL - Switzerland TA - Front Neurol JT - Frontiers in neurology JID - 101546899 PMC - PMC11405338 OTO - NOTNLM OT - COVID-19 OT - Post-acute COVID-19 Syndrome OT - Post-acute COVID-19 Vaccination Syndrome OT - SARS-CoV-2 OT - WHOQOL-BREF OT - computer-assisted cognitive training OT - phosphatidylcholine COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/09/18 06:42 MHDA- 2024/09/18 06:43 PMCR- 2024/09/03 CRDT- 2024/09/18 04:38 PHST- 2024/04/17 00:00 [received] PHST- 2024/08/23 00:00 [accepted] PHST- 2024/09/18 06:43 [medline] PHST- 2024/09/18 06:42 [pubmed] PHST- 2024/09/18 04:38 [entrez] PHST- 2024/09/03 00:00 [pmc-release] AID - 10.3389/fneur.2024.1419134 [doi] PST - epublish SO - Front Neurol. 2024 Sep 3;15:1419134. doi: 10.3389/fneur.2024.1419134. eCollection 2024. PMID- 39274303 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 17 DP - 2024 Aug 27 TI - Impact of Spa Therapy on Symptoms and Quality of Life in Post-COVID-19 Patients with Chronic Conditions. LID - 10.3390/jcm13175091 [doi] LID - 5091 AB - Background: With limited pharmacological interventions, post-COVID-19 condition is a clinical challenge, and supplementary therapies are essential for symptom relief and enhancing quality of life (QoL). In our prospective observational study, we aimed to evaluate the impact of Salus per aquam (Spa) therapy on post-COVID-19 symptoms and QoL in individuals who suffer from chronic joint, musculoskeletal, skin, and/or respiratory conditions. Methods: A total of 159 individuals undergoing Spa therapy were enrolled, and 78 of them had post-COVID-19 symptoms, assessed using Visual Analogue Scale (VAS) and modified British Medical Research Council Questionnaire (mMRC-DS scales), as well as the Short Form 36 Health Status Survey (SF-36) questionnaire for QoL. Results: Spa therapy significantly reduced most post-COVID-19 symptoms, especially chronic fatigue, pain, brain fog, and persistent cough (all p < 0.05), as well as physical (+72%) and emotional (+66%) limitations. When stratified by sex, males showed a greater improvement from baseline, while females consistently displayed a higher amelioration in all QoL dimensions. Moreover, full vaccination with 3-4 doses significantly protected against SARS-CoV-2 re-infections and post-COVID-19 development (p < 0.05). Conclusions: Spa therapy demonstrated effectiveness in mitigating post-COVID-19 symptoms and enhancing QoL in patients suffering from chronic diseases. FAU - Costantino, Maria AU - Costantino M AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy. AD - University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84121 Salerno, Italy. AD - Non-Profit Association F.I.R.S.Thermae (Interdisciplinary Training, Researches and Spa Sciences), 80078 Pozzuoli, Italy. FAU - Giudice, Valentina AU - Giudice V AUID- ORCID: 0000-0002-7492-6848 AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy. AD - University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84121 Salerno, Italy. FAU - Farroni, Mario AU - Farroni M AD - Non-Profit Association F.I.R.S.Thermae (Interdisciplinary Training, Researches and Spa Sciences), 80078 Pozzuoli, Italy. FAU - Marongiu, Francesco AU - Marongiu F AD - Non-Profit Association F.I.R.S.Thermae (Interdisciplinary Training, Researches and Spa Sciences), 80078 Pozzuoli, Italy. FAU - De Caro, Francesco AU - De Caro F AUID- ORCID: 0000-0001-9659-9940 AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy. AD - University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84121 Salerno, Italy. FAU - Filippelli, Amelia AU - Filippelli A AUID- ORCID: 0000-0002-8235-9118 AD - Department of Medicine, Surgery, and Dentistry, University of Salerno, 84081 Baronissi, Italy. AD - University Hospital "San Giovanni di Dio e Ruggi d'Aragona", 84121 Salerno, Italy. LA - eng PT - Journal Article DEP - 20240827 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC11396595 OTO - NOTNLM OT - QoL OT - Spa therapy OT - post COVID OT - vaccination COIS- The authors declare no conflicts of interest. EDAT- 2024/09/14 10:43 MHDA- 2024/09/14 10:44 PMCR- 2024/08/27 CRDT- 2024/09/14 01:13 PHST- 2024/06/27 00:00 [received] PHST- 2024/08/15 00:00 [revised] PHST- 2024/08/23 00:00 [accepted] PHST- 2024/09/14 10:44 [medline] PHST- 2024/09/14 10:43 [pubmed] PHST- 2024/09/14 01:13 [entrez] PHST- 2024/08/27 00:00 [pmc-release] AID - jcm13175091 [pii] AID - jcm-13-05091 [pii] AID - 10.3390/jcm13175091 [doi] PST - epublish SO - J Clin Med. 2024 Aug 27;13(17):5091. doi: 10.3390/jcm13175091. PMID- 39271718 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 2059-0105 (Electronic) IS - 2059-0105 (Linking) VI - 9 IP - 1 DP - 2024 Sep 14 TI - COVID-19 vaccine refusal is driven by deliberate ignorance and cognitive distortions. PG - 167 LID - 10.1038/s41541-024-00951-8 [doi] LID - 167 AB - Vaccine hesitancy was a major challenge during the COVID-19 pandemic. A common but sometimes ineffective intervention to reduce vaccine hesitancy involves providing information on vaccine effectiveness, side effects, and related probabilities. Could biased processing of this information contribute to vaccine refusal? We examined the information inspection of 1200 U.S. participants with anti-vaccination, neutral, or pro-vaccination attitudes before they stated their willingness to accept eight different COVID-19 vaccines. All participants-particularly those who were anti-vaccination-frequently ignored some of the information. This deliberate ignorance, especially toward probabilities of extreme side effects, was a stronger predictor of vaccine refusal than typically investigated demographic variables. Computational modeling suggested that vaccine refusals among anti-vaccination participants were driven by ignoring even inspected information. In the neutral and pro-vaccination groups, vaccine refusal was driven by distorted processing of side effects and their probabilities. Our findings highlight the necessity for interventions tailored to individual information-processing tendencies. CI - (c) 2024. The Author(s). FAU - Fulawka, Kamil AU - Fulawka K AD - Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany. fulawka@mpib-berlin.mpg.de. FAU - Hertwig, Ralph AU - Hertwig R AUID- ORCID: 0000-0002-9908-9556 AD - Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany. FAU - Pachur, Thorsten AU - Pachur T AD - Center for Adaptive Rationality, Max Planck Institute for Human Development, Berlin, Germany. AD - School of Management, Technical University of Munich, Munich, Germany. LA - eng PT - Journal Article DEP - 20240914 PL - England TA - NPJ Vaccines JT - NPJ vaccines JID - 101699863 PMC - PMC11399437 COIS- The authors declare no competing interests. EDAT- 2024/09/14 10:44 MHDA- 2024/09/14 10:45 PMCR- 2024/09/14 CRDT- 2024/09/13 23:30 PHST- 2023/12/11 00:00 [received] PHST- 2024/08/14 00:00 [accepted] PHST- 2024/09/14 10:45 [medline] PHST- 2024/09/14 10:44 [pubmed] PHST- 2024/09/13 23:30 [entrez] PHST- 2024/09/14 00:00 [pmc-release] AID - 10.1038/s41541-024-00951-8 [pii] AID - 951 [pii] AID - 10.1038/s41541-024-00951-8 [doi] PST - epublish SO - NPJ Vaccines. 2024 Sep 14;9(1):167. doi: 10.1038/s41541-024-00951-8. PMID- 39245233 OWN - NLM STAT- MEDLINE DCOM- 20241108 LR - 20260918 IS - 1538-9375 (Electronic) IS - 1525-8610 (Linking) VI - 25 IP - 11 DP - 2024 Nov TI - Delirium Incidence and Predictors in SARS-CoV-2 Vaccinated Residents in Long-Term Care Facilities (LTCF): Insights from the GeroCovid Vax Study. PG - 105251 LID - S1525-8610(24)00673-X [pii] LID - 10.1016/j.jamda.2024.105251 [doi] AB - OBJECTIVE: SARS-CoV-2 vaccination can bring an important benefit for older people in terms of reduction of mortality and hospitalization; however, reports of rare adverse effects like altered consciousness and delirium among this demographic have raised concerns. This study aimed to assess delirium incidence post-SARS-CoV-2 vaccination and its predictors in older residents across 60 Italian long-term care facilities (LTCFs). DESIGN: This is a prospective cohort study considering data from GeroCovid Vax, a multicenter cohort study jointly performed by the Italian Society of Gerontology and Geriatrics (SIGG) (Florence, Italy) and the Italian National Institute of Health (Istituto Superiore di Sanita-ISS, Rome, Italy), and sponsored by the Italian Medicines Agency (Agenzia Italiana del Farmaco-AIFA). SETTING AND PARTICIPANTS: GeroCovid Vax enrolled LTCFs residents aged >/=60 who received at least 1 anti-SARS-CoV-2 vaccine dose. METHODS: Baseline data covered sociodemographic details, chronic diseases, medications, nutritional status, cognitive and functional assessments, mobility, and frailty. Delirium was assessed post-first, second, and booster vaccine doses using DSM-5 criteria. Data analysis involved descriptive statistics, multivariate logistic regression, and network analysis. RESULTS: A total of 2521 participants (mean age 83.10 +/- 9.21 years, 70.7% female) were analyzed. Delirium incidence post-first, second, and booster doses was 3.5%, 1.6%, and 1.5%, respectively. Age, preexisting cognitive disorders, and frailty were significant predictors of delirium, with odds ratios (ORs) of 1.70 (95% CI, 1.08-2.77), 2.05 (95% CI, 1.40-2.97), and 1.77 (95% CI, 1.25-2.52), respectively. Prior use of antipsychotics (OR, 1.75; 95% CI, 1.22-2.51) and antidepressants (OR, 1.77; 95% CI, 1.25-2.52) correlated significantly with delirium. Network analysis indicated a strong association between anorexia and delirium. CONCLUSION AND IMPLICATIONS: Post-vaccination delirium is infrequent and decreases with subsequent doses. Timely assessments for frailty and cognitive impairment could aid in stratifying delirium risk among LTCF residents, facilitating enhanced prevention measures and close monitoring for delirium indicators. CI - Copyright (c) 2024 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Okoye, Chukwuma AU - Okoye C AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden. FAU - Zazzara, Maria Beatrice AU - Zazzara MB AD - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Ceolin, Chiara AU - Ceolin C AD - Department of Neurobiology, Care Sciences and Society, Aging Research Center, Karolinska Institutet and Stockholm University, Stockholm, Sweden; Department of Medicine (DIMED), Geriatrics Division, University of Padova, Padova, Italy. Electronic address: chiara.ceolin.1@phd.unipd.it. FAU - Fedele, Giorgio AU - Fedele G AD - Department of Infectious Diseases, Istituto Superiore di Sanita, Rome, Italy. FAU - Palmieri, Annapina AU - Palmieri A AD - Department of Cardiovascular, Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanita, Rome, Italy. FAU - Abbatecola, Angela Marie AU - Abbatecola AM AD - Alzheimer's Disease Day Clinic, Azienda Sanitaria Locale, Frosinone, Italy. FAU - Malara, Alba AU - Malara A AD - ANASTE Humanitas Foundation, Rome, Italy. FAU - Trevisan, Caterina AU - Trevisan C AD - Department of Medical Sciences, University of Ferrara, Ferrara, Italy. FAU - Timmons, Suzanne AU - Timmons S AD - Centre for Gerontology and Rehabilitation, School of Medicine, University College Cork, Cork, Ireland. FAU - Prato, Rosa AU - Prato R AD - Hygiene Unit, Policlinico Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Fortunato, Francesca AU - Fortunato F AD - Hygiene Unit, Policlinico Foggia Hospital, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. FAU - Del Signore, Susanna AU - Del Signore S AD - Bluecompanion Ltd, Londra, UK. FAU - Bellelli, Giuseppe AU - Bellelli G AD - Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy. FAU - Incalzi, Raffaele Antonelli AU - Incalzi RA AD - Campus Bio-Medico University, Rome, Italy. FAU - Onder, Graziano AU - Onder G AD - Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Universita Cattolica del Sacro Cuore, Rome, Italy. FAU - Coin, Alessandra AU - Coin A AD - Department of Medicine (DIMED), Geriatrics Division, University of Padova, Padova, Italy. CN - GeroCovid Vax Working Group LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20240905 PL - United States TA - J Am Med Dir Assoc JT - Journal of the American Medical Directors Association JID - 100893243 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/administration & dosage MH - *Delirium/epidemiology/prevention & control MH - Incidence MH - Italy/epidemiology MH - *Long-Term Care MH - Prospective Studies MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - frailty OT - long-term facilities OT - older adults OT - vaccine COIS- Disclosures The authors declare no conflicts of interest. EDAT- 2024/09/09 00:50 MHDA- 2024/11/13 13:55 CRDT- 2024/09/08 19:24 PHST- 2024/04/15 00:00 [received] PHST- 2024/07/30 00:00 [revised] PHST- 2024/08/02 00:00 [accepted] PHST- 2024/11/13 13:55 [medline] PHST- 2024/09/09 00:50 [pubmed] PHST- 2024/09/08 19:24 [entrez] AID - S1525-8610(24)00673-X [pii] AID - 10.1016/j.jamda.2024.105251 [doi] PST - ppublish SO - J Am Med Dir Assoc. 2024 Nov;25(11):105251. doi: 10.1016/j.jamda.2024.105251. Epub 2024 Sep 5. PMID- 39220747 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240903 IS - 2050-3121 (Print) IS - 2050-3121 (Electronic) IS - 2050-3121 (Linking) VI - 12 DP - 2024 TI - Effect of COVID 19 pandemic on the neurology department hospitalization with analysis of the neurological complications secondary to COVID 19 and vaccination against COVID 19. PG - 20503121241272518 LID - 10.1177/20503121241272518 [doi] LID - 20503121241272518 AB - OBJECTIVE: We investigated the effect of the pandemic on neurological hospitalizations and complications associated with severe acute respiratory syndrome coronavirus 2 infection or vaccinations. METHODS: We retrospectively analyzed data of patients hospitalized in our neurology division from 1 April 2019 to 31 March 2022 as the opt-out study. We classified the neurological diseases into nine subgroups, evaluated changes of neurological disease characteristics, and analyzed patients hospitalized with the complications from severe acute respiratory syndrome coronavirus 2 infection or after the coronavirus disease 2019 vaccination over three eras based on the pandemic stages: (1) pre-pandemic, (2) during the pandemic but before vaccines, and (3) during the pandemic with vaccines. RESULTS: Overall, 1756 patients were included in the analyses. The patient characteristics significantly changed throughout the pandemic (p < 0.01). Although the number of autoimmune cases did not change throughout the pandemic (p = 0.53), that of psychological cases and that of unknown cases were significantly changed (p < 0.05, p < 0.01). There were four infectious cases and 11 cases following vaccination from 1 April 2020 to 31 March 2022. The 11 postvaccination cases involved 10 kinds of neurological diseases. CONCLUSIONS: The neurological characteristics significantly changed throughout the pandemic and there were diverse neurological complications following vaccinations. CI - (c) The Author(s) 2024. FAU - Matsuzono, Kosuke AU - Matsuzono K AUID- ORCID: 0000-0002-9455-3903 AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Mieno, Makiko AU - Mieno M AD - Department of Medical Informatics, Center for Information, Jichi Medical University, Tochigi, Japan. FAU - Mashiko, Takafumi AU - Mashiko T AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Anan, Yuhei AU - Anan Y AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Ozawa, Tadashi AU - Ozawa T AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Koide, Reiji AU - Koide R AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Tanaka, Ryota AU - Tanaka R AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. FAU - Kimura, Akio AU - Kimura A AD - Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan. FAU - Fujimoto, Shigeru AU - Fujimoto S AD - Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan. LA - eng PT - Journal Article DEP - 20240828 PL - England TA - SAGE Open Med JT - SAGE open medicine JID - 101624744 PMC - PMC11363057 OTO - NOTNLM OT - Autoimmunity OT - COVID-19 OT - COVID-19 vaccines OT - neurologic manifestations OT - stroke COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2024/09/02 08:45 MHDA- 2024/09/02 08:46 PMCR- 2024/08/28 CRDT- 2024/09/02 05:22 PHST- 2024/01/04 00:00 [received] PHST- 2024/07/08 00:00 [accepted] PHST- 2024/09/02 08:46 [medline] PHST- 2024/09/02 08:45 [pubmed] PHST- 2024/09/02 05:22 [entrez] PHST- 2024/08/28 00:00 [pmc-release] AID - 10.1177_20503121241272518 [pii] AID - 10.1177/20503121241272518 [doi] PST - epublish SO - SAGE Open Med. 2024 Aug 28;12:20503121241272518. doi: 10.1177/20503121241272518. eCollection 2024. PMID- 39214187 OWN - NLM STAT- MEDLINE DCOM- 20241218 LR - 20260127 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 31 IP - 1 DP - 2025 Jan TI - Nirmatrelvir/ritonavir treatment and risk for postacute sequelae of COVID-19 in older Singaporeans. PG - 93-100 LID - S1198-743X(24)00418-X [pii] LID - 10.1016/j.cmi.2024.08.019 [doi] AB - OBJECTIVES: Significant heterogeneity has been reported in cohort studies evaluating the impact of early oral antiviral treatment on preventing postacute sequelae after COVID-19. We evaluated the impact of early nirmatrelvir/ritonavir on risk of postacute cardiovascular, neurological, respiratory, and autoimmune diagnoses, as well as postacute symptoms amongst older Singaporeans. METHODS: National COVID-19 registries and healthcare claims databases were used to construct a retrospective population-based cohort enrolling all Singaporeans aged >/=60 years diagnosed with SARS-CoV-2 infection in primary care during Omicron transmission (18 March 2022-4 August 2023). The cohort was divided into nirmatrelvir/ritonavir-treated and untreated groups. Between-group differences in baseline characteristics were adjusted using overlap weighting. Risks of postacute cardiovascular, neurological, respiratory, and autoimmune diagnoses and postacute symptoms (31-180 days) after SARS-CoV-2 infection were contrasted in treated/untreated groups using competing risks regressions (adjusted for demographics/vaccination status/comorbidities). RESULTS: A total of 188 532 older Singaporeans were included; 5.8% (10 905/188 532) received nirmatrelvir/ritonavir. No significantly decreased risk of postacute sequelae (any sequelae: adjusted hazards ratio [aHR], 1.06; 0.94-1.19; cardiovascular sequelae: aHR, 1.01; 0.83-1.24; neurological sequelae: aHR, 1.09; 0.95-1.27; respiratory sequelae: aHR, 1.14; 0.84-1.55; autoimmune sequelae: aHR, 0.76; 0.53-1.09; or any postacute symptom: aHR, 0.97; 0.80-1.18) was observed up to 180 days post-infection in nirmatrelvir/ritonavir-treated individuals vs. untreated cases. Across all vaccination and age subgroups, no significantly decreased risk of any postacute diagnosis/symptom or any cardiovascular, neurological, respiratory, and autoimmune complications up to 180 days post-infection was observed. DISCUSSION: Early outpatient receipt of nirmatrelvir/ritonavir did not significantly reduce risk of postacute cardiovascular, neurological, respiratory, and autoimmune sequelae or the risk of postacute symptoms in a boosted cohort of older Singaporeans. CI - Copyright (c) 2024 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Wee, Liang En AU - Wee LE AD - National Centre for Infectious Diseases, Singapore, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore, Singapore; Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. Electronic address: ian.wee.l.e@singhealth.com.sg. FAU - Lim, Jue Tao AU - Lim JT AD - National Centre for Infectious Diseases, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. FAU - Tay, An Ting AU - Tay AT AD - Ministry of Health, Singapore, Singapore. FAU - Chiew, Calvin J AU - Chiew CJ AD - National Centre for Infectious Diseases, Singapore, Singapore; Ministry of Health, Singapore, Singapore. FAU - Young, Barnaby Edward AU - Young BE AD - National Centre for Infectious Diseases, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore. FAU - Wong, Betty AU - Wong B AD - Ministry of Health, Singapore, Singapore. FAU - Lim, Ruth AU - Lim R AD - Ministry of Health, Singapore, Singapore. FAU - Lee, Ching Li AU - Lee CL AD - Ministry of Health, Singapore, Singapore. FAU - Tan, Joyce AU - Tan J AD - Ministry of Health, Singapore, Singapore. FAU - Vasoo, Shawn AU - Vasoo S AD - National Centre for Infectious Diseases, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Lye, David Chien AU - Lye DC AD - National Centre for Infectious Diseases, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. FAU - Tan, Kelvin Bryan AU - Tan KB AD - National Centre for Infectious Diseases, Singapore, Singapore; Duke-NUS Graduate Medical School, National University of Singapore, Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; Ministry of Health, Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20240828 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (Antiviral Agents) RN - 0 (Drug Combinations) RN - 2494G1JF75 (Lopinavir) RN - 0 (lopinavir-ritonavir drug combination) RN - O3J8G9O825 (Ritonavir) RN - Singaporean people SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Antiviral Agents/therapeutic use MH - Cardiovascular Diseases/epidemiology MH - *COVID-19/epidemiology/complications/prevention & control MH - COVID-19 Drug Treatment MH - *Drug Combinations MH - Lopinavir/therapeutic use MH - Retrospective Studies MH - Risk Factors MH - *Ritonavir/therapeutic use/adverse effects MH - Singapore/epidemiology MH - Southeast Asian People OTO - NOTNLM OT - COVID-19 OT - Long COVID OT - Nirmatrelvir-ritonavir OT - Omicron OT - SARS-CoV-2 EDAT- 2024/08/31 09:49 MHDA- 2024/12/19 00:20 CRDT- 2024/08/30 19:26 PHST- 2024/07/17 00:00 [received] PHST- 2024/08/16 00:00 [revised] PHST- 2024/08/22 00:00 [accepted] PHST- 2024/12/19 00:20 [medline] PHST- 2024/08/31 09:49 [pubmed] PHST- 2024/08/30 19:26 [entrez] AID - S1198-743X(24)00418-X [pii] AID - 10.1016/j.cmi.2024.08.019 [doi] PST - ppublish SO - Clin Microbiol Infect. 2025 Jan;31(1):93-100. doi: 10.1016/j.cmi.2024.08.019. Epub 2024 Aug 28. PMID- 39202641 OWN - NLM STAT- MEDLINE DCOM- 20240829 LR - 20240901 IS - 1648-9144 (Electronic) IS - 1010-660X (Print) IS - 1010-660X (Linking) VI - 60 IP - 8 DP - 2024 Aug 21 TI - The Impact of Long COVID on the Quality of Life. LID - 10.3390/medicina60081359 [doi] LID - 1359 AB - Background and Objectives: The term long COVID refers to patients with a history of confirmed COVID-19 infection, who present symptoms that last for at least 2 months and cannot be explained by another diagnosis. Objectives: The present study aims to determine the most common symptoms of the long COVID syndrome and their impact on the quality of life. Materials and Methods: A prospective observational study was conducted on patients diagnosed with mild and moderate COVID-19 (based on a positive SARS-CoV-2 molecular diagnostic or rapid antigen test and severity form definition) at the Clinical Hospital of Infectious Diseases, Cluj-Napoca, Romania. Clinical examinations with detailed questions about symptoms were performed at the time of the diagnosis of COVID-19 and the six-month follow-up. Two years after COVID-19 infection, patients were invited to complete an online quality-of-life questionnaire regarding long COVID symptoms. Results: A total of 103 patients (35.92% males) with a mean age of 41.56 +/- 11.77 were included in this study. Of the total number of patients, 65.04% presented mild forms of COVID-19. Data regarding the vaccination status showed that 83.5% were vaccinated against SARS-CoV-2. The most common symptoms at diagnosis were cough (80.6%), fatigue (80.4%), odynophagia (76.7%), and headaches (67.6%), with female patients being statistically more likely to experience it (p = 0.014). Patients with moderate forms of the disease had higher levels of both systolic (p = 0.008) and diastolic (p = 0.037) blood pressure at diagnosis, but no statistical difference was observed in the 6-month follow-up. The most common symptoms at 2 years (in 29 respondent subjects) were represented by asthenia (51.7%), headache (34.5%), memory disorders (27.6%), abdominal meteorism (27.6%), and arthralgia (27.6%). In terms of cardiovascular symptoms, fluctuating blood pressure values (20.7%), palpitations (17.2%), and increased heart rate values (17.2%) were recorded. Conclusions: If at the time of diagnosis, the most frequent manifestations of the disease were respiratory, together with headache and fatigue, at re-evaluation, asthenia, decreased effort tolerance, and neuropsychiatric symptoms prevailed. Regarding the cardiovascular changes as part of the long COVID clinical picture, some patients developed prehypertension, palpitations, and tachycardia. FAU - Cozma, Angela AU - Cozma A AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Sitar-Taut, Adela-Viviana AU - Sitar-Taut AV AUID- ORCID: 0000-0001-8590-4583 AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Orasan, Olga Hilda AU - Orasan OH AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Leucuta, Daniel Corneliu AU - Leucuta DC AUID- ORCID: 0000-0003-4218-8622 AD - Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania. FAU - Pocol, Tinca-Codruta AU - Pocol TC AUID- ORCID: 0009-0007-3989-8574 AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Salagean, Octavia AU - Salagean O AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Crisan, Camil AU - Crisan C AUID- ORCID: 0009-0007-9065-1745 AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Sporis, Nicolae-Dan AU - Sporis ND AUID- ORCID: 0000-0001-5584-564X AD - Department of Medical Oncology, Prof. Dr. I. Chiricuta Oncology Institute, 400015 Cluj-Napoca, Romania. FAU - Lazar, Andrada-Luciana AU - Lazar AL AUID- ORCID: 0000-0001-8428-8088 AD - Department of Dermatology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Malinescu, Toma-Vlad AU - Malinescu TV AD - Department of Cardiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Ganea, Andreea-Maria AU - Ganea AM AD - Department of Cardiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Vlad, Calin Vasile AU - Vlad CV AD - Department of Internal Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Horvat, Melinda AU - Horvat M AD - Department of Infectious Diseases and Epidemiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400348 Cluj-Napoca, Romania. FAU - Lupse, Mihaela Sorina AU - Lupse MS AUID- ORCID: 0000-0003-4010-2901 AD - Department of Infectious Diseases and Epidemiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400348 Cluj-Napoca, Romania. FAU - Briciu, Violeta AU - Briciu V AD - Department of Infectious Diseases and Epidemiology, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400348 Cluj-Napoca, Romania. LA - eng PT - Journal Article PT - Observational Study DEP - 20240821 PL - Switzerland TA - Medicina (Kaunas) JT - Medicina (Kaunas, Lithuania) JID - 9425208 SB - IM MH - Humans MH - Female MH - Male MH - *COVID-19/epidemiology/complications MH - *Quality of Life MH - Prospective Studies MH - Adult MH - Middle Aged MH - *Post-Acute COVID-19 Syndrome MH - Romania/epidemiology MH - *SARS-CoV-2 MH - Surveys and Questionnaires MH - Fatigue/etiology MH - Headache/etiology MH - Cough/etiology/physiopathology PMC - PMC11356039 OTO - NOTNLM OT - long COVID OT - omicron variant OT - quality of life COIS- The authors declare no conflicts of interest. EDAT- 2024/08/31 09:53 MHDA- 2024/09/01 16:17 PMCR- 2024/08/21 CRDT- 2024/08/29 01:19 PHST- 2024/08/01 00:00 [received] PHST- 2024/08/16 00:00 [revised] PHST- 2024/08/19 00:00 [accepted] PHST- 2024/09/01 16:17 [medline] PHST- 2024/08/31 09:53 [pubmed] PHST- 2024/08/29 01:19 [entrez] PHST- 2024/08/21 00:00 [pmc-release] AID - medicina60081359 [pii] AID - medicina-60-01359 [pii] AID - 10.3390/medicina60081359 [doi] PST - epublish SO - Medicina (Kaunas). 2024 Aug 21;60(8):1359. doi: 10.3390/medicina60081359. PMID- 39201981 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240901 IS - 2075-4426 (Print) IS - 2075-4426 (Electronic) IS - 2075-4426 (Linking) VI - 14 IP - 8 DP - 2024 Jul 25 TI - Small Fiber Neuropathy Associated with Post-COVID-19 and Post-COVID-19 Vaccination Arthritis: A Rare Post-Infective Syndrome or a New-Onset Disease? LID - 10.3390/jpm14080789 [doi] LID - 789 AB - Post-COVID-19 (PC) and post-COVID-19 vaccination (PCV) syndromes are considered emergent multidisciplinary disorders. PC/PCV small fiber neuropathy (SFN) was rarely described and its association with undifferentiated arthritis (UA) was never defined. We aimed to evaluate PC/PCV-UA associated with the recent onset of severe lower limb paresthesia, compare SFN positive (+) to negative (-) patients, and evaluate changes in biomarkers in SFN+ during treatments. Nineteen PC/PCV-UA-patients with possible SFN underwent skin biopsy at the Usl Tuscany Center (Florence) early arthritis outpatient clinic from September 2021 to March 2024. Eight selected SFN+ were compared to ten SFN- patients. In SFN+ patients, baseline joint ultrasound (US), electromyography (EMG), optical coherence tomography (OCT), and skin biopsy were repeated at six months. Moreover, SFN+ patients were clinically assessed by a 0-10 numeric rating scale for neurological symptoms and DAS28/ESR up to 12 months follow-up. SFN+ patients showed a lower intraepidermal nerve fiber density at histopathological examination of skin biopsies and a higher frequency of OCT and EMG abnormalities in comparison to SFN- patients. In SFN+ patients, US and DAS28/ESR significantly improved, while intraepidermal nerve fiber density did not significantly change at the six-month follow-up. Fatigue, motor impairment, burning pain, brain fog, and sensitivity disorders decreased at long-term follow-up (12 months). FAU - Bandinelli, Francesca AU - Bandinelli F AUID- ORCID: 0000-0002-6874-4941 AD - Rheumatology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Nassini, Romina AU - Nassini R AUID- ORCID: 0000-0002-9223-8395 AD - Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50139 Florence, Italy. AD - Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, 50139 Florence, Italy. FAU - Gherardi, Eleonora AU - Gherardi E AD - Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy. FAU - Chiocchetti, Barbara AU - Chiocchetti B AD - Neurology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Manetti, Mirko AU - Manetti M AUID- ORCID: 0000-0003-3956-8480 AD - Section of Anatomy and Histology, Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy. FAU - Cincotta, Massimo AU - Cincotta M AD - Neurology Department, San Giovanni di Dio Hospital, Usl Tuscany Center, 50143 Florence, Italy. FAU - Nozzoli, Filippo AU - Nozzoli F AD - Section of Pathological Anatomy, Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Nucci, Elena AU - Nucci E AD - Histopathology and Molecular Diagnostics Unit, Careggi University Hospital, University of Florence, 50139 Florence, Italy. FAU - De Logu, Francesco AU - De Logu F AD - Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, 50139 Florence, Italy. FAU - Pimpinelli, Nicola AU - Pimpinelli N AD - Section of Dermatology, Department of Health Sciences, University of Florence, 50125 Florence, Italy. LA - eng PT - Journal Article DEP - 20240725 PL - Switzerland TA - J Pers Med JT - Journal of personalized medicine JID - 101602269 PMC - PMC11355276 OTO - NOTNLM OT - COVID-19 OT - arthritis OT - small fiber neuropathy COIS- The authors declare no conflicts of interest. EDAT- 2024/08/31 09:43 MHDA- 2024/08/31 09:44 PMCR- 2024/07/25 CRDT- 2024/08/29 01:16 PHST- 2024/06/26 00:00 [received] PHST- 2024/07/12 00:00 [revised] PHST- 2024/07/23 00:00 [accepted] PHST- 2024/08/31 09:44 [medline] PHST- 2024/08/31 09:43 [pubmed] PHST- 2024/08/29 01:16 [entrez] PHST- 2024/07/25 00:00 [pmc-release] AID - jpm14080789 [pii] AID - jpm-14-00789 [pii] AID - 10.3390/jpm14080789 [doi] PST - epublish SO - J Pers Med. 2024 Jul 25;14(8):789. doi: 10.3390/jpm14080789. PMID- 39198798 OWN - NLM STAT- MEDLINE DCOM- 20240829 LR - 20250203 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Aug 28 TI - Behavioral, cognitive and emotional determinants of getting vaccinated for COVID-19 and the mediating role of institutional trust among young adults in Cyprus. PG - 2336 LID - 10.1186/s12889-024-19859-y [doi] LID - 2336 AB - BACKGROUND: Vaccination uptake is a complex behavior, influenced by numerous factors. Behavioral science theories are commonly used to explain the psychosocial determinants of an individual's health behavior. This study examined the behavioural, cognitive, and emotional determinants of COVID-19 vaccination intention based on well-established theoretical models: Acceptance and Commitment Therapy (ACT), Capability, Opportunity, Motivation, and Behaviour (COM-B) and the Health Belief Model (HBM). Additionally, it examined the mediating role of institutional trust in the relationship between determinants of these models and vaccination intentions. METHODS: A cross-sectional study was conducted from January to May 2022, where university students in Cyprus completed an online survey. RESULTS: A total of 484 university students completed the online survey, with 23.8% reporting being vaccinated with fewer than three vaccination doses and/or no intention to vaccinate further. Hierarchical logistic regression analysis showed that higher scores in institutional trust, perceived severity, motivation, physical and psychological capability were significantly associated with higher odds of intending to vaccinate. Higher psychological flexibility and not being infected with COVID-19 were also associated with higher odds of vaccination intention, but not in the final model when all determinants were included. Additionally, significant indirect effects of psychological and physical capability, motivation and perceived severity on vaccination intention were found to be mediated by institutional trust. CONCLUSIONS: When tackling COVID-19 vaccination hesitancy, behavioural, cognitive, and emotional aspects should be considered. Stakeholders and policymakers are advised to implement targeted vaccination programs in young people while at the same time building trust and improving their capabilities and motivation towards getting vaccinated. CI - (c) 2024. The Author(s). FAU - Konstantinou, Pinelopi AU - Konstantinou P AD - Department of Psychology, University of Cyprus, Nicosia, Cyprus. AD - Department of Psychology, School of Sciences, University of Central Lancashire, Larnaca, Cyprus. FAU - Kyprianidou, Maria AU - Kyprianidou M AD - Department of Social and Behavioral Science, European University Cyprus, Nicosia, Cyprus. FAU - Christodoulou, Andria AU - Christodoulou A AD - Department of Social and Behavioral Science, European University Cyprus, Nicosia, Cyprus. FAU - McHugh, Louise AU - McHugh L AD - Department of Psychology, University College Dublin, Dublin, Ireland. FAU - Constantinou, Marios AU - Constantinou M AD - Department of Social Sciences, University of Nicosia, Nicosia, Cyprus. FAU - Epiphaniou, Eleni AU - Epiphaniou E AD - Department of Social and Behavioral Science, European University Cyprus, Nicosia, Cyprus. FAU - Vahey, Nigel AU - Vahey N AD - Department of Psychology, Technological University Dublin, Dublin, Ireland. FAU - Nicolaou, Christiana AU - Nicolaou C AD - Department of Nursing, Cyprus University of Technology, Limassol, 3041, Cyprus. FAU - Middleton, Nicos AU - Middleton N AD - Department of Nursing, Cyprus University of Technology, Limassol, 3041, Cyprus. FAU - Karekla, Maria AU - Karekla M AD - Department of Psychology, University of Cyprus, Nicosia, Cyprus. FAU - Kassianos, Angelos P AU - Kassianos AP AD - Department of Psychology, University of Cyprus, Nicosia, Cyprus. angelos.kassianos@cut.ac.cy. AD - Department of Nursing, Cyprus University of Technology, Limassol, 3041, Cyprus. angelos.kassianos@cut.ac.cy. AD - Department of Applied Health Research, UCL, London, UK. angelos.kassianos@cut.ac.cy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240828 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Cyprus MH - Male MH - Female MH - *Trust/psychology MH - Young Adult MH - Cross-Sectional Studies MH - *COVID-19/prevention & control/psychology/epidemiology MH - *COVID-19 Vaccines/administration & dosage MH - *Students/psychology/statistics & numerical data MH - *Intention MH - Adult MH - Universities MH - Adolescent MH - Vaccination/psychology/statistics & numerical data MH - Surveys and Questionnaires MH - Motivation MH - Vaccination Hesitancy/psychology/statistics & numerical data MH - Health Behavior MH - Cognition MH - Emotions PMC - PMC11351732 OTO - NOTNLM OT - Acceptance and Commitment Therapy OT - COM-B model OT - COVID-19 OT - Health Belief Model OT - Vaccination COIS- The authors declare no competing interests. EDAT- 2024/08/31 09:53 MHDA- 2024/08/31 09:54 PMCR- 2024/08/28 CRDT- 2024/08/28 23:50 PHST- 2023/12/17 00:00 [received] PHST- 2024/08/22 00:00 [accepted] PHST- 2024/08/31 09:54 [medline] PHST- 2024/08/31 09:53 [pubmed] PHST- 2024/08/28 23:50 [entrez] PHST- 2024/08/28 00:00 [pmc-release] AID - 10.1186/s12889-024-19859-y [pii] AID - 19859 [pii] AID - 10.1186/s12889-024-19859-y [doi] PST - epublish SO - BMC Public Health. 2024 Aug 28;24(1):2336. doi: 10.1186/s12889-024-19859-y. PMID- 39186606 OWN - NLM STAT- MEDLINE DCOM- 20240826 LR - 20250129 IS - 2573-7732 (Electronic) IS - 2573-7732 (Linking) VI - 8 IP - 8 DP - 2024 Aug 1 TI - Mild Primary or Breakthrough SARS-CoV-2 Infection Promotes Autoantibody Production in Individuals with and without Neuro-PASC. PG - 577-585 LID - 10.4049/immunohorizons.2400033 [doi] AB - Patients with long COVID can develop humoral autoimmunity after severe acute SARS-CoV-2 infection. However, whether similar increases in autoantibody responses occur after mild infection and whether vaccination prior to SARS-CoV-2 breakthrough infection can limit autoantibody responses is unknown. In this study, we demonstrate that mild SARS-CoV-2 infection increases autoantibodies associated with rheumatic autoimmune diseases and diabetes in most individuals, regardless of vaccination status prior to infection. However, patients with long COVID and persistent neurologic and fatigue symptoms (neuro-PASC) have substantially higher autoantibody responses than convalescent control subjects at an average of 8 mo postinfection. Furthermore, high titers of systemic lupus erythematosus- and CNS-associated autoantibodies in patients with neuro-PASC are associated with impaired cognitive performance and greater symptom severity. In summary, we found that mild SARS-CoV-2 primary and breakthrough infections can induce persistent humoral autoimmunity in both patients with neuro-PASC and healthy COVID convalescents, suggesting that a reappraisal of mitigation strategies against SARS-CoV-2 is warranted to prevent transmission and potential development of autoimmunity. CI - Copyright (c) 2024 The Authors. FAU - Visvabharathy, Lavanya AU - Visvabharathy L AUID- ORCID: 0000-0002-8157-4385 AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Dalil, Neda AU - Dalil N AUID- ORCID: 0000-0001-5566-4347 AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Leonor, Lucia AU - Leonor L AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Zhu, Chengsong AU - Zhu C AUID- ORCID: 0000-0001-8872-9450 AD - Genomics and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX. FAU - Orban, Zachary S AU - Orban ZS AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Jimenez, Millenia AU - Jimenez M AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Lim, Patrick H AU - Lim PH AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Penaloza-MacMaster, Pablo AU - Penaloza-MacMaster P AUID- ORCID: 0000-0001-9986-4906 AD - Department of Microbiology-Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL. FAU - Koralnik, Igor J AU - Koralnik IJ AUID- ORCID: 0000-0001-6836-1468 AD - Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL. LA - eng GR - DP2 DA051912/DA/NIDA NIH HHS/United States GR - U54 EB027049/EB/NIBIB NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PL - England TA - Immunohorizons JT - ImmunoHorizons JID - 101708159 RN - 0 (Autoantibodies) RN - 0 (Antibodies, Viral) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19/immunology MH - *Autoantibodies/immunology/blood MH - Male MH - *SARS-CoV-2/immunology MH - Female MH - Middle Aged MH - Adult MH - Aged MH - Autoimmunity/immunology MH - Fatigue/immunology MH - Antibodies, Viral/blood/immunology MH - Breakthrough Infections PMC - PMC11374748 COIS- The authors have no financial conflicts of interest. EDAT- 2024/08/26 19:49 MHDA- 2024/08/27 09:48 PMCR- 2024/08/26 CRDT- 2024/08/26 14:33 PHST- 2024/04/05 00:00 [received] PHST- 2024/07/23 00:00 [accepted] PHST- 2024/08/27 09:48 [medline] PHST- 2024/08/26 19:49 [pubmed] PHST- 2024/08/26 14:33 [entrez] PHST- 2024/08/26 00:00 [pmc-release] AID - 267113 [pii] AID - immunohorizons_2400033 [pii] AID - 10.4049/immunohorizons.2400033 [doi] PST - ppublish SO - Immunohorizons. 2024 Aug 1;8(8):577-585. doi: 10.4049/immunohorizons.2400033. PMID- 39175548 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240824 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 15 DP - 2024 TI - Neurological manifestations of immune origin after COVID-19 vaccination: retrospective case study. PG - 1376474 LID - 10.3389/fphar.2024.1376474 [doi] LID - 1376474 AB - Objectives: To know the frequency and characteristics of neurological manifestations of probable immune origin occurring after exposure to COVID-19 vaccination. In addition, to pre-study the usefulness of the Spanish pharmacovigilance system and lymphocyte transformation test in establishing causality. Methods: Retrospective case study, including patients admitted to the Neurology department from January 2021 to May 2022 with a probable neuroimmune disorder. Demographic, clinical and COVID-19 vaccination antecedent data were collected from medical records. Results: From a total of 108 patients, 30 were excluded due to a different etiological diagnosis after follow-up. Thirty-six patients (46.2%) had received the COVID-19 vaccine in the previous 3 months (21.8% during the previous month). BioNTech-Pfizer vaccine was the most frequent in this group (63.9%). 69/108 were female and mean age 51.2 years (SD 22.59), with no significant difference with not recently-vaccinated (U-Mann Whitney, p = 0.256). The neurological syndromes found were (vaccinated/total): polyradiculoneuropathy (8/16), encephalitis (5/11), multiple sclerosis relapse (5/16), optic neuritis (1/4), myelitis (3/6), cranial neuropathy (6/10), aseptic meningitis (1/3) and others (7/11). Acute immunosuppressive treatment was administered in 61.1% of cases and 47.2% presented complete clinical improvement, without significant differences with non-vaccinated patients (chi-square, p = 0.570). Eleven vaccinated patients were studied in the pharmacovigilance office for possible adverse drug reaction. Causality according to the Spanish pharmacovigilance system (SPVS) algorithm was "Related" to COVID-19 vaccine (score >/= 4) in 11 cases with positive in vitro study (lymphocyte transformation test) to polyethylene glycol-2000 and polysorbate-80 in 4 cases. Conclusion: Neuroimmune disorders appearing after administration of COVID-19 vaccine do not seem to present important differentiating clinical and/or evolutive features. Delayed hypersensitivity to vaccine excipients could be one of the pathophysiological mechanisms, and lymphocyte transformation test is a useful tool to identify it. CI - Copyright (c) 2024 Granja Lopez, Estebas Armas, Lorenzo Dieguez, Puertas Munoz, De Celis Ruiz, Rigual, Fernandez-Fournier, Torres Iglesias, Sanchez Velasco, Tallon Barranco, Rogozina, Ramirez, Gonzalez-Munoz and Lacruz Ballester. FAU - Granja Lopez, Juan AU - Granja Lopez J AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Estebas Armas, Carlos AU - Estebas Armas C AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Lorenzo Dieguez, Manuel AU - Lorenzo Dieguez M AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Puertas Munoz, Inmaculada AU - Puertas Munoz I AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - De Celis Ruiz, Elena AU - De Celis Ruiz E AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Rigual, Ricardo AU - Rigual R AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Fernandez-Fournier, Mireya AU - Fernandez-Fournier M AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Torres Iglesias, Gabriel AU - Torres Iglesias G AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Sanchez Velasco, Sara AU - Sanchez Velasco S AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Tallon Barranco, Antonio AU - Tallon Barranco A AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. FAU - Rogozina, Olga AU - Rogozina O AD - Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Ramirez, Elena AU - Ramirez E AD - Clinical Pharmacology Department, La Paz University Hospital-IdiPAZ, Faculty of Medicine, Universidad Autonoma de Madrid, Madrid, Spain. FAU - Gonzalez-Munoz, Miguel AU - Gonzalez-Munoz M AD - Immunology Department, La Paz University Hospital-IdiPAZ, Madrid, Spain. FAU - Lacruz Ballester, Laura AU - Lacruz Ballester L AD - Neurology Department and Stroke Center, Laboratory of Neurological and Cerebrovascular Sciences, Hospital La Paz Institute for Health Research Institute-IdiPAZ (La Paz University Hospital-Universidad Autonoma de Madrid), Madrid, Spain. LA - eng PT - Journal Article DEP - 20240808 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC11338880 OTO - NOTNLM OT - COVID-19 vaccination OT - Spanish pharmacovigilance system causality algorithm OT - autoimmune disorders OT - cranial neuropathy OT - lymphocyte transformation test OT - polyradiculoneuropathy COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/08/23 06:41 MHDA- 2024/08/23 06:42 PMCR- 2024/08/08 CRDT- 2024/08/23 04:14 PHST- 2024/01/25 00:00 [received] PHST- 2024/07/19 00:00 [accepted] PHST- 2024/08/23 06:42 [medline] PHST- 2024/08/23 06:41 [pubmed] PHST- 2024/08/23 04:14 [entrez] PHST- 2024/08/08 00:00 [pmc-release] AID - 1376474 [pii] AID - 10.3389/fphar.2024.1376474 [doi] PST - epublish SO - Front Pharmacol. 2024 Aug 8;15:1376474. doi: 10.3389/fphar.2024.1376474. eCollection 2024. PMID- 39156891 OWN - NLM STAT- MEDLINE DCOM- 20240819 LR - 20260812 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 15 DP - 2024 TI - High serum prevalence of autoreactive IgG antibodies against peripheral nerve structures in patients with neurological post-COVID-19 vaccination syndrome. PG - 1404800 LID - 10.3389/fimmu.2024.1404800 [doi] LID - 1404800 AB - BACKGROUND: Patients suffering from neurological symptoms after COVID-19 vaccination (post-COVID-19 vaccination syndrome (PCVS)) have imposed an increasing challenge on medical practice, as diagnostic precision and therapeutic options are lacking. Underlying autoimmune dysfunctions, including autoantibodies, have been discussed in neurological disorders after SARS-CoV-2 infection and vaccination. Here, we describe the frequency and targets of autoantibodies against peripheral nervous system tissues in PCVS. METHODS: Sera from 50 PCVS patients with peripheral neurological symptoms after COVID-19 vaccination and 35 vaccinated healthy controls were used in this study. IgG autoreactivity was measured via indirect immunofluorescence assays on mouse sciatic nerve teased fibers. The frequencies of autoantibodies were compared between groups using Fisher's exact test. Serum anti-ganglioside antibodies were measured in ganglioside blots. Autoantibody target identification was performed using immunoprecipitation coupled to mass spectrometry. Subsequent target confirmation was conducted via cell-based assays and ELISA. RESULTS: Compared with controls, PCVS patients had a significantly greater frequency of autoantibodies against peripheral nervous system structures (9/50(18%) vs 1/35(3%); p=0.04). Autoantibodies bound to paranodes (n=5), axons (n=4), Schmidt-Lanterman incisures (n=2) and Schwann cell nuclei (n=1). Conversely, antibodies against gangliosides were absent in PCVS patients. Target identification and subsequent confirmation revealed various subunits of neurofilaments as well as DFS-70 as autoantibody epitopes. CONCLUSION: Our data suggest that autoantibodies against nervous system tissue could be relevant in PCVS patients. Autoantibodies against neurofilaments and cell nuclei with so far non-established links to this disease spectrum should be further elucidated to determine their biomarker potential. CI - Copyright (c) 2024 Arlt, Breuer, Trampenau, Boesl, Kirchner, Mertins, Sanchez-Sendin, Nasouti, Mayrhofer, Bluthner, Endres, Pruss and Franke. FAU - Arlt, Friederike A AU - Arlt FA AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Breuer, Ameli AU - Breuer A AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Trampenau, Elli AU - Trampenau E AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. FAU - Kirchner, Marieluise AU - Kirchner M AD - Core Unit Proteomics, Berlin Institute of Health at Charite - Universitatsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Berlin, Germany. FAU - Mertins, Philipp AU - Mertins P AD - Core Unit Proteomics, Berlin Institute of Health at Charite - Universitatsmedizin Berlin and Max Delbruck Center for Molecular Medicine, Berlin, Germany. FAU - Sanchez-Sendin, Elisa AU - Sanchez-Sendin E AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Nasouti, Mahoor AU - Nasouti M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Mayrhofer, Marie AU - Mayrhofer M AD - Department of Autoimmune Diagnostics, Medizinisches Versorgungszentrum (MVZ) Laboratory PD Dr. Volkmann & Colleagues, Karlsruhe, Germany. FAU - Bluthner, Martin AU - Bluthner M AD - Department of Autoimmune Diagnostics, Medizinisches Versorgungszentrum (MVZ) Laboratory PD Dr. Volkmann & Colleagues, Karlsruhe, Germany. FAU - Endres, Matthias AU - Endres M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. AD - German Center for Cardiovascular Diseases (DZHK), Berlin, Germany. AD - Center for Stroke Research Berlin (CSB), Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Mental Health (DZPG), Berlin, Germany. FAU - Pruss, Harald AU - Pruss H AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, corporate member of Freie Universitat and Humboldt-Universitat zu Berlin, Berlin, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240802 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (Autoantibodies) RN - 0 (Immunoglobulin G) RN - 0 (COVID-19 Vaccines) RN - 0 (Gangliosides) SB - IM MH - Humans MH - *Autoantibodies/immunology/blood MH - Male MH - Female MH - *Immunoglobulin G/immunology/blood MH - Middle Aged MH - *COVID-19/immunology MH - *SARS-CoV-2/immunology MH - *COVID-19 Vaccines/immunology/administration & dosage MH - Aged MH - Mice MH - Animals MH - Adult MH - Vaccination MH - Gangliosides/immunology MH - Peripheral Nerves/immunology PMC - PMC11327052 OTO - NOTNLM OT - COVID-19 vaccination OT - DFS-70 OT - SARS-CoV-2 vaccination OT - autoantibody OT - neurofilament autoantibodies OT - peripheral nerve OT - post-COVID-19 vaccination syndrome (PCVS) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/08/19 06:42 MHDA- 2024/08/19 06:43 PMCR- 2024/01/01 CRDT- 2024/08/19 05:16 PHST- 2024/03/21 00:00 [received] PHST- 2024/07/11 00:00 [accepted] PHST- 2024/08/19 06:43 [medline] PHST- 2024/08/19 06:42 [pubmed] PHST- 2024/08/19 05:16 [entrez] PHST- 2024/01/01 00:00 [pmc-release] AID - 10.3389/fimmu.2024.1404800 [doi] PST - epublish SO - Front Immunol. 2024 Aug 2;15:1404800. doi: 10.3389/fimmu.2024.1404800. eCollection 2024. PMID- 39151826 OWN - NLM STAT- MEDLINE DCOM- 20250423 LR - 20260527 IS - 1527-3296 (Electronic) IS - 0196-6553 (Linking) VI - 53 IP - 2 DP - 2025 Feb TI - Prevalence of infection and reinfection among health care workers in a hospital of Northern China between BA.5/BF.7 and XBB.1.5 wave. PG - 228-238 LID - S0196-6553(24)00643-6 [pii] LID - 10.1016/j.ajic.2024.08.009 [doi] AB - BACKGROUND: To analyze the epidemiological characteristics of the SARS-CoV-2 infection and reinfection associated with the emergence of Omicron variant in Healthcare workers (HCWs). METHODS: We enrolled 760 HCWs who received 2-4 vaccination doses of COVID-19 and followed by BA.5/BF.7 and/or XBB.1.5 breakthrough infections between December 2022 and July 2023. Serum sample from each individual were collected approximately 1,3 and 6 months after last exposure. IgM, IgG and Total antibodies against SARS-CoV-2 were measured by chemiluminescent immunoassay. Meanwhile, we created an Enterprise WeChat link for HCWs to self-report SARS-CoV-2 infections, symptoms and post COVID-19 conditions. RESULTS: Our study revealed that the reinfection rate among HCWs reached 26.1%. The main symptoms were fever (91.2% vs 60.1%), cough (78.8% vs 58.0%), and sore throat (75.4% vs 59.6%) during infection and reinfection in Omicron BA.5/BF.7 and XBB.1.5 wave, and the interval for reinfection ranged from 91 to 210 days (median 152). Fatigue (23.6%), memory loss (18.8%) and coughing (18.6%) were the most prevalent long COVID symptoms, with a higher prevalence among female HCWs. CONCLUSIONS: HCWs reinfection with SARS-CoV-2 causes milder symptoms, but high reinfection rate and short intervals. Strengthen infection prevention and control is crucial to mitigating infection risk and improving health services. CI - Copyright (c) 2024 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Song, Xue-Dong AU - Song XD AD - Department of Clinical Laboratory Medicine, Hebei Medical University, Shijiazhuang, Hebei, China; Department of Laboratory Medicine, Handan Central Hospital, Hebei Medical University, Handan, Hebei, China. FAU - Gao, Hui-Xia AU - Gao HX AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Tan, Hao AU - Tan H AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Xie, Yan-Yan AU - Xie YY AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Zhang, Xin AU - Zhang X AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Zhang, Chen-Min AU - Zhang CM AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. FAU - Wang, Yu-Ling AU - Wang YL AD - Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address: 1149497466@qq.com. FAU - Dai, Er-Hei AU - Dai EH AD - Department of Clinical Laboratory Medicine, Hebei Medical University, Shijiazhuang, Hebei, China; Hebei Key Laboratory of Immune Mechanism of Major Infectious Diseases and New Technology of Diagnosis and Treatment, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China. Electronic address: daierhei@hebmu.edu.cn. LA - eng PT - Journal Article DEP - 20240814 PL - United States TA - Am J Infect Control JT - American journal of infection control JID - 8004854 RN - 0 (Antibodies, Viral) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Female MH - Male MH - *Reinfection/epidemiology MH - *Health Personnel/statistics & numerical data MH - Adult MH - China/epidemiology MH - *SARS-CoV-2/immunology MH - Prevalence MH - Middle Aged MH - Antibodies, Viral/blood MH - Hospitals MH - Immunoglobulin G/blood OTO - NOTNLM OT - Antibody response OT - Long COVID symptoms OT - Omicron variant OT - SARS-CoV-2 OT - SARS-CoV-2 infection EDAT- 2024/08/17 15:42 MHDA- 2025/01/20 22:52 CRDT- 2024/08/16 19:23 PHST- 2024/05/05 00:00 [received] PHST- 2024/08/06 00:00 [revised] PHST- 2024/08/09 00:00 [accepted] PHST- 2025/01/20 22:52 [medline] PHST- 2024/08/17 15:42 [pubmed] PHST- 2024/08/16 19:23 [entrez] AID - S0196-6553(24)00643-6 [pii] AID - 10.1016/j.ajic.2024.08.009 [doi] PST - ppublish SO - Am J Infect Control. 2025 Feb;53(2):228-238. doi: 10.1016/j.ajic.2024.08.009. Epub 2024 Aug 14. PMID- 39095276 OWN - NLM STAT- MEDLINE DCOM- 20240913 LR - 20250904 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 42 IP - 25 DP - 2024 Nov 14 TI - Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China. PG - 126150 LID - S0264-410X(24)00811-9 [pii] LID - 10.1016/j.vaccine.2024.07.051 [doi] AB - BACKGROUND: In late 2022, China became the first country to roll out mucosal COVID-19 vaccines. No prior study has yet compared the immunization stress-related responses (ISRR) among different routes of COVID-19 vaccine delivery. We aimed to compare the immunization-related psychological stress and ISRR between mucosal and intramuscular COVID-19 vaccines. METHODS: A cross-sectional questionnaire survey using a biopsychosocial framework design was performed from January 11 to 20, 2023. Adults with COVID-19 vaccination were eligible for the study, and a total of 1073 adults participated with community-based sample. Primary outcomes were the psychological stress levels and prevalence of ISRR. Multivariate regression models were employed to compare these outcomes between the two vaccination groups. The potential mediating effects of stress on vaccination and ISRR were examined using bootstrap sampling method. To further ensure the robustness of our results, sensitivity analysis with propensity score matching was performed. FINDINGS: In the univariate analysis, participants who received mucosal vaccination reported significantly lower stress levels compared to those who received intramuscular vaccination (3.39 +/- 3.02 vs. 3.93 +/- 3.24, P = .006). The prevalence of overall ISRR was significantly lower in the mucosal group compared to the intramuscular group (38.4% vs. 47.9%, P = .002). Multivariate regression models revealed that participants who received mucosal vaccination had a significantly lower stress level (beta = -0.516, 95% CI: -0.852 to -0.180; P = .003) and 38.7% fewer overall ISRR (OR = 0.613, 95% CI: 0.427 to 0.881; P = .008), particularly in terms of neurological symptoms. The immunization-related stress mediated the association between vaccination type and ISRR, with indirect effects estimated at 0.0663 (95% CI: 0.0195 to 0.1346) for overall ISRR. CONCLUSIONS: Mucosal COVID-19 vaccination was associated with reduced psychological stress and physical responses, as compared to intramuscular vaccination, which may contribute to increased trust and compliance with routine or mass vaccination efforts in the future. CI - Copyright (c) 2024. Published by Elsevier Ltd. FAU - Jiang, Minghuan AU - Jiang M AD - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China; Institute for Global Health and Development, Peking University, Beijing, China. FAU - Zhang, Haijun AU - Zhang H AD - Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China; China Center for Health Development Studies, Peking University, Beijing, China; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. FAU - Yao, Xuelin AU - Yao X AD - Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an, China; Center for Drug Safety and Policy Research, Xi'an Jiaotong University, Xi'an, China. FAU - Wang, Yang AU - Wang Y AD - China Center for Health Development Studies, Peking University, Beijing, China. FAU - Lai, Xiaozhen AU - Lai X AD - Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China; China Center for Health Development Studies, Peking University, Beijing, China; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. FAU - Fang, Hai AU - Fang H AD - China Center for Health Development Studies, Peking University, Beijing, China; Peking University Health Science Center - Chinese Center for Disease Control and Prevention Joint Research Center for Vaccine Economics, Beijing, China. Electronic address: hfang@hsc.pku.edu.cn. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240801 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Male MH - Female MH - Cross-Sectional Studies MH - China/epidemiology MH - Adult MH - *COVID-19/prevention & control/epidemiology MH - Injections, Intramuscular MH - Middle Aged MH - *COVID-19 Vaccines/administration & dosage MH - *Stress, Psychological MH - Vaccination/psychology/statistics & numerical data MH - Surveys and Questionnaires MH - SARS-CoV-2/immunology MH - Administration, Mucosal MH - Young Adult OTO - NOTNLM OT - COVID-19 vaccination OT - Immunization-related stress OT - Intramuscular vaccination OT - Mucosal vaccination COIS- Declaration of competing interest Authors declare no conflict of interests. EDAT- 2024/08/03 10:42 MHDA- 2024/09/14 10:43 CRDT- 2024/08/02 21:54 PHST- 2023/07/12 00:00 [received] PHST- 2024/07/15 00:00 [revised] PHST- 2024/07/15 00:00 [accepted] PHST- 2024/09/14 10:43 [medline] PHST- 2024/08/03 10:42 [pubmed] PHST- 2024/08/02 21:54 [entrez] AID - S0264-410X(24)00811-9 [pii] AID - 10.1016/j.vaccine.2024.07.051 [doi] PST - ppublish SO - Vaccine. 2024 Nov 14;42(25):126150. doi: 10.1016/j.vaccine.2024.07.051. Epub 2024 Aug 1. PMID- 39066428 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240729 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 7 DP - 2024 Jul 18 TI - Clinical and Diagnostic Features of Post-Acute COVID-19 Vaccination Syndrome (PACVS). LID - 10.3390/vaccines12070790 [doi] LID - 790 AB - Post-acute COVID-19 vaccination syndrome (PACVS) is a chronic disease triggered by SARS-CoV-2 vaccination (estimated prevalence 0.02%). PACVS is discriminated from the normal post-vaccination state by altered receptor antibodies, most notably angiotensin II type 1 and alpha-2B adrenergic receptor antibodies. Here, we investigate the clinical phenotype using a study registry encompassing 191 PACVS-affected persons (159 females/32 males; median ages: 39/42 years). Unbiased clustering (modified Jaccard index) of reported symptoms revealed a prevalent cross-cohort symptomatology of malaise and chronic fatigue (>80% of cases). Overlapping clusters of (i) peripheral nerve dysfunction, dysesthesia, motor weakness, pain, and vasomotor dysfunction; (ii) cardiovascular impairment; and (iii) cognitive impairment, headache, and visual and acoustic dysfunctions were also frequently represented. Notable abnormalities of standard serum markers encompassing increased interleukins 6 and 8 (>80%), low free tri-iodine thyroxine (>80%), IgG subclass imbalances (>50%), impaired iron storage (>50%), and increased soluble neurofilament light chains (>30%) were not associated with specific symptoms. Based on these data, 131/191 participants fit myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and simultaneously also several other established dysautonomia syndromes. Furthermore, 31/191 participants fit none of these syndromes. In conclusion, PACVS could either be an outlier of ME/CFS or a dysautonomia syndrome sui generis. FAU - Mundorf, Anna Katharina AU - Mundorf AK AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Semmler, Amelie AU - Semmler A AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Heidecke, Harald AU - Heidecke H AD - CellTrend GmbH, 14943 Luckenwalde, Germany. FAU - Schott, Matthias AU - Schott M AD - Division for Specific Endocrinology, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Steffen, Falk AU - Steffen F AD - Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (RMN2), Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany. FAU - Bittner, Stefan AU - Bittner S AD - Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), Rhine Main Neuroscience Network (RMN2), Medical Center, Johannes Gutenberg University Mainz, 55131 Mainz, Germany. FAU - Lackner, Karl J AU - Lackner KJ AD - University Medical Center, Johannes Gutenberg University Mainz, 55122 Mainz, Germany. FAU - Schulze-Bosse, Karin AU - Schulze-Bosse K AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Pawlitzki, Marc AU - Pawlitzki M AD - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Meuth, Sven Guenther AU - Meuth SG AUID- ORCID: 0000-0003-2571-3501 AD - Department of Neurology, Medical Faculty, Heinrich-Heine-University, 40225 Dusseldorf, Germany. FAU - Klawonn, Frank AU - Klawonn F AUID- ORCID: 0000-0001-9613-182X AD - Biostatistics Research Group, Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany. AD - Department of Computer Science, Ostfalia University, 38302 Wolfenbuttel, Germany. FAU - Ruhrlander, Jana AU - Ruhrlander J AUID- ORCID: 0009-0006-9537-8138 AD - Selbsthilfegruppe Post-Vac-Syndrom Deutschland e.V., 34121 Kassel, Germany. FAU - Boege, Fritz AU - Boege F AUID- ORCID: 0000-0002-0780-1033 AD - Central Institute for Clinical Chemistry and Laboratory Diagnostics, Medical Faculty, University Hospital Dusseldorf, Heinrich-Heine-University, 40225 Dusseldorf, Germany. LA - eng PT - Journal Article DEP - 20240718 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11281408 OTO - NOTNLM OT - PACVS OT - cognitive impairment OT - interleukin-6 OT - interleukin-8 OT - malaise/chronic fatigue OT - peripheral nerve dysfunction OT - post-acute COVID-19 vaccination syndrome COIS- Harald Heidecke is co-owner and chief executive officer of CellTrend GmbH, Luckenwalde, Germany. The other authors have no conflicts of interest to declare. EDAT- 2024/07/27 10:46 MHDA- 2024/07/27 10:47 PMCR- 2024/07/18 CRDT- 2024/07/27 01:31 PHST- 2024/06/03 00:00 [received] PHST- 2024/07/10 00:00 [revised] PHST- 2024/07/10 00:00 [accepted] PHST- 2024/07/27 10:47 [medline] PHST- 2024/07/27 10:46 [pubmed] PHST- 2024/07/27 01:31 [entrez] PHST- 2024/07/18 00:00 [pmc-release] AID - vaccines12070790 [pii] AID - vaccines-12-00790 [pii] AID - 10.3390/vaccines12070790 [doi] PST - epublish SO - Vaccines (Basel). 2024 Jul 18;12(7):790. doi: 10.3390/vaccines12070790. PMID- 39013656 OWN - NLM STAT- MEDLINE DCOM- 20240716 LR - 20250204 IS - 2044-6055 (Electronic) IS - 2044-6055 (Linking) VI - 14 IP - 7 DP - 2024 Jul 16 TI - Comparing COVID-19 vaccination coverage, adverse reactions and impact of social determinants of health on vaccine hesitancy in ADRD/MCI and non-ADRD/MCI population: protocol for a retrospective cross-sectional study. PG - e082988 LID - 10.1136/bmjopen-2023-082988 [doi] LID - e082988 AB - INTRODUCTION: COVID-19 vaccination is crucial for vulnerable people with underlying chronic conditions such as Alzheimer's disease and related dementias (ADRD) and mild cognitive impairment (MCI). These individuals face unique challenges, including higher risk of COVID-19, difficulties in adopting preventive behaviours and vaccine hesitancy due to concerns about adverse reactions. Therefore, efforts to promote vaccination, including boosters tailored to the currently circulating virus, are essential for people with ADRD/MCI. OBJECTIVE: The primary purpose of this study protocol is to conduct a comprehensive analysis of COVID-19 vaccination coverage and adverse reactions among individuals with ADRD/MCI in comparison to those without ADRD/MCI. Additionally, the proposed study aims to investigate the impact of social determinants of health on COVID-19 vaccination and vaccine hesitancy in individuals with ADRD/MCI. METHODS AND ANALYSIS: A retrospective cross-sectional study will be conducted utilising data from the All of Us (AoU) Researcher Workbench. Relevant data fields are extracted from sources including demographic information, COVID-19 Vaccine Survey, Basic Survey, Health Access & Utilization, Social Determinants of Health, and Electronic Health Record (EHR) data. Data on vaccination, adverse reactions and vaccine hesitancy will be collected through COVID-19 vaccine survey questionnaires. Propensity score matching and binary logistic regression will be applied to assess the vaccination rates and vaccine hesitancy, while controlling for demographic characteristics and social determinants of health factors. ETHICS AND DISSEMINATION: This study protocol received approval from the Institutional Review Board at Florida State University (STUDY00004571). Results will be disseminated through publication in peer-reviewed journals and presented at scientific conferences. CI - (c) Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Yang, Yijiong AU - Yang Y AUID- ORCID: 0000-0002-6644-4179 AD - College of Nursing, Florida State University, Tallahassee, Florida, USA yijiongyang@gmail.com. FAU - Park, Hyejin AU - Park H AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Li, Chengdong AU - Li C AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Song, Dan AU - Song D AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. FAU - Wang, Jing AU - Wang J AD - College of Nursing, Florida State University, Tallahassee, Florida, USA. LA - eng PT - Journal Article DEP - 20240716 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Cross-Sectional Studies MH - Retrospective Studies MH - *COVID-19/prevention & control/epidemiology/psychology MH - *Vaccination Hesitancy/psychology/statistics & numerical data MH - *Social Determinants of Health MH - *COVID-19 Vaccines/adverse effects/administration & dosage MH - SARS-CoV-2 MH - Vaccination Coverage/statistics & numerical data MH - Cognitive Dysfunction/prevention & control MH - Alzheimer Disease/psychology MH - Dementia/psychology MH - Research Design MH - Male MH - Female PMC - PMC11253747 OTO - NOTNLM OT - COVID-19 OT - Chronic Disease OT - Dementia OT - GERIATRIC MEDICINE OT - PUBLIC HEALTH COIS- Competing interests: None declared. EDAT- 2024/07/17 00:41 MHDA- 2024/07/17 00:42 PMCR- 2024/07/16 CRDT- 2024/07/16 21:53 PHST- 2024/07/17 00:42 [medline] PHST- 2024/07/17 00:41 [pubmed] PHST- 2024/07/16 21:53 [entrez] PHST- 2024/07/16 00:00 [pmc-release] AID - bmjopen-2023-082988 [pii] AID - 10.1136/bmjopen-2023-082988 [doi] PST - epublish SO - BMJ Open. 2024 Jul 16;14(7):e082988. doi: 10.1136/bmjopen-2023-082988. PMID- 38974645 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240709 IS - 1658-3639 (Print) IS - 1658-7774 (Electronic) IS - 1658-3639 (Linking) VI - 18 IP - 4 DP - 2024 Jul-Aug TI - Undesirable effects of COVID-19 vaccination on Saudi population: A descriptive study, Winter 2022. PG - 32-45 AB - OBJECTIVE: The development of coronavirus disease 2019 (COVID-19) vaccines was a crucial preventative measure toward controlling the pandemic. Several side effects have been reported. This study investigated the long-term side effects reported by the Saudi population. post-COVID-19 vaccination. METHODS: The cross-sectional study involved Saudi participants of both genders, aged >/=16 years, and had received at least one dose of any of the available vaccines in Saudi Arabia. They were asked to fill out an online questionnaire divided into three sections: Demographics, medical history, and side effects that appeared post-COVID-19 vaccines. RESULTS: The findings indicated that the undesirable effects were reported by 82% of the participants. These side effects involve three categories: The most common, additional or reported, and persistent side effects. The most common side effects were pain at the site of injection (88.16%), bone pain/joint pain (68.7%), and fatigue (68.46%). Menstrual disorders (n = 46), hair loss (n = 34), and memory problems (n = 19) were reported by participants as additional side effects. Among all side effects, fatigue, joint pain, hair loss, and menstrual disorders were the most persistent side effects. Moreover, 190 participants reported that they were diagnosed with diseases soon after receiving the COVID-19 vaccine including COVID-19, thyroid gland disorder, and irritable bowel disease. The quality of life of some of the participants was affected by post-COVID-19 vaccines, as 25.28% had anxiety, 21.22% had depression, and 33.16% had discomfort. CONCLUSION: These findings may contribute to understanding the effect of COVID-19 vaccines on the Saudi population's health and public opinion about these vaccines. CI - Copyright: (c) International Journal of Health Sciences. FAU - AlGhamdi, Shareefa A AU - AlGhamdi SA AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. AD - Vitamin D Pharmacogenomics Research Group, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - AlGhamdi, Abeer S AU - AlGhamdi AS AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Al-Ogailan, Abeer A AU - Al-Ogailan AA AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Ghazwani, Aishah H AU - Ghazwani AH AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Redhwan, Esraa Z AU - Redhwan EZ AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. FAU - Alkinani, Khadijah B AU - Alkinani KB AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. AD - Department of Public Health, Health Sciences College at Leith, Umm Al Qura University, Makkah, Saudi Arabia. FAU - Hasaballah, Nojod H AU - Hasaballah NH AD - Department of Biochemistry, Faculty of Sciences, King Abdulaziz University, Jeddah, Saudi Arabia. AD - Nanomedicine Unit, Center of Innovations in Personalized Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. LA - eng PT - Journal Article PL - United States TA - Int J Health Sci (Qassim) JT - International journal of health sciences JID - 101528042 PMC - PMC11226936 OTO - NOTNLM OT - Coronavirus OT - covid OT - covid-19 OT - pandemic OT - vaccine COIS- The authors certify that there is no conflict of interest to declare. EDAT- 2024/07/08 12:42 MHDA- 2024/07/08 12:43 PMCR- 2024/07/01 CRDT- 2024/07/08 07:35 PHST- 2024/07/08 12:43 [medline] PHST- 2024/07/08 12:42 [pubmed] PHST- 2024/07/08 07:35 [entrez] PHST- 2024/07/01 00:00 [pmc-release] AID - IJHS-18-32 [pii] PST - ppublish SO - Int J Health Sci (Qassim). 2024 Jul-Aug;18(4):32-45. PMID- 38958179 OWN - NLM STAT- MEDLINE DCOM- 20250214 LR - 20260922 IS - 1537-7385 (Electronic) IS - 0894-9115 (Linking) VI - 104 IP - 3 DP - 2025 Mar 1 TI - Symptoms Patterns and Health-Related Quality of Life in a Real-Life Cohort of Long-COVID Patients: Complexity to Optimize Rehabilitation Treatment. PG - 231-235 LID - 10.1097/PHM.0000000000002578 [doi] AB - OBJECTIVE: We wanted to identify prevalent symptoms and patterns of long-COVID syndrome, assess the impact on health-related quality of life, and explore factors linked to lower quality of life, including vaccination status and symptom count, in a real-life cohort. DESIGN: This is an observational retrospective study. RESULTS: We assessed 133 patients and 85 completed the evaluations. The most common symptoms reported were motor deficit (95.29%) and fatigue (94.12%), while respiratory symptoms, cognitive deficits, and weakness (76.47%) were less frequent. Many patients experienced multiple symptoms, with the majority reporting 5-8 symptoms simultaneously, most associated with fatigue. However, the number of symptoms did not correlate with health-related quality of life as measured by the 12-Item Short Form Survey questionnaire. Finally, vaccination status did not significantly affect 12-Item Short Form Survey scores or the number of reported symptoms. CONCLUSIONS: Our analysis highlighted the presence of diverse multisystemic symptoms in long-COVID patients. Many individuals experienced multiple associated symptoms, negatively affecting their overall quality of life. Neither vaccination status nor the number of symptoms appeared to influence reported quality of life. This emphasizes the need for a comprehensive, early, and multidisciplinary approach to address the syndrome's diverse symptoms. CI - Copyright (c) 2024 The Author(s). Published by Wolters Kluwer Health, Inc. FAU - Maccarone, Maria Chiara AU - Maccarone MC AUID- ORCID: 0000-0003-2793-1334 AD - From the Department of Neuroscience, Rehabilitation Unit, University of Padua, Padua, Italy (MCM, DC, SM); and Physical Medicine and Rehabilitation School, Department of Neuroscience, University of Padua, Padua, Italy (GR, SM). FAU - Coraci, Daniele AU - Coraci D FAU - Regazzo, Gianluca AU - Regazzo G FAU - Masiero, Stefano AU - Masiero S LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20240827 PL - United States TA - Am J Phys Med Rehabil JT - American journal of physical medicine & rehabilitation JID - 8803677 SB - IM MH - Humans MH - *Quality of Life MH - Female MH - Male MH - Retrospective Studies MH - *COVID-19/rehabilitation/complications/psychology/physiopathology MH - Middle Aged MH - Aged MH - Fatigue MH - Adult MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - Post-Acute COVID-19 Syndrome MH - Aged, 80 and over COIS- Financial disclosure statements have been obtained, and no conflicts of interest have been reported by the authors or by any individuals in control of the content of this article. EDAT- 2024/07/03 13:19 MHDA- 2025/02/14 06:21 CRDT- 2024/07/03 07:03 PHST- 2025/02/14 06:21 [medline] PHST- 2024/07/03 13:19 [pubmed] PHST- 2024/07/03 07:03 [entrez] AID - 00002060-990000000-00545 [pii] AID - 10.1097/PHM.0000000000002578 [doi] PST - ppublish SO - Am J Phys Med Rehabil. 2025 Mar 1;104(3):231-235. doi: 10.1097/PHM.0000000000002578. Epub 2024 Aug 27. PMID- 38957067 OWN - NLM STAT- MEDLINE DCOM- 20240703 LR - 20260503 IS - 2208-7958 (Electronic) VI - 53 IP - 7 DP - 2024 Jul TI - Previously healthy unvaccinated adults have significant functional limitations in the medium and long term after mild COVID-19. PG - 491-497 LID - 10.31128/AJGP-07-23-6900 [doi] AB - BACKGROUND AND OBJECTIVES: Ongoing symptoms of COVID-19 can persist for weeks or months after the initial COVID-19 infection. The aim of this study was to identify persistent symptoms (fatigue, cognition, quality of life, anxiety, depression and physical measures) in unvaccinated community-managed patients following COVID-19 infection. METHOD: This was a prospective nested observational study of health and wellbeing measures determined seven and 13 months after COVID-19 infection, alongside physical abilities after 18 months. RESULTS: Data analyses were completed on 62 participants (60% female, median age 35 years). Severe fatigue was noted in 47% of participants at seven months and this had not improved significantly by 13 months (45%). Quality of life and mental health scores were significantly worse in individuals with severe fatigue. One-quarter of participants demonstrated mild cognitive impairment at seven months. After 18 months, walking and lung function were normal, but grip strength was reduced in 26% of participants. DISCUSSION: A significant proportion of unvaccinated COVID-19 patients had not returned to pre-illness levels of health and function after one year; screening functional ability and mental wellbeing is warranted in unvaccinated people with COVID-19. FAU - Bower, Wendy F AU - Bower WF AD - FACP, PhD, BAppSc (Physio), Principal Investigator TANGO Research Group and Senior Clinician Physiotherapist, Department of Medicine and Community Care, the Royal Melbourne Hospital, Melbourne; Associate Professor, University of Melbourne, Melbourne; Visiting Professor, Ghent University, Belgium. wendy.bower@mh.org.au. FAU - D'Souza, Aruska N AU - D'Souza AN AD - PhD, BPhysio, Allied Health Research and Knowledge Translation Lead, Department of Allied Health, The Royal Melbourne Hospital, Melbourne, Vic. FAU - Barson, Elizabeth AU - Barson E AD - BBSc (Hons), DPsych (Clinical), Clinical Psychologist, Psychosocial Oncology Program, Peter MacCallum Cancer Centre, Melbourne, Vic. FAU - Marston, Celia AU - Marston C AD - BAppSc (OT), MPallCare, Occupational Therapy Research Lead, Department of Allied Health, The Royal Melbourne Hospital, Melbourne, Vic; Adjunct Lecturer, School of Primary and Allied Health Care, Monash University, Melbourne, Vic. FAU - Granger, Catherine L AU - Granger CL AD - PhD, Associate Professor, Department of Physiotherapy, University of Melbourne, Vic; Department of Physiotherapy, Royal Melbourne Hospital, Vic. FAU - Beach, Lisa AU - Beach L AD - BPhysio, MPhysio, Physiotherapist, Department of Allied Health, Royal Melbourne Hospital, Melbourne, Vic. FAU - Bond, Katherine AU - Bond K AD - DTM@H, FRACP, FRCPA, MBBS, BSci, Head of Microbiology, Department of Microbiology, The Royal Melbourne Hospital, Melbourne, Vic; Department of Microbiology and Immunology, The University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, Vic. FAU - Khan, Fary AU - Khan F AD - AM, MBBS, MD, FAFRM (RACP), Director of Rehabilitation, The Royal Melbourne Hospital, Melbourne, Vic; Professorial Fellow, The University of@Melbourne, Melbourne, Vic. LA - eng PT - Journal Article PT - Observational Study PL - Australia TA - Aust J Gen Pract JT - Australian journal of general practice JID - 101718099 SB - IM MH - Humans MH - *COVID-19/complications/physiopathology MH - Female MH - Male MH - Prospective Studies MH - Adult MH - *Quality of Life/psychology MH - SARS-CoV-2 MH - Fatigue/etiology/physiopathology MH - Anxiety/etiology/psychology MH - Depression/etiology/psychology/physiopathology MH - Cognitive Dysfunction/etiology/physiopathology MH - Middle Aged MH - Unvaccinated Persons EDAT- 2024/07/03 06:42 MHDA- 2024/07/03 06:43 CRDT- 2024/07/03 03:23 PHST- 2024/07/03 06:43 [medline] PHST- 2024/07/03 06:42 [pubmed] PHST- 2024/07/03 03:23 [entrez] AID - 10.31128/AJGP-07-23-6900 [doi] PST - ppublish SO - Aust J Gen Pract. 2024 Jul;53(7):491-497. doi: 10.31128/AJGP-07-23-6900. PMID- 38932397 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240629 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 6 DP - 2024 Jun 17 TI - Factors Related to Caregivers' Intention to Vaccinate Their Elderly Family Members with Major Neurocognitive Disorders against COVID-19. LID - 10.3390/vaccines12060668 [doi] LID - 668 AB - Vaccination helps reduce the risk of coronavirus disease 2019 (COVID-19) infection in elderly individuals with major neurocognitive disorders (MNDs). However, some caregivers are hesitant to have their elderly family members with MNDs vaccinated against COVID-19. This study explored the factors influencing caregivers' intentions to vaccinate elderly family members with MNDs against COVID-19. A total of 232 caregivers of elderly family members with MNDs participated in this study. In this survey, data regarding COVID-19 vaccination acceptance, fear, side effects, family members' attitudes toward vaccination, mental health status, neuropsychiatric symptoms, and cognitive impairments were collected from the elderly participants with MNDs. The associations between these variables and the caregivers' intention to vaccinate their elderly family members with MNDs against COVID-19 were examined using a multivariable linear regression analysis model. The results revealed that caregivers' perceived familial support for vaccination, the perceived value of vaccination, and autonomy to vaccinate elder family members were positively correlated with caregivers' intention to vaccinate elderly family members with MNDs, whereas elderly family members' age was negatively correlated with caregiver intentions. This study demonstrated that caregiver factors (perceived familial support, value of vaccination, and autonomy) and elderly family members' age were correlated with caregiver intention. These factors should be considered in developing interventions to enhance caregivers' intentions to vaccinate their elderly family members with MNDs against COVID-19. FAU - Huang, Mei-Feng AU - Huang MF AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80754, Taiwan. AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. FAU - Yeh, Yi-Chun AU - Yeh YC AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80754, Taiwan. AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. FAU - Liu, Tai-Ling AU - Liu TL AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80754, Taiwan. AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. FAU - Hsiao, Ray C AU - Hsiao RC AD - Department of Psychiatry, Seattle Children's, Seattle, WA 98195, USA. AD - Department of Psychiatry and Behavioral Sciences, School of Medicine, University of Washington, Seattle, WA 98105, USA. FAU - Chen, Cheng-Sheng AU - Chen CS AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80754, Taiwan. AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. FAU - Yen, Cheng-Fang AU - Yen CF AUID- ORCID: 0000-0003-1156-4939 AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 80754, Taiwan. AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. AD - College of Professional Studies, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan. LA - eng PT - Journal Article DEP - 20240617 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC11209509 OTO - NOTNLM OT - COVID-19 OT - caregiver OT - major neurocognitive disorder OT - vaccine COIS- The authors declare no conflicts of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/06/17 CRDT- 2024/06/27 01:28 PHST- 2024/04/28 00:00 [received] PHST- 2024/05/29 00:00 [revised] PHST- 2024/06/12 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:28 [entrez] PHST- 2024/06/17 00:00 [pmc-release] AID - vaccines12060668 [pii] AID - vaccines-12-00668 [pii] AID - 10.3390/vaccines12060668 [doi] PST - epublish SO - Vaccines (Basel). 2024 Jun 17;12(6):668. doi: 10.3390/vaccines12060668. PMID- 38932239 OWN - NLM STAT- MEDLINE DCOM- 20240627 LR - 20250513 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 16 IP - 6 DP - 2024 Jun 12 TI - Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms? LID - 10.3390/v16060947 [doi] LID - 947 AB - The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256-0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270-0.590), pain (OR0.368, 95% CI 0.248-0.548), dyspnea at rest (OR0.580, 95%CI 0.361-0.933), concentration loss (OR0.368, 95%CI 0.151-0.901), memory loss (OR0.399, 95%CI 0.270-0.590), hair loss (OR0.103, 95%CI 0.052-0.207), and skin rashes (OR0.037, 95%CI 0.005-0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors. FAU - Fernandez-de-Las-Penas, Cesar AU - Fernandez-de-Las-Penas C AUID- ORCID: 0000-0003-3772-9690 AD - Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain. AD - Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark. FAU - Franco-Moreno, Anabel AU - Franco-Moreno A AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain. FAU - Ruiz-Ruigomez, Maria AU - Ruiz-Ruigomez M AUID- ORCID: 0000-0003-1538-3043 AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain. FAU - Arrieta-Ortubay, Estibaliz AU - Arrieta-Ortubay E AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain. FAU - Ryan-Murua, Pablo AU - Ryan-Murua P AUID- ORCID: 0000-0002-4212-7419 AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain. AD - CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Investigacion Carlos III (ISCIIII), 28220 Madrid, Spain. FAU - Lumbreras-Bermejo, Carlos AU - Lumbreras-Bermejo C AD - Department of Internal Medicine, Hospital Universitario Doce de Octubre, 28041 Madrid, Spain. FAU - Del-Valle-Loarte, Pablo AU - Del-Valle-Loarte P AUID- ORCID: 0000-0003-0748-2594 AD - Department of Internal Medicine, Hospital Universitario Severo Ochoa, 28911 Madrid, Spain. FAU - Pellicer-Valero, Oscar J AU - Pellicer-Valero OJ AUID- ORCID: 0000-0002-0104-1029 AD - Image Processing Laboratory (IPL), Universitat de Valencia, Parc Cientific, Paterna, 46980 Valencia, Spain. FAU - Giordano, Rocco AU - Giordano R AUID- ORCID: 0000-0003-1331-129X AD - Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark. AD - Department of Oral and Maxillofacial Surgery, Aalborg University Hospital, DK 9100 Aalborg, Denmark. FAU - Arendt-Nielsen, Lars AU - Arendt-Nielsen L AD - Center for Neuroplasticity and Pain (CNAP), Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK 9220 Aalborg, Denmark. AD - Department of Gastroenterology & Hepatology, Mech-Sense, Clinical Institute, Aalborg University Hospital, DK 9100 Aalborg, Denmark. AD - Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, DK 9100 Aalborg, Denmark. FAU - Martin-Garrido, Isabel AU - Martin-Garrido I AD - Department of Internal Medicine, Hospital Virgen del Rocio, 41012 Sevilla, Spain. FAU - Torres-Macho, Juan AU - Torres-Macho J AUID- ORCID: 0000-0002-8860-6837 AD - Department of Internal Medicine, Hospital Universitario Infanta Leonor-Virgen de la Torre, 28031 Madrid, Spain. AD - Department of Medicine, School of Medicine, Universidad Complutense de Madrid, 28040 Madrid, Spain. LA - eng GR - LONG-COVID-EXP-CM/Comunidad de Madrid/ GR - NNF21OC0067235/Novo Nordisk Foundation/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240612 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 3QKI37EEHE (remdesivir) RN - OF5P57N2ZX (Alanine) RN - 415SHH325A (Adenosine Monophosphate) RN - 0 (Antiviral Agents) SB - IM MH - Humans MH - *Alanine/analogs & derivatives/therapeutic use/administration & dosage MH - *Adenosine Monophosphate/analogs & derivatives/therapeutic use/administration & dosage MH - Female MH - Male MH - *Antiviral Agents/therapeutic use MH - *COVID-19 Drug Treatment MH - Middle Aged MH - *SARS-CoV-2/drug effects MH - *COVID-19/complications MH - Case-Control Studies MH - Post-Acute COVID-19 Syndrome MH - Adult MH - Aged PMC - PMC11209434 OTO - NOTNLM OT - antiviral OT - long-COVID OT - post-COVID-19 OT - remdesivir COIS- The authors declare no conflict of interest. EDAT- 2024/06/27 06:42 MHDA- 2024/06/27 06:43 PMCR- 2024/06/12 CRDT- 2024/06/27 01:27 PHST- 2024/05/23 00:00 [received] PHST- 2024/06/08 00:00 [revised] PHST- 2024/06/09 00:00 [accepted] PHST- 2024/06/27 06:43 [medline] PHST- 2024/06/27 06:42 [pubmed] PHST- 2024/06/27 01:27 [entrez] PHST- 2024/06/12 00:00 [pmc-release] AID - v16060947 [pii] AID - viruses-16-00947 [pii] AID - 10.3390/v16060947 [doi] PST - epublish SO - Viruses. 2024 Jun 12;16(6):947. doi: 10.3390/v16060947. PMID- 38918610 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20261010 IS - 1529-2916 (Electronic) IS - 1529-2908 (Linking) VI - 25 IP - 7 DP - 2024 Jul TI - Vaccination prevents cognitive impairment after breakthrough infection with SARS-CoV-2. PG - 1136-1137 LID - 10.1038/s41590-024-01869-y [doi] LA - eng PT - Journal Article PL - United States TA - Nat Immunol JT - Nature immunology JID - 100941354 RN - 0 (COVID-19 Vaccines) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *COVID-19/prevention & control/immunology MH - *SARS-CoV-2/immunology MH - *Cognitive Dysfunction/prevention & control/immunology MH - *COVID-19 Vaccines/immunology MH - *Vaccination MH - Breakthrough Infections EDAT- 2024/06/26 00:42 MHDA- 2024/07/05 00:42 CRDT- 2024/06/25 23:42 PHST- 2024/07/05 00:42 [medline] PHST- 2024/06/26 00:42 [pubmed] PHST- 2024/06/25 23:42 [entrez] AID - 10.1038/s41590-024-01869-y [pii] AID - 10.1038/s41590-024-01869-y [doi] PST - ppublish SO - Nat Immunol. 2024 Jul;25(7):1136-1137. doi: 10.1038/s41590-024-01869-y. PMID- 38902519 OWN - NLM STAT- MEDLINE DCOM- 20240704 LR - 20260813 IS - 1529-2916 (Electronic) IS - 1529-2908 (Print) IS - 1529-2908 (Linking) VI - 25 IP - 7 DP - 2024 Jul TI - Vaccination reduces central nervous system IL-1beta and memory deficits after COVID-19 in mice. PG - 1158-1171 LID - 10.1038/s41590-024-01868-z [doi] AB - Up to 25% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit postacute cognitive sequelae. Although millions of cases of coronavirus disease 2019 (COVID-19)-mediated memory dysfunction are accumulating worldwide, the underlying mechanisms and how vaccination lowers risk are unknown. Interleukin-1 (IL-1), a key component of innate immune defense against SARS-CoV-2 infection, is elevated in the hippocampi of individuals with COVID-19. Here we show that intranasal infection of C57BL/6J mice with SARS-CoV-2 Beta variant leads to central nervous system infiltration of Ly6C(hi) monocytes and microglial activation. Accordingly, SARS-CoV-2, but not H1N1 influenza virus, increases levels of brain IL-1beta and induces persistent IL-1R1-mediated loss of hippocampal neurogenesis, which promotes postacute cognitive deficits. Vaccination with a low dose of adenoviral-vectored spike protein prevents hippocampal production of IL-1beta during breakthrough SARS-CoV-2 infection, loss of neurogenesis and subsequent memory deficits. Our study identifies IL-1beta as one potential mechanism driving SARS-CoV-2-induced cognitive impairment in a new mouse model that is prevented by vaccination. CI - (c) 2024. The Author(s), under exclusive licence to Springer Nature America, Inc. FAU - Vanderheiden, Abigail AU - Vanderheiden A AUID- ORCID: 0000-0003-1321-4510 AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Hill, Jeremy D AU - Hill JD AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Jiang, Xiaoping AU - Jiang X AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Deppen, Ben AU - Deppen B AD - Center for Neuroimmunology and Neuroinfectious Diseases, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Bamunuarachchi, Gayan AU - Bamunuarachchi G AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Soudani, Nadia AU - Soudani N AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Joshi, Astha AU - Joshi A AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Cain, Matthew D AU - Cain MD AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. FAU - Boon, Adrianus C M AU - Boon ACM AUID- ORCID: 0000-0002-4700-8224 AD - Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. AD - Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. FAU - Klein, Robyn S AU - Klein RS AUID- ORCID: 0000-0003-0281-1352 AD - Schulich School of Medicine and Dentistry, Department of Microbiology and Immunology, Western University, London, Ontario, Canada. rklein@wustl.edu. AD - Schulich School of Medicine and Dentistry, Western Institute of Neuroscience, Western University, London, Ontario, Canada. rklein@wustl.edu. LA - eng GR - R35NS122310/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)/ GR - R35 NS122310/NS/NINDS NIH HHS/United States GR - R01NS104471/U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS)/ GR - R01AI139251/U.S. Department of Health & Human Services | National Institutes of Health (NIH)/ GR - F32NS128065/Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)/ GR - F32 NS128065/NS/NINDS NIH HHS/United States PT - Journal Article DEP - 20240620 PL - United States TA - Nat Immunol JT - Nature immunology JID - 100941354 RN - 0 (Interleukin-1beta) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (COVID-19 Vaccines) RN - 0 (spike protein, SARS-CoV-2) RN - 0 (IL1B protein, mouse) RN - 0 (Receptors, Interleukin-1 Type I) RN - SARS-CoV-2 variants SB - IM MH - Animals MH - *Interleukin-1beta/metabolism/immunology MH - Mice MH - *COVID-19/immunology/prevention & control MH - *SARS-CoV-2/immunology MH - *Hippocampus/immunology/metabolism MH - *Mice, Inbred C57BL MH - *Memory Disorders/immunology MH - *Neurogenesis/immunology MH - Vaccination MH - Spike Glycoprotein, Coronavirus/immunology MH - COVID-19 Vaccines/immunology MH - Male MH - Humans MH - Microglia/immunology/metabolism MH - Disease Models, Animal MH - Receptors, Interleukin-1 Type I/metabolism/genetics MH - Monocytes/immunology/metabolism MH - Female PMC - PMC13148132 MID - NIHMS2004192 COIS- Competing interests The authors declare no competing interests. EDAT- 2024/06/21 00:42 MHDA- 2024/07/05 00:42 PMCR- 2026/05/06 CRDT- 2024/06/20 23:28 PHST- 2023/11/21 00:00 [received] PHST- 2024/05/13 00:00 [accepted] PHST- 2024/07/05 00:42 [medline] PHST- 2024/06/21 00:42 [pubmed] PHST- 2024/06/20 23:28 [entrez] PHST- 2026/05/06 00:00 [pmc-release] AID - 10.1038/s41590-024-01868-z [pii] AID - 10.1038/s41590-024-01868-z [doi] PST - ppublish SO - Nat Immunol. 2024 Jul;25(7):1158-1171. doi: 10.1038/s41590-024-01868-z. Epub 2024 Jun 20. PMID- 38818170 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240601 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 10 DP - 2024 May 30 TI - COVID-19 vaccination may prevent postoperative delirium in elderly patients undergoing elective non-cardiac surgery: The PNDRFAP and PNDABLE studies. PG - e30414 LID - 10.1016/j.heliyon.2024.e30414 [doi] LID - e30414 AB - BACKGROUND: Postoperative delirium (POD) often occurs in elderly patients after surgery. We conducted two clinical studies to determine whether COVID-19 vaccination has a protective effect on POD and to explore the role of CSF biomarkers in this process. METHODS: We conducted two clinical studies, Perioperative Neurocognitive Disorder Risk Factor and Prognosis (PNDRFAP) and Perioperative Neurocognitive Disorder and Biomarker Lifestyle (PNDABLE), in which patients more than or equal to 65 years old who have had elective non-cardiac surgery were enrolled. The preoperative cognitive status of patients were evaluated by Mini-Mental State Examination (MMSE) one day preoperatively. Confusion Assessment Method (CAM) was used to diagnose POD. We used the mediation model to analyze the relationship between CSF biomarkers, COVID-19 vaccination and POD, as well as Dynamic Nomogram to calculate the incidence of Non-Postoperative Delirium (NPOD). The main outcome of these studies was the incidence of POD during seven days postoperatively or before discharge, which was assessed by CAM. RESULTS: In the final, 705 participants were enrolled in the PNDRFAP study, and 638 patients in the PNDABLE. In both studies, we found that the occurrence of POD was lower in patients who had injected COVID-19 vaccination before surgery compared with those without vaccination (PNDRFAP: 10.20 % [21/205] vs 25.80 % [129/500], P < 0.001; PNDABLE: 2.40 % [4/164] vs 34.60 % [164/474], P < 0.001). Mediation analysis showed that the protective effect of preoperative COVID-19 vaccine on POD was significantly mediated by CSF Abeta42 (proportion = 17.56 %), T-tau (proportion = 19.64 %), Abeta42/T-tau (proportion = 29.67 %), and Abeta42/P-tau (proportion = 12.26 %). CONCLUSIONS: COVID-19 vaccine is a protective factor for POD in old patients, which is associated with CSF biomarkers. CI - (c) 2024 Published by Elsevier Ltd. FAU - Zhang, Haoran AU - Zhang H AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Zhang, Aihua AU - Zhang A AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Lin, Yanan AU - Lin Y AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Li, Chuan AU - Li C AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Yang, Yunchao AU - Yang Y AD - Department of Anesthesiology, Qingdao University Medical College, Qingdao, Shandong, China. FAU - Dong, Rui AU - Dong R AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Lin, Xu AU - Lin X AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Wang, Bin AU - Wang B AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. FAU - Bi, Yanlin AU - Bi Y AD - Department of Anesthesiology, Qingdao Municipal Hospital, Qingdao, Shandong, China. LA - eng PT - Journal Article DEP - 20240507 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC11137356 OTO - NOTNLM OT - COVID-19 vaccine OT - CSF biomarkers OT - Mediation analysis OT - Perioperative neurocognitive disorders OT - Postoperative delirium COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/05/31 06:41 MHDA- 2024/05/31 06:42 PMCR- 2024/05/07 CRDT- 2024/05/31 03:57 PHST- 2023/11/16 00:00 [received] PHST- 2024/04/22 00:00 [revised] PHST- 2024/04/25 00:00 [accepted] PHST- 2024/05/31 06:42 [medline] PHST- 2024/05/31 06:41 [pubmed] PHST- 2024/05/31 03:57 [entrez] PHST- 2024/05/07 00:00 [pmc-release] AID - S2405-8440(24)06445-4 [pii] AID - e30414 [pii] AID - 10.1016/j.heliyon.2024.e30414 [doi] PST - epublish SO - Heliyon. 2024 May 7;10(10):e30414. doi: 10.1016/j.heliyon.2024.e30414. eCollection 2024 May 30. PMID- 38806183 OWN - NLM STAT- MEDLINE DCOM- 20241128 LR - 20241129 IS - 1460-2393 (Electronic) IS - 1460-2393 (Linking) VI - 117 IP - 10 DP - 2024 Oct 1 TI - A potential association between COVID-19 vaccination and development of Alzheimer's disease. PG - 709-716 LID - 10.1093/qjmed/hcae103 [doi] AB - BACKGROUND: The challenges of the COVID-19 pandemic extend to concerns about vaccine side effects, particularly potential links to neurodegenerative diseases such as Alzheimer's disease (AD). AIM: This study investigates the association between COVID-19 vaccination and the onset of AD and its prodromal state, mild cognitive impairment (MCI). DESIGN: A nationwide, retrospective cohort study leveraging data from the Korean National Health Insurance Service was conducted. METHODS: The study, conducted in Seoul, South Korea, analyzed data from a random 50% sample of city residents aged 65 and above, totaling 558 017 individuals. Participants were divided into vaccinated and unvaccinated groups, with vaccinations including mRNA and cDNA vaccines. The study focused on AD and MCI incidences post-vaccination, identified via ICD-10 codes, using multivariable logistic and Cox regression analyses. Patients with vascular dementia or Parkinson's disease served as controls. RESULTS: Findings showed an increased incidence of MCI and AD in vaccinated individuals, particularly those receiving mRNA vaccines, within three months post-vaccination. The mRNA vaccine group exhibited a significantly higher incidence of AD (odds ratio [OR]: 1.225; 95% confidence interval [CI]: 1.025-1.464; P = 0.026) and MCI (OR: 2.377; CI: 1.845-3.064; P < 0.001) compared to the unvaccinated group. No significant relationship was found with vascular dementia or Parkinson's disease. CONCLUSIONS: Preliminary evidence suggests a potential link between COVID-19 vaccination, particularly mRNA vaccines, and increased incidences of AD and MCI. This warrants the need for further research to elucidate the relationship between vaccine-induced immune responses and neurodegenerative processes, advocating for continuous monitoring and investigation into the vaccines' long-term neurological impacts. CI - (c) The Author(s) 2024. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Roh, Jee Hoon AU - Roh JH AUID- ORCID: 0000-0002-3243-0529 AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Neurology, Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Jung, Inha AU - Jung I AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. FAU - Suh, Yunsun AU - Suh Y AD - Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea. AD - Department of Physiology, Korea University College of Medicine, Seoul, Republic of Korea. AD - Steinhardt School of Culture, Education, and Human Development, New York University, New York, NY, USA. FAU - Kim, Min-Ho AU - Kim MH AD - Informatization Department, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea. LA - eng GR - RS-2023-00220894/National Research Foundation/ GR - Korea Dementia Research/ GR - Korea Dementia Research Center/ GR - HU21C0066/Ministry of Health & Welfare and Ministry of Science and ICT/ GR - K2123751/Korea University/ GR - Republic of Korea/ PT - Journal Article PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - Aged, 80 and over MH - Female MH - Humans MH - Male MH - *Alzheimer Disease/epidemiology MH - *Cognitive Dysfunction/epidemiology/etiology MH - *COVID-19/prevention & control/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - Incidence MH - Republic of Korea/epidemiology MH - Retrospective Studies MH - Vaccination/adverse effects EDAT- 2024/05/29 00:49 MHDA- 2024/11/29 05:20 CRDT- 2024/05/28 20:34 PHST- 2024/03/02 00:00 [received] PHST- 2024/05/06 00:00 [revised] PHST- 2024/11/29 05:20 [medline] PHST- 2024/05/29 00:49 [pubmed] PHST- 2024/05/28 20:34 [entrez] AID - 7684274 [pii] AID - 10.1093/qjmed/hcae103 [doi] PST - ppublish SO - QJM. 2024 Oct 1;117(10):709-716. doi: 10.1093/qjmed/hcae103. PMID- 38803830 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240529 IS - 1664-1078 (Print) IS - 1664-1078 (Electronic) IS - 1664-1078 (Linking) VI - 15 DP - 2024 TI - Wilson Disease and the COVID-19 pandemic: exploring patients' mental health and vaccination attitudes in a longitudinal study. PG - 1326802 LID - 10.3389/fpsyg.2024.1326802 [doi] LID - 1326802 AB - INTRODUCTION: The COVID-19 pandemic significantly impacted the mental health of individuals with chronic conditions such as Wilson's Disease (WD). This study investigates stress, anxiety, depression, quality of life, cognitive function, vaccination rates, infection rates, and perceptions related to the pandemic and vaccines among WD patients. METHODS: The study analyzed COVID-19 perceptions and vaccine attitudes of 62 adult WD patients enrolled in the international multisite WD Registry. A subgroup of 33 participants completed a series of mental health scales. The effect of working essentially, income loss, wellness activity initiation, and infection of COVID-19 during the pandemic was observed. RESULTS: Results indicate that, overall, the pandemic did not exacerbate anxiety or cognitive function in WD patients but did lead to increased depression among essential workers. Patients experiencing income loss exhibited higher levels of stress and anxiety. Despite these challenges, WD patients showed high vaccination rates and positive attitudes towards vaccines. DISCUSSION: The findings underscore the significant impact of the pandemic on the mental health of WD patients. CI - Copyright (c) 2024 Coskun, Aydin, Tosun, To, Rubman, Schilsky and Zimbrean. FAU - Coskun, Ayse K AU - Coskun AK AD - Department of Surgery, Yale University School of Medicine, New Haven, CT, United States. FAU - Aydin, Adem AU - Aydin A AD - Department of Surgery, Yale University School of Medicine, New Haven, CT, United States. FAU - Tosun, Sumeyra AU - Tosun S AD - Medgar Evers College, CUNY, Brooklyn, NY, United States. FAU - To, Uyen AU - To U AD - Medicine and Surgery, Yale University School of Medicine, New Haven, CT, United States. FAU - Rubman, Susan AU - Rubman S AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. FAU - Schilsky, Michael L AU - Schilsky ML AD - Medicine and Surgery, Yale University School of Medicine, New Haven, CT, United States. FAU - Zimbrean, Paula C AU - Zimbrean PC AD - Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States. LA - eng PT - Journal Article DEP - 20240513 PL - Switzerland TA - Front Psychol JT - Frontiers in psychology JID - 101550902 PMC - PMC11129684 OTO - NOTNLM OT - COVID-19 OT - Wilson Disease OT - cognitive functions OT - mental health OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/05/28 06:43 MHDA- 2024/05/28 06:44 PMCR- 2024/05/13 CRDT- 2024/05/28 03:46 PHST- 2023/10/23 00:00 [received] PHST- 2024/04/29 00:00 [accepted] PHST- 2024/05/28 06:44 [medline] PHST- 2024/05/28 06:43 [pubmed] PHST- 2024/05/28 03:46 [entrez] PHST- 2024/05/13 00:00 [pmc-release] AID - 10.3389/fpsyg.2024.1326802 [doi] PST - epublish SO - Front Psychol. 2024 May 13;15:1326802. doi: 10.3389/fpsyg.2024.1326802. eCollection 2024. PMID- 38789939 OWN - NLM STAT- MEDLINE DCOM- 20240525 LR - 20261020 IS - 1471-2318 (Electronic) IS - 1471-2318 (Linking) VI - 24 IP - 1 DP - 2024 May 24 TI - Modeling mortality prediction in older adults with dementia receiving COVID-19 vaccination. PG - 454 LID - 10.1186/s12877-024-04982-7 [doi] LID - 454 AB - OBJECTIVE: This study compared COVID-19 outcomes between vaccinated and unvaccinated older adults with and without cognitive impairment. METHOD: Electronic health records from Israel from March 2020-February 2022 were analyzed for a large cohort (N = 85,288) aged 65 + . Machine learning constructed models to predict mortality risk from patient factors. Outcomes examined were COVID-19 mortality and hospitalization post-vaccination. RESULTS: Our study highlights the significant reduction in mortality risk among older adults with cognitive disorders following COVID-19 vaccination, showcasing a survival rate improvement to 93%. Utilizing machine learning for mortality prediction, we found the XGBoost model, enhanced with inverse probability of treatment weighting, to be the most effective, achieving an AUC-PR value of 0.89. This underscores the importance of predictive analytics in identifying high-risk individuals, emphasizing the critical role of vaccination in mitigating mortality and supporting targeted healthcare interventions. CONCLUSIONS: COVID-19 vaccination strongly reduced poor outcomes in older adults with cognitive impairment. Predictive analytics can help identify highest-risk cases requiring targeted interventions. CI - (c) 2024. The Author(s). FAU - Radomyslsky, Zorian AU - Radomyslsky Z AD - Maccabi Healthcare Services, 6812509, Tel Aviv-Jaffa, Israel. radomysl_z@mac.org.il. AD - Ariel University, School of Health Sciences, Ariel, Israel. radomysl_z@mac.org.il. FAU - Kivity, Sara AU - Kivity S AD - Maccabi Healthcare Services, 6812509, Tel Aviv-Jaffa, Israel. dejav_s@mac.org.il. FAU - Alon, Yaniv AU - Alon Y AD - Nursing Department, School of Health Professions, Faculty of Medical & Health Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel. FAU - Saban, Mor AU - Saban M AD - Nursing Department, School of Health Professions, Faculty of Medical & Health Sciences, Tel Aviv University, Ramat Aviv, Tel Aviv, 69978, Israel. LA - eng PT - Journal Article DEP - 20240524 PL - England TA - BMC Geriatr JT - BMC geriatrics JID - 100968548 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/prevention & control/mortality/epidemiology MH - Male MH - Female MH - *COVID-19 Vaccines/administration & dosage MH - Israel/epidemiology MH - Aged, 80 and over MH - *Dementia/mortality MH - *Machine Learning MH - Vaccination MH - Hospitalization/trends MH - Cohort Studies MH - Cognitive Dysfunction/epidemiology PMC - PMC11127399 OTO - NOTNLM OT - COVID-19 vaccination OT - Cognitive impairment OT - Mortality OT - Older adults OT - Predictive analytics COIS- The authors declare no competing interests. EDAT- 2024/05/25 05:43 MHDA- 2024/05/25 10:54 PMCR- 2024/05/24 CRDT- 2024/05/24 23:44 PHST- 2023/10/21 00:00 [received] PHST- 2024/04/16 00:00 [accepted] PHST- 2024/05/25 10:54 [medline] PHST- 2024/05/25 05:43 [pubmed] PHST- 2024/05/24 23:44 [entrez] PHST- 2024/05/24 00:00 [pmc-release] AID - 10.1186/s12877-024-04982-7 [pii] AID - 4982 [pii] AID - 10.1186/s12877-024-04982-7 [doi] PST - epublish SO - BMC Geriatr. 2024 May 24;24(1):454. doi: 10.1186/s12877-024-04982-7. PMID- 38687984 OWN - NLM STAT- MEDLINE DCOM- 20240430 LR - 20250513 IS - 2369-2960 (Electronic) IS - 2369-2960 (Linking) VI - 10 DP - 2024 Apr 30 TI - Defining the Subtypes of Long COVID and Risk Factors for Prolonged Disease: Population-Based Case-Crossover Study. PG - e49841 LID - 10.2196/49841 [doi] LID - e49841 AB - BACKGROUND: There have been over 772 million confirmed cases of COVID-19 worldwide. A significant portion of these infections will lead to long COVID (post-COVID-19 condition) and its attendant morbidities and costs. Numerous life-altering complications have already been associated with the development of long COVID, including chronic fatigue, brain fog, and dangerous heart rhythms. OBJECTIVE: We aim to derive an actionable long COVID case definition consisting of significantly increased signs, symptoms, and diagnoses to support pandemic-related clinical, public health, research, and policy initiatives. METHODS: This research employs a case-crossover population-based study using International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) data generated at Veterans Affairs medical centers nationwide between January 1, 2020, and August 18, 2022. In total, 367,148 individuals with ICD-10-CM data both before and after a positive COVID-19 test were selected for analysis. We compared ICD-10-CM codes assigned 1 to 7 months following each patient's positive test with those assigned up to 6 months prior. Further, 350,315 patients had novel codes assigned during this window of time. We defined signs, symptoms, and diagnoses as being associated with long COVID if they had a novel case frequency of >/=1:1000, and they significantly increased in our entire cohort after a positive test. We present odds ratios with CIs for long COVID signs, symptoms, and diagnoses, organized by ICD-10-CM functional groups and medical specialty. We used our definition to assess long COVID risk based on a patient's demographics, Elixhauser score, vaccination status, and COVID-19 disease severity. RESULTS: We developed a long COVID definition consisting of 323 ICD-10-CM diagnosis codes grouped into 143 ICD-10-CM functional groups that were significantly increased in our 367,148 patient post-COVID-19 population. We defined 17 medical-specialty long COVID subtypes such as cardiology long COVID. Patients who were COVID-19-positive developed signs, symptoms, or diagnoses included in our long COVID definition at a proportion of at least 59.7% (268,320/449,450, based on a denominator of all patients who were COVID-19-positive). The long COVID cohort was 8 years older with more comorbidities (2-year Elixhauser score 7.97 in the patients with long COVID vs 4.21 in the patients with non-long COVID). Patients who had a more severe bout of COVID-19, as judged by their minimum oxygen saturation level, were also more likely to develop long COVID. CONCLUSIONS: An actionable, data-driven definition of long COVID can help clinicians screen for and diagnose long COVID, allowing identified patients to be admitted into appropriate monitoring and treatment programs. This long COVID definition can also support public health, research, and policy initiatives. Patients with COVID-19 who are older or have low oxygen saturation levels during their bout of COVID-19, or those who have multiple comorbidities should be preferentially watched for the development of long COVID. CI - (c)Skyler Resendez, Steven H Brown, Hugo Sebastian Ruiz Ayala, Prahalad Rangan, Jonathan Nebeker, Diane Montella, Peter L Elkin. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 30.04.2024. FAU - Resendez, Skyler AU - Resendez S AUID- ORCID: 0000-0002-0422-2335 AD - Department of Biomedical Informatics, University at Buffalo, State University of New York, Buffalo, NY, United States. FAU - Brown, Steven H AU - Brown SH AUID- ORCID: 0000-0001-6103-1845 AD - Office of Health Informatics, Department of Veterans Affairs, Washington, DC, United States. FAU - Ruiz Ayala, Hugo Sebastian AU - Ruiz Ayala HS AUID- ORCID: 0009-0006-9458-1177 AD - Department of Biomedical Informatics, University at Buffalo, State University of New York, Buffalo, NY, United States. FAU - Rangan, Prahalad AU - Rangan P AUID- ORCID: 0009-0001-3095-7255 AD - Department of Biomedical Informatics, University at Buffalo, State University of New York, Buffalo, NY, United States. FAU - Nebeker, Jonathan AU - Nebeker J AUID- ORCID: 0000-0001-5355-5008 AD - Office of Health Informatics, Department of Veterans Affairs, Washington, DC, United States. FAU - Montella, Diane AU - Montella D AUID- ORCID: 0000-0001-9396-8798 AD - Office of Health Informatics, Department of Veterans Affairs, Washington, DC, United States. FAU - Elkin, Peter L AU - Elkin PL AUID- ORCID: 0000-0001-9616-6811 AD - Department of Biomedical Informatics, University at Buffalo, State University of New York, Buffalo, NY, United States. AD - Office of Health Informatics, Department of Veterans Affairs, Washington, DC, United States. LA - eng GR - R21 AA026954/AA/NIAAA NIH HHS/United States GR - R25 LM014213/LM/NLM NIH HHS/United States GR - T15 LM012495/LM/NLM NIH HHS/United States GR - UL1 TR001412/TR/NCATS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20240430 PL - Canada TA - JMIR Public Health Surveill JT - JMIR public health and surveillance JID - 101669345 SB - IM MH - Humans MH - *COVID-19/epidemiology/complications MH - Risk Factors MH - Male MH - *Post-Acute COVID-19 Syndrome MH - Female MH - *Cross-Over Studies MH - Middle Aged MH - United States/epidemiology MH - Aged MH - International Classification of Diseases MH - Adult PMC - PMC11094603 OTO - NOTNLM OT - COVID-19 OT - COVID-19 testing OT - COVID-19 treatment OT - PASC OT - United States OT - Veterans Affairs OT - clinician OT - diagnosis OT - health care support OT - long COVID OT - long COVID cause OT - mobile phone OT - pandemic OT - policy initiatives OT - postacute sequelae of COVID-19 OT - public health OT - public safety COIS- Conflicts of Interest: None declared. EDAT- 2024/04/30 18:49 MHDA- 2024/04/30 18:50 PMCR- 2024/04/30 CRDT- 2024/04/30 16:53 PHST- 2023/06/11 00:00 [received] PHST- 2024/02/15 00:00 [accepted] PHST- 2024/01/19 00:00 [revised] PHST- 2024/04/30 18:50 [medline] PHST- 2024/04/30 18:49 [pubmed] PHST- 2024/04/30 16:53 [entrez] PHST- 2024/04/30 00:00 [pmc-release] AID - v10i1e49841 [pii] AID - 10.2196/49841 [doi] PST - epublish SO - JMIR Public Health Surveill. 2024 Apr 30;10:e49841. doi: 10.2196/49841. PMID- 38664729 OWN - NLM STAT- MEDLINE DCOM- 20240426 LR - 20240506 IS - 1471-2393 (Electronic) IS - 1471-2393 (Linking) VI - 24 IP - 1 DP - 2024 Apr 25 TI - Patterns of peripartum depression and anxiety during the pre-vaccine COVID-19 pandemic. PG - 310 LID - 10.1186/s12884-024-06518-8 [doi] LID - 310 AB - BACKGROUND: Pregnant people are vulnerable to new or worsening mental health conditions. This study aims to describe prevalence and course of depression and anxiety symptoms in pregnancy during the pre-vaccine COVID-19 pandemic. METHODS: This is a prospective cohort study of pregnant individuals with known or suspected COVID-19. Participants completed Edinburgh Postnatal Depression Scale (EPDS) and Generalized-Anxiety Disorder-7 (GAD-7) questionnaires, screening tools for depression and anxiety, at 34weeks gestational age, 6-8weeks postpartum, and 6months postpartum. Prevalence of elevated depressive and anxiety symptoms at each visit was described. Univariable logistic regression analysis was used to determine the association between demographic and clinical factors and those with elevated depression or anxiety symptoms. RESULTS: 317 participants were included. The prevalence of elevated antepartum depression symptoms was 14.6%, 10.3%, and 20.6% at 34weeks gestational age, 6-8weeks postpartum, and 6months postpartum, respectively. The rate of elevated anxiety symptoms was 15.1%, 10.0%, and 17.3% at 34weeks gestational age, 6-8weeks postpartum, and 6months postpartum, respectively. A prior history of depression and/or anxiety (p's < 0.03), as well as higher EPDS and GAD-7 scores at enrollment (p's < 0.04) associated with elevated depression and anxiety symptoms throughout pregnancy and the postpartum period. Quarantining during pregnancy was associated with elevated anxiety symptoms at 34weeks gestational age in univariate (P = 0.027) analyses. COVID-19 diagnosis and hospitalization were not associated with elevated depression or anxiety symptoms. CONCLUSIONS: Elevated depression and anxiety symptoms were prevalent throughout pregnancy and the postpartum period, particularly in those with prior depression and/or anxiety and who quarantined. Strategies that target social isolation may mitigate potential adverse consequences for pregnant people, and continued vigilance in recognition of depression and anxiety in pregnancy should be considered. CI - (c) 2024. The Author(s). FAU - Altendahl, Marie R AU - Altendahl MR AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California, 200 Medical Plaza, Suite 430, Los Angeles, CA, 90095, USA. AD - David Geffen School of Medicine, University of California, Los Angeles, CA, USA. FAU - Xu, Liwen AU - Xu L AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California, 200 Medical Plaza, Suite 430, Los Angeles, CA, 90095, USA. FAU - Asiodu, Ifeyinwa AU - Asiodu I AD - Department of Family Health Care Nursing, University of California, San Francisco, CA, USA. FAU - Boscardin, W John AU - Boscardin WJ AD - Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA. AD - Department of Medicine, University of California, San Francisco, CA, USA. FAU - Gaw, Stephanie L AU - Gaw SL AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA, USA. FAU - Flaherman, Valerie J AU - Flaherman VJ AD - Department of Pediatrics, University of California, San Francisco, CA, USA. FAU - Jacoby, Vanessa L AU - Jacoby VL AD - Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA, USA. FAU - Richards, Misty C AU - Richards MC AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California, 200 Medical Plaza, Suite 430, Los Angeles, CA, 90095, USA. AD - David Geffen School of Medicine, University of California, Los Angeles, CA, USA. AD - Division of Child and Adolescent Psychiatry, University of California, Los Angeles, CA, USA. FAU - Krakow, Deborah AU - Krakow D AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California, 200 Medical Plaza, Suite 430, Los Angeles, CA, 90095, USA. AD - David Geffen School of Medicine, University of California, Los Angeles, CA, USA. AD - Department of Human Genetics, University of California, Los Angeles, CA, USA. AD - Department of Orthopaedic Surgery, University of California, Los Angeles, CA, USA. FAU - Afshar, Yalda AU - Afshar Y AD - Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of California, 200 Medical Plaza, Suite 430, Los Angeles, CA, 90095, USA. yafshar@mednet.ucla.edu. AD - David Geffen School of Medicine, University of California, Los Angeles, CA, USA. yafshar@mednet.ucla.edu. LA - eng GR - UL1 TR000004/TR/NCATS NIH HHS/United States PT - Journal Article DEP - 20240425 PL - England TA - BMC Pregnancy Childbirth JT - BMC pregnancy and childbirth JID - 100967799 SB - IM UOF - Res Sq. 2022 Dec 13:rs.3.rs-2294673. doi: 10.21203/rs.3.rs-2294673/v1. PMID: 36561172 MH - Humans MH - Female MH - Pregnancy MH - *COVID-19/psychology/epidemiology/prevention & control MH - Adult MH - *Depression/epidemiology/psychology MH - Prospective Studies MH - *Anxiety/epidemiology MH - *Peripartum Period/psychology MH - Prevalence MH - SARS-CoV-2 MH - Pregnancy Complications/psychology/epidemiology MH - Psychiatric Status Rating Scales MH - Depression, Postpartum/epidemiology PMC - PMC11044399 OTO - NOTNLM OT - Anxiety OT - COVID-19 OT - Depression OT - Maternal mental health OT - Pregnancy COIS- The authors declare no competing interests. EDAT- 2024/04/26 00:51 MHDA- 2024/04/26 07:25 PMCR- 2024/04/25 CRDT- 2024/04/25 23:50 PHST- 2022/11/20 00:00 [received] PHST- 2024/04/15 00:00 [accepted] PHST- 2024/04/26 07:25 [medline] PHST- 2024/04/26 00:51 [pubmed] PHST- 2024/04/25 23:50 [entrez] PHST- 2024/04/25 00:00 [pmc-release] AID - 10.1186/s12884-024-06518-8 [pii] AID - 6518 [pii] AID - 10.1186/s12884-024-06518-8 [doi] PST - epublish SO - BMC Pregnancy Childbirth. 2024 Apr 25;24(1):310. doi: 10.1186/s12884-024-06518-8. PMID- 38592016 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240411 IS - 2077-0383 (Print) IS - 2077-0383 (Electronic) IS - 2077-0383 (Linking) VI - 13 IP - 5 DP - 2024 Feb 21 TI - Long-COVID Prevalence and Its Association with Health Outcomes in the Post-Vaccine and Antiviral-Availability Era. LID - 10.3390/jcm13051208 [doi] LID - 1208 AB - Background and Objectives: After recovering from COVID-19, patients may experience persistent symptoms, known as post-COVID-19 syndrome or long COVID, which include a range of continuing health problems. This research explores the prevalence, associated factors, and overall health outcomes of long COVID during a period of extensive vaccination and antiviral treatment availability in Thailand. Materials and Methods: This observational study involved 390 adult patients with COVID-19 between January and March 2022. Beginning three months after their diagnosis, these patients were interviewed via telephone every three months for a period of one year. The data collection process included gathering demographic information and administering a standardized questionnaire that addressed the patients' physical condition following COVID-19, their mental health, sleep disturbances, and overall quality of life. Results: The cohort consisted of 390 participants, with an average age of 31.8 +/- 13.6. Among them, 96.7% (n = 377) were vaccinated, and 98.2% (n = 383) underwent antiviral treatment. Long-COVID prevalence was observed at 77.7%, with the most frequently reported symptoms being fatigue (64.1%) and cough (43.9%). Regarding mental health, depression was reported by 8.2% of the participants, anxiety by 4.1%, and poor sleep quality by 33.3%. Advanced statistical analysis using multivariable logistic regression showed significant links between long-COVID symptoms and patients aged below 60 (p = 0.042), as well as the initial symptom of cough (p = 0.045). In the subset of long-COVID sufferers, there was a notable correlation in females with symptoms such as headaches (p = 0.001), dizziness (p = 0.007), and brain fog (p = 0.013). Conclusions: Despite the extensive distribution of vaccines and antiviral therapies, the prevalence of long COVID remains high, being associated particularly with individuals under 60 and those exhibiting a cough as an early symptom. The study further reveals that mental health issues related to long COVID are profound, going beyond the scope of physical symptomatology. FAU - Jangnin, Ramida AU - Jangnin R AD - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Ritruangroj, Worraya AU - Ritruangroj W AD - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Kittisupkajorn, Sirada AU - Kittisupkajorn S AD - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Sukeiam, Pattarapa AU - Sukeiam P AD - Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Inchai, Juthamas AU - Inchai J AUID- ORCID: 0000-0001-5497-7704 AD - Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Maneeton, Benchalak AU - Maneeton B AUID- ORCID: 0000-0001-6125-6489 AD - Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Maneetorn, Narong AU - Maneetorn N AD - Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Chaiard, Jindarat AU - Chaiard J AUID- ORCID: 0000-0001-7722-1619 AD - Faculty of Nursing, Chiang Mai University, Chiang Mai 50200, Thailand. FAU - Theerakittikul, Theerakorn AU - Theerakittikul T AUID- ORCID: 0000-0001-6182-6218 AD - Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. AD - Sleep Disorder Center, Center for Medical Excellence, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. LA - eng GR - COV11/2565/Faculty of medicine, Chiang Mai University/ PT - Journal Article DEP - 20240221 PL - Switzerland TA - J Clin Med JT - Journal of clinical medicine JID - 101606588 PMC - PMC10931928 OTO - NOTNLM OT - COVID-19 OT - health impact OT - long COVID OT - post-vaccinated OT - quality of life COIS- The authors declare no conflict of interest. EDAT- 2024/04/09 12:44 MHDA- 2024/04/09 12:45 PMCR- 2024/02/21 CRDT- 2024/04/09 10:13 PHST- 2024/01/16 00:00 [received] PHST- 2024/02/07 00:00 [revised] PHST- 2024/02/10 00:00 [accepted] PHST- 2024/04/09 12:45 [medline] PHST- 2024/04/09 12:44 [pubmed] PHST- 2024/04/09 10:13 [entrez] PHST- 2024/02/21 00:00 [pmc-release] AID - jcm13051208 [pii] AID - jcm-13-01208 [pii] AID - 10.3390/jcm13051208 [doi] PST - epublish SO - J Clin Med. 2024 Feb 21;13(5):1208. doi: 10.3390/jcm13051208. PMID- 38580808 OWN - NLM STAT- MEDLINE DCOM- 20250512 LR - 20260724 IS - 2196-8837 (Electronic) IS - 2197-3792 (Print) IS - 2196-8837 (Linking) VI - 12 IP - 3 DP - 2025 Jun TI - Survival Analysis and Socio-Cognitive Factors in the Timing of COVID-19 Vaccination Among Mexican-Origin Youth. PG - 1630-1640 LID - 10.1007/s40615-024-01995-1 [doi] AB - OBJECTIVE: The COVID-19 pandemic disproportionately affected ethnic minority populations and exacerbated preexisting health disparities. The current study aims to promote vaccine uptake among Mexican-origin youth from immigrant families by examining their time to COVID-19 vaccine uptake and assessing the influence of demographic, cognitive, and social factors on the incidence of COVID-19 vaccination. METHODS: The study conducted Survival Analysis using a Cox proportional hazards model based on a sample of 202 Mexican-origin youth (61.39% female; M(age) = 20.41) with data collected from August 2021 to January 2023 in central Texas. RESULTS: The results show a critical time period for vaccine uptake (i.e., in the first six months after the vaccines were publicly available), evidenced by a surge decrease in COVID-19 unvaccination probability. In addition, more positive attitudes toward the COVID-19 vaccine (Hazard ratio/HR = 1.89, 95% Confidence Interval/CI = [1.64, 2.18]), greater motivation (HR = 2.29, 95% CI = [1.85, 2.85]), higher education levels (HR = 1.52, 95% CI = [1.24, 1.86]), and fewer general barriers to COVID-19 vaccine knowledge (HR = 0.75, 95% CI = [0.60, 0.94]) were associated with greater incidences of receiving COVID-19 vaccines at any given time point during the pandemic. CONCLUSION: The findings suggest that COVID-19 vaccine uptake among Mexican-origin youth occurred primarily within the initial months of vaccines being publicly distributed. To encourage vaccination among Mexican-origin youth, sustained COVID-19 vaccine promotion efforts are needed by targeting their motivation and positive attitudes and reducing barriers to vaccine information, particularly for youth with lower education levels. CI - (c) 2024. W. Montague Cobb-NMA Health Institute. FAU - Kim, Su Yeong AU - Kim SY AUID- ORCID: 0000-0001-9222-2505 AD - Department of Human Development and Family Sciences, The University of Texas at Austin, Austin, TX, USA. su.yeong.kim@utexas.edu. FAU - Wen, Wen AU - Wen W AUID- ORCID: 0000-0002-4575-1057 AD - Department of Human Development and Family Sciences, The University of Texas at Austin, Austin, TX, USA. FAU - Coulter, Kiera M AU - Coulter KM AUID- ORCID: 0000-0002-8111-4952 AD - Population Research Center, The University of Texas at Austin, Austin, TX, USA. FAU - Du, Yayu AU - Du Y AUID- ORCID: 0009-0003-1767-8539 AD - Department of Human Development and Family Sciences, The University of Texas at Austin, Austin, TX, USA. FAU - Tse, Hin Wing AU - Tse HW AUID- ORCID: 0000-0003-2781-1279 AD - Department of Human Development and Family Sciences, The University of Texas at Austin, Austin, TX, USA. FAU - Hou, Yang AU - Hou Y AUID- ORCID: 0000-0002-7360-5751 AD - Department of Behavioral Sciences and Social Medicine, Florida State University, Tallahassee, FL, USA. FAU - Chen, Shanting AU - Chen S AUID- ORCID: 0000-0003-3390-2513 AD - Department of Psychology, University of Florida, Gainesville, FL, USA. FAU - Shen, Yishan AU - Shen Y AUID- ORCID: 0000-0002-4068-828X AD - School of Family and Consumer Sciences, Texas State University, San Marcos, TX, USA. LA - eng GR - T32 HD007081/HD/NICHD NIH HHS/United States GR - P2C HD042849/HD/NICHD NIH HHS/United States GR - R24 HD042849/HD/NICHD NIH HHS/United States GR - 1R21MD012706-01A1/MD/NIMHD NIH HHS/United States GR - R03 HD060045/HD/NICHD NIH HHS/United States GR - 3R21MD-012706-02S1/MD/NIMHD NIH HHS/United States GR - R21 MD012706/MD/NIMHD NIH HHS/United States GR - 1651128/Division of Behavioral and Cognitive Sciences/ GR - 0956123/Division of Behavioral and Cognitive Sciences/ GR - 1R21MD012706-01A1/MD/NIMHD NIH HHS/United States GR - 3R21MD-012706-02S1/MD/NIMHD NIH HHS/United States GR - 5R03HD060045-02/Eunice Kennedy Shriver National Institute of Child Health and Human Development/ GR - 5P2CHD042849-20/Eunice Kennedy Shriver National Institute of Child Health and Human Development/ GR - T32HD007081-45/Eunice Kennedy Shriver National Institute of Child Health and Human Development/ GR - 2699/Russell Sage Foundation/ GR - 10023427/Spencer Foundation/ GR - JRG-102/Hogg Foundation for Mental Health/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240405 PL - Switzerland TA - J Racial Ethn Health Disparities JT - Journal of racial and ethnic health disparities JID - 101628476 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Female MH - Humans MH - Male MH - Young Adult MH - *COVID-19/ethnology/mortality/prevention & control MH - *COVID-19 Vaccines/administration & dosage MH - Health Knowledge, Attitudes, Practice/ethnology MH - *Mexican Americans/statistics & numerical data/psychology MH - Proportional Hazards Models MH - Survival Analysis MH - Texas/epidemiology/ethnology MH - Time Factors MH - *Vaccination/statistics & numerical data/psychology PMC - PMC11984467 MID - NIHMS2068095 OTO - NOTNLM OT - COVID-19 OT - Mexican-origin OT - Survival analysis OT - Vaccine OT - Youth COIS- Declarations. Ethical Approval: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board at the University of Texas at Austin, protocol number 2015-01-0006. Consent to Participate: Informed consent was obtained from all individual participants included in the study. Competing Interests: The authors report there are no competing interests to declare. EDAT- 2024/04/06 00:42 MHDA- 2025/05/12 12:34 PMCR- 2025/06/01 CRDT- 2024/04/05 23:27 PHST- 2023/11/07 00:00 [received] PHST- 2024/03/27 00:00 [accepted] PHST- 2024/03/02 00:00 [revised] PHST- 2025/05/12 12:34 [medline] PHST- 2024/04/06 00:42 [pubmed] PHST- 2024/04/05 23:27 [entrez] PHST- 2025/06/01 00:00 [pmc-release] AID - 10.1007/s40615-024-01995-1 [pii] AID - 10.1007/s40615-024-01995-1 [doi] PST - ppublish SO - J Racial Ethn Health Disparities. 2025 Jun;12(3):1630-1640. doi: 10.1007/s40615-024-01995-1. Epub 2024 Apr 5. PMID- 38574425 OWN - NLM STAT- MEDLINE DCOM- 20240416 LR - 20240416 IS - 1476-5616 (Electronic) IS - 0033-3506 (Linking) VI - 230 DP - 2024 May TI - Risk factors and early preventive measures for long COVID in non-hospitalized patients: analysis of a large cohort in the United Arab Emirates. PG - 198-206 LID - S0033-3506(24)00102-1 [pii] LID - 10.1016/j.puhe.2024.02.031 [doi] AB - OBJECTIVES: Long COVID is characterized by persistent symptoms lasting for 4 weeks or more following the acute infection with SARS-CoV-2. Risk factors for long COVID and the impact of pre-COVID vaccination and treatment during acute COVID-19 remain uncertain. This study aimed to investigate patient-specific factors associated with long COVID in a large cohort of non-hospitalized adult patients with mild to moderate COVID-19 in Dubai. STUDY DESIGN: Cohort study. METHODS: The study included 28,375 non-hospitalized adult patients diagnosed with mild to moderate COVID-19 between January 1, 2021, and September 31, 2022, in Dubai, who were followed up for 90 days. The presence of long COVID symptoms was documented by physicians during patient visits to the family medicine department. Furthermore, long COVID-related risk factors were collected and analyzed, including patient demographics, comorbidities, pre-COVID vaccination status, and the COVID-related treatments received during the acute phase of the illness. Cox proportional hazard models were applied for the statistical analysis. RESULTS: Among the cohort, 2.8% of patients experienced long COVID symptoms during the 90-day follow-up. Patients with long COVID tended to be younger, female, and of Caucasian race. Common symptoms included fatigue, muscle pain, respiratory symptoms, abdominal and neurological symptoms, allergic reactions, skin rashes, and hair loss. Risk factors for long COVID were identified as diabetes mellitus, asthma, and Vitamin D deficiency. Females and Caucasians had a higher risk of long COVID during the pre-Omicron period compared to the Omicron period. Pre-COVID vaccination was associated with a reduced risk of long COVID in all patient subgroups. Treatment with favipiravir or sotrovimab during the acute phase of COVID-19 was linked to a decreased risk of long COVID, although favipiravir showed limited effectiveness in the high-risk group. CONCLUSION: This study contributes to the existing knowledge by identifying risk factors for long COVID among non-hospitalized patients and emphasizing the potential benefits of pre-COVID vaccination and timely treatment. CI - Copyright (c) 2024 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved. FAU - Saheb Sharif-Askari, Fatemeh AU - Saheb Sharif-Askari F AD - Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates. FAU - Ali Hussain Alsayed, Hawra AU - Ali Hussain Alsayed H AD - Department of Pharmacy, Rashid Hospital, Dubai Academic Health Corporation, Dubai, United Arab Emirates. FAU - Saheb Sharif-Askari, Narjes AU - Saheb Sharif-Askari N AD - Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Saddik, Basema AU - Saddik B AD - Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Family and Community Medicine, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; School of Population Health, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia. FAU - Al Sayed Hussain, Ali AU - Al Sayed Hussain A AD - Department of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab Emirates. FAU - Halwani, Rabih AU - Halwani R AD - Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates; Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Saudi Arabia. Electronic address: rhalwani@sharjah.ac.ae. LA - eng PT - Journal Article DEP - 20240403 PL - Netherlands TA - Public Health JT - Public health JID - 0376507 RN - EW5GL2X7E0 (favipiravir) RN - 0 (Amides) RN - 0 (Pyrazines) SB - IM MH - Adult MH - Humans MH - Female MH - *Post-Acute COVID-19 Syndrome MH - *COVID-19/epidemiology/prevention & control MH - United Arab Emirates/epidemiology MH - SARS-CoV-2 MH - Cohort Studies MH - Risk Factors MH - *Amides MH - *Pyrazines OTO - NOTNLM OT - Asthma OT - Diabetes OT - Long COVID OT - Pre-COVID vaccine OT - Vitamin D deficiency EDAT- 2024/04/05 00:42 MHDA- 2024/04/16 12:43 CRDT- 2024/04/04 18:05 PHST- 2023/07/06 00:00 [received] PHST- 2024/02/07 00:00 [revised] PHST- 2024/02/29 00:00 [accepted] PHST- 2024/04/16 12:43 [medline] PHST- 2024/04/05 00:42 [pubmed] PHST- 2024/04/04 18:05 [entrez] AID - S0033-3506(24)00102-1 [pii] AID - 10.1016/j.puhe.2024.02.031 [doi] PST - ppublish SO - Public Health. 2024 May;230:198-206. doi: 10.1016/j.puhe.2024.02.031. Epub 2024 Apr 3. PMID- 38549052 OWN - NLM STAT- MEDLINE DCOM- 20240401 LR - 20260318 IS - 1471-2458 (Electronic) IS - 1471-2458 (Linking) VI - 24 IP - 1 DP - 2024 Mar 28 TI - How do people with long COVID utilize COVID-19 vaccination and rehabilitation services and what are their experiences with these services? results of a qualitative study with 48 participants from Germany. PG - 915 LID - 10.1186/s12889-024-18380-6 [doi] LID - 915 AB - BACKGROUND: Studies estimate that at least 7.5% of adults are affected by long-term symptoms such as fatigue or cognitive impairment after the acute phase of COVID-19. COVID-19 vaccination may reduce the risk of long COVID. Rehabilitation can have a positive impact on recovery. This study aims to present the experiences of people with long COVID with COVID-19 vaccination and rehabilitation. Such research is important because perceptions of these measures can impact healthcare utilization and health status. METHODS: 48 adults with long COVID participated in this qualitative study, 25 of them in one-on-one interviews and 23 in focus groups. Participants were recruited via calls for participation on the websites and social media channels of two university hospitals and with the help of respondents' networks. The conversations were audio-recorded, transcribed, and analyzed using qualitative content analysis. Subsequently, the results were compared, interpreted, and discussed by scientific literature. RESULTS: 35 study participants reported that they had received a COVID-19 vaccination and 16 of them stated that they had utilized a rehabilitation service. These participants had varying experiences with COVID-19 vaccination and rehabilitation. Nine of them stated that they developed long COVID despite vaccination before COVID-19. Ten participants reported vaccine reactions, and two participants reported severe side effects. Two participants reported persistent deterioration of their long COVID symptoms after vaccination. This led to uncertainty about the safety, benefits, and handling of COVID-19 vaccination. However, most participants perceived the vaccine as effective regarding milder COVID-19 sequelae. Four participants felt their rehabilitation was helpful and four participants felt it was unhelpful. Two persons found the combination of inpatient rehabilitation and rehabilitation sport helpful. CONCLUSIONS: Several implications can be derived from this study: (1) researchers should explore the effects of COVID-19 vaccination on long COVID symptoms; (2) vaccination campaigns should be more responsive to the perspectives of people with long COVID on vaccination; (3) care planners should build rehabilitation facilities specialized in long COVID; (4) rehabilitation providers should train their professionals regarding long COVID and develop rehabilitation programs tailored to different clinical pictures. TRIAL REGISTRATION: German register for clinical trials DRKS00026007, 09 September 2021. CI - (c) 2024. The Author(s). FAU - Schmachtenberg, Tim AU - Schmachtenberg T AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. tim.schmachtenberg@med.uni-goettingen.de. AD - Department of Rheumatology and Immunology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany. tim.schmachtenberg@med.uni-goettingen.de. FAU - Konigs, Gloria AU - Konigs G AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - Roder, Sascha AU - Roder S AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. AD - Department of Social Work, University of Applied Sciences and Arts Bielefeld, Interaktion 1, 33619, Bielefeld, Germany. FAU - Muller, Frank AU - Muller F AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. AD - Department of Family Medicine, College of Human Medicine, Michigan State University, 15 Michigan St NE, Grand Rapids, 49503, East Lansing, MI, USA. FAU - Mullenmeister, Christina AU - Mullenmeister C AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - Schroder, Dominik AU - Schroder D AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. FAU - El-Sayed, Iman AU - El-Sayed I AD - Department of General Practice, University Medical Center Gottingen, Humboldtallee 38, 37073, Gottingen, Germany. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240328 PL - England TA - BMC Public Health JT - BMC public health JID - 100968562 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - German people SB - IM MH - Adult MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - Vaccination MH - *Vaccines MH - European People PMC - PMC10976759 OTO - NOTNLM OT - COVID-19 vaccination OT - Germany OT - Long COVID OT - Qualitative study OT - Rehabilitation OT - SARS-CoV-2 COIS- The authors declare no competing interests. EDAT- 2024/03/29 06:45 MHDA- 2024/04/01 06:43 PMCR- 2024/03/28 CRDT- 2024/03/29 00:35 PHST- 2023/10/09 00:00 [received] PHST- 2024/03/18 00:00 [accepted] PHST- 2024/04/01 06:43 [medline] PHST- 2024/03/29 06:45 [pubmed] PHST- 2024/03/29 00:35 [entrez] PHST- 2024/03/28 00:00 [pmc-release] AID - 10.1186/s12889-024-18380-6 [pii] AID - 18380 [pii] AID - 10.1186/s12889-024-18380-6 [doi] PST - epublish SO - BMC Public Health. 2024 Mar 28;24(1):915. doi: 10.1186/s12889-024-18380-6. PMID- 38522148 OWN - NLM STAT- MEDLINE DCOM- 20240427 LR - 20250408 IS - 1873-5347 (Electronic) IS - 0277-9536 (Linking) VI - 348 DP - 2024 May TI - One-size fits all? Evaluating group differences in an integrated social cognition model to understand COVID-19 vaccine intention and uptake. PG - 116780 LID - S0277-9536(24)00224-7 [pii] LID - 10.1016/j.socscimed.2024.116780 [doi] AB - Vaccine programs significantly reduce disease burden within a population. The COVID-19 vaccine facilitated a return to "normal"; however, vaccine coverage remains below target levels. Identifying predictors of vaccine uptake is vital for individual and community health. The present study used the Reasoned Action Approach and integrated hazard-specific risk perception, to predict COVID-19 vaccine intention and uptake behavior. Informed by the diffusion of innovations theory, differences in associations and model effects were tested by early adopter status of the seasonal influenza vaccine. We recruited participants online within the United States for a longitudinal survey study. The integrated social cognition model provided an acceptable to ideal fit for both groups but performed better among the not early adopter group with better fit statistics, mostly stronger effect sizes, and greater variance accounted for in intention to vaccinate against COVID-19. Instrumental attitudes toward the COVID-19 vaccine predicted intention for both groups, and uptake among the non-early adopters. Capacity predicted intention among early adopters, and behavior among non-early adopters. Among non-early adopters, subjective norms had a direct effect on intention and an indirect effect on vaccine uptake behavior. Intervention research to support COVID-19 vaccine uptake focusing on the utility of vaccines, fostering self-efficacy, and providing normative information is warranted. CI - Copyright (c) 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Kowalsky, Jennifer M AU - Kowalsky JM AD - Department of Psychology, The Ohio State University, USA. Electronic address: kowalsky.9@osu.edu. FAU - Buelow, Melissa T AU - Buelow MT AD - Department of Psychology, The Ohio State University, USA. FAU - Brunell, Amy B AU - Brunell AB AD - Department of Psychology, The Ohio State University, USA. LA - eng PT - Journal Article DEP - 20240318 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Intention MH - *COVID-19 Vaccines/administration & dosage MH - Male MH - Female MH - *COVID-19/prevention & control/psychology MH - Adult MH - Longitudinal Studies MH - *Social Cognition MH - United States MH - Middle Aged MH - SARS-CoV-2 MH - Health Knowledge, Attitudes, Practice MH - Surveys and Questionnaires OTO - NOTNLM OT - Behavior OT - COVID-19 OT - Early adopter OT - Reasoned action approach OT - Risk perception OT - United States OT - Vaccine COIS- Declaration of competing interest The Authors declare that there is no conflict of interest. EDAT- 2024/03/25 00:42 MHDA- 2024/04/28 07:25 CRDT- 2024/03/24 19:01 PHST- 2023/10/04 00:00 [received] PHST- 2024/03/06 00:00 [revised] PHST- 2024/03/10 00:00 [accepted] PHST- 2024/04/28 07:25 [medline] PHST- 2024/03/25 00:42 [pubmed] PHST- 2024/03/24 19:01 [entrez] AID - S0277-9536(24)00224-7 [pii] AID - 10.1016/j.socscimed.2024.116780 [doi] PST - ppublish SO - Soc Sci Med. 2024 May;348:116780. doi: 10.1016/j.socscimed.2024.116780. Epub 2024 Mar 18. PMID- 38521675 OWN - NLM STAT- MEDLINE DCOM- 20240416 LR - 20250829 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 42 IP - 11 DP - 2024 Apr 19 TI - Exploring associations between the Big Five personality traits and cognitive ability with COVID-19 vaccination hesitancy and uptake among mothers and offspring in a UK prospective cohort study. PG - 2817-2826 LID - S0264-410X(24)00305-0 [pii] LID - 10.1016/j.vaccine.2024.03.018 [doi] AB - BACKGROUND: Vaccines reduce the severity of symptoms, and risk of hospitalisation and death from infectious diseases. Yet, vaccination hesitancy persists. Research identifying psychological risk factors for vaccination hesitancy is limited and reports conflicting results. This study sought to address these inconsistencies and explore the role of personality and cognitive ability in COVID-19 vaccination hesitancy and uptake in a prospective cohort study. METHODS: Data came from young adults (Generation-1; G1) and their mothers (Generation-0; G0) in the Avon Longitudinal Study of Parents and Children (ALSPAC). Multinomial logistic regressions, adjusting for several sociodemographic confounders, were used to explore whether personality and cognitive ability were associated with COVID-19 vaccination hesitancy and uptake. 4,960 G1 and 4,853 G0 mothers were included in the study population. FINDINGS: Among G1, 38.4% exhibited vaccination hesitancy, yet 91.9% of the cohort received the vaccine. In adjusted models, higher levels of openness, agreeableness, conscientiousness, and cognitive ability were associated with an increased probability of wanting the vaccine. Similarly, higher levels of agreeableness, openness and cognitive ability were associated with an increased probability of vaccination uptake. However, the evidence of associations with vaccine uptake were generally weaker than with vaccination hesitancy. 56.7% of the offspring who did not want the vaccine either received the vaccine or intended to, whilst 43.3% still had no intention.Among G0 mothers, 25.6% were vaccination hesitant, yet 99.0% of the cohort received the vaccine. 3.1% said they did not want the vaccine; approximately 80% of these either received the vaccine or intended to. We found inconclusive evidence for an association between cognitive ability and vaccination hesitancy among G0 mothers. INTERPRETATION: This study identified psychological factors associated with vaccination hesitancy and uptake. If these associations are causal, these findings may help design more effective vaccination hesitancy interventions. CI - Copyright (c) 2024. Published by Elsevier Ltd. FAU - Condie, Jennifer AU - Condie J AD - Centre for Trials Research, Cardiff University, Cardiff, Neuadd Meirionnydd CF14 4YS, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK. FAU - Northstone, Kate AU - Northstone K AD - Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK. FAU - Major-Smith, Daniel AU - Major-Smith D AD - Centre for Academic Child Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK. FAU - Halstead, Isaac AU - Halstead I AD - Centre for Academic Child Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, UK. Electronic address: isaac.halstead@bristol.ac.uk. LA - eng GR - 217065/Z/19/Z/UK Medical Research Council/ GR - 217065/Z/19/Z/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240322 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Child MH - Young Adult MH - Humans MH - *COVID-19 Vaccines MH - Longitudinal Studies MH - Prospective Studies MH - Vaccination Hesitancy MH - *COVID-19 MH - Vaccination MH - Cognition MH - Personality MH - United Kingdom OTO - NOTNLM OT - ALSPAC OT - Attitude-behaviour gap OT - Cognitive ability OT - Personality OT - Vaccination hesitancy OT - Vaccination uptake COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/03/24 00:42 MHDA- 2024/04/16 12:42 CRDT- 2024/03/23 23:22 PHST- 2023/09/05 00:00 [received] PHST- 2024/01/17 00:00 [revised] PHST- 2024/03/07 00:00 [accepted] PHST- 2024/04/16 12:42 [medline] PHST- 2024/03/24 00:42 [pubmed] PHST- 2024/03/23 23:22 [entrez] AID - S0264-410X(24)00305-0 [pii] AID - 10.1016/j.vaccine.2024.03.018 [doi] PST - ppublish SO - Vaccine. 2024 Apr 19;42(11):2817-2826. doi: 10.1016/j.vaccine.2024.03.018. Epub 2024 Mar 22. PMID- 38508863 OWN - NLM STAT- MEDLINE DCOM- 20240401 LR - 20241025 IS - 1326-5377 (Electronic) IS - 0025-729X (Linking) VI - 220 IP - 6 DP - 2024 Apr 1 TI - Long COVID in a highly vaccinated but largely unexposed Australian population following the 2022 SARS-CoV-2 Omicron wave: a cross-sectional survey. PG - 323-330 LID - 10.5694/mja2.52256 [doi] AB - OBJECTIVE: To estimate the prevalence of long COVID among Western Australian adults, a highly vaccinated population whose first major exposure to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was during the 2022 Omicron wave, and to assess its impact on health service use and return to work or study. STUDY DESIGN: Follow-up survey (completed online or by telephone). SETTING, PARTICIPANTS: Adult Western Australians surveyed 90 days after positive SARS-CoV-2 test results (polymerase chain reaction or rapid antigen testing) during 16 July - 3 August 2022 who had consented to follow-up contact for research purposes. MAIN OUTCOME MEASURES: Proportion of respondents with long COVID (ie, reporting new or ongoing symptoms or health problems, 90 days after positive SARS-CoV-2 test result); proportion with long COVID who sought health care for long COVID-related symptoms two to three months after infection; proportion who reported not fully returning to previous work or study because of long COVID-related symptoms. RESULTS: Of the 70 876 adults with reported SARS-CoV-2 infections, 24 024 consented to contact (33.9%); after exclusions, 22 744 people were invited to complete the survey, of whom 11 697 (51.4%) provided complete responses. Our case definition for long COVID was satisfied by 2130 respondents (18.2%). The risk of long COVID was greater for women (v men: adjusted risk ratio [aRR], 1.5; 95% confidence interval [CI], 1.4-1.6) and for people aged 50-69 years (v 18-29 years: aRR, 1.6; 95% CI, 1.4-1.9) or with pre-existing health conditions (aRR, 1.5; 95% CI, 1.4-1.7), as well as for people who had received two or fewer COVID-19 vaccine doses (v four or more: aRR, 1.4; 95% CI, 1.2-1.8) or three doses (aRR, 1.3; 95% CI, 1.1-1.5). The symptoms most frequently reported by people with long COVID were fatigue (1504, 70.6%) and concentration difficulties (1267, 59.5%). In the month preceding the survey, 814 people had consulted general practitioners (38.2%) and 34 reported being hospitalised (1.6%) with long COVID. Of 1779 respondents with long COVID who had worked or studied before the infection, 318 reported reducing or discontinuing this activity (17.8%). CONCLUSION: Ninety days after infection with the Omicron SARS-CoV-2 variant, 18.2% of survey respondents reported symptoms consistent with long COVID, of whom 38.7% (7.1% of all survey respondents) sought health care for related health concerns two to three months after the acute infection. CI - (c) 2024 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd. FAU - Woldegiorgis, Mulu AU - Woldegiorgis M AUID- ORCID: 0000-0001-6489-980X AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. AD - National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT. FAU - Cadby, Gemma AU - Cadby G AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. FAU - Ngeh, Sera AU - Ngeh S AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. FAU - Korda, Rosemary J AU - Korda RJ AD - National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT. FAU - Armstrong, Paul K AU - Armstrong PK AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. FAU - Maticevic, Jelena AU - Maticevic J AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. FAU - Knight, Paul AU - Knight P AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. FAU - Jardine, Andrew AU - Jardine A AD - Environmental Health Directorate, Western Australia Department of Health, Perth, WA. FAU - Bloomfield, Lauren E AU - Bloomfield LE AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. AD - The University of Notre Dame Australia, Fremantle, WA. FAU - Effler, Paul V AU - Effler PV AD - Communicable Disease Control Directorate, Western Australia Department of Health, Perth, WA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240320 PL - Australia TA - Med J Aust JT - The Medical journal of Australia JID - 0400714 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants RN - Australians SB - IM MH - Adult MH - Male MH - Female MH - Humans MH - *SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - Cross-Sectional Studies MH - COVID-19 Vaccines MH - Australia/epidemiology MH - *COVID-19/epidemiology MH - *Australasian People OTO - NOTNLM OT - COVID-19 OT - Health services OT - Models, statistical OT - Population health OT - Prevention and control OT - Public health OT - Public policy EDAT- 2024/03/21 00:44 MHDA- 2024/04/01 06:43 CRDT- 2024/03/20 22:13 PHST- 2023/07/24 00:00 [received] PHST- 2023/10/25 00:00 [accepted] PHST- 2024/04/01 06:43 [medline] PHST- 2024/03/21 00:44 [pubmed] PHST- 2024/03/20 22:13 [entrez] AID - 10.5694/mja2.52256 [doi] PST - ppublish SO - Med J Aust. 2024 Apr 1;220(6):323-330. doi: 10.5694/mja2.52256. Epub 2024 Mar 20. PMID- 38504678 OWN - NLM STAT- MEDLINE DCOM- 20240321 LR - 20240506 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 12 DP - 2024 TI - Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway. PG - 1320059 LID - 10.3389/fpubh.2024.1320059 [doi] LID - 1320059 AB - INTRODUCTION: A substantial proportion of the over 700 million COVID-19 cases world-wide experience long-term symptoms. The objectives of this study were to compare symptom trajectories and risk factors for post-COVID-19 condition after Delta and Omicron infection. METHODS: This study consecutively recruited patients with SARS-CoV-2 infection from November 2021 to March 2022. We recorded demographics, comorbidities, vaccination status, sick leave, and 18 symptoms during acute infection and after 4 months. The primary outcome measures were symptoms during acute infection and after 4 months. Secondary outcome measures were work and school absenteeism. RESULTS: We followed a cohort of 1,374 non-hospitalized COVID-19 patients in Bergen, Norway, at three time points. The median age was 39.8 years and 11% were children <16 years. Common acute upper respiratory symptoms waned during follow-up. Fatigue remained common from acute infection (40%) until after 4 months (37%). Four months post-infection, patients reported increased frequencies of dyspnea (from 15% during acute illness to 25% at 4 months, p < 0.001), cognitive symptoms (from 9 to 32%, p < 0.001) and depression (from 1 to 17%, p < 0.001). Patients infected with Omicron reported less dyspnea (22% versus 27%, p = 0.046) and smell/taste problems (5% versus 19%, p < 0.001) at 4 months follow-up than those with Delta infection. Comorbidities and female sex were risk factors for persistent dyspnea and cognitive symptoms. Ten percent reported sick leave after acute illness, and vaccination reduced the risk of absenteeism (adjusted risk ratio: 0.36, 95% confidence interval: 0.15, 0.72, p = 0.008). CONCLUSION: At 4 months, home-isolated patients infected with Omicron reported overall comparable symptom burden, but less dyspnea and smell/taste problems than Delta infected patients. Several acute symptoms waned during follow-up. It is worrying that dyspnea, neurocognitive symptoms, and particularly depression, increased significantly during the first 4 months after acute infection. Previous vaccination was protective against prolonged sick leave. CI - Copyright (c) 2024 Iversen, Blomberg, Haug, Kittang, Ozgumus, Cox and Langeland. FAU - Iversen, Arild AU - Iversen A AD - Chief Municipal Doctor's Office, Bergen, Norway. AD - Department of Clinical Science, University of Bergen, Bergen, Norway. FAU - Blomberg, Bjorn AU - Blomberg B AD - Department of Clinical Science, University of Bergen, Bergen, Norway. AD - National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway. FAU - Haug, Kjell AU - Haug K AD - Chief Municipal Doctor's Office, Bergen, Norway. AD - Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. FAU - Kittang, Bard AU - Kittang B AD - Department of Clinical Science, University of Bergen, Bergen, Norway. AD - Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway. AD - Department of Nursing Home Medicine, Bergen Municipality, Bergen, Norway. FAU - Ozgumus, Turkuler AU - Ozgumus T AD - Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway. FAU - Cox, Rebecca Jane AU - Cox RJ AD - Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway. AD - Department of Microbiology, Haukeland University Hospital, Bergen, Norway. FAU - Langeland, Nina AU - Langeland N AD - Department of Clinical Science, University of Bergen, Bergen, Norway. AD - National Centre for Tropical Infectious Diseases, Department of Medicine, Haukeland University Hospital, Bergen, Norway. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240305 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 SB - IM MH - Child MH - Humans MH - Female MH - Adult MH - Acute Disease MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - Disease Progression MH - Norway/epidemiology MH - Dyspnea PMC - PMC10948556 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - delta variant OT - omicron variant OT - post-COVID-19 condition COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2024/03/20 06:45 MHDA- 2024/03/21 12:44 PMCR- 2024/03/05 CRDT- 2024/03/20 03:55 PHST- 2023/10/11 00:00 [received] PHST- 2024/02/22 00:00 [accepted] PHST- 2024/03/21 12:44 [medline] PHST- 2024/03/20 06:45 [pubmed] PHST- 2024/03/20 03:55 [entrez] PHST- 2024/03/05 00:00 [pmc-release] AID - 10.3389/fpubh.2024.1320059 [doi] PST - epublish SO - Front Public Health. 2024 Mar 5;12:1320059. doi: 10.3389/fpubh.2024.1320059. eCollection 2024. PMID- 38495122 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241103 IS - 2688-2663 (Electronic) IS - 2688-2663 (Linking) VI - 5 IP - 4 DP - 2024 Apr TI - Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions. PG - e513 LID - 10.1002/mco2.513 [doi] LID - e513 AB - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recently caused a global pandemic, resulting in more than 702 million people being infected and over 6.9 million deaths. Patients with coronavirus disease (COVID-19) may suffer from diarrhea, sleep disorders, depression, and even cognitive impairment, which is associated with long COVID during recovery. However, there remains no consensus on effective treatment methods. Studies have found that patients with COVID-19 have alterations in microbiota and their metabolites, particularly in the gut, which may be involved in the regulation of immune responses. Consumption of probiotics may alleviate the discomfort caused by inflammation and oxidative stress. However, the pathophysiological process underlying the alleviation of COVID-19-related symptoms and complications by targeting the microbiota remains unclear. In the current study, we summarize the latest research and evidence on the COVID-19 pandemic, together with symptoms of SARS-CoV-2 and vaccine use, with a focus on the relationship between microbiota alterations and COVID-19-related symptoms and vaccine use. This work provides evidence that probiotic-based interventions may improve COVID-19 symptoms by regulating gut microbiota and systemic immunity. Probiotics may also be used as adjuvants to improve vaccine efficacy. CI - (c) 2024 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. FAU - Qiu, Yong AU - Qiu Y AD - Department of Anesthesiology National Clinical Research Center for Geriatrics and The Research Units of West China (2018RU012) West China Hospital Sichuan University Chengdu China. AD - Laboratory of Anesthesia and Critical Care Medicine National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology West China Hospital Sichuan University Chengdu China. FAU - Mo, Chunheng AU - Mo C AUID- ORCID: 0000-0003-2781-2132 AD - Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE State Key Laboratory of Biotherapy West China Second University Hospital Sichuan University Chengdu China. FAU - Chen, Lu AU - Chen L AD - Department of Anesthesiology National Clinical Research Center for Geriatrics and The Research Units of West China (2018RU012) West China Hospital Sichuan University Chengdu China. AD - Laboratory of Anesthesia and Critical Care Medicine National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology West China Hospital Sichuan University Chengdu China. FAU - Ye, Wanlin AU - Ye W AD - Department of Anesthesiology National Clinical Research Center for Geriatrics and The Research Units of West China (2018RU012) West China Hospital Sichuan University Chengdu China. AD - Laboratory of Anesthesia and Critical Care Medicine National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology West China Hospital Sichuan University Chengdu China. FAU - Chen, Guo AU - Chen G AD - Department of Anesthesiology National Clinical Research Center for Geriatrics and The Research Units of West China (2018RU012) West China Hospital Sichuan University Chengdu China. AD - Laboratory of Anesthesia and Critical Care Medicine National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology West China Hospital Sichuan University Chengdu China. FAU - Zhu, Tao AU - Zhu T AD - Department of Anesthesiology National Clinical Research Center for Geriatrics and The Research Units of West China (2018RU012) West China Hospital Sichuan University Chengdu China. AD - Laboratory of Anesthesia and Critical Care Medicine National-Local Joint Engineering Research Center of Translational Medicine of Anesthesiology West China Hospital Sichuan University Chengdu China. LA - eng PT - Journal Article PT - Review DEP - 20240315 PL - China TA - MedComm (2020) JT - MedComm JID - 101769925 PMC - PMC10943180 OTO - NOTNLM OT - COVID-19 OT - gut microbiota OT - immunity OT - probiotics OT - vaccine COIS- All authors declare no conflict of interest. EDAT- 2024/03/18 06:42 MHDA- 2024/03/18 06:43 PMCR- 2024/03/15 CRDT- 2024/03/18 04:16 PHST- 2023/08/28 00:00 [received] PHST- 2024/02/20 00:00 [revised] PHST- 2024/02/21 00:00 [accepted] PHST- 2024/03/18 06:43 [medline] PHST- 2024/03/18 06:42 [pubmed] PHST- 2024/03/18 04:16 [entrez] PHST- 2024/03/15 00:00 [pmc-release] AID - MCO2513 [pii] AID - 10.1002/mco2.513 [doi] PST - epublish SO - MedComm (2020). 2024 Mar 15;5(4):e513. doi: 10.1002/mco2.513. eCollection 2024 Apr. PMID- 38486297 OWN - NLM STAT- MEDLINE DCOM- 20240318 LR - 20241115 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 22 IP - 1 DP - 2024 Mar 14 TI - Risk of encephalitis and meningitis after COVID-19 vaccination in South Korea: a self-controlled case series analysis. PG - 123 LID - 10.1186/s12916-024-03347-6 [doi] LID - 123 AB - BACKGROUND: Several neurological manifestations shortly after a receipt of coronavirus infectious disease 2019 (COVID-19) vaccine have been described in the recent case reports. Among those, we sought to evaluate the risk of encephalitis and meningitis after COVID-19 vaccination in the entire South Korean population. METHODS: We conducted self-controlled case series (SCCS) analysis using the COVID-19 immunization record data from the Korea Disease Control Agency between February 2021 and March 2022, linked with the National Health Insurance Database between January 2021 and October 2022. We retrieved all medical claims of adults aged 18 years or older who received at least one dose of COVID-19 vaccines (BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S), and included only those who had a diagnosis record for encephalitis or meningitis within the 240-day post-vaccination period. With day 0 defined as the date of vaccination, risk window was defined as days 1-28 and the control window as the remainder period excluding the risk windows within the 240-day period. We used conditional Poisson regression to estimate the incidence rate ratios (IRR) with 95% confidence intervals (CI), stratified by dose and vaccine type. RESULTS: From 129,956,027 COVID-19 vaccine doses administered to 44,564,345 individuals, there were 251 and 398 cases of encephalitis and meningitis during the risk window, corresponding to 1.9 and 3.1 cases per 1 million doses, respectively. Overall, there was an increased risk of encephalitis in the first 28 days of COVID-19 vaccination (IRR 1.26; 95% CI 1.08-1.47), which was only significant after a receipt of ChAdOx1-S (1.49; 1.03-2.15). For meningitis, no increased risk was observed after any dose of COVID-19 vaccine (IRR 1.03; 95% CI 0.91-1.16). CONCLUSIONS: Our findings suggest an overall increased risk of encephalitis after COVID-19 vaccination. However, the absolute risk was small and should not impede COVID-19 vaccine confidence. No significant association was found between the risk of meningitis and COVID-19 vaccination. CI - (c) 2024. The Author(s). FAU - Kim, Ju Hwan AU - Kim JH AD - School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea. FAU - Yoon, Dongwon AU - Yoon D AD - School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea. FAU - Ko, Hwa Yeon AU - Ko HY AD - School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. FAU - Jung, Kyungyeon AU - Jung K AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea. FAU - Sunwoo, Jun-Sang AU - Sunwoo JS AD - Department of Neurology, Kangbuk Samsung Hospital, Seoul, South Korea. FAU - Shin, Won Chul AU - Shin WC AD - Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, South Korea. FAU - Byun, Jung-Ick AU - Byun JI AD - Department of Neurology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, South Korea. jbyun@khu.ac.kr. FAU - Shin, Ju-Young AU - Shin JY AUID- ORCID: 0000-0003-1010-7525 AD - School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. shin.jy@skku.edu. AD - Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea. shin.jy@skku.edu. AD - Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, South Korea. shin.jy@skku.edu. LA - eng GR - 2021-05-008/Korea Disease Control and Prevention Agency/ PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240314 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (COVID-19 Vaccines) RN - JT2NS6183B (Ad26COVS1) RN - 0 (BNT162 Vaccine) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM MH - Adult MH - Humans MH - COVID-19 Vaccines/adverse effects MH - Ad26COVS1 MH - BNT162 Vaccine MH - *COVID-19/epidemiology/prevention & control MH - *Encephalitis MH - *Meningitis/epidemiology/etiology MH - *Communicable Diseases MH - Republic of Korea/epidemiology MH - Vaccination/adverse effects MH - ChAdOx1 nCoV-19 PMC - PMC10941581 OTO - NOTNLM OT - COVID-19 vaccine OT - Encephalitis OT - Meningitis OT - Self-controlled case series COIS- Dr. Shin received grants from the Ministry of Food and Drug Safety, the Ministry of Health and Welfare, the National Research Foundation of Korea, and the Government-wide R&D Fund for Infectious Disease Research and Pharmaceutical Companies, including Pfizer, UCB, and LG Chem. No other relationships or activities have influenced the submitted work. EDAT- 2024/03/15 06:44 MHDA- 2024/03/18 06:44 PMCR- 2024/03/14 CRDT- 2024/03/15 00:52 PHST- 2023/11/27 00:00 [received] PHST- 2024/03/07 00:00 [accepted] PHST- 2024/03/18 06:44 [medline] PHST- 2024/03/15 06:44 [pubmed] PHST- 2024/03/15 00:52 [entrez] PHST- 2024/03/14 00:00 [pmc-release] AID - 10.1186/s12916-024-03347-6 [pii] AID - 3347 [pii] AID - 10.1186/s12916-024-03347-6 [doi] PST - epublish SO - BMC Med. 2024 Mar 14;22(1):123. doi: 10.1186/s12916-024-03347-6. PMID- 38425890 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240302 IS - 2353-5571 (Electronic) IS - 2353-4184 (Print) IS - 2353-5571 (Linking) VI - 12 IP - 1 DP - 2024 TI - Priming congruence and COVID-19 vaccination intention: a mediation analysis. PG - 79-86 LID - 10.5114/hpr/157228 [doi] AB - BACKGROUND: This study took place at the height of the fifth wave of COVID-19 in France, coinciding with stigmatizing communication toward the unvaccinated. We hypothesized that adherence to this communication would facilitate or inhibit the effects of priming on vaccination intention, depending on whether the priming included a dimension of connection to others. PARTICIPANTS AND PROCEDURE: In a convenience online French sample (N = 1800, M age = 26.30), vaccination intention was asked after love priming, no love/prejudice priming, materialism priming, or a control condition. Participants also reported their adherence to restrictive measures, i.e., media control, vaccination pass, and mandatory vaccination. RESULTS: Vaccination intention was higher in the no love/prejudice and materialism conditions than in the love and control conditions. Adherence to restrictive measures mediated the effect of prejudice or materialism priming on intention to get vaccinated. CONCLUSIONS: Implications of these results are discussed in light of the socially situated cognition perspective and the congruence of (a) a societal context of communication toward the vaccine and the unvaccinated, (b) the participant's degree of adherence to that communication, (c) the theme of priming, whether or not related to feeling connected to others. Implications of materialism priming are discussed, and the effect of commitment on intention to get vaccinated. CI - Copyright (c) Institute of Psychology, University of Gdansk. FAU - Lamy, Lubomir AU - Lamy L AUID- ORCID: 0000-0001-6114-2641 AD - Paris Cite University, Paris, France. FAU - Fischer-Lokou, Jacques AU - Fischer-Lokou J AUID- ORCID: 0000-0001-8601-6772 AD - Southern Brittany University, Rennes, France. FAU - Gueguen, Nicolas AU - Gueguen N AUID- ORCID: 0000-0002-8963-1751 AD - Southern Brittany University, Rennes, France. FAU - Guegan, Jerome AU - Guegan J AUID- ORCID: 0000-0002-6275-7258 AD - Paris Cite University, Paris, France. LA - eng PT - Journal Article DEP - 20230321 PL - Poland TA - Health Psychol Rep JT - Health psychology report JID - 101677269 PMC - PMC10900976 OTO - NOTNLM OT - love OT - materialism OT - prejudice OT - socially situated cognition EDAT- 2024/03/01 06:44 MHDA- 2024/03/01 06:45 PMCR- 2023/03/21 CRDT- 2024/03/01 03:55 PHST- 2022/07/23 00:00 [received] PHST- 2022/09/19 00:00 [revised] PHST- 2022/12/07 00:00 [accepted] PHST- 2024/03/01 06:45 [medline] PHST- 2024/03/01 06:44 [pubmed] PHST- 2024/03/01 03:55 [entrez] PHST- 2023/03/21 00:00 [pmc-release] AID - 157228 [pii] AID - 10.5114/hpr/157228 [doi] PST - epublish SO - Health Psychol Rep. 2023 Mar 21;12(1):79-86. doi: 10.5114/hpr/157228. eCollection 2024. PMID- 38400146 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240227 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 12 IP - 2 DP - 2024 Feb 5 TI - The Impact of Clinical Factors and SARS-CoV-2 Variants on Antibody Production in Vaccinated German Healthcare Professionals Infected Either with the Delta or the Omicron Variant. LID - 10.3390/vaccines12020163 [doi] LID - 163 AB - BACKGROUND: The aim of the rapid introduction of vaccines during the COVID-19 pandemic was a reduction in SARS-CoV-2 transmission and a less frequent occurrence of severe COVID-19 courses. Thus, we evaluated COVID-19 severity in vaccinated individuals to examine variant-specific symptom characteristics and their clinical impact on the serological immune response. METHODS: A total of 185 individuals previously vaccinated against and infected with the SARS-CoV-2 Delta (B.1.617.2) or Omicron (BA.4 and BA.5) variant, were enrolled for anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig level detection. A structured survey regarding medical history was conducted. RESULTS: In 99.5 percent of cases, outpatient treatment was satisfactory. Specific symptoms associated with variants included ageusia and anosmia in patients with Delta infections and throat pain in Omicron infections. Among Delta-infected individuals with specific symptoms, significantly higher levels of anti-N antibodies were observed. CONCLUSION: Our study identified variant-specific differences in the amount of SARS-CoV-2 antibody production and COVID-19 symptoms. Despite this, vaccinated individuals with Omicron or Delta infections generally experienced mild disease courses. Additionally, asymptomatic individuals exhibit lower anti-SARS-CoV-2 antibody levels, indicating a clinical correlation between disease-specific antibodies and distinct symptoms, particularly in the case of the Delta variant. In follow-up studies, exploring post-COVID syndrome and focusing on cognitive symptoms in the acute phase of Omicron infections is crucial as it has the potential to longitudinally impact the lives of those affected. FAU - Gerhards, Catharina AU - Gerhards C AUID- ORCID: 0000-0001-7197-9242 AD - Institute for Clinical Chemistry, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Steingass, Marlene AU - Steingass M AD - Institute for Clinical Chemistry, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Heininger, Alexandra AU - Heininger A AD - Department of Hygiene, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Lange, Bettina AU - Lange B AUID- ORCID: 0000-0002-3454-2081 AD - Department of Hygiene, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Hetjens, Michael AU - Hetjens M AD - Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health Baden-Wurttemberg, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg of University, 68167 Mannheim, Germany. FAU - Gerigk, Marlis AU - Gerigk M AD - Institute of Medical Microbiology and Hygiene, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Neumaier, Michael AU - Neumaier M AD - Institute for Clinical Chemistry, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Evliyaoglu, Osman AU - Evliyaoglu O AUID- ORCID: 0000-0002-5780-9068 AD - Institute for Clinical Chemistry, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. FAU - Kittel, Maximilian AU - Kittel M AD - Institute for Clinical Chemistry, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany. LA - eng PT - Journal Article DEP - 20240205 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC10893335 OTO - NOTNLM OT - COVID-19 after vaccination OT - SARS-CoV-2 vaccination OT - anti-N abs OT - anti-S1/RBS OT - anti-SARS-CoV-2 antibodies OT - serological immune response OT - vaccination breakthrough COIS- The authors declare no conflicts of interest. EDAT- 2024/02/24 11:45 MHDA- 2024/02/24 11:46 PMCR- 2024/02/05 CRDT- 2024/02/24 01:23 PHST- 2023/12/14 00:00 [received] PHST- 2024/01/22 00:00 [revised] PHST- 2024/02/02 00:00 [accepted] PHST- 2024/02/24 11:46 [medline] PHST- 2024/02/24 11:45 [pubmed] PHST- 2024/02/24 01:23 [entrez] PHST- 2024/02/05 00:00 [pmc-release] AID - vaccines12020163 [pii] AID - vaccines-12-00163 [pii] AID - 10.3390/vaccines12020163 [doi] PST - epublish SO - Vaccines (Basel). 2024 Feb 5;12(2):163. doi: 10.3390/vaccines12020163. PMID- 38390078 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240224 IS - 2405-8440 (Print) IS - 2405-8440 (Electronic) IS - 2405-8440 (Linking) VI - 10 IP - 4 DP - 2024 Feb 29 TI - Country of origin effects in explaining motivations for COVID-19 vaccine acceptance: A cognitive-affective-norm approach. PG - e25901 LID - 10.1016/j.heliyon.2024.e25901 [doi] LID - e25901 AB - This study aims to broaden the understanding of the motivational factors influencing vaccine acceptance framed as product country image (PCI) by exploring the role of overall country image (OCI), vaccine knowledge and information inconsistency, in addition to the three most commonly investigated constructs: vaccine efficacy, fear of vaccine and social norm. A self-administered questionnaire was distributed online to 593 Vietnamese participants to collect data on COVID-19 vaccines from four different countries: the USA, the UK, Russia and China. Structural equation modelling was employed to test the proposed model and hypotheses. The results indicated that OCI had a positive effect on vaccine acceptance for vaccines from the USA and Russia, but a non-significant effect for vaccines from the UK and a negative effect for vaccines from China. Vaccine efficacy, social norm and subjective knowledge had a positive effect for most vaccines, while fear of the vaccine and information inconsistency had negative effects for certain vaccines. The results suggest that vaccine efficacy and social norm are more stable and significant predictors of vaccine acceptance than other constructs. Moreover, OCI moderated the effects of vaccine efficacy, fear of the vaccine, information inconsistency, subjective knowledge and social norm on vaccine acceptance for certain vaccines. CI - (c) 2024 The Authors. FAU - Olsen, Svein Ottar AU - Olsen SO AD - School of Business and Economics, UiT the Arctic University of Norway, N-9037 Tromso, Norway. FAU - Tuu, Ho Huy AU - Tuu HH AD - Economics Faculty, Nha Trang University, 02 Nguyen Dinh Chieu, Nha Trang, Viet Nam. LA - eng PT - Journal Article DEP - 20240211 PL - England TA - Heliyon JT - Heliyon JID - 101672560 PMC - PMC10881345 OTO - NOTNLM OT - Attitude theory OT - COVID-19 OT - Country of origin OT - Vaccine acceptance OT - Vietnam COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/23 06:42 MHDA- 2024/02/23 06:43 PMCR- 2024/02/11 CRDT- 2024/02/23 03:52 PHST- 2023/07/03 00:00 [received] PHST- 2024/01/29 00:00 [revised] PHST- 2024/02/05 00:00 [accepted] PHST- 2024/02/23 06:43 [medline] PHST- 2024/02/23 06:42 [pubmed] PHST- 2024/02/23 03:52 [entrez] PHST- 2024/02/11 00:00 [pmc-release] AID - S2405-8440(24)01932-7 [pii] AID - e25901 [pii] AID - 10.1016/j.heliyon.2024.e25901 [doi] PST - epublish SO - Heliyon. 2024 Feb 11;10(4):e25901. doi: 10.1016/j.heliyon.2024.e25901. eCollection 2024 Feb 29. PMID- 38382013 OWN - NLM STAT- MEDLINE DCOM- 20240223 LR - 20260611 IS - 1526-632X (Electronic) IS - 0028-3878 (Linking) VI - 102 IP - 5 DP - 2024 Mar 12 TI - SARS-CoV-2 Infection and Risk of Postacute Psychiatric and Neurologic Diagnoses: A Nationwide Danish Cohort Study. PG - e208113 LID - 10.1212/WNL.0000000000208113 [doi] AB - BACKGROUND AND OBJECTIVES: The extent and burden of postacute psychiatric and neurologic manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not yet fully understood. To evaluate the association between SARS-CoV-2 infection and postacute manifestations of psychiatric and neurologic disorders, we conducted a nationwide cohort study including the entire Danish population aged 12 years or older on March 1, 2020. METHODS: Individuals were followed up for SARS-CoV-2 infection and diagnosis of subsequent psychiatric and neurologic disorders from March 1, 2020, to January 31, 2023, using the Danish nationwide coronavirus disease 2019 (COVID-19) test surveillance database and the Danish National Patient Registry. The main period of interest was 1-12 months after infection. Incidence rate ratios (IRRs) of new onset of 11 psychiatric and 30 neurologic disorders were calculated by comparing incidence rates of disorders between SARS-CoV-2-positive individuals and individuals without a positive test (nonpositive individuals). Stratified analyses were conducted according to COVID-19 vaccination status, variant period, age, sex, and severity of infection. RESULTS: Overall, 1,775,639 individuals in the study cohort (n = 3,239,008) were tested SARS-CoV-2 positive during follow-up. SARS-CoV-2-positive individuals compared with nonpositive individuals were at 24% reduced risk of any psychiatric disease (IRR 0.76, 95% CI 0.74-0.78) in the postacute period. The risk of any neurologic disorder was slightly higher among SARS-CoV-2-positive individuals than among those without a positive test (IRR 1.05, 95% CI 1.04-1.07). IRRs for specific disorders varied considerably from a 3.9-fold increased risk of change in sense of smell or taste (IRR 3.91, 95% CI 2.77-5.53) to a 29% reduced risk of dementia (IRR 0.71, 95% CI 0.65-0.78). The severity of infection and vaccination status, more so than age, sex, and variant, were found to significantly influence the stratified IRRs. Compared with nonpositive individuals, hospitalized patients with COVID-19 were at a 2.1-fold (IRR 2.05, 95% CI 1.78-2.37) increased risk of psychiatric disorders and at a 2.4-fold increased risk of neurologic disorders (IRR 2.44, 95% CI 2.29-2.60). DISCUSSION: Our study does not support previous findings of substantial postacute neurologic and psychiatric morbidities among the general population of SARS-CoV-2-infected individuals, but does corroborate an elevated risk among the most severe cases with COVID-19. FAU - Nielsen, Nete M AU - Nielsen NM AD - From the Department of Epidemiology Research (N.M.N., L.S., J.V.H., A.H.), Statens Serum Institut, Copenhagen; Focused Research Unit in Neurology (N.M.N.), Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa; Center for Neuropsychiatric Depression Research (P.V.), Mental Health Center Glostrup and University of Copenhagen, Glostrup; Clinical Institute (P.V.), University of Copenhagen, and Pharmacovigilance Research Center (A.H.), Department of Drug Design and Pharmacology, University of Copenhagen, Denmark. FAU - Spiliopoulos, Lampros AU - Spiliopoulos L AUID- ORCID: 0000-0001-9668-3587 AD - From the Department of Epidemiology Research (N.M.N., L.S., J.V.H., A.H.), Statens Serum Institut, Copenhagen; Focused Research Unit in Neurology (N.M.N.), Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa; Center for Neuropsychiatric Depression Research (P.V.), Mental Health Center Glostrup and University of Copenhagen, Glostrup; Clinical Institute (P.V.), University of Copenhagen, and Pharmacovigilance Research Center (A.H.), Department of Drug Design and Pharmacology, University of Copenhagen, Denmark. FAU - Hansen, Jorgen V AU - Hansen JV AD - From the Department of Epidemiology Research (N.M.N., L.S., J.V.H., A.H.), Statens Serum Institut, Copenhagen; Focused Research Unit in Neurology (N.M.N.), Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa; Center for Neuropsychiatric Depression Research (P.V.), Mental Health Center Glostrup and University of Copenhagen, Glostrup; Clinical Institute (P.V.), University of Copenhagen, and Pharmacovigilance Research Center (A.H.), Department of Drug Design and Pharmacology, University of Copenhagen, Denmark. FAU - Videbech, Poul AU - Videbech P AD - From the Department of Epidemiology Research (N.M.N., L.S., J.V.H., A.H.), Statens Serum Institut, Copenhagen; Focused Research Unit in Neurology (N.M.N.), Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa; Center for Neuropsychiatric Depression Research (P.V.), Mental Health Center Glostrup and University of Copenhagen, Glostrup; Clinical Institute (P.V.), University of Copenhagen, and Pharmacovigilance Research Center (A.H.), Department of Drug Design and Pharmacology, University of Copenhagen, Denmark. FAU - Hviid, Anders AU - Hviid A AD - From the Department of Epidemiology Research (N.M.N., L.S., J.V.H., A.H.), Statens Serum Institut, Copenhagen; Focused Research Unit in Neurology (N.M.N.), Department of Neurology, Hospital of Southern Jutland, University of Southern Denmark, Aabenraa; Center for Neuropsychiatric Depression Research (P.V.), Mental Health Center Glostrup and University of Copenhagen, Glostrup; Clinical Institute (P.V.), University of Copenhagen, and Pharmacovigilance Research Center (A.H.), Department of Drug Design and Pharmacology, University of Copenhagen, Denmark. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240221 PL - United States TA - Neurology JT - Neurology JID - 0401060 RN - 0 (COVID-19 Vaccines) SB - IM CIN - Neurology. 2024 Mar 12;102(5):e209211. doi: 10.1212/WNL.0000000000209211. PMID: 38381997 MH - Humans MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - Cohort Studies MH - COVID-19 Vaccines MH - *Nervous System Diseases/epidemiology MH - Denmark/epidemiology EDAT- 2024/02/21 18:43 MHDA- 2024/02/23 06:42 CRDT- 2024/02/21 16:13 PHST- 2024/02/23 06:42 [medline] PHST- 2024/02/21 18:43 [pubmed] PHST- 2024/02/21 16:13 [entrez] AID - 10.1212/WNL.0000000000208113 [doi] PST - ppublish SO - Neurology. 2024 Mar 12;102(5):e208113. doi: 10.1212/WNL.0000000000208113. Epub 2024 Feb 21. PMID- 38361434 OWN - NLM STAT- MEDLINE DCOM- 20241101 LR - 20260808 IS - 1552-6372 (Electronic) IS - 1524-8399 (Linking) VI - 25 IP - 6 DP - 2024 Nov TI - Describing the Lived Experience and Resource Needs of Individuals With Long COVID. PG - 963-970 LID - 10.1177/15248399241228823 [doi] AB - Individuals with long COVID report diverse symptoms lasting weeks or months after initial infection, causing significant psychosocial distress. Navigating health care interactions are often difficult for these individuals due to the diffuse nature of their symptoms, a lack of effective treatment options, and skepticism from some providers. To better understand these challenges, this study sought to further describe the lived experience of individuals with long COVID. A survey was conducted with individuals evaluated for long COVID at a specialty clinic (n = 200), which included questions about prior conditions, symptoms, use of medical and support services, and information and resource needs. Participants reported a mean of 10.75 persistent symptoms, the most common being fatigue and difficulty concentrating, with broad effects on daily functioning. Participants saw a mean of 5.92 providers for treatment of their symptoms, and 88.5% identified health care providers as a trusted source of information. Interest in research findings (60.5%) and opportunities for participation (47.5%) were moderate and varied by COVID vaccination status. Unvaccinated individuals (n = 27) also reported less trust in government sources of information, less college education, lower household income, and greater likelihood of having public insurance. Our findings suggest that individuals with long COVID experience many ongoing and complex symptoms with diverse effects on daily living; that health care providers are an important source for public health messaging about long COVID; and that unvaccinated individuals are likely to have differing needs and receptiveness to information than vaccinated individuals with long COVID. FAU - Von Nordheim, David AU - Von Nordheim D AD - Washington University in St. Louis, St. Louis, MO, USA. FAU - Johnson, Mikayla AU - Johnson M AD - Washington University in St. Louis, St. Louis, MO, USA. FAU - Caburnay, Charlene AU - Caburnay C AD - Washington University in St. Louis, St. Louis, MO, USA. FAU - Alleman, Sarah AU - Alleman S AD - Washington University in St. Louis, St. Louis, MO, USA. FAU - Kreuter, Matthew AU - Kreuter M AD - Washington University in St. Louis, St. Louis, MO, USA. FAU - McQueen, Amy AU - McQueen A AUID- ORCID: 0000-0003-0332-3983 AD - Washington University in St. Louis, St. Louis, MO, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240215 PL - United States TA - Health Promot Pract JT - Health promotion practice JID - 100890609 SB - IM MH - Humans MH - *COVID-19/psychology/epidemiology MH - Female MH - Male MH - Middle Aged MH - Adult MH - SARS-CoV-2 MH - Aged MH - Post-Acute COVID-19 Syndrome MH - Surveys and Questionnaires MH - Health Services Needs and Demand OTO - NOTNLM OT - COVID vaccination status OT - information needs OT - long COVID OT - long COVID symptoms OT - post-COVID OT - survey study EDAT- 2024/02/16 06:43 MHDA- 2024/11/01 06:21 CRDT- 2024/02/16 02:43 PHST- 2024/11/01 06:21 [medline] PHST- 2024/02/16 06:43 [pubmed] PHST- 2024/02/16 02:43 [entrez] AID - 10.1177/15248399241228823 [doi] PST - ppublish SO - Health Promot Pract. 2024 Nov;25(6):963-970. doi: 10.1177/15248399241228823. Epub 2024 Feb 15. PMID- 38347305 OWN - NLM STAT- MEDLINE DCOM- 20251202 LR - 20251205 IS - 1532-7558 (Electronic) IS - 1070-5503 (Print) IS - 1070-5503 (Linking) VI - 32 IP - 5 DP - 2025 Oct TI - The Effect of Being Vaccinated and National Vaccination Rates on Individuals' Cognitions, Emotions, and Economic Expectations: Evidence from Israel. PG - 788-797 LID - 10.1007/s12529-024-10269-3 [doi] AB - BACKGROUND: Israel was the first nation to establish a vaccination program during the COVID-19 pandemic. Thus, its citizens could look to no other country to help them judge its influence. People's predictions of their safety should depend on whether they were vaccinated, whereas their predictions regarding the COVID-19 pandemic should be based on the degree of progress of the vaccination program. We expected people to understand that the program would improve their safety by reducing the number of infected people around them. METHOD: An original panel survey was conducted covering the pandemic's first year. Respondents reported their vaccination status, emotions, evaluations of their safety, and predictions about the spread of COVID-19 and the Israeli gross domestic product. RESULTS: Estimates of fixed-effects models using the survey data suggest that being vaccinated affected people's cognitions about their own safety and their emotions but not their expectations regarding the situation in Israel as a whole. In contrast, the vaccination rate in Israel affected only the respondents' expectations about the spread of COVID-19, their own income, and Israel's gross domestic product. CONCLUSIONS: Being vaccinated is important for people's personal emotional and cognitive relief during a pandemic. A high vaccination rate improves people's economic expectations, which is important to the recovery of economic activity. CI - (c) 2024. The Author(s). FAU - Lahav, Eyal AU - Lahav E AUID- ORCID: 0000-0002-7840-9506 AD - The Open University of Israel, University Road 1, Raanana, Israel. eyalla@openu.ac.il. FAU - Shahrabani, Shosh AU - Shahrabani S AD - Economics and Management Department, The Max Stern Yezreel Valley College, Emek Yezreel, Israel. FAU - Rosenboim, Mosi AU - Rosenboim M AD - Guilford Glazer Faculty of Business and Management, Ben Gurion University of the Negev, Beer Sheva, Israel. FAU - Tsutsui, Yoshiro AU - Tsutsui Y AD - Kyoto Bunkyo University, Kyoto, Japan. LA - eng PT - Journal Article DEP - 20240212 PL - England TA - Int J Behav Med JT - International journal of behavioral medicine JID - 9421097 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Israel MH - *COVID-19/prevention & control/psychology MH - *Emotions MH - Male MH - Female MH - Adult MH - *Vaccination/psychology/statistics & numerical data MH - Middle Aged MH - *COVID-19 Vaccines MH - *Cognition MH - SARS-CoV-2 MH - Surveys and Questionnaires MH - Young Adult MH - Aged MH - *Health Knowledge, Attitudes, Practice PMC - PMC12672598 OTO - NOTNLM OT - COVID-19 OT - Emotions OT - Perceived risk OT - Prevention behavior OT - Vaccination COIS- Declarations. Informed Consent: Informed Consent was obtained from all individual participants included in the study. Ethical Approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Research Involving Human Participants and/or Animals: Not applicable. Competing Interests: The authors declare no conflict of interest. EDAT- 2024/02/13 00:42 MHDA- 2025/12/02 12:57 PMCR- 2024/02/12 CRDT- 2024/02/12 23:34 PHST- 2024/02/04 00:00 [accepted] PHST- 2025/12/02 12:57 [medline] PHST- 2024/02/13 00:42 [pubmed] PHST- 2024/02/12 23:34 [entrez] PHST- 2024/02/12 00:00 [pmc-release] AID - 10.1007/s12529-024-10269-3 [pii] AID - 10269 [pii] AID - 10.1007/s12529-024-10269-3 [doi] PST - ppublish SO - Int J Behav Med. 2025 Oct;32(5):788-797. doi: 10.1007/s12529-024-10269-3. Epub 2024 Feb 12. PMID- 38327486 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240211 IS - 2821-1723 (Electronic) IS - 2821-1723 (Linking) VI - 2 IP - 1 DP - 2023 Apr TI - COVID-19 vaccine-hesitancy is associated with lower cortical volume in elderly individuals. PG - 35-41 LID - 10.52547/nl.2.1.35 [doi] AB - BACKGROUND: According to a large number of scientific reports, the main problem is COVID-19 vaccine hesitancy which slowed down the vaccination program. Previous studies revealed that COVID-19 vaccine hesitancy is associated with lower cognitive performance. However, the neurobiology of such behavior is less known, and investigating the brain structural patterns in this regard can extend our knowledge on the basis of this behavior. This study aimed to investigate the link between brain structural features including cortical and subcortical volume with COVID-19 vaccine hesitancy in elderly individuals. METHODS: A total of 221 healthy subjects without any cognitive impairment with a mean age of 63.7 +/- 6.1 were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database. Overall, 87 vaccine-hesitant (VH) and 134 vaccine-accepted (VA) were entered into this study. The difference in the volume of cortical and subcortical regions was investigated between VH and VA groups. RESULTS: There was no significant difference in cognitive status measured by MMSE, MoCA, ADAS-cog, and RAVLT between VA and VH groups (P>0.05). The analysis showed that VA subjects had significantly higher left pars orbitalis (P: 0.013), left precentral (P: 0.042), right caudal anterior cingulate (P: 0.044), and right isthmus cingulate (P: 0.013) volume compared to the VH group. There was no significant difference in other cortical and subcortical regions. CONCLUSION: In conclusion, this finding demonstrated that in the era of complicated decision-making due to social media reports, elderly adults with smaller frontal and cingulate regions are more likely to be vaccine-hesitant. These findings can highlight the link between cortical regions and health-protective behaviors such as taking up the offer of vaccination. FAU - Nabizadeh, Fardin AU - Nabizadeh F AD - Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. AD - School of Medicine, Iran University of Medical Sciences, Tehran, Iran. CN - Alzheimer's disease Neuroimaging Initiative (ADNI) LA - eng GR - P30 AG010129/AG/NIA NIH HHS/United States GR - U01 AG024904/AG/NIA NIH HHS/United States PT - Journal Article DEP - 20220415 PL - Iran TA - Neurol Lett JT - Neurology letters JID - 9918752185506676 PMC - PMC10847881 MID - NIHMS1962532 OTO - NOTNLM OT - COVID-19 OT - brain OT - cingulate OT - cognition OT - hesitancy OT - vaccine COIS- Conflict of interest The author declares no conflict of interest regarding the publication of this paper. EDAT- 2024/02/08 06:42 MHDA- 2024/02/08 06:43 PMCR- 2024/02/07 CRDT- 2024/02/08 04:05 PHST- 2024/02/08 06:43 [medline] PHST- 2024/02/08 06:42 [pubmed] PHST- 2024/02/08 04:05 [entrez] PHST- 2024/02/07 00:00 [pmc-release] AID - 10.52547/nl.2.1.35 [doi] PST - ppublish SO - Neurol Lett. 2023 Apr;2(1):35-41. doi: 10.52547/nl.2.1.35. Epub 2022 Apr 15. PMID- 38327277 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240210 IS - 2667-193X (Electronic) IS - 2667-193X (Linking) VI - 30 DP - 2024 Feb TI - Prevalence and determinants of post-acute sequelae after SARS-CoV-2 infection (Long COVID) among adults in Mexico during 2022: a retrospective analysis of nationally representative data. PG - 100688 LID - 10.1016/j.lana.2024.100688 [doi] LID - 100688 AB - BACKGROUND: Post-acute sequelae after SARS-CoV-2 infection (PASC) remains a concerning long-term complication of COVID-19. Here, we aimed to characterize the epidemiology of PASC in Mexico during 2022 and identify potential associations of covariates with PASC prevalence using nationally representative data. METHODS: We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) from 24,434 participants, representing 85,521,661 adults >/=20 years. PASC was defined using both the National Institute for Health and Care Excellence (NICE) definition and a PASC score >/=12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and periods of predominance of SARS-CoV-2 circulating variants. Determinants of PASC were assessed using log-binomial regression models adjusted by survey weights. FINDINGS: Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95% CI 11.89-12.99) of adults >/=20 years in Mexico in 2022. The most common persistent symptoms were fatigue, musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, and chest pain. PASC was present in 21.21% (95% CI 19.74-22.68) of subjects with previously diagnosed COVID-19. Over 28.6% of patients with PASC reported symptoms persistence >/=6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance. INTERPRETATION: PASC remains a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemic. Promoting SARS-CoV-2 reinfection prevention and booster vaccination may be useful in reducing PASC burden. FUNDING: This research was supported by Instituto Nacional de Geriatria in Mexico. CI - (c) 2024 The Author(s). FAU - Bello-Chavolla, Omar Yaxmehen AU - Bello-Chavolla OY AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. FAU - Fermin-Martinez, Carlos A AU - Fermin-Martinez CA AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. AD - MD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Ramirez-Garcia, Daniel AU - Ramirez-Garcia D AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. AD - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Vargas-Vazquez, Arsenio AU - Vargas-Vazquez A AD - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Fernandez-Chirino, Luisa AU - Fernandez-Chirino L AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. FAU - Basile-Alvarez, Martin Roberto AU - Basile-Alvarez MR AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. AD - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Sanchez-Castro, Paulina AU - Sanchez-Castro P AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. AD - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Nunez-Luna, Alejandra AU - Nunez-Luna A AD - Research Division, Instituto Nacional de Geriatria, Mexico City, Mexico. AD - Facultad de Medicina, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico. FAU - Antonio-Villa, Neftali Eduardo AU - Antonio-Villa NE AD - Department of Endocrinology, Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico. LA - eng PT - Journal Article DEP - 20240203 PL - England TA - Lancet Reg Health Am JT - Lancet regional health. Americas JID - 9918232503006676 PMC - PMC10847769 OTO - NOTNLM OT - COVID-19 OT - Long COVID OT - Mexico OT - PASC OT - Sequelae COIS- Nothing to disclose. EDAT- 2024/02/08 06:42 MHDA- 2024/02/08 06:43 PMCR- 2024/02/03 CRDT- 2024/02/08 04:03 PHST- 2023/07/19 00:00 [received] PHST- 2023/12/26 00:00 [revised] PHST- 2024/01/21 00:00 [accepted] PHST- 2024/02/08 06:43 [medline] PHST- 2024/02/08 06:42 [pubmed] PHST- 2024/02/08 04:03 [entrez] PHST- 2024/02/03 00:00 [pmc-release] AID - S2667-193X(24)00015-2 [pii] AID - 100688 [pii] AID - 10.1016/j.lana.2024.100688 [doi] PST - epublish SO - Lancet Reg Health Am. 2024 Feb 3;30:100688. doi: 10.1016/j.lana.2024.100688. eCollection 2024 Feb. PMID- 38315620 OWN - NLM STAT- MEDLINE DCOM- 20240319 LR - 20250127 IS - 2369-2960 (Electronic) IS - 2369-2960 (Linking) VI - 10 DP - 2024 Mar 18 TI - Predicting COVID-19 Vaccination Uptake Using a Small and Interpretable Set of Judgment and Demographic Variables: Cross-Sectional Cognitive Science Study. PG - e47979 LID - 10.2196/47979 [doi] LID - e47979 AB - BACKGROUND: Despite COVID-19 vaccine mandates, many chose to forgo vaccination, raising questions about the psychology underlying how judgment affects these choices. Research shows that reward and aversion judgments are important for vaccination choice; however, no studies have integrated such cognitive science with machine learning to predict COVID-19 vaccine uptake. OBJECTIVE: This study aims to determine the predictive power of a small but interpretable set of judgment variables using 3 machine learning algorithms to predict COVID-19 vaccine uptake and interpret what profile of judgment variables was important for prediction. METHODS: We surveyed 3476 adults across the United States in December 2021. Participants answered demographic, COVID-19 vaccine uptake (ie, whether participants were fully vaccinated), and COVID-19 precaution questions. Participants also completed a picture-rating task using images from the International Affective Picture System. Images were rated on a Likert-type scale to calibrate the degree of liking and disliking. Ratings were computationally modeled using relative preference theory to produce a set of graphs for each participant (minimum R(2)>0.8). In total, 15 judgment features were extracted from these graphs, 2 being analogous to risk and loss aversion from behavioral economics. These judgment variables, along with demographics, were compared between those who were fully vaccinated and those who were not. In total, 3 machine learning approaches (random forest, balanced random forest [BRF], and logistic regression) were used to test how well judgment, demographic, and COVID-19 precaution variables predicted vaccine uptake. Mediation and moderation were implemented to assess statistical mechanisms underlying successful prediction. RESULTS: Age, income, marital status, employment status, ethnicity, educational level, and sex differed by vaccine uptake (Wilcoxon rank sum and chi-square P<.001). Most judgment variables also differed by vaccine uptake (Wilcoxon rank sum P<.05). A similar area under the receiver operating characteristic curve (AUROC) was achieved by the 3 machine learning frameworks, although random forest and logistic regression produced specificities between 30% and 38% (vs 74.2% for BRF), indicating a lower performance in predicting unvaccinated participants. BRF achieved high precision (87.8%) and AUROC (79%) with moderate to high accuracy (70.8%) and balanced recall (69.6%) and specificity (74.2%). It should be noted that, for BRF, the negative predictive value was <50% despite good specificity. For BRF and random forest, 63% to 75% of the feature importance came from the 15 judgment variables. Furthermore, age, income, and educational level mediated relationships between judgment variables and vaccine uptake. CONCLUSIONS: The findings demonstrate the underlying importance of judgment variables for vaccine choice and uptake, suggesting that vaccine education and messaging might target varying judgment profiles to improve uptake. These methods could also be used to aid vaccine rollouts and health care preparedness by providing location-specific details (eg, identifying areas that may experience low vaccination and high hospitalization). CI - (c)Nicole L Vike, Sumra Bari, Leandros Stefanopoulos, Shamal Lalvani, Byoung Woo Kim, Nicos Maglaveras, Martin Block, Hans C Breiter, Aggelos K Katsaggelos. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 18.03.2024. FAU - Vike, Nicole L AU - Vike NL AUID- ORCID: 0000-0002-8617-2377 AD - Department of Computer Science, University of Cincinnati, Cincinnati, OH, United States. FAU - Bari, Sumra AU - Bari S AUID- ORCID: 0000-0002-2406-2463 AD - Department of Computer Science, University of Cincinnati, Cincinnati, OH, United States. FAU - Stefanopoulos, Leandros AU - Stefanopoulos L AUID- ORCID: 0000-0002-2682-5639 AD - Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, United States. AD - School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Lalvani, Shamal AU - Lalvani S AUID- ORCID: 0000-0002-2677-8019 AD - Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, United States. FAU - Kim, Byoung Woo AU - Kim BW AUID- ORCID: 0000-0001-7612-4833 AD - Department of Computer Science, University of Cincinnati, Cincinnati, OH, United States. FAU - Maglaveras, Nicos AU - Maglaveras N AUID- ORCID: 0000-0002-4919-0664 AD - School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece. FAU - Block, Martin AU - Block M AUID- ORCID: 0009-0004-8601-1372 AD - Integrated Marketing Communications, Medill School, Northwestern University, Evanston, IL, United States. FAU - Breiter, Hans C AU - Breiter HC AUID- ORCID: 0000-0002-4385-2778 AD - Department of Computer Science, University of Cincinnati, Cincinnati, OH, United States. AD - Department of Psychiatry, Massachusetts General Hospital, Harvard School of Medicine, Boston, MA, United States. FAU - Katsaggelos, Aggelos K AU - Katsaggelos AK AUID- ORCID: 0000-0003-4554-0070 AD - Department of Electrical and Computer Engineering, Northwestern University, Evanston, IL, United States. AD - Department of Computer Science, Northwestern University, Evanston, IL, United States. AD - Department of Radiology, Northwestern University, Evanston, IL, United States. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, Non-P.H.S. DEP - 20240318 PL - Canada TA - JMIR Public Health Surveill JT - JMIR public health and surveillance JID - 101669345 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Humans MH - *COVID-19 Vaccines MH - Judgment MH - Cross-Sectional Studies MH - *COVID-19/epidemiology/prevention & control MH - Vaccination MH - Cognitive Science MH - Ethnicity PMC - PMC10953811 OTO - NOTNLM OT - aversion OT - balanced random forest OT - behavioral economics OT - cognitive science OT - judgment OT - machine learning OT - mediation OT - mobile phone OT - moderation OT - relative preference theory OT - reward OT - smartphone COIS- Conflicts of Interest: A provisional patent has been submitted by the following authors (NLV, SB, HCB, SL, LS, and AKK): "Methods of predicting vaccine uptake," provisional application # 63/449,460. EDAT- 2024/02/05 14:45 MHDA- 2024/03/19 06:43 PMCR- 2024/03/18 CRDT- 2024/02/05 12:53 PHST- 2023/04/11 00:00 [received] PHST- 2024/01/10 00:00 [accepted] PHST- 2023/08/08 00:00 [revised] PHST- 2024/03/19 06:43 [medline] PHST- 2024/02/05 14:45 [pubmed] PHST- 2024/02/05 12:53 [entrez] PHST- 2024/03/18 00:00 [pmc-release] AID - v10i1e47979 [pii] AID - 10.2196/47979 [doi] PST - epublish SO - JMIR Public Health Surveill. 2024 Mar 18;10:e47979. doi: 10.2196/47979. PMID- 38252638 OWN - NLM STAT- MEDLINE DCOM- 20240124 LR - 20260626 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 19 IP - 1 DP - 2024 TI - Characteristics and burden of acute COVID-19 and long-COVID: Demographic, physical, mental health, and economic perspectives. PG - e0297207 LID - 10.1371/journal.pone.0297207 [doi] LID - e0297207 AB - BACKGROUND: COVID-19 infection and its associated consequence, known as long-COVID, lead to a significant burden on the global healthcare system and limitations in people's personal and work lives. This study aims to provide further insight into the impact of acute and ongoing COVID-19 symptoms and investigates the role of patients' gender and vaccination status. METHODS: 416 individuals (73.9% female) between the ages of 16 and 80 years (M = 44.18, SD = 12.90) with self-reported symptoms of long-COVID participated in an online survey conducted between March and May 2022. RESULTS: 6.0%, 74.3%, and 19.7% of all respondents reported having had an asymptomatic, mild, or severe acute illness, respectively. Out of all participants, 7.8% required hospitalization. The most prevalent symptoms during the acute infection (Mdn = 23.50 symptoms, IQR = 13-39) included fatigue, exhaustion, cough, brain fog, and memory problems. The median long-COVID disease duration was 12.10 months (IQR = 2.8-17.4). Among 64 inquired long-COVID symptoms (Mdn = 17.00 symptoms, IQR = 9-27), participants reported fatigue, exhaustion, memory problems, brain fog, and dyspnea as the most common ongoing symptoms, which were generally experienced as fluctuating and deteriorating after physical or cognitive activity. Common consequences of long-COVID included financial losses (40.5%), changes in the participants' profession (41.0%), stress resistance (87.5%), sexual life (38.1%), and mood (72.1%), as well as breathing difficulties (41.3%), or an increased drug intake (e.g., medicine, alcohol; 44.6%). In addition, vaccinated individuals exhibited a shorter acute illness duration and an earlier onset of long-COVID symptoms. In general, women reported more long-COVID symptoms than men. CONCLUSION: Long-COVID represents a heterogeneous disease and impacts multiple life aspects of those affected. Tailored rehabilitation programs targeting the plurality of physical and mental symptoms are needed. CI - Copyright: (c) 2024 Leitner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Leitner, Manuel AU - Leitner M AUID- ORCID: 0000-0001-5267-1103 AD - Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria. FAU - Potz, Gloria AU - Potz G AD - digitAAL Life GmbH, Graz, Austria. FAU - Berger, Martin AU - Berger M AD - Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria. FAU - Fellner, Maria AU - Fellner M AD - digitAAL Life GmbH, Graz, Austria. FAU - Spat, Stephan AU - Spat S AD - digitAAL Life GmbH, Graz, Austria. FAU - Koini, Marisa AU - Koini M AUID- ORCID: 0000-0002-1756-1379 AD - Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz, Austria. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20240122 PL - United States TA - PLoS One JT - PloS one JID - 101285081 SB - IM MH - Male MH - Female MH - Humans MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Post-Acute COVID-19 Syndrome MH - *COVID-19/epidemiology MH - Mental Health MH - Acute Disease MH - Dyspnea MH - Fatigue MH - Memory Disorders MH - Mental Fatigue MH - Demography PMC - PMC10802963 COIS- The authors have declared that no competing interests exist. EDAT- 2024/01/22 18:42 MHDA- 2024/01/24 06:43 PMCR- 2024/01/22 CRDT- 2024/01/22 13:33 PHST- 2023/08/26 00:00 [received] PHST- 2023/12/30 00:00 [accepted] PHST- 2024/01/24 06:43 [medline] PHST- 2024/01/22 18:42 [pubmed] PHST- 2024/01/22 13:33 [entrez] PHST- 2024/01/22 00:00 [pmc-release] AID - PONE-D-23-25386 [pii] AID - 10.1371/journal.pone.0297207 [doi] PST - epublish SO - PLoS One. 2024 Jan 22;19(1):e0297207. doi: 10.1371/journal.pone.0297207. eCollection 2024. PMID- 38228087 OWN - NLM STAT- MEDLINE DCOM- 20240402 LR - 20240827 IS - 2092-7193 (Electronic) IS - 2092-7193 (Linking) VI - 46 DP - 2024 TI - The bounds of meta-analytics and an alternative method. PG - e2024016 LID - 10.4178/epih.e2024016 [doi] LID - e2024016 AB - OBJECTIVES: Meta-analysis is a statistical appraisal of the data analytic implications of published articles (Y), estimating parameters including the odds ratio and relative risk. This information is helpful for evaluating the significance of the findings. The Higgins I2 index is often used to measure heterogeneity among studies. The objectives of this article are to amend the Higgins I2 index score in a novel and innovative way and to make it more useful in practice. METHODS: Heterogeneity among study populations can be affected by many sources, including the sample size and study design. They influence the Cochran Q score and, thus, the Higgins I2 score. In this regard, the I2 score is not an absolute indicator of heterogeneity. Q changes by bound as Y increases unboundedly. An innovative methodology is devised to show the conditional and unconditional probability structures. RESULTS: Various properties are derived, including showing that a zero correlation between Q and Y does not necessarily mean that they are independent. A new alternative statistic, S2, is derived and applied to mild cognitive impairment and coronavirus disease 2019 vaccination for meta-analysis. CONCLUSIONS: A hidden shortcoming of the Higgins I2 index is overcome in this article by amending the Higgins I2 score. The usefulness of the proposed methodology is illustrated using 2 examples. The findings have potential health policy implications. FAU - Shanmugam, Ramalingam AU - Shanmugam R AD - School of Health Administration, Texas State University, San Marcos, TX, USA. FAU - Tabatabai, Mohammad AU - Tabatabai M AD - Meharry Medical College, School of Graduate Studies, Nashville, TN, USA. FAU - Wilus, Derek AU - Wilus D AD - Meharry Medical College, School of Graduate Studies, Nashville, TN, USA. FAU - Singh, Karan P AU - Singh KP AD - Department of Epidemiology and Biostatistics, School of Medicine, The University of Texas at Tyler, Tyler, TX, USA. LA - eng GR - G12 MD007586/MD/NIMHD NIH HHS/United States GR - U54 MD007586/MD/NIMHD NIH HHS/United States PT - Journal Article PT - Meta-Analysis DEP - 20240107 PL - Korea (South) TA - Epidemiol Health JT - Epidemiology and health JID - 101519472 SB - IM MH - Humans MH - *COVID-19/epidemiology MH - *Cognitive Dysfunction PMC - PMC11040225 OTO - NOTNLM OT - COVID-19 OT - Cognitive impairment OT - Heterogeneity OT - Risk OT - Vaccination COIS- Conflict of interest The authors have no conflicts of interest to declare for this study. EDAT- 2024/01/17 00:41 MHDA- 2024/04/02 06:46 PMCR- 2024/01/07 CRDT- 2024/01/16 18:10 PHST- 2023/08/25 00:00 [received] PHST- 2023/12/25 00:00 [accepted] PHST- 2024/04/02 06:46 [medline] PHST- 2024/01/17 00:41 [pubmed] PHST- 2024/01/16 18:10 [entrez] PHST- 2024/01/07 00:00 [pmc-release] AID - epih.e2024016 [pii] AID - epih-46-e2024016 [pii] AID - 10.4178/epih.e2024016 [doi] PST - ppublish SO - Epidemiol Health. 2024;46:e2024016. doi: 10.4178/epih.e2024016. Epub 2024 Jan 7. PMID- 38191556 OWN - NLM STAT- MEDLINE DCOM- 20240110 LR - 20240112 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 14 IP - 1 DP - 2024 Jan 9 TI - Characteristics of long COVID and the impact of COVID-19 vaccination on long COVID 2 years following COVID-19 infection: prospective cohort study. PG - 854 LID - 10.1038/s41598-023-50024-4 [doi] LID - 854 AB - This prospective cohort study aimed to identify characteristics of long COVID and any potential mitigating effects of COVID-19 vaccinations in patients 24 months following COVID-19 infection. Adult patients diagnosed with COVID-19 between February 17, 2020, and March 24, 2020, were scheduled to visit the study hospital four times (6, 12, 18, and 24 months after infection) to assess their symptoms, quality of life, and mental health. Among the 235 patients, 121 (51.5%) completed the study visits. Of these, 59.5% were female, with a median age of 52 years. Mild to moderate disease severity were identified in 101 (83.4%) patients. A total of 75 participants (62.0%) were still experiencing long COVID symptoms 24 months after acute infection. Fatigue, amnesia, difficulty concentrating, and insomnia were the most common symptoms. The frequency of neuropsychiatric symptoms did not differ based on vaccination status or the number of doses received. Quality of life improved over time for the participants, but 32.2% of respondents still reported anxiety/depression at the end of the study. Overall, our cohort demonstrates that long COVID can persist up to 24 months after COVID-19 infection, affecting mental health and quality of life. CI - (c) 2024. The Author(s). FAU - Kim, Yoonjung AU - Kim Y AUID- ORCID: 0000-0002-7454-4014 AD - Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, 130, Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea. FAU - Bae, Sohyun AU - Bae S AUID- ORCID: 0000-0002-3755-8249 AD - Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, 130, Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea. FAU - Chang, Hyun-Ha AU - Chang HH AUID- ORCID: 0000-0002-9405-2121 AD - Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, 130, Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea. FAU - Kim, Shin-Woo AU - Kim SW AUID- ORCID: 0000-0002-0206-7108 AD - Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University Hospital, Kyungpook National University, 130, Dongdeok-ro, Jung-gu, Daegu, 41944, Republic of Korea. ksw2kms@knu.ac.kr. LA - eng PT - Journal Article DEP - 20240109 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Humans MH - Female MH - Middle Aged MH - Male MH - *Post-Acute COVID-19 Syndrome MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Prospective Studies MH - Quality of Life MH - Vaccination PMC - PMC10774352 COIS- The authors declare no competing interests. EDAT- 2024/01/09 00:42 MHDA- 2024/01/10 06:41 PMCR- 2024/01/09 CRDT- 2024/01/08 23:47 PHST- 2023/07/11 00:00 [received] PHST- 2023/12/14 00:00 [accepted] PHST- 2024/01/10 06:41 [medline] PHST- 2024/01/09 00:42 [pubmed] PHST- 2024/01/08 23:47 [entrez] PHST- 2024/01/09 00:00 [pmc-release] AID - 10.1038/s41598-023-50024-4 [pii] AID - 50024 [pii] AID - 10.1038/s41598-023-50024-4 [doi] PST - epublish SO - Sci Rep. 2024 Jan 9;14(1):854. doi: 10.1038/s41598-023-50024-4. PMID- 38186472 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240109 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 12 DP - 2023 Dec TI - Long COVID-19 Syndrome: Insights From a Major Tertiary Center in the UK on Who Is at Greater Risk. PG - e50027 LID - 10.7759/cureus.50027 [doi] LID - e50027 AB - INTRODUCTION: The COVID-19 pandemic triggered the unprecedented 'long COVID' crisis, with persistent symptoms beyond two months post-infection. This study explores the nexus between long COVID symptoms, patient demographics such as age, gender, and smoking, and clinical factors like vaccination, disease severity, and comorbidities. METHODS: A retrospective analysis of records was conducted between September 2021 and December 2022. The analysis covered adults with confirmed COVID-19 diagnoses. Data encompassed demographics, medical history, vaccination, disease severity, hospitalization, treatments, and post-COVID symptoms, analyzed using logistic regression. RESULTS: Among 289 participants, the average age was 51.51 years. Around 62.6% were females, and 93% received the COVID-19 vaccination, i.e., primarily the mRNA vaccine (48.4%) and the adenovirus vector-based vaccine (34.8%). Reinfections occurred in 11.76% of cases. Disease severity varied, with 75% having mild, 15% having moderate, and 10% having severe infections. Hospitalization rates were significant (25.6%), including 10.7% requiring intensive care. Thirteen distinct post-COVID symptoms were reported. Fatigue, shortness of breath upon exertion, and brain fog emerged as the most prevalent symptoms. Notably, females exhibited higher symptom prevalence. Significant correlations were established between higher BMI and smoking with augmented symptomatology. Conversely, a link between booster doses and symptom reduction was discerned. Using multinomial regression analysis, gender and smoking were identified as predictors of post-COVID-19 symptoms. CONCLUSION: The study underscores obesity, smoking, and the female gender's impact on long COVID symptoms; boosters show promise in alleviation. Respiratory pathology might underlie persistent symptoms in cases with radiological abnormalities and abnormal spirometry. Findings contribute to risk stratification, intervention strategies, and further research. CI - Copyright (c) 2023, Tariq Khan et al. FAU - Tariq Khan, Saad AU - Tariq Khan S AD - Medicine, Darlington Memorial Hospital, Darlington, GBR. FAU - Rashid, Khalid AU - Rashid K AD - General Internal Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Ansar, Farrukh AU - Ansar F AD - Medicine, Northwest School of Medicine, Khyber Medical University, Peshawar, PAK. FAU - Khan, Muhammad Y AU - Khan MY AD - Medical Education, Pak International Medical College, Peshawar, PAK. FAU - Ali Khan, Fahd AU - Ali Khan F AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Ebrahim Husain Ahmed Ali Ismaeel, Rawan AU - Ebrahim Husain Ahmed Ali Ismaeel R AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Hanif Mohammed, Raheem AU - Hanif Mohammed R AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Mustafa, Rehan AU - Mustafa R AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Tariq Khan, Bisma AU - Tariq Khan B AD - Medicine, Shaukat Khanum Memorial Hospital and Research Centre, Lahore, PAK. FAU - Tariq, Behram AU - Tariq B AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Husssain, Mubbashar AU - Husssain M AD - Medicine, James Cook University Hospital, Middlesbrough, GBR. FAU - Waheed, Aamir AU - Waheed A AD - Internal Medicine, Northampton General Hospital, Northampton, GBR. LA - eng PT - Journal Article DEP - 20231206 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10767765 OTO - NOTNLM OT - covid-19 OT - covid-19 vaccine OT - long covid-19 OT - post-covid-19 symptoms OT - predictors of post covid-19 syndrome COIS- The authors have declared that no competing interests exist. EDAT- 2024/01/08 06:42 MHDA- 2024/01/08 06:43 PMCR- 2023/12/06 CRDT- 2024/01/08 04:25 PHST- 2023/12/06 00:00 [accepted] PHST- 2024/01/08 06:43 [medline] PHST- 2024/01/08 06:42 [pubmed] PHST- 2024/01/08 04:25 [entrez] PHST- 2023/12/06 00:00 [pmc-release] AID - 10.7759/cureus.50027 [doi] PST - epublish SO - Cureus. 2023 Dec 6;15(12):e50027. doi: 10.7759/cureus.50027. eCollection 2023 Dec. PMID- 38166817 OWN - NLM STAT- MEDLINE DCOM- 20240105 LR - 20240106 IS - 1471-2334 (Electronic) IS - 1471-2334 (Linking) VI - 24 IP - 1 DP - 2024 Jan 2 TI - Factors affecting subsequent dose of COVID-19 vaccine uptake based on BASNEF model among older adults. PG - 18 LID - 10.1186/s12879-023-08903-8 [doi] LID - 18 AB - BACKGROUND: Vaccination is a primary prevention approach to preventing disease by disconnecting the transmission chain. The current study utilized a BASNEF model framework to identify factors influencing subsequent doses of COVID-19 vaccination among older adults. METHODS: This cross-sectional study was performed in the west of Iran in May 2022. The participants were selected via multi-stage sampling. Finally, 1120 participants contributed to the present study. The questionnaire consisted of three sections: a) Socio-demographic characteristics, b) cognitive impairments tests, and c) Questionnaire about the subsequent dose of COVID-19 vaccine uptake based on the BASNEF model. Data were analyzed using the software IBM AMOS-20 and SPSS-23 via one-way analysis of variance (ANOVA) and independent sample T-tests were used, too. The significance level of statistical tests was regarded as less than 0.05. RESULTS: The presented results of analyzing 50% of the variance of vaccination intention as the dependent variable (R square = 0.497) and 10% of the behavior variance as the dependent variable (R square = 0.104) can be explained based on the BASNEF model. The enabling factors (beta = 0.636, p < 0.001) and the intention (beta = 0.322, p < 0.001) were important factors for subsequent doses of COVID-19 vaccine uptake in older adults. CONCLUSION: So, planning and implementing promotional intervention programs for older people (over 65; 80), females, illiterate, widows and divorced, good economic status, and urban areas is essential. It seems that enabling factors such as free vaccinations, vaccination inaccessible places such as public social security agencies, social supports such as involvement of the government and physicians, and improving information by the medium or knowledge-sharing experience, which can be further used to enhance the acceptance of subsequent doses of COVID-19 uptake in older adults. CI - (c) 2023. The Author(s). FAU - Barati, Majid AU - Barati M AD - Social Determinants of Health Research Center, Hamadan University of Medical Sciences and Department of Public Health, Asadabad School of Medical sciences, Asadabad, Iran, Hamadan, IR, Iran. FAU - Jormand, Hanieh AU - Jormand H AUID- ORCID: 0000-0002-4582-1473 AD - Urology and Nephrology Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. jormand69h@gmail.com. FAU - Khazaei, Salman AU - Khazaei S AD - Department of Epidemiology, School of Public and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. FAU - Bashirian, Saeed AU - Bashirian S AD - Department of Public Health, School of Public Health and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. FAU - Sadri, Mohadeseh AU - Sadri M AD - Iranian Research Center on Aging, University of Social Walfare and Rehablitation Sciences, Tehran, IR, Iran. FAU - Afshari, Maryam AU - Afshari M AD - Department of Public Health, School of Public Health and Social Determinants of Health Research Center, Hamadan University of Medical Sciences, Hamadan, IR, Iran. LA - eng GR - 140002281477/Hamadan University of Medical Sciences/ PT - Journal Article DEP - 20240102 PL - England TA - BMC Infect Dis JT - BMC infectious diseases JID - 100968551 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Humans MH - Aged MH - COVID-19 Vaccines MH - *COVID-19/prevention & control MH - Cross-Sectional Studies MH - Analysis of Variance MH - *Cognitive Dysfunction MH - Vaccination PMC - PMC10763401 OTO - NOTNLM OT - Aging OT - COVID-19 vaccines OT - Immunosenescence OT - Intention COIS- The authors declare that they have no competing interests. EDAT- 2024/01/04 01:18 MHDA- 2024/01/05 06:43 PMCR- 2024/01/02 CRDT- 2024/01/03 09:16 PHST- 2023/09/04 00:00 [received] PHST- 2023/12/13 00:00 [accepted] PHST- 2024/01/05 06:43 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 09:16 [entrez] PHST- 2024/01/02 00:00 [pmc-release] AID - 10.1186/s12879-023-08903-8 [pii] AID - 8903 [pii] AID - 10.1186/s12879-023-08903-8 [doi] PST - epublish SO - BMC Infect Dis. 2024 Jan 2;24(1):18. doi: 10.1186/s12879-023-08903-8. PMID- 38130975 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240103 IS - 2396-8923 (Electronic) IS - 2396-8923 (Linking) VI - 8 IP - 1 DP - 2023 TI - COVID's long shadow: How SARS-CoV-2 infection, COVID-19 severity, and vaccination status affect long-term cognitive performance and health. PG - bpad038 LID - 10.1093/biomethods/bpad038 [doi] LID - bpad038 AB - COVID-19 affects a variety of organs and systems of the body including the central nervous system. Recent research has shown that COVID-19 survivors often experience neurological and psychiatric complications that can last for months after infection. We conducted a large Internet study using online tests to analyze the effects of SARS-CoV-2 infection, COVID-19 severity, and vaccination on health, intelligence, memory, and information processing precision and speed in a cohort of 4445 subjects. We found that both SARS-CoV-2 infection and COVID-19 severity were associated with negative impacts on patients' health. Furthermore, we observed a negative association between COVID-19 severity and cognitive performance. Younger participants had a higher likelihood of SARS-CoV-2 contraction, while the elderly had a higher likelihood of severe COVID-19 and vaccination. The association between age and COVID-19 severity was primarily mediated by older participants' impaired long-term health. Vaccination was positively associated with intelligence and the precision of information processing. However, the positive association between vaccination and intelligence was likely mediated by achieved education, which was itself strongly associated with the likelihood of being vaccinated. CI - (c) The Author(s) 2023. Published by Oxford University Press. FAU - Flegr, Jaroslav AU - Flegr J AUID- ORCID: 0000-0002-0822-0126 AD - Department of Philosophy and History of Sciences, Faculty of Science, Laboratory of Evolutionary Biology, Charles University, Prague 128 00, Czechia. FAU - Latifi, Ashkan AU - Latifi A AD - Department of Philosophy and History of Sciences, Faculty of Science, Laboratory of Evolutionary Biology, Charles University, Prague 128 00, Czechia. LA - eng SI - figshare/10.6084/m9.figshare.22586446.v1 PT - Journal Article DEP - 20231207 PL - England TA - Biol Methods Protoc JT - Biology methods & protocols JID - 101693064 PMC - PMC10733723 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - cognition OT - cognitive performance OT - long-term effects OT - mental health COIS- The authors declare no competing interests. EDAT- 2023/12/22 06:42 MHDA- 2023/12/22 06:43 PMCR- 2023/12/07 CRDT- 2023/12/22 04:08 PHST- 2023/11/09 00:00 [received] PHST- 2023/11/30 00:00 [revised] PHST- 2023/12/05 00:00 [accepted] PHST- 2023/12/22 06:43 [medline] PHST- 2023/12/22 06:42 [pubmed] PHST- 2023/12/22 04:08 [entrez] PHST- 2023/12/07 00:00 [pmc-release] AID - bpad038 [pii] AID - 10.1093/biomethods/bpad038 [doi] PST - epublish SO - Biol Methods Protoc. 2023 Dec 7;8(1):bpad038. doi: 10.1093/biomethods/bpad038. eCollection 2023. PMID- 38065769 OWN - NLM STAT- MEDLINE DCOM- 20240102 LR - 20240425 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 42 IP - 2 DP - 2024 Jan 12 TI - The intention to get COVID-19 booster vaccination and its association with cognitive and emotional factors: A survey of Chinese COVID-19 infected people in Hong Kong. PG - 206-212 LID - S0264-410X(23)01448-2 [pii] LID - 10.1016/j.vaccine.2023.12.015 [doi] AB - BACKGROUND: Although the pandemic has ended officially, COVID-19 remains impactful. Booster COVID-19 vaccination is still needed to protect individuals against COVID-19 and the disease's harmful consequences. This study investigated the prevalence of the intention to get booster COVID-19 vaccination after receiving the COVID-19 diagnosis and its associated factors among people reporting prior COVID-19. METHODS: A population-based anonymous telephone survey was conducted in Hong Kong, China from June to August 2022 among Chinese people reporting prior COVID-1 between February and August 2022 and having taken up >/=2 doses of COVID-19 vaccines prior to COVID-19 diagnosis. RESULTS: The prevalence of the intention to get booster vaccination was 59.2 %. Older age (>60 years), being currently married, not employed full-time, and having chronic diseases were positively associated with the intention to get booster vaccination. Adjusted for the background factors, higher levels of the cognitive factors of perceived susceptibility to COVID-19, perceived acquired moderate-to-strong immunity against COVID-19, and perceived adequate knowledge of COVID-19 were positively associated with the intention to get booster vaccination; stronger perceived severity of prior infection despite vaccination was negatively associated with the intention outcome. In contrast, stronger mental distress due to COVID-19, illness concern, and emotional representation were positively associated with the intention. Self-perceived long COVID status was not a significant factor. DISCUSSION: The prevalence of the intention to get booster COVID-19 vaccination was limited, especially among younger people reporting prior COVID-19. Health promotion is still required among people reporting prior COVID-19 and may emphasize the significant cognitive factors positively associated with the intention. Future studies are needed to confirm the findings, clarify the role of emotional factors on booster vaccination, and explore other factors of the intention to get booster vaccination among people reporting prior COVID-19. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Yu, Yanqiu AU - Yu Y AD - School of Public Health, Fudan University, Shanghai, China. FAU - Zhang, Xiaoying AU - Zhang X AD - College of Public Health, Shanghai University of Medicine and Health Sciences, Shanghai, China. FAU - Lau, Mason M C AU - Lau MMC AD - Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. FAU - Lau, Joseph T F AU - Lau JTF AD - Public Mental Health Center, School of Mental Health, Wenzhou Medical University, Wenzhou, China; Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, China. Electronic address: jlau@cuhk.edu.hk. LA - eng PT - Journal Article DEP - 20231207 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) RN - Chinese people RN - COVID-19 vaccine booster shot SB - IM MH - Hong Kong/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - China MH - Cognition MH - East Asian People MH - Immunization, Secondary MH - COVID-19 Testing MH - Post-Acute COVID-19 Syndrome MH - *COVID-19 Vaccines/administration & dosage MH - Humans MH - *Intention MH - Emotions OTO - NOTNLM OT - Booster vaccination OT - COVID-19 vaccination OT - Cognitive factors OT - Emotional factors OT - People reporting prior COVID-19 COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/12/09 05:43 MHDA- 2024/01/02 11:42 CRDT- 2023/12/08 21:59 PHST- 2023/06/30 00:00 [received] PHST- 2023/12/01 00:00 [revised] PHST- 2023/12/02 00:00 [accepted] PHST- 2024/01/02 11:42 [medline] PHST- 2023/12/09 05:43 [pubmed] PHST- 2023/12/08 21:59 [entrez] AID - S0264-410X(23)01448-2 [pii] AID - 10.1016/j.vaccine.2023.12.015 [doi] PST - ppublish SO - Vaccine. 2024 Jan 12;42(2):206-212. doi: 10.1016/j.vaccine.2023.12.015. Epub 2023 Dec 7. PMID- 37990079 OWN - NLM STAT- MEDLINE DCOM- 20240311 LR - 20261010 IS - 1530-0447 (Electronic) IS - 0031-3998 (Linking) VI - 95 IP - 4 DP - 2024 Mar TI - Children with severe neurological symptoms associated with SARS-CoV-2 infection during Omicron pandemic in China. PG - 1088-1094 LID - 10.1038/s41390-023-02904-8 [doi] AB - BACKGROUND: To analyze the clinical characteristics and outcomes of children with severe neurological symptoms associated with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the Omicron pandemic in China. METHODS: This study used a questionnaire to obtain data from pediatric intensive care unit (PICU) centers in seven tertiary hospitals in Northeast China from December 1, 2022, to January 31, 2023. RESULTS: A total of 255 patients were confirmed to have SARS-CoV-2 infection, and 45 patients (17.65 %) were included in this study. Of these, seven (15.6%) patients died, and the median time from admission to death was 35 h (IQR, 14-120 h). Twenty (52.6%) survivors experienced neurological sequelae. Patients with platelet counts lower than 100 x 10(9)/L had a higher incidence of complications such as multiple organ dysfunction, mechanical ventilation rate, and mortality. Cranial magnetic resonance imaging (MRI) always reveals cerebral tissue edema, with some severe lesions forming a softening site. CONCLUSION: Children infected with SARS-CoV-2 often exhibit severe neurological symptoms, and in some cases, they may rapidly develop malignant cerebral edema or herniation, leading to a fatal outcome. An early decrease in platelet count may associated with an unfavorable prognosis. IMPACT: Since early December 2022, China has gradually adjusted its prevention and control policy of SARS-CoV-2; Omicron outbreaks have occurred in some areas for a relatively short period. Due to the differences in ethnicity, endemic strains and vaccination status, there was a little difference from what has been reported about children with SARS-CoV-2 infection with severe neurological symptoms in abroad. This is the first multicenter clinical study in children with nervous system involvement after acute SARS-CoV-2 infection in China, and helpful for pediatricians to have a more comprehensive understanding of the clinical symptoms and prognosis of such disease. CI - (c) 2023. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc. FAU - Zhang, Tao AU - Zhang T AD - Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. FAU - Zhang, Qiao-Feng AU - Zhang QF AD - Department of Pediatric Intensive Care Unit, Dalian Women and Children's Medical Group, Dalian, China. FAU - Yang, Hong-Mei AU - Yang HM AD - Department of Pediatric Intensive Care Unit, Dalian Women and Children's Medical Group, Dalian, China. FAU - Liu, Pin AU - Liu P AD - Department of Pediatric Intensive Care Unit, Shenyang Children's Hospital, Shenyang, China. FAU - Sun, Peng AU - Sun P AD - Department of Pediatric Intensive Care Unit, Shenyang Children's Hospital, Shenyang, China. FAU - Li, Yu-Mei AU - Li YM AD - Department of Pediatric Intensive Care Unit, The First Hospital of Jilin University, Changchun, China. FAU - Zhang, Zhen AU - Zhang Z AD - Department of Pediatric Intensive Care Unit, The First Hospital of Jilin University, Changchun, China. FAU - Huang, Yan-Zhi AU - Huang YZ AD - Changchun Children's Hospital, Changchun, China. FAU - Yu, Xin-Yan AU - Yu XY AD - Department of Critical Medicine, Jiangnan Hospital of the Sixth Affiliated Hospital of Harbin Medical University (Harbin Children's Hospital), Harbin, China. FAU - Chao-Lu-Men, Qi-Qi-Ge AU - Chao-Lu-Men QQ AD - Department of Intensive Care Unit, Inner Mongolia Medical University Affiliated Hospital, Hohhot, China. FAU - Su, Qin AU - Su Q AD - Department of Intensive Care Unit, Inner Mongolia Medical University Affiliated Hospital, Hohhot, China. FAU - Liu, Chun-Feng AU - Liu CF AD - Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. zhliu258@hotmail.com. LA - eng PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20231121 PL - United States TA - Pediatr Res JT - Pediatric research JID - 0100714 SB - IM MH - Child MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Pandemics MH - *Brain Edema MH - China/epidemiology MH - Retrospective Studies EDAT- 2023/11/22 06:42 MHDA- 2024/03/11 06:43 CRDT- 2023/11/22 00:43 PHST- 2023/04/15 00:00 [received] PHST- 2023/11/02 00:00 [accepted] PHST- 2023/10/16 00:00 [revised] PHST- 2024/03/11 06:43 [medline] PHST- 2023/11/22 06:42 [pubmed] PHST- 2023/11/22 00:43 [entrez] AID - 10.1038/s41390-023-02904-8 [pii] AID - 10.1038/s41390-023-02904-8 [doi] PST - ppublish SO - Pediatr Res. 2024 Mar;95(4):1088-1094. doi: 10.1038/s41390-023-02904-8. Epub 2023 Nov 21. PMID- 37951998 OWN - NLM STAT- MEDLINE DCOM- 20231113 LR - 20260127 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Nov 11 TI - Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study. PG - 19688 LID - 10.1038/s41598-023-46912-4 [doi] LID - 19688 AB - We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who took nirmatrelvir/ritonavir and 250 who did not. The primary outcome was the development of one or more of eleven prespecified long COVID symptoms, assessed through a structured telephone interview four months after the positive SARS-CoV-2 test. Multivariable logistic regression models controlled for age, sex, race/ethnicity, chronic conditions, and COVID-19 vaccination status. We found that participants who took nirmatrelvir/ritonavir were no less likely to develop long COVID symptoms, compared to those who did not take the medication (44% vs. 49.6%, p = 0.21). Taking nirmatrelvir/ritonavir was associated with a lower odds of two of the eleven long COVID symptoms, brain fog (OR 0.58, 95% CI 0.38-0.88) and chest pain/tightness (OR 0.51, 95% CI 0.28-0.91). Our finding that treatment with nirmatrelvir/ritonavir was not associated with a lower risk of developing long COVID is different from prior studies that obtained data only from electronic medical records. CI - (c) 2023. The Author(s). FAU - Congdon, Seth AU - Congdon S AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. scongdon@montefiore.org. FAU - Narrowe, Zev AU - Narrowe Z AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Yone, Nang AU - Yone N AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Gunn, Jacob AU - Gunn J AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Deng, Yuting AU - Deng Y AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. FAU - Nori, Priya AU - Nori P AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. FAU - Cowman, Kelsie AU - Cowman K AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. FAU - Islam, Marjan AU - Islam M AD - Department of Critical Care Medicine, Montefiore Medical Center, Bronx, NY, USA. FAU - Rikin, Sharon AU - Rikin S AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. FAU - Starrels, Joanna AU - Starrels J AD - Department of Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY, 10467, USA. LA - eng PT - Journal Article DEP - 20231111 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 RN - 0 (COVID-19 Vaccines) RN - O3J8G9O825 (Ritonavir) RN - 0 (Antiviral Agents) RN - 7R9A5P7H32 (nirmatrelvir) RN - 0 (Lactams) RN - GMW67QNF9C (Leucine) RN - 0 (Nitriles) RN - 9DLQ4CIU6V (Proline) SB - IM MH - Adult MH - Humans MH - *COVID-19 MH - COVID-19 Drug Treatment MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - Retrospective Studies MH - Ritonavir/therapeutic use MH - SARS-CoV-2 MH - Chest Pain MH - Antiviral Agents/therapeutic use MH - Lactams MH - Leucine MH - Nitriles MH - Proline PMC - PMC10640584 COIS- The authors declare no competing interests. EDAT- 2023/11/12 00:42 MHDA- 2023/11/13 06:42 PMCR- 2023/11/11 CRDT- 2023/11/11 23:30 PHST- 2023/08/03 00:00 [received] PHST- 2023/11/07 00:00 [accepted] PHST- 2023/11/13 06:42 [medline] PHST- 2023/11/12 00:42 [pubmed] PHST- 2023/11/11 23:30 [entrez] PHST- 2023/11/11 00:00 [pmc-release] AID - 10.1038/s41598-023-46912-4 [pii] AID - 46912 [pii] AID - 10.1038/s41598-023-46912-4 [doi] PST - epublish SO - Sci Rep. 2023 Nov 11;13(1):19688. doi: 10.1038/s41598-023-46912-4. PMID- 37944296 OWN - NLM STAT- MEDLINE DCOM- 20231201 LR - 20231217 IS - 1532-8171 (Electronic) IS - 0735-6757 (Linking) VI - 75 DP - 2024 Jan TI - Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research. PG - 122-127 LID - S0735-6757(23)00534-X [pii] LID - 10.1016/j.ajem.2023.09.051 [doi] AB - OBJECTIVE: Long COVID has afflicted tens of millions globally leaving many previously-healthy persons severely and indefinitely debilitated. The objective here was to report cases of complete, rapid remission of severe forms of long COVID following certain monoclonal antibody (MCA) infusions and review the corresponding pathophysiological implications. DESIGN: Case histories of the first three index events (among others) are presented. Unaware of others with similar remissions, each subject independently completed personal narratives and standardized surveys regarding demographics/occupation, past history, and the presence and respective severity grading of 33 signs/symptoms associated with long COVID, comparing the presence/severity of those symptoms during the pre-COVID, long-COVID, post-vaccination, and post-MCA phases. SETTING: Patient interviews, e-mails and telephone conversations. SUBJECTS: Three previously healthy, middle-aged, highly-functioning persons, two women and one man (ages 60, 43, and 63 years respectively) who, post-acute COVID-19 infection, developed chronic, unrelenting fatigue and cognitive impairment along with other severe, disabling symptoms. Each then independently reported incidental and unanticipated complete remissions within days of MCA treatment. INTERVENTIONS: The casirivimab/imdevimab cocktail. MEASUREMENTS AND MAIN RESULTS: Irrespective of sex, age, medical history, vaccination status, or illness duration (18, 8 and 5 months, respectively), each subject experienced the same complete remission of their persistent disabling disease within a week of MCA infusion. Each rapidly returned to normal health and previous lifestyles/occupations with normalized exercise tolerance, still sustained to date over two years later. CONCLUSIONS: These index cases provide compelling clinical signals that MCA infusions may be capable of treating long COVID in certain cases, including those with severe debilitation. While the complete and sustained remissions observed here may only apply to long COVID resulting from pre-Delta variants and the specific MCA infused, the striking rapid and complete remissions observed in these cases also provide mechanistic implications for treating/managing other post-viral chronic conditions and long COVID from other variants. CI - Copyright (c) 2023 The Authors. Published by Elsevier Inc. All rights reserved. FAU - Scheppke, Kenneth A AU - Scheppke KA AD - Florida Department of Health, 4052 Bald Cypress Way, Tallahassee, FL 32399, USA; Palm Beach County Fire Rescue, 405 Pike Road, West Palm Beach, FL 33411, USA; Broward Sheriff's Office, 2601 West Broward Boulevard, Ft Lauderdale, FL 33312, USA. FAU - Pepe, Paul E AU - Pepe PE AD - Palm Beach County Fire Rescue, 405 Pike Road, West Palm Beach, FL 33411, USA; Broward Sheriff's Office, 2601 West Broward Boulevard, Ft Lauderdale, FL 33312, USA; Broward Health Medical Center, 1600 S Andrews Ave, Fort Lauderdale, FL 33316, USA; Department of Management, Policy and Community Health, School of Public Health, University of Texas Health Sciences Center, 1200 Pressler St, Houston, TX 77030, USA; Dallas County EMS/Public Safety Agencies, Suite 500, 500 Elm St, Dallas, TX 75202, USA. Electronic address: Dr.PaulPepe@GMail.com. FAU - Jui, Jonathan AU - Jui J AD - Department of Emergency Medicine, Oregon Health & Sciences University, CDW-EM, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. FAU - Crowe, Remle P AU - Crowe RP AD - ESO, 11500 Alterra Pkwy #100, Austin, TX 78758, USA. FAU - Scheppke, Eric K AU - Scheppke EK AD - Edward Via College of Osteopathic Medicine-Auburn, 910 S Donahue Dr, Auburn, AL 36832, USA. FAU - Klimas, Nancy G AU - Klimas NG AD - Institute for Neuro-Immune Medicine, Nova Southeastern University, 7595 SW 33rd Street, Fourth Floor, Ft Lauderdale, FL 33314, USA; Miami Veterans Administration Medical Center, 1201 NW 16th St, Miami, FL 33125, USA. FAU - Marty, Aileen M AU - Marty AM AD - Department of Translational Medicine, Florida International University, 885 SW 109th Ave, PG-5, Suite 1313, Miami, FL, 33199, USA. LA - eng PT - Journal Article DEP - 20231004 PL - United States TA - Am J Emerg Med JT - The American journal of emergency medicine JID - 8309942 RN - 0 (Antibodies, Monoclonal) RN - SARS-CoV-2 variants SB - IM MH - Male MH - Middle Aged MH - Humans MH - Female MH - *Antibodies, Monoclonal/therapeutic use MH - Post-Acute COVID-19 Syndrome MH - *COVID-19 MH - SARS-CoV-2 OTO - NOTNLM OT - COVID-19 OT - Immune response imbalance OT - Long COVID OT - Monoclonal antibody treatment OT - Post-acute sequelae SARS-CoV-2 infection OT - SARS-CoV-2 complications COIS- Declaration of Competing Interest None of the authors have any related conflict of interest concerning the elements of this report stewarded by the Florida Department of Health. EDAT- 2023/11/10 00:44 MHDA- 2023/12/01 06:44 CRDT- 2023/11/09 18:08 PHST- 2023/07/31 00:00 [received] PHST- 2023/09/29 00:00 [accepted] PHST- 2023/12/01 06:44 [medline] PHST- 2023/11/10 00:44 [pubmed] PHST- 2023/11/09 18:08 [entrez] AID - S0735-6757(23)00534-X [pii] AID - 10.1016/j.ajem.2023.09.051 [doi] PST - ppublish SO - Am J Emerg Med. 2024 Jan;75:122-127. doi: 10.1016/j.ajem.2023.09.051. Epub 2023 Oct 4. PMID- 41383902 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20251212 LR - 20260925 IS - 2770-730X (Electronic) IS - 2770-7296 (Print) IS - 2770-7296 (Linking) VI - 1 IP - 2 DP - 2023 Dec TI - Neurological manifestations with jugular vein thrombosis linked to an inflammatory profile may be a sequela of long COVID. PG - 170-175 LID - 10.1002/nep3.24 [doi] AB - More than 670 million cases of coronavirus disease 2019 (COVID-19) have been recorded worldwide in the 3 years since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. About 45% of survivors of COVID-19 develop a syndrome known as long-term COVID, in which symptoms persist even months after the acute infection. About 76% of patients with long COVID experience neurological manifestations. Moreover, patients who have survived COVID-19 have an increased risk of cerebral venous thrombosis. This case report describes a 41-year-old woman who developed neurological manifestations associated with jugular vein thrombosis 24 h after administration of the Oxford-AstraZeneca (ChAdOx1 nCoV-19) vaccine (AstraZeneca-Serum Institute of India). She had been infected with SARS-CoV-2 three months before vaccination. Although initially suspected to be a case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in view of her recent vaccination, the patient did not have any hallmarks of VITT, such as thrombocytopenia, an increased d-dimer level, or antibodies against platelet factor-4. Moreover, the neurological manifestations were associated with a high concentration of inflammatory cytokines, including interleukin (IL)-6, IL-17A, and IL-21, and elevated neutrophil levels in cerebrospinal fluid, suggesting that inflammatory immune components had a role in the development of thrombotic events and pointing to an alternative diagnosis. In this case, the laboratory results indicated that the neurological manifestations associated with jugular vein thrombosis were not associated with VITT. Therefore, we propose that the thrombosis of the left jugular vein was a sequela of SARS-CoV-2 infection. CI - (c) 2023 The Authors. Neuroprotection published by John Wiley & Sons Ltd on behalf of Chinese Medical Association. FAU - Mendoza-Portillo, Elizabeth AU - Mendoza-Portillo E AUID- ORCID: 0000-0003-0380-3856 AD - Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez Ciudad de Mexico Mexico. FAU - Aleman-Navarro, Estefania AU - Aleman-Navarro E AD - Instituto de Biotecnologia Universidad Nacional Autonoma de Mexico (UNAM) Cuernavaca Morelos Mexico. FAU - Prieto, G Aleph AU - Prieto GA AUID- ORCID: 0000-0001-9517-6989 AD - Instituto de Neurobiologia UNAM-Juriquilla Queretaro Mexico. AD - Institute for Memory Impairments and Neurological Disorders University of California-Irvine Irvine California USA. FAU - Rosenstein, Yvonne AU - Rosenstein Y AUID- ORCID: 0000-0003-4040-4256 AD - Instituto de Biotecnologia Universidad Nacional Autonoma de Mexico (UNAM) Cuernavaca Morelos Mexico. FAU - Lozano-Nuevo, Jose J AU - Lozano-Nuevo JJ AD - Hospital General de Ticoman Secretaria de Salud de la Ciudad de Mexico Ciudad de Mexico Mexico. FAU - Perez-Lopez, Araceli AU - Perez-Lopez A AUID- ORCID: 0000-0002-5399-1958 AD - Unidad de Investigacion en Biomedicina Facultad de Estudios Superiores Iztacala, UNAM Tlalneplantla Estado de Mexico Mexico. LA - eng PT - Journal Article DEP - 20231109 PL - England TA - Neuroprotection JT - Neuroprotection (Chichester, England) JID - 9918452086806676 PMC - PMC12486927 OTO - NOTNLM OT - cerebral venous thrombosis OT - long COVID OT - vaccine COIS- The authors declare that there is no conflict of interest. EDAT- 2023/11/09 00:00 MHDA- 2023/11/09 00:01 PMCR- 2023/11/09 CRDT- 2025/12/12 04:34 PHST- 2023/03/15 00:00 [received] PHST- 2023/06/21 00:00 [revised] PHST- 2023/07/05 00:00 [accepted] PHST- 2023/11/09 00:01 [medline] PHST- 2023/11/09 00:00 [pubmed] PHST- 2025/12/12 04:34 [entrez] PHST- 2023/11/09 00:00 [pmc-release] AID - NEP324 [pii] AID - 10.1002/nep3.24 [doi] PST - epublish SO - Neuroprotection. 2023 Nov 9;1(2):170-175. doi: 10.1002/nep3.24. eCollection 2023 Dec. PMID- 37938599 OWN - NLM STAT- MEDLINE DCOM- 20231114 LR - 20250728 IS - 2045-2322 (Electronic) IS - 2045-2322 (Linking) VI - 13 IP - 1 DP - 2023 Nov 8 TI - Longitudinal study of disease severity and external factors in cognitive failure after COVID-19 among Indonesian population. PG - 19405 LID - 10.1038/s41598-023-46334-2 [doi] LID - 19405 AB - The COVID-19 infection is assumed to induce cognitive failure. Identifying the relationship between COVID-19, the effect of vaccination and medication, and accommodating non-COVID-19 factors to cognitive failure is essential. This study was conducted in Indonesia from September 2021 to January 2023. Demographic information, clinical data, comorbidities, vaccination, and medication during COVID-19 were obtained, as well as a 6-month cognitive assessment with Cognitive Failures Questionnaire/CFQ, Fatigue Severity Score, and Generalized Anxiety Disorder (GAD-7). A Structural Equation Model explains the relationship between potential predictors and cognitive failure. The average score of CFQ after 6 months was 45.6 +/- 23.1 out of 100. The severity of the disease, which was associated with vaccination status, age, previous infection, and unit of treatment (p < 0.05), was not related to cognitive failure (p = 0.519), although there is a significant direct impact of worst vaccination status to cognitive failure(p < 0.001). However, age, fatigue, and current anxiety were associated with higher cognitive failure (p < 0.001), although comorbidities and recent headaches were not significant in other models (p > 0.05). This study concludes that cognitive failure after COVID-19 is a multifactorial event and does not solely depend on COVID-19 severity. It is crucial to re-address the factors related to the long-term efficacy of vaccination and medication and focus on non-health factors affecting cognitive failure.Trial Registration: NCT05060562. CI - (c) 2023. The Author(s). FAU - Herman, Bumi AU - Herman B AD - College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand. AD - Department of Family and Preventive Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. FAU - Wong, Martin Chi Sang AU - Wong MCS AD - The Faculty of Medicine, JC School of Public Health, The Chinese University of Hongkong, Hong Kong, China. AD - The Faculty of Medicine, The Centre for Health Education and Health Promotion, The Chinese University of Hong Kong, Hong Kong, China. AD - School of Public Health, The Peking University, Beijing, China. AD - School of Public Health, Fudan University, Shanghai, China. AD - School of Public Health, The Chinese Academy of Medical Sciences and Peking Union Medical Colleges, Beijing, China. FAU - Chantharit, Prawat AU - Chantharit P AD - Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. FAU - Hannanu, Firdaus Fabrice AU - Hannanu FF AD - Department of Family and Preventive Medicine, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. AD - Department of Radiology, Brainstem Imaging Laboratory, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, USA. FAU - Viwattanakulvanid, Pramon AU - Viwattanakulvanid P AD - College of Public Health Sciences, Chulalongkorn University, Bangkok, Thailand. pramon.v@chula.ac.th. LA - eng SI - ClinicalTrials.gov/NCT05060562 PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20231108 PL - England TA - Sci Rep JT - Scientific reports JID - 101563288 SB - IM EIN - Sci Rep. 2023 Dec 18;13(1):22514. doi: 10.1038/s41598-023-48244-9. PMID: 38110434 MH - Humans MH - Cognition MH - *COVID-19/complications/epidemiology MH - Fatigue/epidemiology/etiology MH - Indonesia/epidemiology MH - Longitudinal Studies MH - Patient Acuity PMC - PMC10632387 COIS- The authors declare no competing interests. EDAT- 2023/11/08 12:43 MHDA- 2023/11/09 06:42 PMCR- 2023/11/08 CRDT- 2023/11/08 11:42 PHST- 2023/02/20 00:00 [received] PHST- 2023/10/31 00:00 [accepted] PHST- 2023/11/09 06:42 [medline] PHST- 2023/11/08 12:43 [pubmed] PHST- 2023/11/08 11:42 [entrez] PHST- 2023/11/08 00:00 [pmc-release] AID - 10.1038/s41598-023-46334-2 [pii] AID - 46334 [pii] AID - 10.1038/s41598-023-46334-2 [doi] PST - epublish SO - Sci Rep. 2023 Nov 8;13(1):19405. doi: 10.1038/s41598-023-46334-2. PMID- 37922371 OWN - NLM STAT- MEDLINE DCOM- 20231226 LR - 20241202 IS - 1399-3062 (Electronic) IS - 1398-2273 (Print) IS - 1398-2273 (Linking) VI - 25 IP - 6 DP - 2023 Dec TI - Post-acute sequelae of COVID-19 in solid organ transplant recipients. PG - e14167 LID - 10.1111/tid.14167 [doi] AB - BACKGROUND: Post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC), defined as prolonged symptoms following an episode of COVID-19, is not well-characterized in solid organ transplant recipients (SOTR). In this study, we aimed to assess the prevalence of PASC in SOTR, its descriptive characteristics, and associated risk factors. METHODS: We retrospectively identified SOTRs with acute COVID-19 between June 1, 2020 and April 15, 2022, and abstracted demographic and medical history, characteristics of acute COVID-19 illness, and COVID-19 vaccination status. We defined PASC as ongoing/new symptoms present at 6 weeks or longer following acute COVID-19 diagnosis. RESULTS: Among 208 SOTRs with acute COVID-19, 72 (35%) developed PASC. Common symptoms were respiratory symptoms (67%), headache (40%), and difficulty concentrating (10%). Severe acute COVID-19 disease and presence of respiratory symptoms were associated with higher odds of PASC in multivariable analyses, while receipt of at least one COVID-19 vaccination prior to transplantation was protective. CONCLUSION: We found that PASC occurs in about a third of SOTRs with acute COVID-19 and has similar symptoms as described previously in immunocompetent hosts. Pre-transplant vaccination may be protective. Further prospective multicenter studies are needed. CI - (c) 2023 Wiley Periodicals LLC. FAU - Sigler, Rachel AU - Sigler R AUID- ORCID: 0000-0002-8861-1150 AD - Division of Infectious Diseases, The University of Kansas Health System, Kansas City, Kansas, USA. FAU - Covarrubias, Karina AU - Covarrubias K AD - Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, California, USA. FAU - Chen, Benjamin AU - Chen B AD - Division of Infectious Disease and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA. FAU - Rubarth, Rodrigo Barriola AU - Rubarth RB AD - Department of Medicine, University of California, San Diego, San Diego, California, USA. FAU - Torosian, Kelly AU - Torosian K AD - Department of Medicine, University of California, San Diego, San Diego, California, USA. FAU - Sanchez, Claudia Ramirez AU - Sanchez CR AD - Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, California, USA. FAU - Bharti, Ajay AU - Bharti A AD - Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, California, USA. FAU - DeGruttola, Victor AU - DeGruttola V AD - Department of Biostatistics, Harvard University School of Public Health, Boston, Massachusetts, USA. FAU - Aslam, Saima AU - Aslam S AUID- ORCID: 0000-0002-4051-5629 AD - Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California, San Diego, San Diego, California, USA. LA - eng GR - T15 LM011271/LM/NLM NIH HHS/United States GR - T15LM011271/LM/NLM NIH HHS/United States PT - Journal Article DEP - 20231103 PL - Denmark TA - Transpl Infect Dis JT - Transplant infectious disease : an official journal of the Transplantation Society JID - 100883688 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/epidemiology MH - COVID-19 Testing MH - *COVID-19 Vaccines/administration & dosage MH - Disease Progression MH - *Organ Transplantation MH - Post-Acute COVID-19 Syndrome/epidemiology MH - Retrospective Studies MH - *Transplant Recipients PMC - PMC10841400 MID - NIHMS1939159 OTO - NOTNLM OT - COVID-19 OT - immunocompromise OT - long COVID OT - post-acute sequelae of COVID-19 OT - solid organ transplant COIS- Potential Conflicts of Interest: RS: declares no conflict of interest. KC: declares no conflict of interest. BC: declares no conflict of interest. CR: declares no conflict of interest. RR: declares no conflict of interest. KT: declares no conflict of interest AB: declares no conflict of interest. VG: declares no conflict of interest. SA: Consultant for BioMx and Phico. Medical Advisory Board for Pherecydes. Research funding from the Cystic Fibrosis Foundation, NIH/NCATS, NIH/NIAID and Contrafect Corporation. EDAT- 2023/11/03 18:43 MHDA- 2023/12/25 06:42 PMCR- 2024/12/01 CRDT- 2023/11/03 14:13 PHST- 2023/09/07 00:00 [revised] PHST- 2023/06/14 00:00 [received] PHST- 2023/09/23 00:00 [accepted] PHST- 2023/12/25 06:42 [medline] PHST- 2023/11/03 18:43 [pubmed] PHST- 2023/11/03 14:13 [entrez] PHST- 2024/12/01 00:00 [pmc-release] AID - 10.1111/tid.14167 [doi] PST - ppublish SO - Transpl Infect Dis. 2023 Dec;25(6):e14167. doi: 10.1111/tid.14167. Epub 2023 Nov 3. PMID- 37849724 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20231023 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 11 DP - 2023 TI - Association between COVID-19 vaccination and critical outcomes among older adults with dementia: a comparative cohort study. PG - 1281266 LID - 10.3389/fpubh.2023.1281266 [doi] LID - 1281266 AB - BACKGROUND: As COVID-19 vaccines became available, understanding their potential benefits in vulnerable populations has gained significance. This study explored the advantages of COVID-19 vaccination in individuals with cognitive disorders by analyzing health-related variables and outcomes. METHODS: A prospective cohort study analyzed electronic medical records of 25,733 older adults with cognitive disorders and 65,544 older adults without cognitive disorders from March 2020 to February 2022. COVID-19 vaccination status was the primary exposure variable, categorized as fully vaccinated or unvaccinated. The primary outcomes measured were all-cause mortality and hospitalization rates within 14 and 400 days post-vaccination. Data on vaccination status, demographics, comorbidities, testing history, and clinical outcomes were collected from electronic health records. The study was ethically approved by the relevant medical facility's Institutional Review Board (0075-22-MHS). RESULTS: Vaccinated individuals had significantly lower mortality rates in both groups. In the research group, the mortality rate was 52% (n = 1852) for unvaccinated individuals and 7% (n = 1,241) for vaccinated individuals (p < 0.001). Similarly, in the control group, the mortality rate was 13.58% (n = 1,508) for unvaccinated individuals and 1.85% (n = 936) for vaccinated individuals (p < 0.001), despite higher COVID-19 positivity rates. In the research group, 30.26% (n = 1,072) of unvaccinated individuals tested positive for COVID-19, compared to 37.16% (n = 6,492) of vaccinated individuals (p < 0.001). In the control group, 17.31% (n = 1922) of unvaccinated individuals were COVID-19 positive, while 37.25% (n = 18,873) of vaccinated individuals tested positive (p < 0.001). Vaccination also showed potential benefits in mental health support. The usage of antipsychotic drugs was lower in vaccinated individuals (28.43%, n = 4,967) compared to unvaccinated individuals (37.48%, n = 1,328; 95% CI [0.92-1.28], p < 0.001). Moreover, vaccinated individuals had lower antipsychotic drug prescription rates (23.88%, n = 4,171) compared to unvaccinated individuals (27.83%, n = 968; 95% CI [-1.02 to -0.63], p < 0.001). Vaccination appeared to have a positive impact on managing conditions like diabetes, with 38.63% (n = 6,748) of vaccinated individuals having diabetes compared to 41.55% (n = 1,472) of unvaccinated individuals (95% CI [0.24, 0.48], p < 0.001). DISCUSSION: The findings highlight the importance of vaccination in safeguarding vulnerable populations during the pandemic and call for further research to optimize healthcare strategies for individuals with cognitive disorders. CI - Copyright (c) 2023 Radomyslsky, Kivity, Lidar, Bentur, Korn, Nissanholtz-Gannot, Sternberg, Halevi Hochwald, Reges, Alon and Saban. FAU - Radomyslsky, Zorian AU - Radomyslsky Z AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Kivity, Sara AU - Kivity S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Lidar, Shira AU - Lidar S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Bentur, Netta AU - Bentur N AD - Department of Occupational Therapy, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Korn, Liat AU - Korn L AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Nissanholtz-Gannot, Rachel AU - Nissanholtz-Gannot R AD - Department of Health System Management, Ariel University, Ariel, Israel. AD - Mayers-JDC-Brookdale Institute, Jerusalem, Israel. FAU - Sternberg, Shelley AU - Sternberg S AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Halevi Hochwald, Inbal AU - Halevi Hochwald I AD - School of Nursing, Max Stern Yezreel Valley College, Emek Yezreel, Israel. FAU - Reges, Orna AU - Reges O AD - Department of Health System Management, Ariel University, Ariel, Israel. FAU - Alon, Yaniv AU - Alon Y AD - Nursing Department, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Saban, Mor AU - Saban M AD - Nursing Department, School of Health Sciences, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20231002 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Aged MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines MH - Cohort Studies MH - Prospective Studies MH - Vaccination MH - *Diabetes Mellitus MH - *Dementia/epidemiology PMC - PMC10578450 OTO - NOTNLM OT - COVID-19 OT - dementia OT - mild cognitive impairment OT - psychiatric disorder diagnosis OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/10/18 06:43 MHDA- 2023/10/23 01:18 PMCR- 2023/10/02 CRDT- 2023/10/18 03:55 PHST- 2023/08/22 00:00 [received] PHST- 2023/09/15 00:00 [accepted] PHST- 2023/10/23 01:18 [medline] PHST- 2023/10/18 06:43 [pubmed] PHST- 2023/10/18 03:55 [entrez] PHST- 2023/10/02 00:00 [pmc-release] AID - 10.3389/fpubh.2023.1281266 [doi] PST - epublish SO - Front Public Health. 2023 Oct 2;11:1281266. doi: 10.3389/fpubh.2023.1281266. eCollection 2023. PMID- 37819703 OWN - NLM STAT- MEDLINE DCOM- 20231102 LR - 20241217 IS - 2369-2960 (Electronic) IS - 2369-2960 (Linking) VI - 9 DP - 2023 Oct 11 TI - Immune-Boosting Effect of the COVID-19 Vaccine: Real-World Bidirectional Cohort Study. PG - e47272 LID - 10.2196/47272 [doi] LID - e47272 AB - BACKGROUND: As the SARS-CoV-2 attenuates and antibodies from the COVID-19 vaccine decline, long-term attention should be paid to the durability of primary booster administration and the preventive effect of the second or multiple booster doses of the COVID-19 vaccine. OBJECTIVE: This study aimed to explore the durability of primary booster administration and the preventive effect of second or multiple booster doses of the COVID-19 vaccine. METHODS: We established a bidirectional cohort in Guizhou Province, China. Eligible participants who had received the primary booster dose were enrolled for blood sample collection and administration of the second booster dose. A retrospective cohort for the time of administration was constructed to evaluate antibody attenuation 6-12 months after the primary booster dose, while a prospective cohort on the vaccine effect of the second booster dose was constructed for 4 months after the second administration. RESULTS: Between September 21, 2022, and January 30, 2023, a total of 327 participants were included in the final statistical analysis plan. The retrospective cohort revealed that approximately 6-12 months after receiving the primary booster, immunoglobulin G (IgG) slowly declined with time, while immunoglobulin A (IgA) remained almost constant. The prospective cohort showed that 28 days after receiving the second booster, the antibody levels were significantly improved. Higher levels of IgG and IgA were associated with better protection against COVID-19 infection for vaccine recipients. Regarding the protection of antibody levels against post-COVID-19 symptoms, the increase of the IgG had a protective effect on brain fog and sleep quality, while IgA had a protective effect on shortness of breath, brain fog, impaired coordination, and physical pain. CONCLUSIONS: The IgG and IgA produced by the second booster dose of COVID-19 vaccines can protect against SARS-CoV-2 infection and may alleviate some post-COVID-19 symptoms. Further data and studies on secondary booster administration are required to confirm these conclusions. CI - (c)Ming Liu, Tianshuo Zhao, Qiuyue Mu, Ruizhi Zhang, Chunting Liu, Fei Xu, Luxiang Liang, Linglu Zhao, Suye Zhao, Xianming Cai, Mingting Wang, Ninghua Huang, Tian Feng, Shiguang Lei, Guanghong Yang, Fuqiang Cui. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 11.10.2023. FAU - Liu, Ming AU - Liu M AUID- ORCID: 0009-0002-5329-1385 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Zhao, Tianshuo AU - Zhao T AUID- ORCID: 0000-0001-5279-3215 AD - Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China. AD - Vaccine Research Center, School of Public Health, Peking University, Beijing, China. AD - Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China. FAU - Mu, Qiuyue AU - Mu Q AUID- ORCID: 0009-0002-1241-043X AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Zhang, Ruizhi AU - Zhang R AUID- ORCID: 0009-0007-4471-731X AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Liu, Chunting AU - Liu C AUID- ORCID: 0009-0006-9426-6476 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Xu, Fei AU - Xu F AUID- ORCID: 0009-0000-0815-7836 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Liang, Luxiang AU - Liang L AUID- ORCID: 0009-0009-1999-3333 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Zhao, Linglu AU - Zhao L AUID- ORCID: 0009-0008-2937-6278 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Zhao, Suye AU - Zhao S AUID- ORCID: 0000-0001-8606-8062 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Cai, Xianming AU - Cai X AUID- ORCID: 0009-0006-5457-9267 AD - Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China. AD - Vaccine Research Center, School of Public Health, Peking University, Beijing, China. AD - Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China. FAU - Wang, Mingting AU - Wang M AUID- ORCID: 0009-0001-8064-5030 AD - Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China. AD - Vaccine Research Center, School of Public Health, Peking University, Beijing, China. AD - Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China. FAU - Huang, Ninghua AU - Huang N AUID- ORCID: 0009-0002-5072-2645 AD - Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China. AD - Vaccine Research Center, School of Public Health, Peking University, Beijing, China. AD - Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China. FAU - Feng, Tian AU - Feng T AUID- ORCID: 0009-0007-5412-9730 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Lei, Shiguang AU - Lei S AUID- ORCID: 0009-0004-6217-5399 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Yang, Guanghong AU - Yang G AUID- ORCID: 0000-0001-5541-5869 AD - Guizhou Center for Disease Control and Prevention, Guiyang, China. FAU - Cui, Fuqiang AU - Cui F AUID- ORCID: 0000-0001-5279-3215 AD - Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, China. AD - Vaccine Research Center, School of Public Health, Peking University, Beijing, China. AD - Center for Infectious Diseases and Policy Research & Global Health and Infectious Diseases Group, Peking University, Beijing, China. AD - Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231011 PL - Canada TA - JMIR Public Health Surveill JT - JMIR public health and surveillance JID - 101669345 RN - 0 (COVID-19 Vaccines) RN - 0 (Immunoglobulin A) RN - 0 (Immunoglobulin G) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - Cohort Studies MH - *COVID-19/epidemiology/prevention & control MH - Retrospective Studies MH - Prospective Studies MH - SARS-CoV-2 MH - Immunoglobulin A MH - Immunoglobulin G PMC - PMC10569382 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccine OT - SARS-CoV-2 OT - bidirectional cohort study OT - booster administration OT - real-world study OT - vaccine efficacy COIS- Conflicts of Interest: None declared. EDAT- 2023/10/11 14:43 MHDA- 2023/11/02 12:45 PMCR- 2023/10/11 CRDT- 2023/10/11 11:53 PHST- 2023/03/14 00:00 [received] PHST- 2023/08/08 00:00 [accepted] PHST- 2023/06/25 00:00 [revised] PHST- 2023/11/02 12:45 [medline] PHST- 2023/10/11 14:43 [pubmed] PHST- 2023/10/11 11:53 [entrez] PHST- 2023/10/11 00:00 [pmc-release] AID - v9i1e47272 [pii] AID - 10.2196/47272 [doi] PST - epublish SO - JMIR Public Health Surveill. 2023 Oct 11;9:e47272. doi: 10.2196/47272. PMID- 37794431 OWN - NLM STAT- MEDLINE DCOM- 20231006 LR - 20240803 IS - 1745-6215 (Electronic) IS - 1745-6215 (Linking) VI - 24 IP - 1 DP - 2023 Oct 4 TI - Bacillus Calmette-Guerin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. PG - 636 LID - 10.1186/s13063-023-07662-w [doi] LID - 636 AB - BACKGROUND: A large epidemic, such as that observed with SARS-CoV-2, seriously challenges available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Bacillus Calmette-Guerin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in vitro and in vivo. Preliminary analyses suggest that regions of the world with existing BCG vaccination programs have lower incidence and mortality from COVID-19. We hypothesize that BCG vaccination can reduce SARS-CoV-2 infection and disease severity. METHODS: This will be a placebo-controlled adaptive multi-center randomized controlled trial. A total of 1800 individuals considered to be at high risk, including those with comorbidities (hypertension, diabetes, obesity, reactive airway disease, smokers), racial and ethnic minorities, elderly, teachers, police, restaurant wait-staff, delivery personnel, health care workers who are defined as personnel working in a healthcare setting, at a hospital, medical center or clinic (veterinary, dental, ophthalmology), and first responders (paramedics, firefighters, or law enforcement), will be randomly assigned to two treatment groups. The treatment groups will receive intradermal administration of BCG vaccine or placebo (saline) with groups at a 1:1 ratio. Individuals will be tracked for evidence of SARS-CoV-2 infection and severity as well as obtaining whole blood to track immunological markers, and a sub-study will include cognitive function and brain imaging. The majority of individuals will be followed for 6 months, with an option to extend for another 6 months, and the cognitive sub-study duration is 2 years. We will plot Kaplan-Meier curves that will be plotted comparing groups and hazard ratios and p-values reported using Cox proportional hazard models. DISCUSSION: It is expected this trial will allow evaluation of the effects of BCG vaccination at a population level in high-risk healthcare individuals through a mitigated clinical course of SARS-CoV-2 infection and inform policy making during the ongoing epidemic. TRIAL REGISTRATION: ClinicalTrials.gov NCT04348370. Registered on April 16, 2020. CI - (c) 2023. BioMed Central Ltd., part of Springer Nature. FAU - DiNardo, Andrew R AU - DiNardo AR AD - Global and Immigrant Health, Baylor College of Medicine, Houston, TX, 77030, USA. AD - Radboud Center for Infectious Diseases, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Arditi, Moshe AU - Arditi M AD - Departments of Pediatrics and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA. FAU - Kamat, Ashish M AU - Kamat AM AD - Department of Urology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. FAU - Koster, Kent J AU - Koster KJ AD - Center for Airborne Pathogen Research and Imaging, Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Carrero, Santiago AU - Carrero S AD - Global and Immigrant Health, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Nishiguchi, Tomoki AU - Nishiguchi T AD - Global and Immigrant Health, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Lebedev, Maxim AU - Lebedev M AD - Center for Airborne Pathogen Research and Imaging, Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Benjamin, Aaron B AU - Benjamin AB AD - Center for Airborne Pathogen Research and Imaging, Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Avalos, Pablo AU - Avalos P AD - Cedars-Sinai Medical Center, Regenerative Medicine Institute, Los Angeles, CA, 90048, USA. FAU - Lozano, Marisa AU - Lozano M AD - Department of Urology, UT MD Anderson Cancer Center, Houston, TX, 77030, USA. FAU - Moule, Madeleine G AU - Moule MG AD - Institute of Immunology & Infection Research, School of Biological Sciences, University of Edinburgh, Edinburgh, UK. FAU - McCune, Brittany AU - McCune B AD - Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Herron, Baysia AU - Herron B AD - Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Ladki, Malik AU - Ladki M AD - Global and Immigrant Health, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Sheikh, Daanish AU - Sheikh D AD - Global and Immigrant Health, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Spears, Matthew AU - Spears M AD - College of Osteopathic Medicine, Sam Houston State University, Conroe, TX, 77304, USA. FAU - Herrejon, Ivan A AU - Herrejon IA AD - Department of Psychological and Brain Sciences, Texas A&M University, College Station, TX, 77843, USA. FAU - Dodge, Courtney AU - Dodge C AD - Texas A&M School of Medicine, Round Rock, TX, 78665, USA. FAU - Kumar, Sathish AU - Kumar S AD - Center for Airborne Pathogen Research and Imaging, Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Hutchison, Robert W AU - Hutchison RW AD - Department of Pharmacy Practice, Texas A&M School of Pharmacy, College Station, TX, 77843, USA. FAU - Ofili, Theresa U AU - Ofili TU AD - Department of Pharmacy Practice, Texas A&M School of Pharmacy, College Station, TX, 77843, USA. FAU - Opperman, Lynne A AU - Opperman LA AD - Center for Craniofacial Research and Diagnosis, Texas A&M School of Dentistry, Dallas, TX, 75246, USA. FAU - Bernard, Jessica A AU - Bernard JA AD - Department of Psychological and Brain Sciences, Texas A&M Institute for Neuroscience, Texas A&M University, College Station, TX, 77843, USA. FAU - Lerner, Seth P AU - Lerner SP AD - Scott Department of Urology, Baylor College of Medicine, Houston, TX, 77030, USA. FAU - Udeani, George AU - Udeani G AD - Department of Pharmacy Practice, Texas A&M School of Pharmacy, Kingsville, TX, 78363, USA. FAU - Neal, Gabriel AU - Neal G AD - Primary Care and Rural Medicine, Texas A&M School of Medicine, Bryan, TX, 77807, USA. FAU - Netea, Mihai G AU - Netea MG AD - Radboud University Medical Center, Nijmegen, The Netherlands. FAU - Cirillo, Jeffrey D AU - Cirillo JD AUID- ORCID: 0000-0003-3058-2702 AD - Center for Airborne Pathogen Research and Imaging, Texas A&M School of Medicine, Bryan, TX, 77807, USA. jdcirillo@tamu.edu. LA - eng SI - ClinicalTrials.gov/NCT04348370 GR - K23 AI141681/AI/NIAID NIH HHS/United States PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20231004 PL - England TA - Trials JT - Trials JID - 101263253 RN - 0 (BCG Vaccine) SB - IM MH - Humans MH - Aged MH - *SARS-CoV-2 MH - *COVID-19/prevention & control MH - BCG Vaccine MH - Vaccination MH - Health Personnel MH - Immunity PMC - PMC10548680 OTO - NOTNLM OT - BCG vaccination OT - COVID-19 OT - Healthcare workers OT - Immune training OT - Pandemic OT - Randomized controlled trial COIS- The authors declare that they have no competing interests. EDAT- 2023/10/05 01:00 MHDA- 2023/10/06 06:43 PMCR- 2023/10/04 CRDT- 2023/10/04 23:44 PHST- 2023/01/29 00:00 [received] PHST- 2023/09/19 00:00 [accepted] PHST- 2023/10/06 06:43 [medline] PHST- 2023/10/05 01:00 [pubmed] PHST- 2023/10/04 23:44 [entrez] PHST- 2023/10/04 00:00 [pmc-release] AID - 10.1186/s13063-023-07662-w [pii] AID - 7662 [pii] AID - 10.1186/s13063-023-07662-w [doi] PST - epublish SO - Trials. 2023 Oct 4;24(1):636. doi: 10.1186/s13063-023-07662-w. PMID- 41505577 STAT- Publisher PB - Patient-Centered Outcomes Research Institute (PCORI) CTI - PCORI Final Research Reports DP - 2023 Oct BTI - Testing an Education Program about COVID-19 Infection for People Living with Serious Mental Illness AB - BACKGROUND: People with serious mental illness (SMI), including schizophrenia, bipolar disorder, and severe depression, represent the population most at risk for health disparities in the United States, with multiple co-occurring medical and social vulnerabilities that place them at disproportionate risk for COVID-19 acquisition, morbidity, and mortality. Without education, training, and support for prevention of COVID-19, negative outcomes for this group could have spillover effects on the larger community. The COVID-19 pandemic emerged approximately 5 months after the launch in fall 2019 of our pragmatic clinical study, "Integrated Physical and Mental Health Self-Management Compared with Chronic Disease Self-Management," which compared the Integrated Illness Management and Recovery (IIMR) program, an intervention developed specifically for people with SMI, and the Chronic Disease Self-Management Program (CDSMP), developed for use in the general population. This study enrolled adult service users from 2 large community mental health centers: 1 in Louisville, Kentucky, and 1 in Clarksville, Tennessee. We applied for and received a COVID-19 Enhancement award to develop a 3-session intervention to add to IIMR so that we could teach people with SMI how to avoid catching or spreading COVID-19. OBJECTIVES: The objectives of this study were to (1) gather timely information about the needs of people with SMI and co-morbid medical illness in the context of the pandemic to inform the co-design of a 3-session module that would provide education and coaching on preventing COVID-19 and reducing social isolation and (2) evaluate the impact of the module on the primary and secondary outcomes (primary: knowledge and use of measures to prevent contracting and spreading COVID-19 developed for use in this study; secondary: use of health care services for COVID-19-related concerns and perceived isolation and social disconnectedness [social determinants of health]). We also explored differential response with respect to race and ethnicity (Black vs White adults), age (older [ie, 55 years of age or older] vs younger adults), and psychiatric diagnosis (schizophrenia spectrum vs mood disorders). METHODS: We first conducted a comprehensive needs assessment with both health care professionals and service users to inform co-development and evaluation of a tailored, individually delivered, 3-session COVID-19 educational and skills training intervention. The intervention would address topics such as knowledge about transmission and symptoms of COVID-19, vaccines, preventive behaviors, coping skills, and social connectedness. All participants were community-dwelling individuals recruited from the parent study who had a diagnosis of schizoaffective disorder, schizophrenia, bipolar disorder, or major depression and a co-morbid medical condition who needed illness self-management training for 1 or both conditions. Participants were excluded from participating in the parent study if they were living in an institution (eg, hospital, nursing home), did not speak English, or had dementia or cognitive impairment based on a score less than 20 on the Telephone Interview for Cognitive Status. The COVID-19 module was delivered individually over 6 weeks to 80 participants randomly assigned in the parent study to receive IIMR; the 82 participants randomly assigned to receive the CDSMP who joined the Enhancement portion of the study did not receive the additional training on COVID-19. Both groups were assessed at baseline, 6 weeks, and 12 weeks using a scale we created to measure knowledge and engagement in behaviors to prevent COVID-19. Enrollment occurred from November 2020 to January 2022, with all follow-up assessments completed in April 2022. RESULTS: We conducted a needs assessment, then created a primary outcome measure corresponding to COVID-19 prevention knowledge and behaviors as well as a 3-session, tailored COVID-19 prevention module. Knowledge and enactment of the most widely promoted methods for preventing COVID-19 (ie, hand washing, masking, and physical distancing) did not differ between the groups and were broadly accepted. The intervention was associated with statistically significant modest improvements for the IIMR group vs the CDSMP group in prevention knowledge (mainly greater increase in rejection of prevention myths from baseline to follow-up) and greater increase from baseline to follow-up in knowledge of proper response to suspected symptoms of COVID-19. Those in the IIMR group also received the SARS-CoV-2 vaccine at a higher rate than those in the CDSMP group (72% vs 63%), which did not reach statistical significance (Fisher exact test P = .17) but is a promising, clinically significant finding from a population health perspective. Analysis by site revealed the greatest difference in vaccination rates between the IIMR and CDSMP groups at the Kentucky site (85% vs 71%). The only statistically significant subgroup effect was the larger effect of IIMR on preventive knowledge among participants 55 years of age or older. There were no significant differences between or within the groups in knowledge of the symptoms of COVID-19, knowledge of how it can be transmitted or prevented, or attitudes about COVID-19-related behaviors. CONCLUSIONS: This project resulted in creation of an easy-to-use, manual-based, standardized, 3-session intervention that provides education and training on how to prevent COVID-19 and other highly contagious illnesses. The intervention was appealing and associated with modest statistically significant improvements in knowledge, with the greatest improvements in knowledge of proper responses to suspected symptoms of COVID-19 and a trend toward increased acceptance of the SARS-CoV-2 vaccine in people with SMI at high risk because of multiple health disparities. This unique intervention may also reduce risk of negative outcomes of COVID-19 or future pandemics for other at-risk groups. LIMITATIONS: The evolution of the pandemic, including shifting recommendations regarding safety measures, posed a challenge for participants and likely affected the study data (eg, responses to assessment questions may have been affected by local indoor mask mandates, vaccination status). Nevertheless, the study was delivered as intended, and outcomes of this real-world evaluation of a novel education and coaching intervention, as provided to a diverse group of individuals at high risk of negative outcomes from COVID-19, is generalizable to the broader population of people with SMI. CI - Copyright (c) 2023. Dartmouth-Hitchcock Clinic. All Rights Reserved. FAU - Pratt, Sarah AU - Pratt S AD - Department of Psychiatry, Dartmouth-Hitchcock Clinic, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire FAU - Bartels, Stephen AU - Bartels S AD - The Mongan Institute, Massachusetts General Hospital, Boston FAU - Ferron, Joelle AU - Ferron J AD - Department of Psychiatry, Dartmouth-Hitchcock Clinic, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire FAU - Santos, Meghan AU - Santos M AD - Department of Psychiatry, Dartmouth-Hitchcock Clinic, Lebanon, New Hampshire FAU - Mueser, Kim AU - Mueser K AD - Department of Occupational Therapy, Boston University, Boston, Massachusetts LA - eng PT - Review PT - Book PL - Washington (DC) EDAT- 2023/10/01 00:00 CRDT- 2023/10/01 00:00 AID - NBK620128 [bookaccession] AID - 10.25302/10.2023.PCS.2017C27724IC [doi] PMID- 37762029 OWN - NLM STAT- MEDLINE DCOM- 20230929 LR - 20230930 IS - 1422-0067 (Electronic) IS - 1422-0067 (Linking) VI - 24 IP - 18 DP - 2023 Sep 6 TI - Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly. LID - 10.3390/ijms241813728 [doi] LID - 13728 AB - Although the safety and efficacy of COVID-19 vaccines in older people are critical to their success, little is known about their immunogenicity among elderly residents of long-term care facilities (LTCFs). A single-center prospective cohort study was conducted: a total IgG antibody titer, neutralizing antibodies against Wild-type, Delta Plus, and Omicron BA.2 variants and T cell response, were measured eight months after the second dose of BNT162b2 vaccine (T0) and at least 15 days after the booster (T1). Forty-nine LTCF residents, with a median age of 84.8 +/- 10.6 years, were enrolled. Previous COVID-19 infection was documented in 42.9% of the subjects one year before T0. At T1, the IgG titers increased up to 10-fold. This ratio was lower in the subjects with previous COVID-19 infection. At T1, IgG levels were similar in both groups. The neutralizing activity against Omicron BA.2 was significantly lower (65%) than that measured against Wild-type and Delta Plus (90%). A significant increase of T cell-specific immune response was observed after the booster. Frailty, older age, sex, cognitive impairment, and comorbidities did not affect antibody titers or T cell response. In the elderly sample analyzed, the BNT162b2 mRNA COVID-19 vaccine produced immunogenicity regardless of frailty. FAU - Dalla Gasperina, Daniela AU - Dalla Gasperina D AUID- ORCID: 0000-0002-1187-6222 AD - Department of Medicine and Technological Innovation, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy. FAU - Veronesi, Giovanni AU - Veronesi G AUID- ORCID: 0000-0002-4119-6615 AD - Research Centre in Epidemiology and Preventive Medicine (EPIMED), Department of Medicine and Surgery, University of Insubria, 21100 Varese, Italy. FAU - Castelletti, Carlo M AU - Castelletti CM AD - Molina's Foundation, 21100 Varese, Italy. FAU - Varchetta, Stefania AU - Varchetta S AUID- ORCID: 0000-0002-0289-2896 AD - Clinical Immunology-Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Ottolini, Sabrina AU - Ottolini S AD - Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy. FAU - Mele, Dalila AU - Mele D AUID- ORCID: 0000-0002-5217-2766 AD - Microbiology and Molecular Virology Unit, Fondazione IRCCS Policlinico S. Matteo, 27100 Pavia, Italy. FAU - Ferrari, Giuseppe AU - Ferrari G AD - Molina's Foundation, 21100 Varese, Italy. FAU - Shaik, Amruth K B AU - Shaik AKB AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. FAU - Celesti, Fabrizio AU - Celesti F AD - Center for Immuno-Oncology, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100 Siena, Italy. FAU - Dentali, Francesco AU - Dentali F AD - Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy. FAU - Accolla, Roberto S AU - Accolla RS AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. FAU - Forlani, Greta AU - Forlani G AUID- ORCID: 0000-0003-1987-7761 AD - Laboratory of General Pathology and Immunology "Giovanna Tosi", Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy. LA - eng GR - NA/FONDAZIONE MOLINA/ PT - Journal Article DEP - 20230906 PL - Switzerland TA - Int J Mol Sci JT - International journal of molecular sciences JID - 101092791 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - 0 (Immunoglobulin G) RN - COVID-19 vaccine booster shot SB - IM MH - *COVID-19/prevention & control MH - Immunization, Secondary MH - Immunoglobulin G MH - Prospective Studies MH - Humans MH - *Frailty MH - Immunity, Cellular MH - Aged, 80 and over MH - BNT162 Vaccine MH - COVID-19 Vaccines MH - Aged PMC - PMC10530943 OTO - NOTNLM OT - BNT162b2 mRNA COVID-19 vaccine OT - Omicron BA.2 OT - cellular immunity OT - long-term care facilities elderly residents OT - neutralizing antibodies COIS- The authors declare no conflict of interest. The funders had no role in the study's design; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. EDAT- 2023/09/28 06:42 MHDA- 2023/09/29 06:44 PMCR- 2023/09/06 CRDT- 2023/09/28 01:16 PHST- 2023/08/04 00:00 [received] PHST- 2023/08/22 00:00 [revised] PHST- 2023/08/26 00:00 [accepted] PHST- 2023/09/29 06:44 [medline] PHST- 2023/09/28 06:42 [pubmed] PHST- 2023/09/28 01:16 [entrez] PHST- 2023/09/06 00:00 [pmc-release] AID - ijms241813728 [pii] AID - ijms-24-13728 [pii] AID - 10.3390/ijms241813728 [doi] PST - epublish SO - Int J Mol Sci. 2023 Sep 6;24(18):13728. doi: 10.3390/ijms241813728. PMID- 37672962 OWN - NLM STAT- MEDLINE DCOM- 20230918 LR - 20230926 IS - 1879-1646 (Electronic) IS - 0167-6296 (Linking) VI - 91 DP - 2023 Sep TI - Cognitive ability, health policy, and the dynamics of COVID-19 vaccination. PG - 102802 LID - S0167-6296(23)00079-6 [pii] LID - 10.1016/j.jhealeco.2023.102802 [doi] AB - We examine the relationship between cognitive ability and prompt COVID-19 vaccination using individual-level data on more than 700,000 individuals in Sweden. We find a strong positive association between cognitive ability and swift vaccination, which remains even after controlling for confounding variables with a twin-design. The results suggest that the complexity of the vaccination decision may make it difficult for individuals with lower cognitive abilities to understand the benefits of vaccination. Consistent with this, we show that simplifying the vaccination decision through pre-booked vaccination appointments alleviates almost all of the inequality in vaccination behavior. CI - Copyright (c) 2023. Published by Elsevier B.V. FAU - Elinder, Mikael AU - Elinder M AD - Department of Economics, Uppsala University, Uppsala, Sweden. FAU - Erixson, Oscar AU - Erixson O AD - Institute for Housing and Urban Research, Uppsala University, Uppsala, Sweden. Electronic address: oscar.erixson@ibf.uu.se. FAU - Ohman, Mattias AU - Ohman M AD - Institute for Housing and Urban Research, Uppsala University, Uppsala, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230819 PL - Netherlands TA - J Health Econ JT - Journal of health economics JID - 8410622 RN - 0 (COVID-19 Vaccines) MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines/therapeutic use MH - Health Policy MH - Cognition MH - Sweden/epidemiology OTO - NOTNLM OT - Administrative data OT - COVID-19 OT - Intelligence OT - Nudge OT - Twin-design OT - Vaccination COIS- Declaration of Competing Interest The authors declare that they have no relevant or material financial interests that relate to the research described in this paper. EDAT- 2023/09/07 00:41 MHDA- 2023/09/18 12:44 CRDT- 2023/09/06 18:13 PHST- 2023/05/02 00:00 [received] PHST- 2023/08/15 00:00 [revised] PHST- 2023/08/18 00:00 [accepted] PHST- 2023/09/18 12:44 [medline] PHST- 2023/09/07 00:41 [pubmed] PHST- 2023/09/06 18:13 [entrez] AID - S0167-6296(23)00079-6 [pii] AID - 10.1016/j.jhealeco.2023.102802 [doi] PST - ppublish SO - J Health Econ. 2023 Sep;91:102802. doi: 10.1016/j.jhealeco.2023.102802. Epub 2023 Aug 19. PMID- 37654668 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260518 IS - 2589-5370 (Electronic) IS - 2589-5370 (Linking) VI - 62 DP - 2023 Aug TI - Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. PG - 102107 LID - 10.1016/j.eclinm.2023.102107 [doi] LID - 102107 AB - BACKGROUND: Lack of specific definitions of clinical characteristics, disease severity, and risk and preventive factors of post-COVID-19 syndrome (PCS) severely impacts research and discovery of new preventive and therapeutics drugs. METHODS: This prospective multicenter cohort study was conducted from February 2020 to June 2022 in 5 countries, enrolling SARS-CoV-2 out- and in-patients followed at 3-, 6-, and 12-month from diagnosis, with assessment of clinical and biochemical features, antibody (Ab) response, Variant of Concern (VoC), and physical and mental quality of life (QoL). Outcome of interest was identification of risk and protective factors of PCS by clinical phenotype, setting, severity of disease, treatment, and vaccination status. We used SF-36 questionnaire to assess evolution in QoL index during follow-up and unsupervised machine learning algorithms (principal component analysis, PCA) to explore symptom clusters. Severity of PCS was defined by clinical phenotype and QoL. We also used generalized linear models to analyse the impact of PCS on QoL and associated risk and preventive factors. CT registration number: NCT05097677. FINDINGS: Among 1796 patients enrolled, 1030 (57%) suffered from at least one symptom at 12-month. PCA identified 4 clinical phenotypes: chronic fatigue-like syndrome (CFs: fatigue, headache and memory loss, 757 patients, 42%), respiratory syndrome (REs: cough and dyspnoea, 502, 23%); chronic pain syndrome (CPs: arthralgia and myalgia, 399, 22%); and neurosensorial syndrome (NSs: alteration in taste and smell, 197, 11%). Determinants of clinical phenotypes were different (all comparisons p < 0.05): being female increased risk of CPs, NSs, and CFs; chronic pulmonary diseases of REs; neurological symptoms at SARS-CoV-2 diagnosis of REs, NSs, and CFs; oxygen therapy of CFs and REs; and gastrointestinal symptoms at SARS-CoV-2 diagnosis of CFs. Early treatment of SARS-CoV-2 infection with monoclonal Ab (all clinical phenotypes), corticosteroids therapy for mild/severe cases (NSs), and SARS-CoV-2 vaccination (CPs) were less likely to be associated to PCS (all comparisons p < 0.05). Highest reduction in QoL was detected in REs and CPs (43.57 and 43.86 vs 57.32 in PCS-negative controls, p < 0.001). Female sex (p < 0.001), gastrointestinal symptoms (p = 0.034) and renal complications (p = 0.002) during the acute infection were likely to increase risk of severe PCS (QoL <50). Vaccination and early treatment with monoclonal Ab reduced the risk of severe PCS (p = 0.01 and p = 0.03, respectively). INTERPRETATION: Our study provides new evidence suggesting that PCS can be classified by clinical phenotypes with different impact on QoL, underlying possible different pathogenic mechanisms. We identified factors associated to each clinical phenotype and to severe PCS. These results might help in designing pathogenesis studies and in selecting high-risk patients for inclusion in therapeutic and management clinical trials. FUNDING: The study received funding from the Horizon 2020 ORCHESTRA project, grant 101016167; from the Netherlands Organisation for Health Research and Development (ZonMw), grant 10430012010023; from Inserm, REACTing (REsearch & ACtion emergING infectious diseases) consortium and the French Ministry of Health, grant PHRC 20-0424. CI - (c) 2023 The Authors. FAU - Gentilotti, Elisa AU - Gentilotti E AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Gorska, Anna AU - Gorska A AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Tami, Adriana AU - Tami A AD - University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Groningen, The Netherlands. FAU - Gusinow, Roy AU - Gusinow R AD - The Life & Medical Sciences Institute (LIMES), University of Bonn-Institute for Computational Biology, Helmholtz Munich; Research Center for Environmental Health, Neuherberg, Germany. FAU - Mirandola, Massimo AU - Mirandola M AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Rodriguez Bano, Jesus AU - Rodriguez Bano J AD - Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital Universitario Virgen Macarena, Departamento de Medicina, Universidad de Sevilla, Spain. AD - Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain. AD - CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. FAU - Palacios Baena, Zaira R AU - Palacios Baena ZR AD - Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital Universitario Virgen Macarena, Departamento de Medicina, Universidad de Sevilla, Spain. AD - Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain. AD - CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. FAU - Rossi, Elisa AU - Rossi E AD - CINECA Interuniversity Consortium, Bologna, Italy. FAU - Hasenauer, Jan AU - Hasenauer J AD - The Life & Medical Sciences Institute (LIMES), University of Bonn-Institute for Computational Biology, Helmholtz Munich; Research Center for Environmental Health, Neuherberg, Germany. FAU - Lopes-Rafegas, Iris AU - Lopes-Rafegas I AD - Barcelona Institute for Global Health (ISGlobal), Hospital Clinic, University of Barcelona, Spain. FAU - Righi, Elda AU - Righi E AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Caroccia, Natascia AU - Caroccia N AD - Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. FAU - Cataudella, Salvatore AU - Cataudella S AD - CINECA Interuniversity Consortium, Bologna, Italy. FAU - Pasquini, Zeno AU - Pasquini Z AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Osmo, Thomas AU - Osmo T AD - Centre Informatique National de l'Enseignement Superieur CINES, France. FAU - Del Piccolo, Lidia AU - Del Piccolo L AD - Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. FAU - Savoldi, Alessia AU - Savoldi A AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Kumar-Singh, Samir AU - Kumar-Singh S AD - Molecular Pathology Group, Cell Biology & Histology, and Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Antwerp, Belgium. FAU - Mazzaferri, Fulvia AU - Mazzaferri F AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Caponcello, Maria Giulia AU - Caponcello MG AD - Unidad Clinica de Enfermedades Infecciosas y Microbiologia, Hospital Universitario Virgen Macarena, Departamento de Medicina, Universidad de Sevilla, Spain. AD - Instituto de Biomedicina de Sevilla (IBiS)/CSIC, Seville, Spain. AD - CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain. FAU - de Boer, Gerolf AU - de Boer G AD - University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Groningen, The Netherlands. FAU - Hara, Gabriel Levy AU - Hara GL AD - Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional, Facultad de Medicina, Universidad de Buenos Aires, Argentina. CN - ORCHESTRA Study Group FAU - De Nardo, Pasquale AU - De Nardo P AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Malhotra, Surbhi AU - Malhotra S AD - Molecular Pathology Group, Cell Biology & Histology, and Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Antwerp, Belgium. FAU - Canziani, Lorenzo Maria AU - Canziani LM AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. FAU - Ghosn, Jade AU - Ghosn J AD - Universite Paris Cite, INSERM IAME UMR 1137, Paris, France. AD - AP-HP Nord, Hopital Bichat, Department of Infectious and Tropical Diseases, Paris, France. FAU - Florence, Aline-Marie AU - Florence AM AD - Universite Paris Cite, INSERM IAME UMR 1137, Paris, France. AD - AP-HP Nord, Hopital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France. FAU - Lafhej, Nadhem AU - Lafhej N AD - AP-HP Nord, Hopital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France. FAU - van der Gun, Bernardina T F AU - van der Gun BTF AD - University of Groningen, University Medical Center Groningen, Department of Medical Microbiology and Infection Prevention, Groningen, The Netherlands. FAU - Giannella, Maddalena AU - Giannella M AD - Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. AD - Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. FAU - Laouenan, Cedric AU - Laouenan C AD - Universite Paris Cite, INSERM IAME UMR 1137, Paris, France. AD - AP-HP Nord, Hopital Bichat, Department of Epidemiology Biostatistics and Clinical Research, Paris, France. FAU - Tacconelli, Evelina AU - Tacconelli E AD - Infectious Disease, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. LA - eng SI - ClinicalTrials.gov/NCT05097677 PT - Journal Article DEP - 20230721 PL - England TA - EClinicalMedicine JT - EClinicalMedicine JID - 101733727 PMC - PMC10466236 OTO - NOTNLM OT - COVID-19 OT - Long-term sequelae OT - Post-COVID syndrome OT - Prediction model OT - SARS-CoV-2 COIS- AT received a grant from the Netherlands Organization for Health Research and Development (ZonMw) (grant number 10430012010023). JG received funding from ViiV Healthcare, Gilead Sciences, Theratechnologies, Astra-Zeneca, and Merck, all outside this study. MG received funding for lectures at educational events from Pfizer, Shionogi, MSD, Menarini, and Gilead, all outside this study. All other authors have nothing to declare. FIR - Pinho Guedes, Mariana Nunes IR - Pinho Guedes MN FIR - Maccarrone, Gaia IR - Maccarrone G FIR - Pezzani, Maria Diletta IR - Pezzani MD FIR - Sibani, Marcella IR - Sibani M FIR - Davies, Ruth Joanna IR - Davies RJ FIR - Vitali, Stefania IR - Vitali S FIR - Franchina, Giorgia IR - Franchina G FIR - Tomassini, Giorgia IR - Tomassini G FIR - Sciammarella, Concetta IR - Sciammarella C FIR - Cecchetto, Riccardo IR - Cecchetto R FIR - Gibellini, Davide IR - Gibellini D FIR - De Toffoli, Chiara Konishi IR - De Toffoli CK FIR - Rosini, Giulia IR - Rosini G FIR - Perlini, Chiara IR - Perlini C FIR - Meroi, Marco IR - Meroi M FIR - Cioli Puviani, Filippo IR - Cioli Puviani F FIR - Fasan, Daniele IR - Fasan D FIR - Micheletto, Claudio IR - Micheletto C FIR - Montemezzi, Stefania IR - Montemezzi S FIR - Cardobi, Nicolo IR - Cardobi N FIR - Vantini, Gianluca IR - Vantini G FIR - Mazzali, Gloria IR - Mazzali G FIR - Stabile, Giovanni IR - Stabile G FIR - Marcanti, Maddalena IR - Marcanti M FIR - Zonta, Marco Pattaro IR - Zonta MP FIR - Cali, Deborah IR - Cali D FIR - Mason, Anna IR - Mason A FIR - Perlini, Cinzia IR - Perlini C FIR - Gisondi, Paolo IR - Gisondi P FIR - Mongardi, Maria IR - Mongardi M FIR - Sorbello, Simona IR - Sorbello S FIR - Wold, Karin I IR - Wold KI FIR - Vincenti-Gonzalez, Maria F IR - Vincenti-Gonzalez MF FIR - Veloo, Alida Cm IR - Veloo AC FIR - Harmsma, Valerie Pr IR - Harmsma VP FIR - Pantano, Daniele IR - Pantano D FIR - van der Meer, Margriet IR - van der Meer M FIR - Gard, Lilli IR - Gard L FIR - Lizarazo, Erley F IR - Lizarazo EF FIR - Knoester, Marjolein IR - Knoester M FIR - Friedrich, Alex W IR - Friedrich AW FIR - Niesters, Hubert Gm IR - Niesters HG FIR - Viale, Pierluigi IR - Viale P FIR - Marzolla, Domenico IR - Marzolla D FIR - Cosentino, Federica IR - Cosentino F FIR - Di Chiara, Michela IR - Di Chiara M FIR - Fornaro, Giacomo IR - Fornaro G FIR - Bonazzetti, Cecilia IR - Bonazzetti C FIR - Tazza, Beatrice IR - Tazza B FIR - Toschi, Alice IR - Toschi A FIR - Vetamanu, Oana IR - Vetamanu O FIR - Giacomini, Maria Eugenia IR - Giacomini ME FIR - Trapani, Fabio IR - Trapani F FIR - Marconi, Lorenzo IR - Marconi L FIR - Attard, Luciano IR - Attard L FIR - Tedeschi, Sara IR - Tedeschi S FIR - Gabrielli, Liliana IR - Gabrielli L FIR - Lazzarotto, Tiziana IR - Lazzarotto T FIR - Olivares, Paula IR - Olivares P FIR - Castilla, Javier IR - Castilla J FIR - Velez, Javier IR - Velez J FIR - Almadana, Virginia IR - Almadana V FIR - Martin-Barrera, Lucia IR - Martin-Barrera L FIR - Martin-Gutierrez, Ana Belen IR - Martin-Gutierrez AB FIR - Gutierrez-Campos, David IR - Gutierrez-Campos D FIR - Fernandez-Regana, Marta IR - Fernandez-Regana M FIR - Silva-Campos, Ana IR - Silva-Campos A FIR - Fernandez-Riejos, Patricia IR - Fernandez-Riejos P FIR - Garcia-Sanchez, M Isabel IR - Garcia-Sanchez MI FIR - Giuliano, Carla V IR - Giuliano CV FIR - Lopez, Carlota IR - Lopez C FIR - Neumann, Gabriela IR - Neumann G FIR - Camporro, Julieta IR - Camporro J FIR - de Vedia, Lautaro IR - de Vedia L FIR - Agugliaro, Hugo IR - Agugliaro H FIR - Scipione, Gabriella IR - Scipione G FIR - Dellacasa, Chiara IR - Dellacasa C FIR - Chandramouli, Balasubramanian IR - Chandramouli B FIR - Gioiosa, Silvia IR - Gioiosa S FIR - Naranjo, Juan Mata IR - Naranjo JM FIR - Ortali, Maurizio IR - Ortali M FIR - Konnova, Angelina IR - Konnova A FIR - Gupta, Akshita IR - Gupta A FIR - Smet, Mathias IR - Smet M FIR - Hotterbeekx, An IR - Hotterbeekx A FIR - Berkell, Matilda IR - Berkell M FIR - Sicuri, Elisa IR - Sicuri E FIR - Bachelet, Delphine IR - Bachelet D FIR - Bouadma, Lila IR - Bouadma L FIR - Cervantes-Gonzalez, Minerva IR - Cervantes-Gonzalez M FIR - Chair, Anissa IR - Chair A FIR - Charpentier, Charlotte IR - Charpentier C FIR - Chenard, Leo IR - Chenard L FIR - Descamps, Diane IR - Descamps D FIR - Doan, Hang IR - Doan H FIR - Duval, Xavier IR - Duval X FIR - Esposito-Farese, Marina IR - Esposito-Farese M FIR - Hoffmann, Isabelle IR - Hoffmann I FIR - Kafif, Ouifiya IR - Kafif O FIR - Le Hingrat, Quentin IR - Le Hingrat Q FIR - Letrou, Sophie IR - Letrou S FIR - Mentre, France IR - Mentre F FIR - Schneider, Marion IR - Schneider M FIR - Tardivon, Coralie IR - Tardivon C FIR - Timsit, Jean-Francois IR - Timsit JF FIR - Tubiana, Sarah IR - Tubiana S FIR - Abrous, Amal IR - Abrous A FIR - Couffin-Cadiergues, Sandrine IR - Couffin-Cadiergues S FIR - Da Silva, Fernanda Dias IR - Da Silva FD FIR - Esperou, Helene IR - Esperou H FIR - Houas, Ikram IR - Houas I FIR - Jaafoura, Salma IR - Jaafoura S FIR - Papadopoulos, Aurelie IR - Papadopoulos A FIR - Ansart, Severine IR - Ansart S FIR - Auvet, Adrien IR - Auvet A FIR - Bani-Sadr, Firouze IR - Bani-Sadr F FIR - Bernard, L IR - Bernard L FIR - Bissuel, Francois IR - Bissuel F FIR - Botelho-Nevers, Elisabeth IR - Botelho-Nevers E FIR - Bouhour, Damien IR - Bouhour D FIR - Cabie, Andre IR - Cabie A FIR - Caraux Paz, Pauline IR - Caraux Paz P FIR - Chidiac, Christian IR - Chidiac C FIR - Chirouze, Catherine IR - Chirouze C FIR - Chroboczek, Tomasz IR - Chroboczek T FIR - Cordel, Hugues IR - Cordel H FIR - Courtois, Roxane IR - Courtois R FIR - De Castro, Nathalie IR - De Castro N FIR - Diamamntis, Sylvain IR - Diamamntis S FIR - Diehl, Jean-Luc IR - Diehl JL FIR - Djossou, Felix IR - Djossou F FIR - Dorival, Celine IR - Dorival C FIR - Epaulard, Olivier IR - Epaulard O FIR - Gaborieau, Valerie IR - Gaborieau V FIR - Goehringer, Francois IR - Goehringer F FIR - Gousseff, Marie IR - Gousseff M FIR - Jamard, Simon IR - Jamard S FIR - Joseph, Cedric IR - Joseph C FIR - Lacombe, Karine IR - Lacombe K FIR - Le Mestre, Soizic IR - Le Mestre S FIR - Le Moing, Vincent IR - Le Moing V FIR - Lelievre, Jean-Daniel IR - Lelievre JD FIR - Lesens, Olivier IR - Lesens O FIR - Machado, M IR - Machado M FIR - Maillet, Mylene IR - Maillet M FIR - Manda, Victoria IR - Manda V FIR - Martin-Blondel, Guillaume IR - Martin-Blondel G FIR - Martinot, Martin IR - Martinot M FIR - Meysonnier, Vanina IR - Meysonnier V FIR - Molina, Jean-Michel IR - Molina JM FIR - Oziol, Eric IR - Oziol E FIR - Pestre, Vincent IR - Pestre V FIR - Piroth, Lionel IR - Piroth L FIR - Poissy, Julien IR - Poissy J FIR - Rabaud, Christian IR - Rabaud C FIR - Raffi, Francois IR - Raffi F FIR - Rammaert, Blandine IR - Rammaert B FIR - Rapp, Christophe IR - Rapp C FIR - Rebaudet, Stanislas IR - Rebaudet S FIR - Roger, Pierre-Marie IR - Roger PM FIR - Roux, Damien IR - Roux D FIR - Senneville, Eric IR - Senneville E FIR - Tattevin, Pierre IR - Tattevin P FIR - Wiedemann, Aurelie IR - Wiedemann A FIR - Zucman, David IR - Zucman D EDAT- 2023/09/01 06:42 MHDA- 2023/09/01 06:43 PMCR- 2023/07/21 CRDT- 2023/09/01 03:59 PHST- 2023/05/03 00:00 [received] PHST- 2023/06/30 00:00 [revised] PHST- 2023/06/30 00:00 [accepted] PHST- 2023/09/01 06:42 [pubmed] PHST- 2023/09/01 06:43 [medline] PHST- 2023/09/01 03:59 [entrez] PHST- 2023/07/21 00:00 [pmc-release] AID - S2589-5370(23)00284-5 [pii] AID - 102107 [pii] AID - 10.1016/j.eclinm.2023.102107 [doi] PST - epublish SO - EClinicalMedicine. 2023 Jul 21;62:102107. doi: 10.1016/j.eclinm.2023.102107. eCollection 2023 Aug. PMID- 37611865 OWN - NLM STAT- MEDLINE DCOM- 20231129 LR - 20231129 IS - 1469-0691 (Electronic) IS - 1198-743X (Linking) VI - 29 IP - 12 DP - 2023 Dec TI - Risk of Bell's palsy following SARS-CoV-2 infection: a nationwide cohort study. PG - 1581-1586 LID - S1198-743X(23)00397-X [pii] LID - 10.1016/j.cmi.2023.08.014 [doi] AB - OBJECTIVES: Despite some evidence of an increased risk of neurologic symptoms following viral vector COVID-19 vaccine administration, it is unclear whether SARS-CoV-2 infection is associated with Bell's palsy (BP), especially over a long enough follow-up period. METHODS: The study population of this nationwide population-based study was derived from the South Korean population, including 11 593 365 and 36 565 099 participants with and without COVID-19, respectively. The Fine and Gray's regression model was utilized to calculate the adjusted subdistribution hazard ratio (aSHR), considering death as a competing risk, to assess the association between SARS-CoV-2 infection and the risk of BP. All participants were followed up from 1 December 2021, until the incident BP, SARS-CoV-2 infection, death, or 31 March 2022. Subgroup analyses were conducted based on participants' vaccination status (completion of the primary series vs. unvaccinated). RESULTS: COVID-19 was associated with an increased risk of BP in all participants (aSHR, 1.24; CI, 1.19-1.29). However, the size of the COVID-19-related BP risk was significantly lower among those who completed the primary series of the COVID-19 vaccine (aSHR, 1.20; 95% CI, 1.15-1.25) compared to those who were unvaccinated (aSHR, 1.84; 95% CI, 1.59-2.12; p for interaction: <0.001). The severity of COVID-19 exhibited a gradual escalation in BP risk for both vaccinated and unvaccinated individuals. DISCUSSION: While both unvaccinated individuals and those who completed the primary series of the COVID-19 vaccine may be at an increased risk of developing BP due to COVID-19, the risk appears to be lower among those who completed the vaccination. CI - Copyright (c) 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Kim, Hye Jun AU - Kim HJ AD - Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. FAU - Jeong, Seogsong AU - Jeong S AD - Department of Biomedical Informatics, CHA University School of Medicine, Seongnam, South Korea. FAU - Song, Jihun AU - Song J AD - Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. FAU - Park, Sun Jae AU - Park SJ AD - Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea. FAU - Oh, Yun Hwan AU - Oh YH AD - Department of Family Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, South Korea. FAU - Jung, Jaehun AU - Jung J AD - Department of Preventive Medicine, Gachon University College of Medicine, Incheon, South Korea. FAU - Choi, Nam-Kyong AU - Choi NK AD - Department of Health Convergence College of Science and Industry Convergence, Ewha Womans University, Seoul, South Korea. FAU - Park, Sang Min AU - Park SM AD - Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea; Department of Family Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: smpark.snuh@gmail.com. LA - eng PT - Journal Article DEP - 20230821 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Bell Palsy/epidemiology/etiology MH - Cohort Studies MH - *COVID-19/complications/epidemiology MH - *COVID-19 Vaccines/adverse effects MH - SARS-CoV-2 OTO - NOTNLM OT - Bell's palsy OT - COVID-19 OT - COVID-19 vaccine OT - Mass screening OT - Public health OT - SARS-CoV-2 EDAT- 2023/08/24 00:42 MHDA- 2023/11/29 06:43 CRDT- 2023/08/23 19:26 PHST- 2023/01/30 00:00 [received] PHST- 2023/08/14 00:00 [revised] PHST- 2023/08/15 00:00 [accepted] PHST- 2023/11/29 06:43 [medline] PHST- 2023/08/24 00:42 [pubmed] PHST- 2023/08/23 19:26 [entrez] AID - S1198-743X(23)00397-X [pii] AID - 10.1016/j.cmi.2023.08.014 [doi] PST - ppublish SO - Clin Microbiol Infect. 2023 Dec;29(12):1581-1586. doi: 10.1016/j.cmi.2023.08.014. Epub 2023 Aug 21. PMID- 37591707 OWN - NLM STAT- MEDLINE DCOM- 20230911 LR - 20230911 IS - 1873-2518 (Electronic) IS - 0264-410X (Linking) VI - 41 IP - 40 DP - 2023 Sep 15 TI - Are intelligent people more likely to get vaccinated? The association between COVID-19 vaccine adherence and cognitive profiles. PG - 5848-5853 LID - S0264-410X(23)00951-9 [pii] LID - 10.1016/j.vaccine.2023.08.019 [doi] AB - INTRODUCTION: Since vaccination adherence is crucial in reducing morbidity and mortality during a pandemic, we characterized the association between demographic, intelligence, and personal attributes and COVID-19 vaccination adherence among young adults. METHODS: Cohort study including vaccination data of 185,061 personnel, collected during 13 months of COVID-19 vaccination campaign, while a wide array of vaccination incentives were offered. The effect of demographic data (age, gender and socioeconomic status), military medical fitness - fit for combat service, administrative service, or unfit (volunteering), general intelligence score (GIS) and military social score (MSS) assessing social abilities, on vaccine adherence (allocating by IMOH guidelines) was examined. RESULTS: Adherent (vs. nonadherent) personnel presented higher GIS (mean 5.68 +/- 1.84 vs. 4.72 +/- 1.91) and MSS (median 26 (IQR 23-29) vs. 24 (IQR 19-26)), p < 0.001 for both. Higher intelligence was the strongest predictor for vaccine adherence (OR = 5.38, 95 %CI 5.11-5.67, p < 0.001). The probability for vaccine adherence increased in association with escalating GIS scores, with highest GIS females more likely to adhere to vaccination than same-level males (OR = 5.66, 95 %CI 5.09-6.28 vs. OR = 3.69, 95 %CI 3.45-3.94, respectively, p < 0.001 for both). Medically fit service-members were approximately three times as likely to be adherent than volunteering personnel (OR = 2.90 (95 %CI 2.65-3.17) for administrative and OR = 2.94 (95 %CI 2.70-3.21) for combative fitness, p < 0.001 for both). CONCLUSIONS: During a COVID-19 vaccination campaign, addressing vaccine hesitancy contributing factors and providing wide vaccine availability, GIS and physical fitness had the strongest association with vaccination adherence among young adults. When planning future vaccination campaigns, implementing these insights should be considered to improve adherence. CI - Copyright (c) 2023. Published by Elsevier Ltd. FAU - Zur, Meital AU - Zur M AD - Pharmacoepidemiology Research Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Israel; Israeli Defense Forces Medical Corps, Ramat Gan 5262000, Israel. Electronic address: Meitalz3333@gmail.com. FAU - Shelef, Leah AU - Shelef L AD - Department of Military Medicine, Faculty of Medicine, The Hebrew University of Jerusalem 91120, Israel; The School of Social Work, Sapir Academic College, D. N. Hof Ashkelon, 79165, Israel. FAU - Glassberg, Elon AU - Glassberg E AD - Israeli Defense Forces Medical Corps, Ramat Gan 5262000, Israel; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel; The Uniformed Services, University of the Health Sciences, Bethesda, MD, USA. FAU - Fink, Noam AU - Fink N AD - Israeli Defense Forces Medical Corps, Ramat Gan 5262000, Israel; Department of Military Medicine, Faculty of Medicine, The Hebrew University of Jerusalem 91120, Israel. FAU - Matok, Ilan AU - Matok I AD - Pharmacoepidemiology Research Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, 91120, Israel. FAU - Friedensohn, Limor AU - Friedensohn L AD - Israeli Defense Forces Medical Corps, Ramat Gan 5262000, Israel; Department of Military Medicine, Faculty of Medicine, The Hebrew University of Jerusalem 91120, Israel; Division of Endocrinology, Diabetes and Metabolism, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel. LA - eng PT - Journal Article DEP - 20230815 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Female MH - Male MH - Young Adult MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19/prevention & control MH - Cohort Studies MH - Intelligence MH - Cognition OTO - NOTNLM OT - Adherence OT - Vaccine COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/08/18 00:42 MHDA- 2023/09/11 06:42 CRDT- 2023/08/17 21:52 PHST- 2023/04/03 00:00 [received] PHST- 2023/08/08 00:00 [accepted] PHST- 2023/09/11 06:42 [medline] PHST- 2023/08/18 00:42 [pubmed] PHST- 2023/08/17 21:52 [entrez] AID - S0264-410X(23)00951-9 [pii] AID - 10.1016/j.vaccine.2023.08.019 [doi] PST - ppublish SO - Vaccine. 2023 Sep 15;41(40):5848-5853. doi: 10.1016/j.vaccine.2023.08.019. Epub 2023 Aug 15. PMID- 37584095 OWN - NLM STAT- MEDLINE DCOM- 20231216 LR - 20240727 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 31 IP - 1 DP - 2024 Jan TI - Amantadine in unvaccinated patients with early, mild to moderate COVID-19: A randomized, placebo-controlled, double-blind trial. PG - e16045 LID - 10.1111/ene.16045 [doi] LID - e16045 AB - BACKGROUND AND PURPOSE: Adamantanes were listed as an interesting option as an early intervention against COVID-19. We aimed to evaluate the effectiveness of amantadine in preventing the progression of COVID-19 and its neurological sequelae. METHODS: Unvaccinated patients with confirmed SARS-CoV-2 infection within 5 days were enrolled. Subjects were randomized (50:50) to amantadine (AMD; 100 mg twice daily) or placebo (PLB) for 14 days. The Ordinal Scale for Clinical Improvement of the World Health Organization (OSCI-WHO) was the primary measure. Secondary endpoints included assessment for fatigue; depression, disorders of smell and taste, and sleepiness on Days 1 and 15. RESULTS: We enrolled 99 patients (49 AMD and 50 PLB). Disease progression (OSCI-WHO = 4) was observed in 6% (AMD) and 8% (PLB) patients (p > 0.05) with further deterioration (OSCI-WHO>4) in 0% (AMD) and 8% (PLB) patients (p > 0.05). Complete recovery on Day 15 was 60% higher in the AMD compared with the PLB group (p = 0.025). There was improvement in taste (AMD: p = 0.003; PLB: p = 0.0001) and smell (AMD: p = 0.005; PLB: p = 0.0004) but not in fatigue in both groups. Improvement was observed in the AMD (p = 0.010) but not in the PLB group (p = 0.058) when assessing depression as well as sleepiness (AMD: p = 0.0002; PLB: p = 0.341). There was one death in the PLB group (2.0%) and none in the AMD group (p > 0.05) until Day 210. Overall, the drug was well tolerated. CONCLUSION: The central effects of amantadine on the nervous system with reduction of sleepiness and depression might have had a supportive effect on faster recovery in early COVID-19 patients. CI - (c) 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology. FAU - Rejdak, Konrad AU - Rejdak K AUID- ORCID: 0000-0002-7019-6681 AD - Department of Neurology, Medical University of Lublin, Lublin, Poland. FAU - Fiedor, Piotr AU - Fiedor P AD - Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland. FAU - Bonek, Robert AU - Bonek R AD - Department of Neurology and Clinical Neuroimmunology, Regional Specialist Hospital, Grudziadz, Poland. FAU - Lukasiak, Jacek AU - Lukasiak J AD - Regional Hospital SPZZOZ in Wyszkomicronw, Wyszkomicronw, Poland. FAU - Chelstowski, Waldemar AU - Chelstowski W AD - Regional Hospital SPZZOZ in Wyszkomicronw, Wyszkomicronw, Poland. FAU - Kiciak, Slawomir AU - Kiciak S AD - Independent Voivodeship Hospital "Jana Bozego" in Lublin, Lublin, Poland. FAU - Dabrowski, Piotr AU - Dabrowski P AD - Independent Voivodeship Hospital "Jana Bozego" in Lublin, Lublin, Poland. FAU - Gala-Bladzinska, Agnieszka AU - Gala-Bladzinska A AD - Collegium Medicum, University of Rzeszow and St. Queen Jadwiga Clinical District Hospital No. 2, Rzeszow, Poland. FAU - Dec, Mateusz AU - Dec M AD - SPZOZ Kalwaria Zebrzydowska, Kalwaria Zebrzydowska, Poland. FAU - Papuc, Ewa AU - Papuc E AD - Department of Neurology, Medical University of Lublin, Lublin, Poland. FAU - Zasybska, Adriana AU - Zasybska A AD - Department of Neurology, Medical University of Lublin, Lublin, Poland. FAU - Kaczor, Marcin AU - Kaczor M AD - Jagiellonian University Medical College, Krakow, Poland. FAU - Grieb, Pawel AU - Grieb P AD - Department of Experimental Pharmacology, Mossakowski Medical Research Institute, Polish Academy of Sciences, Warsaw, Poland. CN - COV-PREVENT Study Group LA - eng GR - Agencja Badan Medycznych/ PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20230914 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - BF4C9Z1J53 (Amantadine) SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Sleepiness MH - Amantadine/therapeutic use MH - Double-Blind Method MH - Fatigue/drug therapy MH - Treatment Outcome PMC - PMC11235826 OTO - NOTNLM OT - COVID-19 OT - amantadine OT - neurological and psychiatric complications OT - outcome OT - trial COIS- K.R. has received speaking honoraria and travel expenses for participation in scientific meetings, and participated in advisory boards previously with Bayer, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme and Teva Pharmaceuticals. R.B. has received speaking honoraria and travel expenses for participation in scientific meetings, and participated in advisory boards previously with Biogen, CSL Behring, Merck Healthcare KGaA, Novartis, Roche, Sanofi-Genzyme and Takeda. All the other authors declare no competing interests. EDAT- 2023/08/16 06:42 MHDA- 2023/12/17 09:46 PMCR- 2023/09/14 CRDT- 2023/08/16 04:13 PHST- 2023/07/24 00:00 [revised] PHST- 2023/06/26 00:00 [received] PHST- 2023/08/08 00:00 [accepted] PHST- 2023/12/17 09:46 [medline] PHST- 2023/08/16 06:42 [pubmed] PHST- 2023/08/16 04:13 [entrez] PHST- 2023/09/14 00:00 [pmc-release] AID - ENE16045 [pii] AID - 10.1111/ene.16045 [doi] PST - ppublish SO - Eur J Neurol. 2024 Jan;31(1):e16045. doi: 10.1111/ene.16045. Epub 2023 Sep 14. PMID- 37515731 OWN - NLM STAT- MEDLINE DCOM- 20230921 LR - 20230930 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 270 IP - 10 DP - 2023 Oct TI - Neurological symptoms after COVID-19 vaccination: a report on the clinical presentation of the first 50 patients. PG - 4673-4677 LID - 10.1007/s00415-023-11895-9 [doi] AB - OBJECTIVES: Neurological symptoms associated with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) vaccination were discovered in the context of billions of administered vaccine doses. The clinical manifestations often resemble post Coronavirus Disease 2019 (post-COVID-19) syndrome (PCS) features and may be considered as post-COVID-19 vaccine syndrome (PVS). Data regarding frequency, severity and pathophysiological mechanisms are scarce. METHODS: We assessed routine clinical examinations in 50 patients reporting new-onset neurological symptoms after SARS-CoV-2 vaccination, including neurological examination, laboratory and electrophysiology tests, as well as self-report questionnaires measuring fatigue, depressive symptoms, anxiety, risk of somatic symptom disorder, and health-related quality of life. Patients were included when symptoms occurred after confirmed COVID-19 vaccination and without prior SARS-CoV-2 infection, and if no alternative diagnosis was found to explain the symptoms. RESULTS: The most frequently reported symptoms were paraesthesia (56%), fatigue (46%) and cognitive impairment (36%). Neurological, routine laboratory, and electrophysiological examinations did not yield distinct pathological findings. Neuropsychological testing of a subgroup revealed deficits in attention, executive function and memory. DISCUSSION: The spectrum of clinical manifestations post-vaccination poses a substantial overlap with PCS symptoms. As no pathological findings were obtained in routine diagnostics, uncertainty remains about the underlying pathophysiological mechanisms and requires further investigation beyond routine work-up. CI - (c) 2023. The Author(s). FAU - Gerhard, Ameli AU - Gerhard A AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Raeder, Vanessa AU - Raeder V AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Pernice, Helena Franziska AU - Pernice HF AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Boesl, Fabian AU - Boesl F AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Schroeder, Maria AU - Schroeder M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Richter, Jonathan AU - Richter J AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. FAU - Endres, Matthias AU - Endres M AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. AD - Excellence Cluster NeuroCure, Berlin, Germany. AD - German Center for Cardiovascular Research (DZHK), Berlin, Germany. FAU - Pruss, Harald AU - Pruss H AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany. FAU - Hahn, Katrin AU - Hahn K AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Berlin Institute of Health (BIH), Berlin, Germany. FAU - Audebert, Heinrich J AU - Audebert HJ AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. AD - Center for Stroke Research Berlin, Berlin, Germany. FAU - Franke, Christiana AU - Franke C AUID- ORCID: 0000-0002-5609-2472 AD - Department of Neurology and Experimental Neurology, Charite-Universitatsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt-Universitat Zu Berlin, Berlin, Germany. christiana.franke@charite.de. LA - eng GR - FR 4479/1-1/Deutsche Forschungsgemeinschaft/ GR - PR 1274/8-1/Deutsche Forschungsgemeinschaft/ PT - Journal Article DEP - 20230729 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Quality of Life MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - Fatigue/etiology MH - Neurologic Examination PMC - PMC10511371 OTO - NOTNLM OT - Cognitive impairment OT - Fatigue OT - Paresthesia OT - Post-COVID-19 syndrome (PCS) OT - Post-COVID-19 vaccine syndrome (PVS) OT - SARS-CoV-2 vaccination COIS- All other authors have no competing interests to declare that are relevant to the content of this article. EDAT- 2023/07/29 21:45 MHDA- 2023/09/21 06:42 PMCR- 2023/07/29 CRDT- 2023/07/29 11:13 PHST- 2023/06/13 00:00 [received] PHST- 2023/07/20 00:00 [accepted] PHST- 2023/07/18 00:00 [revised] PHST- 2023/09/21 06:42 [medline] PHST- 2023/07/29 21:45 [pubmed] PHST- 2023/07/29 11:13 [entrez] PHST- 2023/07/29 00:00 [pmc-release] AID - 10.1007/s00415-023-11895-9 [pii] AID - 11895 [pii] AID - 10.1007/s00415-023-11895-9 [doi] PST - ppublish SO - J Neurol. 2023 Oct;270(10):4673-4677. doi: 10.1007/s00415-023-11895-9. Epub 2023 Jul 29. PMID- 37515407 OWN - NLM STAT- MEDLINE DCOM- 20231115 LR - 20231115 IS - 1365-2753 (Electronic) IS - 1356-1294 (Linking) VI - 29 IP - 8 DP - 2023 Dec TI - Unveiling the interplay between evidence, values and cognitive biases. The case of the failure of the AstraZeneca COVID-19 vaccine. PG - 1294-1301 LID - 10.1111/jep.13903 [doi] AB - This paper depicts a Covid science case, that of the AstraZeneca Vaxzevria vaccine, with specific focus on what happened in Italy. Given that we believe acknowledging the role of non-evidential factors in medicine is an important insight into the recent philosophy of science, we illustrate how in the case of Vaxzevria, the interplay between facts, values (both epistemic and non-epistemic) and cognitive biases may have possibly led to different institutional decisions based on the same evidence. The structure of the paper is as follows. First, we provide a glossary of the relevant terms involved, that is to say, epistemic values, non-epistemic values and cognitive biases. Second, we sketch a timeline of Vaxzevria's approvals and suspensions by relevant institutional healthcare authorities with special focus on Italy and the Italian Medicines Agency. Then we show the interplay between the evidence base, epistemic as well as non-epistemic values and cognitive biases using a narrative review of political decisions along with newspaper and social media content pertaining to Vaxzevria. We briefly compare Italy with other European countries to show that different political decisions were made on the basis of the same evidence. CI - (c) 2023 The Authors. Journal of Evaluation in Clinical Practice published by John Wiley & Sons Ltd. FAU - Amoretti, M Cristina AU - Amoretti MC AUID- ORCID: 0000-0003-2892-577X AD - DAFIST, Philosophy Section, University of Genoa, Genova, Italy. FAU - Lalumera, Elisabetta AU - Lalumera E AUID- ORCID: 0000-0002-0345-0838 AD - Department for Life Quality Studies, University of Bologna, Rimini, Italy. LA - eng PT - Journal Article PT - Review DEP - 20230729 PL - England TA - J Eval Clin Pract JT - Journal of evaluation in clinical practice JID - 9609066 RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - ChAdOx1 nCoV-19 MH - *COVID-19/prevention & control MH - Bias MH - Cognition OTO - NOTNLM OT - COVID-19 OT - cognitive bias OT - communication OT - philosophy of medicine OT - vaccination OT - values in science EDAT- 2023/07/29 11:49 MHDA- 2023/11/15 06:42 CRDT- 2023/07/29 03:15 PHST- 2023/07/06 00:00 [revised] PHST- 2023/04/20 00:00 [received] PHST- 2023/07/11 00:00 [accepted] PHST- 2023/11/15 06:42 [medline] PHST- 2023/07/29 11:49 [pubmed] PHST- 2023/07/29 03:15 [entrez] AID - 10.1111/jep.13903 [doi] PST - ppublish SO - J Eval Clin Pract. 2023 Dec;29(8):1294-1301. doi: 10.1111/jep.13903. Epub 2023 Jul 29. PMID- 37514967 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230801 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 7 DP - 2023 Jun 25 TI - Fatigue Potentially Reduces the Effect of Transcranial Magnetic Stimulation on Depression Following COVID-19 and Its Vaccination. LID - 10.3390/vaccines11071151 [doi] LID - 1151 AB - COVID-19's long-term effects, known as Long-COVID, present psychiatric and physical challenges in recovered patients. Similarly, rare long-term post-vaccination side effects, resembling Long-COVID, are emerging (called Post-Vaccine). However, effective treatments for both conditions are scarce. Our clinical experience suggests that transcranial magnetic stimulation (TMS) often aids recovery in Long-COVID and Post-Vaccine patients. However, its effectiveness is reduced in patients with severe fatigue. Therefore, we retrospectively analysed Tokyo TMS Clinic's outpatient records (60 in total; mean age, 38 years) to compare Long-COVID and post-vaccine patients' characteristics and symptoms, assess the impact of TMS on their symptoms, and investigate the role of fatigue in depression recovery with TMS. The primary outcome was the regression coefficient of the initial fatigue score on depression score improvement using TMS. Secondary outcomes included psychiatric/physical scores before and after TMS and their improvement rates. We found no differences in the initial symptoms and background factors between Long-COVID and Post-Vaccine patients. After ten TMS sessions, all psychiatric and physical symptom scores improved significantly. TMS improves depression, insomnia, anxiety, and related neuropsychiatric symptoms, which were the primary complaints in this study. Thus, we conclude that TMS improves depression and anxiety. The effectiveness of TMS in treating depression in Long-COVID and Post-Vaccine patients decreased as fatigue severity increased. In conclusion, TMS relieved depressive symptoms following COVID-19 and vaccination; however, fatigue may hinder its effectiveness. FAU - Kamamuta, Ayane AU - Kamamuta A AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Takagi, Yuki AU - Takagi Y AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Takahashi, Mizuki AU - Takahashi M AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Kurihara, Kana AU - Kurihara K AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Shibata, Hibiki AU - Shibata H AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Tanaka, Kanata AU - Tanaka K AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. FAU - Hata, Katsuhiko AU - Hata K AUID- ORCID: 0000-0002-4778-3036 AD - Tokyo TMS Clinic, Tokyo 150-0021, Japan. AD - Department of Physics, Tokyo University of Science, Tokyo 162-8601, Japan. AD - Department of Neuroscience, Research Center for Mathematical Medicine, Tokyo 183-0014, Japan. AD - Department of Sports and Medical Science, Graduate School of Emergency Medical System, Kokushikan University, Tokyo 206-8515, Japan. LA - eng GR - KAKENHI 21H03327/Japan Society for the Promotion of Science/ GR - KAKENHI 21H03327/Japan Society for the Promotion of Science/ GR - 29303/The Watanabe Foundation/ PT - Journal Article DEP - 20230625 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC10383898 OTO - NOTNLM OT - fatigue OT - long-COVID OT - transcranial magnetic stimulation COIS- The authors declare no conflict of interest. EDAT- 2023/07/29 11:51 MHDA- 2023/07/29 11:52 PMCR- 2023/06/25 CRDT- 2023/07/29 01:44 PHST- 2023/05/11 00:00 [received] PHST- 2023/06/17 00:00 [revised] PHST- 2023/06/21 00:00 [accepted] PHST- 2023/07/29 11:52 [medline] PHST- 2023/07/29 11:51 [pubmed] PHST- 2023/07/29 01:44 [entrez] PHST- 2023/06/25 00:00 [pmc-release] AID - vaccines11071151 [pii] AID - vaccines-11-01151 [pii] AID - 10.3390/vaccines11071151 [doi] PST - epublish SO - Vaccines (Basel). 2023 Jun 25;11(7):1151. doi: 10.3390/vaccines11071151. PMID- 37498459 OWN - NLM STAT- MEDLINE DCOM- 20240325 LR - 20260505 IS - 1556-0961 (Electronic) IS - 1541-6933 (Print) IS - 1541-6933 (Linking) VI - 40 IP - 2 DP - 2024 Apr TI - Outcomes After Decompressive Surgery for Severe Cerebral Venous Sinus Thrombosis Associated or Not Associated with Vaccine-Induced Immune Thrombosis with Thrombocytopenia: A Multicenter Cohort Study. PG - 621-632 LID - 10.1007/s12028-023-01782-6 [doi] AB - BACKGROUND: Clinical observations indicated that vaccine-induced immune thrombosis with thrombocytopenia (VITT)-associated cerebral venous sinus thrombosis (CVST) often has a space-occupying effect and thus necessitates decompressive surgery (DS). While comparing with non-VITT CVST, this study explored whether VITT-associated CVST exhibits a more fulminant clinical course, different perioperative and intensive care unit management, and worse long-term outcome. METHODS: This multicenter, retrospective cohort study collected patient data from 12 tertiary centers to address priorly formulated hypotheses concerning the clinical course, the perioperative management with related complications, extracerebral complications, and the functional outcome (modified Rankin Scale) in patients with VITT-associated and non-VITT CVST, both with DS. RESULTS: Both groups, each with 16 patients, were balanced regarding demographics, kind of clinical symptoms, and radiological findings at hospital admission. Severity of neurological symptoms, assessed with the National Institute of Health Stroke Scale, was similar between groups at admission and before surgery, whereas more patients with VITT-associated CVST showed a relevant midline shift (>/= 4 mm) before surgery (100% vs. 68.8%, p = 0.043). Patients with VITT-associated CVST tended to undergo DS early, i.e., /= 4 weeks and > 12 weeks of SARS-CoV-2 symptoms) were registered according to the established international criteria. RESULTS: ARD patients and non-ARD controls, balanced for age and sex, had high and comparable frequencies of >/= 4 weeks post-acute COVID-19 (58.3% vs. 53.1%, p = 0.6854) and > 12 weeks post-acute COVID-19 (39.8% vs. 46.9%, p = 0.5419). Regarding >/= 4 weeks post-acute COVID-19, frequencies of >/= 3 symptoms were similar in ARD and non-ARD controls (54% vs. 41.2%, p = 0.7886), and this was also similar in > 12 weeks post-acute COVID-19 (68.3% vs. 88.2%, p = 0.1322). Further analysis of the risk factors for >/= 4 weeks post-acute COVID-19 in ARD patients revealed that age, sex, clinical severity of COVID-19, reinfection, and autoimmune diseases were not associated with this condition (p > 0.05). The clinical manifestations of post-acute COVID-19 were similar in both groups (p > 0.05), with fatigue and memory loss being the most frequent manifestations. CONCLUSION: We provide novel data demonstrating that immune/inflammatory ARD disturbances after third dose vaccination do not seem to be a major determinant of post-acute COVID-19 since its pattern is very similar to that of the general population. Clinical Trials platform (NCT04754698). CI - (c) 2023. The Author(s). FAU - Silva, Clovis Artur AU - Silva CA AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. AD - Pediatric Rheumatology Unit, Instituto da Crianca e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. FAU - de Vinci Kanda Kupa, Leonard AU - de Vinci Kanda Kupa L AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Medeiros-Ribeiro, Ana Cristina AU - Medeiros-Ribeiro AC AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Pasoto, Sandra Gofinet AU - Pasoto SG AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Saad, Carla Goncalves Schahin AU - Saad CGS AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Yuki, Emily Figueiredo Neves AU - Yuki EFN AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Landim, Joaquim Ivo Vasques Dantas AU - Landim JIVD AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Leda, Victor Hugo Ferreira E AU - Leda VHFE AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - de Camargo Correia, Luisa Sacchi AU - de Camargo Correia LS AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Sartori, Artur Fonseca AU - Sartori AF AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Martins, Carolina Campagnoli Machado Freire AU - Martins CCMF AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Ribeiro, Carolina Torres AU - Ribeiro CT AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Waridel, Filipe AU - Waridel F AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - de Oliveira Martins, Victor Adriano AU - de Oliveira Martins VA AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Shinjo, Samuel Katsuyuki AU - Shinjo SK AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Andrade, Danieli Castro Oliveira AU - Andrade DCO AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Sampaio-Barros, Percival Degrava AU - Sampaio-Barros PD AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Neto, Eduardo Ferreira Borba AU - Neto EFB AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. FAU - Aikawa, Nadia Emi AU - Aikawa NE AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. AD - Pediatric Rheumatology Unit, Instituto da Crianca e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil. FAU - Bonfa, Eloisa AU - Bonfa E AUID- ORCID: 0000-0002-0520-4681 AD - Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Av. Dr. Arnaldo, 455, sala 3190 - Cerqueira Cesar, Sao Paulo, SP, 01246-903, Brazil. eloisa.bonfa@hc.fm.usp.br. LA - eng SI - ClinicalTrials.gov/NCT04754698 PT - Clinical Trial, Phase IV PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230608 PL - England TA - Adv Rheumatol JT - Advances in rheumatology (London, England) JID - 101734172 RN - 0 (sinovac COVID-19 vaccine) RN - 0 (Vaccines, Inactivated) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *Autoimmune Diseases/drug therapy/epidemiology MH - *COVID-19/epidemiology/prevention & control MH - Prospective Studies MH - Retrospective Studies MH - *Rheumatic Diseases/drug therapy MH - SARS-CoV-2 MH - Male MH - Female MH - Vaccines, Inactivated MH - COVID-19 Vaccines PMC - PMC10248954 OTO - NOTNLM OT - Autoimmune diseases OT - COVID-19 OT - Long COVID-19 OT - Post-COVID-19 syndrome COIS- The authors declare no competing interests. EDAT- 2023/06/09 01:09 MHDA- 2023/06/12 06:42 PMCR- 2023/06/08 CRDT- 2023/06/08 23:46 PHST- 2023/02/22 00:00 [received] PHST- 2023/05/29 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2023/06/09 01:09 [pubmed] PHST- 2023/06/08 23:46 [entrez] PHST- 2023/06/08 00:00 [pmc-release] AID - 10.1186/s42358-023-00309-z [pii] AID - 309 [pii] AID - 10.1186/s42358-023-00309-z [doi] PST - epublish SO - Adv Rheumatol. 2023 Jun 8;63(1):26. doi: 10.1186/s42358-023-00309-z. PMID- 37278994 OWN - NLM STAT- MEDLINE DCOM- 20230616 LR - 20260518 IS - 1538-3598 (Electronic) IS - 0098-7484 (Print) IS - 0098-7484 (Linking) VI - 329 IP - 22 DP - 2023 Jun 13 TI - Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection. PG - 1934-1946 LID - 10.1001/jama.2023.8823 [doi] AB - IMPORTANCE: SARS-CoV-2 infection is associated with persistent, relapsing, or new symptoms or other health effects occurring after acute infection, termed postacute sequelae of SARS-CoV-2 infection (PASC), also known as long COVID. Characterizing PASC requires analysis of prospectively and uniformly collected data from diverse uninfected and infected individuals. OBJECTIVE: To develop a definition of PASC using self-reported symptoms and describe PASC frequencies across cohorts, vaccination status, and number of infections. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational cohort study of adults with and without SARS-CoV-2 infection at 85 enrolling sites (hospitals, health centers, community organizations) located in 33 states plus Washington, DC, and Puerto Rico. Participants who were enrolled in the RECOVER adult cohort before April 10, 2023, completed a symptom survey 6 months or more after acute symptom onset or test date. Selection included population-based, volunteer, and convenience sampling. EXPOSURE: SARS-CoV-2 infection. MAIN OUTCOMES AND MEASURES: PASC and 44 participant-reported symptoms (with severity thresholds). RESULTS: A total of 9764 participants (89% SARS-CoV-2 infected; 71% female; 16% Hispanic/Latino; 15% non-Hispanic Black; median age, 47 years [IQR, 35-60]) met selection criteria. Adjusted odds ratios were 1.5 or greater (infected vs uninfected participants) for 37 symptoms. Symptoms contributing to PASC score included postexertional malaise, fatigue, brain fog, dizziness, gastrointestinal symptoms, palpitations, changes in sexual desire or capacity, loss of or change in smell or taste, thirst, chronic cough, chest pain, and abnormal movements. Among 2231 participants first infected on or after December 1, 2021, and enrolled within 30 days of infection, 224 (10% [95% CI, 8.8%-11%]) were PASC positive at 6 months. CONCLUSIONS AND RELEVANCE: A definition of PASC was developed based on symptoms in a prospective cohort study. As a first step to providing a framework for other investigations, iterative refinement that further incorporates other clinical features is needed to support actionable definitions of PASC. FAU - Thaweethai, Tanayott AU - Thaweethai T AD - Massachusetts General Hospital, Boston. AD - Harvard Medical School, Boston, Massachusetts. FAU - Jolley, Sarah E AU - Jolley SE AD - University of Colorado Anschutz Medical Campus, Aurora. FAU - Karlson, Elizabeth W AU - Karlson EW AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - Levitan, Emily B AU - Levitan EB AD - University of Alabama at Birmingham. FAU - Levy, Bruce AU - Levy B AD - Harvard Medical School, Boston, Massachusetts. AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - McComsey, Grace A AU - McComsey GA AD - Case Western Reserve University, Cleveland, Ohio. FAU - McCorkell, Lisa AU - McCorkell L AD - Patient-Led Research Collaborative, Calabasas, California. FAU - Nadkarni, Girish N AU - Nadkarni GN AD - Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Parthasarathy, Sairam AU - Parthasarathy S AD - The University of Arizona College of Medicine, Tucson. FAU - Singh, Upinder AU - Singh U AD - Stanford University School of Medicine, Stanford, California. FAU - Walker, Tiffany A AU - Walker TA AD - Emory University School of Medicine, Atlanta, Georgia. FAU - Selvaggi, Caitlin A AU - Selvaggi CA AD - Massachusetts General Hospital, Boston. FAU - Shinnick, Daniel J AU - Shinnick DJ AD - Massachusetts General Hospital, Boston. FAU - Schulte, Carolin C M AU - Schulte CCM AD - Massachusetts General Hospital, Boston. FAU - Atchley-Challenner, Rachel AU - Atchley-Challenner R AD - Mass General Brigham, Boston, Massachusetts. FAU - Alba, George A AU - Alba GA AD - Massachusetts General Hospital, Boston. FAU - Alicic, Radica AU - Alicic R AD - University of Washington, Seattle. FAU - Altman, Natasha AU - Altman N AD - University of Colorado Anschutz Medical Campus, Aurora. FAU - Anglin, Khamal AU - Anglin K AD - University of California, San Francisco. FAU - Argueta, Urania AU - Argueta U AD - University of California, San Francisco. FAU - Ashktorab, Hassan AU - Ashktorab H AD - Howard University, Washington, DC. FAU - Baslet, Gaston AU - Baslet G AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - Bassett, Ingrid V AU - Bassett IV AD - Massachusetts General Hospital, Boston. FAU - Bateman, Lucinda AU - Bateman L AD - Bateman Horne Center, Salt Lake City, Utah. FAU - Bedi, Brahmchetna AU - Bedi B AD - Emory University School of Medicine, Atlanta, Georgia. FAU - Bhattacharyya, Shamik AU - Bhattacharyya S AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - Bind, Marie-Abele AU - Bind MA AD - Massachusetts General Hospital, Boston. FAU - Blomkalns, Andra L AU - Blomkalns AL AD - Stanford University, Stanford, California. FAU - Bonilla, Hector AU - Bonilla H AD - Stanford University, Stanford, California. FAU - Brim, Hassan AU - Brim H AD - Pathology Department, Howard University, Washington, DC. FAU - Bush, Patricia A AU - Bush PA AD - Kaiser Foundation Health Plan of Georgia Inc, Atlanta. FAU - Castro, Mario AU - Castro M AD - University of Kansas Medical Center, Kansas City. FAU - Chan, James AU - Chan J AD - Massachusetts General Hospital, Boston. FAU - Charney, Alexander W AU - Charney AW AD - Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Chen, Peter AU - Chen P AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Chibnik, Lori B AU - Chibnik LB AD - Massachusetts General Hospital, Boston. FAU - Chu, Helen Y AU - Chu HY AD - University of Washington School of Medicine, Seattle. FAU - Clifton, Rebecca G AU - Clifton RG AD - George Washington University, Washington, DC. FAU - Costantine, Maged M AU - Costantine MM AD - The Ohio State University, Columbus. FAU - Cribbs, Sushma K AU - Cribbs SK AD - Emory University School of Medicine, Atlanta, Georgia. FAU - Davila Nieves, Sylvia I AU - Davila Nieves SI AD - Universidad de Puerto Rico Recinto de Ciencias Medicas, San Juan, Puerto Rico. FAU - Deeks, Steven G AU - Deeks SG AD - University of California, San Francisco. FAU - Duven, Alexandria AU - Duven A AD - Swedish Medical Center, Seattle, Washington. FAU - Emery, Ivette F AU - Emery IF AD - MaineHealth, Portland. FAU - Erdmann, Nathan AU - Erdmann N AD - University of Alabama at Birmingham. FAU - Erlandson, Kristine M AU - Erlandson KM AD - University of Colorado Anschutz Medical Campus, Aurora. FAU - Ernst, Kacey C AU - Ernst KC AD - The University of Arizona, Tucson. FAU - Farah-Abraham, Rachael AU - Farah-Abraham R AD - Emory University, Atlanta, Georgia. FAU - Farner, Cheryl E AU - Farner CE AD - The University of Texas Health Science Center at San Antonio. FAU - Feuerriegel, Elen M AU - Feuerriegel EM AD - University of Colorado Anschutz Medical Campus, Aurora. FAU - Fleurimont, Judes AU - Fleurimont J AD - University of Illinois Chicago. FAU - Fonseca, Vivian AU - Fonseca V AD - Tulane University Health Sciences Center, New Orleans, Louisiana. FAU - Franko, Nicholas AU - Franko N AD - University of Washington, Seattle. FAU - Gainer, Vivian AU - Gainer V AD - Partners HealthCare Systems, Boston, Massachusetts. FAU - Gander, Jennifer C AU - Gander JC AD - Kaiser Permanente Georgia, Atlanta. FAU - Gardner, Edward M AU - Gardner EM AD - Denver Health, Denver, Colorado. FAU - Geng, Linda N AU - Geng LN AD - Stanford University, Stanford, California. FAU - Gibson, Kelly S AU - Gibson KS AD - MetroHealth Medical Center, Cleveland, Ohio. FAU - Go, Minjoung AU - Go M AD - Stanford University School of Medicine, Stanford, California. FAU - Goldman, Jason D AU - Goldman JD AD - Swedish Medical Center, Seattle, Washington. FAU - Grebe, Halle AU - Grebe H AD - University of California, San Francisco. FAU - Greenway, Frank L AU - Greenway FL AD - Pennington Biomedical Research Center, Baton Rouge, Louisiana. FAU - Habli, Mounira AU - Habli M AD - TriHealth, Cincinnati, Ohio. FAU - Hafner, John AU - Hafner J AD - University of Illinois Chicago College of Medicine. FAU - Han, Jenny E AU - Han JE AD - Emory University School of Medicine, Atlanta, Georgia. FAU - Hanson, Keith A AU - Hanson KA AD - University of Illinois College of Medicine at Peoria. FAU - Heath, James AU - Heath J AD - Institute for Systems Biology, Seattle, Washington. FAU - Hernandez, Carla AU - Hernandez C AD - UH Cleveland Medical Center, Cleveland, Ohio. FAU - Hess, Rachel AU - Hess R AD - University of Utah Schools of the Health Sciences, Salt Lake City. FAU - Hodder, Sally L AU - Hodder SL AD - West Virginia Clinical and Translational Science Institute, Morgantown. FAU - Hoffman, Matthew K AU - Hoffman MK AD - Christiana Care Health Services Inc, Newark, Delaware. FAU - Hoover, Susan E AU - Hoover SE AD - Sanford Health, Sioux Falls, South Dakota. FAU - Huang, Beatrice AU - Huang B AD - University of California, San Francisco. FAU - Hughes, Brenna L AU - Hughes BL AD - Duke University, Durham, North Carolina. FAU - Jagannathan, Prasanna AU - Jagannathan P AD - Stanford University, Stanford, California. FAU - John, Janice AU - John J AD - Cambridge Health Alliance, Cambridge, Massachusetts. FAU - Jordan, Michael R AU - Jordan MR AD - Tufts Medical Center, Boston, Massachusetts. FAU - Katz, Stuart D AU - Katz SD AD - New York University Grossman School of Medicine, New York. FAU - Kaufman, Elizabeth S AU - Kaufman ES AD - MetroHealth Campus of Case Western Reserve University, Cleveland, Ohio. FAU - Kelly, John D AU - Kelly JD AD - University of California, San Francisco. FAU - Kelly, Sara W AU - Kelly SW AD - University of Illinois College of Medicine at Peoria. FAU - Kemp, Megan M AU - Kemp MM AD - University of Washington, Seattle. FAU - Kirwan, John P AU - Kirwan JP AD - Pennington Biomedical Research Center, Baton Rouge, Louisiana. FAU - Klein, Jonathan D AU - Klein JD AD - University of Illinois Chicago. FAU - Knox, Kenneth S AU - Knox KS AD - The University of Arizona College of Medicine, Phoenix. FAU - Krishnan, Jerry A AU - Krishnan JA AD - University of Illinois Hospital and Health Sciences System, Chicago. FAU - Kumar, Andre AU - Kumar A AD - Stanford University School of Medicine, Stanford, California. FAU - Laiyemo, Adeyinka O AU - Laiyemo AO AD - Howard University College of Medicine, Washington, DC. FAU - Lambert, Allison A AU - Lambert AA AD - University of Washington, Seattle. FAU - Lanca, Margaret AU - Lanca M AD - Harvard Medical School, Boston, Massachusetts. FAU - Lee-Iannotti, Joyce K AU - Lee-Iannotti JK AD - The University of Arizona College of Medicine, Phoenix. FAU - Logarbo, Brian P AU - Logarbo BP AD - Tulane University, New Orleans, Louisiana. FAU - Longo, Michele T AU - Longo MT AD - Tulane School of Medicine, New Orleans, Louisiana. FAU - Luciano, Carlos A AU - Luciano CA AD - Universidad de Puerto Rico, San Juan, Puerto Rico. FAU - Lutrick, Karen AU - Lutrick K AD - The University of Arizona, Tucson. FAU - Maley, Jason H AU - Maley JH AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Mallett, Gail AU - Mallett G AD - Department of ObGyn/Maternal Fetal Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. FAU - Marathe, Jai G AU - Marathe JG AD - Boston University, Boston, Massachusetts. FAU - Marconi, Vincent AU - Marconi V AD - Emory University, Atlanta, Georgia. FAU - Marshall, Gailen D AU - Marshall GD AD - University of Mississippi, Oxford. FAU - Martin, Christopher F AU - Martin CF AD - Emory University, Atlanta, Georgia. FAU - Matusov, Yuri AU - Matusov Y AD - Cedars-Sinai Medical Center, Los Angeles, California. FAU - Mehari, Alem AU - Mehari A AD - Howard University College of Medicine, Washington, DC. FAU - Mendez-Figueroa, Hector AU - Mendez-Figueroa H AD - McGovern Medical School at The University of Texas Health Science Center at Houston. FAU - Mermelstein, Robin AU - Mermelstein R AD - University of Illinois Chicago. FAU - Metz, Torri D AU - Metz TD AD - University of Utah Health, Salt Lake City. FAU - Morse, Richard AU - Morse R AD - Massachusetts General Hospital, Boston. FAU - Mosier, Jarrod AU - Mosier J AD - University of Arizona, Tucson. FAU - Mouchati, Christian AU - Mouchati C AD - Case Western Reserve University School of Medicine, Cleveland, Ohio. FAU - Mullington, Janet AU - Mullington J AD - Harvard Medical School, Boston, Massachusetts. FAU - Murphy, Shawn N AU - Murphy SN AD - Massachusetts General Hospital, Boston. FAU - Neuman, Robert B AU - Neuman RB AD - Kaiser Foundation Health Plan of Georgia Inc, Atlanta. FAU - Nikolich, Janko Z AU - Nikolich JZ AD - The University of Arizona, Tucson. FAU - Ofotokun, Ighovwerha AU - Ofotokun I AD - Emory University School of Medicine, Atlanta, Georgia. FAU - Ojemakinde, Elizabeth AU - Ojemakinde E AD - Morehouse School of Medicine, Atlanta, Georgia. FAU - Palatnik, Anna AU - Palatnik A AD - Medical College of Wisconsin, Milwaukee. FAU - Palomares, Kristy AU - Palomares K AD - Saint Peter's University Hospital, Brunswick, New Jersey. FAU - Parimon, Tanyalak AU - Parimon T AD - Cedars-Sinai Health System, Los Angeles, California. FAU - Parry, Samuel AU - Parry S AD - University of Pennsylvania, Philadelphia. FAU - Patterson, Jan E AU - Patterson JE AD - The University of Texas Health Science Center at San Antonio. FAU - Patterson, Thomas F AU - Patterson TF AD - The University of Texas Health Science Center at San Antonio. FAU - Patzer, Rachel E AU - Patzer RE AD - Emory University, Atlanta, Georgia. FAU - Peluso, Michael J AU - Peluso MJ AD - University of California, San Francisco. FAU - Pemu, Priscilla AU - Pemu P AD - Morehouse School of Medicine, Atlanta, Georgia. FAU - Pettker, Christian M AU - Pettker CM AD - Yale School of Medicine, New Haven, Connecticut. FAU - Plunkett, Beth A AU - Plunkett BA AD - Harvard Medical School, Boston, Massachusetts. AD - NorthShore University HealthSystem, Evanston, Illinois. FAU - Pogreba-Brown, Kristen AU - Pogreba-Brown K AD - The University of Arizona, Tucson. FAU - Poppas, Athena AU - Poppas A AD - Warren Alpert Medical School, Brown University, Providence, Rhode Island. FAU - Quigley, John G AU - Quigley JG AD - University of Illinois Chicago. FAU - Reddy, Uma AU - Reddy U AD - Columbia University Irving Medical Center, New York, New York. FAU - Reece, Rebecca AU - Reece R AD - West Virginia University School of Medicine, Morgantown. FAU - Reeder, Harrison AU - Reeder H AD - Massachusetts General Hospital, Boston. FAU - Reeves, W B AU - Reeves WB AD - Department of Medicine, The University of Texas Health Science Center at San Antonio. FAU - Reiman, Eric M AU - Reiman EM AD - Banner Alzheimer's Institute, Phoenix, Arizona. FAU - Rischard, Franz AU - Rischard F AD - Banner University Medical Center Tucson, Arizona. FAU - Rosand, Jonathan AU - Rosand J AD - Massachusetts General Hospital, Boston. FAU - Rouse, Dwight J AU - Rouse DJ AD - Brown University, Providence, Rhode Island. FAU - Ruff, Adam AU - Ruff A AD - The University of Kansas Medical Center, Kansas City. FAU - Saade, George AU - Saade G AD - Eastern Virginia Medical School, Norfolk. FAU - Sandoval, Grecio J AU - Sandoval GJ AD - Milken Institute of Public Health, The George Washington University, Washington, DC. FAU - Santana, Jorge L AU - Santana JL AD - School of Medicine, University of Puerto Rico, San Juan, Puerto Rico. FAU - Schlater, Shannon M AU - Schlater SM AD - University of Utah Health, Salt Lake City. FAU - Sciurba, Frank C AU - Sciurba FC AD - Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Shepherd, Fitzgerald AU - Shepherd F AD - Boston University School of Medicine, Boston, Massachusetts. FAU - Sherif, Zaki A AU - Sherif ZA AD - Howard University College of Medicine, Washington, DC. FAU - Simhan, Hyagriv AU - Simhan H AD - University of Pittsburgh, Pittsburgh, Pennsylvania. FAU - Singer, Nora G AU - Singer NG AD - MetroHealth Medical Center, Cleveland, Ohio. FAU - Skupski, Daniel W AU - Skupski DW AD - Weill Cornell Medicine, New York, New York. FAU - Sowles, Amber AU - Sowles A AD - University of Utah Health, Salt Lake City. FAU - Sparks, Jeffrey A AU - Sparks JA AD - Brigham and Women's Hospital, Boston, Massachusetts. FAU - Sukhera, Fatima I AU - Sukhera FI AD - The University of Oklahoma, Norman. FAU - Taylor, Barbara S AU - Taylor BS AD - The University of Texas Health Science Center at San Antonio. FAU - Teunis, Larissa AU - Teunis L AD - Emory University, Atlanta, Georgia. FAU - Thomas, Robert J AU - Thomas RJ AD - Beth Israel Deaconess Medical Center, Boston, Massachusetts. FAU - Thorp, John M AU - Thorp JM AD - The University of North Carolina at Chapel Hill. FAU - Thuluvath, Paul AU - Thuluvath P AD - Mercy Medical Center, Baltimore, Maryland. FAU - Ticotsky, Amberly AU - Ticotsky A AD - Cambridge Health Alliance, Cambridge, Massachusetts. FAU - Tita, Alan T AU - Tita AT AD - University of Alabama, Birmingham. FAU - Tuttle, Katherine R AU - Tuttle KR AD - University of Washington, Seattle. FAU - Urdaneta, Alfredo E AU - Urdaneta AE AD - Stanford University School of Medicine, Stanford, California. FAU - Valdivieso, Daisy AU - Valdivieso D AD - University of California, San Francisco. FAU - VanWagoner, Timothy M AU - VanWagoner TM AD - University of Oklahoma Health Sciences Center, Oklahoma City. FAU - Vasey, Andrew AU - Vasey A AD - University of Nebraska Medical Center, Omaha. FAU - Verduzco-Gutierrez, Monica AU - Verduzco-Gutierrez M AD - The University of Texas Health Science Center at San Antonio. FAU - Wallace, Zachary S AU - Wallace ZS AD - Massachusetts General Hospital, Boston. FAU - Ward, Honorine D AU - Ward HD AD - Tufts Medical Center, Boston, Massachusetts. FAU - Warren, David E AU - Warren DE AD - University of Nebraska Medical Center, Omaha. FAU - Weiner, Steven J AU - Weiner SJ AD - The George Washington University Biostatistics Center, Rockville, Maryland. FAU - Welch, Shelley AU - Welch S AD - West Virginia University, Morgantown. FAU - Whiteheart, Sidney W AU - Whiteheart SW AD - University of Kentucky, Lexington. FAU - Wiley, Zanthia AU - Wiley Z AD - Emory University, Atlanta, Georgia. FAU - Wisnivesky, Juan P AU - Wisnivesky JP AD - Icahn School of Medicine at Mount Sinai, New York, New York. FAU - Yee, Lynn M AU - Yee LM AD - Feinberg School of Medicine, Northwestern University, Chicago, Illinois. FAU - Zisis, Sokratis AU - Zisis S AD - Case Western Reserve University, Cleveland, Ohio. FAU - Horwitz, Leora I AU - Horwitz LI AD - New York University Grossman School of Medicine, New York. FAU - Foulkes, Andrea S AU - Foulkes AS AD - Massachusetts General Hospital, Boston. AD - Harvard Medical School, Boston, Massachusetts. CN - RECOVER Consortium LA - eng GR - OT2 HL156812/HL/NHLBI NIH HHS/United States GR - UG1 HD027869/HD/NICHD NIH HHS/United States GR - K23 AI157875/AI/NIAID NIH HHS/United States GR - UM1 TR004409/TR/NCATS NIH HHS/United States GR - UG1 HD040544/HD/NICHD NIH HHS/United States GR - UL1 TR004419/TR/NCATS NIH HHS/United States GR - OT2 HL161841/HL/NHLBI NIH HHS/United States GR - UG1 HD040500/HD/NICHD NIH HHS/United States GR - R01 HL162373/HL/NHLBI NIH HHS/United States GR - R01 DK130351/DK/NIDDK NIH HHS/United States GR - P30 AG072946/AG/NIA NIH HHS/United States GR - U10 HD040500/HD/NICHD NIH HHS/United States GR - UL1 TR001863/TR/NCATS NIH HHS/United States GR - UG1 HD087230/HD/NICHD NIH HHS/United States GR - UL1 TR002538/TR/NCATS NIH HHS/United States GR - UG1 HD027915/HD/NICHD NIH HHS/United States GR - UG1 HD087192/HD/NICHD NIH HHS/United States GR - OT2 HL161847/HL/NHLBI NIH HHS/United States GR - L30 AI126521/AI/NIAID NIH HHS/United States GR - K23 AI146268/AI/NIAID NIH HHS/United States GR - S10 OD026880/OD/NIH HHS/United States GR - K23 AI159518/AI/NIAID NIH HHS/United States GR - S10 OD030463/OD/NIH HHS/United States GR - UM1 TR004528/TR/NCATS NIH HHS/United States GR - UL1 TR002319/TR/NCATS NIH HHS/United States GR - U54 GM115428/GM/NIGMS NIH HHS/United States GR - L30 AI147159/AI/NIAID NIH HHS/United States GR - R01 HL161386/HL/NHLBI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - JAMA JT - JAMA JID - 7501160 SB - IM CIN - JAMA. 2023 Jun 13;329(22):1918-1919. doi: 10.1001/jama.2023.8961. PMID: 37227710 CIN - JAMA. 2023 Oct 17;330(15):1492. doi: 10.1001/jama.2023.15712. PMID: 37847276 CIN - JAMA. 2023 Oct 17;330(15):1491-1492. doi: 10.1001/jama.2023.15709. PMID: 37847279 MH - Female MH - Adult MH - Humans MH - Middle Aged MH - Male MH - *SARS-CoV-2 MH - *COVID-19/complications MH - Prospective Studies MH - Post-Acute COVID-19 Syndrome MH - Cohort Studies MH - Disease Progression MH - Fatigue PMC - PMC10214179 COIS- Conflict of Interest Disclosures: Dr Thaweethai reported receiving grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) and serving as co-investigator of the RECOVER Data Resource Core. Dr Jolley reported receiving grants from the NIH/NHLBI. Dr Karlson reported receiving grants from the NIH. Dr Levitan reported receiving grants from the NIH and Amgen. Dr Levy reported receiving grants from the NHLBI and personal fees or research support from Entrinsic Bioscience, Nocion Therapeutics, Gossamer Bio, AstraZeneca, Novartis, Sanofi, Amgen, Genentech, Pieris Pharmaceuticals, and SRA. Dr McComsey reported serving as a consultant for Gilead, Merck, Janssen, and GlaxoSmithKline and receiving research support from Pfizer, Genentech, and Roche. Ms McCorkell reported receiving personal fees from NIH RECOVER and research funding as a subcontractor from the NIH and the Patient-Centered Outcomes Research Institute (PCORI). Dr Parthasarathy reported receiving grants from the NIH, NHLBI, Sergey-Brin Foundation, and Regeneron and personal fees from Jazz Pharmaceuticals. Dr Singh reported receiving grants from Pfizer and serving as an advisor to Regeneron and Gilead. Dr Walker reported receiving grants from the NHLBI. Mr Shinnick reported receiving grants from the NIH/NHLBI. Dr Horwitz reported receiving grants from the NIH and serving on an ad hoc committee for the National Academy of Medicine. Dr Foulkes reported receiving grants from the NIH/NHLBI and personal fees from the Round Table Group and serving as principal investigator of the RECOVER Data Resource Core. Dr Alba reported receiving personal fees from Minerva Biotechnologies. Dr Alicic reported receiving grants from the NIH, the Centers for Disease Control and Prevention, and Travere Therapeutics and personal fees from Boehringer Ingelheim. Dr Ashktorab reported receiving grants from the NIH. Dr Bhattacharyya reported receiving grants from NIH RECOVER, Alexion Pharmaceuticals, UCB, and Massachusetts Consortium on Pathogen Readiness and personal fees from American Academy of Neurology and UpToDate. Dr Castro reported receiving grants from the NIH, American Lung Association, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GlaxoSmithKline, Novartis, Pulmatrix, Sanofi, Shionogi, and Theravance Biopharma; personal fees from Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, AstraZeneca, GlaxoSmithKline, Genentech, Teva Pharmaceutical Industries, Sanofi, Merck, Novartis, Arrowhead Pharmaceuticals, and Regeneron; stock options from Aer Therapeutics; and royalties from Elsevier. Dr Chu reported receiving grants from the NIH and personal fees from Merck, Vir Biotechnology, AbbVie, Ellume, Pfizer, and the Bill and Melinda Gates Foundation; serving on advisory boards for Merck and AbbVie; conducting CME teaching with Medscape, Vindico, and Clinical Care Options; and receiving research funding from Gates Ventures and support and reagents from Ellume and Cepheid. Dr Clifton reported receiving grants from the NIH. Dr Costantine reported receiving grants from the NIH, Baxter International, and Siemens Healthcare and personal fees from Quidel, Progenity, and Siemens Healthcare. Dr Davila Nieves reported receiving grants from the NIH. Dr Deeks reported receiving grants from the NIH. Dr Emery reported receiving grants from the NIH. Dr Erdmann reported receiving grants from the NIH and personal fees from Perspectum and having a patent for Plantform. Dr Erlandson reported receiving grant funding and advisory fee payments from Gilead Sciences (paid to the University of Colorado) and advisory fee payments from Merck and ViiV (paid to the University of Colorado) in the last 3 years. Ms Gainer reported receiving grants from NIH RECOVER. Dr Geng reported receiving grants from Pfizer and personal fees from UnitedHealthcare. Dr Gibson reported receiving grants from the NIH. Dr Go reported receiving grants from the NIH. Dr Goldman reported receiving grants from Gilead Sciences and Merck; personal fees from Gilead Sciences and Eli Lilly; contracted research from Gilead Sciences, Eli Lilly, and Regeneron Pharmaceuticals; and nonfinancial support from Adaptive Biotechnologies, Labcorp, and Monogram Biosciences. Dr Greenway reported receiving grants from the NIH. Dr Heath reported receiving grants from Merck and Gilead Sciences, personal fees from Regeneron Pharmaceuticals, and being a board member for IsoPlexis. Dr Hess reported receiving grants from the NIH and being a member of a data and safety monitoring board for Astellas Pharmaceuticals. Dr Hodder reported receiving grants from the NHLBI. Dr Hoffman reported receiving grants from the NHLBI. Dr Hughes reported receiving honorarium from UpToDate and personal fees from AMAG Pharmaceuticals. Ms John reported receiving grants from the NIH. Dr Katz reported receiving grants from the NIH. Dr Klein reported receiving grants from NIH RECOVER and consulting fees from Gilead Sciences. Dr Knox reported receiving grants from the NIH. Dr Krishnan reported receiving grants from the NIH/NHLBI; personal fees from GlaxoSmithKline, AstraZeneca, CereVu Medical, BData, Propeller, ResMed, American Board of Internal Medicine, American Academy of Allergy, Asthma, and Immunology; and research funding from the NIH, PCORI, American Lung Association, COPD Foundation, and the Sergey Brin Family Foundation. Dr Laiyemo reported receiving grants from the NIH. Dr Lambert reported receiving grants from the NIH and the PCORI and serving as a site principal investigator for trials funded by Vertex and Aceragan. Dr Luciano reported receiving grants from the NIH and speaker fees from Sanofi-Genzyme. Ms Mallett reported receiving grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. Dr Marathe reported receiving grants from NIH RECOVER and funding from Boston Medical Center. Dr Marconi reported receiving grants from the Centers for Disease Control and Prevention, Veteran Affairs, and the NIH; grants, personal fees, nonfinancial support, and other from Eli Lilly and Gilead; grants and personal fees from ViiV; and nonfinancial support from Bayer. Dr Marshall reported receiving grants from the NIH. Mr Martin reported receiving grants from the NIH. Dr Metz reported receiving grants from the NIH and Pfizer and personal fees from Pfizer. Mr Morse reported receiving grants from the NIH/NHLBI. Dr Mullington reported receiving grants from the NIH and Open Medicine Foundation and speaker and book chapter contribution for Idorsia Pharmaceuticals. Dr Murphy reported receiving grants from the NIH/NHLBI. Dr Nikolich reported receiving grants from the NIH/NHLBI. Dr Ojemakinde reported receiving grants from the NIH. Dr Parry reported receiving grants from NIH RECOVER paid to Penn and funding from the Sergey Brin Family Foundation. Dr Peluso reported receiving personal fees from Gilead Sciences and AstraZeneca. Dr Pogreba-Brown reported receiving grants from NIH RECOVER. Dr Poppas reported owning stock in GE and serving as an UpToDate contributor and co-editor of Hurst and Fuster's The Heart. Dr Quigley reported receiving grants from the NIH, Pfizer, AbbVie, and Teva Pharmaceutical Industries and personal fees from Alexion Pharmaceuticals, Servier Laboratories, Agios Pharmaceuticals, and Rigel Pharmaceuticals. Dr Reiman reported receiving grants from the NIH. Dr Rischard reported receiving grants from the NIH/NHLBI, Bayer, Janssen, Merck, Aerovate Therapeutics, and Respira Therapeutics and consulting relationships with Acceleron Pharma and United Therapeutics. Dr Rosand reported receiving grants from the NIH and the American Heart Association and personal fees from the National Football League and Takeda Pharmaceutical Co. Dr Shepherd reported receiving grants from NIH RECOVER. Dr Simhan reported receiving grants from the NIH. Dr Singer reported receiving grants from Case Western Reserve University and MetroHealth. Dr Sparks reported receiving grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the R. Bruce and Joan M. Mickey Research Scholar Fund, the Llura Gund Award for Rheumatoid Arthritis Research and Care, Brigham and Women's Hospital, and Bristol Myers Squibb and personal fees from Bristol Myers Squibb, AbbVie, Amgen, Boehringer Ingelheim, Gilead Sciences, Inova Diagnostics, Janssen, Optum, and Pfizer. Dr Thomas reported receiving personal fees from Guidepoint Global and GLG Councils and having a patent for ECG-spectrogram with royalties paid from MyCardio LLC through Beth Israel Deaconess Medical Center. Dr Thuluvath reported receiving grants from Mercy Medical Center. Dr Tita reported receiving grants from Pfizer. Dr VanWagoner reported receiving grants from the NIH. Dr Vasey reported receiving grants from NIH RECOVER. Dr Wallace reported receiving grants from Bristol Myers Squibb, Sanofi, and Horizon Therapeutics and personal fees from Sanofi, Novartis, Shionogi, Visterra, Horizon Therapeutics, PPD Inc, Zenas BioPharma, and Medpace. Dr Warren reported receiving grants from the NIH. Mr Weiner reported receiving grants from the NIH. Ms Welch reported receiving grants from the NIH. Dr Wisnivesky reported receiving personal fees from PPD Inc, Banook, Sanofi, Atea Pharmaceuticals, and Prospero and grants from Regeneron Pharmaceuticals, Axella, Sanofi, and Arnold. Dr Yee reported receiving grants from the NIH. No other disclosures were reported. FIR - Aberg, Judith A IR - Aberg JA FIR - Adolphi, Natalie L IR - Adolphi NL FIR - Ahirwar, Shreya IR - Ahirwar S FIR - Ahmed, Shifa IR - Ahmed S FIR - Ahuja, Neera IR - Ahuja N FIR - Aikawa, Masanori IR - Aikawa M FIR - Akerlundh, Almary IR - Akerlundh A FIR - Akintonwa, Teresa T IR - Akintonwa TT FIR - Al-Jadiri, Aseel IR - Al-Jadiri A FIR - Alekhina, Natalya IR - Alekhina N FIR - Algren, Heather A IR - Algren HA FIR - Alshawabkeh, Akram N IR - Alshawabkeh AN FIR - Ammar, Nariman IR - Ammar N FIR - Anand, Adit IR - Anand A FIR - Anderson, Brett R IR - Anderson BR FIR - Aponte-Soto, Lisa IR - Aponte-Soto L FIR - Aschner, Judy L IR - Aschner JL FIR - Atha, Mary M IR - Atha MM FIR - Atz, Andrew M IR - Atz AM FIR - Aupperle, Robin L IR - Aupperle RL FIR - Ayache, Mirna IR - Ayache M FIR - Azziz-Baumgartner, Eduardo IR - Azziz-Baumgartner E FIR - Bailey, L C IR - Bailey LC FIR - Baker, Fiona C IR - Baker FC FIR - Balaraman, Venkataraman IR - Balaraman V FIR - Bandy, Jennifer A IR - Bandy JA FIR - Banerjee, Dithi IR - Banerjee D FIR - Barch, Deanna M IR - Barch DM FIR - Bardes, James M IR - Bardes JM FIR - Barlocker, Jackson IR - Barlocker J FIR - Barr, R G IR - Barr RG FIR - Baskin-Sommers, Arielle IR - Baskin-Sommers A FIR - Basu, Sanjib IR - Basu S FIR - Battaglia, Tracy A IR - Battaglia TA FIR - Baucom, Leah IR - Baucom L FIR - Beamon, Carmen J IR - Beamon CJ FIR - Beaty, Casey L IR - Beaty CL FIR - Beckmann, Noam D IR - Beckmann ND FIR - Berry, Jasmine A IR - Berry JA FIR - Bhadelia, Nahid IR - Bhadelia N FIR - Bhargava, Daksh IR - Bhargava D FIR - Bhuiyan, Sultana IR - Bhuiyan S FIR - Bian, Jiang IR - Bian J FIR - Bime, Christian IR - Bime C FIR - Bjork, James M IR - Bjork JM FIR - Black, Lora J IR - Black LJ FIR - Blish, Catherine A IR - Blish CA FIR - Block, Jason P IR - Block JP FIR - Bogie, Amanda IR - Bogie A FIR - Bolliger, Dawn IR - Bolliger D FIR - Bonaventura, William IR - Bonaventura W FIR - Bose-Brill, Seuli IR - Bose-Brill S FIR - Bower, Mary B IR - Bower MB FIR - Boyd, Andrew D IR - Boyd AD FIR - Boyineni, Jerusha IR - Boyineni J FIR - Bradfute, Steven B IR - Bradfute SB FIR - Bramante, Carolyn T IR - Bramante CT FIR - Brannock, M D IR - Brannock MD FIR - Bremner, J D IR - Bremner JD FIR - Brosnahan, Shari B IR - Brosnahan SB FIR - Buchbinder, Natalie C IR - Buchbinder NC FIR - Bueler, Elliott IR - Bueler E FIR - Buhimschi, Irina A IR - Buhimschi IA FIR - Bukulmez, Hulya IR - Bukulmez H FIR - Bunnell, H T IR - Bunnell HT FIR - Buse, John B IR - Buse JB FIR - Calhoun, Elizabeth A IR - Calhoun EA FIR - Cao, Tingyi IR - Cao T FIR - Carrithers, Michael D IR - Carrithers MD FIR - Carton, Thomas W IR - Carton TW FIR - Case, Abigail IR - Case A FIR - Casey, B J IR - Casey BJ FIR - Casimero, Faye Victoria C IR - Casimero FVC FIR - Castro, Lauren IR - Castro L FIR - Cato, Teresa IR - Cato T FIR - Ceger, Patricia IR - Ceger P FIR - Cerullo, Connie L IR - Cerullo CL FIR - Chang, Linda IR - Chang L FIR - Chang, Arunee A IR - Chang AA FIR - Chebrolu, Praneeth IR - Chebrolu P FIR - Chen, Yong IR - Chen Y FIR - Chen, Li Qing IR - Chen LQ FIR - Chen, Benjamin K IR - Chen BK FIR - Chestek, David IR - Chestek D FIR - Chew, Robert F IR - Chew RF FIR - Chisolm, Deena J IR - Chisolm DJ FIR - Chow, Dominic C IR - Chow DC FIR - Chrisant, Maryanne R IR - Chrisant MR FIR - Christakis, Dimitri A IR - Christakis DA FIR - Chute, Christopher G IR - Chute CG FIR - Cicek, Mine S IR - Cicek MS FIR - Clark, Cheryl R IR - Clark CR FIR - Clark, Duncan B IR - Clark DB FIR - Clarke, Geoffrey D IR - Clarke GD FIR - Clouser, Katharine N IR - Clouser KN FIR - Connors, Thomas J IR - Connors TJ FIR - Cook, Judith A IR - Cook JA FIR - Coombs, Krista IR - Coombs K FIR - Cordon-Cardo, Carlos IR - Cordon-Cardo C FIR - Costello, Julie L IR - Costello JL FIR - Cottrell, Lesley IR - Cottrell L FIR - Cowan, Kelly IR - Cowan K FIR - Cowell, Lindsay G IR - Cowell LG FIR - Cranford, Savannah IR - Cranford S FIR - Cronin, Jamie IR - Cronin J FIR - Cummins, Mollie R IR - Cummins MR FIR - Curry, Hannah L IR - Curry HL FIR - D'Sa, Viren IR - D'Sa V FIR - Dabney, Sean G IR - Dabney SG FIR - Daniel, Casey L IR - Daniel CL FIR - Dapretto, Mirella IR - Dapretto M FIR - Darbar, Dawood IR - Darbar D FIR - Darden, Paul M IR - Darden PM FIR - Dasgupta, Raktima IR - Dasgupta R FIR - Dasgupta, Soham IR - Dasgupta S FIR - Davis Blakley, Felicia IR - Davis Blakley F FIR - Dea, Katherine IR - Dea K FIR - Deakyne Davies, Sara J IR - Deakyne Davies SJ FIR - Decker, Lauren A IR - Decker LA FIR - DeFronzo, Ralph A IR - DeFronzo RA FIR - Dehority, Walter IR - Dehority W FIR - Deitchman, Amelia N IR - Deitchman AN FIR - Del Alcazar, James IR - Del Alcazar J FIR - Del Boccio, Phoebe IR - Del Boccio P FIR - Del Rio, Carlos IR - Del Rio C FIR - Del Rios, Marina IR - Del Rios M FIR - DeLisa, Julie A IR - DeLisa JA FIR - Deoni, Sean C IR - Deoni SC FIR - Diaz, Maya Z IR - Diaz MZ FIR - Dickinson, John D IR - Dickinson JD FIR - Dionne, Audrey IR - Dionne A FIR - Diviak, Kathleen R IR - Diviak KR FIR - Donohue, Sarah E IR - Donohue SE FIR - Downey, Michael J IR - Downey MJ FIR - Dozor, Allen J IR - Dozor AJ FIR - Dreyer, Benard P IR - Dreyer BP FIR - Dummer, Kirsten B IR - Dummer KB FIR - Durstenfeld, Matthew S IR - Durstenfeld MS FIR - Dworkin, Mark S IR - Dworkin MS FIR - Edmonds, Sherrie L IR - Edmonds SL FIR - Elias, Matthew D IR - Elias MD FIR - Elifritz, Jamie IR - Elifritz J FIR - Ellingworth, Evan IR - Ellingworth E FIR - Elliott, Amy J IR - Elliott AJ FIR - Ellison, Angela M IR - Ellison AM FIR - Enger, Mike L IR - Enger ML FIR - Espinosa, Joaquin M IR - Espinosa JM FIR - Esquenazi-Karonika, Shari IR - Esquenazi-Karonika S FIR - Evans, Michael D IR - Evans MD FIR - Evans, Danielle N IR - Evans DN FIR - Facelli, Julio C IR - Facelli JC FIR - Fang, Camila S IR - Fang CS FIR - Faustino, E Vincent S IR - Faustino EVS FIR - Fayad Lara, Maria E IR - Fayad Lara ME FIR - Feldman, Candace H IR - Feldman CH FIR - Fiks, Alexander G IR - Fiks AG FIR - Fineman, Rebecca IR - Fineman R FIR - Finn, Aloke V IR - Finn AV FIR - Fischer, Melinda S IR - Fischer MS FIR - Fitzgerald, Megan L IR - Fitzgerald ML FIR - Flaherman, Valerie J IR - Flaherman VJ FIR - Flotte, Thomas J IR - Flotte TJ FIR - Forsha, Daniel IR - Forsha D FIR - Fortune, Meghan R IR - Fortune MR FIR - Foxe, John J IR - Foxe JJ FIR - Franks, Nicole IR - Franks N FIR - Freedman, Michael B IR - Freedman MB FIR - Freeland, Catherine E IR - Freeland CE FIR - Friedman, Naomi P IR - Friedman NP FIR - Fry, Greta IR - Fry G FIR - Gage Witvliet, Margot IR - Gage Witvliet M FIR - Gallagher, Emily J IR - Gallagher EJ FIR - Gallagher, Richard IR - Gallagher R FIR - Garavan, Hugh IR - Garavan H FIR - Gaur, Sunanda M IR - Gaur SM FIR - Gee, Dylan G IR - Gee DG FIR - Gennaro, Maria Laura IR - Gennaro ML FIR - Gerald, Lynn B IR - Gerald LB FIR - Ghosh, Saikat B IR - Ghosh SB FIR - Giacino, Joseph T IR - Giacino JT FIR - Girvin, Andrew T IR - Girvin AT FIR - Godfrey, Stephanie L IR - Godfrey SL FIR - Goldberg, Mark P IR - Goldberg MP FIR - Goodman, Steven N IR - Goodman SN FIR - Gordon, Howard S IR - Gordon HS FIR - Gouripeddi, Ramkiran IR - Gouripeddi R FIR - Graham, Paige IR - Graham P FIR - Granger, Joey P IR - Granger JP FIR - Gray, Kevin M IR - Gray KM FIR - Greimes, Tina IR - Greimes T FIR - Gross, Rachel S IR - Gross RS FIR - Guthe, Nicholas IR - Guthe N FIR - Gutter, Evan IR - Gutter E FIR - Haasnoot, Stephanie IR - Haasnoot S FIR - Hadley, Emily C IR - Hadley EC FIR - Haendel, Melissa A IR - Haendel MA FIR - Hafner, Stephanie IR - Hafner S FIR - Halabi, Katia C IR - Halabi KC FIR - Hanley, Patrick C IR - Hanley PC FIR - Harahsheh, Ashraf S IR - Harahsheh AS FIR - Harkins, Michelle S IR - Harkins MS FIR - Hartwig, Kimberly L IR - Hartwig KL FIR - Hasbani, Keren IR - Hasbani K FIR - Hasek, Sharon IR - Hasek S FIR - Hauser, Kristine S IR - Hauser KS FIR - Heath, Andrew C IR - Heath AC FIR - Hebson, Camden L IR - Hebson CL FIR - Heitzeg, Mary M IR - Heitzeg MM FIR - Hendrickson, Monica IR - Hendrickson M FIR - Henrich, Timothy J IR - Henrich TJ FIR - Hernandez-Romieu, Alfonso C IR - Hernandez-Romieu AC FIR - Hester, Christina M IR - Hester CM FIR - Higginbotha M, Miranda IR - Higginbotha M M FIR - Hill, Sophia IR - Hill S FIR - Hirabayashi, Kathryn IR - Hirabayashi K FIR - Ho, On IR - Ho O FIR - Hobart-Porter, Laura IR - Hobart-Porter L FIR - Hoffman, M C IR - Hoffman MC FIR - Holtcamp, Maryann IR - Holtcamp M FIR - Hong, Travis K IR - Hong TK FIR - Horne, Benjamin D IR - Horne BD FIR - Horowitz, Carol R IR - Horowitz CR FIR - Hsia, Daniel S IR - Hsia DS FIR - Hsu, Harvey IR - Hsu H FIR - Hsue, Priscilla Y IR - Hsue PY FIR - Huentelman, Matthew IR - Huentelman M FIR - Huerta, Bryan E IR - Huerta BE FIR - Huling, Jared D IR - Huling JD FIR - Hummel, Kathy IR - Hummel K FIR - Iacono, William G IR - Iacono WG FIR - Ibanez, Alejandra L IR - Ibanez AL FIR - Ibeawuchi, Carmel IR - Ibeawuchi C FIR - Irby, Katherine IR - Irby K FIR - Ismail, Nahed IR - Ismail N FIR - Jacobus, Joanna IR - Jacobus J FIR - Jacoby, Vanessa L IR - Jacoby VL FIR - Jason, Leonard A IR - Jason LA FIR - Javia, Vidhi IR - Javia V FIR - Jennette, Kyle J IR - Jennette KJ FIR - Jernigan, Terry L IR - Jernigan TL FIR - Jiang, Sihang IR - Jiang S FIR - Jing, Naimin IR - Jing N FIR - Johnny, Jace D IR - Johnny JD FIR - Johnson, Nadia IR - Johnson N FIR - Johnson, Brandi IR - Johnson B FIR - Johnson, Brandon IR - Johnson B FIR - Jone, Pei-Ni IR - Jone PN FIR - Judd, Suzanne E IR - Judd SE FIR - Juskowich, Joy J IR - Juskowich JJ FIR - Kabagambe, Edmond K IR - Kabagambe EK FIR - Kaelber, David C IR - Kaelber DC FIR - Kanjilal, Diane G IR - Kanjilal DG FIR - Kansal, Mayank M IR - Kansal MM FIR - Kasmarcak, Tyler J IR - Kasmarcak TJ FIR - Kaufman, Daniel IR - Kaufman D FIR - Kawakami, Rika IR - Kawakami R FIR - Kellogg, Dean L IR - Kellogg DL FIR - Kent, Denise A IR - Kent DA FIR - Kewlani, Deepshikha IR - Kewlani D FIR - Khullar, Dhruv IR - Khullar D FIR - Kim, Keri S IR - Kim KS FIR - Kim, Arthur Y IR - Kim AY FIR - Kinser, Patricia A IR - Kinser PA FIR - Kleinman, Lawrence C IR - Kleinman LC FIR - Klerman, Elizabeth B IR - Klerman EB FIR - Kluko, Matthew J IR - Kluko MJ FIR - Knight, Stacey IR - Knight S FIR - Kobayashi, Misaki IR - Kobayashi M FIR - Kopp, Karla J IR - Kopp KJ FIR - Koropsak, Michael IR - Koropsak M FIR - Kosut, Jessica S IR - Kosut JS FIR - Kraig, Ellen IR - Kraig E FIR - Krausert, Amanda IR - Krausert A FIR - Krieger, Ana C IR - Krieger AC FIR - Krishna, Hema IR - Krishna H FIR - Krishnamoorthy, Aparna IR - Krishnamoorthy A FIR - Krishnan, Sankaran S IR - Krishnan SS FIR - Lahs, James P IR - Lahs JP FIR - Laird, Angela R IR - Laird AR FIR - Laleau, Victoria IR - Laleau V FIR - Lamendola-Essel, Michelle F IR - Lamendola-Essel MF FIR - Landeo-Gutierrez, Jeremy IR - Landeo-Gutierrez J FIR - Lang, Sean M IR - Lang SM FIR - Larson, Christine L IR - Larson CL FIR - Lash, James P IR - Lash JP FIR - Lasky-Su, Jessica IR - Lasky-Su J FIR - Laynor, Gregory IR - Laynor G FIR - Lee, Simon IR - Lee S FIR - Lee, Grace M IR - Lee GM FIR - Lee, F E IR - Lee FE FIR - Lee, Matthew A IR - Lee MA FIR - Leese, Peter J IR - Leese PJ FIR - Lefebvre, R C IR - Lefebvre RC FIR - Levreault, Angelica J IR - Levreault AJ FIR - Lewis, Kennedy C IR - Lewis KC FIR - Li, Lu IR - Li L FIR - Lim, Peter Paul C IR - Lim PPC FIR - Lin, Janet Y IR - Lin JY FIR - Lisdahl, Krista M IR - Lisdahl KM FIR - Litvack, Matthew B IR - Litvack MB FIR - Liu, Xiaokang IR - Liu X FIR - Lloyd, Jennifer IR - Lloyd J FIR - Logue, Jennifer K IR - Logue JK FIR - Loomba, Johanna J IR - Loomba JJ FIR - Lorman, Vitaly IR - Lorman V FIR - Lu, Yiwen IR - Lu Y FIR - Ludwig, Katelyn R IR - Ludwig KR FIR - Lutz, Allison M IR - Lutz AM FIR - Mack, Jeri IR - Mack J FIR - Mahmoud, Abeer M IR - Mahmoud AM FIR - Maier, Cheryl L IR - Maier CL FIR - Malakooti, Shahdi K IR - Malakooti SK FIR - Malchenko, Sergey IR - Malchenko S FIR - Mallett, Gail L IR - Mallett GL FIR - Maranga, Gabrielle IR - Maranga G FIR - Martel, Megan W IR - Martel MW FIR - Martin-Herz, Susanne P IR - Martin-Herz SP FIR - Martinez-Lage, Maria IR - Martinez-Lage M FIR - Maughan, Christine IR - Maughan C FIR - Mauntel-Medici, Cammeo IR - Mauntel-Medici C FIR - May, Heidi T IR - May HT FIR - Mayer, Kenneth H IR - Mayer KH FIR - Mazzotti, Diego R IR - Mazzotti DR FIR - McCallum, Caitryn M IR - McCallum CM FIR - McCrindle, Brian W IR - McCrindle BW FIR - McCulloh, Russell J IR - McCulloh RJ FIR - McDonald, Dylan IR - McDonald D FIR - McInnis, Stephanie IR - McInnis S FIR - McMurry, Julie A IR - McMurry JA FIR - Mejias, Asuncion IR - Mejias A FIR - Melamed, Jonathan IR - Melamed J FIR - Menchaca, Martha IR - Menchaca M FIR - Mendelsohn, Alan L IR - Mendelsohn AL FIR - Miele, Lucio IR - Miele L FIR - Miglis, Mitchell G IR - Miglis MG FIR - Milne, Cris IR - Milne C FIR - Milner, Joshua D IR - Milner JD FIR - Mitchell, Roger A IR - Mitchell RA FIR - Mittleman, Murray A IR - Mittleman MA FIR - Mohandas, Sindhu IR - Mohandas S FIR - Monteiro, Jonathan G IR - Monteiro JG FIR - Monzon, Vanessa IR - Monzon V FIR - Moreno, David J IR - Moreno DJ FIR - Morgan, Lerraughn M IR - Morgan LM FIR - Morozyuk, Dmitry IR - Morozyuk D FIR - Morse, Keith E IR - Morse KE FIR - Moyneur, Erick IR - Moyneur E FIR - Mudumbi, Praveen C IR - Mudumbi PC FIR - MYller-Oehring, Eva M IR - MYller-Oehring EM FIR - Muramatsu, Naoko IR - Muramatsu N FIR - Musick, Hugh IR - Musick H FIR - Nagavedu, Kshema IR - Nagavedu K FIR - Nahin, Erica R IR - Nahin ER FIR - Nambiar, Anoop M IR - Nambiar AM FIR - Natelson, Benjamin H IR - Natelson BH FIR - Neale, Michael C IR - Neale MC FIR - Ness-Cochinwala, Manette IR - Ness-Cochinwala M FIR - Newburger, Jane W IR - Newburger JW FIR - Newman, Lisa T IR - Newman LT FIR - Nguyen, Amber N IR - Nguyen AN FIR - Nichols, Lauren IR - Nichols L FIR - Nolan, Sheila M IR - Nolan SM FIR - Noland, Seth IR - Noland S FIR - Novak, Richard M IR - Novak RM FIR - O'Connor, George T IR - O'Connor GT FIR - O'Keefe, John J IR - O'Keefe JJ FIR - Ogbogu, Princess U IR - Ogbogu PU FIR - Oliveira, Carlos R IR - Oliveira CR FIR - Oster, Matthew E IR - Oster ME FIR - Padera, Robert F IR - Padera RF FIR - Paik, Henry H IR - Paik HH FIR - Pajor, Nathan M IR - Pajor NM FIR - Pan, Huaqin Helen IR - Pan HH FIR - Pant, Deepti IR - Pant D FIR - Partridge, Andrew IR - Partridge A FIR - Patel, Payal B IR - Patel PB FIR - Patel, Saaya IR - Patel S FIR - Patel, Khushboo IR - Patel K FIR - Paulus, Martin P IR - Paulus MP FIR - Payne, Ronald M IR - Payne RM FIR - Pearman, Ann IR - Pearman A FIR - Peralta-Carcelen, Myriam IR - Peralta-Carcelen M FIR - Perez, Nicolas L IR - Perez NL FIR - Pfaff, Emily R IR - Pfaff ER FIR - Pillers, De-Ann M IR - Pillers DM FIR - Pitsch, Chloe E IR - Pitsch CE FIR - Pliskin, Neil H IR - Pliskin NH FIR - Portman, Michael A IR - Portman MA FIR - Postelnicu, Radu IR - Postelnicu R FIR - Potter, Jennifer S IR - Potter JS FIR - Prabhakar, Bellur S IR - Prabhakar BS FIR - Prahalad, Priya IR - Prahalad P FIR - Prasad, Bharati IR - Prasad B FIR - Predki, Barbara IR - Predki B FIR - Preiss, Alexander J IR - Preiss AJ FIR - Prendergast, Heather M IR - Prendergast HM FIR - Quinn, Davin K IR - Quinn DK FIR - Quintana, Yuri IR - Quintana Y FIR - Rabideau, Dustin J IR - Rabideau DJ FIR - Radosta, Jonathan M IR - Radosta JM FIR - Radwell, Jeffrey IR - Radwell J FIR - Raissy, Hengameh IR - Raissy H FIR - Ramchandran, Ramaswamy IR - Ramchandran R FIR - Randall, Isabelle IR - Randall I FIR - Rao, Suchitra IR - Rao S FIR - Rapkiewicz, Amy IR - Rapkiewicz A FIR - Rasmussen, Sonja A IR - Rasmussen SA FIR - Razzaghi, Hanieh IR - Razzaghi H FIR - Rebello, Candida J IR - Rebello CJ FIR - Rebolledo, Paulina A IR - Rebolledo PA FIR - Reddy, Neha V IR - Reddy NV FIR - Reddy, Unma M IR - Reddy UM FIR - Reedy, Cara IR - Reedy C FIR - Rehman, Jalees IR - Rehman J FIR - Reichard, R R IR - Reichard RR FIR - Reid, Kayleigh M IR - Reid KM FIR - Reusch, Jane E IR - Reusch JE FIR - Rhee, Kyung E IR - Rhee KE FIR - Rice, Mary B IR - Rice MB FIR - Rizzo, John-Ross R IR - Rizzo JR FIR - Roan, Nadia R IR - Roan NR FIR - Robarts, Polly IR - Robarts P FIR - Roberts, Timothy R IR - Roberts TR FIR - Rochez, Nitza IR - Rochez N FIR - Rodgers, Kathleen E IR - Rodgers KE FIR - Rogerson, Colin M IR - Rogerson CM FIR - Romero, Maria E IR - Romero ME FIR - Rosas, Johana M IR - Rosas JM FIR - Rosenzweig, Erika B IR - Rosenzweig EB FIR - Rothman, Russell L IR - Rothman RL FIR - Rouphael, Nadine G IR - Rouphael NG FIR - Russell, Mark W IR - Russell MW FIR - Rutherfoord, Melissa IR - Rutherfoord M FIR - Sabati, Arash A IR - Sabati AA FIR - Sader, Samer B IR - Sader SB FIR - Salehi, Marzieh IR - Salehi M FIR - Salisbury, Amy L IR - Salisbury AL FIR - Sampson, Barbara A IR - Sampson BA FIR - Sanil, Yamuna IR - Sanil Y FIR - Sato, Alice I IR - Sato AI FIR - Saydah, Sharon H IR - Saydah SH FIR - Schechter, Michael S IR - Schechter MS FIR - Schenck, Edward J IR - Schenck EJ FIR - Schlepphorst, Katherine I IR - Schlepphorst KI FIR - Schuchard, Julia IR - Schuchard J FIR - Schuh, Tina L IR - Schuh TL FIR - Sculley, Jennifer A IR - Sculley JA FIR - Seifert, Alan C IR - Seifert AC FIR - Sekar, Anisha K IR - Sekar AK FIR - Selvarangan, Rangaraj IR - Selvarangan R FIR - Seshadri, Sudha IR - Seshadri S FIR - Sesso, Howard D IR - Sesso HD FIR - Shah, Dimpy P IR - Shah DP FIR - Shakti, Divya IR - Shakti D FIR - Shapiro, Nancy L IR - Shapiro NL FIR - Sharma, Suchetha IR - Sharma S FIR - Sharma, Kumar IR - Sharma K FIR - Sharma, Shubhi IR - Sharma S FIR - Sharma, Kavita IR - Sharma K FIR - Shaw, Gwendolyn IR - Shaw G FIR - Shemesh, Eyal IR - Shemesh E FIR - Shen, Yishan IR - Shen Y FIR - Shenkman, Elizabeth IR - Shenkman E FIR - Shiau, Stephanie IR - Shiau S FIR - Siciliano, Michelle IR - Siciliano M FIR - Simsir, Aylin IR - Simsir A FIR - Smith, Veronica E IR - Smith VE FIR - Snowden, Jessica N IR - Snowden JN FIR - Solomon, Isaac H IR - Solomon IH FIR - Spikes, Leslie A IR - Spikes LA FIR - Squeglia, Lindsay M IR - Squeglia LM FIR - Srivastava, Shubhika IR - Srivastava S FIR - St Jean, Mary L IR - St Jean ML FIR - Stapleford, Kenneth A IR - Stapleford KA FIR - Stein, Cheryl R IR - Stein CR FIR - Stevenson, Michelle D IR - Stevenson MD FIR - Stewart de Ramirez, Sarah A IR - Stewart de Ramirez SA FIR - Stiles, Lauren E IR - Stiles LE FIR - Stock, Aryeh IR - Stock A FIR - Stockwell, Melissa S IR - Stockwell MS FIR - Stone, James R IR - Stone JR FIR - Stratford, Jeran IR - Stratford J FIR - StYrmer, Til IR - StYrmer T FIR - Subbian, Vignesh IR - Subbian V FIR - Sun, Jun IR - Sun J FIR - Suthar, Mehul S IR - Suthar MS FIR - Sylvera, Ashley IR - Sylvera A FIR - Systrom, David M IR - Systrom DM FIR - Szmuszkovicz, Jacqueline IR - Szmuszkovicz J FIR - Talavera-Barber, Maria M IR - Talavera-Barber MM FIR - Tantisira, Kelan G IR - Tantisira KG FIR - Tartt, Nancy IR - Tartt N FIR - Terlinde, Tracy IR - Terlinde T FIR - Teufel, Ronald J IR - Teufel RJ FIR - Thacker, Deepika IR - Thacker D FIR - Thakrar, Mansi IR - Thakrar M FIR - Thibodeau, Stephen N IR - Thibodeau SN FIR - Thomas, Gelise L IR - Thomas GL FIR - Thomason, Moriah E IR - Thomason ME FIR - Tong, Jiayi IR - Tong J FIR - Torres, Robert IR - Torres R FIR - Traenkner, Jessica IR - Traenkner J FIR - Tragus, Robin IR - Tragus R FIR - Trinity, Joel D IR - Trinity JD FIR - Tronieri, Jena S IR - Tronieri JS FIR - Troxel, Andrea B IR - Troxel AB FIR - Truong, Jennifer IR - Truong J FIR - Truong, Dongngan T IR - Truong DT FIR - Tsevat, Joel IR - Tsevat J FIR - Udosen, Mmekom M IR - Udosen MM FIR - Unterberger, Kristen IR - Unterberger K FIR - Utz, Paul J IR - Utz PJ FIR - Vaccarino, Viola IR - Vaccarino V FIR - Vallejos, Brittany B IR - Vallejos BB FIR - Vanden Hoek, Terry L IR - Vanden Hoek TL FIR - Vangeepuram, Nita IR - Vangeepuram N FIR - Varma, Jay K IR - Varma JK FIR - Vernon, Suzanne D IR - Vernon SD FIR - Vidal, Crystal M IR - Vidal CM FIR - Vivensi, Sara IR - Vivensi S FIR - Vohra, Adam S IR - Vohra AS FIR - Wagner, Laura K IR - Wagner LK FIR - Wang, Fei IR - Wang F FIR - Warburton, David IR - Warburton D FIR - Warner, Megan R IR - Warner MR FIR - Watkins, Rebecca L IR - Watkins RL FIR - Watson, Sara E IR - Watson SE FIR - Webb, Ryan IR - Webb R FIR - Weeks, Ryan M IR - Weeks RM FIR - Weiner, Mark G IR - Weiner MG FIR - Werzberger, Alan IR - Werzberger A FIR - West, Shelby C IR - West SC FIR - Weyer, Jordan C IR - Weyer JC FIR - Wheeler, Jennifer L IR - Wheeler JL FIR - Wilkins, Kenneth J IR - Wilkins KJ FIR - Williams, Natasha J IR - Williams NJ FIR - Williams, Charles T IR - Williams CT FIR - Wimberly, Erika S IR - Wimberly ES FIR - Winter, Terra J IR - Winter TJ FIR - Woller, Scott C IR - Woller SC FIR - Wong, Rachel IR - Wong R FIR - Wood, Jeremy P IR - Wood JP FIR - Wood, John C IR - Wood JC FIR - Wood, Marion J J IR - Wood MJJ FIR - Wu, Qiong IR - Wu Q FIR - Xia, Yinglin IR - Xia Y FIR - Xu, Jie IR - Xu J FIR - Yang, Samuel IR - Yang S FIR - Yin, H S IR - Yin HS FIR - Yin, Hsiang S IR - Yin HS FIR - Yoo, Yun Jae IR - Yoo YJ FIR - Young, Chloe E IR - Young CE FIR - Young, Natalie M IR - Young NM FIR - Zang, Chengxi IR - Zang C FIR - Zempsky, William T IR - Zempsky WT FIR - Zhang, Bingyu IR - Zhang B FIR - Zhang, Yongkang IR - Zhang Y FIR - Zhang, Dazheng IR - Zhang D FIR - Zimmerman, Emily IR - Zimmerman E FIR - Andrefsky, John IR - Andrefsky J FIR - Marrazzo, Jeanne M IR - Marrazzo JM FIR - Dixon, Jennifer IR - Dixon J FIR - Gale, Lisa IR - Gale L FIR - Maholovich, Phoebe IR - Maholovich P FIR - Sudhindra, Praveen IR - Sudhindra P FIR - Thompson, Tiffany IR - Thompson T FIR - Sheehan, Elyce IR - Sheehan E FIR - Parada, Alisha IR - Parada A FIR - Knowlton, Kiirk IR - Knowlton K FIR - Anderson, Jeffrey L IR - Anderson JL FIR - McIntyre, Marjorie IR - McIntyre M FIR - McCandless, Sean IR - McCandless S FIR - Montoya, Sarah IR - Montoya S FIR - Davis, Debra IR - Davis D FIR - Spanier, Eric IR - Spanier E FIR - Wodushek, Thomas IR - Wodushek T FIR - Sokol, Ron IR - Sokol R FIR - Maldonado, Yvonne IR - Maldonado Y FIR - Jacobson, Karen IR - Jacobson K FIR - Yang, Samuel IR - Yang S FIR - Jia, Xiaolin Kathleen IR - Jia XK FIR - Scott, Jake IR - Scott J FIR - Quintero, Orlando IR - Quintero O FIR - Haddad, Francois IR - Haddad F FIR - Valantine, Hannah IR - Valantine H FIR - Zamanian, Roham IR - Zamanian R FIR - Pathak, Divya IR - Pathak D FIR - Boyce, Jeanette IR - Boyce J FIR - Facco, Francesca IR - Facco F FIR - Hankle, Sarah IR - Hankle S FIR - Vargo, John A IR - Vargo JA FIR - Campbell, Donna IR - Campbell D FIR - Armstrong, Donna IR - Armstrong D FIR - Mann, Madison IR - Mann M FIR - Burrell, Nicole IR - Burrell N FIR - Bartholomew, Anna IR - Bartholomew A FIR - Grobman, William A IR - Grobman WA FIR - Cackovic, Barbara IR - Cackovic B FIR - Klopfenstein, Baylee IR - Klopfenstein B FIR - Weigand, Samantha IR - Weigand S FIR - Snow, E Kaye IR - Snow EK FIR - Fennig, Kathleen IR - Fennig K FIR - Esplin, M Sean IR - Esplin MS FIR - Lamb, Denise IR - Lamb D FIR - Nelsen, Amanda IR - Nelsen A FIR - Phipers, Jocelyn IR - Phipers J FIR - Fischer, Lauren IR - Fischer L FIR - Docter, Olivia IR - Docter O FIR - Brown, Jeanette IR - Brown J FIR - DeMartino, Angelica IR - DeMartino A FIR - Allard, Donna IR - Allard D FIR - Miller, Emily IR - Miller E FIR - Bousleiman, Sabine Z IR - Bousleiman SZ FIR - Loffredo, Megan M IR - Loffredo MM FIR - Vanneman, Ashley IR - Vanneman A FIR - Beche, Imene IR - Beche I FIR - Chan-Akeley, Rosalyn IR - Chan-Akeley R FIR - Pacheco, Luis D IR - Pacheco LD FIR - DeVolder, Jennfier D IR - DeVolder JD FIR - Salazar, Ashley IR - Salazar A FIR - Thibodeaux, Lisa IR - Thibodeaux L FIR - Cornwell, Jennifer IR - Cornwell J FIR - Nounes, Amelia A IR - Nounes AA FIR - Sweet, Eugenia IR - Sweet E FIR - Pierse, Abigail IR - Pierse A FIR - Desantis, Brittany IR - Desantis B FIR - Gill-Jones, Parmjit IR - Gill-Jones P FIR - Hackney, David N IR - Hackney DN FIR - Chauhan, Suneet P IR - Chauhan SP FIR - Ortiz, Felecia IR - Ortiz F FIR - Treadway, Jenifer IR - Treadway J FIR - Rugerio, Juanita IR - Rugerio J FIR - Clark, Kelly IR - Clark K FIR - Leatherland, Molly IR - Leatherland M FIR - Timlin, Sally IR - Timlin S FIR - Grinnan, Chelsea IR - Grinnan C FIR - Ferrara, Jennifer IR - Ferrara J FIR - Kominiarek, Michelle IR - Kominiarek M FIR - Jones, Dequana IR - Jones D FIR - Reynolds, Trista IR - Reynolds T FIR - Kearns, Katherine M IR - Kearns KM FIR - Saffian, Eleanor IR - Saffian E FIR - Karasti, Mariana IR - Karasti M FIR - Pizzi, Chrsitinia IR - Pizzi C FIR - Filipczak, Anna IR - Filipczak A FIR - Long, Emily IR - Long E FIR - Mitchell, Megan IR - Mitchell M FIR - Barrett, Katia J IR - Barrett KJ FIR - Mullowney, Celia IR - Mullowney C FIR - Macones, George A IR - Macones GA EDAT- 2023/06/06 13:09 MHDA- 2023/06/16 06:42 PMCR- 2023/11/25 CRDT- 2023/06/06 11:32 PHST- 2023/06/16 06:42 [medline] PHST- 2023/06/06 13:09 [pubmed] PHST- 2023/06/06 11:32 [entrez] PHST- 2023/11/25 00:00 [pmc-release] AID - 2805540 [pii] AID - joi230062 [pii] AID - 10.1001/jama.2023.8823 [doi] PST - ppublish SO - JAMA. 2023 Jun 13;329(22):1934-1946. doi: 10.1001/jama.2023.8823. PMID- 37261310 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230604 IS - 2055-1029 (Print) IS - 2055-1029 (Electronic) IS - 2055-1029 (Linking) VI - 10 IP - 1 DP - 2023 Jan-Jun TI - Do cognition and emotion matter? A study of COVID-19 vaccination decision-making in college students. PG - 20551029231179163 LID - 10.1177/20551029231179163 [doi] LID - 20551029231179163 AB - The unparalleled speed of COVID-19 vaccine development has necessitated an expansion of existing knowledge on vaccination decision-making. The current study explored (1) how cognitions and emotions shaped college students' COVID-19 vaccination decisions, and (2) where vaccination-inclined and vaccination-hesitant students converged and diverged in their decision-making process. Seventy-seven students participated in 26 focus groups to discuss their complex thoughts and feelings regarding COVID-19 vaccination, offering a more nuanced understanding of COVID-19 vaccination decision-making that has not been fully captured by quantitative studies. Thematic analysis found that vaccination-inclined participants and their hesitant counterparts reported differential patterns of positive and negative emotions, systematic appraisals, and heuristics in decision-making. Future research should investigate the roles of hope and relief, non-health-related benefits of vaccination, social trust, and interpersonal influence in vaccination decision-making. CI - (c) The Author(s) 2023. FAU - Chen, Nien-Tsu Nancy AU - Chen NN AUID- ORCID: 0000-0001-8814-2115 AD - Department of Communication, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 FAU - Kee, Kimmy AU - Kee K AD - Department of Psychology, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 FAU - Villalobos, Bianca T AU - Villalobos BT AD - Department of Psychological Science, , Edinburg, TX, USAUniversity of Texas Rio Grande Valley. FAU - Ortiz, Miriam AU - Ortiz M AD - Department of Psychological Science, , Edinburg, TX, USAUniversity of Texas Rio Grande Valley. FAU - Lee, HyeSun AU - Lee H AD - Department of Psychology, , Camarillo, CA, USACalifornia State University Channel Islands. RINGGOLD: 14703 LA - eng PT - Journal Article DEP - 20230530 PL - England TA - Health Psychol Open JT - Health psychology open JID - 101642883 PMC - PMC10227488 OTO - NOTNLM OT - affect OT - beliefs OT - cognitive processing OT - emotions OT - health behaviour OT - health promotion OT - public health psychology OT - qualitative methods OT - theory of planned behaviour COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2023/06/01 13:09 MHDA- 2023/06/01 13:10 PMCR- 2023/05/30 CRDT- 2023/06/01 10:39 PHST- 2023/06/01 13:10 [medline] PHST- 2023/06/01 13:09 [pubmed] PHST- 2023/06/01 10:39 [entrez] PHST- 2023/05/30 00:00 [pmc-release] AID - 10.1177_20551029231179163 [pii] AID - 10.1177/20551029231179163 [doi] PST - epublish SO - Health Psychol Open. 2023 May 30;10(1):20551029231179163. doi: 10.1177/20551029231179163. eCollection 2023 Jan-Jun. PMID- 37231308 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20230619 IS - 1432-1041 (Electronic) IS - 0031-6970 (Print) IS - 0031-6970 (Linking) VI - 79 IP - 7 DP - 2023 Jul TI - Seronegative acute encephalitis following COVID-19 vaccines: a case series of an overlooked diagnosis with literature review. PG - 975-987 LID - 10.1007/s00228-023-03510-7 [doi] AB - PURPOSE: Autoimmune encephalitis is a neurological emergency of new-onset altered mental status, caused by an exaggerated immune-mediated response that targets the central nervous system. Autoimmune encephalitis has become an emerging differential diagnosis, when a classical infection cannot explain neurological symptoms. Displaying overlapping clinical presentations, ranging from the insidious onset of cognitive deficiency to more severe forms of encephalopathy with refractory seizures, autoimmune encephalitis can be challenging for clinicians. When evidence of malignancy is absent and pathogenic autoantibodies are undetected, with typical clinical and imaging features of autoimmune encephalitis, seronegative autoimmune encephalitis may be considered. Recently, vaccination-related autoimmune encephalitis and acute encephalitis after COVID-19 vaccination have attracted attention. METHODS AND RESULTS: We report a case series consisting of three patients with autoimmune encephalitis occurring shortly after COVID-19 vaccination and a current review of all previous reported autoimmune encephalitis related to COVID-19 vaccines. CONCLUSION: We emphasise on the prompt diagnosis of autoimmune encephalitis induced by Covid-19 vaccines and its timely treatment to improve the clinical outcome of this severe neurological condition. Post-licencing vaccine safety surveillance for potential adverse events is essential for vaccine safety and public confidence. CI - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Mansour, Khadija AU - Mansour K AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. khadija.mansour2@gmail.com. FAU - Chadli, Zohra AU - Chadli Z AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Ghachem, Ichrak AU - Ghachem I AD - Department of Neurology, Taher Sfar University Hospital, Mahdia, Tunisia. FAU - Fredj, Nadia Ben AU - Fredj NB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Romdhane, Haifa Ben AU - Romdhane HB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Fadhel, Najah Ben AU - Fadhel NB AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Boughatas, Naceurs AU - Boughatas N AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Aouam, Karim AU - Aouam K AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Chaabane, Amel AU - Chaabane A AD - Department of Pharmacology, Fattouma Bourguiba University Hospital of Monastir, Monastir, Tunisia. FAU - Younes, Samia AU - Younes S AD - Department of Neurology, Taher Sfar University Hospital, Mahdia, Tunisia. LA - eng PT - Journal Article PT - Review DEP - 20230526 PL - Germany TA - Eur J Clin Pharmacol JT - European journal of clinical pharmacology JID - 1256165 RN - 0 (COVID-19 Vaccines) RN - Hashimoto's encephalitis SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Autoimmune Diseases of the Nervous System MH - Hashimoto Disease MH - Humans MH - COVID-19 Testing MH - *Encephalitis/diagnosis/etiology PMC - PMC10212735 OTO - NOTNLM OT - Adverse drug reaction OT - Autoimmune encephalitis OT - COVID-19 vaccines OT - Neuroinflammation OT - Neurological complications COIS- The authors declare no competing interests. EDAT- 2023/05/26 01:05 MHDA- 2023/06/19 13:08 PMCR- 2023/05/26 CRDT- 2023/05/25 23:34 PHST- 2023/02/19 00:00 [received] PHST- 2023/05/16 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2023/05/26 01:05 [pubmed] PHST- 2023/05/25 23:34 [entrez] PHST- 2023/05/26 00:00 [pmc-release] AID - 10.1007/s00228-023-03510-7 [pii] AID - 3510 [pii] AID - 10.1007/s00228-023-03510-7 [doi] PST - ppublish SO - Eur J Clin Pharmacol. 2023 Jul;79(7):975-987. doi: 10.1007/s00228-023-03510-7. Epub 2023 May 26. PMID- 37227580 OWN - NLM STAT- MEDLINE DCOM- 20230623 LR - 20230623 IS - 1720-8319 (Electronic) IS - 1594-0667 (Print) IS - 1594-0667 (Linking) VI - 35 IP - 7 DP - 2023 Jul TI - Vaccine uptake in caregivers family members and patients with dementia and relationship with severity of dementia and caregiver burden: a cross-sectional study. PG - 1565-1569 LID - 10.1007/s40520-023-02443-6 [doi] AB - We cross sectionally evaluated COVID-19 and seasonal flu vaccination rates among 94 dyads consisting of informal caregiver family member and non-institutionalized patient with dementia observed in family-medicine practice in Zagreb, Croatia. COVID-19 vaccination rates in caregivers (78.7%) and patients with dementia (82.9%) were significantly higher than in general population. Caregiver and patient COVID-19 vaccination status (CVS) did not correlate. Among caregivers, seasonal flu vaccination (P = 0.004) but no other investigated factors related to caregiving or dementia severity showed significant association with CVS. Among patients with dementia, CVS was significantly associated with lower number of caregiver hours dedicated per week (P = 0.017), higher caregiver SF-36 role emotional HRQoL (P = 0.017), younger patient age (P = 0.027), higher MMSE (P = 0.030), higher Barthel index (P = 0.006), absence of neuropsychiatric symptoms of agitation and aggression (P = 0.031), lower overall caregiver burden (P = 0.034), lower burden of personal strain (P = 0.023) and lower burden of frustration (P = 0.016). Caregiving and severity of dementia-related factors significantly affect patient, but not caregiver CVS. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG. FAU - Lucijanic, Jelena AU - Lucijanic J AUID- ORCID: 0000-0001-7566-8708 AD - Health Care Center Zagreb-West, Prilaz Baruna Filipovica 11, 10000, Zagreb, Croatia. jemileti@yahoo.com. FAU - Hanzevacki, Miroslav AU - Hanzevacki M AD - Health Care Center Zagreb-West, Prilaz Baruna Filipovica 11, 10000, Zagreb, Croatia. AD - School of Medicine, University of Zagreb, Zagreb, Croatia. FAU - Bazdaric, Ksenija AU - Bazdaric K AD - Faculty of Health Studies, University of Rijeka, Rijeka, Croatia. FAU - Jurin, Ivana AU - Jurin I AD - Cardiology Department, University Hospital Dubrava, Zagreb, Croatia. FAU - Lucijanic, Marko AU - Lucijanic M AD - School of Medicine, University of Zagreb, Zagreb, Croatia. AD - Hematology Department, University Hospital Dubrava, Zagreb, Croatia. LA - eng PT - Journal Article DEP - 20230525 PL - Germany TA - Aging Clin Exp Res JT - Aging clinical and experimental research JID - 101132995 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Caregivers/psychology MH - Cross-Sectional Studies MH - Caregiver Burden MH - COVID-19 Vaccines MH - Cost of Illness MH - *COVID-19/prevention & control MH - Family/psychology MH - *Dementia/epidemiology PMC - PMC10209576 OTO - NOTNLM OT - Alzheimer disease OT - Caregiver burden OT - Dementia OT - SARS-CoV-2 OT - Vaccination COIS- All authors declare they have no conflict of interest. EDAT- 2023/05/25 13:06 MHDA- 2023/06/23 06:42 PMCR- 2023/05/25 CRDT- 2023/05/25 11:32 PHST- 2023/04/11 00:00 [received] PHST- 2023/05/12 00:00 [accepted] PHST- 2023/06/23 06:42 [medline] PHST- 2023/05/25 13:06 [pubmed] PHST- 2023/05/25 11:32 [entrez] PHST- 2023/05/25 00:00 [pmc-release] AID - 10.1007/s40520-023-02443-6 [pii] AID - 2443 [pii] AID - 10.1007/s40520-023-02443-6 [doi] PST - ppublish SO - Aging Clin Exp Res. 2023 Jul;35(7):1565-1569. doi: 10.1007/s40520-023-02443-6. Epub 2023 May 25. PMID- 37195793 OWN - NLM STAT- MEDLINE DCOM- 20230925 LR - 20230926 IS - 1546-3141 (Electronic) IS - 0361-803X (Linking) VI - 221 IP - 4 DP - 2023 Oct TI - Continued Infarction Growth and Penumbral Consumption After Reperfusion in Vaccine-Naive Patients With COVID-19: A Case-Control Study. PG - 517-525 LID - 10.2214/AJR.23.29296 [doi] AB - BACKGROUND. Neurologic sequelae of SARS-CoV-2 include potentially malignant cerebrovascular events arising from complex hemodynamic, hematologic, and inflammatory processes occurring in concert. OBJECTIVE. This study concerns the hypothesis that despite angiographic reperfusion COVID-19 promotes continued consumption of at-risk tissue volumes after acute ischemic stroke (AIS), yielding critical insights into prognostication and monitoring paradigms in vaccine-naive patients experiencing AIS. METHODS. This retrospective study compared 100 consecutive COVID-19 patients with AIS presenting between March 2020 and April 2021 with a contemporaneous cohort of 282 AIS patients without COVID-19. Reperfusion classes were dichotomized into positive (extended thrombolysis in cerebral ischemia [eTICI] score = 2c-3) and negative (eTICI score < 2c) groups. All patients underwent endovascular therapy after initial CT perfusion imaging (CTP) to document infarction core and total hypoperfusion volumes. RESULTS. Ten COVID-positive (mean age +/- SD, 67 +/- 12 years; seven men, three women) and 144 COVID-negative patients (mean age, 71 +/- 16 years; 76 men, 68 women) undergoing endovascular reperfusion, with antecedent CTP and follow-up imaging, comprised the final dataset. Initial infarction core and total hypoperfusion volumes (mean +/- SD) were 1.5 +/- 18 mL and 85 +/- 100 mL in COVID-negative patients and 30.5 +/- 34 mL and 117 +/- 80.5 mL in COVID-positive patients, respectively. Final infarction volumes were significantly larger in patients with COVID-19, with median volumes of 77.8 mL versus 18.2 mL among control patients (p = .01), as were normalized measures of infarction growth relative to baseline infarction volume (p = .05). In adjusted logistic parametric regression models, COVID positivity emerged as a significant predictor for continued infarct growth (OR, 5.10 [95% CI, 1.00-25.95]; p = .05). CONCLUSION. These findings support the potentially aggressive clinical course of cerebrovascular events in patients with COVID-19, suggesting greater infarction growth and ongoing consumption of at-risk tissues, even after angiographic reperfusion. CLINICAL IMPACT. SARS-CoV-2 infection may promote continued infarction progression despite angiographic reperfusion in vaccine-naive patients with large-vessel occlusion AIS. The findings carry potential implications for prognostication, treatment selection, and surveillance for infarction growth among revascularized patients in future waves of infection by novel viral strains. FAU - Dehkharghani, Seena AU - Dehkharghani S AD - Department of Radiology, New York University Langone Medical Center, Center for Biomedical Imaging, 660 1st Ave, 2nd Fl, New York, NY 10016. AD - Department of Neurology, New York University Langone Health, New York, NY. FAU - Vogel, Andre AU - Vogel A AD - Department of Radiology, New York University Grossman School of Medicine, New York, NY. FAU - Jandhyala, Nora AU - Jandhyala N AD - Department of Radiology, New York University Grossman School of Medicine, New York, NY. FAU - Chung, Charlotte AU - Chung C AD - Department of Radiology, New York University Langone Medical Center, Center for Biomedical Imaging, 660 1st Ave, 2nd Fl, New York, NY 10016. FAU - Shu, Liqi AU - Shu L AD - Department of Neurology, Brown University, Providence, RI. FAU - Frontera, Jennifer AU - Frontera J AD - Department of Neurology, New York University Langone Health, New York, NY. FAU - Yaghi, Shadi AU - Yaghi S AD - Department of Neurology, Brown University, Providence, RI. LA - eng PT - Journal Article DEP - 20230517 PL - United States TA - AJR Am J Roentgenol JT - AJR. American journal of roentgenology JID - 7708173 SB - IM MH - Male MH - Humans MH - Female MH - Middle Aged MH - Aged MH - Aged, 80 and over MH - *Stroke/therapy MH - *Brain Ischemia/therapy MH - Case-Control Studies MH - Retrospective Studies MH - *Ischemic Stroke/diagnostic imaging MH - Tomography, X-Ray Computed/methods MH - *COVID-19 MH - SARS-CoV-2 MH - Infarction MH - Reperfusion/methods MH - Treatment Outcome MH - *Endovascular Procedures/methods OTO - NOTNLM OT - COVID-19 OT - CT OT - CT perfusion imaging OT - ischemic stroke OT - penumbral imaging EDAT- 2023/05/17 13:10 MHDA- 2023/09/25 06:42 CRDT- 2023/05/17 12:03 PHST- 2023/09/25 06:42 [medline] PHST- 2023/05/17 13:10 [pubmed] PHST- 2023/05/17 12:03 [entrez] AID - 10.2214/AJR.23.29296 [doi] PST - ppublish SO - AJR Am J Roentgenol. 2023 Oct;221(4):517-525. doi: 10.2214/AJR.23.29296. Epub 2023 May 17. PMID- 37187756 OWN - NLM STAT- MEDLINE DCOM- 20230517 LR - 20260927 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection. PG - 1147549 LID - 10.3389/fimmu.2023.1147549 [doi] LID - 1147549 AB - INTRODUCTION: The incidence of long COVID is substantial, even in people with mild to moderate acute COVID-19. The role of early viral kinetics in the subsequent development of long COVID is largely unknown, especially in individuals who were not hospitalized for acute COVID-19. METHODS: Seventy-three non-hospitalized adult participants were enrolled within approximately 48 hours of their first positive SARS-CoV-2 RT-PCR test, and mid-turbinate nasal and saliva samples were collected up to 9 times within the first 45 days after enrollment. Samples were assayed for SARS-CoV-2 using RT-PCR and additional SARS-CoV-2 test results were abstracted from the clinical record. Each participant indicated the presence and severity of 49 long COVID symptoms at 1-, 3-, 6-, 12-, and 18-months post-COVID-19 diagnosis. Time from acute COVID-19 illness onset to SARS-CoV-2 RNA clearance greater or less than 28 days was tested for association with the presence or absence of each of 49 long COVID symptoms at 90+ days from acute COVID-19 symptom onset. RESULTS: Self-reported brain fog and muscle pain at 90+ days after acute COVID-19 onset were negatively associated with viral RNA clearance within 28 days of acute COVID-19 onset with adjustment for age, sex, BMI >/= 25, and COVID vaccination status prior to COVID-19 (brain fog: aRR 0.46, 95% CI 0.22-0.95; muscle pain: aRR 0.28, 95% CI 0.08-0.94). Participants reporting higher severity brain fog or muscle pain at 90+ days after acute COVID-19 onset were less likely to have cleared SARS-CoV-2 RNA within 28 days. The acute viral RNA decay trajectories of participants who did and did not later go on to experience brain fog 90+ days after acute COVID-19 onset were distinct. DISCUSSION: This work indicates that at least two long COVID symptoms - brain fog and muscle pain - at 90+ days from acute COVID-19 onset are specifically associated with prolonged time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute COVID-19. This finding provides evidence that delayed immune clearance of SARS-CoV-2 antigen or greater amount or duration of viral antigen burden in the upper respiratory tract during acute COVID-19 are directly linked to long COVID. This work suggests that host-pathogen interactions during the first few weeks after acute COVID-19 onset have an impact on long COVID risk months later. CI - Copyright (c) 2023 Antar, Yu, Demko, Hu, Tornheim, Blair, Thomas and Manabe. FAU - Antar, Annukka A R AU - Antar AAR AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Yu, Tong AU - Yu T AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Demko, Zoe O AU - Demko ZO AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Hu, Chen AU - Hu C AD - Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Tornheim, Jeffrey A AU - Tornheim JA AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Blair, Paul W AU - Blair PW AD - Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO), Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States. FAU - Thomas, David L AU - Thomas DL AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. FAU - Manabe, Yukari C AU - Manabe YC AD - Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States. LA - eng GR - K08 AI143391/AI/NIAID NIH HHS/United States GR - K23 AI135102/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20230428 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 RN - 0 (RNA, Viral) SB - IM UOF - medRxiv. 2023 Jan 19:2023.01.18.23284742. doi: 10.1101/2023.01.18.23284742. PMID: 36711478 MH - Adult MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - RNA, Viral/genetics MH - COVID-19 Testing MH - Myalgia MH - Respiratory System MH - Brain PMC - PMC10176965 OTO - NOTNLM OT - COVID-19 OT - brain fog OT - cognitive dysfunction OT - long COVID OT - pain OT - post-acute COVID-19 syndrome OT - post-acute sequelae of SARS-CoV-2 infection OT - reservoir COIS- Author PB was employed by Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. YM has received research grant support through Johns Hopkins University from Hologic, Cepheid, Roche, ChemBio, Becton Dickinson, and miDiagnostics and has provided consultative support to Abbott. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/05/16 01:09 MHDA- 2023/05/17 06:42 PMCR- 2023/04/28 CRDT- 2023/05/15 19:30 PHST- 2023/01/18 00:00 [received] PHST- 2023/04/13 00:00 [accepted] PHST- 2023/05/17 06:42 [medline] PHST- 2023/05/16 01:09 [pubmed] PHST- 2023/05/15 19:30 [entrez] PHST- 2023/04/28 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1147549 [doi] PST - epublish SO - Front Immunol. 2023 Apr 28;14:1147549. doi: 10.3389/fimmu.2023.1147549. eCollection 2023. PMID- 37141019 OWN - NLM STAT- MEDLINE DCOM- 20230508 LR - 20230508 IS - 1930-7810 (Electronic) IS - 0278-6133 (Linking) VI - 42 IP - 5 DP - 2023 May TI - Effects of diagnosis threat on cognitive complaints after COVID-19. PG - 335-342 LID - 10.1037/hea0001286 [doi] AB - OBJECTIVE: The term "long-COVID" refers to the persistence of neurological symptoms after being ill with COVID-19 (e.g., headaches, fatigue, and attentional impairment). Providing information about long-COVID (i.e., "diagnosis threat") increased subjective cognitive complaints among recovered COVID-19 patients compared with those exposed to neutral information (Winter & Braw, 2022). Notably, this effect was particularly prominent among more suggestible participants. Our aim in the current study was to validate these initial findings and to explore the impact of additional variables (e.g., suggestibility). METHOD: Recovered patients (n = 270) and controls (n = 290) reported daily cognitive failures after being randomly assigned to either a diagnosis threat (exposure to an article providing information regarding long-COVID) or a control condition. RESULTS: Recovered patients, but not controls, reported more cognitive failures in the diagnosis threat condition compared with the control condition. Diagnosis threat added significantly to the prediction of cognitive complaints based on relevant demographic variables and suggestibility. Diagnosis threat and suggestibility interacted (i.e., suggestible individuals were particularly vulnerable to the impact of a diagnosis threat). CONCLUSIONS: Diagnosis threat may contribute to the persistence of complaints regarding cognitive impairment among recovered COVID-19 patients. Suggestibility may be an underlying mechanism that increases the impact of diagnosis threat. Other factors, such as vaccination status, may be at play though we are only at the initial stages of research concerning their impact. These may be the focus of future research, aiding in identifying risk factors for experiencing COVID-19 symptoms past the resolution of its acute phase. (PsycInfo Database Record (c) 2023 APA, all rights reserved). FAU - Winter, Daniella AU - Winter D AD - Department of Psychology, Ariel University. FAU - Braw, Yoram AU - Braw Y AD - Department of Psychology, Ariel University. LA - eng PT - Journal Article PL - United States TA - Health Psychol JT - Health psychology : official journal of the Division of Health Psychology, American Psychological Association JID - 8211523 SB - IM MH - Humans MH - *COVID-19 MH - *Cognitive Dysfunction/diagnosis/etiology MH - Forecasting MH - Cognition MH - Fatigue/diagnosis/epidemiology/etiology MH - COVID-19 Testing EDAT- 2023/05/04 18:42 MHDA- 2023/05/08 06:42 CRDT- 2023/05/04 12:23 PHST- 2023/05/08 06:42 [medline] PHST- 2023/05/04 18:42 [pubmed] PHST- 2023/05/04 12:23 [entrez] AID - 2023-68974-004 [pii] AID - 10.1037/hea0001286 [doi] PST - ppublish SO - Health Psychol. 2023 May;42(5):335-342. doi: 10.1037/hea0001286. PMID- 37101263 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20240917 IS - 1741-7015 (Electronic) IS - 1741-7015 (Linking) VI - 21 IP - 1 DP - 2023 Apr 26 TI - Third dose mRNA vaccination against SARS-CoV-2 reduces medical complaints seen in primary care: a matched cohort study. PG - 157 LID - 10.1186/s12916-023-02870-2 [doi] LID - 157 AB - BACKGROUND: SARS-CoV-2 mRNA vaccination has been associated with both side effects and a reduction in COVID-related complaints due to the decrease in COVID-19 incidence. We aimed to investigate if individuals who received three doses of SARS-CoV-2 mRNA vaccines had a lower incidence of (a) medical complaints and (b) COVID-19-related medical complaints, both as seen in primary care, when compared to individuals who received two doses. METHODS: We conducted a daily longitudinal exact one-to-one matching study based on a set of covariates. We obtained a matched sample of 315,650 individuals aged 18-70 years who received the 3rd dose at 20-30 weeks after the 2nd dose and an equally large control group who did not. Outcome variables were diagnostic codes as reported by general practitioners or emergency wards, both alone and in combination with diagnostic codes of confirmed COVID-19. For each outcome, we estimated cumulative incidence functions with hospitalization and death as competing events. RESULTS: We found that the number of medical complaints was lower in individuals aged 18-44 years who received three doses compared to those who received two doses. The differences in estimates per 100,000 vaccinated were as follows: fatigue 458 less (95% confidence interval: 355-539), musculoskeletal pain 171 less (48-292), cough 118 less (65-173), heart palpitations 57 less (22-98), shortness of breath 118 less (81-149), and brain fog 31 less (8-55). We also found a lower number of COVID-19-related medical complaints: per 100,000 individuals aged 18-44 years vaccinated with three doses, there were 102 (76-125) fewer individuals with fatigue, 32 (18-45) fewer with musculoskeletal pain, 30 (14-45) fewer with cough, and 36 (22-48) fewer with shortness of breath. There were no or fewer differences in heart palpitations (8 (1-16)) or brain fog (0 (- 1-8)). We observed similar results, though more uncertain, for individuals aged 45-70 years, both for medical complaints and for medical complaints that were COVID-19 related. CONCLUSIONS: Our findings suggest that a 3rd dose of SARS-CoV-2 mRNA vaccine administered 20-30 weeks after the 2nd dose may reduce the incidence of medical complaints. It may also reduce the COVID-19-related burden on primary healthcare services. CI - (c) 2023. The Author(s). FAU - Methi, Fredrik AU - Methi F AUID- ORCID: 0000-0002-7091-0806 AD - Norwegian Institute of Public Health, Postboks 222, Skoyen, Oslo, N-0213, Norway. fredrik.methi@fhi.no. FAU - Gran, Jon Michael AU - Gran JM AD - Oslo Centre for Biostatistics & Epidemiology, Department of Biostatistic, University of Oslo, Oslo, Norway. AD - Oslo Centre for Biostatistics & Epidemiology, Oslo University Hospital, Oslo, Norway. FAU - Valberg, Morten AU - Valberg M AD - Oslo Centre for Biostatistics & Epidemiology, Oslo University Hospital, Oslo, Norway. AD - Department of Community Medicine & Global Health, University of Oslo, Oslo, Norway. FAU - Kinge, Jonas Minet AU - Kinge JM AD - Norwegian Institute of Public Health, Postboks 222, Skoyen, Oslo, N-0213, Norway. AD - Department of Health Management and Health Economics, University of Oslo, Oslo, Norway. FAU - Telle, Kjetil AU - Telle K AD - Norwegian Institute of Public Health, Postboks 222, Skoyen, Oslo, N-0213, Norway. FAU - Magnusson, Karin AU - Magnusson K AD - Norwegian Institute of Public Health, Postboks 222, Skoyen, Oslo, N-0213, Norway. AD - Clinical Epidemiology Unit, Orthopedics, Department of Clinical Sciences Lund, Lund University, Lund, Sweden. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230426 PL - England TA - BMC Med JT - BMC medicine JID - 101190723 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - SARS-CoV-2/genetics MH - Cohort Studies MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Cough MH - *Musculoskeletal Pain MH - Dyspnea MH - Fatigue MH - RNA, Messenger MH - Primary Health Care MH - Vaccination PMC - PMC10132437 OTO - NOTNLM OT - COVID-19 OT - Cough OT - Fatigue OT - Primary care OT - SARS-CoV-2 OT - Vaccination COIS- The authors declare that they have no competing interests. EDAT- 2023/04/27 00:42 MHDA- 2023/04/28 06:41 PMCR- 2023/04/26 CRDT- 2023/04/26 23:43 PHST- 2022/09/29 00:00 [received] PHST- 2023/04/18 00:00 [accepted] PHST- 2023/04/28 06:41 [medline] PHST- 2023/04/27 00:42 [pubmed] PHST- 2023/04/26 23:43 [entrez] PHST- 2023/04/26 00:00 [pmc-release] AID - 10.1186/s12916-023-02870-2 [pii] AID - 2870 [pii] AID - 10.1186/s12916-023-02870-2 [doi] PST - epublish SO - BMC Med. 2023 Apr 26;21(1):157. doi: 10.1186/s12916-023-02870-2. PMID- 37091031 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230425 IS - 2249-4863 (Print) IS - 2278-7135 (Electronic) IS - 2249-4863 (Linking) VI - 12 IP - 2 DP - 2023 Feb TI - Impact of COVID-19 vaccines on the health status of young female adults from India: A cross-sectional study. PG - 338-351 LID - 10.4103/jfmpc.jfmpc_1574_22 [doi] AB - PURPOSE: Reports suggest that females experience more adverse events post-coronavirus disease 2019 (COVID-19) vaccination compared to males. However, no gender-specific data on the impact of vaccines on the Indian population are available. The present study was intended to understand the impact of COVID-19 vaccines on the health status of young Indian female adults and to identify the factors associated with experiencing adverse events post-vaccination. METHODS: A web-based survey was conducted among 433 young female adults who have taken at least one dose of the COVID-19 vaccine. The prevalence and duration of systemic and generalized symptoms were analyzed using descriptive statistics. The factors associated with symptoms post-vaccination were analyzed using binary logistic regression. Adjusted odds ratios and 95% confidence intervals were computed. A P value of /=18) patients with PASC. PASC was defined as experiencing constitutional (palpitations, malaise/fatigue, headache) or systemic (sleep disorder, shortness of breath, mood/anxiety disorders, cough and cognitive impairment) symptoms beyond the 28-day postinfection period. STATISTICAL ANALYSIS: We fit multivariable logistic regression models and report estimated likelihood of PASC associated with vaccination or mAb treatment as adjusted ORs with 95% CIs. RESULTS: Primary analyses included 53 239 subjects (54.9% female), of whom 5929, 11.1% (95% CI 10.9% to 11.4%), experienced PASC. Both vaccinated breakthrough cases (vs unvaccinated) and mAb-treated patients (vs untreated) had lower likelihoods for developing PASC, aOR (95% CI): 0.58 (0.52-0.66), and 0.77 (0.69-0.86), respectively. Vaccination was associated with decreased odds of developing all constitutional and systemic symptoms except for taste and smell changes. For all symptoms, vaccination was associated with lower likelihood of experiencing PASC compared with mAb treatment. Replication analysis found identical frequency of PASC (11.2%, 95% CI 11.1 to 11.3) and similar protective effects against PASC for the COVID-19 vaccine: 0.25 (0.21-0.30) and mAb treatment: 0.62 (0.59-0.66). CONCLUSION: Although both COVID-19 vaccines and mAbs decreased the likelihood of PASC, vaccination remains the most effective tool for the prevention of long-term consequences of COVID-19. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Tannous, Jonika AU - Tannous J AUID- ORCID: 0000-0003-4022-9267 AD - Department of Neurosurgery, Houston Methodist Research Institute, Houston, Texas, USA. FAU - Pan, Alan P AU - Pan AP AUID- ORCID: 0000-0002-8782-8024 AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Potter, Thomas AU - Potter T AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Bako, Abdulaziz T AU - Bako AT AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Dlouhy, Katharine AU - Dlouhy K AD - Houston Methodist Research Institute, Houston, Texas, USA. FAU - Drews, Ashley AU - Drews A AD - Houston Methodist Academic Institute, Houston, Texas, USA. AD - Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA. FAU - Sostman, Henry Dirk AU - Sostman HD AD - Houston Methodist Academic Institute, Houston Methodist, Houston, Texas, USA. FAU - Vahidy, Farhaan S AU - Vahidy FS AUID- ORCID: 0000-0002-3464-2111 AD - Houston Methodist Research Institute, Houston, Texas, USA fvahidy@houstonmethodist.org. AD - Houston Methodist Academic Institute, Houston, Texas, USA. LA - eng PT - Journal Article DEP - 20230405 PL - England TA - BMJ Open JT - BMJ open JID - 101552874 RN - 0 (Antibodies, Monoclonal) RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Female MH - Humans MH - Male MH - Antibodies, Monoclonal/therapeutic use MH - Antibodies, Viral MH - *COVID-19/prevention & control/therapy MH - *COVID-19 Vaccines MH - Disease Progression MH - Registries MH - Retrospective Studies MH - SARS-CoV-2 MH - *Post-Acute COVID-19 Syndrome/drug therapy/prevention & control PMC - PMC10083521 OTO - NOTNLM OT - COVID-19 OT - Epidemiology OT - Public health COIS- Competing interests: None declared. EDAT- 2023/04/06 06:00 MHDA- 2023/04/07 10:18 PMCR- 2023/04/05 CRDT- 2023/04/05 20:53 PHST- 2023/04/07 10:18 [medline] PHST- 2023/04/05 20:53 [entrez] PHST- 2023/04/06 06:00 [pubmed] PHST- 2023/04/05 00:00 [pmc-release] AID - bmjopen-2022-067611 [pii] AID - 10.1136/bmjopen-2022-067611 [doi] PST - epublish SO - BMJ Open. 2023 Apr 5;13(4):e067611. doi: 10.1136/bmjopen-2022-067611. PMID- 37009342 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240915 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 15 IP - 3 DP - 2023 Mar TI - COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS): A Review. PG - e36955 LID - 10.7759/cureus.36955 [doi] LID - e36955 AB - POTS (Postural Orthostatic Tachycardia Syndrome) is a multisystem disorder characterized by the abnormal autonomic response to an upright posture, causing orthostatic intolerance and excessive tachycardia without hypotension. Recent reports suggest that a significant percentage of COVID-19 survivors develop POTS within 6 to 8 months of infection. Prominent symptoms of POTS include fatigue, orthostatic intolerance, tachycardia, and cognitive impairment. The exact mechanisms of post-COVID-19 POTS are unclear. Still, different hypotheses have been given, including autoantibody production against autonomic nerve fibers, direct toxic effects of SARS-CoV-2, or sympathetic nervous system stimulation secondary to infection. Physicians should have a high suspicion of POTS in COVID-19 survival when presented with symptoms of autonomic dysfunction and should conduct diagnostic tests like the Tilt table and others to confirm it. The management of COVID-19-related POTS requires a comprehensive approach. Most patients respond to initial non-pharmacological options, but when the symptoms become more severe and they do not respond to the non-pharmacological approach, pharmacological options are considered. We have limited understanding and knowledge of post-COVID-19 POTS, and further research is warranted to improve our understanding and formulate a better management plan. CI - Copyright (c) 2023, Mallick et al. FAU - Mallick, Deobrat AU - Mallick D AD - Internal Medicine, Christus Spohn Hospital, Corpus Christi, USA. FAU - Goyal, Lokesh AU - Goyal L AD - Hospital Medicine, Christus Spohn Hospital, Corpus Christi, USA. FAU - Chourasia, Prabal AU - Chourasia P AD - Hospital Medicine, Mary Washington Hospital, Fredericksburg, USA. FAU - Zapata, Miana R AU - Zapata MR AD - Internal Medicine, University of the Incarnate Word School of Osteopathic Medicine, Corpus Christi, USA. FAU - Yashi, Kanica AU - Yashi K AD - Internal Medicine, Bassett Health Care, Cooperstown, USA. FAU - Surani, Salim AU - Surani S AD - Anesthesiology, Mayo Clinic, Rochester, USA. AD - Medicine, Texas A&M University, College Station, USA. AD - Medicine, University of North Texas, Dallas, USA. AD - Internal Medicine, Pulmonary Associates, Corpus Christi, USA. AD - Clinical Medicine, University of Houston, Houston, USA. LA - eng PT - Journal Article PT - Review DEP - 20230331 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC10065129 OTO - NOTNLM OT - covid-19 OT - covid-19 vaccine OT - postural orthostatic tachycardia syndrome OT - pots OT - sars-cov-2 COIS- The authors have declared that no competing interests exist. EDAT- 2023/04/04 06:00 MHDA- 2023/04/04 06:01 PMCR- 2023/03/31 CRDT- 2023/04/03 04:26 PHST- 2023/03/31 00:00 [accepted] PHST- 2023/04/04 06:01 [medline] PHST- 2023/04/03 04:26 [entrez] PHST- 2023/04/04 06:00 [pubmed] PHST- 2023/03/31 00:00 [pmc-release] AID - 10.7759/cureus.36955 [doi] PST - epublish SO - Cureus. 2023 Mar 31;15(3):e36955. doi: 10.7759/cureus.36955. eCollection 2023 Mar. PMID- 36991236 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230724 IS - 2364-1746 (Electronic) IS - 2364-1754 (Print) IS - 2364-1754 (Linking) VI - 9 IP - 2 DP - 2023 Jun TI - Guillain-Barre Syndrome due to COVID-19 Vero Cell Vaccination Associated with Concomitant COVID-19 Infection-induced ARDS and Treated Successfully by Therapeutic Plasma Exchange: A First Case Report from Vietnam. PG - 271-280 LID - 10.1007/s41030-023-00219-x [doi] AB - Post-vaccination adverse reactions have been reported with varying symptoms and severity owing to research and production time pressures during the coronavirus disease 2019 (COVID-19) pandemic. In this article, we report a rare case of Guillain-Barre syndrome (GBS) in a patient with COVID-19 with acute respiratory distress syndrome (ARDS) after receiving Sinopharm's Vero Cell vaccine (China). The patient who was initially negative for COVID-19 was diagnosed with GBS based on paralysis that developed from the lower extremities to the upper extremities, as confirmed by cytoalbuminologic dissociation in the cerebrospinal fluid. The patient's condition worsened with ARDS caused by COVID-19 infection during the hospital stay, and SpO(2) decreased to 83% while receiving oxygen through a non-rebreather mask (15 l/min) on day 6. The patient was treated with standard therapy for severe COVID-19, invasive mechanical ventilation, and five cycles of therapeutic plasma exchange (TPE) with 5% albumin replacement on day 11 due to severe progression. The patient was weaned off the ventilator on day 28, discharged on day 42, and was completely healthy after 6 months without any neurological sequelae until now. Our report showed the potential of TPE for GBS treatment in critically ill patients with COVID-19 after COVID-19 vaccination. CI - (c) 2023. The Author(s). FAU - Duong-Quy, Sy AU - Duong-Quy S AUID- ORCID: 0000-0002-5926-9544 AD - Clinical Research Unit, Lam Dong Medical College and Bio-Medical Research Centre, Dalat, Vietnam. sduongquy.jfvp@gmail.com. AD - Immuno-Allergology Division, Hershey Medical Center, Penn State Medical College, Hershey, PA, USA. sduongquy.jfvp@gmail.com. AD - Outpatient Department, Pham Ngoc Thach Medical University, Ho Chi Minh, Vietnam. sduongquy.jfvp@gmail.com. AD - Department of Respiratory Functional Exploration, University Medical Center, University of Medicine and Pharmacy, Ho Chi Minh, Vietnam. sduongquy.jfvp@gmail.com. FAU - Huynh-Truong-Anh, Duc AU - Huynh-Truong-Anh D AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Nguyen-Quang, Tien AU - Nguyen-Quang T AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Nguyen-Thi-Kim, Thanh AU - Nguyen-Thi-Kim T AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Tran-Ngoc-Anh, Thuy AU - Tran-Ngoc-Anh T AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Nguyen-Van-Hoai, Nam AU - Nguyen-Van-Hoai N AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Do-Thi-Thu, Mai AU - Do-Thi-Thu M AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Nguyen-Van, Tinh AU - Nguyen-Van T AD - Department of Emergency and ICU, Binh Duong General Hospital, Thuan An, Binh Duong, Vietnam. FAU - Tang-Thi-Thao, Tram AU - Tang-Thi-Thao T AD - Clinical Research Unit, Lam Dong Medical College and Bio-Medical Research Centre, Dalat, Vietnam. FAU - Nguyen-Tuan, Anh AU - Nguyen-Tuan A AD - Clinical Research Unit, Lam Dong Medical College and Bio-Medical Research Centre, Dalat, Vietnam. FAU - Nguyen-Van, Toi AU - Nguyen-Van T AD - Clinical Research Unit, Lam Dong Medical College and Bio-Medical Research Centre, Dalat, Vietnam. FAU - Tran-Xuan, Quynh AU - Tran-Xuan Q AD - Department of Internal Medicine, Can Tho University of Medicine and Pharmacy, Can Tho, Vietnam. FAU - Vu-Tran-Thien, Quan AU - Vu-Tran-Thien Q AD - Department of Respiratory Functional Exploration, University Medical Center, University of Medicine and Pharmacy, Ho Chi Minh, Vietnam. FAU - Trinh-Du, The AU - Trinh-Du T AD - Department of Intensive Care Unit, Ninh Thuan General Hospital, Phan Rang, Ninh Thuan, Vietnam. FAU - Tran-Thai, Tuan AU - Tran-Thai T AD - Department of Intensive Care Unit, Ninh Thuan General Hospital, Phan Rang, Ninh Thuan, Vietnam. FAU - Nguyen-Duy, Thai AU - Nguyen-Duy T AD - National Institute for Control of Vaccines and Biologicals, Ministry of Health, Hanoi, Vietnam. FAU - Tran-Van, Huong AU - Tran-Van H AD - Department of Medicine, Nam Anh General Hospital, Di An, Binh Duong, Vietnam. AD - Department of Public Health, Thang Long University, Hanoi, Vietnam. FAU - Vo-Thi-Kim, Anh AU - Vo-Thi-Kim A AD - Department of Medicine, Nam Anh General Hospital, Di An, Binh Duong, Vietnam. kimanh7282@gmail.com. AD - Department of Public Health, Thang Long University, Hanoi, Vietnam. kimanh7282@gmail.com. LA - eng PT - Journal Article DEP - 20230329 PL - United States TA - Pulm Ther JT - Pulmonary therapy JID - 101687144 CIN - Pulm Ther. 2023 Sep;9(3):451-453. doi: 10.1007/s41030-023-00237-9. PMID: 37486562 PMC - PMC10057680 OTO - NOTNLM OT - ARDS OT - Binh Duong OT - COVID-19 OT - Guillain-Barre syndrome OT - SARS-CoV-2 OT - Vaccination OT - Vero cell COIS- All named authors have nothing to disclose. EDAT- 2023/03/30 06:00 MHDA- 2023/03/30 06:01 PMCR- 2023/03/29 CRDT- 2023/03/29 23:26 PHST- 2023/01/30 00:00 [received] PHST- 2023/02/27 00:00 [accepted] PHST- 2023/03/30 06:01 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 23:26 [entrez] PHST- 2023/03/29 00:00 [pmc-release] AID - 10.1007/s41030-023-00219-x [pii] AID - 219 [pii] AID - 10.1007/s41030-023-00219-x [doi] PST - ppublish SO - Pulm Ther. 2023 Jun;9(2):271-280. doi: 10.1007/s41030-023-00219-x. Epub 2023 Mar 29. PMID- 36990297 OWN - NLM STAT- MEDLINE DCOM- 20230612 LR - 20260127 IS - 1090-2139 (Electronic) IS - 0889-1591 (Print) IS - 0889-1591 (Linking) VI - 111 DP - 2023 Jul TI - COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis. PG - 211-229 LID - S0889-1591(23)00079-X [pii] LID - 10.1016/j.bbi.2023.03.022 [doi] AB - Empirical evidence addressing the association between SARS-CoV-2 vaccination and long COVID would guide public health priorities and inform personal health decisions. Herein, the co-primary objectives are to determine the differential risk of long COVID in vaccinated versus unvaccinated patients, and the trajectory of long COVID following vaccination. Of 2775 articles identified via systematic search, 17 were included, and 6 were meta-analyzed. Meta-analytic results determined that at least one vaccine dose was associated with a protective effect against long COVID (OR 0.539, 95% CI 0.295-0.987, p = 0.045, N = 257 817). Qualitative analysis revealed that trajectories of pre-existing long COVID following vaccination were mixed, with most patients reporting no changes. The evidence herein supports SARS-CoV-2 vaccination for the prevention of long COVID, and recommends long COVID patients adhere to standard SARS-CoV-2 vaccination schedules. CI - Copyright (c) 2023 Elsevier Inc. All rights reserved. FAU - Ceban, Felicia AU - Ceban F AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Kulzhabayeva, Dana AU - Kulzhabayeva D AD - Department of Psychology, University of Toronto, Toronto, Ontario, Canada. FAU - Rodrigues, Nelson B AU - Rodrigues NB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Di Vincenzo, Joshua D AU - Di Vincenzo JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada. FAU - Gill, Hartej AU - Gill H AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Subramaniapillai, Mehala AU - Subramaniapillai M AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada. FAU - Lui, Leanna M W AU - Lui LMW AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. FAU - Cao, Bing AU - Cao B AD - Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of Education, Southwest University, Chongqing 400715, China. FAU - Mansur, Rodrigo B AU - Mansur RB AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - Ho, Roger C AU - Ho RC AD - Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore; Institute for Health Innovation and Technology (iHealthtech), National University of Singapore, Singapore 119077, Singapore. FAU - Burke, Matthew J AU - Burke MJ AD - Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada; Department of Neurology, Division of Cognitive Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. FAU - Rhee, Taeho Greg AU - Rhee TG AD - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA. FAU - Rosenblat, Joshua D AU - Rosenblat JD AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. FAU - McIntyre, Roger S AU - McIntyre RS AD - Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Brain and Cognition Discovery Foundation, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada; Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address: roger.mcintyre@bcdf.org. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review DEP - 20230327 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 RN - 0 (COVID-19 Vaccines) RN - 0 (CI 987) RN - 0 (Phenols) RN - 0 (Thiazoles) SB - IM EIN - Brain Behav Immun. 2024 Jan;115:758. doi: 10.1016/j.bbi.2023.09.020. PMID: 37806865 MH - Humans MH - *COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Vaccination MH - Phenols MH - Thiazoles PMC - PMC10067136 OTO - NOTNLM OT - Bipolar disorder OT - COVID-19 OT - Cognition OT - Depression OT - Inflammation OT - Long COVID OT - Mood disorders OT - Population health OT - Post-COVID-19 condition OT - Post-COVID-19 syndrome OT - Post-acute sequelae of COVID-19 PASC OT - Prevention OT - SARS-CoV-2 OT - Treatment OT - Vaccination COIS- Declaration of Competing Interest Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes,Neumora Therapeutics, Boehringer Ingelheim,Sage,Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, IntraCellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger S. McIntyre is a CEO of Braxia Scientific Corp. Dr. Roger Ho received funding from NUS Department of Psychological Medicine (R-177-000-100-001/R-177-000-003-001) and NUS iHeathtech Other Operating Expenses (R-722-000-004-731). Leanna M. W. Lui has received personal fees from Braxia Scientific Corp and honoraria from Medscape. Dr. Joshua D. Rosenblat is the medical director of Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Leanna Lui has received personal fees from Braxia Scientific Corp and honoraria Medscape. EDAT- 2023/03/30 06:00 MHDA- 2023/06/12 06:42 PMCR- 2023/03/27 CRDT- 2023/03/29 19:33 PHST- 2022/09/13 00:00 [received] PHST- 2023/03/10 00:00 [revised] PHST- 2023/03/23 00:00 [accepted] PHST- 2023/06/12 06:42 [medline] PHST- 2023/03/30 06:00 [pubmed] PHST- 2023/03/29 19:33 [entrez] PHST- 2023/03/27 00:00 [pmc-release] AID - S0889-1591(23)00079-X [pii] AID - 10.1016/j.bbi.2023.03.022 [doi] PST - ppublish SO - Brain Behav Immun. 2023 Jul;111:211-229. doi: 10.1016/j.bbi.2023.03.022. Epub 2023 Mar 27. PMID- 36969243 OWN - NLM STAT- MEDLINE DCOM- 20230328 LR - 20231101 IS - 1664-3224 (Electronic) IS - 1664-3224 (Linking) VI - 14 DP - 2023 TI - Gut and airway microbiota dysbiosis and their role in COVID-19 and long-COVID. PG - 1080043 LID - 10.3389/fimmu.2023.1080043 [doi] LID - 1080043 AB - The gut microbiota plays a crucial role in human health and disease. Gut dysbiosis is known to be associated with increased susceptibility to respiratory diseases and modifications in the immune response and homeostasis of the lungs (the so-called gut-lung axis). Furthermore, recent studies have highlighted the possible role of dysbiosis in neurological disturbances, introducing the notion of the "gut-brain axis." During the last 2 years, several studies have described the presence of gut dysbiosis during coronavirus disease 2019 (COVID-19) and its relationship with disease severity, SARS-CoV-2 gastrointestinal replication, and immune inflammation. Moreover, the possible persistence of gut dysbiosis after disease resolution may be linked to long-COVID syndrome and particularly to its neurological manifestations. We reviewed recent evidence on the association between dysbiosis and COVID-19, investigating the possible epidemiologic confounding factors like age, location, sex, sample size, the severity of disease, comorbidities, therapy, and vaccination status on gut and airway microbial dysbiosis in selected studies on both COVID-19 and long-COVID. Moreover, we analyzed the confounding factors strictly related to microbiota, specifically diet investigation and previous use of antibiotics/probiotics, and the methodology used to study the microbiota (alpha- and beta-diversity parameters and relative abundance tools). Of note, only a few studies focused on longitudinal analyses, especially for long-term observation in long-COVID. Lastly, there is a lack of knowledge regarding the role of microbiota transplantation and other therapeutic approaches and their possible impact on disease progression and severity. Preliminary data seem to suggest that gut and airway dysbiosis might play a role in COVID-19 and in long-COVID neurological symptoms. Indeed, the development and interpretation of these data could have important implications for future preventive and therapeutic strategies. CI - Copyright (c) 2023 Ancona, Alagna, Alteri, Palomba, Tonizzo, Pastena, Muscatello, Gori and Bandera. FAU - Ancona, Giuseppe AU - Ancona G AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Alagna, Laura AU - Alagna L AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Alteri, Claudia AU - Alteri C AD - Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. AD - Multimodal Research Area, Bambino Gesu Children Hospital (IRCCS), Rome, Italy. FAU - Palomba, Emanuele AU - Palomba E AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy. FAU - Tonizzo, Anna AU - Tonizzo A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy. FAU - Pastena, Andrea AU - Pastena A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy. FAU - Muscatello, Antonio AU - Muscatello A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. FAU - Gori, Andrea AU - Gori A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy. FAU - Bandera, Alessandra AU - Bandera A AD - Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. AD - Department of Pathophysiology and Transplantation, Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review DEP - 20230308 PL - Switzerland TA - Front Immunol JT - Frontiers in immunology JID - 101560960 SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - Dysbiosis MH - *Gastrointestinal Microbiome/physiology PMC - PMC10030519 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - dysbiosis OT - gut-brain-axis OT - gut-lung-axis OT - long Covid OT - microbiome OT - microbiota COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2023/03/28 06:00 MHDA- 2023/03/28 19:07 PMCR- 2023/03/08 CRDT- 2023/03/27 03:35 PHST- 2022/10/25 00:00 [received] PHST- 2023/02/13 00:00 [accepted] PHST- 2023/03/28 19:07 [medline] PHST- 2023/03/27 03:35 [entrez] PHST- 2023/03/28 06:00 [pubmed] PHST- 2023/03/08 00:00 [pmc-release] AID - 10.3389/fimmu.2023.1080043 [doi] PST - epublish SO - Front Immunol. 2023 Mar 8;14:1080043. doi: 10.3389/fimmu.2023.1080043. eCollection 2023. PMID- 36963124 OWN - NLM STAT- MEDLINE DCOM- 20230411 LR - 20250626 IS - 1532-2653 (Electronic) IS - 0967-5868 (Print) IS - 0967-5868 (Linking) VI - 111 DP - 2023 May TI - Acute disseminated encephalomyelitis (ADEM) following COVID-19 vaccination: A systematic review. PG - 57-70 LID - S0967-5868(23)00066-8 [pii] LID - 10.1016/j.jocn.2023.03.008 [doi] AB - BACKGROUND: Although global vaccination against COVID-19 infection has its excellence, potential side effects are yet of concern. Several lines of evidence have proposed ADEM occurrence after SARS-CoV-2 infection. Moreover, a large number of case reports and case series have also suggested the casual association between ADEM and COVID-19 vaccination. To better understand the development of ADEM following COVID-19 vaccination and its potential association, we aimed to systematically review ADEM cases reported after COVID-19 vaccination. METHODS: We conducted a comprehensive systematic search using three databases including PubMed, Scopus, and Web of Science. Studies that reported ADEM after COVID-19 vaccination were eligible to include in our study. Observational studies, case reports, and case series which reported cases of ADEM with sufficient detail to confirm clinical diagnosis following COVID-19 vaccination were eligible to enter our study. RESULTS: Twenty studies were included in our systematic review after the abstract and full-text screening with a total of 54 cases. Among included patients, 45 (85.1 %) developed ADEM after the first dose of the COVID-19 vaccine, and seven (12.9 %) cases experienced ADEM after the second dose. The median time interval between vaccination and neurological symptoms was 14 days which ranged from 12 h to 63 days. Twelve (22.2 %) patients experienced symptoms of muscle weakness, ten (18.5 %) presented unconsciousness, nine (16.6 %) patients had urinary complaints, nine (16.6 %) had visual impairments, and five (9.2 %) experienced a seizure. After treatments, four (13.8 %) patients died. Forty-six patients had clinical improvement (85.1 %), also improvement in brain MRI was observed among 44 (81.4 %) patients. CONCLUSION: In conclusion, it is not clear that ADEM could be a potential complication of COVID-19 vaccination based on the current evidence and further studies are needed. However, this rare condition should not trigger stopping the mass vaccination programs since the only way to eradicate the current pandemic of COVID-19 is to extend the number of immunized people. CI - Copyright (c) 2023 Elsevier Ltd. All rights reserved. FAU - Nabizadeh, Fardin AU - Nabizadeh F AD - Neuroscience Research Group (NRG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Fardinnabizade1378@gmail.com. FAU - Noori, Maryam AU - Noori M AD - Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Urology Research Center, Tehran University of Medical Science, Tehran, Iran. FAU - Rahmani, Shayan AU - Rahmani S AD - School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Hosseini, Helia AU - Hosseini H AD - Faculty of Medicine, Tehran University of Medical Sciences, Iran. LA - eng PT - Journal Article PT - Systematic Review DEP - 20230322 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (COVID-19 Vaccines) SB - IM CIN - J Clin Neurosci. 2023 Sep;115:164. doi: 10.1016/j.jocn.2023.04.010. PMID: 37088619 MH - Humans MH - *COVID-19/prevention & control/complications MH - *COVID-19 Vaccines/adverse effects MH - *Encephalomyelitis, Acute Disseminated/etiology/diagnosis MH - Observational Studies as Topic MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC10030273 OTO - NOTNLM OT - ADEM OT - Acute disseminated encephalomyelitis OT - COVID-19 vaccination OT - Neurological OT - SARS-CoV-2 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/03/25 06:00 MHDA- 2023/04/11 06:41 PMCR- 2023/03/22 CRDT- 2023/03/24 19:00 PHST- 2022/11/09 00:00 [received] PHST- 2023/03/13 00:00 [revised] PHST- 2023/03/16 00:00 [accepted] PHST- 2023/04/11 06:41 [medline] PHST- 2023/03/25 06:00 [pubmed] PHST- 2023/03/24 19:00 [entrez] PHST- 2023/03/22 00:00 [pmc-release] AID - S0967-5868(23)00066-8 [pii] AID - 10.1016/j.jocn.2023.03.008 [doi] PST - ppublish SO - J Clin Neurosci. 2023 May;111:57-70. doi: 10.1016/j.jocn.2023.03.008. Epub 2023 Mar 22. PMID- 36951829 OWN - NLM STAT- MEDLINE DCOM- 20230607 LR - 20230721 IS - 2168-6114 (Electronic) IS - 2168-6106 (Print) IS - 2168-6106 (Linking) VI - 183 IP - 6 DP - 2023 Jun 1 TI - Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. PG - 554-564 LID - 10.1001/jamainternmed.2023.0743 [doi] AB - IMPORTANCE: Post-COVID-19 condition (PCC), also known as long COVID, affects many individuals. Prevention of PCC is an urgent public health priority. OBJECTIVE: To examine whether treatment with nirmatrelvir in the acute phase of COVID-19 is associated with reduced risk of PCC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used the health care databases of the US Department of Veterans Affairs (VA) to identify patients who had a SARS-CoV-2 positive test result between January 3, 2022, and December 31, 2022, who were not hospitalized on the day of the positive test result, who had at least 1 risk factor for progression to severe COVID-19 illness, and who had survived the first 30 days after SARS-CoV-2 diagnosis. Those who were treated with oral nirmatrelvir within 5 days after the positive test (n = 35 717) and those who received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection (control group, n = 246 076) were identified. EXPOSURES: Treatment with nirmatrelvir or receipt of no COVID-19 antiviral or antibody treatment based on prescription records. MAIN OUTCOMES AND MEASURES: Inverse probability weighted survival models were used to estimate the association of nirmatrelvir (vs control) with post-acute death, post-acute hospitalization, and a prespecified panel of 13 post-acute COVID-19 sequelae (components of PCC) and reported in relative scale as relative risk (RR) or hazard ratio (HR) and in absolute scale as absolute risk reduction in percentage at 180 days (ARR). RESULTS: A total of 281 793 patients (mean [SD] age, 61.99 [14.96]; 242 383 [86.01%] male) who had a positive SARS-CoV-2 test result and had at least 1 risk factor for progression to severe COVID-19 illness were studied. Among them, 246 076 received no COVID-19 antiviral or antibody treatment during the acute phase of SARS-CoV-2 infection, and 35 717 received oral nirmatrelvir within 5 days after the positive SARS-CoV-2 test result. Compared with the control group, nirmatrelvir was associated with reduced risk of PCC (RR, 0.74; 95% CI, 0.72-0.77; ARR, 4.51%; 95% CI, 4.01-4.99), including reduced risk of 10 of 13 post-acute sequelae (components of PCC) in the cardiovascular system (dysrhythmia and ischemic heart disease), coagulation and hematologic disorders (pulmonary embolism and deep vein thrombosis), fatigue and malaise, acute kidney disease, muscle pain, neurologic system (neurocognitive impairment and dysautonomia), and shortness of breath. Nirmatrelvir was also associated with reduced risk of post-acute death (HR, 0.53; 95% CI, 0.46-0.61); ARR, 0.65%; 95% CI, 0.54-0.77), and post-acute hospitalization (HR, 0.76; 95% CI, 0.73-0.80; ARR, 1.72%; 95% CI, 1.42-2.01). Nirmatrelvir was associated with reduced risk of PCC in people who were unvaccinated, vaccinated, and boosted, and in people with primary SARS-CoV-2 infection and reinfection. CONCLUSIONS AND RELEVANCE: This cohort study found that in people with SARS-CoV-2 infection who had at least 1 risk factor for progression to severe disease, treatment with nirmatrelvir within 5 days of a positive SARS-CoV-2 test result was associated with reduced risk of PCC across the risk spectrum in this cohort and regardless of vaccination status and history of prior infection; the totality of findings suggests that treatment with nirmatrelvir during the acute phase of COVID-19 may reduce the risk of post-acute adverse health outcomes. FAU - Xie, Yan AU - Xie Y AD - Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri. AD - Veterans Research and Education Foundation of St Louis, St Louis, Missouri. FAU - Choi, Taeyoung AU - Choi T AD - Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri. AD - Veterans Research and Education Foundation of St Louis, St Louis, Missouri. FAU - Al-Aly, Ziyad AU - Al-Aly Z AD - Clinical Epidemiology Center, Research and Development Service, VA St Louis Health Care System, St Louis, Missouri. AD - Veterans Research and Education Foundation of St Louis, St Louis, Missouri. AD - Department of Medicine, Washington University School of Medicine, St Louis, Missouri. AD - Nephrology Section, Medicine Service, VA St Louis Health Care System, St Louis, Missouri. AD - Institute for Public Health, Washington University in St Louis, St Louis, Missouri. LA - eng PT - Journal Article PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United States TA - JAMA Intern Med JT - JAMA internal medicine JID - 101589534 RN - 0 (Antiviral Agents) SB - IM CIN - JAMA Intern Med. 2023 Jun 1;183(6):565. doi: 10.1001/jamainternmed.2023.0760. PMID: 36951848 MH - Male MH - United States/epidemiology MH - Humans MH - Middle Aged MH - Female MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - COVID-19 Testing MH - Cohort Studies MH - Antiviral Agents/therapeutic use MH - Disease Progression PMC - PMC10037200 COIS- Conflict of Interest Disclosures: Dr Al-Aly reported receiving consultation fees from Gilead Sciences and Tonix Pharmaceuticals and consulting (uncompensated) for Pfizer. EDAT- 2023/03/24 06:00 MHDA- 2023/06/07 06:42 PMCR- 2023/03/23 CRDT- 2023/03/23 11:33 PHST- 2023/06/07 06:42 [medline] PHST- 2023/03/24 06:00 [pubmed] PHST- 2023/03/23 11:33 [entrez] PHST- 2023/03/23 00:00 [pmc-release] AID - 2802878 [pii] AID - ioi230016 [pii] AID - 10.1001/jamainternmed.2023.0743 [doi] PST - ppublish SO - JAMA Intern Med. 2023 Jun 1;183(6):554-564. doi: 10.1001/jamainternmed.2023.0743. PMID- 36936268 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230321 IS - 2754-0413 (Electronic) IS - 2754-0413 (Linking) VI - 2 IP - 1 DP - 2023 TI - Effect of covid-19 vaccination on long covid: systematic review. PG - e000385 LID - 10.1136/bmjmed-2022-000385 [doi] LID - e000385 AB - OBJECTIVE: To determine the effect of covid-19 vaccination, given before and after acute infection with the SARS-CoV-2 virus, or after a diagnosis of long covid, on the rates and symptoms of long covid. DESIGN: Systematic review. DATA SOURCES: PubMed, Embase, and Cochrane covid-19 trials, and Europe PubMed Central (Europe PMC) for preprints, from 1 January 2020 to 3 August 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Trials, cohort studies, and case-control studies reporting on patients with long covid and symptoms of long covid, with vaccination before and after infection with the SARS-CoV-2 virus, or after a diagnosis of long covid. Risk of bias was assessed with the ROBINS-I tool. RESULTS: 1645 articles were screened but no randomised controlled trials were found. 16 observational studies from five countries (USA, UK, France, Italy, and the Netherlands) were identified that reported on 614 392 patients. The most common symptoms of long covid that were studied were fatigue, cough, loss of sense of smell, shortness of breath, loss of taste, headache, muscle ache, difficulty sleeping, difficulty concentrating, worry or anxiety, and memory loss or confusion. 12 studies reported data on vaccination before infection with the SARS-CoV-2 virus, and 10 showed a significant reduction in the incidence of long covid: the odds ratio of developing long covid with one dose of vaccine ranged from 0.22 to 1.03; with two doses, odds ratios were 0.25-1; with three doses, 0.16; and with any dose, 0.48-1.01. Five studies reported on vaccination after infection, with odds ratios of 0.38-0.91. The high heterogeneity between studies precluded any meaningful meta-analysis. The studies failed to adjust for potential confounders, such as other protective behaviours and missing data, thus increasing the risk of bias and decreasing the certainty of evidence to low. CONCLUSIONS: Current studies suggest that covid-19 vaccines might have protective and therapeutic effects on long covid. More robust comparative observational studies and trials are needed, however, to clearly determine the effectiveness of vaccines in preventing and treating long covid. PROTOCOL REGISTRATION: Open Science Framework https://osf.io/e8jdy. CI - (c) Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Byambasuren, Oyungerel AU - Byambasuren O AUID- ORCID: 0000-0002-8641-1286 AD - Bond University, Robina, Queensland, Australia. FAU - Stehlik, Paulina AU - Stehlik P AUID- ORCID: 0000-0002-5397-228X AD - Bond University, Robina, Queensland, Australia. FAU - Clark, Justin AU - Clark J AUID- ORCID: 0000-0003-0133-1613 AD - Bond University, Robina, Queensland, Australia. FAU - Alcorn, Kylie AU - Alcorn K AD - Gold Coast University Hospital, Southport, Queensland, Australia. FAU - Glasziou, Paul AU - Glasziou P AUID- ORCID: 0000-0001-7564-073X AD - Bond University, Robina, Queensland, Australia. LA - eng PT - Journal Article DEP - 20230201 PL - England TA - BMJ Med JT - BMJ medicine JID - 9918487584306676 PMC - PMC9978692 OTO - NOTNLM OT - covid-19 COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2023/03/21 06:00 MHDA- 2023/03/21 06:01 PMCR- 2023/02/01 CRDT- 2023/03/20 03:43 PHST- 2022/09/26 00:00 [received] PHST- 2022/12/14 00:00 [accepted] PHST- 2023/03/20 03:43 [entrez] PHST- 2023/03/21 06:00 [pubmed] PHST- 2023/03/21 06:01 [medline] PHST- 2023/02/01 00:00 [pmc-release] AID - bmjmed-2022-000385 [pii] AID - 10.1136/bmjmed-2022-000385 [doi] PST - epublish SO - BMJ Med. 2023 Feb 1;2(1):e000385. doi: 10.1136/bmjmed-2022-000385. eCollection 2023. PMID- 36858287 OWN - NLM STAT- MEDLINE DCOM- 20230731 LR - 20230731 IS - 2666-9919 (Electronic) IS - 2666-9919 (Linking) VI - 53 IP - 5 DP - 2023 Aug TI - COVID-19 long-term sequelae: Omicron versus Alpha and Delta variants. PG - 104688 LID - S2666-9919(23)00050-7 [pii] LID - 10.1016/j.idnow.2023.104688 [doi] AB - BACKGROUND: The study aimed to assess the association between three predominant SARS-CoV-2 variants (Alpha, Delta, and Omicron) and the risk of developing long COVID (persistence of physical, medical, and cognitive symptoms more than 4 weeks after infection), post-COVID-19 syndrome (symptoms extending beyond 12 weeks), and viral persistence (testing positive beyond 4 weeks despite clinical resolution). METHODS: Retrospective study of 325 patients hospitalized for COVID-19 with genomic sequencing information. For each SARS-CoV-2 variant, sample characteristics, frequency of symptoms, and long-term sequelae were compared using Chi-squared test, Fisher's exact test, Kruskal-Wallis test, and Dunn's test as appropriate. Odds ratios (OR) were calculated using logistic regression models to assess the association of risk factors and sequelae. RESULTS: The adjusted model showed that the Omicron (vs Alpha) variant (OR, 0.30; 95% CI 0.16-0.56), admission to ICU (OR, 1.14; 95% CI 1.05-1.23), and being treated with antiviral or immunomodulatory drugs (OR, 2.01; 95% CI 1.23-3.27) predicted long COVID and post-COVID-19 syndrome. Viral persistence showed no difference between variants. CONCLUSIONS: The Omicron variant was associated with significantly lower odds of developing long-term sequelae from COVID-19 compared with previous variants, while severity of illness indicators increased the risk. Vaccination status, age, sex, and comorbidities were not found to predict sequelae development. This information has implications for both health managers and clinicians when deciding on the appropriate clinical management and subsequent outpatient follow-up of these patients. More studies with non-hospitalized patients are still necessary. CI - Copyright (c) 2023. Published by Elsevier Masson SAS. FAU - Hernandez-Aceituno, Ana AU - Hernandez-Aceituno A AD - Direccion General de Salud Publica, Canary Islands, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. Electronic address: Anahdez989@gmail.com. FAU - Garcia-Hernandez, Abigail AU - Garcia-Hernandez A AD - Direccion General de Salud Publica, Canary Islands, Spain; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. FAU - Larumbe-Zabala, Eneko AU - Larumbe-Zabala E AD - Direccion General de Salud Publica, Canary Islands, Spain; Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias (FIISC), Canary Islands, Spain. LA - eng PT - Journal Article DEP - 20230228 PL - France TA - Infect Dis Now JT - Infectious diseases now JID - 101775152 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome MH - Retrospective Studies PMC - PMC9970656 OTO - NOTNLM OT - Long COVID OT - Post-COVID-19 OT - Sequelae OT - Variants COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/03/02 06:00 MHDA- 2023/07/31 06:43 PMCR- 2023/02/28 CRDT- 2023/03/01 19:26 PHST- 2022/10/14 00:00 [received] PHST- 2023/02/10 00:00 [revised] PHST- 2023/02/17 00:00 [accepted] PHST- 2023/07/31 06:43 [medline] PHST- 2023/03/02 06:00 [pubmed] PHST- 2023/03/01 19:26 [entrez] PHST- 2023/02/28 00:00 [pmc-release] AID - S2666-9919(23)00050-7 [pii] AID - 104688 [pii] AID - 10.1016/j.idnow.2023.104688 [doi] PST - ppublish SO - Infect Dis Now. 2023 Aug;53(5):104688. doi: 10.1016/j.idnow.2023.104688. Epub 2023 Feb 28. PMID- 36852481 OWN - NLM STAT- MEDLINE DCOM- 20230316 LR - 20230330 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 19 IP - 1 DP - 2023 Dec 31 TI - COVID-19 risk perception, cognitive dissonance, and vaccine hesitancy. PG - 2180217 LID - 10.1080/21645515.2023.2180217 [doi] LID - 2180217 AB - The COVID-19 pandemic has shown that despite having high risk for severe disease, some individuals had low-risk perception and consequently they refused vaccination. This was more common among individuals with distrust in the government and the scientific organizations. Cognitive dissonance occurs when a person participates in an action that goes against one's beliefs. In order to reduce the dissonance, the individual often avoids the action. Recently, dissonance-based interventions have been shown to be effective in changing various health, environmental, and social behaviors. The impact of these interventions may persist for several years. Cognitive dissonance may be another mechanism for vaccine refusal among people with mistrust in the system. There is a need to investigate the role of cognitive dissonance in vaccine refusal and the effectiveness of dissonance-based interventions to reduce vaccine hesitancy among individuals with high risk for severe disease and low vaccination rates. FAU - Equils, Ozlem AU - Equils O AD - MiOra Non-Profit Organization, Los Angeles, California, USA. FAU - Bakaj Berishaj, Amonda AU - Bakaj Berishaj A AD - MiOra Non-Profit Organization, Los Angeles, California, USA. FAU - Stice, Eric AU - Stice E AD - Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, USA. FAU - da Costa, Christopher AU - da Costa C AD - MiOra Non-Profit Organization, Los Angeles, California, USA. AD - Coalition for Epidemic Preparedness Innovations, USA. LA - eng PT - Journal Article DEP - 20230227 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 SB - IM MH - Humans MH - *Vaccination Hesitancy MH - Cognitive Dissonance MH - Pandemics MH - *COVID-19/prevention & control MH - Perception MH - Vaccination PMC - PMC10026885 OTO - NOTNLM OT - COVID-19 OT - cognitive dissonance OT - risk perception OT - vaccine hesitancy COIS- No potential conflict of interest was reported by the author(s). EDAT- 2023/03/01 06:00 MHDA- 2023/03/17 06:00 PMCR- 2023/02/27 CRDT- 2023/02/28 02:53 PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/17 06:00 [medline] PHST- 2023/02/28 02:53 [entrez] PHST- 2023/02/27 00:00 [pmc-release] AID - 2180217 [pii] AID - 10.1080/21645515.2023.2180217 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2023 Dec 31;19(1):2180217. doi: 10.1080/21645515.2023.2180217. Epub 2023 Feb 27. PMID- 36851668 OWN - NLM STAT- MEDLINE DCOM- 20230307 LR - 20230410 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 15 IP - 2 DP - 2023 Feb 6 TI - Humoral SARS-CoV-2 Immune Response in COVID-19 Recovered Vaccinated and Unvaccinated Individuals Related to Post-COVID-Syndrome. LID - 10.3390/v15020454 [doi] LID - 454 AB - BACKGROUND: The duration of anti-SARS-CoV-2-antibody detectability up to 12 months was examined in individuals after either single convalescence or convalescence and vaccination. Moreover, variables that might influence an anti-RBD/S1 antibody decline and the existence of a post-COVID-syndrome (PCS) were addressed. METHODS: Forty-nine SARS-CoV-2-qRT-PCR-confirmed participants completed a 12-month examination of anti-SARS-CoV-2-antibody levels and PCS-associated long-term sequelae. Overall, 324 samples were collected. Cell-free DNA (cfDNA) was isolated and quantified from EDTA-plasma. As cfDNA is released into the bloodstream from dying cells, it might provide information on organ damage in the late recovery of COIVD-19. Therefore, we evaluated cfDNA concentrations as a biomarker for a PCS. In the context of antibody dynamics, a random forest-based logistic regression with antibody decline as the target was performed and internally validated. RESULTS: The mean percentage dynamic related to the maximum measured value was 96 (+/-38)% for anti-RBD/S1 antibodies and 30 (+/-26)% for anti-N antibodies. Anti-RBD/S1 antibodies decreased in 37%, whereas anti-SARS-CoV-2-anti-N antibodies decreased in 86% of the subjects. Clinical anti-RBD/S1 antibody decline prediction models, including vascular and other diseases, were cross-validated (highest AUC 0.74). Long-term follow-up revealed no significant reduction in PCS prevalence but an increase in cognitive impairment, with no indication for cfDNA as a marker for a PCS. CONCLUSION: Long-term anti-RBD/S1-antibody positivity was confirmed, and clinical parameters associated with declining titers were presented. A fulminant decrease in anti-SARS-CoV-2-anti-N antibodies was observed (mean change to maximum value 30 (+/-26)%). Anti-RBD/S1 antibody titers of SARS-CoV-2 recovered subjects boosted with a vaccine exceeded the maximum values measured after single infection by 235 +/- 382-fold, with no influence on preexisting PCS. PCS long-term prevalence was 38.6%, with an increase in cognitive impairment compromising the quality of life. Quantified cfDNA measured in the early post-COVID-19 phase might not be an effective marker for PCS identification. FAU - Gerhards, Catharina AU - Gerhards C AUID- ORCID: 0000-0001-7197-9242 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Kittel, Maximilian AU - Kittel M AUID- ORCID: 0000-0002-2580-5038 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Ast, Volker AU - Ast V AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Bugert, Peter AU - Bugert P AD - Institute of Transfusion Medicine and Immunology, Heidelberg University, 68167 Mannheim, Germany. AD - Medical Faculty Mannheim, European Center for Angioscience (ECAS), Heidelberg University, 68167 Mannheim, Germany. FAU - Froelich, Matthias F AU - Froelich MF AUID- ORCID: 0000-0001-8501-2147 AD - Department of Radiology and Nuclear Medicine, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. FAU - Hetjens, Michael AU - Hetjens M AD - Department of Biomedical Informatics, Center for Preventive Medicine and Digital Health, Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany. FAU - Haselmann, Verena AU - Haselmann V AUID- ORCID: 0000-0002-8380-6581 AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Neumaier, Michael AU - Neumaier M AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. FAU - Thiaucourt, Margot AU - Thiaucourt M AD - Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany. LA - eng PT - Journal Article DEP - 20230206 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Antibodies, Viral) RN - 0 (Cell-Free Nucleic Acids) RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Antibodies, Viral MH - *Cell-Free Nucleic Acids MH - Convalescence MH - *COVID-19/complications MH - Immunity, Humoral MH - Quality of Life MH - SARS-CoV-2 MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome/etiology PMC - PMC9966735 OTO - NOTNLM OT - anti-SARS-CoV-2 antibodies OT - antibody dynamics OT - antibody kinetics OT - longitudinal assessment OT - post-COVID syndrome OT - post-vaccination boosting OT - serological immune response COIS- The authors have declared no conflict of interest. EDAT- 2023/03/01 06:00 MHDA- 2023/03/03 06:00 PMCR- 2023/02/06 CRDT- 2023/02/28 01:40 PHST- 2022/12/20 00:00 [received] PHST- 2023/02/01 00:00 [revised] PHST- 2023/02/03 00:00 [accepted] PHST- 2023/02/28 01:40 [entrez] PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/06 00:00 [pmc-release] AID - v15020454 [pii] AID - viruses-15-00454 [pii] AID - 10.3390/v15020454 [doi] PST - epublish SO - Viruses. 2023 Feb 6;15(2):454. doi: 10.3390/v15020454. PMID- 36851318 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240929 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 2 DP - 2023 Feb 15 TI - Cognitive and Behavioral Factors Predicting the Decision to Vaccinate against COVID-19 in Clinical Psychiatric Population-A Cross-Sectional Survey. LID - 10.3390/vaccines11020441 [doi] LID - 441 AB - The spread of the COVID-19 virus created more than a medical crisis, while it also negatively affected the mental health of the general population. This context increased the vulnerability of the psychiatric population. While research interest highly targeted vaccine hesitancy and acceptance, many studies focused on trust issues-both in vaccine efficacy and in communication with authorities. Less is known about the psychological underpinnings of the COVID vaccination decision, specifically in the high-uncertainty circumstances due to the novelty of the virus. In a cross-sectional study, we investigated the predictive value of several cognitive (perceived risk, vulnerability, uncertainty, and trust in one's decision) and behavioral (previous vaccinations, social media use, and practicing preventive behavior) factors, for the vaccination decision against COVID-19, for 252 psychiatric inpatients (data collected between September 2021 and February 2022). Demographics and diagnostics were also considered. We found a significant relationship between the "Perceived risk of vaccination" and the choice of vaccination (chi(2)(2, N = 252) = 58.59, p 0.05) in this special population. No other behavioral factors, diagnosis, or demographics were significant as predictors, for the clinical psychiatric population surveyed, except the educational level. Implications for future vaccination acceptance of this special population are discussed. FAU - Marcu, Gabriela Mariana AU - Marcu GM AUID- ORCID: 0000-0003-2508-3749 AD - Department of Psychology, Faculty of Social Sciences and Humanities, "Lucian Blaga" University of Sibiu, 550201 Sibiu, Romania. AD - Collective of Scientific Research in Neurosciences of the Clinical Psychiatry Hospital "Dr. Gheorghe Preda", 550082 Sibiu, Romania. AD - Division of Physiology and Neuroscience, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. FAU - Radu, Ana Maria AU - Radu AM AD - Department of Psychology, Faculty of Social Sciences and Humanities, "Lucian Blaga" University of Sibiu, 550201 Sibiu, Romania. AD - Psychology Department, Faculty of Sociology and Psychology, West University of Timisoara, 300223 Timisoara, Romania. FAU - Bucuta, Mihaela Dana AU - Bucuta MD AD - Department of Psychology, Faculty of Social Sciences and Humanities, "Lucian Blaga" University of Sibiu, 550201 Sibiu, Romania. FAU - Fleaca, Radu Sorin AU - Fleaca RS AUID- ORCID: 0000-0002-2444-9828 AD - Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. FAU - Tanasescu, Ciprian AU - Tanasescu C AD - Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. FAU - Roman, Mihai Dan AU - Roman MD AUID- ORCID: 0000-0001-9856-8515 AD - Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. FAU - Boicean, Adrian AU - Boicean A AD - Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. FAU - Bacila, Ciprian Ionut AU - Bacila CI AD - Collective of Scientific Research in Neurosciences of the Clinical Psychiatry Hospital "Dr. Gheorghe Preda", 550082 Sibiu, Romania. AD - Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania. LA - eng GR - contract no. 28 PFE/30 December 2021/Ministry of Research, Innovation and Digitization/ PT - Journal Article DEP - 20230215 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9961952 OTO - NOTNLM OT - COVID-19 OT - decision-making OT - health beliefs OT - prediction OT - preventive behavior OT - psychiatric population OT - risk perception OT - trust OT - vaccination COIS- The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. EDAT- 2023/03/01 06:00 MHDA- 2023/03/01 06:01 PMCR- 2023/02/15 CRDT- 2023/02/28 01:33 PHST- 2023/01/06 00:00 [received] PHST- 2023/02/09 00:00 [revised] PHST- 2023/02/09 00:00 [accepted] PHST- 2023/02/28 01:33 [entrez] PHST- 2023/03/01 06:00 [pubmed] PHST- 2023/03/01 06:01 [medline] PHST- 2023/02/15 00:00 [pmc-release] AID - vaccines11020441 [pii] AID - vaccines-11-00441 [pii] AID - 10.3390/vaccines11020441 [doi] PST - epublish SO - Vaccines (Basel). 2023 Feb 15;11(2):441. doi: 10.3390/vaccines11020441. PMID- 36842195 OWN - NLM STAT- MEDLINE DCOM- 20230320 LR - 20230320 IS - 1876-035X (Electronic) IS - 1876-0341 (Print) IS - 1876-0341 (Linking) VI - 16 IP - 4 DP - 2023 Apr TI - Long COVID symptoms in hospital employees after post-vaccination SARS-CoV-2 infection in Austria: A study on self-reported incidence and associated factors. PG - 596-602 LID - S1876-0341(23)00061-8 [pii] LID - 10.1016/j.jiph.2023.02.017 [doi] AB - PURPOSE: Post acute sequelae of SARS-CoV-2 infection are defined by persistence or re-occurrence of symptoms six to 12 weeks after SARS-CoV-2 infections. METHODS: Twice vaccinated hospital employees after mild to moderate post-vaccination SARS-CoV-2 infection completed a questionnaire on the incidence of general, respiratory, neuropsychiatric, dermatological and gastrointestinal symptoms, experienced during their acute infection and eight weeks after recovery. Post acute sequelae of SARS-CoV-2 infection were analysed in relation to socio-demographic-, health-, virus- and acute infection-related characteristics. RESULTS: 73 participants, 25 women and 48 men with a mean age of 40.9 years, with a post-vaccination SARS-CoV-2 infection completed the survey. Out of these 93 % reported at least one symptom at time of initial SARS-CoV-2 infection, 31.5 %, predominantly women, reported post acute sequelae at least eight weeks after the acute infection stage. Fatigue, dysgeusia and dysosmia, headache or difficulty concentrating and shortness of breath during acute infection, BMI> 25 and pre-existing pulmonary disorders were associated with post acute sequelae of SARS-CoV-2 infection. Participants with initially more than five symptoms were four times more likely to report post acute sequelae. CONCLUSION: It is suggested that the multiplicity of symptoms during acute SARS-CoV-2 infections increases the risk for post acute symptoms. CI - Copyright (c) 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Brunner-Ziegler, Sophie AU - Brunner-Ziegler S AD - Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria. Electronic address: sophie.brunner-ziegler@meduniwien.ac.at. FAU - Bauerle, Martin AU - Bauerle M AD - Department of Internal Medicine II, Division of Angiology, Medical University of Vienna, Vienna, Austria. FAU - Bruhl, Peter AU - Bruhl P AD - Medical Directorate, Vienna General Hospital, Vienna, Austria. FAU - Kornek, Gabriela AU - Kornek G AD - Medical Directorate, Vienna General Hospital, Vienna, Austria. FAU - Parschalk, Bernhard AU - Parschalk B AD - Department of Otorhinolaryngology, Medical University of Vienna, Vienna, Austria. FAU - Savic, Rebeka AU - Savic R AD - Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria. FAU - Schnetzinger, Maximilian AU - Schnetzinger M AD - Department of Anaesthesia, Critical Care and Pain Medicine, Medical University of Vienna, Vienna, Austria. FAU - Spath, Tibor AU - Spath T AD - Department of Hospital Epidemiology and Infection Control, Medical University of Vienna, Vienna, Austria. FAU - Strassl, Robert Paul AU - Strassl RP AD - Division of Clinical Virology, Medical University of Vienna, Vienna, Austria. FAU - Handisurya, Alessandra AU - Handisurya A AD - Department of Dermatology, Medical University of Vienna, Vienna, Austria. FAU - Thalhammer, Florian AU - Thalhammer F AD - Department of Urology, Medical University of Vienna, Vienna, Austria. LA - eng PT - Journal Article DEP - 20230223 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 SB - IM MH - Male MH - Female MH - Humans MH - Adult MH - *Post-Acute COVID-19 Syndrome MH - *COVID-19/epidemiology MH - Self Report MH - Austria/epidemiology MH - Incidence MH - SARS-CoV-2 MH - Disease Progression MH - Vaccination MH - Hospitals PMC - PMC9946725 OTO - NOTNLM OT - Hospital employees OT - Post acute sequelae of SARS-CoV-2 infection OT - Post-vaccination SARS-CoV-2 infection COIS- The authors don t have to disclose any financial or non-financial interests that are directly or indirectly related to the work submitted for publication. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors have no competing interests to declare and no financial or personal interest to disclose. EDAT- 2023/02/27 06:00 MHDA- 2023/03/21 06:00 PMCR- 2023/02/23 CRDT- 2023/02/26 18:05 PHST- 2022/10/26 00:00 [received] PHST- 2023/01/30 00:00 [revised] PHST- 2023/02/19 00:00 [accepted] PHST- 2023/02/27 06:00 [pubmed] PHST- 2023/03/21 06:00 [medline] PHST- 2023/02/26 18:05 [entrez] PHST- 2023/02/23 00:00 [pmc-release] AID - S1876-0341(23)00061-8 [pii] AID - 10.1016/j.jiph.2023.02.017 [doi] PST - ppublish SO - J Infect Public Health. 2023 Apr;16(4):596-602. doi: 10.1016/j.jiph.2023.02.017. Epub 2023 Feb 23. PMID- 36840605 OWN - NLM STAT- MEDLINE DCOM- 20230501 LR - 20230503 IS - 1477-0970 (Electronic) IS - 1352-4585 (Print) IS - 1352-4585 (Linking) VI - 29 IP - 4-5 DP - 2023 Apr TI - Acute central nervous system inflammation following COVID-19 vaccination: An observational cohort study. PG - 595-605 LID - 10.1177/13524585231154780 [doi] AB - BACKGROUND: Reports suggest a potential association between coronavirus disease 2019 (COVID-19) vaccines and acute central nervous system (CNS) inflammation. OBJECTIVE: The main objective of this study is to describe features of acute CNS inflammation following COVID-19 vaccination. METHODS: A retrospective observational cohort study was performed at the BARLO MS Centre in Toronto, Canada. Clinicians reported acute CNS inflammatory events within 60 days after a COVID-19 vaccine from March 2021 to August 2022. Clinical characteristics were evaluated. RESULTS: Thirty-eight patients (median age 39 (range: 20-82) years; 60.5% female) presented within 0-55 (median 15) days of a receiving a COVID-19 vaccine and were diagnosed with relapsing remitting multiple sclerosis (MS) (n = 16), post-vaccine transverse myelitis (n = 7), clinically isolated syndrome (n = 5), MS relapse (n = 4), tumefactive demyelination (n = 2), myelin oligodendrocyte glycoprotein antibody disease (n = 1), neuromyelitis optica spectrum disorder (n = 1), chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (n = 1) and primary autoimmune cerebellar ataxia (n = 1). Twenty-two received acute treatment and 21 started disease-modifying therapy. Sixteen received subsequent COVID-19 vaccination, of which 87.5% had no new or worsening neurological symptoms. CONCLUSION: To our knowledge, this is the largest study describing acute CNS inflammation after COVID-19 vaccination. We could not determine whether the number of inflammatory events was higher than expected. FAU - Lee, Sydney AU - Lee S AUID- ORCID: 0000-0002-8591-2062 AD - Department of Medicine, University of Toronto, St. Michael's Hospital, Toronto, ON, Canada. FAU - Muccilli, Alexandra AU - Muccilli A AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Schneider, Raphael AU - Schneider R AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada Li Ka Shing Knowledge Institute, Toronto, ON, Canada. FAU - Selchen, Daniel AU - Selchen D AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada. FAU - Krysko, Kristen M AU - Krysko KM AUID- ORCID: 0000-0003-0090-597X AD - Division of Neurology, Department of Medicine, BARLO MS Centre, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada Li Ka Shing Knowledge Institute, Toronto, ON, Canada. LA - eng PT - Journal Article PT - Observational Study DEP - 20230225 PL - England TA - Mult Scler JT - Multiple sclerosis (Houndmills, Basingstoke, England) JID - 9509185 RN - 0 (COVID-19 Vaccines) RN - 0 (Myelin-Oligodendrocyte Glycoprotein) SB - IM MH - Female MH - Humans MH - Male MH - COVID-19 Vaccines/adverse effects MH - Retrospective Studies MH - *COVID-19/prevention & control MH - Neoplasm Recurrence, Local MH - Central Nervous System MH - *Neuromyelitis Optica MH - Cohort Studies MH - Inflammation/etiology MH - Vaccination/adverse effects MH - Myelin-Oligodendrocyte Glycoprotein PMC - PMC9969223 OTO - NOTNLM OT - COVID-19 OT - central nervous system OT - demyelinating diseases OT - multiple sclerosis OT - neuroinflammatory diseases OT - vaccination COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article. EDAT- 2023/02/26 06:00 MHDA- 2023/05/01 06:42 PMCR- 2023/02/25 CRDT- 2023/02/25 06:52 PHST- 2023/05/01 06:42 [medline] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/25 06:52 [entrez] PHST- 2023/02/25 00:00 [pmc-release] AID - 10.1177_13524585231154780 [pii] AID - 10.1177/13524585231154780 [doi] PST - ppublish SO - Mult Scler. 2023 Apr;29(4-5):595-605. doi: 10.1177/13524585231154780. Epub 2023 Feb 25. PMID- 36831611 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230228 IS - 2072-6694 (Print) IS - 2072-6694 (Electronic) IS - 2072-6694 (Linking) VI - 15 IP - 4 DP - 2023 Feb 16 TI - Long-COVID in Patients with Cancer Previously Treated with Early Anti-SARS-CoV-2 Therapies in an Out-of-Hospital Setting: A Single-Center Experience. LID - 10.3390/cancers15041269 [doi] LID - 1269 AB - The incidence of long COVID in a cohort of patients with cancer with or without previous treatment with early therapies anti-SARS-CoV-2 in an out-of-hospital setting have to be elucidated. We prospectively enrolled all patients treated for a solid tumor at the department of Medical Oncology of the Fondazione IRCCS Policlinico San Matteo with a positive SARS-CoV-2 antigen or polymerase chain reaction test from January to September 2022 (Omicron surge). Ninety-seven patients answered the survey questions by telephone at least 12 weeks after COVID-19 diagnosis in order to evaluate the incidence of long COVID symptoms. Only twelve patients (12.4%) reported long COVID. No significant difference between early therapies anti-SARS-CoV-2 31 and long COVID (p = 0.443) was seen. The female sex (p = 0.024) and diabetes mellitus (p = 0.014) are significantly associated with long COVID. No statistically significant difference between the two groups (Long COVID vs. No Long COVID) according to the time to nasal swab viral clearance (p = 0.078). The overlap between the symptoms related to the oncological disease/oncological treatment and the symptoms of long COVID is one of the main future challenges that oncologists will have to manage. FAU - Lasagna, Angioletta AU - Lasagna A AUID- ORCID: 0000-0002-9611-1164 AD - Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Albi, Giuseppe AU - Albi G AD - Department of Electrical, Computer and Biomedical Engineering, University of Pavia, 27100 Pavia, Italy. FAU - Figini, Simone AU - Figini S AD - Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Basile, Sara AU - Basile S AD - Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Sacchi, Paolo AU - Sacchi P AD - Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. FAU - Bruno, Raffaele AU - Bruno R AD - Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. AD - Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, 27100 Pavia, Italy. FAU - Pedrazzoli, Paolo AU - Pedrazzoli P AUID- ORCID: 0000-0002-9419-7160 AD - Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy. AD - Department of Internal Medicine and Medical Therapy, University of Pavia, 27100 Pavia, Italy. LA - eng GR - grant no 08067620/Policlinico San Matteo Fondazione/ PT - Journal Article DEP - 20230216 PL - Switzerland TA - Cancers (Basel) JT - Cancers JID - 101526829 PMC - PMC9953958 OTO - NOTNLM OT - SARS-CoV-2 OT - brain fog OT - cancer OT - long-COVID OT - nirmatrelvir/ritonavir OT - outcome OT - real-life data OT - remdesivir OT - vaccine COIS- The authors declare no conflict of interest. EDAT- 2023/02/26 06:00 MHDA- 2023/02/26 06:01 PMCR- 2023/02/16 CRDT- 2023/02/25 01:41 PHST- 2023/01/20 00:00 [received] PHST- 2023/02/14 00:00 [revised] PHST- 2023/02/15 00:00 [accepted] PHST- 2023/02/25 01:41 [entrez] PHST- 2023/02/26 06:00 [pubmed] PHST- 2023/02/26 06:01 [medline] PHST- 2023/02/16 00:00 [pmc-release] AID - cancers15041269 [pii] AID - cancers-15-01269 [pii] AID - 10.3390/cancers15041269 [doi] PST - epublish SO - Cancers (Basel). 2023 Feb 16;15(4):1269. doi: 10.3390/cancers15041269. PMID- 36812215 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230407 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 18 IP - 2 DP - 2023 TI - Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of two population-based cohorts. PG - e0281429 LID - 10.1371/journal.pone.0281429 [doi] LID - e0281429 AB - BACKGROUND: Post COVID-19 condition (PCC) is an important complication of SARS-CoV-2 infection, affecting millions worldwide. This study aimed to evaluate the prevalence and severity of post COVID-19 condition (PCC) with novel SARS-CoV-2 variants and after prior vaccination. METHODS: We used pooled data from 1350 SARS-CoV-2-infected individuals from two representative population-based cohorts in Switzerland, diagnosed between Aug 5, 2020, and Feb 25, 2022. We descriptively analysed the prevalence and severity of PCC, defined as the presence and frequency of PCC-related symptoms six months after infection, among vaccinated and non-vaccinated individuals infected with Wildtype, Delta, and Omicron SARS-CoV-2. We used multivariable logistic regression models to assess the association and estimate the risk reduction of PCC after infection with newer variants and prior vaccination. We further assessed associations with the severity of PCC using multinomial logistic regression. To identify groups of individuals with similar symptom patterns and evaluate differences in the presentation of PCC across variants, we performed exploratory hierarchical cluster analyses. RESULTS: We found strong evidence that vaccinated individuals infected with Omicron had reduced odds of developing PCC compared to non-vaccinated Wildtype-infected individuals (odds ratio 0.42, 95% confidence interval 0.24-0.68). The odds among non-vaccinated individuals were similar after infection with Delta or Omicron compared to Wildtype SARS-CoV-2. We found no differences in PCC prevalence with respect to the number of received vaccine doses or timing of last vaccination. The prevalence of PCC-related symptoms among vaccinated, Omicron-infected individuals was lower across severity levels. In cluster analyses, we identified four clusters of diverse systemic, neurocognitive, cardiorespiratory, and musculoskeletal symptoms, with similar patterns across variants. CONCLUSION: The risk of PCC appears to be lowered with infection by the Omicron variant and after prior vaccination. This evidence is crucial to guide future public health measures and vaccination strategies. CI - Copyright: (c) 2023 Ballouz et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. FAU - Ballouz, Tala AU - Ballouz T AUID- ORCID: 0000-0003-2334-8600 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Menges, Dominik AU - Menges D AUID- ORCID: 0000-0001-5970-1846 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Kaufmann, Marco AU - Kaufmann M AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Amati, Rebecca AU - Amati R AUID- ORCID: 0000-0001-5698-9071 AD - Faculty of Biomedical Sciences, Institute of Public Health (IPH), Universita della Svizzera Italiana (USI), Lugano, Switzerland. FAU - Frei, Anja AU - Frei A AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - von Wyl, Viktor AU - von Wyl V AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Fehr, Jan S AU - Fehr JS AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. FAU - Albanese, Emiliano AU - Albanese E AD - Faculty of Biomedical Sciences, Institute of Public Health (IPH), Universita della Svizzera Italiana (USI), Lugano, Switzerland. FAU - Puhan, Milo A AU - Puhan MA AUID- ORCID: 0000-0003-4721-1879 AD - Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich, Switzerland. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230222 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *COVID-19 MH - SARS-CoV-2 MH - Vaccination MH - Cluster Analysis PMC - PMC9946205 COIS- The authors have declared that no competing interests exist. EDAT- 2023/02/23 06:00 MHDA- 2023/02/25 06:00 PMCR- 2023/02/22 CRDT- 2023/02/22 16:21 PHST- 2022/10/27 00:00 [received] PHST- 2023/01/23 00:00 [accepted] PHST- 2023/02/22 16:21 [entrez] PHST- 2023/02/23 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/02/22 00:00 [pmc-release] AID - PONE-D-22-29701 [pii] AID - 10.1371/journal.pone.0281429 [doi] PST - epublish SO - PLoS One. 2023 Feb 22;18(2):e0281429. doi: 10.1371/journal.pone.0281429. eCollection 2023. PMID- 36799523 OWN - NLM STAT- MEDLINE DCOM- 20230321 LR - 20230321 IS - 0028-3843 (Print) IS - 0028-3843 (Linking) VI - 57 IP - 1 DP - 2023 TI - Incidence and characteristics of post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. PG - 53-62 LID - 10.5603/PJNNS.a2023.0011 [doi] AB - BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease mainly affecting the respiratory system; however, a significant prevalence of neurological symptoms has been noted. OBJECTIVES: To investigate the incidence and characteristics of post-COVID-19 parkinsonism and to study dyskinesia related to COVID-19 vaccines. MATERIAL AND METHODS: The MEDLINE, PubMed, Scopus, and Web of Science databases were searched for all manuscripts relevant to post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. Subsequently, we extracted and analysed data from the manuscripts in a structured manner. RESULTS: We found 24 patients with post-COVID-19 parkinsonism, with a mean onset age of 58 years after a mean of 30 days from the COVID-19 onset. Akinetic-rigid (n = 11) and mixed (n = 6) subtypes were the most common. Asymmetry was present in 13/15 patients. Brain MRI was unremarkable in 11/19, whereas dopaminergic system imaging was abnormal in 8/8 patients. Responsiveness to dopaminergic treatment was observed in 12/15 patients. Four patients improved after immunomodulatory therapy. Comorbidities were present in 9/24, encephalopathy symptoms in 11/24, and loss of smell in 9/13 patients. Most patients (n = 14) suffered serious COVID-19- related complications and three were treated with haloperidol. Parkinsonism improved (n = 5) or resolved (n = 4) during the follow-up. Five patients, with a mean age of 52, developed dyskinesia at a mean of 25 hours after receiving the COVID-19 mRNA vaccines. One patient had a history of neuropsychiatric symptoms and developed functional dyskinesia of the tongue. Four patients had a previous history of Parkinson's Disease (PD) with a mean duration of 10 years and developed dyskinesia and dystonia, which resolved (n = 2) or improved (n = 2) during the follow-up. CONCLUSIONS: Post-COVID-19 parkinsonism is a very rare complication, and it is likely that this is an umbrella syndrome that includes many different etiologies. Dyskinesia due to COVID-19 vaccines is exceedingly rare and probably has the same pathophysiological basis as in other conditions with exacerbation of PD symptoms. FAU - Dulski, Jaroslaw AU - Dulski J AUID- ORCID: 0000-0002-5517-9875 AD - Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. Dulski.Jaroslaw@mayo.edu. AD - Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland. Dulski.Jaroslaw@mayo.edu. AD - Neurology Department, St. Adalbert Hospital, Copernicus, Gdansk, Poland. Dulski.Jaroslaw@mayo.edu. FAU - Slawek, Jaroslaw AU - Slawek J AUID- ORCID: 0000-0001-6816-0877 AD - Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland. AD - Neurology Department, St. Adalbert Hospital, Copernicus, Gdansk, Poland. LA - eng PT - Journal Article DEP - 20230217 PL - Poland TA - Neurol Neurochir Pol JT - Neurologia i neurochirurgia polska JID - 0101265 RN - 0 (COVID-19 Vaccines) RN - VTD58H1Z2X (Dopamine) SB - IM MH - Humans MH - Middle Aged MH - *COVID-19/complications MH - *COVID-19 Vaccines/adverse effects MH - Dopamine MH - *Dyskinesia, Drug-Induced/diagnosis/etiology MH - Incidence MH - *Parkinsonian Disorders/etiology OTO - NOTNLM OT - Parkinson's Disease OT - SARS-CoV-2 OT - dopaminergic OT - dystonia OT - levodopa OT - vaccination EDAT- 2023/02/18 06:00 MHDA- 2023/03/03 06:00 CRDT- 2023/02/17 08:23 PHST- 2023/01/16 00:00 [received] PHST- 2023/01/30 00:00 [accepted] PHST- 2023/01/27 00:00 [revised] PHST- 2023/02/18 06:00 [pubmed] PHST- 2023/03/03 06:00 [medline] PHST- 2023/02/17 08:23 [entrez] AID - VM/OJS/J/93722 [pii] AID - 10.5603/PJNNS.a2023.0011 [doi] PST - ppublish SO - Neurol Neurochir Pol. 2023;57(1):53-62. doi: 10.5603/PJNNS.a2023.0011. Epub 2023 Feb 17. PMID- 36785539 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231216 IS - 2667-3215 (Electronic) IS - 2667-3215 (Linking) VI - 3 DP - 2023 Jun TI - Understanding the concept of trust and other factors related to COVID-19 vaccine intentions among Black/African American older adults prior to vaccine development. PG - 100230 LID - 10.1016/j.ssmqr.2023.100230 [doi] AB - BACKGROUND: Black/African Americans are receiving COVID-19 vaccines at much lower rates than whites. However, research is still evolving that explains why these vaccination rates are lower. The aim of this study was to examine the effects of the pandemic among older Black/African Americans, with an emphasis on trust and vaccine intention prior to vaccine development. METHODS: Data were collected between July and September 2020 from 8 virtual focus groups in Detroit, MI and San Francisco Bay Area, CA with 33 older African Americans and 11 caregivers of older African Americans with cognitive impairment, supplemented by one virtual meeting with the project's Community Advisory Board. Inductive/deductive content analysis was used to identify themes. RESULTS: Five major themes influenced the intention to be vaccinated: uncertainty, systemic abandonment, decrease in trust, resistance to vaccines, and opportunities for vaccination. The last theme, opportunities for vaccination, emerged as a result of interaction with our CAB while collecting project data after the vaccines were available which provided additional insights about potential opportunities that would promote the uptake of COVID-19 vaccination among older Black/African Americans. The results also include application of the themes to a multi-layer framework for understanding precarity and the development of an Integrated Logic Model for a Public Health Crisis. CONCLUSIONS: These findings suggest that trust and culturally relevant information need to be addressed immediately to accelerate vaccine uptake among older Black/African Americans. New initiatives are needed to foster trust and address systemic abandonment from all institutions. In addition, culturally relevant public health campaigns about vaccine uptake are needed. Thus, systemic issues need immediate attention to reduce health disparities associated with COVID-19. CI - (c) 2023 The Authors. FAU - Harris, Orlando O AU - Harris OO AD - Department of Community Health Systems, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Perry, Tam E AU - Perry TE AD - School of Social Work, Wayne State University, Detroit, MI, USA. FAU - Johnson, Julene K AU - Johnson JK AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Lichtenberg, Peter AU - Lichtenberg P AD - Institute of Gerontology and Merrill Palmer Skillman Institute, Wayne State University, Detroit, MI, USA. FAU - Washington, Tangy AU - Washington T AD - Community Advisory Board, USA. FAU - Kitt, Bonita AU - Kitt B AD - Community Advisory Board, USA. FAU - Shaw, Michael AU - Shaw M AD - Community Advisory Board, USA. AD - Alameda County Public Health Department, Urban Male Health Initiative, USA. FAU - Keiser, Sahru AU - Keiser S AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Tran, Thi AU - Tran T AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Vest, Leah AU - Vest L AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. FAU - Maloof, Marsha AU - Maloof M AD - Maloof & Associates, San Francisco, CA, USA. FAU - Portacolone, Elena AU - Portacolone E AD - Institute for Health & Aging, School of Nursing, University of California, San Francisco, San Francisco, CA, USA. AD - Philip Lee Institute of Health Policy, University of California, San Francisco, San Francisco, CA, USA. LA - eng GR - K23 MH130250/MH/NIMH NIH HHS/United States GR - L30 MH134327/MH/NIMH NIH HHS/United States PT - Journal Article DEP - 20230204 PL - England TA - SSM Qual Res Health JT - SSM. Qualitative research in health JID - 9918300877606676 PMC - PMC9898052 COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/02/15 06:00 MHDA- 2023/02/15 06:01 PMCR- 2023/02/04 CRDT- 2023/02/14 01:53 PHST- 2022/02/25 00:00 [received] PHST- 2023/02/02 00:00 [revised] PHST- 2023/02/03 00:00 [accepted] PHST- 2023/02/14 01:53 [entrez] PHST- 2023/02/15 06:00 [pubmed] PHST- 2023/02/15 06:01 [medline] PHST- 2023/02/04 00:00 [pmc-release] AID - S2667-3215(23)00014-8 [pii] AID - 100230 [pii] AID - 10.1016/j.ssmqr.2023.100230 [doi] PST - ppublish SO - SSM Qual Res Health. 2023 Jun;3:100230. doi: 10.1016/j.ssmqr.2023.100230. Epub 2023 Feb 4. PMID- 36767087 OWN - NLM STAT- MEDLINE DCOM- 20230214 LR - 20240912 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 20 IP - 3 DP - 2023 Jan 17 TI - Not Getting Vaccinated? It Is a Matter of Problem-Solving Abilities and Socio-Cognitive Polarization. LID - 10.3390/ijerph20031721 [doi] LID - 1721 AB - The anti-COVID-19 vaccination campaign in the United States provided a significant contribution to the control of the virus spread. Despite the recommendations by public health institutions, vaccine skepticism and hesitancy contributed to low vaccine uptake, thus possibly disrupting the management of preventable diseases associated with the COVID-19 infection. The process that led individuals to accept COVID-19 vaccines required the ability to gather, synthesize, and weigh-up information within a novel, dynamically changing, complex, and ambiguous context. To deal with such complexity, we hypothesized that both the ability of reflection and flexible adaptation played a fundamental role. Based on previous research on cognitive predictors of vaccine refusal, we decided to investigate the combined role of two constructs, namely, problem-solving skills and socio-cognitive polarization (SCP), on vaccine acceptance and uptake. Two-hundred-seventy-seven US participants completed an online survey aimed to measure problem-solving ability, through a rebus puzzles task, and SCP, through a composite measure of absolutist thinking, political conservatism, and xenophobia. Mediation analyses indicated that SCP mediated the association between problem-solving ability and vaccine acceptance, so lower problem-solving abilities associated with higher polarization predicted vaccine rejection. Thus, our findings suggested that low problem-solving skills may represent a risk factor for COVID-19 vaccine refusal, with cognitive and social rigidity playing a crucial role in undermining the anti-COVID-19 vaccine uptake. FAU - Cancer, Alice AU - Cancer A AUID- ORCID: 0000-0003-3545-8540 AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. FAU - Salvi, Carola AU - Salvi C AD - Department of Psychiatry and Behavioral Sciences, University of Texas at Austin, Austin, TX 78712, USA. AD - Department of Psychology and Social Sciences, John Cabot University, 00165 Rome, Italy. FAU - Antonietti, Alessandro AU - Antonietti A AUID- ORCID: 0000-0002-7212-8076 AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. FAU - Iannello, Paola AU - Iannello P AD - Department of Psychology, Universita Cattolica del Sacro Cuore, 20123 Milan, Italy. LA - eng PT - Journal Article DEP - 20230117 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines MH - *COVID-19/epidemiology/prevention & control MH - Acclimatization MH - Biological Transport MH - Cognition MH - Vaccination PMC - PMC9914091 OTO - NOTNLM OT - anti-COVID-19 vaccine OT - cognitive flexibility OT - political beliefs OT - problem solving OT - socio-cognitive polarization COIS- The authors declare no conflict of interest. EDAT- 2023/02/12 06:00 MHDA- 2023/02/15 06:00 PMCR- 2023/01/17 CRDT- 2023/02/11 01:11 PHST- 2022/12/31 00:00 [received] PHST- 2023/01/13 00:00 [revised] PHST- 2023/01/15 00:00 [accepted] PHST- 2023/02/11 01:11 [entrez] PHST- 2023/02/12 06:00 [pubmed] PHST- 2023/02/15 06:00 [medline] PHST- 2023/01/17 00:00 [pmc-release] AID - ijerph20031721 [pii] AID - ijerph-20-01721 [pii] AID - 10.3390/ijerph20031721 [doi] PST - epublish SO - Int J Environ Res Public Health. 2023 Jan 17;20(3):1721. doi: 10.3390/ijerph20031721. PMID- 36681970 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230202 IS - 2694-1902 (Electronic) IS - 2694-1902 (Linking) VI - 4 IP - 24 DP - 2022 Dec 12 TI - Transverse myelitis after Johnson & Johnson COVID-19 vaccine: illustrative case. LID - CASE22244 [pii] LID - 10.3171/CASE22244 [doi] AB - BACKGROUND: Transverse myelitis is a rare neurological occurrence with varied presentation. Imaging is necessary to properly diagnose this condition; however, identifying the cause of this condition may often be difficult. OBSERVATIONS: An otherwise healthy patient presented to the clinic with peculiar neurological symptoms without an obvious underlying cause. Imaging evidenced no significant structural defects but did lead to discovery of cord enhancement compatible with a diagnosis of transverse myelitis. Corticosteroid treatment was initiated rapidly to address this pathology, and the patient recovered without deficits. To identify the underlying cause, patient medical history was reviewed thoroughly and compared with existing literature. Previous tuberculosis infection could be a less likely cause of the neurological symptoms. However, recent vaccination with the Johnson & Johnson coronavirus disease 2019 (COVID-19) vaccine could be a more likely cause of the transverse myelitis, which has been rarely reported. LESSONS: Transverse myelitis after COVID-19 infection has been an escalating phenomenon. However, transverse myelitis after COVID-19 vaccination is a rare occurrence that is also on the rise. Given the increased rates of vaccination, transverse myelitis should not be overlooked as a potential pathology, due to the severity of neurological impairment if this condition is not treated rapidly. FAU - Mathew, Ezek AU - Mathew E AD - 1University of North Texas Health Science Center, Fort Worth, Texas; and. FAU - Williamson, Julie AU - Williamson J AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. FAU - Mamo, Lois AU - Mamo L AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. FAU - Dickerman, Rob AU - Dickerman R AD - 2Department of Neurosurgery, The Medical City of Frisco, Frisco, Texas. LA - eng PT - Journal Article DEP - 20221212 PL - United States TA - J Neurosurg Case Lessons JT - Journal of neurosurgery. Case lessons JID - 9918227275606676 PMC - PMC9745584 OTO - NOTNLM OT - Johnson & Johnson COVID-19 vaccine OT - rapid corticosteroid initiation OT - transverse myelitis COIS- Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. EDAT- 2023/01/23 06:00 MHDA- 2023/01/23 06:01 PMCR- 2022/12/12 CRDT- 2023/01/22 14:04 PHST- 2022/05/31 00:00 [received] PHST- 2022/08/12 00:00 [accepted] PHST- 2023/01/22 14:04 [entrez] PHST- 2023/01/23 06:00 [pubmed] PHST- 2023/01/23 06:01 [medline] PHST- 2022/12/12 00:00 [pmc-release] AID - CASE22244 [pii] AID - 10.3171/CASE22244 [doi] PST - epublish SO - J Neurosurg Case Lessons. 2022 Dec 12;4(24):CASE22244. doi: 10.3171/CASE22244. Print 2022 Dec 12. PMID- 36679939 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20261001 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 1 DP - 2022 Dec 30 TI - Cognitive and Cultural Factors That Affect General Vaccination and COVID-19 Vaccination Attitudes. LID - 10.3390/vaccines11010094 [doi] LID - 94 AB - The development of COVID-19 vaccines is a major scientific accomplishment that has armed communities worldwide with powerful epidemic control tools. Yet, COVID-19 vaccination efforts in the US have been marred by persistent vaccine hesitancy. We used survey methodology to explore the impact of different cognitive and cultural factors on the public's general vaccination attitudes, attitudes towards COVID-19 vaccines, and COVID-19 vaccination status. The factors include information literacy, science literacy, attitudes towards science, interpersonal trust, public health trust, political ideology, and religiosity. The analysis suggests that attitudes towards vaccination are influenced by a multitude of factors that operate in a complex manner. General vaccination attitude was most affected by attitudes towards science and public health trust and to a lesser degree by information literacy, science literacy, and religiosity. Attitudes towards COVID-19 vaccines were most affected by public health trust and to a lesser extent by general trust, ideology and attitudes towards science. Vaccination status was most influenced by public health trust. Possible mediating effects of correlated variables in the model need to be further explored. The study underscores the importance of understanding the relationship between public health trust, literacies, and sociocultural factors. FAU - Keselman, Alla AU - Keselman A AD - National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. FAU - Arnott Smith, Catherine AU - Arnott Smith C AUID- ORCID: 0000-0002-3683-2074 AD - Information School, University of Wisconsin-Madison, Madison, WI 53706, USA. FAU - Wilson, Amanda J AU - Wilson AJ AD - National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA. FAU - Leroy, Gondy AU - Leroy G AD - Management Information Systems, University of Arizona, Tucson, AZ 85721, USA. FAU - Kaufman, David R AU - Kaufman DR AD - Medical Informatics Program, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA. LA - eng PT - Journal Article DEP - 20221230 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9865922 OTO - NOTNLM OT - COVID-19 OT - information literacy OT - misinformation OT - science literacy OT - trust OT - vaccination hesitancy COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/22 06:01 PMCR- 2022/12/30 CRDT- 2023/01/21 01:57 PHST- 2022/10/31 00:00 [received] PHST- 2022/12/15 00:00 [revised] PHST- 2022/12/20 00:00 [accepted] PHST- 2023/01/21 01:57 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/22 06:01 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - vaccines11010094 [pii] AID - vaccines-11-00094 [pii] AID - 10.3390/vaccines11010094 [doi] PST - epublish SO - Vaccines (Basel). 2022 Dec 30;11(1):94. doi: 10.3390/vaccines11010094. PMID- 36679929 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230201 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 11 IP - 1 DP - 2022 Dec 30 TI - Development and Validation of the Outcome Expectancy Scale for COVID-19 Vaccination in the Adult General Population. LID - 10.3390/vaccines11010085 [doi] LID - 85 AB - Promotion of COVID-19 vaccination requires understanding its determinants, an important one of which is outcome expectancy. However, reliable and valid measurement tools are absent. This study thus developed and validated an Outcome Expectancy Scale for COVID-19 Vaccination (OES-COVID-19). An inductive approach was used for scale development; content validity of the items was then assessed by an independent evaluation expert panel. Iteratively, 17 scale items were created and validated in a population-based telephone survey conducted among 500 adults of the general population in Hong Kong, China, from August to September 2021. Using half of the sample (n = 249), exploratory factor analyses identified four factors of the OES-COVID-19, including (a) positive contribution to society, (b) functional benefits, (c) protective effect, and (d) negative impacts. Confirmatory factor analysis of these factors conducted on the second subsample (n = 251) was satisfactory. The OES-COVID-19 showed good psychometric properties in terms of internal consistency, absence of floor/ceiling effects, and concurrent validity. The newly created and validated OES-COVID-19 is deemed suitable for application. It may advance future studies related to COVID-19 vaccination behavior and intention, and potentially allows for comparisons across studies. Further validation with modifications across countries, populations, and phase of the pandemic are warranted. FAU - Yu, Yanqiu AU - Yu Y AD - Department of Preventive Medicine and Health Education, School of Public Health, Fudan University, Shanghai 200032, China. AD - Key Laboratory of Public Health Safety, Fudan University, Shanghai 200032, China. FAU - Fong, Vivian W I AU - Fong VWI AD - Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lau, Mason M C AU - Lau MMC AD - Centre for Health Behaviours Research, Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong SAR, China. FAU - Lau, Joseph T F AU - Lau JTF AUID- ORCID: 0000-0003-2344-7107 AD - Zhejiang Provincial Clinical Research Center for Mental Disorders, The Affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou 325000, China. AD - School of Mental Health, Wenzhou Medical University, Wenzhou 325000, China. AD - School of Public Health, Zhejiang University, Hangzhou 310058, China. LA - eng GR - NA/Internal funding of the Center for Health Behaviours Research, the Chinese University of Hong Kong/ PT - Journal Article DEP - 20221230 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9866430 OTO - NOTNLM OT - COVID-19 vaccination OT - China OT - cognition OT - outcome expectancy OT - scale development OT - validation COIS- The authors declare no conflict of interest. EDAT- 2023/01/22 06:00 MHDA- 2023/01/22 06:01 PMCR- 2022/12/30 CRDT- 2023/01/21 01:57 PHST- 2022/12/01 00:00 [received] PHST- 2022/12/25 00:00 [revised] PHST- 2022/12/28 00:00 [accepted] PHST- 2023/01/21 01:57 [entrez] PHST- 2023/01/22 06:00 [pubmed] PHST- 2023/01/22 06:01 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - vaccines11010085 [pii] AID - vaccines-11-00085 [pii] AID - 10.3390/vaccines11010085 [doi] PST - epublish SO - Vaccines (Basel). 2022 Dec 30;11(1):85. doi: 10.3390/vaccines11010085. PMID- 36631153 OWN - NLM STAT- MEDLINE DCOM- 20230113 LR - 20230117 IS - 1756-1833 (Electronic) IS - 0959-8138 (Print) IS - 0959-8138 (Linking) VI - 380 DP - 2023 Jan 11 TI - Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. PG - e072529 LID - 10.1136/bmj-2022-072529 [doi] LID - e072529 AB - OBJECTIVES: To determine the clinical sequelae of long covid for a year after infection in patients with mild disease and to evaluate its association with age, sex, SARS-CoV-2 variants, and vaccination status. DESIGN: Retrospective nationwide cohort study. SETTING: Electronic medical records from an Israeli nationwide healthcare organisation. POPULATION: 1 913 234 Maccabi Healthcare Services members of all ages who did a polymerase chain reaction test for SARS-CoV-2 between 1 March 2020 and 1 October 2021. MAIN OUTCOME MEASURES: Risk of an evidence based list of 70 reported long covid outcomes in unvaccinated patients infected with SARS-CoV-2 matched to uninfected people, adjusted for age and sex and stratified by SARS-CoV-2 variants, and risk in patients with a breakthrough SARS-CoV-2 infection compared with unvaccinated infected controls. Risks were compared using hazard ratios and risk differences per 10 000 patients measured during the early (30-180 days) and late (180-360 days) time periods after infection. RESULTS: Covid-19 infection was significantly associated with increased risks in early and late periods for anosmia and dysgeusia (hazard ratio 4.59 (95% confidence interval 3.63 to 5.80), risk difference 19.6 (95% confidence interval 16.9 to 22.4) in early period; 2.96 (2.29 to 3.82), 11.0 (8.5 to 13.6) in late period), cognitive impairment (1.85 (1.58 to 2.17), 12.8, (9.6 to 16.1); 1.69 (1.45 to 1.96), 13.3 (9.4 to 17.3)), dyspnoea (1.79 (1.68 to 1.90), 85.7 (76.9 to 94.5); 1.30 (1.22 to 1.38), 35.4 (26.3 to 44.6)), weakness (1.78 (1.69 to 1.88), 108.5, 98.4 to 118.6; 1.30 (1.22 to 1.37), 50.2 (39.4 to 61.1)), and palpitations (1.49 (1.35 to 1.64), 22.1 (16.8 to 27.4); 1.16 (1.05 to 1.27), 8.3 (2.4 to 14.1)) and with significant but lower excess risk for streptococcal tonsillitis and dizziness. Hair loss, chest pain, cough, myalgia, and respiratory disorders were significantly increased only during the early phase. Male and female patients showed minor differences, and children had fewer outcomes than adults during the early phase of covid-19, which mostly resolved in the late period. Findings remained consistent across SARS-CoV-2 variants. Vaccinated patients with a breakthrough SARS-CoV-2 infection had a lower risk for dyspnoea and similar risk for other outcomes compared with unvaccinated infected patients. CONCLUSIONS: This nationwide study suggests that patients with mild covid-19 are at risk for a small number of health outcomes, most of which are resolved within a year from diagnosis. CI - (c) Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. FAU - Mizrahi, Barak AU - Mizrahi B AUID- ORCID: 0000-0002-1053-4773 AD - KI Research Institute, Kfar Malal, Israel. FAU - Sudry, Tamar AU - Sudry T AD - KI Research Institute, Kfar Malal, Israel. FAU - Flaks-Manov, Natalie AU - Flaks-Manov N AD - KI Research Institute, Kfar Malal, Israel. FAU - Yehezkelli, Yoav AU - Yehezkelli Y AD - KI Research Institute, Kfar Malal, Israel. FAU - Kalkstein, Nir AU - Kalkstein N AD - KI Research Institute, Kfar Malal, Israel. FAU - Akiva, Pinchas AU - Akiva P AD - KI Research Institute, Kfar Malal, Israel. FAU - Ekka-Zohar, Anat AU - Ekka-Zohar A AD - Maccabi Healthcare Services, Tel Aviv, Israel. FAU - Ben David, Shirley Shapiro AU - Ben David SS AD - Maccabi Healthcare Services, Tel Aviv, Israel. FAU - Lerner, Uri AU - Lerner U AD - Maccabi Healthcare Services, Tel Aviv, Israel. FAU - Bivas-Benita, Maytal AU - Bivas-Benita M AD - KI Research Institute, Kfar Malal, Israel. FAU - Greenfeld, Shira AU - Greenfeld S AD - Maccabi Healthcare Services, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20230111 PL - England TA - BMJ JT - BMJ (Clinical research ed.) JID - 8900488 RN - SARS-CoV-2 variants SB - IM MH - Adult MH - Child MH - Humans MH - Female MH - Male MH - *COVID-19/complications MH - Post-Acute COVID-19 Syndrome MH - SARS-CoV-2 MH - Cohort Studies MH - Retrospective Studies MH - Dyspnea PMC - PMC9832503 COIS- Competing interests: All authors have completed the ICMJE uniform disclosure form at https://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work. EDAT- 2023/01/12 06:00 MHDA- 2023/01/14 06:00 PMCR- 2023/01/11 CRDT- 2023/01/11 20:43 PHST- 2023/01/11 20:43 [entrez] PHST- 2023/01/12 06:00 [pubmed] PHST- 2023/01/14 06:00 [medline] PHST- 2023/01/11 00:00 [pmc-release] AID - bmj-2022-072529.R1 [pii] AID - mizb072529 [pii] AID - 10.1136/bmj-2022-072529 [doi] PST - epublish SO - BMJ. 2023 Jan 11;380:e072529. doi: 10.1136/bmj-2022-072529. PMID- 36591656 OWN - NLM STAT- MEDLINE DCOM- 20230224 LR - 20230227 IS - 1875-8908 (Electronic) IS - 1387-2877 (Linking) VI - 91 IP - 4 DP - 2023 TI - COVID-19 and Alzheimer's Disease: What Is the Connection? PG - 1273-1276 LID - 10.3233/JAD-220955 [doi] AB - Wang et al. found that elderly COVID-19 patients were at risk of AD. The following facts suggest a possible explanation: reactivation of herpes simplex virus type 1 (HSV1) and other herpesviruses can occur in SARS-CoV-2 patients; in cell cultures, HSV1 infection causes occurrence of many AD-like features, as does reactivation of latent HSV1 after addition of certain infectious agents; recurrent experimental reactivation of HSV1-infected mice leads to formation of the main features of AD brains, and to cognitive decline. These suggest that COVID-19 results in repeated reactivation of HSV1 in brain, with subsequent accumulation of damage and eventual development of AD. FAU - Itzhaki, Ruth F AU - Itzhaki RF AD - Institute of Population Ageing, University of Oxford, Oxford, UK. LA - eng PT - Journal Article PL - United States TA - J Alzheimers Dis JT - Journal of Alzheimer's disease : JAD JID - 9814863 SB - IM MH - Animals MH - Mice MH - *Alzheimer Disease MH - *COVID-19 MH - SARS-CoV-2 MH - *Herpes Simplex MH - *Herpesvirus 1, Human/physiology OTO - NOTNLM OT - Alzheimer's disease OT - COVID-10 OT - herpes simplex virus type 1 OT - infections OT - reactivation OT - vaccinations EDAT- 2023/01/03 06:00 MHDA- 2023/02/25 06:00 CRDT- 2023/01/02 05:02 PHST- 2023/01/03 06:00 [pubmed] PHST- 2023/02/25 06:00 [medline] PHST- 2023/01/02 05:02 [entrez] AID - JAD220955 [pii] AID - 10.3233/JAD-220955 [doi] PST - ppublish SO - J Alzheimers Dis. 2023;91(4):1273-1276. doi: 10.3233/JAD-220955. PMID- 36562048 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221224 IS - 1664-1078 (Print) IS - 1664-1078 (Electronic) IS - 1664-1078 (Linking) VI - 13 DP - 2022 TI - COVID-19 vaccination motivation and underlying believing processes: A comparison study between individuals with affective disorder and healthy controls. PG - 935278 LID - 10.3389/fpsyg.2022.935278 [doi] LID - 935278 AB - BACKGROUND: Believing processes represent fundamental brain functions between cognition and emotion. Shortly before the introduction of a compulsory vaccination against COVID-19 in Austria, motives and underlying believing processes regarding the vaccination were collected in individuals with affective disorder (AD) and healthy controls (HC). METHODS: 79 individuals with AD and 173 HC were surveyed online to assess believing processes with the parameters of the credition model (narratives, certainty, emotion, mightiness) about (1) the coronavirus itself and (2) why someone is vaccinated or not. In addition, we calculated congruence scores between content of narrative and type of emotion and divided the narrative content into positive, negative, and indifferent. RESULTS: There were no differences in vaccination status between AD and HC. Higher levels of certainty were observed in HC compared to AD in both vaccinated and unvaccinated individuals. The effects were higher when asked about the motivation to vaccinate or not than about the coronavirus itself. In HC, more positive emotions and more congruence between emotions and narratives were reported during believing in their vaccination motives. No group differences were found in mightiness for both items. Independently from diagnosis, unvaccinated people had high levels of certainty and more negative emotions and narratives while believing in their motives for not getting vaccinated. CONCLUSION: When believing about the COVID-19 vaccination, individuals with AD were more uncertain and experienced fewer positive emotions than HC, although both groups did not differ in vaccination status. These effects were not that strong when believing about the coronavirus in general. CI - Copyright (c) 2022 Dalkner, Fleischmann, Fellendorf, Wagner-Skacel, Schonthaler, Bengesser, Haussl, Tietz, Tmava-Berisha, Lenger and Reininghaus. FAU - Dalkner, Nina AU - Dalkner N AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Fleischmann, Eva AU - Fleischmann E AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Fellendorf, Frederike T AU - Fellendorf FT AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Wagner-Skacel, Jolana AU - Wagner-Skacel J AD - Clinical Department of Medical Psychology, Psychosomatic, and Psychotherapy, Medical University Graz, Graz, Austria. FAU - Schonthaler, Elena M D AU - Schonthaler EMD AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Bengesser, Susanne AU - Bengesser S AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Haussl, Alfred AU - Haussl A AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Tietz, Sophie AU - Tietz S AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Tmava-Berisha, Adelina AU - Tmava-Berisha A AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Lenger, Melanie AU - Lenger M AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. FAU - Reininghaus, Eva Z AU - Reininghaus EZ AD - Clinical Department of Psychiatry and Psychotherapeutic Medicine, Medical University Graz, Graz, Austria. LA - eng PT - Journal Article DEP - 20221206 PL - Switzerland TA - Front Psychol JT - Frontiers in psychology JID - 101550902 PMC - PMC9765308 OTO - NOTNLM OT - COVID-19 vaccination OT - affective disorder OT - cognition OT - credition OT - emotion COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/06 CRDT- 2022/12/23 02:42 PHST- 2022/05/03 00:00 [received] PHST- 2022/08/01 00:00 [accepted] PHST- 2022/12/23 02:42 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/06 00:00 [pmc-release] AID - 10.3389/fpsyg.2022.935278 [doi] PST - epublish SO - Front Psychol. 2022 Dec 6;13:935278. doi: 10.3389/fpsyg.2022.935278. eCollection 2022. PMID- 36560442 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231106 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 12 DP - 2022 Nov 28 TI - COVID-19 Vaccination in Young People with Functional Neurological Disorder: A Case-Control Study. LID - 10.3390/vaccines10122031 [doi] LID - 2031 AB - BACKGROUND: The emergence of acute-onset functional neurological symptoms, the focus of this study, is one of three stress responses related to immunisation. This case-control study documents the experience of 61 young people with past or current functional neurological disorder (FND) in relation to the COVID-19 vaccination program in Australia. METHODS: Information about the young person's/parent's choice and response pertaining to COVID-19 vaccination was collected as part of routine clinical care or FND research program follow-up. RESULTS: 61 young people treated for FND (47 females, mean age = 16.22 years) and 46 healthy controls (34 females, mean age = 16.37 years) were included in the study. Vaccination rates were high: 58/61 (95.1%) in the FND group and 45/46 (97.8%) in the control group. In the FND group, 2 young people (2/61, 3.3%) presented with new-onset FND following COVID-19 vaccination; two young people with resolved FND reported an FND relapse (2/36, 5.56%); and two young people with unresolved FND (2/20, 10.0%) reported an FND exacerbation. In the control group no FND symptoms were reported. CONCLUSIONS: Acute-onset FND symptoms following COVID-19 vaccination are uncommon in the general population. In young people prone to FND, COVID-19 vaccination can sometimes trigger new-onset FND, FND relapse, or FND exacerbation. FAU - Lim, Natalie AU - Lim N AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. FAU - Wood, Nicholas AU - Wood N AD - National Centre for Immunisation Research and Surveillance, Kids Research, Sydney Children's Hospitals Network, Westmead, NSW 2145, Australia. AD - The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Prasad, Archana AU - Prasad A AD - Department of General Medicine, The Children's Hospital at Westmead Clinical School, Westmead, NSW 2145, Australia. FAU - Waters, Karen AU - Waters K AD - Sleep Medicine, The Children's Hospital at Westmead, Westmead Clinical School, Westmead, NSW 2145, Australia. AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Singh-Grewal, Davinder AU - Singh-Grewal D AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Department of Rheumatology, Sydney Children's Hospital Network, Westmead, NSW 2145, Australia. AD - School of Women's and Children's Health, University of New South Wales, Randwick, NSW 2031, Australia. FAU - Dale, Russell C AU - Dale RC AD - Kids Neuroscience Centre, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - The Brain and Mind Centre, University of Sydney, Camperdown, NSW 2050, Australia. FAU - Elkadi, Joseph AU - Elkadi J AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. FAU - Scher, Stephen AU - Scher S AD - McLean Hospital, Belmont, MA 02478, USA. AD - Department of Psychiatry, Harvard Medical School, Boston, MA 02215, USA. AD - Speciality of Psychiatry, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. FAU - Kozlowska, Kasia AU - Kozlowska K AUID- ORCID: 0000-0002-9578-0753 AD - Department of Psychological Medicine, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia. AD - The Children's Hospital at Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Specialty of Child and Adolescent Health, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. AD - Brain Dynamics Centre at Westmead Institute of Medical Research, Faculty of Medicine and Health, University of Sydney, Westmead, NSW 2145, Australia. LA - eng PT - Journal Article DEP - 20221128 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9782633 OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 vaccines OT - adolescents OT - children OT - dissociative neurological symptom reactions (DNSRs) OT - functional (dissociative) seizures OT - functional neurological (conversion) disorder (FND) OT - immunisation stress-related responses (ISRRs) OT - young people COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/11/28 CRDT- 2022/12/23 02:04 PHST- 2022/10/10 00:00 [received] PHST- 2022/11/19 00:00 [revised] PHST- 2022/11/22 00:00 [accepted] PHST- 2022/12/23 02:04 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/11/28 00:00 [pmc-release] AID - vaccines10122031 [pii] AID - vaccines-10-02031 [pii] AID - 10.3390/vaccines10122031 [doi] PST - epublish SO - Vaccines (Basel). 2022 Nov 28;10(12):2031. doi: 10.3390/vaccines10122031. PMID- 36556422 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221227 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 12 DP - 2022 Dec 8 TI - Effect of Vaccination against SARS-CoV-2 on Long COVID-19: A Narrative Review. LID - 10.3390/life12122057 [doi] LID - 2057 AB - Vaccines against SARS-CoV-2 have saved millions of lives and played an important role in containing the COVID-19 pandemic. Vaccination against SARS-CoV-2 is also associated with reduced disease severity and, perhaps, with COVID-19 symptom burden. In this narrative review, we present, in a clinically relevant question-and-answer manner, the evidence regarding the association between vaccination against SARS-CoV-2 and long COVID-19. We discuss how the mechanism of action of vaccines could interplay with the pathophysiology of post-COVID-19 condition. Furthermore, we describe how specific factors, such as the number of vaccine doses and the type of SARS-CoV-2 variants, may affect post-COVID-19 condition. We also discuss the role of timing for vaccination in relation to the onset of long COVID-19 symptoms, as it seems to affect the frequency and severity of the condition. Additionally, we describe the potential modifying effect of age, as well as the association of type and level of immune response with long COVID-19. We also describe how system-specific long COVID-19 sequelae, namely neurocognitive-psychologic symptoms and cardiovascular pathology, could be altered by vaccination. Last, we address the question of whether seasonal influenza vaccination has a meaningful impact on the frequency of long COVID-19. FAU - Tofarides, Andreas G AU - Tofarides AG AD - Department of Internal Medicine, Nicosia General Hospital, Nicosia 2029, Cyprus. AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Christaki, Eirini AU - Christaki E AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Milionis, Haralampos AU - Milionis H AUID- ORCID: 0000-0003-3958-2266 AD - Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 451 10 Ioannina, Greece. FAU - Nikolopoulos, Georgios K AU - Nikolopoulos GK AUID- ORCID: 0000-0002-3307-0246 AD - Medical School, University of Cyprus, Nicosia 2029, Cyprus. LA - eng PT - Journal Article PT - Review DEP - 20221208 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9785763 OTO - NOTNLM OT - SARS-CoV-2 OT - SARS-CoV-2 vaccination OT - SARS-CoV-2 vaccines OT - immunity OT - long COVID-19 OT - post-COVID-19 condition OT - post-COVID-19 sequelae OT - variant COIS- The authors declare no conflict of interest. EDAT- 2022/12/24 06:00 MHDA- 2022/12/24 06:01 PMCR- 2022/12/08 CRDT- 2022/12/23 01:40 PHST- 2022/11/10 00:00 [received] PHST- 2022/12/01 00:00 [revised] PHST- 2022/12/02 00:00 [accepted] PHST- 2022/12/23 01:40 [entrez] PHST- 2022/12/24 06:00 [pubmed] PHST- 2022/12/24 06:01 [medline] PHST- 2022/12/08 00:00 [pmc-release] AID - life12122057 [pii] AID - life-12-02057 [pii] AID - 10.3390/life12122057 [doi] PST - epublish SO - Life (Basel). 2022 Dec 8;12(12):2057. doi: 10.3390/life12122057. PMID- 36535135 OWN - NLM STAT- MEDLINE DCOM- 20230117 LR - 20240912 IS - 1876-035X (Electronic) IS - 1876-0341 (Print) IS - 1876-0341 (Linking) VI - 16 IP - 2 DP - 2023 Feb TI - Neurological Manifestations of hospitalized patients with mild to moderate infection with SARS-CoV-2 Omicron variant in Shanghai, China. PG - 155-162 LID - S1876-0341(22)00345-8 [pii] LID - 10.1016/j.jiph.2022.12.005 [doi] AB - BACKGROUND: Accumulating studies demonstrated that patients with coronavirus disease 2019(COVID-19) could develop a variety of neurological manifestations and long-term neurological sequelae, which may be different from the strains. At the peak of the Omicron variant outbreak in Shanghai, China, no relevant epidemiological data about neurological manifestations associated with this strain was reported. OBJECTIVE: To investigate neurological manifestations and related clinical features in patients with mild to moderate COVID-19 patients with Omicron variant. METHODS: A self-designed clinical information registration form was used to gather the neurological manifestations of mild to moderate COVID-19 patients admitted to a designated hospital in Shanghai from April 18, 2022 to June 1, 2022. Demographics, clinical presentations, laboratory findings, treatments and clinical outcomes were compared between patients with and without neurological manifestations. RESULTS: One hundred sixty-nine(48.1 %) of 351 patients diagnosed with mild to moderate COVID-19 exhibited neurological manifestations, the most common of which were fatigue/weakness(25.1 %) and myalgia(20.7 %), whereas acute cerebrovascular disease(0.9 %), impaired consciousness(0.6 %) and seizure(0.6 %) were rare. Younger age(p = 0.001), female gender(p = 0.026) and without anticoagulant medication(p = 0.042) were associated with increasing proportions of neurological manifestations as revealed by multivariate logistic regressions. Patients with neurological manifestations had lower creatine kinase and myoglobin levels, as well as higher proportion of patchy shadowing on chest scan. Vaccination status, clinical classification of COVID-19 and clinical outcomes were similar between the two groups. CONCLUSIONS: Nearly half of the involved patients have neurological manifestations which were relatively subjective and closely associated with younger age, female gender and without anticoagulation. Patients with neurologic manifestations may be accompanied by increased lung patchy shadowing. CI - Copyright (c) 2022. Published by Elsevier Ltd. FAU - Shen, Xiaolei AU - Shen X AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Wang, Ping AU - Wang P AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Shen, Jun AU - Shen J AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Jiang, Yuhan AU - Jiang Y AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Wu, Li AU - Wu L AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Nie, Xin AU - Nie X AD - Biostatistics Office of Clinical Research Unit, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. FAU - Liu, Jianren AU - Liu J AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Electronic address: liujr021@vip.163.com. FAU - Chen, Wei AU - Chen W AD - Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China. Electronic address: david_chen8106@hotmail.com. LA - eng PT - Journal Article DEP - 20221207 PL - England TA - J Infect Public Health JT - Journal of infection and public health JID - 101487384 RN - SARS-CoV-2 variants SB - IM MH - Humans MH - Female MH - China/epidemiology MH - *COVID-19/complications/epidemiology MH - SARS-CoV-2 MH - Patients PMC - PMC9726211 OTO - NOTNLM OT - COVID-19 OT - Neurological manifestations OT - Omicron OT - SARS-CoV-2 OT - Subjective symptoms COIS- Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/12/20 06:00 MHDA- 2023/01/18 06:00 PMCR- 2022/12/07 CRDT- 2022/12/19 18:20 PHST- 2022/08/25 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/05 00:00 [accepted] PHST- 2022/12/20 06:00 [pubmed] PHST- 2023/01/18 06:00 [medline] PHST- 2022/12/19 18:20 [entrez] PHST- 2022/12/07 00:00 [pmc-release] AID - S1876-0341(22)00345-8 [pii] AID - 10.1016/j.jiph.2022.12.005 [doi] PST - ppublish SO - J Infect Public Health. 2023 Feb;16(2):155-162. doi: 10.1016/j.jiph.2022.12.005. Epub 2022 Dec 7. PMID- 36528446 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20230619 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 41 IP - 27 DP - 2023 Jun 19 TI - Social cognitive predictors of vaccination status, uptake and mitigation behaviors in the Canadian COVID-19 Experiences survey. PG - 4031-4041 LID - S0264-410X(22)01526-2 [pii] LID - 10.1016/j.vaccine.2022.12.010 [doi] AB - Emerging infectious diseases like COVID-19 will remain a concern for the foreseeable future, and determinants of vaccination and other mitigation behaviors are therefore critical to understand. Using data from the first two waves of the Canadian COVID-19 Experiences Survey (CCES; N = 1,958; 66.56 % female), we examined social cognitive predictors of vaccination status, transition to acceptance and mitigation behaviors in a population-representative sample. Findings indicated that all social cognitive variables were strong predictors of mitigation behavior performance at each wave, particularly among unvaccinated individuals. Among those who were vaccine hesitant at baseline, most social cognitive variables predicted transition to fully vaccinated status at follow-up. After controlling for demographic factors and geographic region, greater odds of transitioning from unvaccinated at CCES Wave 1 to fully vaccinated at CCES Wave 2 was predicted most strongly by a perception that one's valued peers were taking up the vaccine (e.g., dynamic norms (OR = 2.13 (CI: 1.54,2.93)), perceived effectiveness of the vaccine (OR = 3.71 (CI: 2.43,5.66)), favorable attitudes toward the vaccine (OR = 2.80 (CI: 1.99,3.95)), greater perceived severity of COVID-19 (OR = 2.02 (CI: 1.42,2.86)), and stronger behavioral intention to become vaccinated (OR = 2.99 (CI: 2.16,4.14)). As a group, social cognitive variables improved prediction of COVID-19 mitigation behaviors (masking, distancing, hand hygiene) by a factor of 5 compared to demographic factors, and improved prediction of vaccination status by a factor of nearly 20. Social cognitive processes appear to be important leverage points for health communications to encourage COVID-19 vaccination and other mitigation behaviors, particularly among initially hesitant members of the general population. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Hall, Peter A AU - Hall PA AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: pahall@uwaterloo.ca. FAU - Meng, Gang AU - Meng G AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Boudreau, Christian AU - Boudreau C AD - Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Ontario, Canada. FAU - Hudson, Anna AU - Hudson A AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. FAU - Quah, Anne C K AU - Quah ACK AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Agar, Thomas AU - Agar T AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Fong, Geoffrey T AU - Fong GT AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada. Electronic address: geoffrey.fong@uwaterloo.ca. LA - eng PT - Journal Article DEP - 20221212 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - Male MH - *COVID-19 Vaccines MH - *COVID-19/epidemiology/prevention & control MH - Canada/epidemiology MH - Vaccination MH - Cognition PMC - PMC9742224 COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/12/18 06:00 MHDA- 2023/06/19 13:08 PMCR- 2022/12/12 CRDT- 2022/12/17 22:04 PHST- 2022/10/14 00:00 [received] PHST- 2022/12/02 00:00 [revised] PHST- 2022/12/03 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2022/12/18 06:00 [pubmed] PHST- 2022/12/17 22:04 [entrez] PHST- 2022/12/12 00:00 [pmc-release] AID - S0264-410X(22)01526-2 [pii] AID - 10.1016/j.vaccine.2022.12.010 [doi] PST - ppublish SO - Vaccine. 2023 Jun 19;41(27):4031-4041. doi: 10.1016/j.vaccine.2022.12.010. Epub 2022 Dec 12. PMID- 36514706 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221222 IS - 2168-8184 (Print) IS - 2168-8184 (Electronic) IS - 2168-8184 (Linking) VI - 14 IP - 12 DP - 2022 Dec TI - Mitogen Activated Protein Kinase (MAPK) Activation, p53, and Autophagy Inhibition Characterize the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein Induced Neurotoxicity. PG - e32361 LID - 10.7759/cureus.32361 [doi] LID - e32361 AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and prions use common pathogenic pathways to induce toxicity in neurons. Infectious prions rapidly activate the p38 mitogen activated protein kinase (MAPK) pathway, and SARS-CoV-2 spike proteins rapidly activate both the p38 MAPK and c-Jun NH2-terminal kinase (JNK) pathways through toll-like receptor signaling, indicating the potential for similar neurotoxicity, causing prion and prion-like disease. In this review, we analyze the roles of autophagy inhibition, molecular mimicry, elevated intracellular p53 levels and reduced Wild-type p53-induced phosphatase 1 (Wip1) and dual-specificity phosphatase (DUSP) expression in neurons in the disease process. The pathways induced by the spike protein via toll-like receptor activation induce both the upregulation of PrP(C) (the normal isoform of the prion protein, PrP) and the expression of beta amyloid. Through the spike-protein-dependent elevation of p53 levels via beta amyloid metabolism, increased PrP(C) expression can lead to PrP misfolding and impaired autophagy, generating prion disease. We conclude that, according to the age of the spike protein-exposed patient and the state of their cellular autophagy activity, excess sustained activity of p53 in neurons may be a catalytic factor in neurodegeneration. An autoimmune reaction via molecular mimicry likely also contributes to neurological symptoms. Overall results suggest that neurodegeneration is in part due to the intensity and duration of spike protein exposure, patient advanced age, cellular autophagy activity, and activation, function and regulation of p53. Finally, the neurologically damaging effects can be cumulatively spike-protein dependent, whether exposure is by natural infection or, more substantially, by repeated mRNA vaccination. CI - Copyright (c) 2022, Kyriakopoulos et al. FAU - Kyriakopoulos, Anthony M AU - Kyriakopoulos AM AD - Infectious Disease, Nasco AD Biotechnology Laboratory, Piraeus, GRC. FAU - Nigh, Greg AU - Nigh G AD - Naturopathy, Immersion Health, Portland, USA. FAU - McCullough, Peter A AU - McCullough PA AD - Cardiology, Truth for Health Foundation, Tucson, USA. FAU - Seneff, Stephanie AU - Seneff S AD - Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, USA. LA - eng PT - Journal Article PT - Review DEP - 20221209 PL - United States TA - Cureus JT - Cureus JID - 101596737 PMC - PMC9733976 OTO - NOTNLM OT - aging OT - autoimmunity OT - autophagy OT - covid-19 OT - mrna vaccines OT - p53 OT - prion and prion-like diseases OT - sars-cov-2 spike protein OT - senescence OT - wip1 COIS- The authors have declared that no competing interests exist. EDAT- 2022/12/15 06:00 MHDA- 2022/12/15 06:01 PMCR- 2022/12/09 CRDT- 2022/12/14 01:59 PHST- 2022/12/08 00:00 [accepted] PHST- 2022/12/14 01:59 [entrez] PHST- 2022/12/15 06:00 [pubmed] PHST- 2022/12/15 06:01 [medline] PHST- 2022/12/09 00:00 [pmc-release] AID - 10.7759/cureus.32361 [doi] PST - epublish SO - Cureus. 2022 Dec 9;14(12):e32361. doi: 10.7759/cureus.32361. eCollection 2022 Dec. PMID- 36510367 OWN - NLM STAT- MEDLINE DCOM- 20231228 LR - 20240909 IS - 1532-7027 (Electronic) IS - 1041-0236 (Linking) VI - 39 IP - 1 DP - 2024 Apr TI - How Information Repertoire Affects Vaccine Hesitancy: Processes of Information Verification and Cognitive Elaboration. PG - 62-72 LID - 10.1080/10410236.2022.2154017 [doi] AB - As information consumption plays a critical role in addressing vaccine hesitancy in the hybrid media environment, it becomes crucial to understand how individuals' use of a combination of channels and sources affects their vaccine hesitancy. Based on information repertoire approaches emphasizing the multiplicity of channels and sources, we investigated different patterns of information repertoire related to the COVID-19 pandemic and how these patterns affected vaccine hesitancy through different informational mechanisms. Our results based on a U.S. sample suggest that while a richer information repertoire related to increased confidence in vaccines through increased information verification, this richness also corresponded with deepened vaccine hesitancy through heightened cognitive elaboration and perceived information inconsistency. Our findings support the utility of repertoire approaches for better understanding health information acquisition in the complex media ecology. FAU - Zhao, Xinyan AU - Zhao X AUID- ORCID: 0000-0002-1970-031X AD - Hussman School of Journalism and Media, University of North Carolina at Chapel Hill. FAU - Ma, Zexin AU - Ma Z AD - Department of Communication, Journalism, and Public Relations, Oakland University. FAU - Xu, Sifan AU - Xu S AD - School of Advertising and Public Relations, University of Tennessee. FAU - Austin, Lucinda L AU - Austin LL AD - Hussman School of Journalism and Media, University of North Carolina at Chapel Hill. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221212 PL - England TA - Health Commun JT - Health communication JID - 8908762 RN - 0 (Vaccines) SB - IM MH - Humans MH - Pandemics MH - Vaccination Hesitancy MH - *COVID-19/epidemiology/prevention & control MH - Cognition MH - Vaccination MH - *Vaccines EDAT- 2022/12/14 06:00 MHDA- 2023/12/28 06:42 CRDT- 2022/12/13 00:13 PHST- 2023/12/28 06:42 [medline] PHST- 2022/12/14 06:00 [pubmed] PHST- 2022/12/13 00:13 [entrez] AID - 10.1080/10410236.2022.2154017 [doi] PST - ppublish SO - Health Commun. 2024 Apr;39(1):62-72. doi: 10.1080/10410236.2022.2154017. Epub 2022 Dec 12. PMID- 36438042 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 9 DP - 2022 TI - Hospital admission and vaccination as predictive factors of long COVID-19 symptoms. PG - 1016013 LID - 10.3389/fmed.2022.1016013 [doi] LID - 1016013 AB - BACKGROUND: Since the beginning of the COVID-19 pandemic, a great variability of symptoms that affect all organs and systems of the body has been identified in patients with SARS-CoV-2 infection; this symptomatology can sometimes persist over time, giving rise to the so-called long COVID or post-COVID. The aim of this study is to delve into the clinical characterization of these patients, as well as to take into account the influence of factors such as hospitalization, admission to ICU, history of pneumonia, or vaccination status on the persistence of symptoms. MATERIAL AND METHODS: An observational, descriptive, multicenter, and retrospective study was designed with a series of cases of people who presented long COVID, which includes univariate, bivariate, and multivariate analyses. Data were obtained from an online ad hoc questionnaire, and statistical analysis was performed using SPSS Software Version 25 (IBM-Inc., Chicago, IL, USA). RESULTS: Hospitalization, ICU admission, history of pneumonia, and vaccination were predictive factors (positive or negative) for the following long-COVID symptoms: headache, menstrual disorders, joint pain, cough, chills, nasal congestion, back pain, abdominal pain, weight loss, eye discomfort, facial erythema, itching, tremors, dizziness, seizures, sleeping difficulty, dry eyes, palpitations, fatigue, paresthesia, dyspnea, aphonia, chest pain, high blood pressure, vomiting, memory loss, brain fog, hypothermia, low blood pressure, sputum or phlegm, lack of concentration, hair loss, and erectile dysfunction. CONCLUSION: This study provides evidence on the clinical characterization of patients suffering from long COVID in order to offer them the most appropriate treatments. CI - Copyright (c) 2022 Romero-Rodriguez, Perula-de Torres, Castro-Jimenez, Gonzalez-Lama, Jimenez-Garcia, Gonzalez-Bernal, Gonzalez-Santos, Velez-Santamaria, Sanchez-Gonzalez and Santamaria-Pelaez. FAU - Romero-Rodriguez, Esperanza AU - Romero-Rodriguez E AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. AD - Multiprofessional Teaching Unit of Family and Community Care, Cordoba and Guadalquivir Health District, Cordoba, Spain. AD - Cordoba and Guadalquivir Health District, Cordoba, Spain. FAU - Perula-de Torres, Luis Angel AU - Perula-de Torres LA AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. AD - Multiprofessional Teaching Unit of Family and Community Care, Cordoba and Guadalquivir Health District, Cordoba, Spain. FAU - Castro-Jimenez, Rafael AU - Castro-Jimenez R AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. AD - Reina Sofia University Hospital, Cordoba, Spain. FAU - Gonzalez-Lama, Jesus AU - Gonzalez-Lama J AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. AD - Health Center "Matrona Antonia Mesa Fernandez", Cabra Clinical Management Unit, AGS Sur de Cordoba, Cordoba, Spain. FAU - Jimenez-Garcia, Celia AU - Jimenez-Garcia C AD - Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain. AD - Cordoba and Guadalquivir Health District, Cordoba, Spain. FAU - Gonzalez-Bernal, Jeronimo J AU - Gonzalez-Bernal JJ AD - Department of Health Sciences, University of Burgos, Burgos, Spain. FAU - Gonzalez-Santos, Josefa AU - Gonzalez-Santos J AD - Department of Health Sciences, University of Burgos, Burgos, Spain. FAU - Velez-Santamaria, Rodrigo AU - Velez-Santamaria R AD - Department of Health Sciences, University of Burgos, Burgos, Spain. FAU - Sanchez-Gonzalez, Esteban AU - Sanchez-Gonzalez E AD - Department of Medicine, Central University of Catalonia, Barcelona, Spain. FAU - Santamaria-Pelaez, Mirian AU - Santamaria-Pelaez M AD - Department of Health Sciences, University of Burgos, Burgos, Spain. LA - eng PT - Journal Article DEP - 20221111 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC9691755 OTO - NOTNLM OT - COVID-19 OT - admission OT - long COVID OT - persistent COVID OT - post-COVID OT - risk factor OT - symptoms COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/29 06:00 MHDA- 2022/11/29 06:01 PMCR- 2022/11/11 CRDT- 2022/11/28 04:09 PHST- 2022/08/10 00:00 [received] PHST- 2022/10/19 00:00 [accepted] PHST- 2022/11/28 04:09 [entrez] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/29 06:01 [medline] PHST- 2022/11/11 00:00 [pmc-release] AID - 10.3389/fmed.2022.1016013 [doi] PST - epublish SO - Front Med (Lausanne). 2022 Nov 11;9:1016013. doi: 10.3389/fmed.2022.1016013. eCollection 2022. PMID- 36413270 OWN - NLM STAT- MEDLINE DCOM- 20230428 LR - 20230428 IS - 2240-2993 (Electronic) IS - 0300-9009 (Print) IS - 0300-9009 (Linking) VI - 123 IP - 2 DP - 2023 Apr TI - Diagnostic challenges of functional neurological disorders after covid-19 disease or vaccination: case series and review of the literature. PG - 553-564 LID - 10.1007/s13760-022-02140-7 [doi] AB - BACKGROUND: Functional neurological disorders have rarely been described in patients recovering from Covid-19 or after vaccination but they are probably under diagnosed. MATERIAL AND METHODS: Six patients referred for rehabilitation of persistent symptoms and/or sequelae of Coronavirus disease 2019 (COVID-19) were diagnosed with functional neurological disorders. A literature review was conducted to identify reported cases of functional neurological disorders after Covid-19 infection or vaccination. RESULTS: In the current case series, patients diagnosed with functional neurological disorders presented high variability of clinical symptoms including hemiplegia, lower limb unilateral or bilateral paralysis, myoclonus, dystonia, tremor and sensory impairment. Four patients were young females with mild Covid-19 infection without hospital admission. Their neurological symptoms developed over the course of 4 weeks after the beginning of Covid-19 symptoms or vaccine administration with normal ancillary exams. One patient presented overlapping functional neurological symptoms and mild impairment of the left common peroneal nerve after prolonged ICU stay. In addition, all patients in our case series reported other non-motor symptoms such as fatigue, cognitive impairment and diffuse pain or dysesthesia, which are compatible with post Covid-19 condition. CONCLUSIONS: It is important that clinicians recognize functional neurological symptoms and consider it as a differential diagnosis in patients with neurological complications of Covid-19 infection and vaccination. CI - (c) 2022. The Author(s) under exclusive licence to Belgian Neurological Society. FAU - Albu, Sergiu AU - Albu S AUID- ORCID: 0000-0001-8310-4208 AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. salbu@guttmann.com. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. salbu@guttmann.com. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. salbu@guttmann.com. FAU - Valles, Margarita AU - Valles M AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. FAU - Kumru, Hatice AU - Kumru H AD - Fundacio Institut Guttmann, Institut Universitari de Neurorehabilitacio Adscrit a la Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain. AD - Universitat Autonoma de Barcelona, Bellaterra (Cerdanyola del Valles), Barcelona, Spain. AD - Fundacio Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Badalona, Barcelona, Spain. LA - eng PT - Journal Article PT - Review DEP - 20221121 PL - Italy TA - Acta Neurol Belg JT - Acta neurologica Belgica JID - 0247035 SB - IM MH - Female MH - Humans MH - *COVID-19/complications/prevention & control MH - Hemiplegia MH - *Dystonic Disorders MH - *Conversion Disorder MH - COVID-19 Testing PMC - PMC9685139 OTO - NOTNLM OT - Covid-19 OT - Functional neurological disorders OT - Post Covid-19 condition OT - Vaccine COIS- The authors have no competing interests to declare that are relevant to the content of this article. EDAT- 2022/11/23 06:00 MHDA- 2023/04/28 06:41 PMCR- 2022/11/24 CRDT- 2022/11/22 11:13 PHST- 2022/09/10 00:00 [received] PHST- 2022/10/31 00:00 [accepted] PHST- 2023/04/28 06:41 [medline] PHST- 2022/11/23 06:00 [pubmed] PHST- 2022/11/22 11:13 [entrez] PHST- 2022/11/24 00:00 [pmc-release] AID - 10.1007/s13760-022-02140-7 [pii] AID - 2140 [pii] AID - 10.1007/s13760-022-02140-7 [doi] PST - ppublish SO - Acta Neurol Belg. 2023 Apr;123(2):553-564. doi: 10.1007/s13760-022-02140-7. Epub 2022 Nov 21. PMID- 36412572 OWN - NLM STAT- MEDLINE DCOM- 20221128 LR - 20221128 IS - 2058-7384 (Electronic) IS - 0394-6320 (Print) IS - 0394-6320 (Linking) VI - 36 DP - 2022 Jan-Dec TI - Epidemiological and clinical characteristics of vaccinated COVID-19 patients: A meta-analysis and systematic review. PG - 3946320221141802 LID - 10.1177/03946320221141802 [doi] LID - 03946320221141802 AB - OBJECTIVE: With the global epidemic of coronavirus disease 2019 (COVID-19), vaccination rates are increasing globally. This study evaluated the relevant clinical manifestations of vaccinated COVID-19 patients. METHODS: We searched carefully in 11 databases such as PubMed, Embase, Scopus, Cochrane Library, Web of Science, Ovid, China National Knowledge Infrastructure Database, Wan Fang Data, Sinomed, VIP Database, and Reading Showing Database up to 26 March 2022. To search for articles that have described the characteristics of vaccinated patients including epidemiological and clinical symptoms. Statistical analysis of the extracted data using STATA 14.0. RESULTS: A total of 58 articles and 263,708 laboratory-confirmed COVID-19 patients were included. Most of the patients in the vaccinated group had more asymptomatic infection and fewer severe illnesses. There were significant differences in ethnicity, and strain infected with COVID-19, and comorbidities (hyperlipidemia, diabetes, obesity, kidney disease, immunocompromised, cardiovascular disease, and tumor) and symptoms (fever, cough, gastrointestinal symptoms, neurological symptoms, and dysgeusia/anosmia) between vaccinated group and unvaccinated group. Oxygen support, use of steroid, days in hospital, hospital treatment, ICU treatment, death, and poor prognosis were also significantly different. CONCLUSION: Compared with the vaccinated group, patients in the unvaccinated group had a more severe clinical manifestations. Vaccines are also protective for infected people. FAU - Tian, Wen AU - Tian W AD - Center of Infectious Diseases, Beijing Ditan Hospital, 12638Capital Medical University, Beijing, China. FAU - Ren, Xingxiang AU - Ren X AUID- ORCID: 0000-0002-5140-1256 AD - Department of Endocrinology, 594822Peking University International Hospital, Beijing, China. FAU - Han, Mei AU - Han M AD - Centre for Evidence-Based Chinese Medicine, 47839Beijing University of Chinese Medicine, Beijing, China. FAU - Zhang, Yuanyuan AU - Zhang Y AD - Beijing Key Laboratory of Emerging Infectious Disease, Beijing Ditan Hospital, 12638Captital Medical University, Beijing, China. FAU - Gao, Xu AU - Gao X AD - Center of Infectious Diseases, Beijing Ditan Hospital, 12638Capital Medical University, Beijing, China. FAU - Chen, Zhihai AU - Chen Z AD - Center of Infectious Diseases, Beijing Ditan Hospital, 12638Capital Medical University, Beijing, China. FAU - Zhang, Wei AU - Zhang W AUID- ORCID: 0000-0001-7148-4776 AD - Center of Infectious Diseases, Beijing Ditan Hospital, 12638Capital Medical University, Beijing, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Systematic Review PL - England TA - Int J Immunopathol Pharmacol JT - International journal of immunopathology and pharmacology JID - 8911335 SB - IM MH - Humans MH - *Cardiovascular Diseases MH - China MH - *COVID-19/epidemiology/prevention & control MH - *Neoplasms MH - Research Design PMC - PMC9692180 OTO - NOTNLM OT - COVID-19 OT - clinical characteristics OT - epidemiological characteristics OT - meta-analysis OT - vaccine COIS- The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. EDAT- 2022/11/23 06:00 MHDA- 2022/11/24 06:00 PMCR- 2022/11/22 CRDT- 2022/11/22 07:53 PHST- 2022/11/22 07:53 [entrez] PHST- 2022/11/23 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2022/11/22 00:00 [pmc-release] AID - 10.1177_03946320221141802 [pii] AID - 10.1177/03946320221141802 [doi] PST - ppublish SO - Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221141802. doi: 10.1177/03946320221141802. PMID- 36375693 OWN - NLM STAT- MEDLINE DCOM- 20221228 LR - 20230103 IS - 1878-3511 (Electronic) IS - 1201-9712 (Print) IS - 1201-9712 (Linking) VI - 126 DP - 2023 Jan TI - Post-acute symptoms 3-15 months after COVID-19 among unvaccinated and vaccinated individuals with a breakthrough infection. PG - 10-13 LID - S1201-9712(22)00596-3 [pii] LID - 10.1016/j.ijid.2022.11.009 [doi] AB - OBJECTIVE: We aimed to describe post-acute sequelae of SARS-CoV-2 infection (PASC) related symptoms 3-15 months after a positive test in SARS-CoV-2 unvaccinated and vaccinated participants with a breakthrough infection. METHODS: Participants of the Norwegian COVID-19 cohort, without a positive SARS-CoV-2 test, completed a questionnaire about PASC-related symptoms between November 2020 and January 2021. About a year later, a second questionnaire (which also included the Everyday Memory Questionnaire [EMQ]-13) was completed by the same participants, most still without a positive SARS-CoV-2 test, but also by unvaccinated and vaccinated participants with a positive test 3-15 months before the questionnaire. Laboratory-confirmed SARS-CoV-2 status (positive or negative swab test determined by reverse transcriptase quantitative polymerase chain reaction) at the time of completing the questionnaire was ascertained from the Mandatory Norwegian Surveillance System for Communicable Diseases. RESULTS: No differences were found in the self-reported PASC symptoms, dyspnea, fatigue, smell/taste changes, concentration problems, or the EMQ-13 score between unvaccinated and vaccinated participants 3-15 months after the positive test. Fewer memory problems were reported among vaccinated than unvaccinated participants. CONCLUSION: SARS-CoV-2 vaccines offer minor protection against PASC symptoms, although fewer memory problems were reported among the vaccinated than the unvaccinated participants. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Brunvoll, Sonja H AU - Brunvoll SH AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: shbrunvoll@gmail.com. FAU - Nygaard, Anders B AU - Nygaard AB AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: anders.b.nygaard@gmail.com. FAU - Fagerland, Morten W AU - Fagerland MW AD - Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: m.w.fagerland@medisin.uio.no. FAU - Holland, Petter AU - Holland P AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: petter.holland@gmail.com. FAU - Ellingjord-Dale, Merete AU - Ellingjord-Dale M AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: mellingjord@hotmail.com. FAU - Dahl, John Arne AU - Dahl JA AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: j.a.dahl@medisin.uio.no. FAU - Soraas, Arne AU - Soraas A AD - Department of Microbiology, Oslo University Hospital, Pb 4950, 0424 Oslo, Norway. Electronic address: arne@meg.no. LA - eng PT - Journal Article DEP - 20221112 PL - Canada TA - Int J Infect Dis JT - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JID - 9610933 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/diagnosis MH - SARS-CoV-2 MH - Breakthrough Infections MH - COVID-19 Vaccines MH - Post-Acute COVID-19 Syndrome MH - Vaccination PMC - PMC9651990 OTO - NOTNLM OT - Long-COVID OT - PASC OT - SARS-CoV-2 OT - Vaccination COIS- Declaration of competing interest The authors have no competing interests to declare. EDAT- 2022/11/15 06:00 MHDA- 2022/12/29 06:00 PMCR- 2022/11/12 CRDT- 2022/11/14 19:26 PHST- 2022/09/09 00:00 [received] PHST- 2022/10/27 00:00 [revised] PHST- 2022/11/08 00:00 [accepted] PHST- 2022/11/15 06:00 [pubmed] PHST- 2022/12/29 06:00 [medline] PHST- 2022/11/14 19:26 [entrez] PHST- 2022/11/12 00:00 [pmc-release] AID - S1201-9712(22)00596-3 [pii] AID - 10.1016/j.ijid.2022.11.009 [doi] PST - ppublish SO - Int J Infect Dis. 2023 Jan;126:10-13. doi: 10.1016/j.ijid.2022.11.009. Epub 2022 Nov 12. PMID- 36367067 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221202 IS - 1738-6586 (Print) IS - 2005-5013 (Electronic) IS - 1738-6586 (Linking) VI - 18 IP - 6 DP - 2022 Nov TI - AI-CoV Study: Autoimmune Encephalitis Associated With COVID-19 and Its Vaccines-A Systematic Review. PG - 692-710 LID - 10.3988/jcn.2022.18.6.692 [doi] AB - BACKGROUND AND PURPOSE: Autoimmune encephalitis (AIE) following coronavirus disease 2019 (COVID-19) is an underexplored condition. This study aims to systematically review the clinico-investigational and pathophysiologic aspects of COVID-19 and its vaccines in association with AIE, and identify the factors predicting neurological severity and outcomes. METHODS: Relevant data sources were searched using appropriate search terms on January 15, 2022. Studies meeting the criteria for AIE having a temporal association with COVID-19 or its vaccines were included. RESULTS: Out of 1,894 citations, we included 61 articles comprising 88 cases: 71 of COVID-19-associated AIE, 3 of possible Bickerstaff encephalitis, and 14 of vaccine-associated AIE.There were 23 definite and 48 possible seronegative AIE cases. Anti-NMDAR (N-methyl-D-aspartate receptor; n=12, 16.9%) was the most common definite AIE. Males were more commonly affected (sex ratio=1.63) in the AIE subgroup. The neurological symptoms included alteredmental state (n=53, 74.6%), movement disorders (n=28, 39.4%), seizures (n=24, 33.8%), behavioural (n=25, 35.2%), and speech disturbances (n=17, 23.9%). The median latency to AIE diagnosis was 14 days (interquartile range=4-22 days). Female sex and ICU admission had higherrisks of sequelae, with odds ratio (OR) of 2.925 (95% confidence interval [CI]=1.005-8.516)and 3.515 (95% CI=1.160-10.650), respectively. Good immunotherapy response was seen in42/48 (87.5%) and 13/13 (100%) of COVID-19-associated and vaccine-associated AIE patients, respectively. Sequelae were reported in 22/60 (36.7%) COVID-19 associated and 10/13 (76.9%) vaccine-associated cases. CONCLUSIONS: The study has revealed diagnostic, therapeutic, and pathophysiological aspects of AIE associated with COVID-19 and its vaccines, and its differences from postinfectious AIE. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration number CRD42021299215. CI - Copyright (c) 2022 Korean Neurological Association. FAU - Samim, M M AU - Samim MM AUID- ORCID: 0000-0002-3367-1455 AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Dhar, Debjyoti AU - Dhar D AUID- ORCID: 0000-0002-4835-4698 AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. deb.dhar.india@gmail.com. FAU - Goyal, Sheetal AU - Goyal S AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Dey, Treshita AU - Dey T AUID- ORCID: 0000-0001-7795-3596 AD - Department of Radiation Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. FAU - Parvin, Naznin AU - Parvin N AUID- ORCID: 0000-0002-7951-5183 AD - Department of Pediatrics, Lady Hardinge Medical College and Hospital, New Delhi, India. FAU - Shah, Rutul D AU - Shah RD AUID- ORCID: 0000-0002-4475-3413 AD - Department of Neurology, Amrita Institute of Medical Sciences, Kochi, Kerala, India. FAU - Singh, Vikram AU - Singh V AUID- ORCID: 0000-0003-4891-1404 AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Chowdhury, Sampurna AU - Chowdhury S AUID- ORCID: 0000-0002-5010-7565 AD - Department of Neurology, All India Institute of Medical Sciences, New Delhi, India. FAU - Lal, Bhavesh Mohan AU - Lal BM AUID- ORCID: 0000-0001-5554-3342 AD - Department of General Medicine, All India Institute of Medical Sciences, New Delhi, India. FAU - Varghese, Nibu AU - Varghese N AUID- ORCID: 0000-0002-1818-2899 AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Gohel, Abhishek AU - Gohel A AUID- ORCID: 0000-0002-7847-4551 AD - Department of Neurology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Chowdhury, Abhishek AU - Chowdhury A AUID- ORCID: 0000-0001-7948-6936 AD - Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India. FAU - Chatterjee, Aritra AU - Chatterjee A AUID- ORCID: 0000-0002-5318-3459 AD - Centre For Biosystems Science and Engineering, Indian Institute of Science, Bangalore, Karnataka, India. FAU - Siddiqui, Shahyan AU - Siddiqui S AUID- ORCID: 0000-0002-8887-6546 AD - Consultant Neuroradiologist, Department of Neuroimaging and Interventional Radiology, STAT Institute of Neurosciences, Hyderabad, India. LA - eng PT - Journal Article PL - Korea (South) TA - J Clin Neurol JT - Journal of clinical neurology (Seoul, Korea) JID - 101252374 PMC - PMC9669562 OTO - NOTNLM OT - COVID-19 OT - COVID-19 vaccine OT - autoimmune encephalitis OT - postinfectious encephalitis COIS- The authors have no potential conflicts of interest to disclose. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/11/01 CRDT- 2022/11/11 04:42 PHST- 2022/03/15 00:00 [received] PHST- 2022/04/19 00:00 [revised] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/11/11 04:42 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/11/01 00:00 [pmc-release] AID - 18.692 [pii] AID - 10.3988/jcn.2022.18.6.692 [doi] PST - ppublish SO - J Clin Neurol. 2022 Nov;18(6):692-710. doi: 10.3988/jcn.2022.18.6.692. PMID- 36366936 OWN - NLM STAT- MEDLINE DCOM- 20230210 LR - 20230323 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 30 IP - 3 DP - 2023 Mar TI - Functional disorders as a common motor manifestation of COVID-19 infection or vaccination. PG - 678-691 LID - 10.1111/ene.15630 [doi] AB - BACKGROUND AND PURPOSE: There have been over 500 million confirmed cases of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), across the globe. To date, a broad spectrum of neurological manifestations following acute infections as well as COVID-19 vaccines have been reported. The aim of this study was to describe the spectrum of neurological manifestations seen in the 'COVID-19 clinic' established in a tertiary Movement Disorders clinic. METHODS: In this consecutive case-series study over the period March 2020-January 2022, clinical information regarding demographic data, clinical history and examination findings, investigation results and video recordings of outpatients with motor manifestations associated with COVID-19 infection or vaccination were reviewed. RESULTS: Twenty-one adult patients were reviewed in this ad hoc clinic at Toronto Western Hospital. The majority of the patients were female (76%) and the mean (range) age was 50.7 +/- 17.2 (21-80) years. Nine patients (43%) presented with motor manifestations following COVID-19 infection. Twelve patients (57%) developed neurological symptoms following at least one dose of the mRNA or viral vector-based COVID-19 vaccine. The most common manifestation observed was a functional movement disorder (43%). The vaccine group demonstrated a higher number of functional disorders compared to the infection group (58% vs. 22%; p = 0.08). CONCLUSION: Functional motor manifestations can be associated with COVID-19 and are likely to be under-reported. In view of the co-existence of functional symptoms, movement disorders and mental health conditions observed in this study, we would advocate the use of dedicated COVID-19 Neurology clinics with full access to an experienced multidisciplinary team. CI - (c) 2022 European Academy of Neurology. FAU - Fung, Wilson K W AU - Fung WKW AUID- ORCID: 0000-0001-7169-4175 AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. FAU - Sa'di, Qais AU - Sa'di Q AUID- ORCID: 0000-0002-3499-4483 AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. FAU - Katzberg, Hans AU - Katzberg H AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Chen, Robert AU - Chen R AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Lang, Anthony E AU - Lang AE AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. FAU - Cheung, Angela M AU - Cheung AM AD - Department of Medicine, UHN, Toronto, Ontario, Canada. AD - Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. FAU - Fasano, Alfonso AU - Fasano A AD - Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada. AD - Division of Neurology, University of Toronto, Toronto, Ontario, Canada. AD - Krembil Research Institute, Toronto, Ontario, Canada. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221208 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (COVID-19 Vaccines) SB - IM CIN - Eur J Neurol. 2023 Feb;30(2):560-561. doi: 10.1111/ene.15639. PMID: 36404130 MH - Adult MH - Aged MH - Female MH - Humans MH - Male MH - Middle Aged MH - *COVID-19/complications/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - *Movement Disorders MH - SARS-CoV-2 MH - Vaccination/adverse effects PMC - PMC9878181 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - functional OT - movement disorders OT - vaccine COIS- None relevant to this work. EDAT- 2022/11/12 06:00 MHDA- 2023/02/11 06:00 PMCR- 2022/12/08 CRDT- 2022/11/11 03:32 PHST- 2022/10/16 00:00 [revised] PHST- 2022/07/17 00:00 [received] PHST- 2022/11/03 00:00 [accepted] PHST- 2022/11/12 06:00 [pubmed] PHST- 2023/02/11 06:00 [medline] PHST- 2022/11/11 03:32 [entrez] PHST- 2022/12/08 00:00 [pmc-release] AID - ENE15630 [pii] AID - 10.1111/ene.15630 [doi] PST - ppublish SO - Eur J Neurol. 2023 Mar;30(3):678-691. doi: 10.1111/ene.15630. Epub 2022 Dec 8. PMID- 36366384 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231102 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 11 DP - 2022 Nov 7 TI - A Social Cognitive Theory Approach to Understanding Parental Attitudes and Intentions to Vaccinate Children during the COVID-19 Pandemic. LID - 10.3390/vaccines10111876 [doi] LID - 1876 AB - The distribution of the COVID-19 vaccine represents a path towards global health after a worldwide pandemic. Yet, the U.S. response to the vaccination rollout has been politically polarized. The aim of this paper is to contribute to the understanding of the contextual factors that influence parents' attitudes towards health officials and their intention to vaccinate children, focusing on communication behaviors, personal factors, and geographic locations. We use Bandura's triadic reciprocal determinism (TRD) model which posits reciprocal influence between personal factors, environmental factors, and behaviors. We found that personal factors (having younger children and identifying as Republican partisans), and the behavioral factor of conservative news use were significantly related to more negative attitudes towards health officials and lower vaccination intentions. Conversely, Democrats and liberal news use were significantly related to warmer attitudes and greater vaccination intentions. The environmental factor of geographic location across four states with different partisan dynamics was not significantly related to attitudes and behavioral intentions. Results from a post-hoc analysis show that news media use and partisanship were the strongest correlates of parents' attitudes towards health officials. This evidence points to the politicization of the COVID-19 vaccine being a key consideration regarding vaccine uptake. FAU - Zhu, Ying AU - Zhu Y AD - College of Communication and Information, Kent State University, 318 University Library, 1125 Risman Drive, Kent, OH 44242, USA. FAU - Beam, Michael AU - Beam M AD - School of Emerging Media & Technology, Kent State University, 550 Hilltop Drive, Kent, OH 44242, USA. FAU - Ming, Yue AU - Ming Y AUID- ORCID: 0000-0002-5682-9817 AD - College of Communication and Information, Kent State University, 318 University Library, 1125 Risman Drive, Kent, OH 44242, USA. FAU - Egbert, Nichole AU - Egbert N AD - School of Communication Studies, Kent State University, P.O. Box 5190, Kent, OH 44242, USA. FAU - Smith, Tara C AU - Smith TC AD - College of Public Health, Kent State University, 800 Hilltop Drive, Kent, OH 44242, USA. LA - eng PT - Journal Article DEP - 20221107 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9697026 OTO - NOTNLM OT - COVID-19 OT - child vaccination OT - political polarization OT - social cognitive theory OT - survey methods COIS- The authors declare no conflict of interest. EDAT- 2022/11/12 06:00 MHDA- 2022/11/12 06:01 PMCR- 2022/11/07 CRDT- 2022/11/11 01:55 PHST- 2022/09/20 00:00 [received] PHST- 2022/10/27 00:00 [revised] PHST- 2022/11/02 00:00 [accepted] PHST- 2022/11/11 01:55 [entrez] PHST- 2022/11/12 06:00 [pubmed] PHST- 2022/11/12 06:01 [medline] PHST- 2022/11/07 00:00 [pmc-release] AID - vaccines10111876 [pii] AID - vaccines-10-01876 [pii] AID - 10.3390/vaccines10111876 [doi] PST - epublish SO - Vaccines (Basel). 2022 Nov 7;10(11):1876. doi: 10.3390/vaccines10111876. PMID- 36345695 OWN - NLM STAT- MEDLINE DCOM- 20230809 LR - 20230810 IS - 1758-0854 (Electronic) IS - 1758-0846 (Print) IS - 1758-0854 (Linking) VI - 15 IP - 3 DP - 2023 Aug TI - Why some people do not get vaccinated against COVID-19: Social-cognitive determinants of vaccination behavior. PG - 825-845 LID - 10.1111/aphw.12411 [doi] AB - It is puzzling that a sizeable percentage of people refuse to get vaccinated against COVID-19. This study aimed to examine social psychological factors influencing their vaccine hesitancy. This longitudinal study traced a cohort of 2663 individuals in 25 countries from the time before COVID-19 vaccines became available (March 2020) to July 2021, when vaccination was widely available. Multilevel logistic regressions were used to examine determinants of actual COVID-19 vaccination behavior by July 2021, with country-level intercept as random effect. Of the 2663 participants, 2186 (82.1%) had been vaccinated by July 2021. Participants' attitude toward COVID-19 vaccines was the strongest predictor of both vaccination intention and subsequent vaccination behavior (p < .001). Perceived risk of getting infected and perceived personal disturbance of infection were also associated with higher likelihood of getting vaccinated (p < .001). However, religiosity, right-wing political orientation, conspiracy beliefs, and low trust in government regarding COVID-19 were negative predictors of vaccination intention and behavior (p < .05). Our findings highlight the importance of attitude toward COVID-19 vaccines and also suggest that certain life-long held convictions that predate the pandemic make people distrustful of their government and likely to accept conspiracy beliefs and therefore less likely to adopt the vaccination behavior. CI - (c) 2022 The Authors. Applied Psychology: Health and Well-Being published by John Wiley & Sons Ltd on behalf of International Association of Applied Psychology. FAU - Han, Qing AU - Han Q AD - Department of Social Policy and Intervention, University of Oxford, Oxford, UK. FAU - Zheng, Bang AU - Zheng B AUID- ORCID: 0000-0003-1814-6692 AD - Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK. AD - Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK. FAU - Abakoumkin, Georgios AU - Abakoumkin G AUID- ORCID: 0000-0002-1671-3561 AD - Laboratory of Psychology, Department of Early Childhood Education, University of Thessaly, Volos, Greece. FAU - Leander, N Pontus AU - Leander NP AD - Department of Social and Organizational Psychology, University of Groningen, Groningen, The Netherlands. AD - Department of Psychology, Wayne State University, Detroit, Michigan, USA. FAU - Stroebe, Wolfgang AU - Stroebe W AD - Department of Social and Organizational Psychology, University of Groningen, Groningen, The Netherlands. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221108 PL - England TA - Appl Psychol Health Well Being JT - Applied psychology. Health and well-being JID - 101502957 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Longitudinal Studies MH - Intention MH - Vaccination PMC - PMC9877847 OTO - NOTNLM OT - COVID-19 OT - longitudinal study OT - social psychological predictors OT - vaccination behavior OT - vaccine hesitancy COIS- All authors report no conflicts of interest. EDAT- 2022/11/09 06:00 MHDA- 2023/08/09 06:43 PMCR- 2022/11/08 CRDT- 2022/11/08 03:22 PHST- 2022/08/21 00:00 [received] PHST- 2022/10/15 00:00 [accepted] PHST- 2023/08/09 06:43 [medline] PHST- 2022/11/09 06:00 [pubmed] PHST- 2022/11/08 03:22 [entrez] PHST- 2022/11/08 00:00 [pmc-release] AID - APHW12411 [pii] AID - 10.1111/aphw.12411 [doi] PST - ppublish SO - Appl Psychol Health Well Being. 2023 Aug;15(3):825-845. doi: 10.1111/aphw.12411. Epub 2022 Nov 8. PMID- 36341005 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240916 IS - 1576-9887 (Print) IS - 1578-8857 (Electronic) IS - 1576-9887 (Linking) VI - 24 IP - 2 DP - 2023 Apr-Jun TI - Differences in elderly stress levels before Covid-19 vaccination: History of exposure to Covid-19 reduces stress before vaccination. PG - 135-140 LID - 10.1016/j.vacun.2022.10.005 [doi] AB - BACKGROUND: The Covid-19 pandemic requires the government to take various prevention and countermeasures, one of which is the Covid-19 Vaccination program, however, the program experiences a high dropout at various doses and causes immunization stress related response (ISRR), especially in the elderly. The research aims to determine differences in the stress levels of the elderly before the covid-19 vaccination. METHODS: Descriptive study with the elderly population who will take vaccinations at the Bojong Purbalingga Health Center. Sampling used random sampling, the inclusion criteria were 45-79 years old, with a total sample of 90 respondents. Research instruments developed by research, relating to vaccination containing cognitive responses (such as difficulty concentrating), physiological responses (such as shortness of breath, dry lips) feelings of fear, anxiety, trust in vaccination. Data were analyzed descriptively with percentages and proportions. RESULTS: The results showed that the most moderate stress levels were middle age (22.2%), women 33.3% had higher stress levels than men (10%), the highest vaccination coverage was 26.7% at a distance of 1-2 KM. The level of stress is in the moderate category 33.3% in the elderly who have never been exposed to Covid-19 and 10% in the elderly who have been exposed. Non-family health workers, 36.7% higher than families of health workers (6.7%). CONCLUSION: Stress levels before vaccination are higher in the elderly who have never been exposed to Covid-19, compared to those who have been exposed to Covid-19. The need for family assistance to prepare for vaccination in the elderly. CI - (c) 2022 Elsevier Espana, S.L.U. All rights reserved. FAU - Setiawan, Kristian Budi AU - Setiawan KB AD - Nursing, Universitas Muhammadiyah Purwokerto, Indonesia. FAU - Hikmawati, Isna AU - Hikmawati I AD - Epidemiology, Universitas Muhammadiyah Purwokerto, Indonesia. FAU - Wardani, Dita Pratiwi Kusuma AU - Wardani DPK AD - Medical Laboratory Engineering, Universitas Muhammadiyah Purwokerto, Indonesia. FAU - Juanita, Juanita AU - Juanita J AD - Civil Engineering, Universitas Muhammadiyah Purwokerto, Indonesia. LA - eng PT - Journal Article DEP - 20221101 PL - Spain TA - Vacunas JT - Vacunas JID - 101528857 PMC - PMC9622388 OTO - NOTNLM OT - Covid-19 OT - Elderly OT - Stress Level OT - Vaccination COIS- The author declares no competing interest. EDAT- 2022/11/08 06:00 MHDA- 2022/11/08 06:01 PMCR- 2022/11/01 CRDT- 2022/11/07 05:10 PHST- 2022/07/29 00:00 [received] PHST- 2022/10/22 00:00 [accepted] PHST- 2022/11/08 06:01 [medline] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/07 05:10 [entrez] PHST- 2022/11/01 00:00 [pmc-release] AID - S1576-9887(22)00190-X [pii] AID - 10.1016/j.vacun.2022.10.005 [doi] PST - ppublish SO - Vacunas. 2023 Apr-Jun;24(2):135-140. doi: 10.1016/j.vacun.2022.10.005. Epub 2022 Nov 1. PMID- 36339206 OWN - NLM STAT- MEDLINE DCOM- 20221108 LR - 20230120 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 10 DP - 2022 TI - Mental health and chest CT scores mediate the relationship between COVID-19 vaccination status and seroconversion time: A cross-sectional observational study in B.1.617.2 (Delta) infection patients. PG - 974848 LID - 10.3389/fpubh.2022.974848 [doi] LID - 974848 AB - BACKGROUND: The coronavirus disease (COVID-19) pandemic, which has been ongoing for more than 2 years, has become one of the largest public health issues. Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is one of the most important interventions to mitigate the COVID-19 pandemic. Our objective is to investigate the relationship between vaccination status and time to seroconversion. METHODS: We conducted a cross-sectional observational study during the SARS-CoV-2 B.1.617.2 outbreak in Jiangsu, China. Participants who infected with the B.1.617.2 variant were enrolled. Cognitive performance, quality of life, emotional state, chest computed tomography (CT) score and seroconversion time were evaluated for each participant. Statistical analyses were performed using one-way ANOVA, univariate and multivariate regression analyses, Pearson correlation, and mediation analysis. RESULTS: A total of 91 patients were included in the analysis, of whom 37.3, 25.3, and 37.3% were unvaccinated, partially vaccinated, and fully vaccinated, respectively. Quality of life was impaired in 30.7% of patients, especially for mental component summary (MCS) score. Vaccination status, subjective cognitive decline, and depression were risk factors for quality-of-life impairment. The chest CT score mediated the relationship of vaccination status with the MCS score, and the MCS score mediated the relationship of the chest CT score with time to seroconversion. CONCLUSION: Full immunization course with an inactivated vaccine effectively lowered the chest CT score and improved quality of life in hospitalized patients. Vaccination status could influence time to seroconversion by affecting CT score and MCS score indirectly. Our study emphasizes the importance of continuous efforts in encouraging a full vaccination course. CI - Copyright (c) 2022 Zhang, Chen, Dai, Lu, Li, Yi, Fu, Li, Liu, Liufu, Long and Zhang. FAU - Zhang, Wen AU - Zhang W AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. AD - Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. AD - Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China. FAU - Chen, Qian AU - Chen Q AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. AD - Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. AD - Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China. FAU - Dai, Jinghong AU - Dai J AD - Department of Pulmonary and Critical Care Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Lu, Jiaming AU - Lu J AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. AD - Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. AD - Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China. FAU - Li, Jie AU - Li J AD - Department of Infectious Disease, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Yi, Yongxiang AU - Yi Y AD - Department of Infectious Diseases, The Second Hospital of Nanjing, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. FAU - Fu, Linqing AU - Fu L AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Li, Xin AU - Li X AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Liu, Jiani AU - Liu J AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Liufu, Jinlong AU - Liufu J AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Long, Cong AU - Long C AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. FAU - Zhang, Bing AU - Zhang B AD - Department of Radiology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. AD - Medical Imaging Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. AD - Institute of Medical Imaging and Artificial Intelligence, Nanjing University, Nanjing, China. AD - Institute of Brain Science, Nanjing University, Nanjing, China. LA - eng PT - Journal Article PT - Observational Study PT - Research Support, Non-U.S. Gov't DEP - 20221019 PL - Switzerland TA - Front Public Health JT - Frontiers in public health JID - 101616579 RN - 0 (COVID-19 Vaccines) RN - SARS-CoV-2 variants SB - IM MH - Humans MH - *SARS-CoV-2 MH - Pandemics MH - COVID-19 Vaccines MH - Seroconversion MH - *COVID-19/prevention & control MH - Mental Health MH - Cross-Sectional Studies MH - Quality of Life MH - Tomography, X-Ray Computed MH - Vaccination PMC - PMC9627027 OTO - NOTNLM OT - B.1.617.2 Delta variant OT - COVID-19 OT - SARS-CoV-2 OT - mental health OT - seroconversion time OT - vaccination COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/08 06:00 MHDA- 2022/11/09 06:00 PMCR- 2022/10/19 CRDT- 2022/11/07 04:41 PHST- 2022/06/23 00:00 [received] PHST- 2022/10/03 00:00 [accepted] PHST- 2022/11/07 04:41 [entrez] PHST- 2022/11/08 06:00 [pubmed] PHST- 2022/11/09 06:00 [medline] PHST- 2022/10/19 00:00 [pmc-release] AID - 10.3389/fpubh.2022.974848 [doi] PST - epublish SO - Front Public Health. 2022 Oct 19;10:974848. doi: 10.3389/fpubh.2022.974848. eCollection 2022. PMID- 36288776 OWN - NLM STAT- MEDLINE DCOM- 20250127 LR - 20250513 IS - 2173-5808 (Electronic) IS - 2173-5808 (Linking) VI - 40 IP - 1 DP - 2025 Jan-Feb TI - Neurological manifestations associated with COVID-19 vaccine. PG - 66-76 LID - S2173-5808(22)00141-9 [pii] LID - 10.1016/j.nrleng.2022.09.007 [doi] AB - INTRODUCTION: Coronavirus disease 2019 (COVID-19) has spread rapidly, giving rise to a pandemic, causing significant morbidity and mortality. In this context, many vaccines have emerged to try to deal with this disease. OBJECTIVE: To review the reported cases of neurological manifestations after the application of COVID-19 vaccines, describing clinical, analytical and neuroimaging findings and health outcomes. METHODS: We carried out a review through bibliographic searches in PubMed. RESULTS: We found 86 articles, including 13 809 patients with a wide spectrum of neurological manifestations temporally associated with COVID-19 vaccination. Most occurred in women (63.89%), with a median age of 50 years. The most frequently reported adverse events were Bell's palsy 4936/13 809 (35.7%), headache (4067/13 809), cerebrovascular events 2412/13 809 (17.47%), Guillain-Barre syndrome 868/13 809 (6.28%), central nervous system demyelination 258/13 809 (1.86%) and functional neurological disorder 398/13 809 (2.88%). Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S). CONCLUSIONS: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. However, it is necessary for health professionals to be familiar with these events, facilitating their early diagnosis and treatment. Large controlled epidemiological studies are necessary to establish a possible causal relationship between vaccination against COVID-19 and neurological adverse events. CI - Copyright (c) 2022. Published by Elsevier Espana, S.L.U. FAU - Alonso Castillo, R AU - Alonso Castillo R AD - Servicio de Neurologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. FAU - Martinez Castrillo, J C AU - Martinez Castrillo JC AD - Servicio de Neurologia, Hospital Universitario Ramon y Cajal, Universidad de Alcala, Madrid, Spain. Electronic address: jcmcastrillo@gmail.com. LA - eng PT - Journal Article PT - Review DEP - 20221023 PL - Spain TA - Neurologia (Engl Ed) JT - Neurologia JID - 101778590 RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (BNT162 Vaccine) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *Nervous System Diseases/chemically induced/etiology MH - *COVID-19/prevention & control MH - Female MH - Middle Aged MH - Male MH - Headache/etiology MH - ChAdOx1 nCoV-19/adverse effects MH - BNT162 Vaccine/adverse effects MH - Guillain-Barre Syndrome/etiology MH - SARS-CoV-2 MH - Adult MH - Bell Palsy/etiology PMC - PMC9595420 OTO - NOTNLM OT - Adverse event OT - COVID-19 vaccines OT - Evento adverso OT - Manifestaciones neurologicas OT - Neurological manifestations OT - Neurological pathology OT - Patologia neurologica OT - SARS-COV-2 vaccines OT - Safety OT - Seguridad OT - Vacunas COVID-19 OT - Vacunas SARS-COV-2 EDAT- 2022/10/27 06:00 MHDA- 2025/01/28 00:21 PMCR- 2022/10/23 CRDT- 2022/10/26 19:23 PHST- 2022/07/22 00:00 [received] PHST- 2022/09/28 00:00 [accepted] PHST- 2025/01/28 00:21 [medline] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/26 19:23 [entrez] PHST- 2022/10/23 00:00 [pmc-release] AID - S2173-5808(22)00141-9 [pii] AID - 10.1016/j.nrleng.2022.09.007 [doi] PST - ppublish SO - Neurologia (Engl Ed). 2025 Jan-Feb;40(1):66-76. doi: 10.1016/j.nrleng.2022.09.007. Epub 2022 Oct 23. PMID- 36288544 OWN - NLM STAT- MEDLINE DCOM- 20230503 LR - 20231108 IS - 1460-2156 (Electronic) IS - 0006-8950 (Print) IS - 0006-8950 (Linking) VI - 146 IP - 5 DP - 2023 May 2 TI - Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. PG - 2142-2152 LID - 10.1093/brain/awac384 [doi] LID - awac384 AB - Brain changes have been reported in the first weeks after SARS-CoV-2 infection. However, limited literature exists about brain alterations in post-COVID syndrome, a condition increasingly associated with cognitive impairment. The present study aimed to evaluate brain functional and structural alterations in patients with post-COVID syndrome, and assess whether these brain alterations were related to cognitive dysfunction. Eighty-six patients with post-COVID syndrome and 36 healthy controls were recruited and underwent neuroimaging acquisition and a comprehensive neuropsychological assessment. Cognitive and neuroimaging examinations were performed 11 months after the first symptoms of SARS-CoV-2. Whole-brain functional connectivity analysis was performed. Voxel-based morphometry was performed to evaluate grey matter volume, and diffusion tensor imaging was carried out to analyse white-matter alterations. Correlations between cognition and brain changes were conducted and Bonferroni corrected. Post-COVID syndrome patients presented with functional connectivity changes, characterized by hypoconnectivity between left and right parahippocampal areas, and between bilateral orbitofrontal and cerebellar areas compared to controls. These alterations were accompanied by reduced grey matter volume in cortical, limbic and cerebellar areas, and alterations in white matter axial and mean diffusivity. Grey matter volume loss showed significant associations with cognitive dysfunction. These cognitive and brain alterations were more pronounced in hospitalized patients compared to non-hospitalized patients. No associations with vaccination status were found. The present study shows persistent structural and functional brain abnormalities 11 months after the acute infection. These changes are associated with cognitive dysfunction and contribute to a better understanding of the pathophysiology of the post-COVID syndrome. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. FAU - Diez-Cirarda, Maria AU - Diez-Cirarda M AUID- ORCID: 0000-0001-6768-189X AD - Department of Neurology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Yus, Miguel AU - Yus M AUID- ORCID: 0000-0003-3191-6743 AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Gomez-Ruiz, Natividad AU - Gomez-Ruiz N AUID- ORCID: 0000-0002-1182-5513 AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Polidura, Carmen AU - Polidura C AUID- ORCID: 0000-0003-2021-0374 AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Gil-Martinez, Lidia AU - Gil-Martinez L AUID- ORCID: 0000-0002-9547-5038 AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Delgado-Alonso, Cristina AU - Delgado-Alonso C AUID- ORCID: 0000-0002-8821-1317 AD - Department of Neurology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Jorquera, Manuela AU - Jorquera M AUID- ORCID: 0000-0002-4920-0359 AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Gomez-Pinedo, Ulises AU - Gomez-Pinedo U AUID- ORCID: 0000-0003-3097-5557 AD - Department of Neurology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Matias-Guiu, Jorge AU - Matias-Guiu J AUID- ORCID: 0000-0001-8162-9043 AD - Department of Neurology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Arrazola, Juan AU - Arrazola J AD - Department of Radiology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. FAU - Matias-Guiu, Jordi A AU - Matias-Guiu JA AUID- ORCID: 0000-0001-5520-2708 AD - Department of Neurology, Hospital Clinico San Carlos, Health Research Institute 'San Carlos' (IdISCC), Universidad Complutense de Madrid, 28040 Madrid, Spain. LA - eng PT - Journal Article PL - England TA - Brain JT - Brain : a journal of neurology JID - 0372537 SB - IM CIN - MMW Fortschr Med. 2023 Oct;165(18):34-35. doi: 10.1007/s15006-023-3065-y. PMID: 37828320 MH - Humans MH - Diffusion Tensor Imaging/methods MH - Magnetic Resonance Imaging/methods MH - *COVID-19 MH - SARS-CoV-2 MH - Brain MH - Neuroimaging/methods MH - Cognition/physiology MH - Gray Matter MH - *White Matter MH - Syndrome PMC - PMC9620345 OTO - NOTNLM OT - cognitive impairment OT - functional connectivity OT - grey matter OT - post-COVID syndrome OT - white matter EDAT- 2022/10/27 06:00 MHDA- 2023/05/03 06:42 PMCR- 2022/10/26 CRDT- 2022/10/26 16:12 PHST- 2022/06/03 00:00 [received] PHST- 2022/09/02 00:00 [revised] PHST- 2022/09/23 00:00 [accepted] PHST- 2023/05/03 06:42 [medline] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/26 16:12 [entrez] PHST- 2022/10/26 00:00 [pmc-release] AID - 6775147 [pii] AID - awac384 [pii] AID - 10.1093/brain/awac384 [doi] PST - ppublish SO - Brain. 2023 May 2;146(5):2142-2152. doi: 10.1093/brain/awac384. PMID- 36284639 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240906 IS - 2475-0379 (Electronic) IS - 2475-0379 (Linking) VI - 6 IP - 7 DP - 2022 Oct TI - Hereditary thrombotic thrombocytopenic purpura and COVID-19: Impacts of vaccination and infection in this rare disease. PG - e12814 LID - 10.1002/rth2.12814 [doi] LID - e12814 AB - INTRODUCTION: Severe COVID-19 is associated with an important increase of von Willebrand factor and mild lowering of ADAMTS13 activity that may, in the presence of a strong inflammatory reaction, increase the risk of acute thrombotic thrombocytopenic purpura (TTP). Although acute episodes of immune-mediated TTP associated with COVID-19 or SARS-CoV-2 vaccination have been reported, data about clinical evolution of hereditary TTP (hTTP) during the pandemic are scarce. METHOD: We conducted a survey among adult patients of the International Hereditary TTP Registry about SARS-CoV-2 vaccination, COVID-19, and occurrence of acute hTTP episodes. RESULTS: Of 122 adult hTTP patients invited to participate, 86 (70.5%) responded. Sixty-five had been vaccinated (75.6%), of which 14 had received in addition a booster, resulting in 139 individual vaccine shots. Although vaccinations in patients on plasma prophylaxis were done within 1 week of the last plasma infusion, all 23 patients treated with plasma on demand were vaccinated without prior plasma infusions. One patient on uninterrupted weekly plasma infusions presented within 3 days from his second vaccination with neurological symptoms and computed tomography scan 9 days later showed subacute ischemic/hemorrhagic frontal lobe infarction. A second male patient developed acute myocarditis after his second dose of mRNA-1273 vaccine. Twelve (14%) patients had COVID-19, associated with an acute hTTP episode in three of them: one patient had a transient ischemic attack, one a stroke, and a pregnant woman was hospitalized to intensify plasma treatment. DISCUSSION: The risk of an acute episode triggered by COVID-19 seems higher than following vaccination in hTTP patients, who can be safely vaccinated against SARS-CoV-2. CI - (c) 2022 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH). FAU - Tarasco, Erika AU - Tarasco E AUID- ORCID: 0000-0002-4387-8476 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Department for BioMedical Research (DBMR) University of Bern Bern Switzerland. FAU - von Krogh, Anne Sophie AU - von Krogh AS AD - Department of Hematology St. Olavs Hospital, Trondheim University Hospital Trondheim Norway. AD - Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology Trondheim Norway. FAU - Hrdlickova, Radomira AU - Hrdlickova R AD - Blood Center University Hospital Ostrava Ostrava Czech Republic. FAU - Braschler, Thomas R AU - Braschler TR AD - Center for Clinical Hematology Luzerne Kantonsspital Lucerne Switzerland. FAU - Iwaniec, Teresa AU - Iwaniec T AD - Department of Hematology Jagiellonian University Medical College Krakow Poland. FAU - Knobl, Paul N AU - Knobl PN AUID- ORCID: 0000-0002-7909-7225 AD - Division of Hematology and Hemostasis, Department of Medicine I Medical University of Vienna Vienna Austria. FAU - Hamada, Eriko AU - Hamada E AUID- ORCID: 0000-0003-0913-2475 AD - Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan. FAU - Pikovsky, Oleg AU - Pikovsky O AD - Transfusion Medicine Institute, Faculty of Health Sciences, Ben-Gurion University of the Negev Soroka University Medical Center Beer-Sheva Israel. FAU - Farese, Stefan AU - Farese S AD - Department of Nephrology Burgerspital Solothurn Switzerland. FAU - Gutwein, Odit AU - Gutwein O AD - Department of Hematology Shamir Medical Center Zerifin Israel. FAU - Kessler, Petr AU - Kessler P AD - Department of Hematology and Transfusion Medicine Hospital Pelhrimov Pelhrimov Czech Republic. FAU - Schultz, Nina H AU - Schultz NH AD - Department of Hematology Oslo University Hospital Oslo Norway. FAU - von Auer, Charis AU - von Auer C AD - Department of Hematology, Oncology, and Pneumology, Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany. FAU - Windyga, Jerzy AU - Windyga J AD - Department of Haemostasis Disorders and Internal Medicine Institute of Hematology and Transfusion Medicine Warsaw Poland. FAU - Friedman, Kenneth AU - Friedman K AD - Division of Hematology and Oncology, Versiti Blood Center of Wisconsin Medical College of Wisconsin Milwaukee Wisconsin USA. FAU - Hrachovinova, Ingrid AU - Hrachovinova I AUID- ORCID: 0000-0003-0300-2063 AD - Institute of Hematology and Blood Transfusion Prague Czech Republic. FAU - George, James N AU - George JN AD - Department of Biostatistics & Epidemiology College of Public Health, University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA. FAU - Matsumoto, Masanori AU - Matsumoto M AUID- ORCID: 0000-0002-7243-3126 AD - Department of Blood Transfusion Medicine Nara Medical University Kashihara Japan. FAU - Schneppenheim, Reinhard AU - Schneppenheim R AD - Department of Pediatric Hematology and Oncology University Medical Center Hamburg-Eppendorf Hamburg Germany. FAU - Lammle, Bernhard AU - Lammle B AUID- ORCID: 0000-0003-4538-5154 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Center for Thrombosis and Hemostasis University Medical Center Mainz Mainz Germany. FAU - Kremer Hovinga, Johanna Anna AU - Kremer Hovinga JA AUID- ORCID: 0000-0002-1300-7135 AD - Department of Hematology and Central Hematology Laboratory Inselspital, Bern University Hospital Bern Switzerland. AD - Department for BioMedical Research (DBMR) University of Bern Bern Switzerland. LA - eng PT - Journal Article DEP - 20221021 PL - United States TA - Res Pract Thromb Haemost JT - Research and practice in thrombosis and haemostasis JID - 101703775 PMC - PMC9585384 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - congenital thrombotic thrombocytopenic purpura (cTTP) OT - hereditary thrombotic thrombocytopenic purpura (hTTP) OT - vaccines EDAT- 2022/10/27 06:00 MHDA- 2022/10/27 06:01 PMCR- 2022/10/21 CRDT- 2022/10/26 02:06 PHST- 2022/04/08 00:00 [received] PHST- 2022/06/17 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/10/26 02:06 [entrez] PHST- 2022/10/27 06:00 [pubmed] PHST- 2022/10/27 06:01 [medline] PHST- 2022/10/21 00:00 [pmc-release] AID - S2475-0379(22)02450-5 [pii] AID - RTH212814 [pii] AID - 10.1002/rth2.12814 [doi] PST - epublish SO - Res Pract Thromb Haemost. 2022 Oct 21;6(7):e12814. doi: 10.1002/rth2.12814. eCollection 2022 Oct. PMID- 36253218 OWN - NLM STAT- MEDLINE DCOM- 20230619 LR - 20230621 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 41 IP - 27 DP - 2023 Jun 19 TI - Cognitive predictors of COVID-19 mitigation behaviors in vaccinated and unvaccinated general population members. PG - 4019-4026 LID - S0264-410X(22)01242-7 [pii] LID - 10.1016/j.vaccine.2022.10.004 [doi] AB - BACKGROUND: Given the long-term threat posed by COVID-19, predictors of mitigation behaviors are critical to identify. Prior studies have found that cognitive factors are associated with some COVID-19 mitigation behaviors, but few studies employ representative samples and no prior studies have examined cognitive predictors of vaccination status. The purpose of the present study was to examine associations between cognitive variables (executive function, delay discounting, and future orientation) and COVID-19 mitigation behaviors (mask wearing, social distancing, hand hygiene and vaccination) in a population representative sample. METHODS: A population representative sample of 2,002 adults completed validated measures of delay discounting, future orientation, and executive function. Participants also reported frequency of mitigation behaviors, vaccination status, and demographics. RESULTS: Future orientation was associated with more mask wearing (beta = 0.160, 95 % CI [0.090, 0.220], p < 0.001), social distancing (beta = 0.150, 95 % CI [0.070, 0.240], p < 0.001), hand hygiene behaviors (beta = 0.090, 95 % CI [0.000, 0.190], p = 0.054), and a higher likelihood of being fully vaccinated (OR = 0.80, 95 % CI [0.670, 0.970], p = 0.020). Lower delay discounting predicted more consistent mask wearing (beta = -0.060, 95 % CI[-0.120, -0.010], p = 0.032) and being fully vaccinated (OR = 1.28, 95 % CI [1.13, 1.44], p < 0.001), while more symptoms of executive dysfunction predicted less mask wearing (beta = -0.240, 95 % CI [-0.320, -0.150] p < 0.001) and hand hygiene (beta = -0.220, 95 % CI [-0.320, -0.130], p < 0.001), but not vaccination status (OR = 0.96, 95 % CI [0.80, 1.16], p = 0.690) or social distancing behaviors (beta = -0.080, 95 % CI [-0.180, 0.020], p = 0.097). Overall, social distancing was the least well-predicted outcome from cognitive factors, while mask wearing was most well-predicted. Vaccination status was not a significant moderator of these effects of cognitive predictors on mitigation behaviors. CONCLUSIONS: Cognitive variables predict significant variability in mitigation behaviors. regardless of vaccination status. In particular, thinking about the future and discounting it less may encourage more consistent implementation of mitigating behaviors. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Hudson, Anna AU - Hudson A AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: a3hudson@uwaterloo.ca. FAU - Hall, Peter A AU - Hall PA AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada; Centre for Bioengineering and Biotechnology, University of Waterloo, Waterloo, Ontario, Canada. Electronic address: pahall@uwaterloo.ca. FAU - Hitchman, Sara C AU - Hitchman SC AD - Department of Communication and Media Research, University of Zurich, Zurich, Switzerland. FAU - Meng, Gang AU - Meng G AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Fong, Geoffrey T AU - Fong GT AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada; Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20221013 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 SB - IM MH - Adult MH - Humans MH - *COVID-19/epidemiology/prevention & control MH - Physical Distancing MH - Probability MH - Vaccination MH - Cognition PMC - PMC9556944 OTO - NOTNLM OT - COVID-19 OT - Executive functions OT - Mitigating behaviors OT - SARS-CoV-2 OT - Vaccination COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/10/18 06:00 MHDA- 2023/06/19 13:08 PMCR- 2022/10/13 CRDT- 2022/10/17 22:04 PHST- 2022/04/29 00:00 [received] PHST- 2022/09/19 00:00 [revised] PHST- 2022/10/05 00:00 [accepted] PHST- 2023/06/19 13:08 [medline] PHST- 2022/10/18 06:00 [pubmed] PHST- 2022/10/17 22:04 [entrez] PHST- 2022/10/13 00:00 [pmc-release] AID - S0264-410X(22)01242-7 [pii] AID - 10.1016/j.vaccine.2022.10.004 [doi] PST - ppublish SO - Vaccine. 2023 Jun 19;41(27):4019-4026. doi: 10.1016/j.vaccine.2022.10.004. Epub 2022 Oct 13. PMID- 36231717 OWN - NLM STAT- MEDLINE DCOM- 20221017 LR - 20250623 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 19 DP - 2022 Sep 29 TI - Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. LID - 10.3390/ijerph191912422 [doi] LID - 12422 AB - The coronavirus disease 2019 (COVID-19) is still in a global pandemic state. Some studies have reported that COVID-19 vaccines had a protective effect against long COVID. However, the conclusions of the studies on the effect of COVID-19 vaccines on long COVID were not consistent. This study aimed to systematically review relevant studies in the real world, and performed a meta-analysis to explore the relationship between vaccination and long COVID. We systematically searched PubMed, Embase, Web of science, and ScienceDirect from inception to 19 September 2022. The PICO (P: patients; I: intervention; C: comparison; O: outcome) was as follows: patients diagnosed with COVID-19 (P); vaccination with COVID-19 vaccines (I); the patients were divided into vaccinated and unvaccinated groups (C); the outcomes were the occurrence of long COVID, as well as the various symptoms of long COVID (O). A fixed-effect model and random-effects model were chosen based on the heterogeneity between studies in order to pool the effect value. The results showed that the vaccinated group had a 29% lower risk of developing long COVID compared with the unvaccinated group (RR = 0.71, 95% CI: 0.58-0.87, p < 0.01). Compared with patients who were not vaccinated, vaccination showed its protective effect in patients vaccinated with two doses (RR = 0.83, 95% CI: 0.74-0.94, p < 0.01), but not one dose (RR = 0.83, 95% CI: 0.65-1.07, p = 0.14). In addition, vaccination was effective against long COVD in patients either vaccinated before SARS-CoV-2 infection/COVID-19 (RR = 0.82, 95% CI: 0.74-0.91, p < 0.01) or vaccinated after SARS-CoV-2 infection/COVID-19 (RR = 0.83, 95% CI: 0.74-0.92, p < 0.01). For long COVID symptoms, vaccination reduced the risk of cognitive dysfunction/symptoms, kidney diseases/problems, myalgia, and sleeping disorders/problems sleeping. Our study shows that COVID-19 vaccines had an effect on reducing the risk of long COVID in patients vaccinated before or after SARS-CoV-2 infection/COVID-19. We suggest that the vaccination rate should be improved as soon as possible, especially for a complete vaccination course. There should be more studies to explore the basic mechanisms of the protective effect of COVID-19 vaccines on long COVID in the future. FAU - Gao, Peng AU - Gao P AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. FAU - Liu, Jue AU - Liu J AUID- ORCID: 0000-0002-1938-9365 AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. AD - Institute for Global Health and Development, Peking University, Yiheyuan Road No. 5, Haidian District, Beijing 100871, China. FAU - Liu, Min AU - Liu M AUID- ORCID: 0000-0002-5059-3743 AD - Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Xueyuan Road No. 38, Haidian District, Beijing 100191, China. LA - eng PT - Journal Article PT - Meta-Analysis PT - Research Support, Non-U.S. Gov't PT - Systematic Review DEP - 20220929 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/complications/epidemiology/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Humans MH - SARS-CoV-2 MH - Vaccination MH - Post-Acute COVID-19 Syndrome PMC - PMC9566528 OTO - NOTNLM OT - COVID-19 vaccine OT - long COVID OT - meta-analysis OT - post COVID-19 condition OT - systematic review COIS- The authors declare no conflict of interest. EDAT- 2022/10/15 06:00 MHDA- 2022/10/18 06:00 PMCR- 2022/09/29 CRDT- 2022/10/14 02:00 PHST- 2022/09/06 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/14 02:00 [entrez] PHST- 2022/10/15 06:00 [pubmed] PHST- 2022/10/18 06:00 [medline] PHST- 2022/09/29 00:00 [pmc-release] AID - ijerph191912422 [pii] AID - ijerph-19-12422 [pii] AID - 10.3390/ijerph191912422 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Sep 29;19(19):12422. doi: 10.3390/ijerph191912422. PMID- 36213920 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221011 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 13 DP - 2022 TI - Believing processes around COVID-19 vaccination: An exploratory study investigating workers in the health sector. PG - 993323 LID - 10.3389/fpsyt.2022.993323 [doi] LID - 993323 AB - BACKGROUND: The processes underlying believing have been labeled "creditions", which are important brain functions between emotion and cognition. Creditions are influenced by both internal and external factors, one of which is the coronavirus disease 2019 (COVID-19) pandemic and the vaccination against the disease. METHODS: To investigate believing processes shortly before the implementation of a mandatory vaccination in Austria, both vaccinated and unvaccinated workers in the health sector (WHS) were surveyed in December 2021/January 2022. In total, 1,062 vaccinated and 97 unvaccinated WHS (920 females) completed the online survey. Beliefs were assessed using the parameters of the credition model (narrative, certainty, emotion, and mightiness) with regard to (1) the COVID-19 pandemic in general, and (2) the vaccination. Type of emotion and narrative were divided into positive, negative, and indifferent. Moreover, the congruence between emotion and narrative was calculated. RESULTS: The vaccination rate of the sample was 91.6%, with a significantly higher percentage of men being in the group of vaccinated (21.1%) as compared to unvaccinated individuals (12.4%). Pertaining beliefs about the COVID-19 vaccination, unvaccinated WHS reported more negative and less positive emotions as well as content of narrative than vaccinated WHS. In addition, they showed higher levels of certainty as well as mightiness while believing and felt less sufficiently informed about governmental and workplace-related COVID-19 measures. The groups did not differ in the type of emotion or content of narrative in their beliefs about the pandemic in general. CONCLUSION: In conclusion, unvaccinated WHS had more negative and less positive emotions and thoughts than vaccinated WHS in their beliefs about the COVID-19 vaccination and their motivations for not having received it. They were more certain about their beliefs and felt stronger negative emotions in their beliefs compared to vaccinated individuals. Providing unvaccinated WHS with adequate information might be helpful in reducing their mental burden. CI - Copyright (c) 2022 Fleischmann, Fellendorf, Schonthaler, Lenger, Hiendl, Bonkat, Wagner-Skacel, Bengesser, Angel, Seitz, Reininghaus and Dalkner. FAU - Fleischmann, Eva AU - Fleischmann E AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Fellendorf, Frederike AU - Fellendorf F AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Schonthaler, Elena M AU - Schonthaler EM AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Lenger, Melanie AU - Lenger M AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Hiendl, Lena AU - Hiendl L AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Bonkat, Nina AU - Bonkat N AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Wagner-Skacel, Jolana AU - Wagner-Skacel J AD - Department of Medical Psychology and Psychotherapy, Medical University of Graz, Graz, Austria. FAU - Bengesser, Susanne AU - Bengesser S AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Angel, Hans-Ferdinand AU - Angel HF AD - Department of Catechetics and Religious Education, Karl-Franzens-University of Graz, Graz, Austria. FAU - Seitz, Rudiger J AU - Seitz RJ AD - Department of Neurology, Medical Faculty, Centre of Neurology and Neuropsychiatry, LVR-Klinikum Dusseldorf, Heinrich-Heine-University of Dusseldorf, Dusseldorf, Germany. FAU - Reininghaus, Eva Z AU - Reininghaus EZ AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. FAU - Dalkner, Nina AU - Dalkner N AD - Department of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. LA - eng PT - Journal Article DEP - 20220921 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC9532762 OTO - NOTNLM OT - COVID-19 vaccination OT - beliefs OT - cognition OT - credition OT - emotion OT - workers in the health sector COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/11 06:00 MHDA- 2022/10/11 06:01 PMCR- 2022/09/21 CRDT- 2022/10/10 04:39 PHST- 2022/07/13 00:00 [received] PHST- 2022/08/30 00:00 [accepted] PHST- 2022/10/10 04:39 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/11 06:01 [medline] PHST- 2022/09/21 00:00 [pmc-release] AID - 10.3389/fpsyt.2022.993323 [doi] PST - epublish SO - Front Psychiatry. 2022 Sep 21;13:993323. doi: 10.3389/fpsyt.2022.993323. eCollection 2022. PMID- 36211689 OWN - NLM STAT- MEDLINE DCOM- 20221011 LR - 20250530 IS - 2296-2565 (Electronic) IS - 2296-2565 (Linking) VI - 10 DP - 2022 TI - COVID-19 vaccination roll-outs in eleven small countries within the WHO European region; Lessons learned. PG - 959227 LID - 10.3389/fpubh.2022.959227 [doi] LID - 959227 AB - The development and administration of COVID-19 vaccines has been an essential element in controlling the COVID-19 pandemic. However, countries worldwide have faced challenges in planning and implementing vaccination strategies. The aim of the current paper is to describe the situation faced by small countries in the WHO European Region in implementing their national vaccination strategies during the first stages of the planned roll-out (up to May 2021). This paper uses information from the WHO Small Countries Initiative (SCI), which includes a network of 11 countries with populations of 71 yrs. (cases, 23.2%; controls, 13.5%; OR, 3.31; 95% CI, 1.28-8.55), presence of diabetes mellitus (37.9% vs. 24%; OR, 1.9; 95% CI, 1.2-3.1), admission hyperglycemia (BSR 351-600 mg/dl), (29.5% vs. 7.6%; OR, 3.11; 95%CI, 1.54-6.33), raised D-dimer levels 5000-10,000 ng/ml (41% vs. 11.8%; OR, 5.2; 95% CI, 3.02-8.9), prophylactic dose anticoagulation (43.2% vs. 28.1%; OR, 1.9; 95%CI, 1.2-3.1), and unvaccinated status of COVID-19 patients (90.5% vs. 75.6%; OR, 3.01; 95% CI, 1.44-6.25). Neurological complications with COVID-19 were associated with increased likelihood of death or invasive mechanical ventilation by day 28 (86.3% vs. 45.1%; OR, 7.66; 95% CI, 4.08-14.4). In case-only analysis (median age, 56 years [IQR, 27,110]; 50.5% women), 67 (70.5%) had CVE, 21 (22.1%) had Encephalitis, and 7 (7.4%) had GBS as neurological manifestations. 28-day mortality among these patients was strongly associated with a lower likelihood of vaccination. (6.1% cases vs. 30.8% controls; OR, .146; 95%CI, .033- .64), being younger 17-45 yrs. (12.2% vs. 46.2%; OR, .162; 95%CI, .045-.58), having no comorbid condition (19.5% vs. 61.5%; OR, .151; 95%CI, .044- .525), having cerebrovascular events and GBS as type of neurological manifestation (76.8% vs.30.8%; OR, 7.46; 95%CI, 2.06-26.96), (2.4% vs. 38.4%; OR, .04; 95%CI, .007- 0.24) respectively, and presence of hypoxemia at admission (91.5% vs. 15.4%; OR, 58.92; 95%CI, 10.83-320.67). CONCLUSION: Old age, presence of Diabetes Mellitus, unvaccinated status of patients, high BSR at admission, high D-dimers, and prophylactic dose anticoagulation were identifies as increased risk factors for developing serious neurological complications among COVID-19 patients. Neurological problems in COVID-19 patients raised death risk 7.6-fold. The most common neurological complication was cerebrovascular events, followed by encephalitis and GBS. Unvaccinated status, cerebrovascular events, and admission hypoxemia are associated with an increased likelihood of 28-day mortality among these patients. FAU - Aslam, Javaria AU - Aslam J AUID- ORCID: 0000-0003-3777-3165 AD - Department of Medicine, Qauid e Azam Medical College, Bahawalpur, Pakistan. AD - Department of Medicine, Sir, Sadiq Abbasi Hospital, Qauid e Azam Medical College, Bahawalpur, Pakistan. FAU - Luqman, Shoaib AU - Luqman S AD - Department of Neurology, Qauid e Azam Medical College, Bahawalpur, Pakistan. FAU - Nazly, Sadaf AU - Nazly S AD - Department of Medicine, Sir, Sadiq Abbasi Hospital, Qauid e Azam Medical College, Bahawalpur, Pakistan. FAU - Saeed, Alina AU - Saeed A AD - Department of Medicine, Sir, Sadiq Abbasi Hospital, Qauid e Azam Medical College, Bahawalpur, Pakistan. FAU - Tariq, Muhammad Sohail AU - Tariq MS AD - Department of Medicine, Qauid e Azam Medical College, Bahawalpur, Pakistan. FAU - Alfaife, Sultan Yahya Mohammad AU - Alfaife SYM AD - Department of General Medicine, General Directorate of Health Affairs, Aseer Region, Ministry of Health, Abha, Saudi Arabia. FAU - Aneela, Irrum AU - Aneela I AD - Department of Rehabilitation Medicine, Astley Ainslie Hospital, Edinburg, Scotland, United Kingdom. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220926 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Anticoagulants) RN - 0 (Blood Glucose) SB - IM MH - Aged MH - Anticoagulants MH - Blood Glucose MH - *COVID-19/complications MH - Case-Control Studies MH - *Diabetes Mellitus/epidemiology MH - *Encephalitis MH - Female MH - Hospitalization MH - Humans MH - Hypoxia MH - Male MH - Middle Aged MH - *Nervous System Diseases/epidemiology/etiology MH - Retrospective Studies MH - SARS-CoV-2 PMC - PMC9512176 COIS- The authors have declared that no competing interests exist. EDAT- 2022/09/27 06:00 MHDA- 2022/09/28 06:00 PMCR- 2022/09/26 CRDT- 2022/09/26 16:43 PHST- 2022/03/02 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/09/26 16:43 [entrez] PHST- 2022/09/27 06:00 [pubmed] PHST- 2022/09/28 06:00 [medline] PHST- 2022/09/26 00:00 [pmc-release] AID - PONE-D-22-05696 [pii] AID - 10.1371/journal.pone.0274485 [doi] PST - epublish SO - PLoS One. 2022 Sep 26;17(9):e0274485. doi: 10.1371/journal.pone.0274485. eCollection 2022. PMID- 36137317 OWN - NLM STAT- MEDLINE DCOM- 20231023 LR - 20260127 IS - 1879-0534 (Electronic) IS - 0010-4825 (Print) IS - 0010-4825 (Linking) VI - 150 DP - 2022 Nov TI - Network analysis between neuron dysfunction and neuroimmune response based on neural single-cell transcriptome of COVID-19 patients. PG - 106055 LID - S0010-4825(22)00768-5 [pii] LID - 10.1016/j.compbiomed.2022.106055 [doi] AB - Despite global vaccination efforts, COVID-19 breakthrough infections caused by variant virus continue to occur frequently, long-term sequelae of COVID-19 infection like neuronal dysfunction emerge as a noteworthy issue. Neuroimmune disorder induced by Inflammatory factor storm was considered as a possible reason, however, little was known about the functional factors affecting neuroimmune response to this virus. Here, using medial prefrontal cortex single cell data of COVID-19 patients, expression pattern analysis indicated that some immune-related pathway genes expressed specifically, including genes associated with T cell receptor, TNF signaling in microglia and Cytokine-cytokine receptor interaction and HIF-1 signaling pathway genes in astrocytes. Besides the well-known immune-related cell type microglia, we also observed immune-related factors like IL17D, TNFRSF1A and TLR4 expressed in Astrocytes. Based on the ligand-receptor relationship of immune-related factors, crosstalk landscape among cell clusters were analyzed. The findings indicated that astrocytes collaborated with microglia and affect excitatory neurons, participating in the process of immune response and neuronal dysfunction. Moreover, subset of astrocytes specific immune factors (hinged neuroimmune genes) were proved to correlate with Covid-19 infection and ventilator-associated pneumonia using multi-tissue RNA-seq and scRNA-seq data. Function characterization clarified that hinged neuroimmune genes were involved in activation of inflammation and hypoxia signaling pathways, which could lead to hyper-responses related neurological sequelae. Finally, a risk model was constructed and testified in RNA-seq and scRNA data of peripheral blood. CI - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Lin, Xiaoyu AU - Lin X AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Nie, Huan AU - Nie H AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Tang, Ran AU - Tang R AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Wang, Pingping AU - Wang P AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Jin, Xiyun AU - Jin X AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Jiang, Qinghua AU - Jiang Q AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. FAU - Han, Fang AU - Han F AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. Electronic address: hanfang@hit.edu.cn. FAU - Chen, Na AU - Chen N AD - Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China; Department of Hematology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, 250021, Shandong, China. Electronic address: nachen1982@126.com. FAU - Li, Yu AU - Li Y AD - School of Life Science and Technology, Harbin Institute of Technology, Harbin, 150000, China. Electronic address: liyugene@hit.edu.cn. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220910 PL - United States TA - Comput Biol Med JT - Computers in biology and medicine JID - 1250250 RN - 0 (Cytokines) RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - *Transcriptome/genetics MH - *COVID-19/genetics MH - Neurons/metabolism MH - Cytokines/metabolism MH - Breakthrough Infections PMC - PMC9462930 OTO - NOTNLM OT - COVID-19 OT - Neural sequelae OT - Neuroimmune characteristics OT - Risk model OT - scRNA-seq COIS- Declaration of competing interest The authors declare no competing interests. EDAT- 2022/09/23 06:00 MHDA- 2023/10/23 00:43 PMCR- 2022/09/10 CRDT- 2022/09/22 18:13 PHST- 2022/07/07 00:00 [received] PHST- 2022/08/21 00:00 [revised] PHST- 2022/08/27 00:00 [accepted] PHST- 2023/10/23 00:43 [medline] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/09/22 18:13 [entrez] PHST- 2022/09/10 00:00 [pmc-release] AID - S0010-4825(22)00768-5 [pii] AID - 106055 [pii] AID - 10.1016/j.compbiomed.2022.106055 [doi] PST - ppublish SO - Comput Biol Med. 2022 Nov;150:106055. doi: 10.1016/j.compbiomed.2022.106055. Epub 2022 Sep 10. PMID- 36136251 OWN - NLM STAT- MEDLINE DCOM- 20221129 LR - 20240908 IS - 1568-5608 (Electronic) IS - 0925-4692 (Print) IS - 0925-4692 (Linking) VI - 30 IP - 6 DP - 2022 Dec TI - Glycyrrhizin and boswellic acids, the golden nutraceuticals: multitargeting for treatment of mild-moderate COVID-19 and prevention of post-COVID cognitive impairment. PG - 1977-1992 LID - 10.1007/s10787-022-01062-3 [doi] AB - Breakthrough infections have been reported in fully vaccinated persons. Furthermore, rebound symptoms have been reported following the new FDA granted emergency use to combat SARS-CoV-2. Glycyrrhizin (GR) and boswellic acids (BAs) combination has been shown to have highly successful actions against COVID-19 in our recent clinical trial. However, the study is limited by the small sample size, and therefore, the aim of this article is to comprehensively evaluate recent evidence on the efficacy of GR and BAs in preventing the development of COVID-19 in patients with mild and moderate infections and in preventing post-COVID-19 cognitive impairment, which is the most important symptom after recovery from Covid-19 disease. We have reviewed and discussed information published since the outbreak of the COVID-19 pandemic until July 2022 on preclinical (in vivo, in vivo and bioinformatics) and clinical studies related to the antiviral, anti-inflammatory and immunomodulatory activity of Gr and BAs. Sixteen studies were performed to determine the efficacy of GR against SARS-CoV-2. Ten studies were used primarily for in vitro and in vivo assays and six used molecular docking studies. However, the antiviral activity of BAs against SARS-CoV-2 was determined in only five studies using molecular modeling and bioinformatics. All these studies confirmed that GR n and BAs have strong antiviral activity and can be used as a therapeutic agent for COVID-19 and as a protective agent against SARS-CoV-2. They may act by inhibiting the main protease SARS-CoV-2 (Mpro) responsible for replication and blocking spike protein-mediated cell entry. Only seven rigorously designed clinical trials regarding the usefulness of GR, BAs or their combinations in the treatment of COVID-19 have been published as of July 2022. Although there is no clinical study regarding the treatment of cognitive impairment after COVID-19 that has been published so far, several preclinical and clinical studies have demonstrated the potential effect of GR and BAs in the prevention and treatment of cognitive impairment by inhibiting the activity of several molecules that activate inflammatory signaling pathway. In conclusion, the findings of our study documented the beneficial use of GR and BAs to treat SARS-CoV-2 and its variants and prevent post-COVID cognitive impairment. However, it warrants further studies with a larger randomized sample size to ensure that the studies have sufficient evidence of benefits against COVID-19 and post-COVID-19 symptoms. CI - (c) 2022. The Author(s). FAU - Gomaa, Adel A AU - Gomaa AA AUID- ORCID: 0000-0002-6462-0917 AD - Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt. a.gomma@aun.edu.eg. FAU - Abdel-Wadood, Yasmin A AU - Abdel-Wadood YA AD - Faculty of Agriculture, Assiut University, Assiut, Egypt. FAU - Gomaa, Mohamed A AU - Gomaa MA AD - Department of Plastic Surgery, Faculty Medicine, Assiut University, Assiut, Egypt. LA - eng PT - Journal Article PT - Review DEP - 20220922 PL - Switzerland TA - Inflammopharmacology JT - Inflammopharmacology JID - 9112626 RN - 6FO62043WK (Glycyrrhizic Acid) RN - 0 (Antiviral Agents) SB - IM MH - Humans MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - Glycyrrhizic Acid/pharmacology/therapeutic use MH - Molecular Docking Simulation MH - Antiviral Agents MH - *Cognitive Dysfunction MH - Dietary Supplements MH - *COVID-19 Drug Treatment PMC - PMC9493173 OTO - NOTNLM OT - Antiinflammatory OT - Antiviral OT - Boswellic acids OT - COVID-19 OT - Clinical trials OT - Cognitive impairment OT - Glycyrrhizin COIS- The author declares no conflict of interest. EDAT- 2022/09/23 06:00 MHDA- 2022/11/30 06:00 PMCR- 2022/09/22 CRDT- 2022/09/22 11:19 PHST- 2022/08/10 00:00 [received] PHST- 2022/08/18 00:00 [accepted] PHST- 2022/09/23 06:00 [pubmed] PHST- 2022/11/30 06:00 [medline] PHST- 2022/09/22 11:19 [entrez] PHST- 2022/09/22 00:00 [pmc-release] AID - 10.1007/s10787-022-01062-3 [pii] AID - 1062 [pii] AID - 10.1007/s10787-022-01062-3 [doi] PST - ppublish SO - Inflammopharmacology. 2022 Dec;30(6):1977-1992. doi: 10.1007/s10787-022-01062-3. Epub 2022 Sep 22. PMID- 36128311 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220922 IS - 1016-1430 (Print) IS - 2251-6840 (Electronic) IS - 1016-1430 (Linking) VI - 36 DP - 2022 TI - Bell's Palsy and COVID-19 Vaccination: A Systematic Review. PG - 85 LID - 10.47176/mjiri.36.85 [doi] LID - 85 AB - Background: Bell's palsy is a rare adverse event reported in COVID-19 vaccines. Given the importance of neurological manifestations, the necessity to highlight and scrutinize the incidence of them following COVID-19 vaccination is needed. This study aimed to systematically review the reported cases of Bell's palsy following vaccination against COVID-19. Methods: This systematic review is conducted based on the Cochrane Collaboration Handbook and PRISMA Statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyzes) and using the Joanna Briggs Institute (JBI) methodology for systematic reviews. The inclusion criteria for the included published studies were patient age >/=18 years, history of Bell's palsy after COVID-19 vaccination and established diagnosis in the patients with COVID-19 vaccination. The exclusion criteria were repeated cases and missing clinical information. The search strategy aimed to find both published and unpublished studies in August 2021 and updated by hand searching in May 2022 using the identified keywords and index terms in Cochrane Library, MEDLINE (PubMed), Web of Science, Scopus, ProQuest, and Google scholar. Finally, the reference lists of all identified reports and articles were searched for additional studies. The JBI critical appraisal tools for case reports or case series were used to assess the risk of bias in the included studies. Results: During the electronic search, hand search, and reference check, we identified 1281 citations, and in hand searching, we detected additional 15 studies. After omitting duplicated citations and assessing the title, abstract, and full text 15 case-report and two case-series studies were included for the critical appraisal process and were included in this study. Pfizer and Moderna vaccines were the most common vaccines among articles that reported the cases of Bell's palsy. Left-sided paralysis was more common than right-sided paralysis. The interval between receiving the vaccine and the onset of facial weakness was between 1 and 48 days. Conclusion: Further studies with larger sample sizes are necessary to assess the association between Bell's palsy and the dose-response of the COVID-19 vaccine. CI - (c) 2022 Iran University of Medical Sciences. FAU - Shahsavarinia, Kavous AU - Shahsavarinia K AD - Emergency and trauma care research center, Tabriz University of Medical Sciences, Tabriz, Iran. AD - Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Mahmoodpoor, Ata AU - Mahmoodpoor A AD - Department of Anesthesiology, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Sadeghi-Ghyassi, Fatemeh AU - Sadeghi-Ghyassi F AD - Faculty of Management & Medical Informatics Tabriz University of Medical Science, Tabriz, Iran. FAU - Nedayi, Arezou AU - Nedayi A AD - Emergency and trauma care research center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Razzaghi, Alireza AU - Razzaghi A AD - Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Zehi Saadat, Mahsa AU - Zehi Saadat M AD - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. FAU - Salehi-Pourmehr, Hanieh AU - Salehi-Pourmehr H AUID- ORCID: 0000-0001-9030-2106 AD - Research center for Evidence-Based Medicine, Iranian EBM Center: A Joanna Briggs Institute Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran. LA - eng PT - Journal Article PT - Review DEP - 20220730 PL - Iran TA - Med J Islam Repub Iran JT - Medical journal of the Islamic Republic of Iran JID - 8910777 PMC - PMC9448503 OTO - NOTNLM OT - Bell's Palsy OT - COVID-19 Vaccination OT - Systematic Review COIS- The authors declare that they have no competing interests. EDAT- 2022/09/22 06:00 MHDA- 2022/09/22 06:01 PMCR- 2022/07/30 CRDT- 2022/09/21 01:58 PHST- 2022/01/27 00:00 [received] PHST- 2022/07/30 00:00 [accepted] PHST- 2022/09/21 01:58 [entrez] PHST- 2022/09/22 06:00 [pubmed] PHST- 2022/09/22 06:01 [medline] PHST- 2022/07/30 00:00 [pmc-release] AID - 10.47176/mjiri.36.85 [doi] PST - epublish SO - Med J Islam Repub Iran. 2022 Jul 30;36:85. doi: 10.47176/mjiri.36.85. eCollection 2022. PMID- 36121081 OWN - NLM STAT- MEDLINE DCOM- 20221215 LR - 20230123 IS - 1873-5592 (Electronic) IS - 1389-4501 (Linking) VI - 23 IP - 17 DP - 2022 TI - Neurological Complications of SARS-CoV-2 Infection and COVID-19 Vaccines: From Molecular Mechanisms to Clinical Manifestations. PG - 1620-1638 LID - 10.2174/1389450123666220919123029 [doi] AB - Coronavirus Disease 2019 (COVID-19) is an infectious disease, caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), that reached pandemic proportions in 2020. Despite the fact that it was initially characterized by pneumonia and acute respiratory distress syndrome, it is now clear that the nervous system is also compromised in one third of these patients. Indeed, a significant proportion of COVID-19 patients suffer nervous system damage via a plethora of mechanisms including hypoxia, coagulopathy, immune response to the virus, and the direct effect of SARS-CoV-2 on endothelial cells, neurons, astrocytes, pericytes and microglia. Additionally, a low number of previously healthy individuals develop a variety of neurological complications after receiving COVID-19 vaccines and a large proportion of COVID-19 survivors experience longlasting neuropsychiatric symptoms. In conclusion, COVID-19 is also a neurological disease, and the direct and indirect effects of the virus on the nervous system have a significant impact on the morbidity and mortality of these patients. Here we will use the concept of the neurovascular unit, assembled by endothelial cells, basement membrane, perivascular astrocytes, neurons and microglia, to review the effects of SARS-CoV-2 in the nervous system. We will then use this information to review data published to this date on the neurological manifestations of COVID-19, the post- COVID syndrome and COVID-19 vaccines. CI - Copyright(c) Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. FAU - Yepes, Manuel AU - Yepes M AD - Division of Neuropharmacology and Neurologic Diseases, Yerkes National Primate Research Center, Atlanta, GA, USA. AD - Department of Neurology & Center for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA, USA. AD - Department of Neurology, Veterans Affairs Medical Center, Atlanta, GA, USA. LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, U.S. Gov't, Non-P.H.S. PL - United Arab Emirates TA - Curr Drug Targets JT - Current drug targets JID - 100960531 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/complications/prevention & control MH - SARS-CoV-2 MH - Endothelial Cells OTO - NOTNLM OT - COVID vaccines OT - COVID-19 OT - SARS-CoV-2 OT - coagulopathy OT - coronavirus OT - neurovascular unit OT - post-COVID EDAT- 2022/09/20 06:00 MHDA- 2022/12/15 06:00 CRDT- 2022/09/19 07:03 PHST- 2022/02/04 00:00 [received] PHST- 2022/05/31 00:00 [revised] PHST- 2022/07/26 00:00 [accepted] PHST- 2022/09/20 06:00 [pubmed] PHST- 2022/12/15 06:00 [medline] PHST- 2022/09/19 07:03 [entrez] AID - CDT-EPUB-126391 [pii] AID - 10.2174/1389450123666220919123029 [doi] PST - ppublish SO - Curr Drug Targets. 2022;23(17):1620-1638. doi: 10.2174/1389450123666220919123029. PMID- 36109857 OWN - NLM STAT- MEDLINE DCOM- 20220919 LR - 20221210 IS - 1945-7359 (Electronic) IS - 1087-3244 (Linking) VI - 46 IP - 4 DP - 2022 Sep 1 TI - Influence of Media Framing on Cognition of COVID-19 Vaccine Effectiveness: The Mediating Role of Emotions. PG - 423-441 LID - 10.5993/AJHB.46.4.4 [doi] AB - Objectives: From the perspective of media framing, this paper explores how factual frame and influence frame affect the cognition of vaccine effectiveness among Chinese netizens, and how emotions vary in the process and act on the cognition. Methods: We first discuss the theoretical framework and propose hypotheses. Drawing on the cognitive theory of emotions and the Pleasure- Arousal-Dominance (PAD) model, the scale and questionnaire were designed, and used to test the influence of media framing over the cognition of vaccine effectiveness by 2-factor ANOVA and Bootstrap methods. Results: The proposed hypotheses were verified. The perceived effectiveness of domestic vaccines corresponding to the factual frame group was on average 0.19 (95% CI 0.641-0.642) higher than that of the influence frame. The impact on audience cognition from reports of positive tendency was on average 0.642 (95% CI 0.641-0.642) higher than that of negative tendency. The indirect effect of the media frame on the perceived effectiveness through the mediating variable emotion was -0.0923, at the 95% level. Conclusions: The audience can understand the effectiveness of COVID-19 vaccines better if the factual frame with actual data and authoritative opinions is adopted, rather than reports of the effects of the vaccines on the virus, the vaccinated, and society. Moreover, media reports should be more positive to mitigate the negative emotions, stimulate the arousal of public opinions, and improve audience cognition of report contents, thereby encouraging vaccine uptake. FAU - Zhang, Wei AU - Zhang W AD - Wei Zhang, School of information, Central University of Finance and Economics, Beijing, China. FAU - Yang, Xinrui AU - Yang X AD - Xinrui Yang, School of information, Central University of Finance and Economics, Beijing, China. FAU - Tao, Kexin AU - Tao K AD - Kexin Tao, School of Information, Central University of Finance and Economics, Beijing, China. FAU - Zhu, Yanchun AU - Zhu Y AD - Yanchun Zhu, Business School, Beijing Normal University, Beijing, China;, Email: zhuyanchun@bnu.edu.cn. FAU - Zhang, Mei AU - Zhang M AD - Mei Zhang, School of Sociology and Psychology, Central University of Finance and Economics, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Am J Health Behav JT - American journal of health behavior JID - 9602338 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Cognition MH - Emotions MH - Humans MH - Surveys and Questionnaires EDAT- 2022/09/17 06:00 MHDA- 2022/09/20 06:00 CRDT- 2022/09/16 00:32 PHST- 2022/09/16 00:32 [entrez] PHST- 2022/09/17 06:00 [pubmed] PHST- 2022/09/20 06:00 [medline] AID - 10.5993/AJHB.46.4.4 [doi] PST - ppublish SO - Am J Health Behav. 2022 Sep 1;46(4):423-441. doi: 10.5993/AJHB.46.4.4. PMID- 36087300 OWN - NLM STAT- MEDLINE DCOM- 20230110 LR - 20250623 IS - 1865-7125 (Electronic) IS - 0341-0382 (Linking) VI - 78 IP - 1-2 DP - 2023 Jan 27 TI - Covid-19 vaccines and neurological complications: a systematic review. PG - 1-8 LID - 10.1515/znc-2022-0092 [doi] AB - The COVID-19 mainly causes respiratory disorders with high infection and severe morbidity and mortality. Neurologists have concerns about potential neurological side effects, profits, and timing of COVID-19 vaccines. This study aimed to review systematically research for the COVID-19 vaccine and neurological complications. Data was searched in Scopus, ISI web of knowledge, Medline, PubMed, Wiley, Embase, International Clinical Trials Registry Platform and Clinical Trials, Cochrane Library, and Google Scholar. Two reviewer authors individually searched and assessed the titles and abstracts of all articles. The third reviewer resolved disagreement between them. Data were documented regarding study location, study design, type of complications, number of patients, various types of COVID-19 vaccine, and type of neurological complications. Six studies in COVID-19 vaccine and neurological complications include two studies about neurological manifestations after the mRNA vaccines, four records about side effects of vector-based vaccine were included in the study. The main neurological complication associated mRNA vaccines were body aches, paresthesia, and difficulty walking, erythema migrans lesion, fatigue, myalgia, and pain in the left lateral deltoid region. The major neurological complication related to vector-based vaccines were urinary retention difficulty, feeding and ambulating, arm soreness, mild fatigue, chills, left-sided facial droop, headaches, a generalized epileptic seizure, hemianopia, and mild aphasia, acute somnolence and right-hand hemiparesis, acute transverse myelitis, deep vein thrombosis in her left leg, a vigilance disorder and a twitching, a severe immobilizing opsoclonus myoclonus syndrome, and encephalitis. A large spectrum of severe neurological unfavorable has been reported. These complications could occur as a result of molecular stimulation and later neuronal damage. Generally, the advantages of COVID-19 vaccination are dominant on the risks of a neurological complication at both individual and population levels. Future investigations will be required to find any relationship between neurological complications and COVID-19 vaccines principally as new strains of the virus and new vaccines are technologically advanced against them. CI - (c) 2022 Walter de Gruyter GmbH, Berlin/Boston. FAU - Allahyari, Fakhri AU - Allahyari F AUID- ORCID: 0000-0001-7088-2588 AD - Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. FAU - Molaee, Hamideh AU - Molaee H AD - Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. FAU - Hosseini Nejad, Javad AU - Hosseini Nejad J AUID- ORCID: 0000-0003-1770-2968 AD - Neuroscience Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220912 PL - Germany TA - Z Naturforsch C J Biosci JT - Zeitschrift fur Naturforschung. C, Journal of biosciences JID - 8912155 RN - 0 (COVID-19 Vaccines) SB - IM MH - Humans MH - Female MH - *COVID-19 Vaccines/adverse effects MH - *COVID-19/prevention & control OTO - NOTNLM OT - Covid-19 vaccine OT - complication OT - neurological OT - neuron OT - side effect EDAT- 2022/09/11 06:00 MHDA- 2023/01/11 06:00 CRDT- 2022/09/10 12:53 PHST- 2022/04/19 00:00 [received] PHST- 2022/08/09 00:00 [accepted] PHST- 2022/09/11 06:00 [pubmed] PHST- 2023/01/11 06:00 [medline] PHST- 2022/09/10 12:53 [entrez] AID - znc-2022-0092 [pii] AID - 10.1515/znc-2022-0092 [doi] PST - epublish SO - Z Naturforsch C J Biosci. 2022 Sep 12;78(1-2):1-8. doi: 10.1515/znc-2022-0092. Print 2023 Jan 27. PMID- 36053197 OWN - NLM STAT- MEDLINE DCOM- 20230216 LR - 20260518 IS - 1460-2393 (Electronic) IS - 1460-2725 (Print) IS - 1460-2393 (Linking) VI - 116 IP - 1 DP - 2023 Feb 14 TI - Vaccination saves lives: a real-time study of patients with chronic diseases and severe COVID-19 infection. PG - 47-56 LID - 10.1093/qjmed/hcac202 [doi] LID - hcac202 AB - OBJECTIVES: This study aims to describe the demographic and clinical profile and ascertain the determinants of outcome among hospitalized coronavirus disease 2019 (COVID-19) adult patients enrolled in the National Clinical Registry for COVID-19 (NCRC). METHODS: NCRC is an on-going data collection platform operational in 42 hospitals across India. Data of hospitalized COVID-19 patients enrolled in NCRC between 1st September 2020 to 26th October 2021 were examined. RESULTS: Analysis of 29 509 hospitalized, adult COVID-19 patients [mean (SD) age: 51.1 (16.2) year; male: 18 752 (63.6%)] showed that 15 678 (53.1%) had at least one comorbidity. Among 25 715 (87.1%) symptomatic patients, fever was the commonest symptom (72.3%) followed by shortness of breath (48.9%) and dry cough (45.5%). In-hospital mortality was 14.5% (n = 3957). Adjusted odds of dying were significantly higher in age group >/=60 years, males, with diabetes, chronic kidney diseases, chronic liver disease, malignancy and tuberculosis, presenting with dyspnoea and neurological symptoms. WHO ordinal scale 4 or above at admission carried the highest odds of dying [5.6 (95% CI: 4.6-7.0)]. Patients receiving one [OR: 0.5 (95% CI: 0.4-0.7)] or two doses of anti-SARS CoV-2 vaccine [OR: 0.4 (95% CI: 0.3-0.7)] were protected from in-hospital mortality. CONCLUSIONS: WHO ordinal scale at admission is the most important independent predictor for in-hospital death in COVID-19 patients. Anti-SARS-CoV2 vaccination provides significant protection against mortality. CI - (c) The Author(s) 2022. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For permissions, please email: journals.permissions@oup.com. FAU - Mukherjee, A AU - Mukherjee A AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Kumar, G AU - Kumar G AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Turuk, A AU - Turuk A AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Bhalla, A AU - Bhalla A AD - Postgraduate Institute of Medical Education & Research, Chandigarh, India. FAU - Bingi, T C AU - Bingi TC AD - Gandhi Medical College, Telangana, India. FAU - Bhardwaj, P AU - Bhardwaj P AD - All Indian Institute of Medical Sciences, Jodhpur, Rajasthan, India. FAU - Baruah, T D AU - Baruah TD AD - All Indian Institute of Medical Sciences, Raipur, Chhattisgarh, India. FAU - Mukherjee, S AU - Mukherjee S AD - College of Medicine, Sagore Dutta Hospital, Kolkata, West Bengal, India. FAU - Talukdar, A AU - Talukdar A AD - Medical College, Kolkata, West Bengal, India. FAU - Ray, Y AU - Ray Y AD - Infectious Disease and Beliaghata General Hospital, Kolkata, West Bengal, India. FAU - John, M AU - John M AD - Christian Medical College, Ludhiana, Punjab, India. FAU - Khambholja, J R AU - Khambholja JR AD - Smt. NHL, Municipal Medical College, Ahmedabad, Gujarat, India. FAU - Patel, A H AU - Patel AH AD - CIMS Hospital, Ahmedabad, Gujarat, India. FAU - Bhuniya, S AU - Bhuniya S AD - All India Institute of Medical Sciences, Bhubaneswar, Odisha, India. FAU - Joshi, R AU - Joshi R AD - All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India. FAU - Menon, G R AU - Menon GR AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Sahu, D AU - Sahu D AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Rao, V V AU - Rao VV AD - National Institute of Medical Statistics, Indian Council of Medical Research, Delhi, India. FAU - Bhargava, B AU - Bhargava B AD - From the Indian Council of Medical Research, New Delhi, India. FAU - Panda, S AU - Panda S AD - From the Indian Council of Medical Research, New Delhi, India. CN - NCRC Study Team LA - eng GR - Indian Council of Medical Research/ PT - Journal Article PL - England TA - QJM JT - QJM : monthly journal of the Association of Physicians JID - 9438285 SB - IM MH - Adult MH - Humans MH - Male MH - Middle Aged MH - *COVID-19/prevention & control MH - SARS-CoV-2 MH - Hospital Mortality MH - Time and Motion Studies MH - Vaccination MH - Chronic Disease PMC - PMC9494346 FIR - Mishra, P IR - Mishra P FIR - Panchal, Y IR - Panchal Y FIR - Sharma, L K IR - Sharma LK FIR - Agarwal, A IR - Agarwal A FIR - Puri, G D IR - Puri GD FIR - Suri, V IR - Suri V FIR - Singla, K IR - Singla K FIR - Mesipogu, R IR - Mesipogu R FIR - Aedula, V S IR - Aedula VS FIR - Mohiuddin, M A IR - Mohiuddin MA FIR - Kumar, D IR - Kumar D FIR - Saurabh, S IR - Saurabh S FIR - Misra, S IR - Misra S FIR - Kannauje, P K IR - Kannauje PK FIR - Kumar, A IR - Kumar A FIR - Shukla, A IR - Shukla A FIR - Pal, A IR - Pal A FIR - Chakraborty, S IR - Chakraborty S FIR - Dutta, M IR - Dutta M FIR - Mondal, T IR - Mondal T FIR - Chakravorty, S IR - Chakravorty S FIR - Bhattacharjee, B IR - Bhattacharjee B FIR - Paul, S R IR - Paul SR FIR - Majumder, D IR - Majumder D FIR - Chatterjee, S IR - Chatterjee S FIR - Abraham, A IR - Abraham A FIR - Varghese, D IR - Varghese D FIR - Thomas, M IR - Thomas M FIR - Shah, N IR - Shah N FIR - Patel, M IR - Patel M FIR - Madan, S IR - Madan S FIR - Desai, A IR - Desai A FIR - Kala Yadhav, M L IR - Kala Yadhav ML FIR - Madhumathi, R IR - Madhumathi R FIR - Chetna, G S IR - Chetna GS FIR - Ojha, U K IR - Ojha UK FIR - Jha, R R IR - Jha RR FIR - Kumar, A IR - Kumar A FIR - Pathak, A IR - Pathak A FIR - Sharma, A IR - Sharma A FIR - Purohit, M IR - Purohit M FIR - Sarangi, L IR - Sarangi L FIR - Rath, M IR - Rath M FIR - Shah, A D IR - Shah AD FIR - Kumar, L IR - Kumar L FIR - Patel, P IR - Patel P FIR - Dulhani, N IR - Dulhani N FIR - Dube, S IR - Dube S FIR - Shrivastava, J IR - Shrivastava J FIR - Mittal, A IR - Mittal A FIR - Patnaik, L IR - Patnaik L FIR - Sahoo, J P IR - Sahoo JP FIR - Sharma, S IR - Sharma S FIR - Katyal, V K IR - Katyal VK FIR - Katyal, A IR - Katyal A FIR - Yadav, N IR - Yadav N FIR - Upadhyay, R IR - Upadhyay R FIR - Srivastava, S IR - Srivastava S FIR - Srivastava, A IR - Srivastava A FIR - Suthar, N N IR - Suthar NN FIR - Shah, N M IR - Shah NM FIR - Rajvansh, K IR - Rajvansh K FIR - Purohit, H IR - Purohit H FIR - Mohapatra, P R IR - Mohapatra PR FIR - Panigrahi, M K IR - Panigrahi MK FIR - Saigal, S IR - Saigal S FIR - Khurana, A IR - Khurana A FIR - Panchal, M IR - Panchal M FIR - Anderpa, M IR - Anderpa M FIR - Patel, D IR - Patel D FIR - Salgar, V IR - Salgar V FIR - Algur, S IR - Algur S FIR - Choudhury, R IR - Choudhury R FIR - Rao, M IR - Rao M FIR - Nithya, D IR - Nithya D FIR - Gupta, B K IR - Gupta BK FIR - Kumar, B IR - Kumar B FIR - Gupta, J IR - Gupta J FIR - Bhandari, S IR - Bhandari S FIR - Agrawal, A IR - Agrawal A FIR - Shameem, M IR - Shameem M FIR - Fatima, N IR - Fatima N FIR - Pala, S IR - Pala S FIR - Nongpiur, V IR - Nongpiur V FIR - Chatterji, S IR - Chatterji S FIR - Mukherjee, S IR - Mukherjee S FIR - Shivnitwar, S K IR - Shivnitwar SK FIR - Tripathy, S IR - Tripathy S FIR - Lokhande, P IR - Lokhande P FIR - Dandu, H IR - Dandu H FIR - Gupta, A IR - Gupta A FIR - Kumar, V IR - Kumar V FIR - Sharma, N IR - Sharma N FIR - Vohra, R IR - Vohra R FIR - Paliwal, A IR - Paliwal A FIR - Pavan Kumar, M IR - Pavan Kumar M FIR - Bikshapathi Rao, A IR - Bikshapathi Rao A FIR - Kikon, N IR - Kikon N FIR - Kikon, R IR - Kikon R FIR - Manohar, K IR - Manohar K FIR - Sathyanarayana Raju, Y IR - Sathyanarayana Raju Y FIR - Madharia, A IR - Madharia A FIR - Chakravarty, J IR - Chakravarty J FIR - Chaubey, M IR - Chaubey M FIR - Bandaru, R K IR - Bandaru RK FIR - Ali Mirza, M IR - Ali Mirza M FIR - Kataria, S IR - Kataria S FIR - Sharma, P IR - Sharma P FIR - Ghosh, S IR - Ghosh S FIR - Hazra, A IR - Hazra A EDAT- 2022/09/03 06:00 MHDA- 2023/02/17 06:00 PMCR- 2022/09/02 CRDT- 2022/09/02 10:04 PHST- 2022/07/04 00:00 [received] PHST- 2022/08/16 00:00 [revised] PHST- 2022/09/03 06:00 [pubmed] PHST- 2023/02/17 06:00 [medline] PHST- 2022/09/02 10:04 [entrez] PHST- 2022/09/02 00:00 [pmc-release] AID - 6687141 [pii] AID - hcac202 [pii] AID - 10.1093/qjmed/hcac202 [doi] PST - ppublish SO - QJM. 2023 Feb 14;116(1):47-56. doi: 10.1093/qjmed/hcac202. PMID- 36016324 OWN - NLM STAT- MEDLINE DCOM- 20220829 LR - 20251031 IS - 1999-4915 (Electronic) IS - 1999-4915 (Linking) VI - 14 IP - 8 DP - 2022 Aug 1 TI - Long-Term Outcomes after Vaccine-Induced Thrombotic Thrombocytopenia. LID - 10.3390/v14081702 [doi] LID - 1702 AB - Vaccine-induced thrombotic thrombocytopenia (VITT), or thrombosis with thrombocytopenia syndrome (TTS), is a rare but serious complication of adenovirus-based vaccines against severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Observation of long-term outcomes is important to guide treatment of affected patients. This single-center consecutive cohort study included all patients diagnosed based on (1) vaccination 4 to 21 days before symptom onset, (2) signs or symptoms of venous or arterial thrombosis, (3) thrombocytopenia < 150/nL, (4) positive anti-platelet factor 4 (PF4) antibody, and (5) elevated D-Dimer > 4 times the upper limit of normal. Nine patients were enrolled. Acute management consisted of parenteral anticoagulants, corticosteroids, intravenous immunoglobulin (IVIG), and/or eculizumab. Eculizumab was successfully used in two patients with recurrent thromboembolic events after IVIG. Direct oral anticoagulants were given after hospital discharge. Median follow-up duration was 300 days (range 153 to 380). All patients survived the acute phase of the disease and were discharged from hospital. One patient died from long-term neurological sequelae of cerebral venous sinus thrombosis 335 days after diagnosis. Eight out of nine patients were alive at last follow-up, and seven had fully recovered. Anti-PF4 antibodies remained detectable for at least 12 weeks after diagnosis, and D-Dimer remained elevated in some patients despite oral anticoagulation. No recurrent thromboembolic events, other signs of VITT relapse, or bleeding complications occurred after discharge. In conclusion, VITT appears to be a highly prothrombotic condition. IVIG is not always successful, and eculizumab may be considered a rescue agent. Long-term management with direct oral anticoagulants appears to be safe and effective. FAU - Panagiota, Victoria AU - Panagiota V AD - Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany. FAU - Dobbelstein, Christiane AU - Dobbelstein C AD - Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany. FAU - Werwitzke, Sonja AU - Werwitzke S AD - Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany. FAU - Ganser, Arnold AU - Ganser A AD - Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany. FAU - Cooper, Nina AU - Cooper N AD - Department of Thrombosis and Hemostasis, Giessen University Hospital, Giessen, Germany, and Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, 35390 Giessen, Germany. FAU - Sachs, Ulrich J AU - Sachs UJ AD - Department of Thrombosis and Hemostasis, Giessen University Hospital, Giessen, Germany, and Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, 35390 Giessen, Germany. FAU - Tiede, Andreas AU - Tiede A AUID- ORCID: 0000-0002-3600-8536 AD - Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany. LA - eng PT - Journal Article DEP - 20220801 PL - Switzerland TA - Viruses JT - Viruses JID - 101509722 RN - 0 (Anticoagulants) RN - 0 (COVID-19 Vaccines) RN - 0 (Covid-19 aAPC vaccine) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Vaccines) SB - IM MH - Anticoagulants/adverse effects MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Cohort Studies MH - Humans MH - Immunoglobulins, Intravenous/adverse effects/therapeutic use MH - SARS-CoV-2 MH - *Thrombocytopenia/chemically induced/drug therapy MH - *Thrombosis MH - *Vaccines PMC - PMC9415056 OTO - NOTNLM OT - AZD1222 OT - COVID-19 OT - ChAdOx1 nCoV-19 OT - SARS-CoV-2 OT - cerebral venous sinus thrombosis OT - cohort studies OT - platelet activation OT - thrombosis OT - vaccination COIS- The authors declare no conflict of interest. EDAT- 2022/08/27 06:00 MHDA- 2022/08/30 06:00 PMCR- 2022/08/01 CRDT- 2022/08/26 01:48 PHST- 2022/06/30 00:00 [received] PHST- 2022/07/28 00:00 [revised] PHST- 2022/07/29 00:00 [accepted] PHST- 2022/08/26 01:48 [entrez] PHST- 2022/08/27 06:00 [pubmed] PHST- 2022/08/30 06:00 [medline] PHST- 2022/08/01 00:00 [pmc-release] AID - v14081702 [pii] AID - viruses-14-01702 [pii] AID - 10.3390/v14081702 [doi] PST - epublish SO - Viruses. 2022 Aug 1;14(8):1702. doi: 10.3390/v14081702. PMID- 36006991 OWN - NLM STAT- MEDLINE DCOM- 20220829 LR - 20260127 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 8 DP - 2022 TI - Good recovery of immunization stress-related responses presenting as a cluster of stroke-like events following CoronaVac and ChAdOx1 vaccinations. PG - e0266118 LID - 10.1371/journal.pone.0266118 [doi] LID - e0266118 AB - BACKGROUND: Immunization stress-related responses presenting as stroke-like symptoms could develop following COVID-19 vaccination. Therefore, this study aimed to describe the clinical characteristics of immunization stress-related responses causing stroke-like events following COVID-19 vaccination in Thailand. METHODS: We conducted a retrospective study of the secondary data of reported adverse events after COVID-19 immunization that presented with neurologic manifestations. Between March 1 and July 31, 2021, we collected and analyzed the medical records of 221 patients diagnosed with stroke-like symptoms following immunization. Two majority types of vaccines were used at the beginning of the vaccination campaign, including CoronaVac (Sinovac) or ChAdOx1 (AstraZeneca). Demographic and medical data included sex, age, vaccine type, sequence dose, time to event, laboratory data, and recovery status as defined by the modified Rankin score. The affected side was evaluated for associations with the injection site. RESULTS: Overall, 221 patients were diagnosed with immunization stress-related responses (stroke-like symptoms) following CoronaVac (Sinovac) or ChAdOx1 (AstraZeneca) vaccinations. Most patients (83.7%) were women. The median (interquartile range) age of onset was 34 (28-42) years in patients receiving CoronaVac and 46 (33.5-60) years in those receiving ChAdOx1. The median interval between vaccination and symptom onset for each vaccine type was 60 (16-960) min and 30 (8.8-750) min, respectively. Sensory symptoms were the most common symptomology. Most patients (68.9%) developed symptoms on the left side of the body; 99.5% of the patients receiving CoronaVac and 100% of those receiving ChAdOx1 had a good outcome (modified Rankin scores /=65 years [older adults]) and date of diagnosis. We assessed the risks of 14 neurological and psychiatric diagnoses after SARS-CoV-2 infection and compared these risks with the matched comparator cohort. The 2-year risk trajectories were represented by time-varying hazard ratios (HRs) and summarised using the 6-month constant HRs (representing the risks in the earlier phase of follow-up, which have not yet been well characterised in children), the risk horizon for each outcome (ie, the time at which the HR returns to 1), and the time to equal incidence in the two cohorts. We also estimated how many people died after a neurological or psychiatric diagnosis during follow-up in each age group. Finally, we compared matched cohorts of patients diagnosed with COVID-19 directly before and after the emergence of the alpha (B.1.1.7), delta (B.1.617.2), and omicron (B.1.1.529) variants. FINDINGS: We identified 1 487 712 patients with a recorded diagnosis of COVID-19 during the study period, of whom 1 284 437 (185 748 children, 856 588 adults, and 242 101 older adults; overall mean age 42.5 years [SD 21.9]; 741 806 [57.8%] were female and 542 192 [42.2%] were male) were adequately matched with an equal number of patients with another respiratory infection. The risk trajectories of outcomes after SARS-CoV-2 infection in the whole cohort differed substantially. While most outcomes had HRs significantly greater than 1 after 6 months (with the exception of encephalitis; Guillain-Barre syndrome; nerve, nerve root, and plexus disorder; and parkinsonism), their risk horizons and time to equal incidence varied greatly. Risks of the common psychiatric disorders returned to baseline after 1-2 months (mood disorders at 43 days, anxiety disorders at 58 days) and subsequently reached an equal overall incidence to the matched comparison group (mood disorders at 457 days, anxiety disorders at 417 days). By contrast, risks of cognitive deficit (known as brain fog), dementia, psychotic disorders, and epilepsy or seizures were still increased at the end of the 2-year follow-up period. Post-COVID-19 risk trajectories differed in children compared with adults: in the 6 months after SARS-CoV-2 infection, children were not at an increased risk of mood (HR 1.02 [95% CI 0.94-1.10) or anxiety (1.00 [0.94-1.06]) disorders, but did have an increased risk of cognitive deficit, insomnia, intracranial haemorrhage, ischaemic stroke, nerve, nerve root, and plexus disorders, psychotic disorders, and epilepsy or seizures (HRs ranging from 1.20 [1.09-1.33] to 2.16 [1.46-3.19]). Unlike adults, cognitive deficit in children had a finite risk horizon (75 days) and a finite time to equal incidence (491 days). A sizeable proportion of older adults who received a neurological or psychiatric diagnosis, in either cohort, subsequently died, especially those diagnosed with dementia or epilepsy or seizures. Risk profiles were similar just before versus just after the emergence of the alpha variant (n=47 675 in each cohort). Just after (vs just before) the emergence of the delta variant (n=44 835 in each cohort), increased risks of ischaemic stroke, epilepsy or seizures, cognitive deficit, insomnia, and anxiety disorders were observed, compounded by an increased death rate. With omicron (n=39 845 in each cohort), there was a lower death rate than just before emergence of the variant, but the risks of neurological and psychiatric outcomes remained similar. INTERPRETATION: This analysis of 2-year retrospective cohort studies of individuals diagnosed with COVID-19 showed that the increased incidence of mood and anxiety disorders was transient, with no overall excess of these diagnoses compared with other respiratory infections. In contrast, the increased risk of psychotic disorder, cognitive deficit, dementia, and epilepsy or seizures persisted throughout. The differing trajectories suggest a different pathogenesis for these outcomes. Children have a more benign overall profile of psychiatric risk than do adults and older adults, but their sustained higher risk of some diagnoses is of concern. The fact that neurological and psychiatric outcomes were similar during the delta and omicron waves indicates that the burden on the health-care system might continue even with variants that are less severe in other respects. Our findings are relevant to understanding individual-level and population-level risks of neurological and psychiatric disorders after SARS-CoV-2 infection and can help inform our responses to them. FUNDING: National Institute for Health and Care Research Oxford Health Biomedical Research Centre, The Wolfson Foundation, and MQ Mental Health Research. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. FAU - Taquet, Maxime AU - Taquet M AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. FAU - Sillett, Rebecca AU - Sillett R AD - Medical Sciences Division, University of Oxford, Oxford, UK. FAU - Zhu, Lena AU - Zhu L AD - Medical Sciences Division, University of Oxford, Oxford, UK. FAU - Mendel, Jacob AU - Mendel J AD - Medical Sciences Division, University of Oxford, Oxford, UK. FAU - Camplisson, Isabella AU - Camplisson I AD - Medical Sciences Division, University of Oxford, Oxford, UK. FAU - Dercon, Quentin AU - Dercon Q AD - MRC Cognition and Brain Sciences Unit, University of Cambridge, UK. FAU - Harrison, Paul J AU - Harrison PJ AD - Department of Psychiatry, University of Oxford, Oxford, UK; Oxford Health NHS Foundation Trust, Oxford, UK. Electronic address: paul.harrison@psych.ox.ac.uk. LA - eng GR - MC_UU_00030/12/MRC_/Medical Research Council/United Kingdom PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220817 PL - England TA - Lancet Psychiatry JT - The lancet. Psychiatry JID - 101638123 RN - SARS-CoV-2 variants SB - IM CIN - Lancet Psychiatry. 2022 Oct;9(10):762-763. doi: 10.1016/S2215-0366(22)00302-9. PMID: 35987198 MH - Adolescent MH - Adult MH - Aged MH - *Brain Ischemia MH - *COVID-19/epidemiology MH - Child MH - Cohort Studies MH - *Dementia/epidemiology MH - Female MH - Humans MH - *Ischemic Stroke MH - Male MH - Retrospective Studies MH - SARS-CoV-2 MH - Seizures MH - *Sleep Initiation and Maintenance Disorders MH - *Stroke PMC - PMC9385200 COIS- Declaration of interests We declare no competing interests. EDAT- 2022/08/21 06:00 MHDA- 2022/09/21 06:00 PMCR- 2022/10/01 CRDT- 2022/08/20 18:52 PHST- 2022/05/10 00:00 [received] PHST- 2022/07/01 00:00 [revised] PHST- 2022/07/11 00:00 [accepted] PHST- 2022/08/21 06:00 [pubmed] PHST- 2022/09/21 06:00 [medline] PHST- 2022/08/20 18:52 [entrez] PHST- 2022/10/01 00:00 [pmc-release] AID - S2215-0366(22)00260-7 [pii] AID - 10.1016/S2215-0366(22)00260-7 [doi] PST - ppublish SO - Lancet Psychiatry. 2022 Oct;9(10):815-827. doi: 10.1016/S2215-0366(22)00260-7. Epub 2022 Aug 17. PMID- 35972594 OWN - NLM STAT- MEDLINE DCOM- 20230131 LR - 20230208 IS - 2731-5541 (Electronic) IS - 2731-5533 (Print) IS - 2731-5533 (Linking) VI - 44 IP - 1 DP - 2023 Feb TI - Rapid Rollout and Initial Uptake of a Booster COVID-19 Vaccine Among Israel Defense Forces Soldiers. PG - 1-14 LID - 10.1007/s10935-022-00702-2 [doi] AB - The surge of breakthrough COVID-19 among fully vaccinated individuals has raised the prospects of booster dose administration. In Israel, concerns of waning immunity and dominance of the B.1.617.2 (delta) variant resulted in approval of a third-dose (booster) vaccination for the entire eligible population starting on August 29, 2021. This study aims to evaluate vaccine uptake for booster doses among a population of previously vaccinated individuals during a rapid rollout and to analyze socio-demographic characteristics associated with vaccine uptake. A cross-sectional study among Israel Defense Forces soldiers with high access to booster doses of BNT162b2. Subjects eligible for booster doses were voluntarily vaccinated at three vaccine sites constructed within soldiers' bases. We analyzed associations between subjects' socio-demographic characteristics and booster vaccine uptake at the culmination of vaccine rollout using logistic regression models. 1157 soldiers from an IDF brigade were eligible for third dose vaccination (received second dose > 5-months before rollout), with 978 (84.5%) receiving a third, booster dose during the study's timeframe. Subjects' median age was 20.5 (IQR 19.7-21.5) and 791 (68.4%) were male. Notable socio-demographic characteristics associated with increased vaccine uptake in a multivariable model included increased age (OR 1.16, 95% CI 1.02-1.31), high socio-economic status (OR 2.12, 95% CI 1.25-3.59) and female sex (OR 1.87, 95% CI 1.26-2.74). Below-average cognitive function score was associated with decreased vaccine uptake (OR 0.61, 95% CI 0.39-0.95). This study demonstrates that real-world vaccine hesitancy remains a major obstacle, even among a population previously acceptant to COVID-19 vaccines. Decreased uptake for vaccines may be associated with socio-demographic variables in-spite of high-access vaccine rollouts. Reasons for vaccine hesitancy among previously vaccinated individuals, along with the benefits of population-wide booster administration should be further investigated. CI - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. FAU - Talmy, Tomer AU - Talmy T AUID- ORCID: 0000-0002-7440-8864 AD - Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan, Israel. ttalmy@gmail.com. AD - Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. ttalmy@gmail.com. FAU - Nitzan, Itay AU - Nitzan I AUID- ORCID: 0000-0001-6925-5157 AD - Israel Defense Forces, Medical Corps, Tel Hashomer, Ramat Gan, Israel. AD - Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. LA - eng PT - Journal Article DEP - 20220816 PL - Switzerland TA - J Prev (2022) JT - Journal of prevention (2022) JID - 9918351283506676 RN - 0 (COVID-19 Vaccines) RN - 0 (BNT162 Vaccine) RN - SARS-CoV-2 variants SB - IM MH - Female MH - Male MH - Humans MH - Young Adult MH - Adult MH - COVID-19 Vaccines/therapeutic use MH - BNT162 Vaccine MH - Cross-Sectional Studies MH - Israel/epidemiology MH - *Military Personnel MH - *COVID-19/epidemiology MH - SARS-CoV-2 PMC - PMC9379899 OTO - NOTNLM OT - Acceptance OT - Booster OT - COVID-19 OT - Hesitancy OT - Military OT - SARS-CoV-2 OT - Vaccine COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: TT is a former employee of Emedgene Technologies, unrelated to the work reported in this paper. EDAT- 2022/08/17 06:00 MHDA- 2023/02/01 06:00 PMCR- 2022/08/16 CRDT- 2022/08/16 11:18 PHST- 2022/07/19 00:00 [accepted] PHST- 2022/08/17 06:00 [pubmed] PHST- 2023/02/01 06:00 [medline] PHST- 2022/08/16 11:18 [entrez] PHST- 2022/08/16 00:00 [pmc-release] AID - 10.1007/s10935-022-00702-2 [pii] AID - 702 [pii] AID - 10.1007/s10935-022-00702-2 [doi] PST - ppublish SO - J Prev (2022). 2023 Feb;44(1):1-14. doi: 10.1007/s10935-022-00702-2. Epub 2022 Aug 16. PMID- 35954625 OWN - NLM STAT- MEDLINE DCOM- 20220815 LR - 20250728 IS - 1660-4601 (Electronic) IS - 1661-7827 (Print) IS - 1660-4601 (Linking) VI - 19 IP - 15 DP - 2022 Jul 28 TI - Acceptance and Adherence to COVID-19 Vaccination-The Role of Cognitive and Emotional Representations. LID - 10.3390/ijerph19159268 [doi] LID - 9268 AB - Vaccine hesitation is a topic of utmost importance, with the COVID-19 pandemic serving as a clear reminder of its timeliness. Besides evaluating COVID-19 vaccine acceptance in a sample of Portuguese people, this study aims at understanding cognitive and emotional representations related to vaccination, and their influence on vaccination hesitation. A cross-sectional online survey was conducted between 27 December 2020 and 27 January 2021. It assessed cognitive and emotional COVID-19 representations; vaccination status; cognitive and emotional representations of vaccination and perceived necessity and concerns about vaccines. Of 31 x 58 participants, 91% accepted taking a COVID-19 vaccine. Among several other significant findings, women (71.3%) more often considered that the pandemic affected their lives (p < 0.001) and were more often concerned with being infected (p < 0.001). Likewise, there were significantly more female participants concerned about taking a COVID-19 vaccine and its possible effects, when compared to the number of male participants (p < 0.001). The number of participants with a higher education level that were more worried about becoming infected was greater (p = 0.001), when compared with those less educated. Regarding age groups, people aged 18 to 24 had fewer concerned participants (9.6%), while the number of individuals aged 55 to 64 had the most (p < 0.001). Somewhat surprisingly, perceiving oneself as extremely informed about COVID-19 was not associated with greater vaccine acceptance (OR = 1.534 [1.160-2.029]; (p = 0.003)). Moreover, people aged 25 to 64 years old and with lower education level were more likely not to accept vaccination (OR = 2.799 [1.085-7.221]; (p = 0.033)). Finally, being more concerned about taking a vaccine lowers its acceptance (OR = 4.001 [2.518-6.356]; (p < 0.001)). Cognitive and emotional representations have a great impact and are reliable predictors of vaccine acceptance. Thus, it is of extreme importance that public health messages be adapted to the different characteristics of the population. FAU - Pinho, Simao AU - Pinho S AUID- ORCID: 0000-0003-1433-3052 AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Sao Joao University Hospital Center, 4200-319 Porto, Portugal. FAU - Cruz, Mariana AU - Cruz M AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Dias, Claudia Camila AU - Dias CC AUID- ORCID: 0000-0001-9356-3272 AD - CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - Knowledge Management Unit and Department of Community Medicine, Information and Health Decision Sciences, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Castro-Lopes, Jose M AU - Castro-Lopes JM AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. FAU - Sampaio, Rute AU - Sampaio R AUID- ORCID: 0000-0002-9009-6653 AD - Department of Biomedicine, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. AD - CINTESIS@RISE, MEDCIDS, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal. LA - eng PT - Journal Article DEP - 20220728 PL - Switzerland TA - Int J Environ Res Public Health JT - International journal of environmental research and public health JID - 101238455 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/epidemiology/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Cognition MH - Cross-Sectional Studies MH - Female MH - Humans MH - Male MH - Middle Aged MH - Pandemics MH - Patient Acceptance of Health Care MH - Vaccination PMC - PMC9368462 OTO - NOTNLM OT - COVID-19 OT - adherence OT - cognition OT - emotion OT - representations OT - vaccination COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2022/08/13 06:00 MHDA- 2022/08/16 06:00 PMCR- 2022/07/28 CRDT- 2022/08/12 01:06 PHST- 2022/06/20 00:00 [received] PHST- 2022/07/24 00:00 [revised] PHST- 2022/07/25 00:00 [accepted] PHST- 2022/08/12 01:06 [entrez] PHST- 2022/08/13 06:00 [pubmed] PHST- 2022/08/16 06:00 [medline] PHST- 2022/07/28 00:00 [pmc-release] AID - ijerph19159268 [pii] AID - ijerph-19-09268 [pii] AID - 10.3390/ijerph19159268 [doi] PST - epublish SO - Int J Environ Res Public Health. 2022 Jul 28;19(15):9268. doi: 10.3390/ijerph19159268. PMID- 35891278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220731 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 7 DP - 2022 Jul 13 TI - A Rare Adverse Effect of the COVID-19 Vaccine on Autoimmune Encephalitis. LID - 10.3390/vaccines10071114 [doi] LID - 1114 AB - Since countries commenced COVID-19 vaccination around the world, many vaccine-related adverse effects have been reported. Among them, short-term memory loss with autoimmune encephalitis (AE) was reported as a rare adverse effect. Since case numbers are limited, this brief report may draw the attention of the medical community to this uncommon adverse effect and serve as a reference for future vaccine improvement. However, given the high risk of adverse outcomes when infected with SARS-CoV-2 and the clearly favorable safety/tolerability profile of existing vaccines, vaccination is still recommended. FAU - Huang, Ying-Fong AU - Huang YF AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Ho, Tzu-Chuan AU - Ho TC AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Chang, Chin-Chuan AU - Chang CC AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Neuroscience Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Electrical Engineering, I-Shou University, Kaohsiung 840, Taiwan. FAU - Shen, Daniel Hueng-Yuan AU - Shen DH AD - Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Chan, Hung-Pin AU - Chan HP AUID- ORCID: 0000-0001-9741-5824 AD - Department of Nuclear Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. FAU - Chuang, Kuo-Pin AU - Chuang KP AUID- ORCID: 0000-0002-3973-8390 AD - Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912, Taiwan. FAU - Tyan, Yu-Chang AU - Tyan YC AUID- ORCID: 0000-0002-1917-5893 AD - Department of Nuclear Medicine, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Department of Medical Imaging and Radiological Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - School of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 912, Taiwan. AD - Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. AD - Center for Cancer Research, Kaohsiung Medical University, Kaohsiung 807, Taiwan. AD - Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. FAU - Yang, Ming-Hui AU - Yang MH AUID- ORCID: 0000-0001-5856-0498 AD - Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan. AD - Center of General Education, Shu-Zen Junior College of Medicine and Management, Kaohsiung 821, Taiwan. LA - eng GR - MOST 109-2221-E-037-001-MY3/Ministry of Science and Technology/ GR - KMUH110-0T02/Kaohsiung Medical University/ GR - NPUST-KMU-111-P002/NPUST-KMU JOINT RESEARCH PROJECT/ PT - Journal Article DEP - 20220713 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9319671 OTO - NOTNLM OT - COVID-19 vaccine OT - adverse effect OT - autoimmune encephalitis OT - lymphocytic pleocytosis OT - short-term memory loss COIS- The authors declare no conflict of interest. EDAT- 2022/07/28 06:00 MHDA- 2022/07/28 06:01 PMCR- 2022/07/13 CRDT- 2022/07/27 01:43 PHST- 2022/05/12 00:00 [received] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/27 01:43 [entrez] PHST- 2022/07/28 06:00 [pubmed] PHST- 2022/07/28 06:01 [medline] PHST- 2022/07/13 00:00 [pmc-release] AID - vaccines10071114 [pii] AID - vaccines-10-01114 [pii] AID - 10.3390/vaccines10071114 [doi] PST - epublish SO - Vaccines (Basel). 2022 Jul 13;10(7):1114. doi: 10.3390/vaccines10071114. PMID- 35843095 OWN - NLM STAT- MEDLINE DCOM- 20220811 LR - 20251031 IS - 1090-2104 (Electronic) IS - 0006-291X (Print) IS - 0006-291X (Linking) VI - 622 DP - 2022 Sep 24 TI - Immunization with 674-685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice. PG - 57-63 LID - S0006-291X(22)00977-9 [pii] LID - 10.1016/j.bbrc.2022.07.016 [doi] AB - COVID-19 is accompanied by strong inflammatory reaction and is often followed by long-term cognitive disorders. The fragment 674-685 of SARS-Cov-2 spike protein was shown to interact with alpha7 nicotinic acetylcholine receptor involved in regulating both inflammatory reactions and cognitive functions. Here we show that mice immunized with the peptide corresponding to 674-685 fragment of SARS-Cov-2 spike protein conjugated to hemocyanin (KLH-674-685) demonstrate decreased level of alpha7 nicotinic acetylcholine receptors, increased levels of IL-1beta and TNFalpha in the brain and impairment of episodic memory. Choline injections prevented alpha7 nicotinic receptor decline and memory loss. Mice injected with immunoglobulins obtained from the blood of (KLH-674-685)-immunized mice also demonstrated episodic memory decline. These data allow suggesting that post-COVID memory impairment in humans is related to SARS-Cov-2 spike protein-specific immune reaction. The mechanisms of such effect are being discussed. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Lykhmus, Olena AU - Lykhmus O AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: olenalykhmus@gmail.com. FAU - Kalashnyk, Olena AU - Kalashnyk O AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: krasota5600@gmail.com. FAU - Koval, Lyudmyla AU - Koval L AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: lyudmyla1koval@gmail.com. FAU - Krynina, Olga AU - Krynina O AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: olyakrynina@gmail.com. FAU - Komisarenko, Serhiy AU - Komisarenko S AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: serhiykom@gmail.com. FAU - Skok, Maryna AU - Skok M AD - Palladin Institute of Biochemistry, NAS of Ukraine, 9, Leontovycha str., 01054, Kyiv, Ukraine. Electronic address: skok@biochem.kiev.ua. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220708 PL - United States TA - Biochem Biophys Res Commun JT - Biochemical and biophysical research communications JID - 0372516 RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (alpha7 Nicotinic Acetylcholine Receptor) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - *COVID-19 MH - Humans MH - Immunization MH - Inflammation MH - Memory Disorders/etiology/metabolism MH - *Memory, Episodic MH - Mice MH - Neuroinflammatory Diseases MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/adverse effects/chemistry/metabolism MH - alpha7 Nicotinic Acetylcholine Receptor/metabolism PMC - PMC9263688 OTO - NOTNLM OT - Antibodies OT - COVID-19 OT - Episodic memory OT - Neuroinflammation OT - SARS-CoV-2 spike protein OT - alpha7 nicotinic acetylcholine receptor COIS- Declaration of competing interest Olena Lykhmus, Olena Kalashnyk, Lyudmyla Koval, Olga Krynina, Serhiy Komisarenko and Maryna Skok, - declare that there is no conflict of interest. EDAT- 2022/07/18 06:00 MHDA- 2022/08/12 06:00 PMCR- 2022/07/08 CRDT- 2022/07/17 18:23 PHST- 2022/05/24 00:00 [received] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/07/18 06:00 [pubmed] PHST- 2022/08/12 06:00 [medline] PHST- 2022/07/17 18:23 [entrez] PHST- 2022/07/08 00:00 [pmc-release] AID - S0006-291X(22)00977-9 [pii] AID - 10.1016/j.bbrc.2022.07.016 [doi] PST - ppublish SO - Biochem Biophys Res Commun. 2022 Sep 24;622:57-63. doi: 10.1016/j.bbrc.2022.07.016. Epub 2022 Jul 8. PMID- 35834042 OWN - NLM STAT- MEDLINE DCOM- 20220824 LR - 20261008 IS - 1432-1076 (Electronic) IS - 0340-6199 (Print) IS - 0340-6199 (Linking) VI - 181 IP - 9 DP - 2022 Sep TI - Long-COVID in immunocompromised children. PG - 3501-3509 LID - 10.1007/s00431-022-04561-1 [doi] AB - Coronavirus disease 2019 (COVID-19) can lead to an illness characterized by persistent symptoms which affect various organs and systems, known as long-COVID. This study aimed to assess the prevalence and clinical characteristics of long-COVID in children with immunodeficiency, in comparison to those without. A self-constructed questionnaire was created, which included questions regarding the child's general health, the course of their COVID-19, their symptoms of long-COVID and its impact on their daily functioning, the diagnosis of multisystem inflammatory syndrome (MIS-C), and vaccination status. The questionnaire was completed by parents of 147 children - 70 children with a diagnosis of immunodeficiency (47.6%) and 77 who were immunocompetent (52.4%). Immunocompetent children were more significantly affected by long-COVID than those immunocompromised. Its prevalence in the first 12-week post-infection was 60.0% and 35.7% in these groups, respectively. Beyond this period, these percentages had dropped to 34.6% and 11.43%, respectively. Children who were immunocompetent reported more often symptoms of fatigue, reduced exercise tolerance, and difficulty concentrating. Meanwhile, there was a slight increase in complaints of gastrointestinal symptoms in immunocompromised patients. The risk of developing long-COVID increased with age and COVID-19 severity in both groups. Furthermore, the daily activities of immunocompetent children were limited more frequently (41.8%) than for those who were immunocompromised (25%). CONCLUSIONS: Although immunocompromised children experienced long-COVID, its prevalence and impact on daily functioning were significantly lower than among immunocompetent children. However, as the pathomechanisms of long-COVID are not yet fully understood, it is not currently possible to fully explain these findings. WHAT IS KNOWN: * Long COVID is characterized by persistent symptoms following COVID-19, which can affect various tissues and organs, as well as mental health. * Due to the similar course of COVID-19 - mainly mild or asymptomatic - among children with and without immunodeficiency, the question arises, over whether the prevalence and severity of long-COVID is also similar in both groups. WHAT IS NEW: * Immunocompromised children also suffer from long-COVID, but the prevalence is significantly lower than in the immunocompetent group of children. * The potential causes of less frequent and milder long-COVID in this group may be the milder course of COVID-19 and the state of reduced immunity protecting against neuroinflammation. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Kuczborska, Karolina AU - Kuczborska K AUID- ORCID: 0000-0003-2644-5588 AD - Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland. k.kuczborska@ipczd.pl. FAU - Buda, Piotr AU - Buda P AUID- ORCID: 0000-0002-3891-4989 AD - Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland. FAU - Ksiazyk, Janusz AU - Ksiazyk J AUID- ORCID: 0000-0002-9136-2722 AD - Department of Pediatrics, Nutrition and Metabolic Disorders, Children's Memorial Health Institute, Av. Dzieci Polskich 20, 04-730, Warsaw, Poland. LA - eng PT - Journal Article DEP - 20220714 PL - Germany TA - Eur J Pediatr JT - European journal of pediatrics JID - 7603873 RN - pediatric multisystem inflammatory disease, COVID-19 related SB - IM MH - Child MH - Humans MH - *Immunocompromised Host MH - *Post-Acute COVID-19 Syndrome/complications/epidemiology MH - *Systemic Inflammatory Response Syndrome/complications/epidemiology MH - COVID-19/complications PMC - PMC9281224 OTO - NOTNLM OT - Immunodeficiency OT - Long-COVID OT - Pediatric population OT - SARS-CoV-2 COIS- The authors declare no competing interests. EDAT- 2022/07/15 06:00 MHDA- 2022/08/25 06:00 PMCR- 2022/07/14 CRDT- 2022/07/14 11:18 PHST- 2022/05/14 00:00 [received] PHST- 2022/07/06 00:00 [accepted] PHST- 2022/06/28 00:00 [revised] PHST- 2022/07/15 06:00 [pubmed] PHST- 2022/08/25 06:00 [medline] PHST- 2022/07/14 11:18 [entrez] PHST- 2022/07/14 00:00 [pmc-release] AID - 10.1007/s00431-022-04561-1 [pii] AID - 4561 [pii] AID - 10.1007/s00431-022-04561-1 [doi] PST - ppublish SO - Eur J Pediatr. 2022 Sep;181(9):3501-3509. doi: 10.1007/s00431-022-04561-1. Epub 2022 Jul 14. PMID- 35830754 OWN - NLM STAT- MEDLINE DCOM- 20220726 LR - 20250103 IS - 1879-1379 (Electronic) IS - 0022-3956 (Print) IS - 0022-3956 (Linking) VI - 152 DP - 2022 Aug TI - Online cognitive behavioural therapy as a psychological vaccine against stress during the COVID-19 pandemic in pregnant women: A randomised controlled trial. PG - 397-405 LID - S0022-3956(22)00380-6 [pii] LID - 10.1016/j.jpsychires.2022.07.016 [doi] AB - The COVID-19 pandemic has affected the population's levels of stress and anxiety due to its contagious nature and the uncertainties generated by its novelty. One population that is especially vulnerable to these psychological consequences are pregnant women. This is why the objective of this study was to test the efficacy of an online stress management programme of a cognitive behavioural nature on pregnant women during the COVID-19 pandemic, in Spain. The trial was controlled and randomised, with a total of 207 pregnant women divided into three groups: the Online Cognitive Behavioural Therapy group (o-CBT) (N = 70); the Online Psychological Support group (o-PS) (N = 69); and the Usual Care group (UC) (N = 68). To test the therapy's efficacy, the women's resilience, perceived stress, pregnancy-specific stress and psychopathological symptoms were assessed before and after the intervention. The o-CBT and o-PS consisted of a programme of 8 group sessions (one per week). The results showed that pregnant women who participated in the o-CBT group presented lower rates of pregnancy-specific stress and perceived stress, as well as greater resilience and lower anxiety, depression and obsessions-compulsions symptoms. These data show the efficacy of the treatment programme and thus confirm the importance of implementing these types of interventions during a woman's pregnancy, especially over periods of major stress, such as during a pandemic. CI - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. FAU - Puertas-Gonzalez, Jose A AU - Puertas-Gonzalez JA AD - Mind, Brain and Behaviour Research Center (CIMCYC), Granada, Spain; Personality, Assessment and Psychological Treatment Department, Faculty of Psychology, University of Granada, Granada, Spain. FAU - Marino-Narvaez, Carolina AU - Marino-Narvaez C AD - Mind, Brain and Behaviour Research Center (CIMCYC), Granada, Spain. FAU - Romero-Gonzalez, Borja AU - Romero-Gonzalez B AD - Psychology Department, Faculty of Education, University of Valladolid, Campus Duques de Soria, Soria, Spain. Electronic address: borja.romero@uva.es. FAU - Sanchez-Perez, Gracia M AU - Sanchez-Perez GM AD - Mind, Brain and Behaviour Research Center (CIMCYC), Granada, Spain. FAU - Peralta-Ramirez, Maria Isabel AU - Peralta-Ramirez MI AD - Mind, Brain and Behaviour Research Center (CIMCYC), Granada, Spain; Personality, Assessment and Psychological Treatment Department, Faculty of Psychology, University of Granada, Granada, Spain. LA - eng PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't DEP - 20220707 PL - England TA - J Psychiatr Res JT - Journal of psychiatric research JID - 0376331 RN - 0 (Vaccines) SB - IM MH - Anxiety/psychology MH - *COVID-19/prevention & control MH - *Cognitive Behavioral Therapy/methods MH - Depression/prevention & control MH - Female MH - Humans MH - Pandemics/prevention & control MH - Pregnancy MH - Pregnant People/psychology MH - Stress, Psychological/psychology MH - *Vaccines PMC - PMC9259661 OTO - NOTNLM OT - COVID-19 OT - Cognitive Behavioural Therapy OT - Pregnancy OT - Psychopathology OT - Resilience OT - Stress COIS- The authors declare no conflict of interest. EDAT- 2022/07/14 06:00 MHDA- 2022/07/27 06:00 PMCR- 2022/07/07 CRDT- 2022/07/13 18:14 PHST- 2021/08/24 00:00 [received] PHST- 2022/06/18 00:00 [revised] PHST- 2022/07/04 00:00 [accepted] PHST- 2022/07/14 06:00 [pubmed] PHST- 2022/07/27 06:00 [medline] PHST- 2022/07/13 18:14 [entrez] PHST- 2022/07/07 00:00 [pmc-release] AID - S0022-3956(22)00380-6 [pii] AID - 10.1016/j.jpsychires.2022.07.016 [doi] PST - ppublish SO - J Psychiatr Res. 2022 Aug;152:397-405. doi: 10.1016/j.jpsychires.2022.07.016. Epub 2022 Jul 7. PMID- 35788744 OWN - NLM STAT- MEDLINE DCOM- 20220811 LR - 20250728 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 269 IP - 9 DP - 2022 Sep TI - SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19. PG - 4581-4603 LID - 10.1007/s00415-022-11237-1 [doi] AB - The SARS-CoV-2 pandemic has raised particular concern for people with Multiple Sclerosis, as these people are believed to be at increased risk of infection, especially those being treated with disease-modifying therapies. Therefore, the objective of this review was to describe how COVID-19 affects people who suffer from Multiple Sclerosis, evaluating the risk they have of suffering an infection by this virus, according to the therapy to which they are subjected as well as the immune response of these patients both to infection and vaccines and the neurological consequences that the virus can have in the long term. The results regarding the increased risk of infection due to treatment are contradictory. B-cell depletion therapies may cause patients to have a lower probability of generating a detectable neutralizing antibody titer. However, more studies are needed to help understand how this virus works, paying special attention to long COVID and the neurological symptoms that it causes. CI - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany. FAU - Munoz-Jurado, Ana AU - Munoz-Jurado A AUID- ORCID: 0000-0002-7908-861X AD - Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, University of Cordoba, Campus of Rabanales, 14071, Cordoba, Spain. b22mujua@uco.es. FAU - Escribano, Begona M AU - Escribano BM AD - Department of Cell Biology, Physiology and Immunology, Faculty of Veterinary Medicine, University of Cordoba, Campus of Rabanales, 14071, Cordoba, Spain. AD - Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. FAU - Aguera, Eduardo AU - Aguera E AD - Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. AD - Neurology Service, Reina Sofia University Hospital, Cordoba, Spain. FAU - Caballero-Villarraso, Javier AU - Caballero-Villarraso J AD - Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. AD - Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain. AD - Clinical Analysis Service, Reina Sofia University Hospital, Cordoba, Spain. FAU - Galvan, Alberto AU - Galvan A AD - Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. AD - Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain. FAU - Tunez, Isaac AU - Tunez I AUID- ORCID: 0000-0002-4493-7087 AD - Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBC), Cordoba, Spain. itunez@uco.es. AD - Department of Biochemistry and Molecular Biology, Faculty of Medicine and Nursing, University of Cordoba, Av. Menendez Pidal, 14004, Cordoba, Spain. itunez@uco.es. AD - Cooperative Research Thematic Excellent Network on Brain Stimulation (REDESTIM), Madrid, Spain. itunez@uco.es. LA - eng PT - Journal Article PT - Review DEP - 20220705 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (Antibodies, Viral) RN - 0 (COVID-19 Vaccines) SB - IM MH - Antibodies, Viral MH - *COVID-19/complications MH - COVID-19 Vaccines/adverse effects MH - Humans MH - *Multiple Sclerosis/complications/therapy MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome PMC - PMC9253265 OTO - NOTNLM OT - Adjuvant treatments OT - Disease-modifying therapies OT - Immunity OT - Multiple sclerosis OT - Neuro-COVID OT - SARS-CoV-2 COIS- The authors declare that they have no conflict of interest. EDAT- 2022/07/06 06:00 MHDA- 2022/08/12 06:00 PMCR- 2022/07/05 CRDT- 2022/07/05 18:46 PHST- 2022/04/08 00:00 [received] PHST- 2022/06/14 00:00 [accepted] PHST- 2022/06/14 00:00 [revised] PHST- 2022/07/06 06:00 [pubmed] PHST- 2022/08/12 06:00 [medline] PHST- 2022/07/05 18:46 [entrez] PHST- 2022/07/05 00:00 [pmc-release] AID - 10.1007/s00415-022-11237-1 [pii] AID - 11237 [pii] AID - 10.1007/s00415-022-11237-1 [doi] PST - ppublish SO - J Neurol. 2022 Sep;269(9):4581-4603. doi: 10.1007/s00415-022-11237-1. Epub 2022 Jul 5. PMID- 35747550 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230602 IS - 2163-0402 (Print) IS - 2163-0933 (Electronic) IS - 2163-0402 (Linking) VI - 12 IP - 3 DP - 2022 Jun TI - SARS-CoV-2 Infection and Vaccination Outcomes in Multiple Sclerosis. PG - e14-e21 LID - 10.1212/CPJ.0000000000001164 [doi] AB - BACKGROUND AND OBJECTIVES: The effects of the SARS-CoV-2 vaccination and infection on clinical outcomes, including relapse risk, have been insufficiently explored in people with multiple sclerosis (PwMS). The objectives of this study were to determine the incidence of new neurologic symptoms or symptom recrudescence among PwMS who received the SARS-CoV-2 vaccine, characterize outcomes after SARS-CoV-2 infection, and assess MS-specific determinants of vaccine hesitancy. METHODS: Online surveys that assessed incidence and severity of SARS-CoV-2 infection, vaccination status/type, reasons for vaccine deferral, and postvaccination symptoms were administered to PwMS. Medical charts were reviewed for consenting respondents. Associations between infection, postvaccination outcomes, and clinical characteristics were compared using chi(2) tests, 2-sample t tests, and adjusted logistic regression models. RESULTS: In total, 292 of 333 respondents were vaccinated, of whom 58% reported postvaccination side effects, most commonly among mRNA vaccine recipients (p = 0.02), younger patients (p < 0.01), and people with relapsing-remitting MS (p = 0.03). Twelve percent endorsed recrudescence of existing MS symptoms, while 3% endorsed new neurologic symptoms postvaccination. Sixty-two participants reported SARS-CoV-2 infection since the start of the pandemic, more frequent in younger individuals (1-year odds ratio [OR] = 0.958, 10-year OR = 0.649, p < 0.01). Neither disease-modifying therapy nor B-cell therapies specifically were associated with vaccine side effects, neurologic symptoms, or SARS-CoV-2 infection. Twenty-one percent of unvaccinated cited a desire for provider guidance before vaccination. DISCUSSION: Our findings provide new data to suggest that among PwMS who received SARS-CoV-2 vaccination, clinical disease worsening is rare and mostly associated with symptom recrudescence, as opposed to new relapses. Postvaccination side effects may occur more often among mRNA vaccine recipients and in younger individuals. CI - (c) 2022 American Academy of Neurology. FAU - Brunn, Jenna A AU - Brunn JA AD - Michigan Medicine (JAB), Department of Neurology, University of Michigan, Ann Arbor; Michigan Medicine (GLD, TJB), Department of Neurology, Division of Sleep Medicine, University of Michigan, Ann Arbor; and Michigan Medicine (ARR, TJB), Department of Neurology, Division of Multiple Sclerosis and Clinical Neuroimmunology, University of Michigan, Ann Arbor. FAU - Dunietz, Galit Levi AU - Dunietz GL AD - Michigan Medicine (JAB), Department of Neurology, University of Michigan, Ann Arbor; Michigan Medicine (GLD, TJB), Department of Neurology, Division of Sleep Medicine, University of Michigan, Ann Arbor; and Michigan Medicine (ARR, TJB), Department of Neurology, Division of Multiple Sclerosis and Clinical Neuroimmunology, University of Michigan, Ann Arbor. FAU - Romeo, Andrew R AU - Romeo AR AD - Michigan Medicine (JAB), Department of Neurology, University of Michigan, Ann Arbor; Michigan Medicine (GLD, TJB), Department of Neurology, Division of Sleep Medicine, University of Michigan, Ann Arbor; and Michigan Medicine (ARR, TJB), Department of Neurology, Division of Multiple Sclerosis and Clinical Neuroimmunology, University of Michigan, Ann Arbor. FAU - Braley, Tiffany J AU - Braley TJ AD - Michigan Medicine (JAB), Department of Neurology, University of Michigan, Ann Arbor; Michigan Medicine (GLD, TJB), Department of Neurology, Division of Sleep Medicine, University of Michigan, Ann Arbor; and Michigan Medicine (ARR, TJB), Department of Neurology, Division of Multiple Sclerosis and Clinical Neuroimmunology, University of Michigan, Ann Arbor. LA - eng PT - Journal Article PL - United States TA - Neurol Clin Pract JT - Neurology. Clinical practice JID - 101577149 PMC - PMC9208419 EDAT- 2022/06/25 06:00 MHDA- 2022/06/25 06:01 PMCR- 2023/06/01 CRDT- 2022/06/24 02:16 PHST- 2021/11/15 00:00 [received] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/06/24 02:16 [entrez] PHST- 2022/06/25 06:00 [pubmed] PHST- 2022/06/25 06:01 [medline] PHST- 2023/06/01 00:00 [pmc-release] AID - NEURCLINPRACT2021070229 [pii] AID - 10.1212/CPJ.0000000000001164 [doi] PST - ppublish SO - Neurol Clin Pract. 2022 Jun;12(3):e14-e21. doi: 10.1212/CPJ.0000000000001164. PMID- 35702684 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231105 IS - 2049-0801 (Print) IS - 2049-0801 (Electronic) IS - 2049-0801 (Linking) VI - 79 DP - 2022 Jul TI - The association between SARS-CoV-2 vaccines and transverse myelitis: A review. PG - 103870 LID - 10.1016/j.amsu.2022.103870 [doi] LID - 103870 AB - In late 2019, the emergence of a new viral strain, later referred to as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) took the shape of a global pandemic, affecting millions of lives and deteriorating economies around the globe. Vaccines were developed at an exceptional rate to combat the viral desolation, all of them being rolled out once they displayed sufficient safety and efficacy. However, assorted adverse events came into attention, one of them being Transverse Myelitis (TM), an infrequent, immune-mediated, focal disease of the spinal cord. This disorder can lead to severe neurological complications including autonomic, sensory, and motor deficits. The literature aims to shed light on TM and its various etiologies, specifically in line with the vaccine, and a comprehensive treatment plan. Discussing and reducing the number of vaccines related adverse events can help succor in bringing down the vaccine hesitancy and ultimately combatting the pandemic. CI - (c) 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. FAU - Naeem, Fatima Naz AU - Naeem FN AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Hasan, Syeda Fatima Saba AU - Hasan SFS AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Ram, Muskaan Doulat AU - Ram MD AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Waseem, Summaiyya AU - Waseem S AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Ahmed, Syed Hassan AU - Ahmed SH AD - Dow University of Health Sciences, Karachi, Pakistan. FAU - Shaikh, Taha Gul AU - Shaikh TG AD - Dow University of Health Sciences, Karachi, Pakistan. LA - eng PT - Journal Article PT - Review DEP - 20220609 PL - England TA - Ann Med Surg (Lond) JT - Annals of medicine and surgery (2012) JID - 101616869 PMC - PMC9181565 OTO - NOTNLM OT - Coronavirus OT - Neurological manifestation OT - Transverse myelitis OT - Vaccine COIS- N/A. EDAT- 2022/06/16 06:00 MHDA- 2022/06/16 06:01 PMCR- 2022/06/09 CRDT- 2022/06/15 02:17 PHST- 2022/04/17 00:00 [received] PHST- 2022/05/19 00:00 [revised] PHST- 2022/05/22 00:00 [accepted] PHST- 2022/06/15 02:17 [entrez] PHST- 2022/06/16 06:00 [pubmed] PHST- 2022/06/16 06:01 [medline] PHST- 2022/06/09 00:00 [pmc-release] AID - S2049-0801(22)00630-6 [pii] AID - 103870 [pii] AID - 10.1016/j.amsu.2022.103870 [doi] PST - epublish SO - Ann Med Surg (Lond). 2022 Jun 9;79:103870. doi: 10.1016/j.amsu.2022.103870. eCollection 2022 Jul. PMID- 35699579 OWN - NLM STAT- MEDLINE DCOM- 20221123 LR - 20221219 IS - 1527-1315 (Electronic) IS - 0033-8419 (Print) IS - 0033-8419 (Linking) VI - 305 IP - 3 DP - 2022 Dec TI - Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. PG - 590-596 LID - 10.1148/radiol.220365 [doi] AB - Vaccination strategies have been at the forefront of controlling the COVID-19 pandemic. An association between vaccine-induced immune thrombotic thrombocytopenia (VITT) and one of these vaccines, the ChAdOx1 nCov-19 vaccine, is now recognized. The purpose of this study was to investigate the frequency and location of thrombosis in each vascular system using CT, MRI, and US to identify additional sites of thrombus in a United Kingdom-wide sample of patients with confirmed VITT. Thirty-two radiology centers identified through the national collaborative Radiology Academic Network for Trainees were invited from the United Kingdom; seven of these contributed to this study. All patients with confirmed VITT notbetween February 3 and May 12, 2021, who met the inclusion criteria were included. The location and extent of thrombi were evaluated using CT, MRI, and US. A total of 40 patients (median age, 41 years [IQR, 32-52]; 22 [55%] men) with confirmed vaccine-induced immune thrombotic thrombocytopenia after administration of their first ChAdOx1 nCov-19 vaccine were included. Thirty-two patients (80%) developed symptoms within the first 14 days, and eight (20%) developed symptoms within 14-28 days. Twenty-nine patients (72%) experienced neurologic symptoms and were confirmed to have cerebral venous sinus thrombosis, 12 (30%) had clinical deterioration and repeat imaging demonstrated extension of their primary thrombus, and eight (20%) died. Twenty-five of 30 patients (83%) who underwent additional imaging had occult thrombosis. In conclusion, patients with VITT are likely to have multiple sites of thrombosis, with the most frequent being cerebral venous sinus thrombosis in combination with pulmonary embolism and portomesenteric venous thrombosis. Whole-body imaging with contrast-enhanced CT can be used to identify occult thrombosis. CI - (c) RSNA, 2022. FAU - Rogers, Priya AU - Rogers P AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Walker, Ieuan AU - Walker I AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Yeung, Jason AU - Yeung J AUID- ORCID: 0000-0003-2415-4824 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Khan, Abeera AU - Khan A AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Gangi, Anmol AU - Gangi A AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Mobashwera, Behnaz AU - Mobashwera B AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Ayto, Robert AU - Ayto R AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Shah, Ali AU - Shah A AUID- ORCID: 0000-0002-7343-8834 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Hermans, Joannes AU - Hermans J AUID- ORCID: 0000-0002-5703-512X AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Murchison, Andrew AU - Murchison A AUID- ORCID: 0000-0001-8886-9891 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Benger, Matthew AU - Benger M AUID- ORCID: 0000-0002-3109-3188 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Apap Mangion, Sean AU - Apap Mangion S AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Mehta, Puja R AU - Mehta PR AUID- ORCID: 0000-0002-0255-407X AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Sztriha, Laszlo AU - Sztriha L AUID- ORCID: 0000-0003-4639-3180 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Ghatorae, Simrit AU - Ghatorae S AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Craven, Brian AU - Craven B AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Scully, Marie AU - Scully M AUID- ORCID: 0000-0002-2443-6517 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Bray, Timothy AU - Bray T AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - Hall-Craggs, Margaret AU - Hall-Craggs M AUID- ORCID: 0000-0001-8734-4065 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). FAU - von Stempel, Conrad AU - von Stempel C AUID- ORCID: 0000-0002-3088-2775 AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). CN - RADIANT Group AD - From the Department of Radiology, Addenbrooke's Hospital, Cambridge, UK (P.R., I.W.); Department of Radiology, University College London Hospital, 235 Euston Rd, UCH Podium 2, London NW1 2BU, UK (J.Y., B.C., M.S., T.B., M.H.C., C.v.S.); Department of Haematology, Queen Alexandra Hospital, Portsmouth, UK (A.K., A.G., B.M., R.A.); Department of Imaging, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK (A.S., J.H.); Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK (A.M.); Department of Neurology, King's College Hospital, London, UK (M.B., S.A.M., P.R.M., L.S.); Department of Imaging, Queen Elizabeth University Hospital, Glasgow, UK (S.G.); Centre for Medical Imaging, University College London, UK (A.S., T.B., M.H.C.); Radiology Academic Network for Trainees (RADIANT), London, UK (P.R., J.Y., A.K., A.G., A.M., M.B., T.B., M.H.C.). LA - eng PT - Journal Article DEP - 20220614 PL - United States TA - Radiology JT - Radiology JID - 0401260 RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) RN - 0 (Vaccines) SB - IM MH - Male MH - Humans MH - Adult MH - Female MH - ChAdOx1 nCoV-19 MH - Pandemics MH - *COVID-19 MH - *Thrombocytopenia/chemically induced/diagnostic imaging MH - *Vaccines MH - Vaccination/adverse effects MH - *Thrombosis MH - *Sinus Thrombosis, Intracranial PMC - PMC9219093 COIS- Disclosures of conflicts of interest: P.R. No relevant relationships. I.W. No relevant relationships. J.Y. No relevant relationships. A.K. No relevant relationships. A.G. No relevant relationships. B.M. No relevant relationships. R.A. Honoraria from Janssen, Abbvie, and MRD; travel and meeting support from Abbvie, Celgene, Takeda, and Janssen. A.S. No relevant relationships. J.H. Honoraria from Bayer and Pfizer; travel and meeting support from Novartis, Bayer, Sobi, and Novo Nordisk. A.M. No relevant relationships. M.B. No relevant relationships. S.A.M. No relevant relationships. P.R.M. No relevant relationships. L.S. No relevant relationships. S.G. No relevant relationships. B.C. No relevant relationships. M.S. No relevant relationships. T.B. National Institute for Health Research clinical lectureship. M.H.C. No relevant relationships. C.v.S. Payment for a seminar from Penumbra Medical; travel grant from the British Society of Interventional Radiology. EDAT- 2022/06/15 06:00 MHDA- 2022/11/24 06:00 PMCR- 2022/06/14 CRDT- 2022/06/14 09:52 PHST- 2022/06/15 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2022/06/14 09:52 [entrez] PHST- 2022/06/14 00:00 [pmc-release] AID - 10.1148/radiol.220365 [doi] PST - ppublish SO - Radiology. 2022 Dec;305(3):590-596. doi: 10.1148/radiol.220365. Epub 2022 Jun 14. PMID- 35696935 OWN - NLM STAT- MEDLINE DCOM- 20220708 LR - 20221221 IS - 1525-5069 (Electronic) IS - 1525-5050 (Print) IS - 1525-5050 (Linking) VI - 133 DP - 2022 Aug TI - COVID-19 vaccine-related frequently asked questions (FAQs) by people with epilepsy and carers in Iran; educational video is included. PG - 108763 LID - S1525-5050(22)00212-8 [pii] LID - 10.1016/j.yebeh.2022.108763 [doi] AB - OBJECTIVE: The aim of the current study was to inquire the questions and concerns of people with epilepsy (PWE) about COVID-19 vaccines in order to provide a more realistic list of their frequently asked questions (FAQs). METHODS: We surveyed all the consecutive PWE or their care-givers who were referred to our neurology clinics (Shiraz University of Medical Sciences) during January-February 2022. We collected their questions and concerns in relation to COVID vaccines based on a predesigned brief questionnaire. Informed consent to participate in the study was obtained from the participants. RESULTS: In total, 452 people participated in the study; 291 people (64.4%) did not have any questions or concerns with regard to the COVID-19 vaccination. Having any questions or concerns about COVID-19 vaccination was significantly associated with not being vaccinated. Questions and concerns about the adverse effects of COVID-19 vaccines [seizure worsening, general adverse effects, long-term effects (e.g., infertility, cognitive dysfunction)] were by far the most common questions by people with epilepsy and their carers. CONCLUSION: Our findings may be used by policy-makers to prepare appropriate educational materials to provide the best targeted and tailored information to people with epilepsy and their carers to convince them of the necessity and safety of COVID-19 vaccination. Such an educational material must include enough information on the associated adverse effects of COVID-19 vaccines and should also discuss some other important issues such as indications of these vaccines in special populations and drug-vaccine interactions. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Asadi-Pooya, Ali A AU - Asadi-Pooya AA AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Jefferson Comprehensive Epilepsy Center, Department of Neurology, Thomas Jefferson University, Philadelphia, USA. Electronic address: aliasadipooya@yahoo.com. FAU - Karimi, Afrooz AU - Karimi A AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Razavizadegan, Seyed Mohammad Ali AU - Razavizadegan SMA AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Ashjazadeh, Nahid AU - Ashjazadeh N AD - Department of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran. FAU - Nemati, Hamid AU - Nemati H AD - Epilepsy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220519 PL - United States TA - Epilepsy Behav JT - Epilepsy & behavior : E&B JID - 100892858 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Caregivers MH - *Epilepsy/psychology MH - Humans MH - Iran/epidemiology MH - SARS-CoV-2 MH - *Vaccines PMC - PMC9117255 OTO - NOTNLM OT - COVID-19 OT - Coronavirus OT - Epilepsy OT - Seizure OT - Vaccine EDAT- 2022/06/14 06:00 MHDA- 2022/07/09 06:00 PMCR- 2022/05/19 CRDT- 2022/06/13 18:24 PHST- 2022/03/09 00:00 [received] PHST- 2022/04/21 00:00 [revised] PHST- 2022/05/17 00:00 [accepted] PHST- 2022/06/14 06:00 [pubmed] PHST- 2022/07/09 06:00 [medline] PHST- 2022/06/13 18:24 [entrez] PHST- 2022/05/19 00:00 [pmc-release] AID - S1525-5050(22)00212-8 [pii] AID - 108763 [pii] AID - 10.1016/j.yebeh.2022.108763 [doi] PST - ppublish SO - Epilepsy Behav. 2022 Aug;133:108763. doi: 10.1016/j.yebeh.2022.108763. Epub 2022 May 19. PMID- 35687921 OWN - NLM STAT- MEDLINE DCOM- 20220712 LR - 20230328 IS - 1532-2653 (Electronic) IS - 0967-5868 (Print) IS - 0967-5868 (Linking) VI - 102 DP - 2022 Aug TI - Meaningful use of imaging resources to rule out cerebral venous sinus thrombosis after ChAdOx1 COVID-19 vaccination: Evaluation of the AHA diagnostic algorithm with a clinical cohort and a systematic data review. PG - 5-12 LID - S0967-5868(22)00245-4 [pii] LID - 10.1016/j.jocn.2022.05.031 [doi] AB - Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous thrombosis (CVST) is an improbable (0.0005%), however potentially lethal complication after ChAdOx1 vaccination. On the other hand, headache is among the most frequent side effects of ChAdOx1 (29.3%). In September 2021, the American Heart Association (AHA) suggested a diagnostic workflow to facilitate risk-adapted use of imaging resources for patients with neurological symptoms after ChAdOx1. We aimed to evaluate the AHA workflow in a retrospective patient cohort presenting at four primary care hospitals in Germany for neurological complaints after ChAdOx1. Scientific literature was screened for case reports of VITT with CVST after ChAdOx1, published until September 1st, 2021. One-hundred-thirteen consecutive patients (77 female, mean age 38.7 +/- 11.9 years) were evaluated at our institutes, including one case of VITT with CVST. Further 228 case reports of VITT with CVST are published in recent literature, which share thrombocytopenia (225/227 reported) and elevated d-dimer levels (100/101 reported). The AHA workflow would have recognized all VITT cases with CVST (100% sensitivity), the number needed to diagnose (NND) was 1:113. Initial evaluation of thrombocytopenia or elevated d-dimer levels would have lowered the NND to 1:68, without cost of sensitivity. Hence, we suggest that in case of normal thrombocyte and d-dimer levels, the access to further diagnostics should be limited by the established clinical considerations regardless of vaccination history. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Fervers, Philipp AU - Fervers P AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Philipp.Fervers@uk-koeln.de. FAU - Kottlors, Jonathan AU - Kottlors J AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Jonathan.Kottlors@uk-koeln.de. FAU - Persigehl, Thorsten AU - Persigehl T AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Thorsten.Persigehl@uk-koeln.de. FAU - Lennartz, Simon AU - Lennartz S AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Simon.Lennartz@uk-koeln.de. FAU - Maus, Volker AU - Maus V AD - Department of Diagnostic and Interventional Radiology, University Hospital Knappschaftskrankenhaus Bochum-Langendreer, University Bochum, Bochum, Germany. Electronic address: Volker.Maus@kk-bochum.de. FAU - Fischer, Sebastian AU - Fischer S AD - Department of Diagnostic and Interventional Radiology, University Hospital Knappschaftskrankenhaus Bochum-Langendreer, University Bochum, Bochum, Germany. Electronic address: Sebastian.Fischer@kk-bochum.de. FAU - Styczen, Hanna AU - Styczen H AD - Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. Electronic address: Hanna.Styczen@uk-essen.de. FAU - Deuschl, Cornelius AU - Deuschl C AD - Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany. Electronic address: Cornelius.Deuschl@uk-essen.de. FAU - Schlamann, Marc AU - Schlamann M AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Marc.Schlamann@uk-koeln.de. FAU - Mpotsaris, Anastasios AU - Mpotsaris A AD - University Clinic for Neuroradiology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: Anastasios.Mpotsaris@med.ovgu.de. FAU - Zubel, Seraphine AU - Zubel S AD - University Clinic for Neuroradiology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany. Electronic address: Seraphine.Zubel@med.ovgu.de. FAU - Schroeter, Michael AU - Schroeter M AD - Department of Neurology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Michael.Schroeter@uk-koeln.de. FAU - Maintz, David AU - Maintz D AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: David.Maintz@uk-koeln.de. FAU - Fink, Gereon Rudolf AU - Fink GR AD - Department of Neurology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Julich, Julich, Germany. Electronic address: G.R.Fink@fz-juelich.de. FAU - Abdullayev, Nuran AU - Abdullayev N AD - Department of Diagnostic and Interventional Radiology, Faculty of Medicine and University Hospital Cologne, University Cologne, Cologne, Germany. Electronic address: Nuran.Abdullayev@uk-koeln.de. LA - eng PT - Journal Article PT - Systematic Review DEP - 20220606 PL - Scotland TA - J Clin Neurosci JT - Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia JID - 9433352 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Algorithms MH - COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Female MH - Humans MH - Male MH - Meaningful Use MH - Middle Aged MH - Retrospective Studies MH - *Sinus Thrombosis, Intracranial/diagnostic imaging/etiology PMC - PMC9167954 OTO - NOTNLM OT - American Heart Association OT - Headache OT - Intracranial thrombosis OT - Meaningful use OT - Vaccines COIS- The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: DM is on the speaker's bureau of Philips Healthcare. AM is a consultant for Stryker, Perflow, Phenox and Balt. SF is a consultant for Microvention. MS received personal honoraria from Alexion, Biogen, Gilead, Roche, and Sanofi. All other authors have nothing to disclose. EDAT- 2022/06/11 06:00 MHDA- 2022/07/14 06:00 PMCR- 2022/06/06 CRDT- 2022/06/10 18:13 PHST- 2022/03/23 00:00 [received] PHST- 2022/05/30 00:00 [revised] PHST- 2022/05/31 00:00 [accepted] PHST- 2022/06/11 06:00 [pubmed] PHST- 2022/07/14 06:00 [medline] PHST- 2022/06/10 18:13 [entrez] PHST- 2022/06/06 00:00 [pmc-release] AID - S0967-5868(22)00245-4 [pii] AID - 10.1016/j.jocn.2022.05.031 [doi] PST - ppublish SO - J Clin Neurosci. 2022 Aug;102:5-12. doi: 10.1016/j.jocn.2022.05.031. Epub 2022 Jun 6. PMID- 35672709 OWN - NLM STAT- MEDLINE DCOM- 20220609 LR - 20220716 IS - 1471-2377 (Electronic) IS - 1471-2377 (Linking) VI - 22 IP - 1 DP - 2022 Jun 7 TI - Inactivated COVID-19 vaccine induced acute stroke-like focal neurologic symptoms: a case series. PG - 210 LID - 10.1186/s12883-022-02739-6 [doi] LID - 210 AB - BACKGROUND: A subgroup of individuals experienced stroke-like symptoms after receiving an inactivated COVID-19 vaccine. We present clinical characteristics, neuroimaging, and outcome of these patients. METHODS: Medical personals who had neurological symptoms after receiving inactivated COVID-19 vaccine were enrolled. Clinical, laboratory investigation and neuroimaging were collected. Subjects were prospectively followed-up on clinical and neuroimaging to detect brain parenchymal or cerebrovascular abnormality. RESULTS: Nineteen out of 385 subjects (4.9%) developed neurological symptoms after vaccination. There was a female predominance (89.5%) with mean age of 34 +/- 7.5 years. Majority of patients (52.6%) had symptoms within 60 min after vaccination. The most common neurological symptoms were numbness (94.7%) followed by headache (52.6%) and weakness (47.4%). The most common neurological signs were sensory deficit (79%) followed by motor weakness (52.6%) and tongue deviation (26.3%). Recurrent headache was observed in most patients (89.5%) during followed up. Serial brain imaging was done in all patients with median follow-up interval of 18 days. There was no evidence of acute brain infarction in any of the patients, 84.2% had no vascular abnormality, 15.8% had transient focal narrowing of cerebral vessels. Outcome was favorable, modified ranking scale 0-1 for all patients at 4 weeks after vaccination. CONCLUSIONS: Transient focal neurological symptoms and deficits can be found after COVID-19 vaccination. However, benefit to stop COVID-19 pandemic by vaccination is outweighed by these seemingly reversible side effects. The pathophysiology underlined these phenomena should be further investigated. CI - (c) 2022. The Author(s). FAU - Roongpiboonsopit, Duangnapa AU - Roongpiboonsopit D AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Naresuan University, 99 Moo 9, Tha Pho, Mueang, Phitsanulok, 65000, Thailand. Duangnapar@nu.ac.th. FAU - Nithisathienchai, Chichaya AU - Nithisathienchai C AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Naresuan University, 99 Moo 9, Tha Pho, Mueang, Phitsanulok, 65000, Thailand. FAU - Akarathanawat, Wasan AU - Akarathanawat W AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Lertutsahakul, Krittanon AU - Lertutsahakul K AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tantivattana, Jarturon AU - Tantivattana J AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Viswanathan, Anand AU - Viswanathan A AD - Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA. FAU - Suwanwela, Nijasri Charnnarong AU - Suwanwela NC AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn Comprehensive Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. LA - eng PT - Journal Article DEP - 20220607 PL - England TA - BMC Neurol JT - BMC neurology JID - 100968555 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Female MH - Headache/etiology MH - Humans MH - Male MH - Pandemics MH - SARS-CoV-2 MH - *Stroke/etiology PMC - PMC9170873 OTO - NOTNLM OT - Case series OT - Inactivated COVID-19 vaccine OT - Neurological complication OT - Stroke-like symptoms COIS- The authors declare that they have no competing interests. EDAT- 2022/06/08 06:00 MHDA- 2022/06/10 06:00 PMCR- 2022/06/07 CRDT- 2022/06/07 23:40 PHST- 2021/11/15 00:00 [received] PHST- 2022/05/24 00:00 [accepted] PHST- 2022/06/07 23:40 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/10 06:00 [medline] PHST- 2022/06/07 00:00 [pmc-release] AID - 10.1186/s12883-022-02739-6 [pii] AID - 2739 [pii] AID - 10.1186/s12883-022-02739-6 [doi] PST - epublish SO - BMC Neurol. 2022 Jun 7;22(1):210. doi: 10.1186/s12883-022-02739-6. PMID- 35668936 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230916 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - COVID-19 Vaccine-Associated Transient Global Amnesia: A Disproportionality Analysis of the WHO Safety Database. PG - 909412 LID - 10.3389/fphar.2022.909412 [doi] LID - 909412 AB - Coronavirus disease 2019 (COVID-19) spread rapidly, resulting in a global pandemic for which vaccines were quickly developed. As their safety continues to be monitored, cases of transient global amnesia (TGA) following mRNA vaccination with elasomeran have been reported. TGA is characterized by sudden onset of anterograde amnesia with preservation of other cognitive functions and resolution within 24 h. We aimed to investigate the potential link of TGA with COVID-19 vaccines. We queried the World Health Organization VigiBase((R)) for all reports of "Transient global amnesia", up to 6 December 2021. Disproportionality analysis relied on the Reporting Odds Ratio (ROR) with its 95% Confidence Interval (CI) and the Information Component (IC). A positive lower end of the 95% CI of the IC (IC025) is used to statistically detect a signal. Of all TGA cases, 289 were associated with a COVID-19 vaccine, representing the most frequent association. Tozinameran was mostly represented (147, 50.8%), followed by AZD1222 (69, 23,8%), elasomeran (60, 20.8%), and JNJ-78436735 (12, 4.2%). With an IC025 > 0, COVID-19 vaccines showed a significant ROR (5.1; 95%CI 4.4-6.0). Tozinameran reached the strongest ROR (4.6; 95%CI 3.9-5.0), followed by elasomeran (4.4; 95%CI 3.4-6.0), AZD1222 (3.8; 95%CI 3.0-5.0), and JNJ-78436735 (3.7; 95%CI 2.1-6.0). Our analysis of COVID-19 vaccines-related TGA reports shows significant disproportionality. Cerebrovascular, inflammatory, or migrainous mechanisms may underlie this association. Yet, numerous confounding factors cannot be tackled with this approach, and causality cannot be ascertained. The identification of this trigger of TGA may help the clinician in his etiological research. CI - Copyright (c) 2022 Merino, Gerard, Van Obberghen, Ben Othman, Ettore, Giordana, Viard, Rocher, Destere, Benoit and Drici. FAU - Merino, Diane AU - Merino D AD - Department of Psychiatry, University Hospital of Nice, Nice, France. AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. FAU - Gerard, Alexandre O AU - Gerard AO AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. AD - Department of Nephrology-Dialysis-Transplantation, University Hospital of Nice, Nice, France. FAU - Van Obberghen, Elise K AU - Van Obberghen EK AD - Department of Neurology, University Hospital of Nice, Nice, France. FAU - Ben Othman, Nouha AU - Ben Othman N AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. FAU - Ettore, Eric AU - Ettore E AD - Department of Psychiatry, University Hospital of Nice, Nice, France. FAU - Giordana, Bruno AU - Giordana B AD - Department of Psychiatry, University Hospital of Nice, Nice, France. FAU - Viard, Delphine AU - Viard D AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. FAU - Rocher, Fanny AU - Rocher F AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. FAU - Destere, Alexandre AU - Destere A AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. FAU - Benoit, Michel AU - Benoit M AD - Department of Psychiatry, University Hospital of Nice, Nice, France. FAU - Drici, Milou-Daniel AU - Drici MD AD - Department of Pharmacology and Pharmacovigilance Center of Nice, University Hospital of Nice, Nice, France. LA - eng PT - Journal Article DEP - 20220520 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9164011 OTO - NOTNLM OT - COVID-19 vaccines OT - adverse drug reaction OT - clinical epidemiology OT - pharmacology OT - transient global amnesia COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/06/08 06:00 MHDA- 2022/06/08 06:01 PMCR- 2022/05/20 CRDT- 2022/06/07 02:20 PHST- 2022/03/31 00:00 [received] PHST- 2022/05/02 00:00 [accepted] PHST- 2022/06/07 02:20 [entrez] PHST- 2022/06/08 06:00 [pubmed] PHST- 2022/06/08 06:01 [medline] PHST- 2022/05/20 00:00 [pmc-release] AID - 909412 [pii] AID - 10.3389/fphar.2022.909412 [doi] PST - epublish SO - Front Pharmacol. 2022 May 20;13:909412. doi: 10.3389/fphar.2022.909412. eCollection 2022. PMID- 35640838 OWN - NLM STAT- MEDLINE DCOM- 20220718 LR - 20221227 IS - 1872-9649 (Electronic) IS - 1568-1637 (Print) IS - 1568-1637 (Linking) VI - 79 DP - 2022 Aug TI - Is COVID-19 really a geriatric syndrome? PG - 101657 LID - S1568-1637(22)00099-X [pii] LID - 10.1016/j.arr.2022.101657 [doi] AB - Geriatric syndromes are a group of medical conditions, such as cognitive impairment, delirium, frailty, dizziness, syncope, and incontinence, associated with age increase. Many studies have reported a higher mortality rate for older COVID-19 patients, which could be explained by the complications of COVID-19, including the components of geriatric syndromes. We read with great interest the paper "Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis" by Nicola Veronese et al. Their valuable work determines how uncertainty and unwillingness towards receiving the COVID-19 vaccine are more prevalent among older adults and how this hesitancy could affect vaccine uptake, and ultimately, the mortality rate. Regarding this paper, we wish to address some points. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Akbarzadeh, Mohammad Amin AU - Akbarzadeh MA AD - Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran; Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Iranian Evidence-Based Medicine (EBM) Centre, Joanna Briggs Institute Affiliated Group, Tabriz, Iran. FAU - Hosseini, Mohammad-Salar AU - Hosseini MS AD - Research Center for Evidence-Based Medicine, Tabriz University of Medical Sciences, Tabriz, Iran; Iranian Evidence-Based Medicine (EBM) Centre, Joanna Briggs Institute Affiliated Group, Tabriz, Iran; Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: hosseini.msalar@gmail.com. LA - eng PT - Journal Article DEP - 20220529 PL - England TA - Ageing Res Rev JT - Ageing research reviews JID - 101128963 RN - 0 (COVID-19 Vaccines) SB - IM MH - Aged MH - *COVID-19 MH - COVID-19 Vaccines MH - *Geriatric Assessment MH - Humans MH - Prevalence MH - Syndrome PMC - PMC9148424 OTO - NOTNLM OT - COVID-19 OT - Geriatric syndrome OT - Immunosenescence OT - Older adults OT - Vaccination EDAT- 2022/06/01 06:00 MHDA- 2022/07/19 06:00 PMCR- 2022/05/29 CRDT- 2022/05/31 19:26 PHST- 2022/03/31 00:00 [received] PHST- 2022/04/23 00:00 [revised] PHST- 2022/05/27 00:00 [accepted] PHST- 2022/06/01 06:00 [pubmed] PHST- 2022/07/19 06:00 [medline] PHST- 2022/05/31 19:26 [entrez] PHST- 2022/05/29 00:00 [pmc-release] AID - S1568-1637(22)00099-X [pii] AID - 101657 [pii] AID - 10.1016/j.arr.2022.101657 [doi] PST - ppublish SO - Ageing Res Rev. 2022 Aug;79:101657. doi: 10.1016/j.arr.2022.101657. Epub 2022 May 29. PMID- 35614173 OWN - NLM STAT- MEDLINE DCOM- 20220819 LR - 20251031 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 43 IP - 9 DP - 2022 Sep TI - Prevalence, characteristics and risk factors in a Moroccan cohort of Long-Covid-19. PG - 5175-5180 LID - 10.1007/s10072-022-06138-0 [doi] AB - INTRODUCTION: Covid-19 can involve persistence of nonspecific symptoms and sequelae that last weeks to months after initial recovery, but the definition of this situation is lacking. Thus, the aim of our study is to estimate the prevalence, symptoms, and signs extending beyond the acute phase of Covid-19 compared to the general population not infected with the virus and to assess the factors influencing the occurrence of these symptoms in developing countries like Morocco. PATIENTS AND METHODS: This study recruited 118 healthcare workers who endured the Covid-19 infection and 118 matched controls that had never experienced it. We have defined Long-Covid-19 according to guidance for NICE, and we used a survey made of direct questions and short answers sent to the recruiters via mail to evaluate the demographic parameters, severity and duration of the Covid-19 symptoms, vaccination against SARS CoV-2, and pulmonary involvement, and a series of general symptoms were looked for. FINDINGS: Our study found that the prevalence of Long-Covid-19 was 47.4%. Compared to the general population, the symptoms with statistical significative results were predominated by asthenia, myalgia, and brain fog. The severity of the pulmonary involvement on chest CT scan was the only risk factor to their occurrence, whereas no effect of the vaccination anti-SARS-CoV-2 was found. CONCLUSION: Comparing to the literature, this study showed that nearly half of the patients who have been infected with SARS-CoV-2 will experience a variety of symptoms after the acute phase of this infection, and that it would be a real burden even in the youngest. We also found that vaccination against SARS-Cov-2 has no impact on this prevalence, which is to the best of our knowledge has never been previously studied. CI - (c) 2022. Fondazione Societa Italiana di Neurologia. FAU - El Otmani, Hicham AU - El Otmani H AUID- ORCID: 0000-0003-0870-1808 AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. hichamotmani@yahoo.com. AD - Genetics Laboratory and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. hichamotmani@yahoo.com. FAU - Nabili, Salma AU - Nabili S AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. FAU - Berrada, Malika AU - Berrada M AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. FAU - Bellakhdar, Salma AU - Bellakhdar S AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. FAU - El Moutawakil, Bouchra AU - El Moutawakil B AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. AD - Genetics Laboratory and Molecular Pathology, Faculty of Medicine and Pharmacy, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. FAU - Abdoh Rafai, Mohammed AU - Abdoh Rafai M AD - Neurology Department, Faculty of Medicine and Pharmacy, Ibn Rochd Hospital, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. AD - Research Laboratory of Neurological Disease and Neurosensory Handicap, Faculty of Medicine and Pharmacy, Hassan II University, Rue Tarik Ibn Ziad, 20360, Casablanca, Morocco. LA - eng PT - Journal Article DEP - 20220525 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 SB - IM MH - *COVID-19/complications/epidemiology MH - Humans MH - Morocco/epidemiology MH - Prevalence MH - Risk Factors MH - SARS-CoV-2 MH - Post-Acute COVID-19 Syndrome PMC - PMC9132567 OTO - NOTNLM OT - Comparative study OT - Covid-19 OT - Long terms OT - Vaccination COIS- The authors declare no competing interests. EDAT- 2022/05/26 06:00 MHDA- 2022/08/20 06:00 PMCR- 2022/05/25 CRDT- 2022/05/25 23:22 PHST- 2021/10/14 00:00 [received] PHST- 2022/05/12 00:00 [accepted] PHST- 2022/05/26 06:00 [pubmed] PHST- 2022/08/20 06:00 [medline] PHST- 2022/05/25 23:22 [entrez] PHST- 2022/05/25 00:00 [pmc-release] AID - 10.1007/s10072-022-06138-0 [pii] AID - 6138 [pii] AID - 10.1007/s10072-022-06138-0 [doi] PST - ppublish SO - Neurol Sci. 2022 Sep;43(9):5175-5180. doi: 10.1007/s10072-022-06138-0. Epub 2022 May 25. PMID- 35599972 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240905 IS - 0941-0643 (Print) IS - 1433-3058 (Electronic) IS - 0941-0643 (Linking) VI - 34 IP - 17 DP - 2022 TI - Who are the 'silent spreaders'?: contact tracing in spatio-temporal memory models. PG - 14859-14879 LID - 10.1007/s00521-022-07210-8 [doi] AB - The COVID-19 epidemic has swept the world for over two years. However, a large number of infectious asymptomatic COVID-19 cases (ACCs) are still making the breaking up of the transmission chains very difficult. Efforts by epidemiological researchers in many countries have thrown light on the clinical features of ACCs, but there is still a lack of practical approaches to detect ACCs so as to help contain the pandemic. To address the issue of ACCs, this paper presents a neural network model called Spatio-Temporal Episodic Memory for COVID-19 (STEM-COVID) to identify ACCs from contact tracing data. Based on the fusion Adaptive Resonance Theory (ART), the model encodes a collective spatio-temporal episodic memory of individuals and incorporates an effective mechanism of parallel searches for ACCs. Specifically, the episodic traces of the identified positive cases are used to map out the episodic traces of suspected ACCs using a weighted evidence pooling method. To evaluate the efficacy of STEM-COVID, a realistic agent-based simulation model for COVID-19 spreading is implemented based on the recent epidemiological findings on ACCs. The experiments based on rigorous simulation scenarios, manifesting the current situation of COVID-19 spread, show that the STEM-COVID model with weighted evidence pooling has a higher level of accuracy and efficiency for identifying ACCs when compared with several baselines. Moreover, the model displays strong robustness against noisy data and different ACC proportions, which partially reflects the effect of breakthrough infections after vaccination on the virus transmission. CI - (c) The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2022. FAU - Hu, Yue AU - Hu Y AUID- ORCID: 0000-0002-8115-7020 AD - College of Systems Engineering, National University of Defense Technology, Changsha, Hunan 410073 China. GRID: grid.412110.7. ISNI: 0000 0000 9548 2110 FAU - Subagdja, Budhitama AU - Subagdja B AD - School of Computing and Information Systems, Singapore Management University, 178902 Singapore, Singapore. GRID: grid.412634.6. ISNI: 0000 0001 0697 8112 FAU - Tan, Ah-Hwee AU - Tan AH AD - School of Computing and Information Systems, Singapore Management University, 178902 Singapore, Singapore. GRID: grid.412634.6. ISNI: 0000 0001 0697 8112 FAU - Quek, Chai AU - Quek C AD - School of Computer Science and Engineering, Nanyang Technological University, 639798 Singapore, Singapore. GRID: grid.59025.3b. ISNI: 0000 0001 2224 0361 FAU - Yin, Quanjun AU - Yin Q AD - College of Systems Engineering, National University of Defense Technology, Changsha, Hunan 410073 China. GRID: grid.412110.7. ISNI: 0000 0000 9548 2110 LA - eng PT - Journal Article DEP - 20220514 PL - England TA - Neural Comput Appl JT - Neural computing & applications JID - 9313239 PMC - PMC9107326 OTO - NOTNLM OT - ART-based spatio-temporal episodic memory OT - Asymptomatic coronavirus carriers OT - COVID-19 simulation OT - Realistic scenarios OT - Weighted evidence pooling COIS- Conflict of interestAll authors declare that no conflict of interest exists. EDAT- 2022/05/24 06:00 MHDA- 2022/05/24 06:01 PMCR- 2022/05/14 CRDT- 2022/05/23 03:46 PHST- 2021/10/26 00:00 [received] PHST- 2022/03/29 00:00 [accepted] PHST- 2022/05/24 06:00 [pubmed] PHST- 2022/05/24 06:01 [medline] PHST- 2022/05/23 03:46 [entrez] PHST- 2022/05/14 00:00 [pmc-release] AID - 7210 [pii] AID - 10.1007/s00521-022-07210-8 [doi] PST - ppublish SO - Neural Comput Appl. 2022;34(17):14859-14879. doi: 10.1007/s00521-022-07210-8. Epub 2022 May 14. PMID- 35543105 OWN - NLM STAT- MEDLINE DCOM- 20221123 LR - 20221123 IS - 1601-5215 (Electronic) IS - 0924-2708 (Linking) VI - 34 IP - 6 DP - 2022 Dec TI - Neuropsychiatric symptoms in post-COVID-19 long haulers. PG - 318-329 LID - 10.1017/neu.2022.13 [doi] AB - BACKGROUND: Long haulers have been recently reported after contracting coronavirus disease (COVID-19). In the present study, we aimed to screen for the neuropsychiatric signs detected <1 to >6 months after infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to determine whether vaccination has an effect on them. METHODS: An online survey was conducted among participants who had been diagnosed with laboratory-confirmed SARS-CoV-2 infection. The clinical signs and durations of neuropsychiatric complaints and their correlations to sex, age, severity of COVID-19 signs, and vaccination status were screened. RESULTS: A total of 2218 individuals, including 1358 females and 860 males, with an age range of 12-70 years, submitted their responses. The respondents experienced cognitive dysfunction, mood alteration, depression, tinnitus, sleep disorders, and loss of taste and smell, with prevalence rates ranging from 18.9% (tinnitus) to 63.9% (loss of taste and smell). Of the respondents, 2.2-7.7% confirmed the persistence of symptoms for >6 months. Tinnitus was the least common complaint, and only 2.2% of the study participants had tinnitus for >6 months. Meanwhile, mood alteration persisted for >6 months in 7.6% of the study participants. More respondents who received two doses of BNT162b2 vaccine showed persistent symptoms than those in the other groups. Disease severity and female sex were identified as potential determinants of the development and persistency of such symptoms. CONCLUSION: Post-COVID neuropsychiatric symptoms were present in considerable percentages of the study participants with SARS-CoV-2 infection, persisting for >6 months in up to 7.6% of the participants. FAU - Alghamdi, Hussam Y AU - Alghamdi HY AD - College of Medicine, Taif University, Al-Taif21944, Saudi Arabia. FAU - Alrashed, Abdulaziz M AU - Alrashed AM AD - College of Medicine, Taif University, Al-Taif21944, Saudi Arabia. FAU - Jawhari, Amjad M AU - Jawhari AM AD - College of Medicine, Taif University, Al-Taif21944, Saudi Arabia. FAU - Abdel-Moneim, Ahmed S AU - Abdel-Moneim AS AUID- ORCID: 0000-0002-3148-6782 AD - Microbiology Department, College of Medicine, Taif University, Al-Taif, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220511 PL - England TA - Acta Neuropsychiatr JT - Acta neuropsychiatrica JID - 9612501 RN - 0 (BNT162 Vaccine) SB - IM MH - Male MH - Female MH - Humans MH - Child MH - Adolescent MH - Young Adult MH - Adult MH - Middle Aged MH - Aged MH - *COVID-19/epidemiology MH - SARS-CoV-2 MH - *Ageusia MH - *Tinnitus MH - BNT162 Vaccine OTO - NOTNLM OT - Post-COVID-19 OT - SARS-COV-2 OT - long haulers OT - neuropsychiatry EDAT- 2022/05/12 06:00 MHDA- 2022/11/24 06:00 CRDT- 2022/05/11 04:33 PHST- 2022/05/12 06:00 [pubmed] PHST- 2022/11/24 06:00 [medline] PHST- 2022/05/11 04:33 [entrez] AID - S0924270822000138 [pii] AID - 10.1017/neu.2022.13 [doi] PST - ppublish SO - Acta Neuropsychiatr. 2022 Dec;34(6):318-329. doi: 10.1017/neu.2022.13. Epub 2022 May 11. PMID- 35536849 OWN - NLM STAT- MEDLINE DCOM- 20220512 LR - 20231103 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 17 IP - 5 DP - 2022 TI - Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. PG - e0268050 LID - 10.1371/journal.pone.0268050 [doi] LID - e0268050 AB - BACKGROUND: The resurgence of COVID-19 cases since June 2021, referred to as the fourth COVID-19 wave, has led to the approval and administration of booster vaccines. Our study aims to identify any associations between vaccine status with the characteristics and outcomes of patients hospitalized with severe COVID-19 disease. METHODS: We retrospectively reviewed all COVID-19 patients admitted to a large tertiary center between July 25 and October 25, 2021 (fourth wave in Israel). Univariant and multivariant analyses of variables associated with vaccine status were performed. FINDINGS: Overall, 349 patients with severe or critical disease were included. Patients were either not vaccinated (58%), had the first two vaccine doses (35%) or had the booster vaccine (7%). Vaccinated patients were significantly older, male predominant, and with a higher number of comorbidities including diabetes, hyperlipidemia, ischemic heart disease, heart failure, immunodeficient state, kidney disease and cognitive decline. Time from the first symptom to hospital admission was longer among non-vaccinated patients (7.2 +/- 4.4 days, p = 0.002). Critical disease (p<0.05), admissions to the intensive care unit (p = 0.01) and advanced oxygen support (p = 0.004) were inversely proportional to the number of vaccines given, lowest among the booster vaccine group. Death (20%, p = 0.83) and hospital stay duration (8.05+/- 8.47, p = 0.19) were similar between the groups. CONCLUSION: Hospitalized vaccinated patients with severe COVID-19 had significantly higher rates of most known risk factors for COVID-19 adverse outcomes. Still, all disease outcomes were similar or better compared with the non-vaccinated patients. FAU - Freund, Ophir AU - Freund O AUID- ORCID: 0000-0002-7272-5284 AD - Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Tau, Luba AU - Tau L AD - Infectious Diseases Unit, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel. FAU - Weiss, Tali Epstein AU - Weiss TE AD - Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Zornitzki, Lior AU - Zornitzki L AUID- ORCID: 0000-0003-3245-2653 AD - Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Frydman, Shir AU - Frydman S AD - Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Jacob, Giris AU - Jacob G AD - Medicine F, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Bornstein, Gil AU - Bornstein G AD - Internal Medicine B, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. LA - eng PT - Journal Article DEP - 20220510 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/epidemiology/prevention & control MH - COVID-19 Vaccines/therapeutic use MH - Hospitalization MH - Humans MH - Male MH - Retrospective Studies MH - SARS-CoV-2 PMC - PMC9089907 COIS- The authors have declared that no competing interests exist. EDAT- 2022/05/11 06:00 MHDA- 2022/05/14 06:00 PMCR- 2022/05/10 CRDT- 2022/05/10 13:35 PHST- 2022/01/12 00:00 [received] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/10 13:35 [entrez] PHST- 2022/05/11 06:00 [pubmed] PHST- 2022/05/14 06:00 [medline] PHST- 2022/05/10 00:00 [pmc-release] AID - PONE-D-22-00969 [pii] AID - 10.1371/journal.pone.0268050 [doi] PST - epublish SO - PLoS One. 2022 May 10;17(5):e0268050. doi: 10.1371/journal.pone.0268050. eCollection 2022. PMID- 35527791 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 22 DP - 2022 Jul TI - Brain and behavior in health communication: The Canadian COVID-19 Experiences Project. PG - 100467 LID - 10.1016/j.bbih.2022.100467 [doi] LID - 100467 AB - BACKGROUND: Vaccine hesitancy and inconsistent mitigation behavior performance have been significant challenges throughout the COVID-19 pandemic. In Canada, despite relatively high vaccine availability and uptake, willingness to accept booster shots and maintain mitigation behaviors in the post-acute phase of COVID-19 remain uncertain. The aim of the Canadian COVID-19 Experiences Project (CCEP) is threefold: 1) to identify social-cognitive and neurocognitive predictors of mitigation behaviors, 2) to identify optimal communication strategies to promote vaccination and mitigation behaviors, and 3) to examine brain health outcomes of SARS-CoV-2 infection and examine their longevity. METHODS: The CCEP is comprised of two components: a conventional population survey (Study 1) and a functionally interconnected laboratory study (Study 2). Study 1 will involve 6 waves of data collection. Wave 1, completed between 28 September and 21 October 2021, recruited 1,958 vaccine-hesitant (49.8%) and fully vaccinated (50.2%) adults using quota sampling to ensure maximum statistical power. Measures included a variety of social cognitive (e.g., beliefs, intentions) and neurocognitive (e.g., delay discounting) measures, followed by an opportunity to view and rate a set of professionally produced COVID-19 public service announcement (PSA) videos for perceived efficacy. Study 2 employs the same survey items and PSAs but coupled with lab-based eye tracking and functional near-infrared spectroscopy (fNIRS) to directly quantify neural indicators of attention capture and self-reflection in a smaller community sample. In the final phase of the project, subjective impressions and neural indicators of PSA efficacy will be compared and used to inform recommendations for construction of COVID-19 PSAs into the post-acute phase of the pandemic. DISCUSSION: The CCEP provides a framework for evaluating effective COVID-19 communication strategies by levering conventional population surveys and the latest eye-tracking and brain imaging metrics. The CCEP will also yield important information about the brain health impacts of SARS-CoV-2 in the general population, in relation to current and future virus variants as they emerge. CI - (c) 2022 The Authors. FAU - Hall, Peter A AU - Hall PA AD - School of Public Health Sciences, University of Waterloo, Waterloo, Canada. AD - Department of Psychology, University of Waterloo, Waterloo, Canada. AD - Centre for Bioengineering and Biotechnology, University of Waterloo, Waterloo, Canada. FAU - Fong, Geoffrey T AU - Fong GT AD - School of Public Health Sciences, University of Waterloo, Waterloo, Canada. AD - Department of Psychology, University of Waterloo, Waterloo, Canada. AD - Ontario Institute for Cancer Research, Toronto, Ontario, Canada. FAU - Hitchman, Sara C AU - Hitchman SC AD - Department of Communication and Media Research, University of Zurich, Zurich, Switzerland. FAU - Quah, Anne C K AU - Quah ACK AD - Department of Psychology, University of Waterloo, Waterloo, Canada. FAU - Agar, Thomas AU - Agar T AD - Department of Psychology, University of Waterloo, Waterloo, Canada. FAU - Meng, Gang AU - Meng G AD - Department of Psychology, University of Waterloo, Waterloo, Canada. FAU - Ayaz, Hasan AU - Ayaz H AD - School of Biomedical Engineering, Science and Health Systems, Drexel University, USA. AD - Department of Psychological and Brain Sciences, College of Arts and Sciences, Drexel University, Philadelphia, PA, USA. AD - Drexel Solutions Institute, Drexel University, Philadelphia, PA, USA. FAU - Dore, Bruce P AU - Dore BP AD - Desautels Faculty of Management, McGill University, Montreal, Canada. FAU - Sakib, Mohammad N AU - Sakib MN AD - School of Public Health Sciences, University of Waterloo, Waterloo, Canada. FAU - Hudson, Anna AU - Hudson A AD - School of Public Health Sciences, University of Waterloo, Waterloo, Canada. FAU - Boudreau, Christian AU - Boudreau C AD - Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada. LA - eng PT - Journal Article DEP - 20220502 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC9060711 OTO - NOTNLM OT - Behavior OT - COVID-19 OT - Mitigation OT - Prevention OT - SARS-CoV-2 OT - Vaccine COIS- The authors have no competing interests. EDAT- 2022/05/10 06:00 MHDA- 2022/05/10 06:01 PMCR- 2022/05/02 CRDT- 2022/05/09 03:47 PHST- 2022/04/28 00:00 [received] PHST- 2022/04/28 00:00 [accepted] PHST- 2022/05/09 03:47 [entrez] PHST- 2022/05/10 06:00 [pubmed] PHST- 2022/05/10 06:01 [medline] PHST- 2022/05/02 00:00 [pmc-release] AID - S2666-3546(22)00057-6 [pii] AID - 100467 [pii] AID - 10.1016/j.bbih.2022.100467 [doi] PST - ppublish SO - Brain Behav Immun Health. 2022 Jul;22:100467. doi: 10.1016/j.bbih.2022.100467. Epub 2022 May 2. PMID- 35512900 OWN - NLM STAT- MEDLINE DCOM- 20220509 LR - 20220609 IS - 1532-8686 (Electronic) IS - 0037-1963 (Linking) VI - 59 IP - 2 DP - 2022 Apr TI - The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT). PG - 115-119 LID - S0037-1963(22)00006-3 [pii] LID - 10.1053/j.seminhematol.2022.02.003 [doi] AB - This review paper explores the potential psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia, also called vaccine-induced immune thrombocytopenia, and thrombosis (VITT). In the absence of any literature to date we have extrapolated data from similar conditions, particularly data pertaining to the critical care population. We discuss both the direct and indirect effects of thrombosis, likely psychiatric and psychological challenges during recovery, and ethical issues around vaccination. We have also suggested a comprehensive guide to the psychiatric assessment and management of patients presenting with VITT with the aim of early identification of problems and maximizing rehabilitation potential and quality of life. CI - Copyright (c) 2022 Elsevier Inc. All rights reserved. FAU - Carpenter, Lindsay J AU - Carpenter LJ AD - Oxford Psychological Medicine Centre, Oxford University Hospitals NHS Foundation Trust, UK. Electronic address: lindsay.carpenter@ouh.nhs.uk. FAU - Solomons, Luke AU - Solomons L AD - Oxford Psychological Medicine Centre, Oxford University Hospitals NHS Foundation Trust, UK. FAU - Grabe, Hans J AU - Grabe HJ AD - Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Germany. FAU - Pavord, Sue AU - Pavord S AD - Department Hematology, Oxford University Hospitals NHS Foundation Trust, UK. LA - eng PT - Journal Article PT - Review DEP - 20220218 PL - United States TA - Semin Hematol JT - Seminars in hematology JID - 0404514 RN - 0 (Vaccines) SB - IM MH - Humans MH - *Purpura, Thrombocytopenic, Idiopathic/chemically induced/psychology MH - Quality of Life MH - *Thrombosis/chemically induced MH - *Vaccines/adverse effects OTO - NOTNLM OT - Covid-19 OT - Vaccine-induced immune thrombocytopenia and thrombosis (VITT) OT - Vaccine-induced immune thrombotic thrombocytopenia (VITT) OT - neuropsychiatric symptoms OT - psychosocial assessment EDAT- 2022/05/06 06:00 MHDA- 2022/05/10 06:00 CRDT- 2022/05/05 21:04 PHST- 2022/01/21 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/05/05 21:04 [entrez] PHST- 2022/05/06 06:00 [pubmed] PHST- 2022/05/10 06:00 [medline] AID - S0037-1963(22)00006-3 [pii] AID - 10.1053/j.seminhematol.2022.02.003 [doi] PST - ppublish SO - Semin Hematol. 2022 Apr;59(2):115-119. doi: 10.1053/j.seminhematol.2022.02.003. Epub 2022 Feb 18. PMID- 35496775 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20260301 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 22 DP - 2022 Jul TI - Cognitive deficits and memory impairments after COVID-19 (Covishield) vaccination. PG - 100463 LID - 10.1016/j.bbih.2022.100463 [doi] AB - Vaccination is an essential public health strategy to control the 2019 Coronavirus (COVID-19) pandemic. While the benefits of the COVID-19 vaccines far outweigh the risks, side effects continue to be reported in the literature. We report a 65-year-old man who developed cognitive deficits and memory impairments following his first dose of Oxford AstraZeneca vaccine (Covishield). The onset of acute cognitive deficits and memory impairments could be another complication to COVID-19 vaccination that physicians and neurologists need to be warned to. Monitoring the safety of COVID-19 vaccines and describing side effects associated with them is essential to improve safety profiles and enhance public trust. CI - (c) 2022 The Authors. FAU - Chaurasia, Bipin AU - Chaurasia B AD - Department of Neurosurgery, Bhawani Hospital and Research Centre, Birgunj, Nepal. FAU - Chavda, Vishal AU - Chavda V AD - Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA. FAU - Lu, Bingwei AU - Lu B AD - Department of Pathology, Stanford School of Medicine, Stanford University Medical Center, USA. FAU - Garg, Kanwaljeet AU - Garg K AD - Department of Neurosurgery, All India Institute of Medical Sciences, New Delhi, India. FAU - Montemurro, Nicola AU - Montemurro N AD - Department of Neurosurgery, Azienda Ospedaliera Universitaria Pisana (AOUP), University of Pisa, Pisa, Italy. LA - eng PT - Journal Article DEP - 20220423 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC9034829 OTO - NOTNLM OT - COVID-19 OT - Cognitive deficits OT - Coronavirus OT - SARS-CoV OT - Vaccination COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2022/05/03 06:00 MHDA- 2022/05/03 06:01 PMCR- 2022/04/23 CRDT- 2022/05/02 06:54 PHST- 2022/03/05 00:00 [received] PHST- 2022/04/12 00:00 [revised] PHST- 2022/04/20 00:00 [accepted] PHST- 2022/05/02 06:54 [entrez] PHST- 2022/05/03 06:00 [pubmed] PHST- 2022/05/03 06:01 [medline] PHST- 2022/04/23 00:00 [pmc-release] AID - S2666-3546(22)00053-9 [pii] AID - 100463 [pii] AID - 10.1016/j.bbih.2022.100463 [doi] PST - ppublish SO - Brain Behav Immun Health. 2022 Jul;22:100463. doi: 10.1016/j.bbih.2022.100463. Epub 2022 Apr 23. PMID- 35455293 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230308 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 4 DP - 2022 Apr 1 TI - Cognition and Behavior of COVID-19 Vaccination Based on the Health Belief Model: A Cross-Sectional Study. LID - 10.3390/vaccines10040544 [doi] LID - 544 AB - Background: Vaccination is the most effective method for the prevention of COVID-19. However, willingness to be vaccinated is not consistent. This study aimed to explore vaccine cognition, risk perception, and health behavior of COVID-19 in China. Methods: A cross-sectional survey was performed in Guangdong province, China, including demographic characteristics, health status and preventive behaviors, cognition of COVID-19 vaccination, and the health belief model (HBM). Results: A total of 1640 participants were recruited. The main access to information about COVID-19 and vaccination as through official news and broadcasts (67.3%), social network software (58.7%), and professional popularization (46.2%). The precautions taken were wearing a mask (67.0%) and avoiding gathering together (71.3%). COVID-19 vaccination acceptability was different among different age groups and educational levels (p < 0.001). The major reasons for accepting vaccination included that it was an effective way to prevent COVID-19 (61.8%) and that it was required by working units/schools (51.1%). The fitting effect indexes of the (HBM) Model 2 showed better fitting than those of Model 1. In Model 2, perceived benefits (OR = 3.13, 95% CI: 1.79-5.47), cues to action (OR = 2.23, 95% CI: 1.60-3.11), and different occupations (OR = 1.13, 95% CI: 1.04-1.23) were positively correlated with vaccine acceptance; while perceived susceptibility (OR = 0.47, 95% CI: 0.30-0.74) and perceived barriers (OR = 0.44, 95% CI: 0.29-0.69) were negative factors associated with vaccine acceptance. Conclusion: Different sociodemographic characteristics lead to differences in acceptance of vaccination, and the publicity and credibility of government play an indispensable role in epidemic control. The establishment of the HBM further predicted that perceived susceptibility to COVID-19, benefits of vaccination, barriers of cognition, and cue to action were the influencing factors of intention and health behaviors. FAU - Cai, Zemin AU - Cai Z AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Hu, Wei AU - Hu W AD - Department of Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China. FAU - Zheng, Shukai AU - Zheng S AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Wen, Xilin AU - Wen X AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. FAU - Wu, Kusheng AU - Wu K AUID- ORCID: 0000-0001-5163-2524 AD - Department of Preventive Medicine, Shantou University Medical College, Shantou 515041, China. LA - eng GR - SFK2020-53-42/Kusheng Wu/ GR - 2021ZDZX2023/Kusheng Wu/ PT - Journal Article DEP - 20220401 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC9030847 OTO - NOTNLM OT - COVID-19 vaccination OT - behavior OT - cognition OT - health belief model COIS- The authors declare no conflict of interest. EDAT- 2022/04/24 06:00 MHDA- 2022/04/24 06:01 PMCR- 2022/04/01 CRDT- 2022/04/23 01:06 PHST- 2022/02/25 00:00 [received] PHST- 2022/03/15 00:00 [revised] PHST- 2022/03/30 00:00 [accepted] PHST- 2022/04/23 01:06 [entrez] PHST- 2022/04/24 06:00 [pubmed] PHST- 2022/04/24 06:01 [medline] PHST- 2022/04/01 00:00 [pmc-release] AID - vaccines10040544 [pii] AID - vaccines-10-00544 [pii] AID - 10.3390/vaccines10040544 [doi] PST - epublish SO - Vaccines (Basel). 2022 Apr 1;10(4):544. doi: 10.3390/vaccines10040544. PMID- 35452000 OWN - NLM STAT- MEDLINE DCOM- 20220908 LR - 20250728 IS - 1536-0229 (Electronic) IS - 0363-9762 (Linking) VI - 47 IP - 10 DP - 2022 Oct 1 TI - Alterations in 18 F-FDG PET/MRI and 15 O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study: Reply. PG - e671-e672 LID - 10.1097/RLU.0000000000004223 [doi] FAU - Siripongsatian, Dheeratama AU - Siripongsatian D AD - National Cyclotron and PET Centre, Chulabhorn Hospital, Bangkok, Thailand Dheeratama.sir@cra.ac.th. FAU - Chotipanich, Chanisa AU - Chotipanich C LA - eng PT - Letter DEP - 20220422 PL - United States TA - Clin Nucl Med JT - Clinical nuclear medicine JID - 7611109 RN - 0 (COVID-19 Vaccines) RN - 0 (Radiopharmaceuticals) RN - 059QF0KO0R (Water) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM MH - Brain/diagnostic imaging MH - *COVID-19 MH - COVID-19 Vaccines MH - *Fluorodeoxyglucose F18 MH - Humans MH - Magnetic Resonance Imaging MH - Pilot Projects MH - Positron Emission Tomography Computed Tomography MH - Positron-Emission Tomography MH - Radiopharmaceuticals MH - Vaccination MH - Water COIS- Conflicts of interest and sources of funding: none declared. EDAT- 2022/04/23 06:00 MHDA- 2022/09/09 06:00 CRDT- 2022/04/22 12:13 PHST- 2022/04/23 06:00 [pubmed] PHST- 2022/09/09 06:00 [medline] PHST- 2022/04/22 12:13 [entrez] AID - 00003072-202210000-00046 [pii] AID - 10.1097/RLU.0000000000004223 [doi] PST - ppublish SO - Clin Nucl Med. 2022 Oct 1;47(10):e671-e672. doi: 10.1097/RLU.0000000000004223. Epub 2022 Apr 22. PMID- 35431254 OWN - NLM STAT- MEDLINE DCOM- 20220621 LR - 20220722 IS - 1875-8908 (Electronic) IS - 1387-2877 (Linking) VI - 87 IP - 4 DP - 2022 TI - Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. PG - 1467-1474 LID - 10.3233/JAD-220077 [doi] AB - This study aimed to explore the prevalence and safety of SARS-CoV-2 vaccination in individuals with dementia. Patients with mild cognitive impairment or dementia were recruited at a tertiary memory clinic, from March 15 to September 15, 2021. Information on COVID-19 vaccination and adverse events experienced after vaccine administration were collected from caregivers. Two-hundred-seventy subjects were finally recruited. Among them, 253 (93.7%) had received the vaccine and only 69 (27.3%) experienced adverse events. Cognitive and behavioral changes following immunization were only rarely reported. COVID-19 vaccination is safe and well-tolerated in patients with cognitive impairment who should be prioritized in the vaccination campaign. FAU - Valletta, Martina AU - Valletta M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Canevelli, Marco AU - Canevelli M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. AD - National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. FAU - D'Antonio, Fabrizia AU - D'Antonio F AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Trebbastoni, Alessandro AU - Trebbastoni A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Talarico, Giuseppina AU - Talarico G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Campanelli, Alessandra AU - Campanelli A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Sepe Monti, Micaela AU - Sepe Monti M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Di Vita, Antonella AU - Di Vita A AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Salati, Emanuela AU - Salati E AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Imbriano, Letizia AU - Imbriano L AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Margiotta, Roberta AU - Margiotta R AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Barbetti, Sonia AU - Barbetti S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Diana, Sofia AU - Diana S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Buscarnera, Simona AU - Buscarnera S AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Toccaceli Blasi, Marco AU - Toccaceli Blasi M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Salzillo, Martina AU - Salzillo M AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Pugliese, Giuseppe AU - Pugliese G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. FAU - Vanacore, Nicola AU - Vanacore N AD - National Center for Disease Prevention and Health Promotion, National Institute of Health, Rome, Italy. FAU - Bruno, Giuseppe AU - Bruno G AD - Department of Human Neuroscience, "Sapienza" University, Rome, Italy. LA - eng PT - Letter PL - United States TA - J Alzheimers Dis JT - Journal of Alzheimer's disease : JAD JID - 9814863 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Dementia/epidemiology/psychology MH - Humans MH - Independent Living MH - Prevalence MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - *Vaccines OTO - NOTNLM OT - COVID-19 OT - Cognitive impairment OT - SARS-CoV-2 OT - dementia OT - vaccination OT - vaccines EDAT- 2022/04/19 06:00 MHDA- 2022/06/22 06:00 CRDT- 2022/04/18 05:54 PHST- 2022/04/19 06:00 [pubmed] PHST- 2022/06/22 06:00 [medline] PHST- 2022/04/18 05:54 [entrez] AID - JAD220077 [pii] AID - 10.3233/JAD-220077 [doi] PST - ppublish SO - J Alzheimers Dis. 2022;87(4):1467-1474. doi: 10.3233/JAD-220077. PMID- 35417628 OWN - NLM STAT- MEDLINE DCOM- 20230217 LR - 20250930 IS - 1552-5279 (Electronic) IS - 1552-5260 (Print) IS - 1552-5260 (Linking) VI - 19 IP - 2 DP - 2023 Feb TI - COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. PG - 421-432 LID - 10.1002/alz.12669 [doi] AB - INTRODUCTION: There is lack of data on COVID-19 breakthrough infections in vaccinated patients with dementia in the United States. METHODS: This is a retrospective cohort study of 262,847 vaccinated older adults (age 73.8 +/- 6.81 years old) between December 2020 and August 2021. RESULTS: Among the fully vaccinated patients with dementia, the overall risk of COVID-19 breakthrough infections ranged from 8.6% to 12.4%. Patients with dementia were at increased risk for breakthrough infections compared with patients without dementia, with the highest odds for patients with Lewy body dementia (LBD) (adjusted odds ratio or AOR: 3.06, 95% confidence interval or CI [1.45 to 6.66]), followed by vascular dementia (VD) (AOR: 1.99, 95% CI [1.42 to 2.80]), Alzheimer's disease (AD) (1.53, 95% CI [1.22 to 1.92]), and mild cognitive impairment (MCI) (AOR: 1.78, 95% CI [1.51 to 2.11]). The incidence rate of breakthrough infections among fully vaccinated patients with dementia increased since December 2020 and accelerated after May 2021. The overall risk for hospitalization after breakthrough infections in patients with dementia was 39.5% for AD, 46.2% for VD, and 30.4% for MCI. DISCUSSION: These results highlight the need to continuously monitor breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and outcomes in vaccinated patients with dementia. CI - (c) 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. FAU - Wang, Lindsey AU - Wang L AD - Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. FAU - Davis, Pamela B AU - Davis PB AD - Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. FAU - Kaelber, David C AU - Kaelber DC AD - The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio, USA. FAU - Xu, Rong AU - Xu R AD - Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. LA - eng GR - R01 AG057557/AG/NIA NIH HHS/United States GR - R01 AG076649/AG/NIA NIH HHS/United States GR - UL1 TR002548/TR/NCATS NIH HHS/United States GR - R01 AA029831/AA/NIAAA NIH HHS/United States GR - R56 AG062272/AG/NIA NIH HHS/United States GR - R01 AG061388/AG/NIA NIH HHS/United States GR - RF1 AG076649/AG/NIA NIH HHS/United States GR - R01 EY029297/EY/NEI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20220413 PL - United States TA - Alzheimers Dement JT - Alzheimer's & dementia : the journal of the Alzheimer's Association JID - 101231978 RN - COVID-19 breakthrough infections SB - IM MH - Humans MH - United States/epidemiology MH - Aged MH - Aged, 80 and over MH - *COVID-19/epidemiology MH - Breakthrough Infections MH - Retrospective Studies MH - SARS-CoV-2 MH - Hospitalization MH - *Alzheimer Disease/epidemiology MH - *Dementia, Vascular PMC - PMC9073984 MID - NIHMS1790795 OTO - NOTNLM OT - Alzheimer's Disease OT - COVID-19 OT - Lewy body dementia OT - breakthrough infections OT - dementia OT - frontotemporal dementia OT - mild cognitive impairment OT - patient electronic health records OT - vaccine OT - vascular dementia COIS- Pamela B. Davis has served on External Advisory Board of University of Chicago, Board of trustees of Judson foundation, Board of directors of clinical research forum, Board of directors BioEnterprise. Lindsey Want, David C. Kaelber, and Rong Xu have no outside interests to declare. Lindsey Wang, David C. Kaelber, Pamela B. Davis, and Rong Xu have no financial interests to disclose. EDAT- 2022/04/14 06:00 MHDA- 2023/02/18 06:00 PMCR- 2022/04/13 CRDT- 2022/04/13 17:13 PHST- 2022/01/31 00:00 [revised] PHST- 2022/01/10 00:00 [received] PHST- 2022/03/02 00:00 [accepted] PHST- 2022/04/14 06:00 [pubmed] PHST- 2023/02/18 06:00 [medline] PHST- 2022/04/13 17:13 [entrez] PHST- 2022/04/13 00:00 [pmc-release] AID - ALZ12669 [pii] AID - 10.1002/alz.12669 [doi] PST - ppublish SO - Alzheimers Dement. 2023 Feb;19(2):421-432. doi: 10.1002/alz.12669. Epub 2022 Apr 13. PMID- 35395612 OWN - NLM STAT- MEDLINE DCOM- 20220603 LR - 20230508 IS - 1873-5347 (Electronic) IS - 0277-9536 (Print) IS - 0277-9536 (Linking) VI - 301 DP - 2022 May TI - Cognitive underpinnings of COVID-19 vaccine hesitancy. PG - 114911 LID - S0277-9536(22)00217-9 [pii] LID - 10.1016/j.socscimed.2022.114911 [doi] AB - RATIONALE: Vaccines save lives. Despite the undisputed value of vaccination, vaccine hesitancy continues to be a major global challenge, particularly throughout the COVID-19 global pandemic. Since vaccination decisions are counter-intuitive and cognitively demanding, we propose that vaccine hesitancy is associated with executive function-a group of high-level cognitive skills including attentional control, working memory, inhibition, self-regulation, cognitive flexibility, and strategic planning. OBJECTIVE: We set out to test (i) whether vaccine hesitancy is driven by individual differences in executive function beyond established socio-demographic factors (e.g., education, political orientation, gender, ethnicity, age, religiosity) and depressed mood, and (ii) whether this relationship is exacerbated by situational stress. METHODS: Two studies were conducted with U.S. residents. Using a cross-sectional design, Study 1 examined the associations between executive function, socio-demographic factors, COVID-19 conspiracy beliefs, trust in health authorities, and COVID-19 vaccine hesitancy. Using an experimental design, Study 2 focused solely on unvaccinated individuals and tested the interactive effect of executive function and stress on willingness to receive a COVID-19 vaccine. We used ordinal logistic regressions to analyze the data. RESULTS: Individual differences in executive function predicted participants' COVID-19 conspiracy beliefs, trust in health authorities, and their willingness to vaccinate against COVID-19. Importantly, the unique contribution of executive function to vaccine hesitancy could not be explained by socio-demographic factors or depressed mood. Furthermore, Study 2 revealed that weaker executive function had detrimental effects on COVID-19 vaccine acceptance and trust in health authorities mainly under heightened stress. CONCLUSIONS: Individual differences in executive function and situational stress jointly impact COVID-19 vaccination decisions and need to be considered together when designing health communications aimed at reducing COVID-19 vaccine hesitancy. Interventions that lower stress and promote trust have the potential to increase vaccine acceptance, especially for individuals with weaker executive function. CI - Copyright (c) 2022. Published by Elsevier Ltd. FAU - Acar-Burkay, Sinem AU - Acar-Burkay S AD - University of South-Eastern Norway, Norway. Electronic address: Sinem.Acar-Burkay@usn.no. FAU - Cristian, Daniela-Carmen AU - Cristian DC AD - Bayes Business School, City, University of London, United Kingdom. Electronic address: Daniela.Cristian@city.ac.uk. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220315 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/therapeutic use MH - Cognition MH - Cross-Sectional Studies MH - Humans MH - SARS-CoV-2 MH - Vaccination MH - Vaccination Hesitancy MH - *Vaccines PMC - PMC8920576 OTO - NOTNLM OT - COVID-19 OT - Cognition OT - Executive function OT - Stress OT - Stroop task OT - Trust OT - Vaccination intentions OT - Vaccine acceptance OT - Vaccine hesitancy COIS- The authors declare no competing interest. EDAT- 2022/04/09 06:00 MHDA- 2022/06/07 06:00 PMCR- 2022/03/15 CRDT- 2022/04/08 20:15 PHST- 2021/07/15 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/04/09 06:00 [pubmed] PHST- 2022/06/07 06:00 [medline] PHST- 2022/04/08 20:15 [entrez] PHST- 2022/03/15 00:00 [pmc-release] AID - S0277-9536(22)00217-9 [pii] AID - 114911 [pii] AID - 10.1016/j.socscimed.2022.114911 [doi] PST - ppublish SO - Soc Sci Med. 2022 May;301:114911. doi: 10.1016/j.socscimed.2022.114911. Epub 2022 Mar 15. PMID- 35359538 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220402 IS - 0972-2327 (Print) IS - 1998-3549 (Electronic) IS - 0972-2327 (Linking) VI - 24 IP - 6 DP - 2021 Nov-Dec TI - Neurological Disorders Seen During Second Wave of SARS-CoV-2 Pandemic from Two Tertiary Care Centers in Central and Southern Kerala. PG - 917-926 LID - 10.4103/aian.aian_541_21 [doi] AB - BACKGROUND AND OBJECTIVE: SARS-CoV-2 infections present with predominant respiratory symptoms. Only a few anecdotal reports of neurological involvement have come out from India so far. Adverse neurological events following immunization (AEFI) were also reported. We present the neurological symptoms seen either in association with vaccination or COVID-19 infection during the second wave. METHODS: This was a retrospective study that included consecutive COVID-19 patients' admissions during the second wave of COVID-19 pandemic in two tertiary health care centres in Kerala. Neurological symptoms two weeks prior or thirty days after a positive status of antigen or RTPCR was termed as COVID-19-Associated Neurological Disorders (CAND) and those with neurological symptoms within one month of COVID-19 vaccination was termed as Post-Vaccinal Neurological Disorders (PVND). RESULTS: During the study period, 1270 COVID-19 admissions were reported. We identified neurological symptoms in 42 patients (3.3%), of which 35 were CAND and 7 were PVND. Stroke was the most common (50%), followed by seizures and peripheral nervous system disorders (14.2% each). Encephalitis/demyelination (11.9%) and COVID-19-associated infections (9.5%) were also seen. CONCLUSION: During the SARS-CoV-2 pandemic, CAND and PVND have been emerging. Association of some of these may be fortuitous; however it is worth mentioning as pathogenic mechanisms of COVID-19 affecting various organ systems still remain unclear. Moreover, this may be helpful in future studies designing management options. CI - Copyright: (c) 2006 - 2021 Annals of Indian Academy of Neurology. FAU - George, Minu AU - George M AD - Department of Neurology, Renai Medicity Multi Super Speciality Hospital, Cochin, Kerala, India. FAU - Baby, Neena AU - Baby N AD - Department of Neurology, Renai Medicity Multi Super Speciality Hospital, Cochin, Kerala, India. FAU - Azad, Ameen AU - Azad A AD - Department of Neurology, N. S. Memorial Institute of Medical Sciences, Kollam, Kerala, India. FAU - Rajan, Aswathy AU - Rajan A AD - Department of Neurology, Renai Medicity Multi Super Speciality Hospital, Cochin, Kerala, India. FAU - Radhakrishnan, Suresh Kumar AU - Radhakrishnan SK AD - Department of Neurology, Renai Medicity Multi Super Speciality Hospital, Cochin, Kerala, India. LA - eng PT - Journal Article DEP - 20211217 PL - India TA - Ann Indian Acad Neurol JT - Annals of Indian Academy of Neurology JID - 101273955 PMC - PMC8965958 OTO - NOTNLM OT - COVID associated neurological disorders OT - COVID-19 infection OT - COVID-19 vaccination OT - neurological disorders OT - post vaccinal neurological disorders COIS- There are no conflicts of interest. EDAT- 2022/04/02 06:00 MHDA- 2022/04/02 06:01 PMCR- 2021/11/01 CRDT- 2022/04/01 05:10 PHST- 2021/06/12 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/10/29 00:00 [accepted] PHST- 2022/04/01 05:10 [entrez] PHST- 2022/04/02 06:00 [pubmed] PHST- 2022/04/02 06:01 [medline] PHST- 2021/11/01 00:00 [pmc-release] AID - AIAN-24-917 [pii] AID - 10.4103/aian.aian_541_21 [doi] PST - ppublish SO - Ann Indian Acad Neurol. 2021 Nov-Dec;24(6):917-926. doi: 10.4103/aian.aian_541_21. Epub 2021 Dec 17. PMID- 35357785 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20230309 IS - 0019-1442 (Print) IS - 0019-1442 (Linking) VI - 75 IP - 3-04 DP - 2022 Mar 31 TI - Can we influence the negative drug attitude? Interpretation of the rejection of COVID-19 vaccine in the light of results of a pilot study. PG - 111-116 LID - 10.18071/isz.75.0111 [doi] AB - BACKGROUND AND PURPOSE: Vaccination refusal is a serious obstacle to minimizing the spread of COVID-19. Nevertheless, the rejection of vaccine can be considered the result of a negative attitude towards medical treatment, and according to our previously published data, it can be influenced by the underlying affective state. Increased incidence of affective disorders and anxiety could be observed globally during the pandemic, which may have a significant impact on vaccination acceptance. The aim of our pilot study was to determine the association between clinical improvement of affective and neurocognitive symptoms and change of drug attitude and health control beliefs in a sample of psychiatric patients. METHODS: A data set of 85 patients with psychiatric disorder has been analysed with the use of Patient's Health Belief Questionnaire on Psychiatric Treatment (PHBQPT) with 5 subscales (Negative Aspect of Medication - NA; Positive Aspect of Medication - PA; Doctor health locus of control- Doctor HLOC; Internal HLOC; Psychological Reactance - PR); Hospital Anxiety Depression Scale (HADS-Anx; HADS-Dep) and neurocognitive tests, such as the Stroop test and the Trail Making Tests. All the tests were performed before and after a 14 days treatment. Paired t-tests and generalized linear models were performed to assess the associations between the variables. RESULTS: The baseline scores of NA and HADS-Anx correlated significantly (p=0.001) and after two weeks of treatment NA decreased (p=0.001), while Doctor HLOC and Internal HLOC increased (p=0.001 and p=0.006). The patients performance of the neurocognitive tests improved (all p<0.05). The reduction of HADS-Anx (p=0.002) and HADS-Dep (p=0.006) scores showed significant associations with the decrease of NA. Increase of the PA score was associated with reduction of HADS-Dep (p=0.028). Improvement of neurocognitive functions had no effect on PHBQPT scores. CONCLUSION: Important conclusions can be drawn regarding the rejection of the COVID-19 vaccine based on the associations found between the intensity of affective and anxiety symptoms and the attitude towards treatment. Our findings suggest that affective symptoms have a negative influence on the attitude towards treatment and that the improvement of these symptoms can facilitate the acceptance of the therapy, regardless of diagnosis. The modest effect of the improvement of neurocognitive functioning on the attitude towards drugs and the significant role of affective-emotional factors suggest that the accep-tance of vaccination probably cannot be facilitated solely with the aid of educational programs. Considering the increasing incidence of affective disorders during the COVID-19 pandemic, the screening of affective and anxiety symptoms and treatment of these disorders could be an important step towards the acceptance of the vaccine. Although psychiatry is not considered as a frontline care unit of the COVID cases, more attention is needed to pay on the availability of mental health services because refuse of vaccine can develop due to affective disorders too. FAU - Pogany, Laszlo AU - Pogany L AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. AD - Janos Szentagothai Doctoral School of Neurosciences, Semmelweis University, Budapest. FAU - Horvath, Andras A AU - Horvath AA AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. FAU - Lazary, Judit AU - Lazary J AD - National Institute of Mental Health, Neurology and Neurosurgery, Budapest. AD - Janos Szentagothai Doctoral School of Neurosciences, Semmelweis University, Budapest. LA - eng PT - Journal Article TT - Befolyasolhato-e a negativ gyogyszerszedesi attitud? A Covid-19-vakcinat elutasito magatartas interpretacioja egy elokeszito vizsgalat eredmenyeinek tukreben. PL - Hungary TA - Ideggyogy Sz JT - Ideggyogyaszati szemle JID - 17510500R RN - 0 (COVID-19 Vaccines) SB - IM MH - Anxiety Disorders/diagnosis/epidemiology/psychology MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Humans MH - Pandemics MH - Pilot Projects OTO - NOTNLM OT - anti-vax behavior OT - drug attitude OT - health beliefs OT - psychological reactance OT - rejection of vaccination EDAT- 2022/04/01 06:00 MHDA- 2022/04/05 06:00 CRDT- 2022/03/31 12:07 PHST- 2022/03/31 12:07 [entrez] PHST- 2022/04/01 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] AID - 10.18071/isz.75.0111 [doi] PST - ppublish SO - Ideggyogy Sz. 2022 Mar 31;75(3-04):111-116. doi: 10.18071/isz.75.0111. PMID- 35340304 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240825 IS - 2666-3546 (Electronic) IS - 2666-3546 (Linking) VI - 21 DP - 2022 May TI - Cognitive function following SARS-CoV-2 infection in a population-representative Canadian sample. PG - 100454 LID - 10.1016/j.bbih.2022.100454 [doi] LID - 100454 AB - BACKGROUND: SARS-CoV-2 infection is believed to adversely affect the brain, but the degree of impact on socially relevant cognitive functioning and decision-making is not well-studied, particularly among those less vulnerable to age-related mortality. The current study sought to determine whether infection status and COVID-19 symptom severity are associated with cognitive dysfunction among young and middled-aged adults in the general population, using self-reported lapses in executive control and a standardized decision-making task. METHOD: The survey sample comprised 1958 adults with a mean age of 37 years (SD ​= ​10.4); 60.8% were female. Participants reported SARS-CoV-2 infection history and, among those reporting a prior infection, COVID-19 symptom severity. Primary outcomes were self-reported symptoms of cognitive dysfunction assessed via an abbreviated form of the Barkley Deficits in Executive Functioning Scale (BDEFS) and performance on a validated delay-discounting task. RESULTS: Young and middle-aged adults with a positive SARS-CoV-2 infection history reported a significantly higher number of cognitive dysfunction symptoms (M (adj) ​= ​1.89, SE ​= ​0.08, CI: 1.74, 2.04; n ​= ​175) than their non-infected counterparts (M (adj) ​= ​1.63, SE ​= ​0.08, CI: 1.47,1.80; n ​= ​1599; beta ​= ​0.26, p ​= ​.001). Among those infected, there was a dose-response relationship between COVID-19 symptom severity and level of cognitive dysfunction reported, with moderate (beta ​= ​0.23, CI: 0.003-0.46) and very/extremely severe (beta ​= ​0.69, CI: 0.22-1.16) COVID-19 symptoms being associated with significantly greater cognitive dysfunction. These effects remained reliable and of similar magnitude after controlling for demographics, vaccination status, mitigation behavior frequency, and geographic region, and after removal of those who had been intubated during hospitalization. Very similar-and comparatively larger-effects were found for the delay-discounting task, and when using only PCR confirmed SARS-CoV-2 cases. CONCLUSIONS: Positive SARS-CoV-2 infection history and moderate or higher COVID-19 symptom severity are associated with significant symptoms of cognitive dysfunction and amplified delay discounting among young and middle-aged adults with no history of medically induced coma. CI - (c) 2022 The Author(s). FAU - Hall, Peter A AU - Hall PA AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Meng, Gang AU - Meng G AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. FAU - Hudson, Anna AU - Hudson A AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. FAU - Sakib, Mohammad N AU - Sakib MN AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. FAU - Hitchman, Sara C AU - Hitchman SC AD - Department of Communication and Media Research, University of Zurich, Zurich, Switzerland. FAU - MacKillop, James AU - MacKillop J AD - Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, Ontario, Canada. FAU - Bickel, Warren K AU - Bickel WK AD - Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA, USA. FAU - Fong, Geoffrey T AU - Fong GT AD - School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada. AD - Department of Psychology, University of Waterloo, Waterloo, Ontario, Canada. AD - Ontario Institute for Cancer Research, Toronto, Ontario, Canada. LA - eng PT - Journal Article DEP - 20220321 PL - United States TA - Brain Behav Immun Health JT - Brain, behavior, & immunity - health JID - 101759062 PMC - PMC8934755 OTO - NOTNLM OT - Brain OT - COVID-19 OT - Cognition OT - Delay discounting OT - Executive function OT - OFC OT - SARS-CoV-2 COIS- The authors declare no conflicts of interest. EDAT- 2022/03/29 06:00 MHDA- 2022/03/29 06:01 PMCR- 2022/03/21 CRDT- 2022/03/28 05:06 PHST- 2022/01/16 00:00 [received] PHST- 2022/03/12 00:00 [revised] PHST- 2022/03/12 00:00 [accepted] PHST- 2022/03/28 05:06 [entrez] PHST- 2022/03/29 06:00 [pubmed] PHST- 2022/03/29 06:01 [medline] PHST- 2022/03/21 00:00 [pmc-release] AID - S2666-3546(22)00044-8 [pii] AID - 100454 [pii] AID - 10.1016/j.bbih.2022.100454 [doi] PST - ppublish SO - Brain Behav Immun Health. 2022 May;21:100454. doi: 10.1016/j.bbih.2022.100454. Epub 2022 Mar 21. PMID- 35335073 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 3 DP - 2022 Mar 14 TI - Investigation of a Cluster of Immunization Stress-Related Reactions after Coronavirus Disease 2019 (COVID-19) Vaccination, Thailand, 2021. LID - 10.3390/vaccines10030441 [doi] LID - 441 AB - On 28 April 2021, the investigation team of the Department of Disease Control, Ministry of Public Health, was notified of a cluster of people developing neurological symptoms following COVID-19 vaccination in a province in eastern Thailand. We conducted an investigation from 29 April to 20 May 2021 to confirm the outbreak, describe the epidemiological characteristics and identify possible risk factors. A matched case-control study was conducted. Matching factors were gender and vaccination site. A confirmed case was a person receiving COVID-19 vaccination in the province and developed at least one neurological symptom between 21 April and 20 May 2021. The rapid assessment of the vaccination cold chain system was carried out. We found a total of 36 cases out of 3920 vaccinees (attack rate = 0.92%), all cases were recovered and classified as an immunization stress-related reaction (ISRR) by the National AEFI Expert Committee. An analytic study found that menstruation was significantly associated with ISRR (AOR = 6.84 [95%CI = 1.09-42.91]). The environmental survey suggested that the cold chain system was properly managed. Further studies on other precipitating causes of ISRR should be performed. In terms of recommendation, health providers should pay greater attention to women menstruating during and after COVID-19 immunization. FAU - Mahasing, Chayanit AU - Mahasing C AUID- ORCID: 0000-0002-6023-2124 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Yasopa, Oiythip AU - Yasopa O AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Sansilapin, Chalo AU - Sansilapin C AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Rattanathumsakul, Thanit AU - Rattanathumsakul T AUID- ORCID: 0000-0002-2629-7370 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Thammawijaya, Panithee AU - Thammawijaya P AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Suphanchaimat, Rapeepong AU - Suphanchaimat R AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. AD - International Health Policy Program, Ministry of Public Health, Nonthaburi 11000, Thailand. FAU - Doung-Ngern, Pawinee AU - Doung-Ngern P AUID- ORCID: 0000-0002-1154-4527 AD - Division of Epidemiology, Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand. LA - eng GR - 7200AA19CA00002/United States Agency for International Development/ PT - Journal Article DEP - 20220314 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8954559 OTO - NOTNLM OT - COVID-19 vaccination OT - CoronaVac OT - adverse event following immunization OT - immunization stress-related reaction COIS- The authors declare that there is no conflict of interest. EDAT- 2022/03/27 06:00 MHDA- 2022/03/27 06:01 PMCR- 2022/03/14 CRDT- 2022/03/26 01:02 PHST- 2022/01/11 00:00 [received] PHST- 2022/02/16 00:00 [revised] PHST- 2022/02/22 00:00 [accepted] PHST- 2022/03/26 01:02 [entrez] PHST- 2022/03/27 06:00 [pubmed] PHST- 2022/03/27 06:01 [medline] PHST- 2022/03/14 00:00 [pmc-release] AID - vaccines10030441 [pii] AID - vaccines-10-00441 [pii] AID - 10.3390/vaccines10030441 [doi] PST - epublish SO - Vaccines (Basel). 2022 Mar 14;10(3):441. doi: 10.3390/vaccines10030441. PMID- 35334195 OWN - NLM STAT- MEDLINE DCOM- 20220929 LR - 20221011 IS - 2191-0200 (Electronic) IS - 0334-1763 (Linking) VI - 33 IP - 7 DP - 2022 Oct 26 TI - Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand? PG - 721-743 LID - 10.1515/revneuro-2022-0006 [doi] AB - The devastating characteristic of COVID-19 pandemic calls for immediate and effective solutions to tackle it. Vaccines seem to be the only promising and effective way to fight against the novel coronavirus - even against new mutated variants. Because of the rapid development and distribution of numerous COVID-19 vaccines in different platforms, meticulous evaluation of vaccines' safety is more critical than ever - especially given the fact that most of the candidates have not completed the clinical phase. Therefore, to optimize the vaccines' safety and efficacy, it is highly important to carefully report and scientifically discuss the serious adverse effects following vaccination. In this respect, we discuss different neurological and neuropsychological adverse effects of COVID-19 vaccines including demyelinating diseases, Bell's palsy (BP), cerebrovascular complications, seizures, functional neurological disorders (FNDs), and some other rare adverse events, and hypothetical mechanisms which can lead to the reported side effects. Given the fact that the incidence of such events are rare and most of them are treatable, the current review aims to shed light on how much the relationship between COVID-19 vaccines and these complications can be reliable and provide an insight for future studies with much more meticulous methodologies to discuss the possible correlational or causal relationship between these complications and COVID-19 vaccines and elucidate whether or not the neurological side effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines can count as a considerable threat to public health. CI - (c) 2022 Walter de Gruyter GmbH, Berlin/Boston. FAU - Aliasin, Mohammad Mahdi AU - Aliasin MM AUID- ORCID: 0000-0002-9097-7207 AD - School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. AD - Students' Scientific Research Center, Tehran University of Medical Sciences, 14177 55331 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. FAU - Yazdanpanah, Niloufar AU - Yazdanpanah N AUID- ORCID: 0000-0003-4333-2163 AD - School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. AD - Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, 14197 33151 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. FAU - Rezaei, Nima AU - Rezaei N AUID- ORCID: 0000-0002-3836-1827 AD - Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, 14197 33151 Tehran, Iran. AD - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), 14197 33151 Tehran, Iran. AD - Department of Immunology, School of Medicine, Tehran University of Medical Sciences, 14176 13151 Tehran, Iran. LA - eng PT - Journal Article PT - Review DEP - 20220325 PL - Germany TA - Rev Neurosci JT - Reviews in the neurosciences JID - 8711016 RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/adverse effects MH - Humans MH - Pandemics/prevention & control MH - SARS-CoV-2 MH - Viral Vaccines/adverse effects OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - cerebrovascular complications OT - demyelinating diseases OT - neurological complications EDAT- 2022/03/26 06:00 MHDA- 2022/09/30 06:00 CRDT- 2022/03/25 17:27 PHST- 2022/01/17 00:00 [received] PHST- 2022/02/14 00:00 [accepted] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/09/30 06:00 [medline] PHST- 2022/03/25 17:27 [entrez] AID - revneuro-2022-0006 [pii] AID - 10.1515/revneuro-2022-0006 [doi] PST - epublish SO - Rev Neurosci. 2022 Mar 25;33(7):721-743. doi: 10.1515/revneuro-2022-0006. Print 2022 Oct 26. PMID- 35326363 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220329 IS - 2076-3425 (Print) IS - 2076-3425 (Electronic) IS - 2076-3425 (Linking) VI - 12 IP - 3 DP - 2022 Mar 18 TI - COVID-19 Vaccination and Neurological Manifestations: A Review of Case Reports and Case Series. LID - 10.3390/brainsci12030407 [doi] LID - 407 AB - BACKGROUND: With 10 vaccines approved by the WHO and nearly 48% of people fully vaccinated worldwide, we have observed several individual case studies of neurological manifestations post-COVID-19 vaccination. Through this systematic review, we aim to discern these CNS and PNS manifestations following the COVID-19 vaccine to help produce methods to mitigate them. METHODS: We conducted a thorough literature search of Google Scholar and PubMed from 1 December 2020 until 10 October 2021 and included all the case studies of COVID-19 vaccine-associated neurological side effects. The literature search and data analysis were performed by two independent reviewers according to prespecified inclusion and exclusion criteria using PRISMA. RESULTS: The most common CNS manifestation was CVST (14.47%), found in females (64%) younger than 50 years (71%) after the first AstraZeneca dose (93%). Others included CNS demyelinating disorders (TM, ADEM, MS, NMOSD) (9.30%), encephalopathy/encephalitis (3.10%), and others (4.13%). The most common PNS manifestation was GBS (14.67%) found in males (71%) older than 50 years (79%), followed by Bell's palsy (5.24%) and others (2.10%). Most occurred with the AstraZeneca (28.55%), Pfizer-BioNTech (9.18%), and Moderna (8.16%) vaccines. Nine (64%) out of the 14 patients with CVST died. However, most cases overall (42 out of 51) were non-fatal (82%). CONCLUSION: Several CNS and PNS adverse events have occurred post-COVID-19 vaccination, including CVST, GBS, and TM. High vigilance with early identification and treatment leads to better outcomes. Further studies with non-vaccinated controls might help in understanding the pathophysiologic mechanisms of these neurological manifestations following COVID-19 vaccination. FAU - Sriwastava, Shitiz AU - Sriwastava S AUID- ORCID: 0000-0001-6844-3287 AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. AD - West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA. AD - Department of Biostatistics, West Virginia University, Morgantown, WV 26506, USA. FAU - Sharma, Kanika AU - Sharma K AUID- ORCID: 0000-0001-7847-4319 AD - Smt. N.H.L. Municipal Medical College, Ahmedabad 380006, India. FAU - Khalid, Syed Hassan AU - Khalid SH AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. FAU - Bhansali, Sakhi AU - Bhansali S AD - Calcutta National Medical College, Kolkata 700014, India. FAU - Shrestha, Ashish K AU - Shrestha AK AUID- ORCID: 0000-0002-4614-7783 AD - Kathmandu Medical College Teaching Hospital, Kathmandu 44600, Nepal. FAU - Elkhooly, Mahmoud AU - Elkhooly M AUID- ORCID: 0000-0002-1299-3906 AD - Department of Neuropsychiatry, Minia University, Minia 61519, Egypt. FAU - Srivastava, Samiksha AU - Srivastava S AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. FAU - Khan, Erum AU - Khan E AD - B.J. Medical College and Civil Hospital, Ahmedabad 380016, India. FAU - Jaiswal, Shruti AU - Jaiswal S AD - West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA. FAU - Wen, Sijin AU - Wen S AD - West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA. AD - Department of Biostatistics, West Virginia University, Morgantown, WV 26506, USA. LA - eng GR - U54 GM104942/GM/NIGMS NIH HHS/United States PT - Journal Article PT - Review DEP - 20220318 PL - Switzerland TA - Brain Sci JT - Brain sciences JID - 101598646 PMC - PMC8946610 OTO - NOTNLM OT - COVID-19 vaccination OT - GBS OT - Janssen/Johnson and Johnson and AstraZeneca vaccine OT - Moderna OT - Pfizer BioNTech OT - transverse myelitis COIS- All the authors confirmed no conflict of interest. EDAT- 2022/03/26 06:00 MHDA- 2022/03/26 06:01 PMCR- 2022/03/18 CRDT- 2022/03/25 01:01 PHST- 2022/02/25 00:00 [received] PHST- 2022/03/12 00:00 [revised] PHST- 2022/03/17 00:00 [accepted] PHST- 2022/03/25 01:01 [entrez] PHST- 2022/03/26 06:00 [pubmed] PHST- 2022/03/26 06:01 [medline] PHST- 2022/03/18 00:00 [pmc-release] AID - brainsci12030407 [pii] AID - brainsci-12-00407 [pii] AID - 10.3390/brainsci12030407 [doi] PST - epublish SO - Brain Sci. 2022 Mar 18;12(3):407. doi: 10.3390/brainsci12030407. PMID- 35321225 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220325 IS - 1664-0640 (Print) IS - 1664-0640 (Electronic) IS - 1664-0640 (Linking) VI - 13 DP - 2022 TI - Prevalence of Behavioral and Psychological Symptoms in Patients With Cognitive Decline Before and During the COVID-19 Pandemic. PG - 839683 LID - 10.3389/fpsyt.2022.839683 [doi] LID - 839683 AB - OBJECTIVE: Preventive measures to limit the spread of COVID-19 are essential, but often cause social isolation, affecting the physical and mental health of older adults. Patients with dementia are likely to have worsening behavioral and psychological symptoms of dementia (BPSD) owing to pandemic restrictions. To examine this, we described BPSD before and during the COVID-19 pandemic. METHODS: We identified patients at a memory clinic in Japan between October 2018 and December 2019 (15 months before the pandemic began, n = 1,384) and between April 2020 and June 2021 (15 months after the State of Emergency was declared; n = 675 patients). A propensity score was used to match 576 patients from each group. The Mini-Mental State Exam was used to classify cognitive function into mild and moderate/severe. Dementia Behavioral Disturbance Scale was used to evaluate BPSD. The association between BPSD before and during the pandemic was evaluated using binomial logistic regression models. RESULTS: The levels of frequent night waking were higher in individuals before the pandemic than in those evaluated during the pandemic in both the mild group [adjusted odds ratio (AOR) = 1.82, 95% CI 1.02-3.23] and the moderate/severe group (AOR = 1.96, 95% CI 1.19-3.23). During the pandemic, physical attacks were higher in the mild group (AOR = 4.25, 95% CI 1.12-16.07), while night wandering was higher in the moderate/severe group (AOR = 2.22, 95% CI 1.03-4.81). CONCLUSION: In patients with cognitive impairment, some BPSD were more prevalent during the pandemic, depending on dementia severity. The findings pertaining to the higher frequency of sleep disturbance and aggressiveness during COVID-19 should be used to guide BPSD screening in patients with dementia and to provide evidence-based interventions. CI - Copyright (c) 2022 Kuroda, Sugimoto, Matsumoto, Uchida, Kishino, Suemoto and Sakurai. FAU - Kuroda, Yujiro AU - Kuroda Y AD - Department of Prevention and Care Science, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Sugimoto, Taiki AU - Sugimoto T AD - Department of Prevention and Care Science, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Matsumoto, Nanae AU - Matsumoto N AD - Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan. FAU - Uchida, Kazuaki AU - Uchida K AD - Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Public Health, Graduate School of Health Sciences, Kobe University, Kobe, Japan. FAU - Kishino, Yoshinobu AU - Kishino Y AD - Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Cognitive and Behavioral Science, Nagoya University Graduate School of Medicine, Nagoya, Japan. FAU - Suemoto, Claudia Kimie AU - Suemoto CK AD - Division of Geriatrics, University of Sao Paulo, Sao Paulo, Brazil. FAU - Sakurai, Takashi AU - Sakurai T AD - Department of Prevention and Care Science, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Center for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu, Japan. AD - Department of Cognitive and Behavioral Science, Nagoya University Graduate School of Medicine, Nagoya, Japan. LA - eng PT - Journal Article DEP - 20220307 PL - Switzerland TA - Front Psychiatry JT - Frontiers in psychiatry JID - 101545006 PMC - PMC8934776 OTO - NOTNLM OT - behavioral and psychological symptoms (BPSD) OT - coronavirus disease (COVID-19) OT - dementia-Alzheimer's disease OT - mild cognitive impairment (MCI) OT - social distancing (vaccine) COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/03/25 06:00 MHDA- 2022/03/25 06:01 PMCR- 2022/03/07 CRDT- 2022/03/24 05:10 PHST- 2021/12/20 00:00 [received] PHST- 2022/02/09 00:00 [accepted] PHST- 2022/03/24 05:10 [entrez] PHST- 2022/03/25 06:00 [pubmed] PHST- 2022/03/25 06:01 [medline] PHST- 2022/03/07 00:00 [pmc-release] AID - 10.3389/fpsyt.2022.839683 [doi] PST - epublish SO - Front Psychiatry. 2022 Mar 7;13:839683. doi: 10.3389/fpsyt.2022.839683. eCollection 2022. PMID- 35283306 OWN - NLM STAT- MEDLINE DCOM- 20220526 LR - 20230328 IS - 1469-0691 (Electronic) IS - 1198-743X (Print) IS - 1198-743X (Linking) VI - 28 IP - 6 DP - 2022 Jun TI - Caring for older adults during the COVID-19 pandemic. PG - 785-791 LID - S1198-743X(22)00117-3 [pii] LID - 10.1016/j.cmi.2022.02.040 [doi] AB - BACKGROUND: Elderly patients represent a high-risk group with increased risk of death from COVID-19. Despite the number of published studies, several unmet needs in care for older adults exist. OBJECTIVES: To discuss unmet needs of COVID-19 in this special population. SOURCES: A literature review for studies on COVID-19 in elderly patients published between December 2019 and November 2021 was performed. Clinical questions were formulated to guide the literature search. The search was conducted in the MEDLINE database, combining specific search terms. Two reviewers independently conducted the search and selected the studies according to the prespecified clinical questions. CONTENT: Elderly patients with COVID-19 have peculiar characteristics. They may have atypical clinical presentation, with no fever and with delirium or neurological manifestations as the most common signs, with potential delayed diagnosis and increased risk of death. The reported fatality rates among elderly patients with COVID-19 are extremely high. Several factors, including comorbidities, atypical presentation, and exclusion from intensive care unit care, contribute to this excess of mortality. Age alone is frequently used as a key factor to exclude the elderly from intensive care, but there is evidence that frailty rather than age better predicts the risk of poor outcome in this category. Durability of vaccine efficacy in the elderly remains debated, and the need for a third booster dose is becoming increasingly evident. Finally, efforts to care for elderly patients who have survived after acute COVID-19 should be implemented, considering the high rates of long COVID sequelae and the risk of longitudinal functional and cognitive decline. IMPLICATIONS: We highlight peculiar aspects of COVID-19 in elderly patients and factors contributing to high risk of poor outcome in this category. We also illuminated gaps in current evidence, suggesting future research directions and underlining the need for further studies on the optimal management of elderly patients with COVID-19. CI - Copyright (c) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. FAU - Prendki, Virginie AU - Prendki V AD - Division of Infectious Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland; Faculty of Medicine, University of Geneva, Geneva, Switzerland. FAU - Tiseo, Giusy AU - Tiseo G AD - Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy. FAU - Falcone, Marco AU - Falcone M AD - Infectious Diseases Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Pisana, University of Pisa, Italy. Electronic address: marco.falcone@unipi.it. CN - ESCMID Study Group for Infections in the Elderly (ESGIE) LA - eng PT - Journal Article PT - Review DEP - 20220311 PL - England TA - Clin Microbiol Infect JT - Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases JID - 9516420 SB - IM MH - Aged MH - *COVID-19/epidemiology/therapy MH - *Frailty/diagnosis/epidemiology MH - Humans MH - Pandemics MH - Post-Acute COVID-19 Syndrome PMC - PMC8912971 OTO - NOTNLM OT - COVID-19 OT - Elderly OT - Frailty OT - Geriatric OT - Long COVID OT - Older OT - SARS-CoV-2 OT - Vaccines EDAT- 2022/03/15 06:00 MHDA- 2022/05/27 06:00 PMCR- 2022/03/11 CRDT- 2022/03/14 05:43 PHST- 2021/11/03 00:00 [received] PHST- 2022/02/15 00:00 [revised] PHST- 2022/02/24 00:00 [accepted] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/05/27 06:00 [medline] PHST- 2022/03/14 05:43 [entrez] PHST- 2022/03/11 00:00 [pmc-release] AID - S1198-743X(22)00117-3 [pii] AID - 10.1016/j.cmi.2022.02.040 [doi] PST - ppublish SO - Clin Microbiol Infect. 2022 Jun;28(6):785-791. doi: 10.1016/j.cmi.2022.02.040. Epub 2022 Mar 11. PMID- 35278975 OWN - NLM STAT- MEDLINE DCOM- 20220331 LR - 20240909 IS - 1873-5347 (Electronic) IS - 0277-9536 (Print) IS - 0277-9536 (Linking) VI - 298 DP - 2022 Apr TI - Inside the 'black box' of COVID-19 vaccination beliefs: Revealing the relative importance of public confidence and news consumption habits. PG - 114874 LID - S0277-9536(22)00180-0 [pii] LID - 10.1016/j.socscimed.2022.114874 [doi] AB - RATIONALE: President Biden's goal for 70% of U.S. adults to have received at least one vaccine by July 4, 2021 was not achieved. OBJECTIVE: The aim of this research was to assess the 'black box' of positive COVID-19 vaccination beliefs to determine the relative importance of each factor and thus inform well-targeted and tailored health promotion efforts. METHODS: A cross-sectional survey was conducted in a sample of U.S. adults (N = 1656), assessing the influence of demographic characteristics, cognitive effects, public confidence, and news source variety and evaluation on positive COVID-19 vaccination beliefs. RESULTS: Overall, the strongest predictor of positive beliefs was high confidence in public health officials and political institutions to handle the COVID-19 pandemic effectively, yet negative sentiments toward COVID-19 research and science and COVID-19 vaccine ambivalence reduced the likelihood that beliefs were positive. Cognitive effects and public confidence were identified as key predictors of positive COVID-19 vaccination beliefs over and above party identification. Importantly, high levels of confidence in science and government were mostly driven by positive evaluations of liberal news sources. High levels of COVID-19 science backlash were mostly driven by positive evaluations of conservative news sources. CONCLUSIONS: To motivate COVID-19 vaccination among hesitant or resistant groups in the population, health promotion efforts should seek to reinforce positive COVID-19 vaccination beliefs by increasing public confidence and by reducing COVID-19 science backlash, largely by choosing specific news media and social media platforms (e.g., Breitbart, Fox News, and Facebook) as channels for health promotion and health information dissemination. CI - Copyright (c) 2022 Elsevier Ltd. All rights reserved. FAU - Lueck, Jennifer A AU - Lueck JA AD - Department of Communication, Texas A&M University, 456 Ross St., College Station, TX, USA. Electronic address: jlueck@tamu.edu. FAU - Callaghan, Timothy AU - Callaghan T AD - Department of Health Policy and Management, School of Public Health, Texas A&M University. 212 Adriance Lab Rd. 1266 TAMU, College Station, TX, USA. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20220301 PL - England TA - Soc Sci Med JT - Social science & medicine (1982) JID - 8303205 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines/therapeutic use MH - Cross-Sectional Studies MH - Habits MH - Humans MH - Pandemics/prevention & control MH - Vaccination/psychology PMC - PMC8885110 OTO - NOTNLM OT - Attitude OT - COVID-19 OT - Cognition OT - Health promotion OT - News media OT - Public confidence OT - Vaccine COIS- None. EDAT- 2022/03/13 06:00 MHDA- 2022/04/01 06:00 PMCR- 2022/03/01 CRDT- 2022/03/12 20:16 PHST- 2021/06/28 00:00 [received] PHST- 2022/01/11 00:00 [revised] PHST- 2022/02/26 00:00 [accepted] PHST- 2022/03/13 06:00 [pubmed] PHST- 2022/04/01 06:00 [medline] PHST- 2022/03/12 20:16 [entrez] PHST- 2022/03/01 00:00 [pmc-release] AID - S0277-9536(22)00180-0 [pii] AID - 114874 [pii] AID - 10.1016/j.socscimed.2022.114874 [doi] PST - ppublish SO - Soc Sci Med. 2022 Apr;298:114874. doi: 10.1016/j.socscimed.2022.114874. Epub 2022 Mar 1. PMID- 35239452 OWN - NLM STAT- MEDLINE DCOM- 20220415 LR - 20220516 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - Detection of anti-NMDA receptor antibodies following BBIBP-CorV COVID-19 vaccination in a rituximab-treated person with multiple sclerosis presenting with manifestations of an acute relapse. PG - 2033540 LID - 10.1080/21645515.2022.2033540 [doi] LID - 2033540 AB - Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a relatively unknown autoimmune entity. Scant reports of post-infection/vaccination anti-NMDAR encephalitis exist. We, hereby, reviewed the relevant cases and added to the literature a possible case of anti-NMDAR encephalitis following COVID-19 vaccination with BBIBP-CorV (Sinopharm). A 50-year-old Persian woman with previously known rituximab-treated MS presented complaining of worsening neurological symptoms all gradually starting and worsening after receiving the second dose of BBVIP-CorV 2 weeks before. Notable findings in her physical examination included ataxic gait and Babinski sign. Considering an acute MS relapse, corticosteroid pulse therapy was initiated, and she was referred for MRI, which revealed multiple new plaques. Her serum sample interestingly tested positive for anti-NMDAR antibodies. CSF analysis was unfortunately not performed. She responded well to the corticosteroid pulse therapy and showed substantial resolution of the symptoms. Considering its relatively low cost of workup and the benefits of correct early diagnosis, clinicians are advised to consider autoimmune encephalitis encountering patients with progressive neurological symptoms after the administration of vaccines, including the ones for COVID-19 which are currently being used extensively. FAU - Etemadifar, Masoud AU - Etemadifar M AD - Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Nouri, Hosein AU - Nouri H AUID- ORCID: 0000-0003-1808-0443 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran. FAU - Salari, Mehri AU - Salari M AUID- ORCID: 0000-0001-7102-821X AD - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran Iran. FAU - Sedaghat, Nahad AU - Sedaghat N AUID- ORCID: 0000-0002-2796-6791 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Isfahan, Iran. LA - eng PT - Journal Article DEP - 20220303 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (Adrenal Cortex Hormones) RN - 0 (COVID-19 Vaccines) RN - 0 (Receptors, N-Methyl-D-Aspartate) RN - 4F4X42SYQ6 (Rituximab) SB - IM MH - Adrenal Cortex Hormones MH - *Anti-N-Methyl-D-Aspartate Receptor Encephalitis/diagnosis/drug therapy MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Middle Aged MH - *Multiple Sclerosis MH - Neoplasm Recurrence, Local MH - Receptors, N-Methyl-D-Aspartate MH - Rituximab/therapeutic use MH - Vaccination PMC - PMC9009911 OTO - NOTNLM OT - Anti-N-Methyl-d-Aspartate receptor antibodies OT - Autoimmune encephalitis OT - COVID-19 vaccination OT - case report OT - multiple sclerosis COIS- The authors have no conflicts of interest to declare. EDAT- 2022/03/04 06:00 MHDA- 2022/04/16 06:00 PMCR- 2022/03/03 CRDT- 2022/03/03 17:13 PHST- 2022/03/04 06:00 [pubmed] PHST- 2022/04/16 06:00 [medline] PHST- 2022/03/03 17:13 [entrez] PHST- 2022/03/03 00:00 [pmc-release] AID - 2033540 [pii] AID - 10.1080/21645515.2022.2033540 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):2033540. doi: 10.1080/21645515.2022.2033540. Epub 2022 Mar 3. PMID- 35227552 OWN - NLM STAT- MEDLINE DCOM- 20220401 LR - 20260127 IS - 1873-2364 (Electronic) IS - 0960-8966 (Print) IS - 0960-8966 (Linking) VI - 32 IP - 3 DP - 2022 Mar TI - Early safety and tolerability profile of the BNT162b2 COVID-19 vaccine in myasthenia gravis. PG - 230-235 LID - S0960-8966(22)00030-X [pii] LID - 10.1016/j.nmd.2022.01.013 [doi] AB - Although the COVID-19 vaccines are currently recommended for people with myasthenia gravis (MG), there is no data regarding the safety of the vaccines in this population. In order to investigate the real-life safety data of the BNT162b2 COVID-19 vaccine in people with MG, an anonymous survey was distributed to 142 MG patients. Fifty-six MG patients completed the questionnaire. The median age was 53 years (range 23-83 years); 35 (62.5%) were males, and 25 (44.6%) had associated comorbidities. Thirty-seven participants (66.1%) were treated with immunotherapies. Fifty-five participants (98.2% of the responders) received the BNT162b2 COVID-19 vaccine. Of these, 32 (58.2%) were < 55 years old, and 23 (41.8%) were > 55 years old. Adverse events were more common in patients younger than 55 years old (46.9% Vs. 17.4%; p = 0.0428). Eight participants (14.5%) reported worsening neurological symptoms following the vaccination. Three of those who reported worsening of neurological symptoms (37.5%) required additional treatment. Most events occurred within the first few days after vaccination and resolved within a few weeks. This survey indicates an overall favorable safety and tolerability profile of the BNT162b2 vaccine in people with MG. Additional prospective, large-scale studies are warranted to confirm these findings. CI - Copyright (c) 2022 Elsevier B.V. All rights reserved. FAU - Lotan, Itay AU - Lotan I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: lotan.itay1@gmail.com. FAU - Hellmann, Mark A AU - Hellmann MA AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Friedman, Yitzhak AU - Friedman Y AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Stiebel-Kalish, Hadas AU - Stiebel-Kalish H AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel; Department of Ophthalmology and Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva, Israel. FAU - Steiner, Israel AU - Steiner I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Wilf-Yarkoni, Adi AU - Wilf-Yarkoni A AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel; Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Israel. LA - eng PT - Journal Article DEP - 20220205 PL - England TA - Neuromuscul Disord JT - Neuromuscular disorders : NMD JID - 9111470 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - BNT162 Vaccine MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Female MH - Humans MH - Male MH - Middle Aged MH - *Myasthenia Gravis MH - Prospective Studies MH - SARS-CoV-2 MH - Young Adult PMC - PMC8817458 OTO - NOTNLM OT - COVID-19 OT - Myasthenia gravis OT - Safety OT - Tolerability: Adverse events OT - Vaccine COIS- Declaration of Competing Interest none. EDAT- 2022/03/02 06:00 MHDA- 2022/04/02 06:00 PMCR- 2022/02/05 CRDT- 2022/03/01 05:46 PHST- 2021/08/02 00:00 [received] PHST- 2022/01/25 00:00 [revised] PHST- 2022/01/27 00:00 [accepted] PHST- 2022/03/02 06:00 [pubmed] PHST- 2022/04/02 06:00 [medline] PHST- 2022/03/01 05:46 [entrez] PHST- 2022/02/05 00:00 [pmc-release] AID - S0960-8966(22)00030-X [pii] AID - 10.1016/j.nmd.2022.01.013 [doi] PST - ppublish SO - Neuromuscul Disord. 2022 Mar;32(3):230-235. doi: 10.1016/j.nmd.2022.01.013. Epub 2022 Feb 5. PMID- 35214690 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240824 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 2 DP - 2022 Feb 3 TI - Cerebral Venous Sinus Thrombosis following COVID-19 Vaccination: Analysis of 552 Worldwide Cases. LID - 10.3390/vaccines10020232 [doi] LID - 232 AB - To date, billions of vaccine doses have been administered to restrain the current COVID-19 pandemic worldwide. Rare side effects, including intravascular blood clots, were reported in the general population after vaccination. Among these, cerebral venous sinus thrombosis (CVST) has been considered the most serious one. To shed further light on such an event, we conducted a literature search for case descriptions of CVST in vaccinated people. Findings were analyzed with emphasis on demographic characteristics, type of vaccine, site of thrombosis, clinical and histopathological findings. From 258 potential articles published till September 2021, 41 studies were retrieved for a total of 552 patients. Of these, 492 patients (89.1%) had received AZD1222/Vaxzevria, 45 (8.2%) BNT162b2/CX-024414 Spikevax, 15 (2.7%) JNJ-78436735, and 2 (0.3%) Covishield vaccine. CVST occurred in 382 women and 170 men (mean aged 44 years), and the median timing from the shot was 9 days (range 2-45). Thrombi were predominantly seen in transverse (84%), sigmoid (66%), and/or superior sagittal (56%) sinuses. Brain injury (chiefly intracranial bleeding) occurred in 32% of cases. Of 426 patients with detailed clinical course, 63% were discharged in good clinical conditions, at times with variable neurological sequelae, whereas 37% deceased, largely due to brain injury. This narrative review confirmed CVST as a rare event after (adenoviral vector) COVID-19 vaccination, with a women/men rate ratio of 2.25. Though the pathogenesis of thrombosis is still under discussion, currently available histopathological findings likely indicate an underlying immune vasculitis. FAU - de Gregorio, Cesare AU - de Gregorio C AUID- ORCID: 0000-0003-3022-266X AD - Department of Clinical and Experimental Medicine, Division of Cardiology, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Colarusso, Luigi AU - Colarusso L AUID- ORCID: 0000-0003-2946-0724 AD - Department of Clinical and Experimental Medicine, Division of Cardiology, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Calcaterra, Giuseppe AU - Calcaterra G AD - Department of Cardiology, Postgraduate Medical School of Cardiology, University of Palermo, 90127 Palermo, Italy. FAU - Bassareo, Pier Paolo AU - Bassareo PP AUID- ORCID: 0000-0002-8374-0260 AD - Department of Cardiology, Mater Misericordiae University Hospital Crumlin, University College of Dublin, D07R2WY Dublin, Ireland. FAU - Ieni, Antonio AU - Ieni A AD - Pathology Unit, Department of Human Pathology G. Barresi, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Mazzeo, Anna Teresa AU - Mazzeo AT AD - Department of Human Pathology G. Barresi, Division of Anesthesia and Critical Care, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Ferrazzo, Giuseppe AU - Ferrazzo G AD - Department of Clinical and Experimental Medicine, Division of Cardiology, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Noto, Alberto AU - Noto A AD - Department of Human Pathology G. Barresi, Division of Anesthesia and Critical Care, G. Martino University Hospital Medical School of Messina, 98125 Messina, Italy. FAU - Koniari, Ioanna AU - Koniari I AD - Department of Cardiology, University Hospital of South Manchester, NHS Foundation Trust, Manchester M23 9LT, UK. FAU - Mehta, Jawahar L AU - Mehta JL AUID- ORCID: 0000-0003-0384-2097 AD - Department of Medicine, University of Arkansas for Medical Sciences and the Veterans Affairs Medical Center, Little Rock, AR 72205, USA. FAU - Kounis, Nicholas G AU - Kounis NG AUID- ORCID: 0000-0002-9751-6710 AD - Department of Internal Medicine, Division of Cardiology, University of Patras Medical School, 26221 Patras, Greece. LA - eng PT - Journal Article PT - Review DEP - 20220203 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8874972 OTO - NOTNLM OT - COVID-19 pandemic OT - cardiovascular disease OT - cerebral venous sinus thrombosis OT - side effects OT - vaccination COIS- The authors declare no conflict of interest. EDAT- 2022/02/27 06:00 MHDA- 2022/02/27 06:01 PMCR- 2022/02/03 CRDT- 2022/02/26 01:03 PHST- 2022/01/13 00:00 [received] PHST- 2022/01/28 00:00 [revised] PHST- 2022/01/30 00:00 [accepted] PHST- 2022/02/26 01:03 [entrez] PHST- 2022/02/27 06:00 [pubmed] PHST- 2022/02/27 06:01 [medline] PHST- 2022/02/03 00:00 [pmc-release] AID - vaccines10020232 [pii] AID - vaccines-10-00232 [pii] AID - 10.3390/vaccines10020232 [doi] PST - epublish SO - Vaccines (Basel). 2022 Feb 3;10(2):232. doi: 10.3390/vaccines10020232. PMID- 35201963 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20240826 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - Self-Reported safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among Iranian people with multiple sclerosis. PG - 2041945 LID - 10.1080/21645515.2022.2041945 [doi] LID - 2041945 AB - To affirm the short-term safety of the BBIBP-CorV (Sinopharm) COVID-19 vaccine among people with multiple sclerosis (pwMS), 517 vaccinated and 174 unvaccinated pwMS were interviewed. 16.2% of the vaccinated pwMS reported at least one neurological symptom in their respective vaccine-related at-risk periods (ARP) - a period from the first dose until two weeks after the second dose of the vaccine. In a multivariable logistic regression model, the presence of comorbidities (P = 0.01), use of natalizumab (P = 0.03), and experiencing post-vaccination myalgia (P < 0.01) predicted the development of post-vaccination neurological symptoms. One MS relapse, one COVID-19 contraction, and one ulcerative colitis flare after the first dose, and four MS relapses after the second dose of the vaccine were the only reported serious adverse events during the ARPs. To show if the vaccine provoked MS relapses, we compared the relapse rate of vaccinated pwMS in the vaccine-related ARP with the annualized relapse rate of unvaccinated pwMS in the prior year-a measure of baseline MS relapsing activity in the respective time-using a multivariable Poisson regression model accounting for possible confounders, which failed to show any statistically significant increase (P = 0.78). Hence, subject to replication-as the vaccinated and unvaccinated pwMS differed in baseline characteristics-the BBIBP-CorV vaccine does not seem to affect short-term MS activity. Furthermore, as 83.33% of the unvaccinated pwMS reported fear of possible adverse events to be the reason of their vaccination hesitancy, provision of evidence-based consultations to pwMS is encouraged. Limitations of our study briefly included lack of data for self-controlled analysis of relapse rates, possible presence of recall bias, and lack of on-site validations regarding the clinical outcomes due to the remote nature. FAU - Etemadifar, Masoud AU - Etemadifar M AD - Department of Neurosurgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Abhari, Amir Parsa AU - Abhari AP AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. FAU - Nouri, Hosein AU - Nouri H AUID- ORCID: 0000-0003-1808-0443 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. FAU - Sigari, Amirhossein Akhavan AU - Sigari AA AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Piran Daliyeh, Seyed Mohammad AU - Piran Daliyeh SM AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Maracy, Mohammad Reza AU - Maracy MR AD - Department of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Salari, Mehri AU - Salari M AUID- ORCID: 0000-0001-7102-821X AD - Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran. FAU - Maleki, Shiva AU - Maleki S AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. FAU - Sedaghat, Nahad AU - Sedaghat N AUID- ORCID: 0000-0002-2796-6791 AD - Alzahra Research Institute, Alzahra University Hospital, Isfahan University of Medical Sciences, Isfahan, Iran. AD - Network of Immunity in Infection, Malignancy, and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Iran. LA - eng PT - Journal Article DEP - 20220224 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - Iran MH - *Multiple Sclerosis MH - Recurrence MH - SARS-CoV-2 MH - Self Report PMC - PMC9009900 OTO - NOTNLM OT - BBIBP-CorV OT - Multiple sclerosis OT - SARS-CoV-2, COVID-19 vaccines OT - adverse events OT - vaccine safety COIS- No potential conflict of interest was reported by the author(s). EDAT- 2022/02/25 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/02/24 CRDT- 2022/02/24 17:20 PHST- 2022/02/25 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/02/24 17:20 [entrez] PHST- 2022/02/24 00:00 [pmc-release] AID - 2041945 [pii] AID - 10.1080/21645515.2022.2041945 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):2041945. doi: 10.1080/21645515.2022.2041945. Epub 2022 Feb 24. PMID- 35193171 OWN - NLM STAT- MEDLINE DCOM- 20220805 LR - 20250728 IS - 1758-0854 (Electronic) IS - 1758-0846 (Print) IS - 1758-0854 (Linking) VI - 14 IP - 3 DP - 2022 Aug TI - Predicting COVID-19 booster vaccine intentions. PG - 819-841 LID - 10.1111/aphw.12349 [doi] AB - Achieving broad immunity through vaccination is a cornerstone strategy for long-term management of COVID-19 infections, particularly the prevention of serious cases and hospitalizations. Evidence that vaccine-induced immunity wanes over time points to the need for COVID-19 booster vaccines, and maximum compliance is required to maintain population-level immunity. Little is known of the correlates of intentions to receive booster vaccines among previously vaccinated individuals. The present study applied an integrated model to examine effects of beliefs from multiple social cognition theories alongside sets of generalized, stable beliefs on individuals' booster vaccine intentions. US residents (N = 479) recruited from an online survey panel completed measures of social cognition constructs (attitude, subjective norms, perceived behavioral control, and risk perceptions), generalized beliefs (vaccine hesitancy, political orientation, and free will beliefs), and COVID-19 vaccine intentions. Social cognition constructs were related to booster vaccine intentions, with attitude and subjective norms exhibiting the largest effects. Effects of vaccine hesitancy, political orientation, and free will beliefs on intentions were mediated by the social cognition constructs, and only vaccine hesitancy had a small residual effect on intentions. Findings provide preliminary evidence that contributes to an evidence base of potential targets for intervention messages aimed at promoting booster vaccine intentions. CI - (c) 2022 The Authors. Applied Psychology: Health and Well-Being published by John Wiley & Sons Ltd on behalf of International Association of Applied Psychology. FAU - Hagger, Martin S AU - Hagger MS AUID- ORCID: 0000-0002-2685-1546 AD - Department of Psychological Sciences, University of California, Merced, California, USA. AD - Health Sciences Research Institute, University of California, Merced, California, USA. AD - Faculty of Sport and Health Sciences, University of Jyvaskyla, Jyvaskyla, Finland. AD - School of Applied Psychology, Griffith University, Brisbane, Queensland, Australia. FAU - Hamilton, Kyra AU - Hamilton K AUID- ORCID: 0000-0001-9975-685X AD - Health Sciences Research Institute, University of California, Merced, California, USA. AD - School of Applied Psychology, Griffith University, Brisbane, Queensland, Australia. AD - Menzies Health Institute Queensland, Griffith University, Brisbane, Queensland, Australia. LA - eng PT - Journal Article DEP - 20220222 PL - England TA - Appl Psychol Health Well Being JT - Applied psychology. Health and well-being JID - 101502957 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - Humans MH - Intention MH - Vaccination MH - *Vaccines PMC - PMC9111247 OTO - NOTNLM OT - behavior change OT - integrated models OT - social cognition theory OT - vaccine attitudes and beliefs OT - vaccine hesitancy COIS- The authors have no conflict of interest to declare. EDAT- 2022/02/23 06:00 MHDA- 2022/08/06 06:00 PMCR- 2022/02/22 CRDT- 2022/02/22 20:13 PHST- 2021/11/22 00:00 [received] PHST- 2022/02/08 00:00 [accepted] PHST- 2022/02/23 06:00 [pubmed] PHST- 2022/08/06 06:00 [medline] PHST- 2022/02/22 20:13 [entrez] PHST- 2022/02/22 00:00 [pmc-release] AID - APHW12349 [pii] AID - 10.1111/aphw.12349 [doi] PST - ppublish SO - Appl Psychol Health Well Being. 2022 Aug;14(3):819-841. doi: 10.1111/aphw.12349. Epub 2022 Feb 22. PMID- 35184205 OWN - NLM STAT- MEDLINE DCOM- 20220414 LR - 20221207 IS - 1432-1920 (Electronic) IS - 0028-3940 (Print) IS - 0028-3940 (Linking) VI - 64 IP - 5 DP - 2022 May TI - Cerebral venous sinus thrombosis after adenovirus-vectored COVID-19 vaccination: review of the neurological-neuroradiological procedure. PG - 865-874 LID - 10.1007/s00234-022-02914-z [doi] AB - Cerebral venous and sinus thrombosis (CVST) after adenovirus-vectored COVID-19 ChAdOx1 nCov-19 (Oxford-AstraZeneca) and Ad26.COV2.S (Janssen/Johnson & Johnson) is a rare complication, occurring mainly in individuals under 60 years of age and more frequently in women. It manifests 4-24 days after vaccination. In most cases, antibodies against platelet factor-4/polyanion complexes play a pathogenic role, leading to thrombosis with thrombocytopenia syndrome (TTS) and sometimes a severe clinical or even fatal course. The leading symptom is headache, which usually increases in intensity over a few days. Seizures, visual disturbances, focal neurological symptoms, and signs of increased intracranial pressure are also possible. These symptoms may be combined with clinical signs of disseminated intravascular coagulation such as petechiae or gastrointestinal bleeding. If TTS-CVST is suspected, checking D-dimers, platelet count, and screening for heparin-induced thrombocytopenia (HIT-2) are diagnostically and therapeutically guiding. The imaging method of choice for diagnosis or exclusion of CVST is magnetic resonance imaging (MRI) combined with contrast-enhanced venous MR angiography (MRA). On T2*-weighted or susceptibility weighted MR sequences, the thrombus causes susceptibility artefacts (blooming), that allow for the detection even of isolated cortical vein thromboses. The diagnosis of TTS-CVST can usually be made reliably in synopsis with the clinical and laboratory findings. A close collaboration between neurologists and neuroradiologists is mandatory. TTS-CVST requires specific regimens of anticoagulation and immunomodulation therapy if thrombocytopenia and/or pathogenic antibodies to PF4/polyanion complexes are present. In this review article, the diagnostic and therapeutic steps in cases of suspected TTS associated CSVT are presented. CI - (c) 2022. The Author(s). FAU - Wittstock, Matthias AU - Wittstock M AUID- ORCID: 0000-0001-9904-6436 AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. matthias.wittstock@med.uni-rostock.de. FAU - Walter, Uwe AU - Walter U AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. FAU - Volmer, Erik AU - Volmer E AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. FAU - Storch, Alexander AU - Storch A AD - Department of Neurology, Rostock University Medical Centre, Gehlsheimer Str. 20 18147 Rostock, Germany. FAU - Weber, Marc-Andre AU - Weber MA AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. FAU - Grossmann, Annette AU - Grossmann A AD - Institute for Diagnostic and Interventional Radiology, Paediatric Radiology and Neuroradiology, Rostock University Medical Centre, Rostock, Germany. LA - eng PT - Journal Article PT - Review DEP - 20220219 PL - Germany TA - Neuroradiology JT - Neuroradiology JID - 1302751 RN - JT2NS6183B (Ad26COVS1) RN - 0 (COVID-19 Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM MH - Ad26COVS1 MH - Adenoviridae MH - *COVID-19 MH - COVID-19 Vaccines/adverse effects MH - ChAdOx1 nCoV-19 MH - Female MH - Humans MH - *Intracranial Thrombosis/complications MH - *Sinus Thrombosis, Intracranial/diagnostic imaging/etiology MH - Syndrome MH - *Thrombocytopenia/chemically induced/diagnostic imaging MH - *Thrombosis/chemically induced/complications MH - Vaccination/adverse effects PMC - PMC8929723 OTO - NOTNLM OT - Adenovirus-vectored COVID-19 vaccination OT - Cerebral venous sinus thrombosis OT - Vaccine-induced immune thrombotic thrombocytopenia COIS- We declare that we have no conflict of interest. EDAT- 2022/02/21 06:00 MHDA- 2022/04/15 06:00 PMCR- 2022/02/19 CRDT- 2022/02/20 20:39 PHST- 2021/11/29 00:00 [received] PHST- 2022/02/03 00:00 [accepted] PHST- 2022/02/21 06:00 [pubmed] PHST- 2022/04/15 06:00 [medline] PHST- 2022/02/20 20:39 [entrez] PHST- 2022/02/19 00:00 [pmc-release] AID - 10.1007/s00234-022-02914-z [pii] AID - 2914 [pii] AID - 10.1007/s00234-022-02914-z [doi] PST - ppublish SO - Neuroradiology. 2022 May;64(5):865-874. doi: 10.1007/s00234-022-02914-z. Epub 2022 Feb 19. PMID- 35140464 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240822 IS - 1176-6328 (Print) IS - 1178-2021 (Electronic) IS - 1176-6328 (Linking) VI - 18 DP - 2022 TI - Post COVID-19 Vaccination-Associated Neurological Complications. PG - 137-154 LID - 10.2147/NDT.S343438 [doi] AB - PURPOSE: Neurological sequelae after COVID-19 vaccination are rare. We investigated the possible pathogenesis behind the development of neurological complications within a short period after Saudi residents received a COVID-19 vaccine. PATIENTS AND METHODS: We evaluated 18 patients who recently received a COVID-19 vaccine (Comirnaty and Vaxzevria vaccines) and presented with neurological complications to the Saudi German Hospitals in Jeddah, Saudi Arabia. Neurologists assessed the patients' clinical presentation, radiological investigations, and laboratory findings. RESULTS: Three patients who received the first dose of the Vaxzevria vaccine experienced severe cerebral venous thrombosis, two of them were complicated by intracranial hemorrhage. Their laboratory investigations showed very high d-dimers and severe thrombocytopenia, which have been linked to higher mortality and poor outcome. Ischemic stroke occurred in eight cases (44.4%) with a predominance in older male patients. Three patients presented with seizures, two had optic neuritis. Guillain-Barre syndrome (GBS) and Miller Fisher syndrome (MFS) occurred in two male patients following vaccination with Comirnaty. CONCLUSION: Neurological complications after COVID-19 vaccinations are very rare, and only a few cases have been reported worldwide. The shared pathophysiological basis between COVID-19 viral infection and COVID-19 vaccines stands behind the very rare neurological complications resulting from the hypercoagulable state triggered by the general inflammatory condition. We suspect some differences in the pathogenesis of ischemic stroke caused by COVID-19 infection and COVID-19 vaccines, which render COVID-19 vaccine-associated ischemic stroke more responsive to treatment. To date, no definitive association between the vaccine and GBS has been proven by any strong evidence, but it has recently been added as a very rare side effect of the Janssen COVID-19 vaccine. No possible links of Miller Fisher syndrome to COVID-19 vaccines have been reported before the one reported in this study. CI - (c) 2022 Assiri et al. FAU - Assiri, Sara A AU - Assiri SA AUID- ORCID: 0000-0003-4747-6762 AD - Otolaryngology-Head and Neck Surgery Department, King Faisal Hospital, Taif, Saudi Arabia. FAU - Althaqafi, Raad M M AU - Althaqafi RMM AD - College of Medicine, Taif University, Taif, Saudi Arabia. FAU - Alswat, Khaled AU - Alswat K AD - College of Medicine, Taif University, Taif, Saudi Arabia. FAU - Alghamdi, Ahmed Abdullah AU - Alghamdi AA AD - College of Medicine, Al-Baha University, Al Baha, Saudi Arabia. FAU - Alomairi, Naif E AU - Alomairi NE AD - College of Medicine, Taif University, Taif, Saudi Arabia. AD - Neurology Department, Saudi German Hospital, Jeddah, Saudi Arabia. FAU - Nemenqani, Dalal M AU - Nemenqani DM AD - College of Medicine, Taif University, Taif, Saudi Arabia. FAU - Ibrahim, Zein S AU - Ibrahim ZS AUID- ORCID: 0000-0003-1576-7186 AD - Department of Physiology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt. FAU - Elkady, Ahmed AU - Elkady A AD - Neurology Department, Saudi German Hospital, Jeddah, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220202 PL - New Zealand TA - Neuropsychiatr Dis Treat JT - Neuropsychiatric disease and treatment JID - 101240304 CIN - Neuropsychiatr Dis Treat. 2022 Jun 27;18:1273-1275. doi: 10.2147/NDT.S377357. PMID: 35784516 PMC - PMC8818972 OTO - NOTNLM OT - cerebral venous thrombosis OT - ischemic stroke OT - optic neuritis OT - seizures OT - vaccine COIS- All authors confirm that there are no competing interests to disclose. EDAT- 2022/02/11 06:00 MHDA- 2022/02/11 06:01 PMCR- 2022/02/02 CRDT- 2022/02/10 05:33 PHST- 2021/10/08 00:00 [received] PHST- 2022/01/12 00:00 [accepted] PHST- 2022/02/10 05:33 [entrez] PHST- 2022/02/11 06:00 [pubmed] PHST- 2022/02/11 06:01 [medline] PHST- 2022/02/02 00:00 [pmc-release] AID - 343438 [pii] AID - 10.2147/NDT.S343438 [doi] PST - epublish SO - Neuropsychiatr Dis Treat. 2022 Feb 2;18:137-154. doi: 10.2147/NDT.S343438. eCollection 2022. PMID- 35130960 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220216 IS - 2524-3489 (Electronic) IS - 2524-3489 (Linking) VI - 4 IP - 1 DP - 2022 Feb 8 TI - Guillain-Barre syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy. PG - 6 LID - 10.1186/s42466-022-00172-1 [doi] LID - 6 AB - This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barre-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2. CI - (c) 2022. The Author(s). FAU - Stefanou, Maria Ioanna AU - Stefanou MI AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Karachaliou, Eleni AU - Karachaliou E AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Chondrogianni, Maria AU - Chondrogianni M AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Moschovos, Christos AU - Moschovos C AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Bakola, Eleni AU - Bakola E AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Foska, Aikaterini AU - Foska A AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Melanis, Konstantinos AU - Melanis K AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Andreadou, Elisabeth AU - Andreadou E AD - First Department of Neurology, Aeginition Hospital, National and Kapodistrian University of Athens, Athens, Greece. FAU - Voumvourakis, Konstantinos AU - Voumvourakis K AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. FAU - Papathanasiou, Matilda AU - Papathanasiou M AD - Second Department of Radiology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece. FAU - Boutati, Eleni AU - Boutati E AD - Second Department of Internal Medicine, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Athens, Greece. FAU - Tsivgoulis, Georgios AU - Tsivgoulis G AUID- ORCID: 0000-0002-0640-3797 AD - Second Department of Neurology, National and Kapodistrian University of Athens, School of Medicine, "Attikon" University Hospital, Rimini 1, Chaidari, 12462, Athens, Greece. tsivgoulisgiorg@yahoo.gr. LA - eng PT - Letter DEP - 20220208 PL - England TA - Neurol Res Pract JT - Neurological research and practice JID - 101767802 PMC - PMC8821852 OTO - NOTNLM OT - Ad26.COV2.S OT - Encephalomyelitis OT - Guillain-Barre syndrome OT - SARS-CoV-2 vaccine OT - Transverse myelitis COIS- The authors declare no competing interests. EDAT- 2022/02/09 06:00 MHDA- 2022/02/09 06:01 PMCR- 2022/02/08 CRDT- 2022/02/08 05:38 PHST- 2022/01/05 00:00 [received] PHST- 2022/02/01 00:00 [accepted] PHST- 2022/02/08 05:38 [entrez] PHST- 2022/02/09 06:00 [pubmed] PHST- 2022/02/09 06:01 [medline] PHST- 2022/02/08 00:00 [pmc-release] AID - 10.1186/s42466-022-00172-1 [pii] AID - 172 [pii] AID - 10.1186/s42466-022-00172-1 [doi] PST - epublish SO - Neurol Res Pract. 2022 Feb 8;4(1):6. doi: 10.1186/s42466-022-00172-1. PMID- 35095267 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240829 IS - 1172-0360 (Print) IS - 1179-1977 (Electronic) IS - 1172-0360 (Linking) VI - 38 IP - 2 DP - 2022 TI - Adverse drug reactions from two COVID-19 vaccines reported in Saudi Arabia. PG - 84-92 LID - 10.1007/s40267-022-00893-y [doi] AB - BACKGROUND: Several reports have been published about the impact of coronavirus disease 2019 (COVID-19) vaccines on human health, and each vaccine has a different safety and efficacy profile. The aim of this study was to reveal the nature and classification of reported adverse drug reactions (ADRs) of the two COVID-19 vaccines (tozinameran and ChAdOx1) among citizens and residents living in Saudi Arabia, and show possible differences between the two vaccines and the differences between each batch on the health of populations. METHODS: A cross-sectional study was conducted in Saudi Arabia between December 2020 and March 2021. Saudi citizens and residents aged >/= 16 years who had at least one dose of any batch of either of the two approved COVID-19 vaccines (tozinameran and ChAdOx1) and who reported at least one ADR from the vaccines were included. The study excluded people who reported ADRs after receiving tozinameran or ChAdOx1 vaccines but no information was provided about the vaccine's batch number. RESULTS: During the study period, 12,868 vaccinated people, including a high-risk group (i.e., those with chronic illness or pregnant women), reported COVID-19 vaccine ADRs that had been documented in the General Directorate of Medical Consultations, Saudi Ministry of Health. The study reported several ADRs associated with COVID-19 vaccines, with the most common (> 25%) being fever/chills, general pain/weakness, headache, and injection site reactions. Among healthy and high-risk people, the median onset of all reported ADRs for tozinameran and ChAdOx1 vaccine batches were 1.96 and 1.64 days, respectively (p < 0.01). Furthermore, significant differences (p < 0.05) were recorded between the two studied vaccines in regard to fever/chills, gastrointestinal symptoms, headache, general pain/weakness, and neurological symptoms, with higher incidence rates of these ADRs observed with the ChAdOx1 vaccine than the tozinameran vaccine. However, the tozinameran vaccine was found to cause significantly (p < 0.05) more palpitation, blood pressure variations, upper respiratory tract symptoms, lymph node swelling, and other unspecified ADRs than the ChAdOx1 vaccine. Among patients vaccinated with seven different batches of the tozinameran vaccine, people vaccinated with the T4 and T5 batches reported the most ADRs. CONCLUSION: There were significant differences regarding most of the reported ADRs and their onset among tozinameran and ChAdOx1 vaccines on both healthy people and high-risk individuals living in Saudi Arabia. Moreover, the study found that the frequencies of most listed ADRs were statistically different when seven batches of tozinameran vaccine were compared. CI - (c) The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. FAU - Alfaleh, Amjad AU - Alfaleh A AUID- ORCID: 0000-0003-4375-8834 AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alkattan, Abdullah AU - Alkattan A AUID- ORCID: 0000-0001-5294-8088 AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Radwan, Nashwa AU - Radwan N AD - Department of Public Health and Community Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt. GRID: grid.412258.8. ISNI: 0000 0000 9477 7793 AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Elzohri, Mona AU - Elzohri M AD - Department of Research, General Directorate of Medical Consultations, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Assiut University, Asyut, Egypt. GRID: grid.252487.e. ISNI: 0000 0000 8632 679X FAU - Alzaher, Abrar AU - Alzaher A AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Ibrahim, Mona AU - Ibrahim M AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Community, Environmental and Occupational Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt. GRID: grid.31451.32. ISNI: 0000 0001 2158 2757 FAU - Alsalameen, Eman AU - Alsalameen E AD - Department of Pharmacy, King Khalid University Hospital, Medical City King Saud University, Riyadh, Saudi Arabia. GRID: grid.56302.32. ISNI: 0000 0004 1773 5396 FAU - Alsultan, Amani AU - Alsultan A AD - Department of Sales, Sanofi Aventis Arabia, Jeddah, Saudi Arabia. FAU - Alhabib, Dina AU - Alhabib D AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alshelwah, Alanood AU - Alshelwah A AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Mahmoud, Nagla AU - Mahmoud N AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Sagor, Khlood AU - Sagor K AD - Research and Development Department, General Directorate of School Health, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 FAU - Alabdulkareem, Khaled AU - Alabdulkareem K AD - Department of Research, Assisting Deputyship for Primary Health Care, Ministry of Health, Riyadh, Saudi Arabia. GRID: grid.415696.9. ISNI: 0000 0004 0573 9824 AD - Department of Family Medicine, College of Medicine, Al-Imam Mohammad Bin Saud Islamic University, Riyadh, Saudi Arabia. LA - eng PT - Journal Article DEP - 20220122 PL - New Zealand TA - Drugs Ther Perspect JT - Drugs & therapy perspectives : for rational drug selection and use JID - 9308798 PMC - PMC8783585 COIS- Competing interestsAmjad Alfaleh, Abdullah Alkattan, Nashwa Radwan, Mona Elzohri, Abrar Alzaher, Mona Ibrahim, Eman Alsalameen, Amani Alsultan, Dina Alhabib, Alanood Alshelwah, Nagla Mahmoud, Khlood Sagor, and Khaled Alabdulkareem have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, including employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. EDAT- 2022/02/01 06:00 MHDA- 2022/02/01 06:01 PMCR- 2022/01/22 CRDT- 2022/01/31 05:54 PHST- 2022/01/04 00:00 [accepted] PHST- 2022/02/01 06:00 [pubmed] PHST- 2022/02/01 06:01 [medline] PHST- 2022/01/31 05:54 [entrez] PHST- 2022/01/22 00:00 [pmc-release] AID - 893 [pii] AID - 10.1007/s40267-022-00893-y [doi] PST - ppublish SO - Drugs Ther Perspect. 2022;38(2):84-92. doi: 10.1007/s40267-022-00893-y. Epub 2022 Jan 22. PMID- 35068637 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20250530 IS - 0191-8869 (Print) IS - 0191-8869 (Electronic) IS - 0191-8869 (Linking) VI - 189 DP - 2022 Apr TI - Believing in nothing and believing in everything: The underlying cognitive paradox of anti-COVID-19 vaccine attitudes. PG - 111522 LID - 10.1016/j.paid.2022.111522 [doi] AB - A major reason why some people oppose the COVID-19 vaccine is the influence of misinformation. This study suggests that the cognitive paradox of simultaneously believing known facts less and new, "alternative facts" more is the outcome of a distrust mindset, characterized by spontaneous consideration of alternatives, including misinformation. We captured this paradox and its correlates in a scale that measures individuals' ability to distinguish between the truth value of well-established facts ("Earth rotates eastward around its own axis, completing a full rotation once in about 24 h") and baseless "alternative facts" ("Earth can change its rotation direction and flip its axis, and we will never notice it"). Assuming that an anti-COVID-19 vaccine attitude arises from a chronically distrusting mindset, we sampled participants on Prolific who were pre-screened for their COVID-19 vaccine attitude based on earlier responses. We found that people who rejected COVID-19 vaccines believed well-established facts less, and "alternative facts" more, compared to supporters of the vaccine. Less discernment between truths and falsehoods was correlated with less intellectual humility, more distrust and greater reliance on one's intuition. This observed thought pattern offers insights into theoretical understanding of the antecedents of belief in "alternative facts" and conspiracy theories. CI - (c) 2022 Elsevier Ltd. All rights reserved. FAU - Newman, Devora AU - Newman D AD - Department of Psychology, The Hebrew University of Jerusalem, 9190501, Israel. FAU - Lewandowsky, Stephan AU - Lewandowsky S AD - School of Psychological Science, University of Bristol, Bristol BS8 1TH, UK. AD - School of Psychological Science, University of Western Australia, Perth 6009, Australia. FAU - Mayo, Ruth AU - Mayo R AD - Department of Psychology, The Hebrew University of Jerusalem, 9190501, Israel. LA - eng GR - 101020961/ERC_/European Research Council/International PT - Journal Article DEP - 20220117 PL - England TA - Pers Individ Dif JT - Personality and individual differences JID - 8006972 PMC - PMC8761558 OTO - NOTNLM OT - Alternative facts OT - COVID-19 OT - Distrust OT - Shared reality OT - Vaccine opposition COIS- The authors declare no competing interests. EDAT- 2022/01/25 06:00 MHDA- 2022/01/25 06:01 PMCR- 2022/01/17 CRDT- 2022/01/24 08:46 PHST- 2021/08/11 00:00 [received] PHST- 2021/12/30 00:00 [revised] PHST- 2022/01/11 00:00 [accepted] PHST- 2022/01/24 08:46 [entrez] PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/01/25 06:01 [medline] PHST- 2022/01/17 00:00 [pmc-release] AID - S0191-8869(22)00025-3 [pii] AID - 111522 [pii] AID - 10.1016/j.paid.2022.111522 [doi] PST - ppublish SO - Pers Individ Dif. 2022 Apr;189:111522. doi: 10.1016/j.paid.2022.111522. Epub 2022 Jan 17. PMID- 35068258 OWN - NLM STAT- MEDLINE DCOM- 20220405 LR - 20220405 IS - 1758-1125 (Electronic) IS - 0268-3555 (Linking) VI - 37 IP - 3 DP - 2022 Apr TI - Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice. PG - 180-187 LID - 10.1177/02683555211068948 [doi] AB - OBJECTIVES: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a new and rare syndrome resulting from the largest vaccination campaign against SARS-CoV-2 in the history of mankind. The aim of this review is to clarify underlying mechanisms, pathology, diagnosis, and therapy, with the related clinical implications. METHODS: We performed a comprehensive literature review in order to collect the clinical and treatment data about patients suffering from VITT. PubMed, Ovid Medline, Ovid EMBASE, Scopus, and Web of Science were screened regarding patients who developed VITT. Last search was launched on June 30(th) 2021. RESULTS: Abdominal and/or neurological symptoms develop between 5 and 20 days after vaccine administration and do not involve the lower extremities. VITT is suspected if the platelet count is lower than 100.000/mm(3) and D-dimer is higher than the age-adjusted range. Medical treatment is mainly based on intravenous immunoglobulins, corticosteroids, and anticoagulant drugs with a short plasma half-life, but the complete avoidance of low molecular weight heparin is recommended. Endovascular treatment and/or decompressive craniectomy might be an option in a minority of cases. CONCLUSION: Due to widespread vaccination concerns, the vascular specialist and phlebologist are increasingly consulted to prevent or diagnose VITT. The latter has peculiar and completely different localizations, symptoms, and treatment compared to the common pictures of venous thrombosis. FAU - Zamboni, Paolo AU - Zamboni P AUID- ORCID: 0000-0002-7107-888X AD - Hub Center for Venous and Lymphatic Diseases Regione Emilia-Romagna, Sant'Anna University Hospital of Ferrara, Ferrara, Italy. AD - Department of Morphology, Surgery and Experimental Medicine, 9299University of Ferrara, Ferrara, Italy. FAU - Scerrati, Alba AU - Scerrati A AUID- ORCID: 0000-0002-8607-5323 AD - Department of Morphology, Surgery and Experimental Medicine, 9299University of Ferrara, Ferrara, Italy. AD - Department of Neurosurgery, Sant' Anna University Hospital, Ferrara, Italy. FAU - Sessa, Francesco AU - Sessa F AUID- ORCID: 0000-0003-0357-8791 AD - Department of Clinical and Experimental Medicine, 18567University of Foggia, Foggia, Italy. FAU - Pomara, Cristoforo AU - Pomara C AD - Institute of Legal Medicine, Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", 9298University of Catania, Catania, Italy. FAU - Mannucci, Pier Mannuccio AU - Mannucci PM AD - Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, 9339IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Milan, Italy. LA - eng PT - Journal Article PT - Review DEP - 20220123 PL - England TA - Phlebology JT - Phlebology JID - 9012921 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - *COVID-19 MH - COVID-19 Vaccines/adverse effects MH - Humans MH - SARS-CoV-2 MH - *Thrombocytopenia MH - *Thrombosis MH - *Vaccines/adverse effects MH - *Venous Thrombosis/etiology OTO - NOTNLM OT - Ad.26. COV2.S OT - SARS-CoV-2 OT - Vaccine-induced immune thrombotic thrombocytopenia OT - Vaxzevria OT - cerebral venous sinus thrombosis OT - splanchnic vein thrombosis EDAT- 2022/01/25 06:00 MHDA- 2022/04/06 06:00 CRDT- 2022/01/24 08:45 PHST- 2022/01/25 06:00 [pubmed] PHST- 2022/04/06 06:00 [medline] PHST- 2022/01/24 08:45 [entrez] AID - 10.1177/02683555211068948 [doi] PST - ppublish SO - Phlebology. 2022 Apr;37(3):180-187. doi: 10.1177/02683555211068948. Epub 2022 Jan 23. PMID- 35062869 OWN - NLM STAT- MEDLINE DCOM- 20220125 LR - 20220531 IS - 1129-2377 (Electronic) IS - 1129-2369 (Print) IS - 1129-2369 (Linking) VI - 23 IP - 1 DP - 2022 Jan 21 TI - Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series. PG - 13 LID - 10.1186/s10194-022-01385-0 [doi] LID - 13 AB - BACKGROUND: After the initiation of the COVID-19 vaccination program in Thailand, thousands of patients have experienced unusual focal neurological symptoms. We report 8 patients with focal neurological symptoms after receiving inactivated virus vaccine, CoronaVac. CASE SERIES: Patients were aged 24-48 years and 75% were female. Acute onset of focal neurological symptoms occurred within the first 24 h after vaccination in 75% and between 1-7d in 25%. All presented with lateralized sensory deficits, motor deficits, or both, of 2-14 day duration. Migraine headache occurred in half of the patients. Magnetic resonance imaging of the brain during and after the attacks did not demonstrate any abnormalities suggesting ischemic stroke. All patients showed moderately large regions of hypoperfusion and concurrent smaller regions of hyperperfusion on SPECT imaging while symptomatic. None developed permanent deficits or structural brain injury. DISCUSSIONS: Here, we present a case series of transient focal neurological syndrome following Coronavac vaccination. The characteristic sensory symptoms, history of migraine, female predominant, and abnormal functional brain imaging without structural changes suggest migraine aura as pathophysiology. We propose that pain related to vaccine injection, component of vaccine, such as aluminum, or inflammation related to vaccination might trigger migraine aura in susceptible patients. CI - (c) 2022. The Author(s). FAU - Suwanwela, Nijasri C AU - Suwanwela NC AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. nijasri.C@chula.ac.th. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. nijasri.C@chula.ac.th. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. nijasri.C@chula.ac.th. FAU - Kijpaisalratana, Naruchorn AU - Kijpaisalratana N AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tepmongkol, Supatporn AU - Tepmongkol S AD - Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. AD - Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. AD - Chulalongkorn University Biomedical Imaging Group (CUBIG), Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Rattanawong, Wanakorn AU - Rattanawong W AUID- ORCID: 0000-0001-7277-9699 AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. wanakorn.ra@kmitl.ac.th. AD - Department of Medicine, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Bangkok, Thailand. wanakorn.ra@kmitl.ac.th. FAU - Vorasayan, Pongpat AU - Vorasayan P AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Charnnarong, Chutibhorn AU - Charnnarong C AD - Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Tantivattana, Jarturon AU - Tantivattana J AD - Department of Radiology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. FAU - Roongruang, Sirigunya AU - Roongruang S AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Golden Jubilee Medical Center, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. FAU - Ongphichetmetha, Tatchaporn AU - Ongphichetmetha T AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. FAU - Panjasriprakarn, Poonnakarn AU - Panjasriprakarn P AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. FAU - Chutinet, Aurauma AU - Chutinet A AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Akarathanawat, Wasan AU - Akarathanawat W AD - Division of Neurology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Rama IV Road, Bangkok, 10330, Thailand. AD - Chulalongkorn Stroke Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand. FAU - Saver, Jeffrey L AU - Saver JL AD - Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. LA - eng PT - Journal Article DEP - 20220121 PL - England TA - J Headache Pain JT - The journal of headache and pain JID - 100940562 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - *Brain Ischemia/diagnostic imaging/etiology MH - *COVID-19 MH - COVID-19 Vaccines MH - *Epilepsy MH - Female MH - Humans MH - *Ischemic Stroke MH - Male MH - Middle Aged MH - *Migraine Disorders MH - *Migraine with Aura MH - SARS-CoV-2 MH - *Stroke/diagnostic imaging/etiology MH - Vaccination/adverse effects MH - Young Adult PMC - PMC8777408 OTO - NOTNLM OT - COVID-19 OT - CoronaVac vaccine OT - Cortical spreading depression OT - Neurological deficit OT - Sinovac COIS- All authors declare no conflict of interest in this study. EDAT- 2022/01/23 06:00 MHDA- 2022/01/27 06:00 PMCR- 2022/01/21 CRDT- 2022/01/22 05:31 PHST- 2021/12/09 00:00 [received] PHST- 2021/12/29 00:00 [accepted] PHST- 2022/01/22 05:31 [entrez] PHST- 2022/01/23 06:00 [pubmed] PHST- 2022/01/27 06:00 [medline] PHST- 2022/01/21 00:00 [pmc-release] AID - 10.1186/s10194-022-01385-0 [pii] AID - 1385 [pii] AID - 10.1186/s10194-022-01385-0 [doi] PST - epublish SO - J Headache Pain. 2022 Jan 21;23(1):13. doi: 10.1186/s10194-022-01385-0. PMID- 35062662 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220128 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 10 IP - 1 DP - 2021 Dec 21 TI - How Does Severe Acute Respiratory Syndrome-Coronavirus-2 Affect the Brain and Its Implications for the Vaccines Currently in Use. LID - 10.3390/vaccines10010001 [doi] LID - 1 AB - This mini-review focuses on the mechanisms of how severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) affects the brain, with an emphasis on the role of the spike protein in patients with neurological symptoms. Following infection, patients with a history of neurological complications may be at a higher risk of developing long-term neurological conditions associated with the alpha-synuclein prion, such as Parkinson's disease and Lewy body dementia. Compelling evidence has been published to indicate that the spike protein, which is derived from SARS-CoV-2 and generated from the vaccines currently being employed, is not only able to cross the blood-brain barrier but may cause inflammation and/or blood clots in the brain. Consequently, should vaccine-induced expression of spike proteins not be limited to the site of injection and draining lymph nodes there is the potential of long-term implications following inoculation that may be identical to that of patients exhibiting neurological complications after being infected with SARS-CoV-2. However, further studies are needed before definitive conclusions can be made. FAU - Oldfield, Philip R AU - Oldfield PR AD - Scientific and Regulatory Consultant, Rigaud, QC J0P 1P0, Canada. FAU - Hibberd, Jennifer AU - Hibberd J AD - Faculty of Dentistry, University of Toronto, Toronto, ON M5G 1X3, Canada. FAU - Bridle, Byram W AU - Bridle BW AUID- ORCID: 0000-0002-8335-1118 AD - Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada. LA - eng GR - COVID-19 Rapid Research Fund/Ontario Ministry of Colleges and Universities/ GR - Pandemic Response Challenge Program Grant/National Research Council of Canada/ PT - Journal Article PT - Review DEP - 20211221 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8780773 OTO - NOTNLM OT - Lewy body dementia OT - Parkinson's disease OT - angiotensin-converting enzyme 2 (ACE2) OT - blood-brain barrier (BBB) OT - cytokines OT - good laboratory practice OT - novel coronavirus disease that emerged in 2019 (COVID-19) OT - severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) OT - spike protein COIS- B.W.B. received funding as already noted. The authors have no other conflicts of interest to declare. EDAT- 2022/01/23 06:00 MHDA- 2022/01/23 06:01 PMCR- 2021/12/21 CRDT- 2022/01/22 01:02 PHST- 2021/11/08 00:00 [received] PHST- 2021/12/15 00:00 [revised] PHST- 2021/12/17 00:00 [accepted] PHST- 2022/01/22 01:02 [entrez] PHST- 2022/01/23 06:00 [pubmed] PHST- 2022/01/23 06:01 [medline] PHST- 2021/12/21 00:00 [pmc-release] AID - vaccines10010001 [pii] AID - vaccines-10-00001 [pii] AID - 10.3390/vaccines10010001 [doi] PST - epublish SO - Vaccines (Basel). 2021 Dec 21;10(1):1. doi: 10.3390/vaccines10010001. PMID- 35050428 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20220722 IS - 1590-3478 (Electronic) IS - 1590-1874 (Print) IS - 1590-1874 (Linking) VI - 43 IP - 4 DP - 2022 Apr TI - SARS-CoV-2 vaccine-related neurological complications. PG - 2295-2297 LID - 10.1007/s10072-022-05898-z [doi] AB - OBJECTIVE: To describe three cases with neurological symptoms after SARS-CoV-2 vaccination. METHODS: A case series followed by a review of the literature, describing hypotheses on how neurological symptoms might develop after vaccination. RESULTS: The different temporal relationship between the onset or worsening of different neurological symptoms suggests different pathophysiological mechanisms. Progression of post-infectious myoclonus, caused by a previous SARS-CoV-2-infection, shortly after vaccination suggests a renewed auto-immune mediated crossreaction of antibodies to both viral epitopes and central nervous system components. Thunderclap headache after vaccination suggests a similar pathophysiological mechanism to the headache and other flu-like symptoms described after vaccination against other viruses. This might be ascribed to the activation of immunoinflammatory mediators or accompanying fever. Although headache accompanied by encephalopathy and focal neurological deficit might occur as part of a cytokine release syndrome, this is clinically less likely. CONCLUSIONS: A variety of symptoms, including thunderclap headache, focal deficits and movement disorders, can occur after SARS-CoV-2 vaccination, and an activation or reactivation of the immune system is suggested as most likely cause. However, one should be careful about claiming a direct correlation. It remains important to exclude other causes, such as structural lesions, infections or subarachnoid hemorrhage, and future research is required to understand possible pathophysiological mechanisms and associations with the SARS-CoV-2 vaccine. CI - (c) 2022. Fondazione Societa Italiana di Neurologia. FAU - Oonk, Nicol G M AU - Oonk NGM AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. n.oonk@mst.nl. FAU - Ettema, Anne Rozemarijn AU - Ettema AR AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - van Berghem, Heleen AU - van Berghem H AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - de Klerk, Jabke J AU - de Klerk JJ AD - TriviumMeulenbeltZorg, Borne, the Netherlands. FAU - van der Vegt, Joyce P M AU - van der Vegt JPM AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. FAU - van der Meulen, Matthijs AU - van der Meulen M AD - Department of Neurology, Medisch Spectrum Twente, Enschede, the Netherlands. LA - eng PT - Journal Article PT - Review DEP - 20220120 PL - Italy TA - Neurol Sci JT - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JID - 100959175 RN - 0 (COVID-19 Vaccines) RN - 0 (Viral Vaccines) SB - IM MH - *COVID-19/complications/prevention & control MH - COVID-19 Vaccines/adverse effects MH - Humans MH - SARS-CoV-2 MH - Vaccination/adverse effects MH - *Viral Vaccines PMC - PMC8771172 OTO - NOTNLM OT - COVID-19 OT - Myoclonus OT - SARS-CoV-2 OT - Thunderclap headache OT - Vaccine COIS- The authors declare no competing interests. EDAT- 2022/01/21 06:00 MHDA- 2022/03/16 06:00 PMCR- 2022/01/20 CRDT- 2022/01/20 12:36 PHST- 2021/05/24 00:00 [received] PHST- 2022/01/13 00:00 [accepted] PHST- 2022/01/21 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2022/01/20 12:36 [entrez] PHST- 2022/01/20 00:00 [pmc-release] AID - 10.1007/s10072-022-05898-z [pii] AID - 5898 [pii] AID - 10.1007/s10072-022-05898-z [doi] PST - ppublish SO - Neurol Sci. 2022 Apr;43(4):2295-2297. doi: 10.1007/s10072-022-05898-z. Epub 2022 Jan 20. PMID- 35025789 OWN - NLM STAT- MEDLINE DCOM- 20220203 LR - 20230925 IS - 1536-0229 (Electronic) IS - 0363-9762 (Print) IS - 0363-9762 (Linking) VI - 47 IP - 3 DP - 2022 Mar 1 TI - Alterations in 18F-FDG PET/MRI and 15O-Water PET Brain Findings in Patients With Neurological Symptoms After COVID-19 Vaccination: A Pilot Study. PG - e230-e239 LID - 10.1097/RLU.0000000000004041 [doi] AB - PURPOSE: This study aimed to investigate functional abnormalities in the brain of patients with neurological adverse effects following COVID-19 (coronavirus disease 2019) vaccination using 18F-FDG PET/MRI and 15O-water PET. METHODS: Eight patients (1 man and 7 women, aged 26-47 years [median age, 36.5 years]) who experienced neurological symptoms after the first COVID-19 vaccination underwent CT, MRI, 18F-FDG PET/MRI, and 15O-water PET of the brain. After 7 days, each patient underwent a follow-up 18F-FDG PET/MRI and 15O-water PET of the brain. Imaging data were analyzed using visual and semiquantitative analyses, which included a cluster subtraction workflow (P = 0.05). RESULTS: There was no evidence of vascular abnormalities, acute infarction, or hemorrhage on the CT or MRI scans. On the 15O-water PET images, 1 patient had mildly significant decreases in perfusion in the bilateral thalamus and bilateral cerebellum, and another patient showed a diffuse increase in perfusion in the cerebral white matter. The visual and semiquantitative analyses showed hypometabolism in the bilateral parietal lobes in all 8 patients on both the first and follow-up 18F-FDG PET/MRI scans. Metabolic changes in the bilateral cuneus were also observed during the first visit; all patients exhibited neurological symptoms. Moreover, 6 patients showed hypometabolism, and 2 patients showed hypermetabolism. CONCLUSION: All regions of metabolic abnormality were part of the fear network model that has been implicated in anxiety. Our study findings support the concepts of and provide evidence for the immunization stress-related response and the biopsychosocial model. CI - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved. FAU - Siripongsatian, Dheeratama AU - Siripongsatian D AD - From the National Cyclotron and PET Centre. FAU - Kunawudhi, Anchisa AU - Kunawudhi A AD - From the National Cyclotron and PET Centre. FAU - Promteangtrong, Chetsadaporn AU - Promteangtrong C AD - From the National Cyclotron and PET Centre. FAU - Kiatkittikul, Peerapon AU - Kiatkittikul P AD - From the National Cyclotron and PET Centre. FAU - Jantarato, Attapon AU - Jantarato A AD - From the National Cyclotron and PET Centre. FAU - Choolam, Arthita AU - Choolam A AD - Department of Medicine, Chulabhorn Hospital. FAU - Ponglikitmongkol, Krongkamol AU - Ponglikitmongkol K AD - Department of Medicine, Chulabhorn Hospital. FAU - Siripongboonsitti, Taweegrit AU - Siripongboonsitti T AD - Department of Medicine, Chulabhorn Hospital. FAU - Kaeowirun, Tharathorn AU - Kaeowirun T AD - Department of Radiology, Bhumibol Adulyadej Hospital, Royal Thai Air Force, Bangkok, Thailand. FAU - Chotipanich, Chanisa AU - Chotipanich C AD - From the National Cyclotron and PET Centre. LA - eng PT - Journal Article PL - United States TA - Clin Nucl Med JT - Clinical nuclear medicine JID - 7611109 RN - 0 (COVID-19 Vaccines) RN - 0 (Oxygen Radioisotopes) RN - 0 (Oxygen-15) RN - 059QF0KO0R (Water) RN - 0Z5B2CJX4D (Fluorodeoxyglucose F18) SB - IM CIN - Clin Nucl Med. 2022 Oct 1;47(10):e671. doi: 10.1097/RLU.0000000000004227. PMID: 35439207 MH - Adult MH - Brain/diagnostic imaging MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - *Fluorodeoxyglucose F18 MH - Humans MH - Magnetic Resonance Imaging MH - Male MH - Oxygen Radioisotopes MH - Pilot Projects MH - Positron-Emission Tomography MH - SARS-CoV-2 MH - Vaccination MH - Water PMC - PMC8820745 COIS- Conflicts of interest and sources of funding: none declared. EDAT- 2022/01/14 06:00 MHDA- 2022/02/04 06:00 PMCR- 2022/01/13 CRDT- 2022/01/13 17:24 PHST- 2022/01/14 06:00 [pubmed] PHST- 2022/02/04 06:00 [medline] PHST- 2022/01/13 17:24 [entrez] PHST- 2022/01/13 00:00 [pmc-release] AID - 00003072-202203000-00031 [pii] AID - CNM_210564 [pii] AID - 10.1097/RLU.0000000000004041 [doi] PST - ppublish SO - Clin Nucl Med. 2022 Mar 1;47(3):e230-e239. doi: 10.1097/RLU.0000000000004041. PMID- 34960249 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 12 DP - 2021 Dec 20 TI - mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. LID - 10.3390/vaccines9121503 [doi] LID - 1503 AB - mRNA COVID-19 vaccines have hegemonized the world market, and their administration to the population promises to stop the pandemic. However, the waning of the humoral immune response, which does not seem to last so many months after the completion of the vaccination program, has led us to study the molecular immunological mechanisms of waning immunity in the case of mRNA COVID-19 vaccines. We consulted the published scientific literature and from the few articles we found, we were convinced that there is an immunological memory problem after vaccination. Although mRNA vaccines have been demonstrated to induce antigen-specific memory B cells (MBCs) in the human population, there is no evidence that these vaccines induce the production of long-lived plasma cells (LLPCs), in a SARS-CoV-2 virus naive population. This obstacle, in our point of view, is caused by the presence, in almost all subjects, of a cellular T and B cross-reactive memory produced during past exposures to the common cold coronaviruses. Due to this interference, it is difficult for a vaccination with the Spike protein alone, without adjuvants capable of prolonging the late phase of the generation of the immunological memory, to be able to determine the production of protective LLPCs. This would explain the possibility of previously and completely vaccinated subjects to become infected, already 4-6 months after the completion of the vaccination cycle. FAU - Giannotta, Girolamo AU - Giannotta G AUID- ORCID: 0000-0001-9766-3326 AD - Azienda Sanitaria Provinciale Vibo Valentia, 89900 Vibo Valentia, Italy. FAU - Giannotta, Nicola AU - Giannotta N AUID- ORCID: 0000-0003-1701-7696 AD - Medical and Surgery Sciences, Faculty of Medicine, Magna Graecia University, 88100 Catanzaro, Italy. LA - eng PT - Journal Article PT - Review DEP - 20211220 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8703557 OTO - NOTNLM OT - COVID-19 vaccines OT - SARS-CoV-2 OT - SARS-CoV-2 mRNA vaccines OT - immune memory after COVID-19 disease OT - immune memory after COVID-19 vaccination OT - long-lived plasma cells after mRNA COVID-19 vaccines COIS- The authors declare no conflict of interest. EDAT- 2021/12/29 06:00 MHDA- 2021/12/29 06:01 PMCR- 2021/12/20 CRDT- 2021/12/28 01:06 PHST- 2021/10/26 00:00 [received] PHST- 2021/11/21 00:00 [revised] PHST- 2021/12/14 00:00 [accepted] PHST- 2021/12/28 01:06 [entrez] PHST- 2021/12/29 06:00 [pubmed] PHST- 2021/12/29 06:01 [medline] PHST- 2021/12/20 00:00 [pmc-release] AID - vaccines9121503 [pii] AID - vaccines-09-01503 [pii] AID - 10.3390/vaccines9121503 [doi] PST - epublish SO - Vaccines (Basel). 2021 Dec 20;9(12):1503. doi: 10.3390/vaccines9121503. PMID- 34923427 OWN - NLM STAT- MEDLINE DCOM- 20220216 LR - 20260505 IS - 2211-0356 (Electronic) IS - 2211-0348 (Print) IS - 2211-0348 (Linking) VI - 57 DP - 2022 Jan TI - Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data. PG - 103433 LID - S2211-0348(21)00699-4 [pii] LID - 10.1016/j.msard.2021.103433 [doi] AB - BACKGROUND: Patients with autoimmune disease and on immunotherapy were largely excluded from seminal anti-SARS-CoV-2 vaccine trials. This has led to significant vaccine hesitancy in patients with neuroinflammatory diseases (NID); including, but not limited to: multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), neurosarcoidosis and myelin oligodendrocyte antibody-mediated disease (MOG-AD). Data is urgently needed to help guide clinical care in the NID population. METHODS: This was a cross-sectional observational study evaluating adults with a neurologist-confirmed diagnosis of a neuroinflammatory disease (NID) and a neurologically asymptomatic control population. Participants were recruited from multiple academic centers participating in the MS Resilience to COVID-19 Collaborative study. We analyzed participant responses from a vaccine-specific questionnaire collected between February and May 2021. RESULTS: 1164 participants with NID and 595 controls completed the vaccine survey. Hesitancy rates were similar between NID and control groups (n = 134, 32.7% NID vs. n = 56, 30.6% control; p = 0.82). The most common reasons for hesitancy in NID participants were lack of testing in the autoimmune population and fear of demyelinating/neurologic events. Unvaccinated patients who had discussed vaccination with their doctor were less likely to be hesitant (n=184, 73.6% vs. n=83, 59.7%; p = 0.007). 634 NID patients and 332 controls had received at least one dose of a vaccine against SARS-CoV-2 at the time of survey completion. After adjusting for age, BMI, and comorbidities, there was no difference in self-reported side effects (SE) between groups with the first dose (n = 256, 42.2% NID vs. 141, 45.3% control; p = 0.20) or second dose (n = 246, 67.0% NID vs. n = 114, 64.8% control, p = 0.85) of the mRNA vaccines nor with the viral-vector vaccines (n = 6, 46% NID vs. n = 8, 66% control; p = 0.39). All reported SEs fell into the expected SE profile. There was no difference in report of new/recurrent neurologic symptoms (n = 110, 16.2% vaccinated vs. 71, 18.2% unvaccinated; p = 0.44) nor radiologic disease activity (n = 40, 5.9% vaccinated vs. n = 30, 7.6% unvaccinated) between vaccinated and unvaccinated NID participants. CONCLUSIONS: We found no difference in patient-reported vaccine side effects and no evidence of NID worsening after vaccination. Large-scale real-world evidence is needed for further validation. CI - Copyright (c) 2021. Published by Elsevier B.V. FAU - Epstein, Samantha AU - Epstein S AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. Electronic address: see2132@cumc.columbia.edu. FAU - Xia, Zongqi AU - Xia Z AD - University of Pittsburgh; Department of Neurology; Pittsburgh, PA, USA. FAU - Lee, Annie J AU - Lee AJ AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - Dahl, Megan AU - Dahl M AD - University of Pittsburgh; Department of Neurology; Pittsburgh, PA, USA. FAU - Edwards, Keith AU - Edwards K AD - The Multiple Sclerosis Center of Northeastern New York; Latham, NY, USA. FAU - Levit, Elle AU - Levit E AD - Yale University School of Medicine; Department of Neurology; New Haven, CT, USA. FAU - Longbrake, Erin E AU - Longbrake EE AD - Yale University School of Medicine; Department of Neurology; New Haven, CT, USA. FAU - Perrone, Christopher AU - Perrone C AD - University of Pennsylvania School of Medicine; Department of Neurology; Philadelphia, PA, USA. FAU - Kavak, Katelyn AU - Kavak K AD - State University of New York at Buffalo; Department of Neurology; Buffalo, NY, USA. FAU - Weinstock-Guttman, Bianca AU - Weinstock-Guttman B AD - State University of New York at Buffalo; Department of Neurology; Buffalo, NY, USA. FAU - Diallo, Fatoumata AU - Diallo F AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - Ricci, Adelle AU - Ricci A AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - Riley, Claire S AU - Riley CS AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - De Jager, Philip L AU - De Jager PL AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - Farber, Rebecca AU - Farber R AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. FAU - Wesley, Sarah F AU - Wesley SF AD - Multiple Sclerosis Center and the Center For Translational & Computational Neuroimmunology, Columbia University Irving Medical Center; Department of Neurology. New York, NY, USA. CN - Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative LA - eng PT - Journal Article PT - Observational Study DEP - 20211202 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19 MH - COVID-19 Vaccines MH - Cross-Sectional Studies MH - Humans MH - Neuroinflammatory Diseases MH - *SARS-CoV-2 MH - Vaccination PMC - PMC8638239 EDAT- 2021/12/20 06:00 MHDA- 2022/02/17 06:00 PMCR- 2021/12/02 CRDT- 2021/12/19 21:03 PHST- 2021/09/27 00:00 [received] PHST- 2021/10/26 00:00 [revised] PHST- 2021/11/27 00:00 [accepted] PHST- 2021/12/20 06:00 [pubmed] PHST- 2022/02/17 06:00 [medline] PHST- 2021/12/19 21:03 [entrez] PHST- 2021/12/02 00:00 [pmc-release] AID - S2211-0348(21)00699-4 [pii] AID - 103433 [pii] AID - 10.1016/j.msard.2021.103433 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2022 Jan;57:103433. doi: 10.1016/j.msard.2021.103433. Epub 2021 Dec 2. PMID- 34899999 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 1759-1961 (Print) IS - 1759-1961 (Electronic) IS - 1759-1961 (Linking) VI - 13 IP - 1 DP - 2022 Feb TI - Neuro-COVID-19. PG - 17-23 LID - 10.1111/cen3.12676 [doi] AB - Neuromuscular manifestations of new coronavirus disease 2019 (COVID-19) infection are frequent, and include dizziness, headache, myopathy, and olfactory and gustatory disturbances. Patients with acute central nervous system disorders, such as delirium, impaired consciousness, stroke and convulsive seizures, have a high mortality rate. The encephalitis/encephalopathy that causes consciousness disturbance and seizures can be classified into three conditions, including direct infection with the SARS-CoV-2 virus, encephalopathy caused by central nervous system damage secondary to systemic hypercytokinemia (cytokine storm) and autoimmune-mediated encephalitis that occurs after infection. The sequelae, called post-acute COVID-19 syndrome or long COVID, include neuromuscular manifestations, such as anxiety, depression, sleep disturbance, muscle weakness, brain fog and cognitive impairment. It is desirable to establish diagnostic criteria and treatment for these symptoms. Vaccine-induced thrombotic thrombocytopenia, Guillain-Barre syndrome, bilateral facial paralysis, encephalitis and opsoclonus-myoclonus syndrome have been reported as adverse reactions after the COVID-19 vaccine, although these are rare. CI - (c) 2021 Japanese Society for Neuroimmunology. FAU - Shimohata, Takayoshi AU - Shimohata T AUID- ORCID: 0000-0002-8788-9089 AD - Department of Neurology Gifu University Graduate School of Medicine Gifu Japan. LA - eng PT - Journal Article PT - Review DEP - 20210929 PL - United States TA - Clin Exp Neuroimmunol JT - Clinical & experimental neuroimmunology JID - 101520677 PMC - PMC8652810 OTO - NOTNLM OT - COVID-19 OT - neuromuscular manifestations OT - post-acute COVID-19 syndrome OT - vaccine EDAT- 2021/12/14 06:00 MHDA- 2021/12/14 06:01 PMCR- 2021/09/29 CRDT- 2021/12/13 17:58 PHST- 2021/08/29 00:00 [received] PHST- 2021/09/07 00:00 [revised] PHST- 2021/09/08 00:00 [accepted] PHST- 2021/12/14 06:00 [pubmed] PHST- 2021/12/14 06:01 [medline] PHST- 2021/12/13 17:58 [entrez] PHST- 2021/09/29 00:00 [pmc-release] AID - CEN312676 [pii] AID - 10.1111/cen3.12676 [doi] PST - ppublish SO - Clin Exp Neuroimmunol. 2022 Feb;13(1):17-23. doi: 10.1111/cen3.12676. Epub 2021 Sep 29. PMID- 34894403 OWN - NLM STAT- MEDLINE DCOM- 20220310 LR - 20260127 IS - 1532-5415 (Electronic) IS - 0002-8614 (Linking) VI - 70 IP - 3 DP - 2022 Mar TI - Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study. PG - 650-658 LID - 10.1111/jgs.17620 [doi] AB - BACKGROUND: There is incomplete information regarding evolution of antibody titers against SARS-CoV-2 after a two-dose strategy vaccination with BNT162b2 in older adults in long-term care facilities (LTCFs) with frailty, disability, or cognitive impairment. We aimed to determine IgG antibody titer loss in older adults in LTCFs. METHODS: This is a multicenter longitudinal cohort study including 127 residents (90 females and 37 males) with a mean age of 82.7 years (range 65-99) with different frailty and disability profiles in two LTCFs in Albacete, Spain. Residents received two doses of BNT162b2 as per label, and antibody levels were determined 1 and 6 months after the second dose. Age, sex, previous history of coronavirus disease 2019 (COVID-19), comorbidity (Charlson Index), performance in activities of daily living (Barthel Index), frailty (FRAIL instrument), and cognitive status were assessed. RESULTS: The mean antibody titers 1 and 6 months after the second vaccine dose were 32,145 AU/ml (SD 41,206) and 6182 AU/ml (SD 13,316), respectively. Across all participants, the median antibody titer loss measured 77.6% (interquartile range [IQR] 23.8%). Notably, the decline of titers in individuals with pre-vaccination COVID-19 infection was significantly lower than in those without a history of SARS-CoV-2 infection (72.2% vs. 85.3%; p < 0.001). The median titer decrease per follow-up day was 0.47% (IQR 0.14%) and only pre-vaccination COVID-19 was associated with lower rate of antibody decline at 6 months (hazard ratio 0.17; 95% confidence interval 0.07-0.41; p < 0.001). Frailty, disability, older age, cognitive impairment, or comorbidity were not associated with the extent of antibody loss. CONCLUSIONS: Older adults in LTCFs experience a rapid loss of antibodies over the first 6 months after the second dose of BNT162b2 vaccine. Only pre-vaccination COVID-19 is associated with a slower rate of antibody decrease. Our data support immunization with a third dose in this vulnerable, high-risk population. CI - (c) 2021 The American Geriatrics Society. FAU - Salmeron Rios, Sergio AU - Salmeron Rios S AUID- ORCID: 0000-0002-4405-687X AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Cortes Zamora, Elisa Belen AU - Cortes Zamora EB AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. FAU - Avendano Cespedes, Almudena AU - Avendano Cespedes A AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Romero Rizos, Luis AU - Romero Rizos L AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Jurado, Pedro Manuel AU - Sanchez-Jurado PM AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Nievas, Gines AU - Sanchez-Nievas G AD - Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Mas Romero, Marta AU - Mas Romero M AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Tabernero Sahuquillo, Maria Teresa AU - Tabernero Sahuquillo MT AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Blas Senalada, Jose Joaquin AU - Blas Senalada JJ AD - Department of Microbiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Murillo Romero, Antonio AU - Murillo Romero A AD - Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Garcia Nogueras, Inmaculada AU - Garcia Nogueras I AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Estrella Cazalla, Juan de Dios AU - Estrella Cazalla JD AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Residencia de Mayores Nunez de Balboa, Albacete, Spain. FAU - Andres-Pretel, Fernando AU - Andres-Pretel F AD - Department of Statistics, Foundation of the National Paraplegics Hospital of Toledo, Toledo, Spain. FAU - Lauschke, Volker Martin AU - Lauschke VM AUID- ORCID: 0000-0002-1140-6204 AD - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. AD - Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. FAU - Stebbing, Justin AU - Stebbing J AUID- ORCID: 0000-0002-1117-6947 AD - Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, London, UK. FAU - Abizanda, Pedro AU - Abizanda P AUID- ORCID: 0000-0002-4707-2963 AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Madrid, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. LA - eng GR - CB16/10/00408/Centro de Investigacion Biomedica en Red Fragilidad y Envejecimiento Saludable/ GR - COV20/00004/Instituto de Salud Carlos III/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20211217 PL - United States TA - J Am Geriatr Soc JT - Journal of the American Geriatrics Society JID - 7503062 RN - 0 (BNT162 Vaccine) SB - IM MH - Aged MH - Aged, 80 and over MH - Antibody Formation MH - BNT162 Vaccine/administration & dosage/*immunology MH - COVID-19/*immunology/*prevention & control MH - *Persons with Disabilities MH - Female MH - *Frail Elderly MH - Humans MH - Longitudinal Studies MH - Male MH - Nursing Homes MH - SARS-CoV-2 MH - Spain OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - antibody titers OT - disability OT - frailty OT - immunogenicity OT - nursing homes OT - older adults EDAT- 2021/12/12 06:00 MHDA- 2022/03/11 06:00 CRDT- 2021/12/11 17:03 PHST- 2021/12/02 00:00 [revised] PHST- 2021/09/23 00:00 [received] PHST- 2021/12/05 00:00 [accepted] PHST- 2021/12/12 06:00 [pubmed] PHST- 2022/03/11 06:00 [medline] PHST- 2021/12/11 17:03 [entrez] AID - 10.1111/jgs.17620 [doi] PST - ppublish SO - J Am Geriatr Soc. 2022 Mar;70(3):650-658. doi: 10.1111/jgs.17620. Epub 2021 Dec 17. PMID- 34842783 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211203 IS - 2035-8385 (Print) IS - 2035-8377 (Electronic) IS - 2035-8385 (Linking) VI - 13 IP - 4 DP - 2021 Nov 19 TI - Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. PG - 622-639 LID - 10.3390/neurolint13040061 [doi] AB - Background and Purpose: The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in Wuhan, China in December 2019. Symptoms range from mild flu-like symptoms to more severe presentations, including pneumonia, acute respiratory distress syndrome (ARDS), and even death. In response to the COVID-19 pandemic, the Emergency Use Authorization (EUA) approved the use of several vaccines. Because vaccines have been fast-tracked for emergency use, the short and long-term safety profile has been an area of concern. The aim of this paper is to extensively review published literature regarding post-COVID-19 vaccination neurological complications and characterize neuroimaging findings from three case presentations for early diagnosis and treatment. Methods: The analysis includes data from PubMed and Google Scholar. Articles included were retrieved from database inception beginning December 2020 with no language restrictions. Terms used include "SARS-CoV-2", "post Covid vaccination", "neurological complications", "Guillain-barre Syndrome", "Transverse-myelitis", "Cerebral Venous Sinus thrombosis", and "Cerebral hemorrhage". Results: The literature review yielded several neurological complications post vaccination, including cerebral sinus venous thrombosis, transverse myelitis, Guillain-Barre Syndrome and optic neuritis, to name a few. Patient case presentation findings were consistent with documented results in published literature. Conclusions: We present a case series with a thorough literature review documenting adverse neurological affects following COVID-19 vaccination. Our case presentations and literature review highlight the importance of neuroimaging when diagnosing post-COVID-19 vaccination adverse effects. MRI imaging study is an important tool to be considered in patients presenting with post-COVID-19 vaccination-related unexplained neurological symptoms for accurate diagnosis. FAU - Sriwastava, Shitiz AU - Sriwastava S AUID- ORCID: 0000-0001-6844-3287 AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. AD - West Virginia Clinical and Translational Science Institute, Morgantown, WV 26506, USA. AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. FAU - Shrestha, Ashish K AU - Shrestha AK AUID- ORCID: 0000-0002-4614-7783 AD - Katmandu Medical College, School of Medicine, Kathmandu 44600, Nepal. FAU - Khalid, Syed Hassan AU - Khalid SH AD - Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA. FAU - Colantonio, Mark A AU - Colantonio MA AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. FAU - Nwafor, Divine AU - Nwafor D AUID- ORCID: 0000-0001-7347-9524 AD - School of Medicine, West Virginia University, Morgantown, WV 26506, USA. FAU - Srivastava, Samiksha AU - Srivastava S AD - Department of Neurology, Wayne State University, Detroit, MI 48201, USA. LA - eng PT - Journal Article PT - Review DEP - 20211119 PL - Switzerland TA - Neurol Int JT - Neurology international JID - 101551564 PMC - PMC8628885 OTO - NOTNLM OT - COVID-19 vaccination OT - GBS OT - optic neuropathy OT - transverse myelitis COIS- The authors declare no conflict of interest. EDAT- 2021/11/30 06:00 MHDA- 2021/11/30 06:01 PMCR- 2021/11/19 CRDT- 2021/11/29 12:33 PHST- 2021/09/30 00:00 [received] PHST- 2021/11/12 00:00 [revised] PHST- 2021/11/17 00:00 [accepted] PHST- 2021/11/29 12:33 [entrez] PHST- 2021/11/30 06:00 [pubmed] PHST- 2021/11/30 06:01 [medline] PHST- 2021/11/19 00:00 [pmc-release] AID - neurolint13040061 [pii] AID - neurolint-13-00061 [pii] AID - 10.3390/neurolint13040061 [doi] PST - epublish SO - Neurol Int. 2021 Nov 19;13(4):622-639. doi: 10.3390/neurolint13040061. PMID- 34839149 OWN - NLM STAT- MEDLINE DCOM- 20220113 LR - 20230104 IS - 1872-8421 (Electronic) IS - 0165-5728 (Print) IS - 0165-5728 (Linking) VI - 362 DP - 2022 Jan 15 TI - A systematic review of cases of CNS demyelination following COVID-19 vaccination. PG - 577765 LID - S0165-5728(21)00292-7 [pii] LID - 10.1016/j.jneuroim.2021.577765 [doi] AB - BACKGROUND: Since the emergency use approval of different types of COVID-19 vaccines, several safety concerns have been raised regarding its early and delayed impact on the nervous system. OBJECTIVE: This study aims to systematically review the reported cases of CNS demyelination in association with COVID-19 vaccination, which has not been performed, to our knowledge. METHODS: A systematic review was performed by screening published articles and preprints of cases of CNS demyelination in association with COVID-19 vaccines in PubMed, SCOPUS, EMBASE, Google Scholar, Ovid and medRxiv databases, until September 30, 2021. This study followed PRISMA guidelines. Descriptive findings of reported cases were reviewed and stratified by demographic and clinical findings, diagnostic work-up, management, and overall outcome. RESULTS: A total of 32 cases were identified, with female predominance (68.8%) and median age of 44 years. Eleven cases were reported after Pfizer vaccine, 8 following AstraZeneca vaccine, 6 following Moderna, 5 following Sinovac/ Sinopharm vaccines, and one following each of Sputnik and Johnson&Johnson vaccines. The majority of cases (71.8%) occurred after the first dose of the vaccine, with neurological symptoms manifesting after a median of 9 days. The most common reported presentations were transverse myelitis (12/32) and MS-like pictures (first diagnosis or a relapse) in another 12/32 cases, followed by ADEM- like (5/32), and NMOSD- like (3/32) presentations. History of a previous immune-mediated disease was reported in 17/32 (53.1%) cases. The mRNA-based vaccines resulted in the greatest number of demyelinating syndromes (17/32), followed by viral vector vaccines (10/32), and inactivated vaccines (5/32). Most MS-like episodes (9/12) were triggered by mRNA-based vaccines, while TM occurred following both viral vector and mRNA-based vaccines. Management included high dose methylprednisolone, PLEX, IVIg, or a combination of those, with a favorable outcome in the majority of case; marked/complete improvement (25/32) or stabilized/ partial recovery in the remaining cases. CONCLUSION: This systematic review identified few cases of CNS demyelination following all types of approved COVID-19 vaccines so far. Clinical presentation was heterogenous, mainly following the first dose, however, half of the reported cases had a history of immune-mediated disease. Favorable outcome was observed in most cases. We suggest long-term post-marketing surveillance for these cases, to assess for causality, and ensure the safety of COVID-19 vaccines. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Ismail, Ismail Ibrahim AU - Ismail II AD - Department of Neurology, Ibn Sina Hospital, Kuwait. Electronic address: dr.ismail.ibrahim2012@gmail.com. FAU - Salama, Sara AU - Salama S AD - Department of Neurology and Psychiatry, University of Alexandria, Alexandria, Egypt. LA - eng PT - Journal Article PT - Systematic Review DEP - 20211109 PL - Netherlands TA - J Neuroimmunol JT - Journal of neuroimmunology JID - 8109498 RN - 0 (COVID-19 Vaccines) SB - IM MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Demyelinating Autoimmune Diseases, CNS/*chemically induced/*epidemiology/etiology MH - Humans MH - SARS-CoV-2 PMC - PMC8577051 OTO - NOTNLM OT - COVID-19 OT - Demyelinating disease OT - Multiple sclerosis OT - SARS-CoV-2 OT - Transverse myelitis OT - Vaccine EDAT- 2021/11/29 06:00 MHDA- 2022/01/14 06:00 PMCR- 2021/11/09 CRDT- 2021/11/28 21:03 PHST- 2021/09/10 00:00 [received] PHST- 2021/10/15 00:00 [revised] PHST- 2021/11/04 00:00 [accepted] PHST- 2021/11/29 06:00 [pubmed] PHST- 2022/01/14 06:00 [medline] PHST- 2021/11/28 21:03 [entrez] PHST- 2021/11/09 00:00 [pmc-release] AID - S0165-5728(21)00292-7 [pii] AID - 577765 [pii] AID - 10.1016/j.jneuroim.2021.577765 [doi] PST - ppublish SO - J Neuroimmunol. 2022 Jan 15;362:577765. doi: 10.1016/j.jneuroim.2021.577765. Epub 2021 Nov 9. PMID- 34835235 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211130 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 11 DP - 2021 Nov 9 TI - Explaining COVID-19 Vaccine Rejection Using Social Cognitive Theory in Qassim, Saudi Arabia. LID - 10.3390/vaccines9111304 [doi] LID - 1304 AB - Acceptance of COVID-19 vaccines needs a health promotion approach to address various social, environmental and personal factors leading to vaccine hesitancy. We assessed the vaccine hesitancy rate and applied social cognitive theory (SCT) to understand COVID-19 vaccine rejection in Qassim, Saudi Arabia. A cross-sectional study was conducted among visitors of 10 randomly selected primary health care centers in Buraidah, Saudi Arabia. Data was collected by a self-administrated questionnaire. The variables were grouped into six constructs of SCT. Logistic regression was used to assess the predictors of vaccine rejection. Out of 486 participants included in the study, 30.5% rejected the vaccine. The most common reason for vaccine rejection was uncertainty about the vaccine's effectiveness (78%). Among various constructs of SCT, reciprocal determinism (nationality, income and suffering from COVID-19 infection), behavioral capability (knowledge about vaccine safety), self-efficacy (registered for vaccine), and observational learning (getting the vaccine after friends and family members) were significant predictors. Expectation and reinforcement constructs did not show significant association. There was high vaccine rejection in Qassim, KSA. This calls for further improving the mass education strategies. Social cognitive theory can be used to predict vaccine rejection and to develop strategies to increase the utilization of COVID-19 vaccines in Saudi Arabia. FAU - AlSaeed, Aseel Ali AU - AlSaeed AA AUID- ORCID: 0000-0002-1961-1835 AD - Family Medicine Academy, Qassim Health Cluster, Buraidah 52385, Saudi Arabia. FAU - Rabbani, Unaib AU - Rabbani U AUID- ORCID: 0000-0002-0702-780X AD - Family Medicine Academy, Qassim Health Cluster, Buraidah 52385, Saudi Arabia. LA - eng PT - Journal Article DEP - 20211109 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8623049 OTO - NOTNLM OT - COVID-19 OT - Saudi Arabia OT - barriers to vaccine OT - social cognitive theory OT - vaccine hesitancy COIS- Authors declare that there is no conflict of interest. EDAT- 2021/11/28 06:00 MHDA- 2021/11/28 06:01 PMCR- 2021/11/09 CRDT- 2021/11/27 01:27 PHST- 2021/10/16 00:00 [received] PHST- 2021/11/07 00:00 [revised] PHST- 2021/11/08 00:00 [accepted] PHST- 2021/11/27 01:27 [entrez] PHST- 2021/11/28 06:00 [pubmed] PHST- 2021/11/28 06:01 [medline] PHST- 2021/11/09 00:00 [pmc-release] AID - vaccines9111304 [pii] AID - vaccines-09-01304 [pii] AID - 10.3390/vaccines9111304 [doi] PST - epublish SO - Vaccines (Basel). 2021 Nov 9;9(11):1304. doi: 10.3390/vaccines9111304. PMID- 34803439 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231108 IS - 1303-6092 (Electronic) IS - 1300-0152 (Print) IS - 1300-0152 (Linking) VI - 45 IP - 4 DP - 2021 TI - An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. PG - 342-357 LID - 10.3906/biy-2106-23 [doi] AB - Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed. CI - Copyright (c) 2021 The Author(s). FAU - Ozkan Oktay, Ebru AU - Ozkan Oktay E AUID- ORCID: 0000-0002-0395-9845 AD - Laboratory Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Tuncay, Salih AU - Tuncay S AUID- ORCID: 0000-0003-3838-5228 AD - Food Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Kaman, Tugba AU - Kaman T AUID- ORCID: 0000-0002-5885-0193 AD - Medical and Aromatic Plants Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Karasakal, Omer Faruk AU - Karasakal OF AUID- ORCID: 0000-0001-7803-3249 AD - Medical Laboratory Techniques Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Ozcan, Oznur Ozge AU - Ozcan OO AUID- ORCID: 0000-0001-8992-0556 AD - Physiotherapy Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Soylamis, Tugce AU - Soylamis T AUID- ORCID: 0000-0002-4663-897X AD - Laboratory Technology Program, Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Karahan, Mesut AU - Karahan M AUID- ORCID: 0000-0002-8971-678X AD - Vocational School of Health Services, Uskudar University, Istanbul Turkey. FAU - Konuk, Muhsin AU - Konuk M AUID- ORCID: 0000-0002-6651-718X AD - Department of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Uskudar University, Istanbul Turkey. LA - eng PT - Journal Article PT - Review DEP - 20210830 PL - Turkey TA - Turk J Biol JT - Turkish journal of biology = Turk biyoloji dergisi JID - 9434434 PMC - PMC8573837 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - drugs OT - neurological symptoms OT - neutralizing antibodies OT - vaccines OT - variants COIS- CONFLICT OF INTEREST: none declared EDAT- 2021/11/23 06:00 MHDA- 2021/11/23 06:01 PMCR- 2021/08/30 CRDT- 2021/11/22 06:36 PHST- 2021/06/08 00:00 [received] PHST- 2021/07/28 00:00 [accepted] PHST- 2021/11/22 06:36 [entrez] PHST- 2021/11/23 06:00 [pubmed] PHST- 2021/11/23 06:01 [medline] PHST- 2021/08/30 00:00 [pmc-release] AID - 10.3906/biy-2106-23 [doi] PST - epublish SO - Turk J Biol. 2021 Aug 30;45(4):342-357. doi: 10.3906/biy-2106-23. eCollection 2021. PMID- 34765623 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240929 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 8 DP - 2021 TI - Cognitive Barriers to COVID-19 Vaccine Uptake Among Older Adults. PG - 756275 LID - 10.3389/fmed.2021.756275 [doi] LID - 756275 FAU - Chia, Jonathan L AU - Chia JL AD - School of Social Sciences, Singapore Management University, Singapore, Singapore. FAU - Hartanto, Andree AU - Hartanto A AD - School of Social Sciences, Singapore Management University, Singapore, Singapore. LA - eng PT - Journal Article DEP - 20211026 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC8576177 OTO - NOTNLM OT - COVID-19 OT - cognitive barriers OT - older adults OT - vaccine hesitancy OT - vaccine uptake COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2021/11/13 06:00 MHDA- 2021/11/13 06:01 PMCR- 2021/10/26 CRDT- 2021/11/12 07:07 PHST- 2021/08/10 00:00 [received] PHST- 2021/10/05 00:00 [accepted] PHST- 2021/11/12 07:07 [entrez] PHST- 2021/11/13 06:00 [pubmed] PHST- 2021/11/13 06:01 [medline] PHST- 2021/10/26 00:00 [pmc-release] AID - 10.3389/fmed.2021.756275 [doi] PST - epublish SO - Front Med (Lausanne). 2021 Oct 26;8:756275. doi: 10.3389/fmed.2021.756275. eCollection 2021. PMID- 34735684 OWN - NLM STAT- MEDLINE DCOM- 20220323 LR - 20220716 IS - 1556-2891 (Electronic) IS - 1547-769X (Print) IS - 1547-769X (Linking) VI - 18 IP - 1 DP - 2022 Mar TI - Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination. PG - 74-79 LID - 10.1007/s12024-021-00440-7 [doi] AB - This report describes the clinical context and autopsy findings in the first reported fatal case of acute disseminated encephalomyelitis (ADEM), developed after being vaccinated using the Oxford/AstraZeneca COVID-19 vaccine. ADEM is a rare autoimmune disease, causing demyelination in the brain and spinal cord. A wide variety of precipitating factors can trigger ADEM, and it has long been known to be a rare adverse event following some types of vaccinations. Recently, ADEM has also been associated with COVID-19 infection and (very rarely) with COVID-19 vaccination. The reports of the latter however all pertain to living patients. Our case demonstrates that ADEM should be considered in patients developing neurological symptoms post COVID-19 vaccination, although that this adverse reaction is likely to remain extremely rare. Our report further emphasizes the added value of comprehensive post mortem investigation to confirm ante mortem diagnosis and to determine vaccination safety. CI - (c) 2021. Springer Science+Business Media, LLC, part of Springer Nature. FAU - Permezel, Fiona AU - Permezel F AD - Department of Neurology, Austin Health, Heidelberg, VIC, Australia. FAU - Borojevic, Branko AU - Borojevic B AD - Department of General Medicine, Austin Health, Heidelberg, VIC, Australia. FAU - Lau, Stephanie AU - Lau S AUID- ORCID: 0000-0001-8564-7142 AD - Department of Anatomical Pathology, Austin Health, Heidelberg, VIC, Australia. FAU - de Boer, Hans H AU - de Boer HH AUID- ORCID: 0000-0001-8590-0945 AD - Victorian Institute of Forensic Medicine, Southbank, VIC, Australia. Hans.de.Boer@vifm.org. AD - Department of Forensic Medicine, Monash University, Southbank, VIC, Australia. Hans.de.Boer@vifm.org. LA - eng PT - Journal Article DEP - 20211104 PL - United States TA - Forensic Sci Med Pathol JT - Forensic science, medicine, and pathology JID - 101236111 RN - 0 (COVID-19 Vaccines) SB - IM MH - Brain MH - *COVID-19/prevention & control MH - COVID-19 Vaccines/adverse effects MH - *Encephalomyelitis, Acute Disseminated/diagnosis/etiology MH - Humans MH - Vaccination/adverse effects PMC - PMC8567127 OTO - NOTNLM OT - ADEM OT - Acute disseminated encephalomyelitis OT - Adverse event OT - COVID-19 OT - Forensic pathology OT - Vaccination COIS- The authors have no relevant financial or non-financial interests to disclose. EDAT- 2021/11/05 06:00 MHDA- 2022/03/24 06:00 PMCR- 2021/11/04 CRDT- 2021/11/04 17:35 PHST- 2021/10/13 00:00 [accepted] PHST- 2021/11/05 06:00 [pubmed] PHST- 2022/03/24 06:00 [medline] PHST- 2021/11/04 17:35 [entrez] PHST- 2021/11/04 00:00 [pmc-release] AID - 10.1007/s12024-021-00440-7 [pii] AID - 440 [pii] AID - 10.1007/s12024-021-00440-7 [doi] PST - ppublish SO - Forensic Sci Med Pathol. 2022 Mar;18(1):74-79. doi: 10.1007/s12024-021-00440-7. Epub 2021 Nov 4. PMID- 34696311 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 10 DP - 2021 Oct 19 TI - Differences in Sources of Information, Risk Perception, and Cognitive Appraisals between People with Various Latent Classes of Motivation to Get Vaccinated against COVID-19 and Previous Seasonal Influenza Vaccination: Facebook Survey Study with Latent Profile Analysis in Taiwan. LID - 10.3390/vaccines9101203 [doi] LID - 1203 AB - The present study aimed (1) to identify distinct latent classes of motivation to get vaccinated against coronavirus disease 2019 (COVID-19) and previous seasonal influenza vaccination among people in Taiwan and (2) to examine the roles of sources of information, risk perception, and cognitive appraisals of vaccination against COVID-19 in these classes. We recruited 1047 participants through a Facebook advertisement. The participants' motivation to get vaccinated against COVID-19, previous seasonal influenza vaccination, sources of information about COVID-19 vaccination, risk perception of COVID-19, and cognitive appraisals of vaccination against COVID-19 were determined. We examined the participants' motivation for COVID-19 vaccination and previous seasonal influenza vaccination through latent profile analysis. Four latent classes of motivation were identified: participants with high motivation for COVID-19 vaccination and high seasonal influenza vaccination, those with high motivation for COVID-19 vaccination but low seasonal influenza vaccination, those with low motivation for COVID-19 vaccination but high seasonal influenza vaccination, and those with low motivation for COVID-19 vaccination and low seasonal influenza vaccination. Compared with participants in the latent class of high motivation for COVID-19 vaccination and high seasonal influenza vaccination, those in the other three latent classes had lower levels of positive appraisals of COVID-19 vaccination; participants in the latent class of low motivation for COVID-19 vaccination and low seasonal influenza vaccination had lower risk perception of COVID-19 and were also less likely to obtain information about COVID-19 vaccination from the internet, friends, and family members. The various motivations and behaviors for vaccination, sources of information, risk perception, and cognitive appraisals of vaccination against COVID-19 should be considered in intervention programs aiming to increase people's motivation to get vaccinated against COVID-19. FAU - Chen, Yi-Lung AU - Chen YL AUID- ORCID: 0000-0003-2934-5814 AD - Department of Healthcare Administration, Asia University, Taichung 41354, Taiwan. AD - Department of Psychology, Asia University, Taichung 41354, Taiwan. FAU - Lin, Yen-Ju AU - Lin YJ AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan. FAU - Chang, Yu-Ping AU - Chang YP AUID- ORCID: 0000-0003-2328-6876 AD - School of Nursing, The State University of New York, University at Buffalo, New York, NY 14214-8013, USA. FAU - Chou, Wen-Jiun AU - Chou WJ AD - School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan. AD - Department of Child and Adolescent Psychiatry, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Kaohsiung 83301, Taiwan. FAU - Yen, Cheng-Fang AU - Yen CF AUID- ORCID: 0000-0003-1156-4939 AD - Department of Psychiatry, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. AD - Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan. AD - College of Professional Studies, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan. LA - eng GR - UL1 TR001412/TR/NCATS NIH HHS/United States GR - KMUH109-9M54/Kaohsiung Medical University Hospital/ PT - Journal Article DEP - 20211019 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8538554 OTO - NOTNLM OT - COVID-19 OT - motivation OT - seasonal influenza OT - vaccine COIS- The authors declare no conflict of interest. EDAT- 2021/10/27 06:00 MHDA- 2021/10/27 06:01 PMCR- 2021/10/19 CRDT- 2021/10/26 01:02 PHST- 2021/09/26 00:00 [received] PHST- 2021/10/15 00:00 [revised] PHST- 2021/10/18 00:00 [accepted] PHST- 2021/10/26 01:02 [entrez] PHST- 2021/10/27 06:00 [pubmed] PHST- 2021/10/27 06:01 [medline] PHST- 2021/10/19 00:00 [pmc-release] AID - vaccines9101203 [pii] AID - vaccines-09-01203 [pii] AID - 10.3390/vaccines9101203 [doi] PST - epublish SO - Vaccines (Basel). 2021 Oct 19;9(10):1203. doi: 10.3390/vaccines9101203. PMID- 34696278 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20211029 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 10 DP - 2021 Oct 12 TI - Cognitive Factors Influencing COVID-19 Vaccination Intentions: An Application of the Protection Motivation Theory Using a Probability Community Sample. LID - 10.3390/vaccines9101170 [doi] LID - 1170 AB - COVID-19 vaccines have been shown to provide protection against severe disease and death. However, substantial individual differences in vaccination intentions have hindered achieving optimal vaccination rates across the population. To look for efficient strategies to promote vaccination, this study tested whether the protection motivation theory (PMT), a cognitive model based upon threat and coping appraisals, would account for the differences in vaccination intentions under three scenarios (i.e., in the context of getting vaccinated in general, and in the context of high- and low- efficacy for reducing COVID-19 transmission risk). A phone survey was conducted in early 2021 and obtained a probability community sample (n = 472; 49.2% men) in Macao, China. We found that 54.0% of respondents indicated their relatively strong intention to receive COVID-19 vaccination for high-efficacy vaccines, compared to 29.5% for low-efficacy vaccines and 31.0% for vaccines in general. After adjusting for demographics, self-efficacy (i.e., the perceived capability of receiving COVID-19 vaccines) and maladaptive response reward (i.e., the perceived benefits of not receiving COVID-19 vaccines) were consistently associated with COVID-19 vaccination intentions under all three scenarios. The perceived severity of COVID-19 infection and response cost (i.e., the perceived costs of receiving COVID-19 vaccines) were significantly associated with vaccination intention for high-efficacy vaccines, while the response efficacy of lowering the COVID-19 impact with COVID-19 vaccination was positively associated with vaccination intention for general and low-efficacy vaccines. Given that the relative strength of PMT constructs depends on perceived vaccine efficacy, we recommend taking PMT constructs and vaccine efficacy into account for encouraging vaccination. FAU - Tong, Kwok Kit AU - Tong KK AUID- ORCID: 0000-0001-8594-9300 AD - Department of Psychology, Faculty of Social Sciences, University of Macau, Macao, China. FAU - He, Mu AU - He M AD - Department of Psychology, Faculty of Social Sciences, University of Macau, Macao, China. FAU - Wu, Anise M S AU - Wu AMS AUID- ORCID: 0000-0001-8174-6581 AD - Department of Psychology, Faculty of Social Sciences, University of Macau, Macao, China. AD - Centre for Cognitive and Brain Sciences, Institute of Collaborative Innovation, University of Macau, Macao, China. FAU - Dang, Le AU - Dang L AD - Department of Psychology, Faculty of Social Sciences, University of Macau, Macao, China. AD - Centre for Cognitive and Brain Sciences, Institute of Collaborative Innovation, University of Macau, Macao, China. AD - Faculty of Teacher Education, Pingdingshan University, Pingdingshan 467000, China. FAU - Chen, Juliet Honglei AU - Chen JH AUID- ORCID: 0000-0002-6564-5390 AD - Department of Psychology, Faculty of Social Sciences, University of Macau, Macao, China. AD - Centre for Cognitive and Brain Sciences, Institute of Collaborative Innovation, University of Macau, Macao, China. LA - eng GR - MYRG2019-00125-FSS/Universidade de Macau/ PT - Journal Article DEP - 20211012 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8537765 OTO - NOTNLM OT - COVID-19 OT - intention OT - protection motivation theory OT - vaccine acceptance OT - vaccine efficacy COIS- The authors declare no conflict of interest. EDAT- 2021/10/27 06:00 MHDA- 2021/10/27 06:01 PMCR- 2021/10/12 CRDT- 2021/10/26 01:02 PHST- 2021/08/30 00:00 [received] PHST- 2021/10/09 00:00 [revised] PHST- 2021/10/09 00:00 [accepted] PHST- 2021/10/26 01:02 [entrez] PHST- 2021/10/27 06:00 [pubmed] PHST- 2021/10/27 06:01 [medline] PHST- 2021/10/12 00:00 [pmc-release] AID - vaccines9101170 [pii] AID - vaccines-09-01170 [pii] AID - 10.3390/vaccines9101170 [doi] PST - epublish SO - Vaccines (Basel). 2021 Oct 12;9(10):1170. doi: 10.3390/vaccines9101170. PMID- 34643720 OWN - NLM STAT- MEDLINE DCOM- 20211025 LR - 20231107 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 4 IP - 10 DP - 2021 Oct 1 TI - Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. PG - e2128568 LID - 10.1001/jamanetworkopen.2021.28568 [doi] LID - e2128568 AB - IMPORTANCE: Short-term and long-term persistent postacute sequelae of COVID-19 (PASC) have not been systematically evaluated. The incidence and evolution of PASC are dependent on time from infection, organ systems and tissue affected, vaccination status, variant of the virus, and geographic region. OBJECTIVE: To estimate organ system-specific frequency and evolution of PASC. EVIDENCE REVIEW: PubMed (MEDLINE), Scopus, the World Health Organization Global Literature on Coronavirus Disease, and CoronaCentral databases were searched from December 2019 through March 2021. A total of 2100 studies were identified from databases and through cited references. Studies providing data on PASC in children and adults were included. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines for abstracting data were followed and performed independently by 2 reviewers. Quality was assessed using the Newcastle-Ottawa Scale for cohort studies. The main outcome was frequency of PASC diagnosed by (1) laboratory investigation, (2) radiologic pathology, and (3) clinical signs and symptoms. PASC were classified by organ system, ie, neurologic; cardiovascular; respiratory; digestive; dermatologic; and ear, nose, and throat as well as mental health, constitutional symptoms, and functional mobility. FINDINGS: From a total of 2100 studies identified, 57 studies with 250 351 survivors of COVID-19 met inclusion criteria. The mean (SD) age of survivors was 54.4 (8.9) years, 140 196 (56%) were male, and 197 777 (79%) were hospitalized during acute COVID-19. High-income countries contributed 45 studies (79%). The median (IQR) proportion of COVID-19 survivors experiencing at least 1 PASC was 54.0% (45.0%-69.0%; 13 studies) at 1 month (short-term), 55.0% (34.8%-65.5%; 38 studies) at 2 to 5 months (intermediate-term), and 54.0% (31.0%-67.0%; 9 studies) at 6 or more months (long-term). Most prevalent pulmonary sequelae, neurologic disorders, mental health disorders, functional mobility impairments, and general and constitutional symptoms were chest imaging abnormality (median [IQR], 62.2% [45.8%-76.5%]), difficulty concentrating (median [IQR], 23.8% [20.4%-25.9%]), generalized anxiety disorder (median [IQR], 29.6% [14.0%-44.0%]), general functional impairments (median [IQR], 44.0% [23.4%-62.6%]), and fatigue or muscle weakness (median [IQR], 37.5% [25.4%-54.5%]), respectively. Other frequently reported symptoms included cardiac, dermatologic, digestive, and ear, nose, and throat disorders. CONCLUSIONS AND RELEVANCE: In this systematic review, more than half of COVID-19 survivors experienced PASC 6 months after recovery. The most common PASC involved functional mobility impairments, pulmonary abnormalities, and mental health disorders. These long-term PASC effects occur on a scale that could overwhelm existing health care capacity, particularly in low- and middle-income countries. FAU - Groff, Destin AU - Groff D AD - Department of Surgery, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Sun, Ashley AU - Sun A AD - Department of Surgery, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Ssentongo, Anna E AU - Ssentongo AE AD - Department of Surgery, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Ba, Djibril M AU - Ba DM AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Parsons, Nicholas AU - Parsons N AD - Cognitive Neuroscience Unit, School of Psychology, Deakin University, Melbourne, Victoria, Australia. FAU - Poudel, Govinda R AU - Poudel GR AD - Mary Mackillop Institute for Health Research, Department of Health Sciences, Australian Catholic University, Melbourne, Victoria, Australia. FAU - Lekoubou, Alain AU - Lekoubou A AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. AD - Department of Neurology, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Oh, John S AU - Oh JS AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Ericson, Jessica E AU - Ericson JE AD - Division of Infectious Disease, Department of Pediatrics, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. FAU - Ssentongo, Paddy AU - Ssentongo P AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. AD - Center for Neural Engineering, Department of Engineering, Science and Mechanics, The Pennsylvania State University, State College. FAU - Chinchilli, Vernon M AU - Chinchilli VM AD - Department of Public Health Sciences, Penn State College of Medicine and Milton S. Hershey Medical Center, Hershey, Pennsylvania. LA - eng GR - R01 AI145057/AI/NIAID NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Systematic Review DEP - 20211001 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 SB - IM CIN - Pediatr Ann. 2021 Dec;50(12):e478. doi: 10.3928/19382359-20211117-03. PMID: 34889132 MH - COVID-19/*epidemiology MH - Fatigue/epidemiology MH - Humans MH - Lung Diseases/epidemiology MH - Mental Disorders/epidemiology MH - Mobility Limitation MH - Muscle Weakness/epidemiology MH - Nervous System Diseases MH - *Survivors PMC - PMC8515212 COIS- Conflict of Interest Disclosures: Dr Ericson reported consulting for Allergan outside the submitted work. No other disclosures were reported. EDAT- 2021/10/14 06:00 MHDA- 2021/10/26 06:00 PMCR- 2021/10/13 CRDT- 2021/10/13 12:23 PHST- 2021/10/13 12:23 [entrez] PHST- 2021/10/14 06:00 [pubmed] PHST- 2021/10/26 06:00 [medline] PHST- 2021/10/13 00:00 [pmc-release] AID - 2784918 [pii] AID - zoi210832 [pii] AID - 10.1001/jamanetworkopen.2021.28568 [doi] PST - epublish SO - JAMA Netw Open. 2021 Oct 1;4(10):e2128568. doi: 10.1001/jamanetworkopen.2021.28568. PMID- 34511678 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221221 IS - 0191-8869 (Print) IS - 0191-8869 (Electronic) IS - 0191-8869 (Linking) VI - 185 DP - 2022 Feb TI - Linking the behavioral immune system to COVID-19 vaccination intention: The mediating role of the need for cognitive closure and vaccine hesitancy. PG - 111245 LID - 10.1016/j.paid.2021.111245 [doi] AB - Vaccination has become one of the most effective ways of controlling the spread of COVID-19. Consequently, revealing the evolutionary and cognitive antecedents of COVID-19 vaccine hesitancy and vaccination intention has become crucial. Drawing on the theory of behavioral immune system (BIS), we investigate whether perceived vulnerability to disease (PVD) is associated with vaccination intentions through the need for cognitive closure (NCC) and vaccine hesitancy. The data was collected from 525 adults from Turkey. The structural equation modeling results indicate that of the two dimensions of PVD, germ aversion predicts COVID-19 vaccination intention through sequential mediation of NCC and vaccine hesitancy. Perceived infectability, on the other hand, is directly and positively related to vaccination intention. By showing the mediating role of NCC, our results offer an insight as to why germ aversion translates into vaccine hesitancy, and low vaccination intention. We discuss the potential benefits of considering the roles of BIS and NCC in campaigns and policies targeted at increasing COVID-19 vaccine uptake and suggest implications for such practices. CI - (c) 2021 Elsevier Ltd. All rights reserved. FAU - Solak, Caglar AU - Solak C AD - Department of Psychology, Manisa Celal Bayar University, Turkey. FAU - Peker-Dural, Hilal AU - Peker-Dural H AD - Department of Psychology, Ondokuz Mayis University, Samsun, Turkey. FAU - Karlidag, Sercan AU - Karlidag S AD - Department of Psychology, Altinbas University, Istanbul, Turkey. FAU - Peker, Mehmet AU - Peker M AD - Department of Psychology, Ege University, Izmir, Turkey. LA - eng PT - Journal Article DEP - 20210908 PL - England TA - Pers Individ Dif JT - Personality and individual differences JID - 8006972 PMC - PMC8423810 OTO - NOTNLM OT - Behavioral immune system OT - COVID-19 vaccines OT - Need for cognitive closure OT - Vaccination intention OT - Vaccine hesitancy EDAT- 2021/09/14 06:00 MHDA- 2021/09/14 06:01 PMCR- 2021/09/08 CRDT- 2021/09/13 06:33 PHST- 2021/04/18 00:00 [received] PHST- 2021/08/23 00:00 [revised] PHST- 2021/09/02 00:00 [accepted] PHST- 2021/09/14 06:00 [pubmed] PHST- 2021/09/14 06:01 [medline] PHST- 2021/09/13 06:33 [entrez] PHST- 2021/09/08 00:00 [pmc-release] AID - S0191-8869(21)00624-3 [pii] AID - 111245 [pii] AID - 10.1016/j.paid.2021.111245 [doi] PST - ppublish SO - Pers Individ Dif. 2022 Feb;185:111245. doi: 10.1016/j.paid.2021.111245. Epub 2021 Sep 8. PMID- 34507266 OWN - NLM STAT- MEDLINE DCOM- 20211112 LR - 20221221 IS - 1873-4499 (Electronic) IS - 0899-7071 (Print) IS - 0899-7071 (Linking) VI - 80 DP - 2021 Dec TI - Neurological symptoms and neuroimaging alterations related with COVID-19 vaccine: Cause or coincidence? PG - 348-352 LID - S0899-7071(21)00355-7 [pii] LID - 10.1016/j.clinimag.2021.08.021 [doi] AB - Although vaccination against Coronavirus disease-2019 (COVID-19) is still occurring, several adverse effects temporally related to these vaccines are already being reported, even if through isolated case reports. In the present study, we describe the lesions seen on magnetic resonance imaging (MRI) of three patients who developed neurological symptoms after receiving the ChAdOX1 nCoV-19 vaccine (Oxford/AstraZeneca). The first patient presented with an ischemic stroke in the posterior limb of the left internal capsule, two days after vaccination. The second patient presented with a left facial nerve palsy, seven days after vaccination. The third patient presented with myelitis, eight days after receiving the vaccine. All patients presented the symptoms after the first dose of the vaccine and did not have a history of previous COVID-19. The real incidence of these types of complications is not known yet, but it is important to consider the possibility of COVID-19 vaccine complications, in patients with a recent history of vaccination and recent development of neurological symptoms, even though this association is only casual. Longitudinal studies are necessary to further analyze the incidence of the adverse effects of each vaccine against SARS-CoV-2. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Correa, Diogo Goulart AU - Correa DG AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil; Department of Radiology, Federal Fluminense University, Rua Marques de Parana, 303, Centro, Niteroi, RJ Zip code: 24070-035, Brazil. Electronic address: diogogoulartcorrea@yahoo.com.br. FAU - Canete, Luis Alcides Quevedo AU - Canete LAQ AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. FAU - Dos Santos, Gutemberg Augusto Cruz AU - Dos Santos GAC AD - Department of Neurology, Estacio de Sa University, Avenida das Americas, 700, bloco 8, loja 218, Barra da Tijuca, Rio de Janeiro, RJ Zip code: 22640-100, Brazil. FAU - de Oliveira, Romulo Varella AU - de Oliveira RV AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. FAU - Brandao, Carlos Otavio AU - Brandao CO AD - Department of Neurology, Neurolife Laboratory, Praia do Flamengo, 66, Bloco B, sala 620, Flamengo, Rio de Janeiro, RJ Zip Code: 22210-903, Brazil. FAU - da Cruz, Luiz Celso Hygino Jr AU - da Cruz LCH Jr AD - Department of Radiology, Clinica de Diagnostico por Imagem (CDPI), Avenida das Americas, 4666, 302A, 303, 307, 325, 326, Barra da Tijuca, Rio de Janeiro, RJ Zip Code: 2640-102, Brazil. LA - eng PT - Journal Article DEP - 20210907 PL - United States TA - Clin Imaging JT - Clinical imaging JID - 8911831 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) RN - B5S3K2V0G8 (ChAdOx1 nCoV-19) SB - IM CIN - Clin Imaging. 2022 Feb;82:13-14. doi: 10.1016/j.clinimag.2021.10.017. PMID: 34768220 MH - *COVID-19 MH - COVID-19 Vaccines MH - ChAdOx1 nCoV-19 MH - Humans MH - Neuroimaging MH - SARS-CoV-2 MH - *Vaccines/adverse effects PMC - PMC8421080 OTO - NOTNLM OT - COVID-19 OT - Facial palsy OT - Myelitis OT - Stroke OT - Vaccines COIS- None. EDAT- 2021/09/11 06:00 MHDA- 2021/11/16 06:00 PMCR- 2021/09/07 CRDT- 2021/09/10 20:30 PHST- 2021/06/01 00:00 [received] PHST- 2021/08/22 00:00 [revised] PHST- 2021/08/23 00:00 [accepted] PHST- 2021/09/11 06:00 [pubmed] PHST- 2021/11/16 06:00 [medline] PHST- 2021/09/10 20:30 [entrez] PHST- 2021/09/07 00:00 [pmc-release] AID - S0899-7071(21)00355-7 [pii] AID - 10.1016/j.clinimag.2021.08.021 [doi] PST - ppublish SO - Clin Imaging. 2021 Dec;80:348-352. doi: 10.1016/j.clinimag.2021.08.021. Epub 2021 Sep 7. PMID- 34487856 OWN - NLM STAT- MEDLINE DCOM- 20211012 LR - 20240923 IS - 1873-2747 (Electronic) IS - 0361-9230 (Print) IS - 0361-9230 (Linking) VI - 176 DP - 2021 Nov TI - Mental Health Issues During and After COVID-19 Vaccine Era. PG - 161-173 LID - S0361-9230(21)00260-4 [pii] LID - 10.1016/j.brainresbull.2021.08.012 [doi] AB - The COVID-19 pandemic has persisted for more than a year, and post-COVID-19 sequelae of neurological complications, including direct and indirect effects on the central nervous system (CNS), have been recognized. There is a plethora of evidence for neurological, cognitive, and emotional deficits in COVID-19 patients. Acute neurological symptoms like neuroinflammation, cognitive impairment, loss of smell, and brain stroke are common direct effects among SARS-CoV-2 infected individuals. Work-associated stress, lockdowns, social distancing, and quarantine in response to contain SARS-CoV-2 have also affected the mental health of large populations, regardless of age. Public health emergencies have affected individuals and communities, resulting in emotional reactions and unhealthy behaviors. Although vaccines have been widely distributed and administered among large populations, vaccine hesitancy still exists and may be due to apprehension about vaccine efficacy, preliminary trials, and associated side effects. This review highlights the impact of COVID-19 on the CNS by outlining direct and indirect effects and factors contributing to the decline in people's mental health throughout the COVID-19 pandemic both during and after vaccine administration. Furthermore, we also discuss reasons for vaccine hesitancy and why some groups of people are deprived of vaccines. Finally, we touched upon the social determinants of mental health and their impact on disadvantaged populations during times of crisis which may help policymakers set up some action plans to mitigate the COVID-19 mental health turmoil during this ongoing pandemic. CI - Copyright (c) 2021 Elsevier Inc. All rights reserved. FAU - Pandey, Kabita AU - Pandey K AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Thurman, Michellie AU - Thurman M AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Johnson, Samuel D AU - Johnson SD AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Acharya, Arpan AU - Acharya A AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Johnston, Morgan AU - Johnston M AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Klug, Elizabeth A AU - Klug EA AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Olwenyi, Omalla A AU - Olwenyi OA AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Rajaiah, Rajesh AU - Rajaiah R AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA. FAU - Byrareddy, Siddappa N AU - Byrareddy SN AD - Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu. LA - eng GR - P30 MH062261/MH/NIMH NIH HHS/United States GR - R01 AI129745/AI/NIAID NIH HHS/United States GR - R01 DA052845/DA/NIDA NIH HHS/United States GR - T32 NS105594/NS/NINDS NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Review DEP - 20210903 PL - United States TA - Brain Res Bull JT - Brain research bulletin JID - 7605818 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) SB - IM MH - COVID-19/*psychology MH - COVID-19 Vaccines/administration & dosage MH - Communicable Disease Control MH - Humans MH - Longitudinal Studies MH - Mental Health/trends MH - Pandemics/prevention & control MH - Public Health MH - SARS-CoV-2/pathogenicity MH - Vaccination/*psychology/trends MH - Vaccination Refusal/*psychology/trends MH - Vaccines PMC - PMC8414813 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - mental health OT - social determinants OT - vaccine EDAT- 2021/09/07 06:00 MHDA- 2021/10/13 06:00 PMCR- 2021/09/03 CRDT- 2021/09/06 20:12 PHST- 2021/05/05 00:00 [received] PHST- 2021/08/01 00:00 [revised] PHST- 2021/08/27 00:00 [accepted] PHST- 2021/09/07 06:00 [pubmed] PHST- 2021/10/13 06:00 [medline] PHST- 2021/09/06 20:12 [entrez] PHST- 2021/09/03 00:00 [pmc-release] AID - S0361-9230(21)00260-4 [pii] AID - 10.1016/j.brainresbull.2021.08.012 [doi] PST - ppublish SO - Brain Res Bull. 2021 Nov;176:161-173. doi: 10.1016/j.brainresbull.2021.08.012. Epub 2021 Sep 3. PMID- 34480607 OWN - NLM STAT- MEDLINE DCOM- 20220222 LR - 20220716 IS - 1432-1459 (Electronic) IS - 0340-5354 (Print) IS - 0340-5354 (Linking) VI - 269 IP - 3 DP - 2022 Mar TI - COVID-19 mRNA vaccination leading to CNS inflammation: a case series. PG - 1093-1106 LID - 10.1007/s00415-021-10780-7 [doi] AB - The availability of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), provides hope towards mitigation of the coronavirus disease 2019 (COVID-19) pandemic. Vaccine safety and efficacy has not been established in individuals with chronic autoimmune diseases such as multiple sclerosis (MS). Anecdotal reports suggest that the vaccines may be associated with brain, spinal cord, peripheral nervous system, and cardiac inflammation. Based on the high morbidity and unpredictable course of COVID-19, and the need to achieve herd immunity, vaccination has been recommended for patients with MS. We report clinical and MRI features of seven individuals who received the Moderna (n = 3) or Pfizer (n = 4) SARS-CoV-2 mRNA vaccines. Within one to 21 days of either the first (n = 2) or second (n = 5) vaccine dose, these patients developed neurologic symptoms and MRI findings consistent with active CNS demyelination of the optic nerve, brain, and/or spinal cord. Symptoms included visual loss, dysmetria, gait instability, paresthesias, sphincter disturbance, and limb weakness. Age ranged from 24 to 64 (mean 39.1) years; five were woman (71.4%). The final diagnosis was exacerbation of known stable MS (n = 4, two were receiving disease-modifying therapy at the time of vaccination), new onset MS (n = 2), or new onset neuromyelitis optica (n = 1). All responded to corticosteroid (n = 7) or plasma exchange (n = 1) therapy, with five returning to baseline and two approaching baseline. Large prospective studies are required to further investigate any possible relationship between COVID-19 vaccines and acute CNS demyelination. CI - (c) 2021. Springer-Verlag GmbH Germany, part of Springer Nature. FAU - Khayat-Khoei, Mahsa AU - Khayat-Khoei M AUID- ORCID: 0000-0002-3003-002X AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. FAU - Bhattacharyya, Shamik AU - Bhattacharyya S AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. FAU - Katz, Joshua AU - Katz J AD - The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA, USA. FAU - Harrison, Daniel AU - Harrison D AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. FAU - Tauhid, Shahamat AU - Tauhid S AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. FAU - Bruso, Penny AU - Bruso P AD - The Multiple Sclerosis Center of Northeastern New York, Latham, NY, USA. FAU - Houtchens, Maria K AU - Houtchens MK AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. FAU - Edwards, Keith R AU - Edwards KR AD - The Multiple Sclerosis Center of Northeastern New York, Latham, NY, USA. FAU - Bakshi, Rohit AU - Bakshi R AUID- ORCID: 0000-0001-8601-5534 AD - Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Hale Building for Transformative Medicine, 60 Fenwood Rd, Mailbox 9002L, Boston, MA, 02115, USA. rbakshi@post.harvard.edu. LA - eng PT - Journal Article DEP - 20210904 PL - Germany TA - J Neurol JT - Journal of neurology JID - 0423161 RN - 0 (COVID-19 Vaccines) RN - 0 (RNA, Messenger) SB - IM MH - Adult MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Inflammation MH - Middle Aged MH - RNA, Messenger MH - SARS-CoV-2 MH - Vaccination MH - Young Adult PMC - PMC8417681 OTO - NOTNLM OT - COVID-19 OT - Demyelination OT - Inflammation OT - Multiple sclerosis OT - Neuromyelitis optica OT - SAR-CoV-2 OT - Vaccination COIS- Dr. Bhattacharyya has received consulting fees from Alexion and research support from Alexion and UCB. Dr. Katz has served on speaker's bureaus and advisory boards for Biogen, EMD-Serono, Genentech, Novartis, and Sanofi-Genzyme. Dr. Houtchens has received consulting fees from Biogen, EMD Serono Novartis, and Genentech, and research support from Biogen, Genentech, and Sanofi-Genzyme. Dr. Edwards has received fees for speaking and consulting from Biogen and EMD Serono and research grant support from Biogen, EMD Serono, Genentech, Novartis, and Sanofi-Genzyme. Dr. Bakshi has received consulting fees from EMD Serono and research support from BMS/Celgene and EMD Serono. The other authors have nothing to disclose. EDAT- 2021/09/05 06:00 MHDA- 2022/02/23 06:00 PMCR- 2021/09/04 CRDT- 2021/09/04 12:08 PHST- 2021/07/28 00:00 [received] PHST- 2021/08/26 00:00 [accepted] PHST- 2021/08/26 00:00 [revised] PHST- 2021/09/05 06:00 [pubmed] PHST- 2022/02/23 06:00 [medline] PHST- 2021/09/04 12:08 [entrez] PHST- 2021/09/04 00:00 [pmc-release] AID - 10.1007/s00415-021-10780-7 [pii] AID - 10780 [pii] AID - 10.1007/s00415-021-10780-7 [doi] PST - ppublish SO - J Neurol. 2022 Mar;269(3):1093-1106. doi: 10.1007/s00415-021-10780-7. Epub 2021 Sep 4. PMID- 34479746 OWN - NLM STAT- MEDLINE DCOM- 20220210 LR - 20221221 IS - 1873-5134 (Electronic) IS - 0738-3991 (Print) IS - 0738-3991 (Linking) VI - 105 IP - 2 DP - 2022 Feb TI - Vaccine for yourself, your community, or your country? Examining audiences' response to distance framing of COVID-19 vaccine messages. PG - 284-289 LID - S0738-3991(21)00563-2 [pii] LID - 10.1016/j.pec.2021.08.019 [doi] AB - OBJECTIVE: This study explored the effects of COVID-19 vaccine promotion messages highlighting the benefit at individual, community, and country levels. Based on the cultural theory of risks, we investigated how individuals' valuation of individualism vs. communitarianism and hierarchical vs. egalitarian social structure affect their responses to vaccine messages. METHODS: An online experiment (N = 702) with four video message conditions (individual-centered, community-centered, country-centered, and no message) was conducted. Participants were asked about their cultural cognition worldview, then were randomly assigned to view one message. Participants also reported their willingness to receive COVID-19 vaccines and support for vaccine mandate. RESULTS: Respondents were more likely to get vaccinated and support vaccine mandates after viewing an individual-centered message, less with a community-centered message. Individuals who value individualism were more likely to respond positively to individual-centered messages, but those who believe more in communitarianism value were less likely. CONCLUSION: Results showed that individuals are motivated selectively to respond to certain claims that cohere with their worldview and therefore respond differently to vaccine benefit frames. PRACTICE IMPLICATIONS: The results point to the importance of understanding audiences' worldviews. By identifying this process through hierarchical and individualistic values, properly designed health promotion messages can maximize the desired outcomes. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Yuan, Shupei AU - Yuan S AD - Department of Communication Northern Illinois University DeKalb, IL 60008, USA. Electronic address: syuan@niu.edu. FAU - Chu, Haoran AU - Chu H AD - College of Journalism and Communications University of Florida, Gainesville, FL 32611, USA. Electronic address: chu.h@ufl.edu. LA - eng PT - Journal Article PT - Randomized Controlled Trial DEP - 20210825 PL - Ireland TA - Patient Educ Couns JT - Patient education and counseling JID - 8406280 RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines) MH - *COVID-19 MH - COVID-19 Vaccines MH - Health Promotion MH - Humans MH - SARS-CoV-2 MH - *Vaccines PMC - PMC8384529 OTO - NOTNLM OT - Benefit frames OT - Cultural cognition OT - Health communication OT - Vaccine message COIS- Declaration of Competing Interest The authors have no conflict of interest in the authoring of this manuscript. EDAT- 2021/09/05 06:00 MHDA- 2022/02/11 06:00 PMCR- 2021/08/25 CRDT- 2021/09/04 05:36 PHST- 2021/06/21 00:00 [received] PHST- 2021/08/09 00:00 [revised] PHST- 2021/08/20 00:00 [accepted] PHST- 2021/09/05 06:00 [pubmed] PHST- 2022/02/11 06:00 [medline] PHST- 2021/09/04 05:36 [entrez] PHST- 2021/08/25 00:00 [pmc-release] AID - S0738-3991(21)00563-2 [pii] AID - 10.1016/j.pec.2021.08.019 [doi] PST - ppublish SO - Patient Educ Couns. 2022 Feb;105(2):284-289. doi: 10.1016/j.pec.2021.08.019. Epub 2021 Aug 25. PMID- 34453762 OWN - NLM STAT- MEDLINE DCOM- 20211206 LR - 20220731 IS - 1096-8652 (Electronic) IS - 0361-8609 (Print) IS - 0361-8609 (Linking) VI - 96 IP - 12 DP - 2021 Dec 1 TI - Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases. PG - 1580-1586 LID - 10.1002/ajh.26336 [doi] AB - The recent association of cerebral venous thrombosis (CVT) with COVID-19 vaccinations prompted the current retrospective review of 74 cases of CVT (median age = 44 years, range 15-85; 61% females) associated with myeloproliferative neoplasms (MPNs), seen at the Mayo Clinic, Catholic University of Rome, and University of Florence, between 1991 and 2021. Disease-specific frequencies were 1.3% (39/2893), 1.2% (21/1811) and 0.2% (3/1888) for essential thrombocythemia, polycythemia vera and primary myelofibrosis, respectively. Cerebral venous thrombosis occurred either prior to (n = 20, 27%), at (n = 32, 44%) or after (n = 22) MPN diagnosis. A total of 72% of patients presented with headaches. Transverse (51%), sagittal (43%) and sigmoid sinuses (35%) were involved with central nervous system hemorrhage noted in 10 (14%) patients. In all, 91% of tested patients harbored JAK2V617F. An underlying thrombophilic condition was identified in 19 (31%) cases and history of thrombosis in 10 (14%). Treatment for CVT included systemic anticoagulation alone (n = 27) or in conjunction with aspirin (n = 24), cytoreductive therapy (n = 14), or both (n = 9). At a median follow-up of 5.1 years (range 0.1-28.6), recurrent CVT was documented in three (4%) patients while recurrent arterial and venous thromboses and major hemorrhage were recorded in 11%, 9% and 14%, respectively. Follow-up neurological assessment revealed headaches (n = 9), vision loss (n = 1) and cognitive impairment (n = 1). The current study lends clarity to MPN-associated CVT and highlights its close association with JAK2V617F, younger age and female gender. Clinical features that distinguish COVID vaccine-related CVT from MPN-associated CVT include, in the latter, lower likelihood of concurrent venous thromboses and intracerebral hemorrhage; as a result, MPN-associated CVT was not fatal. CI - (c) 2021 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. FAU - Gangat, Naseema AU - Gangat N AUID- ORCID: 0000-0002-9104-6172 AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Guglielmelli, Paola AU - Guglielmelli P AD - Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. FAU - Betti, Silvia AU - Betti S AD - Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. FAU - Farrukh, Faiqa AU - Farrukh F AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. FAU - Carobbio, Alessandra AU - Carobbio A AD - Foundation of Clinical Research-FROM Ospedale Papa Giovanni XXIII, Bergamo, Italy. FAU - Barbui, Tiziano AU - Barbui T AUID- ORCID: 0000-0003-2747-6327 AD - Foundation of Clinical Research-FROM Ospedale Papa Giovanni XXIII, Bergamo, Italy. FAU - Vannucchi, Alessandro M AU - Vannucchi AM AD - Department of Experimental and Clinical Medicine, CRIMM, Center Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, University of Florence, Florence, Italy. FAU - De Stefano, Valerio AU - De Stefano V AUID- ORCID: 0000-0002-5178-5827 AD - Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. FAU - Tefferi, Ayalew AU - Tefferi A AUID- ORCID: 0000-0003-4605-3821 AD - Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. LA - eng PT - Journal Article PT - Multicenter Study DEP - 20210910 PL - United States TA - Am J Hematol JT - American journal of hematology JID - 7610369 RN - 0 (COVID-19 Vaccines) RN - EC 2.7.10.2 (JAK2 protein, human) RN - EC 2.7.10.2 (Janus Kinase 2) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - COVID-19/*prevention & control MH - COVID-19 Vaccines/*adverse effects MH - Female MH - Humans MH - Intracranial Thrombosis/*etiology/genetics MH - Janus Kinase 2/genetics MH - Male MH - Middle Aged MH - Myeloproliferative Disorders/*complications/genetics MH - Point Mutation MH - Polycythemia Vera/complications/genetics MH - Primary Myelofibrosis/complications/genetics MH - Retrospective Studies MH - Thrombocythemia, Essential/complications/genetics MH - Venous Thrombosis/*etiology/genetics MH - Young Adult PMC - PMC9293093 EDAT- 2021/08/29 06:00 MHDA- 2021/12/15 06:00 PMCR- 2022/07/18 CRDT- 2021/08/28 12:15 PHST- 2021/08/17 00:00 [received] PHST- 2021/08/24 00:00 [accepted] PHST- 2021/08/29 06:00 [pubmed] PHST- 2021/12/15 06:00 [medline] PHST- 2021/08/28 12:15 [entrez] PHST- 2022/07/18 00:00 [pmc-release] AID - AJH26336 [pii] AID - 10.1002/ajh.26336 [doi] PST - ppublish SO - Am J Hematol. 2021 Dec 1;96(12):1580-1586. doi: 10.1002/ajh.26336. Epub 2021 Sep 10. PMID- 34450033 OWN - NLM STAT- MEDLINE DCOM- 20210915 LR - 20211123 IS - 2211-1247 (Electronic) VI - 36 IP - 10 DP - 2021 Sep 7 TI - Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. PG - 109664 LID - S2211-1247(21)01108-6 [pii] LID - 10.1016/j.celrep.2021.109664 [doi] AB - SARS-CoV-2 infection causes respiratory insufficiency and neurological manifestations, including loss of smell and psychiatric disorders, and can be fatal. Most vaccines are based on the spike antigen alone, and although they have shown efficacy at preventing severe disease and death, they do not always confer sterilizing immunity. Here, we interrogate whether SARS-CoV-2 vaccines could be improved by incorporating nucleocapsid as an antigen. We show that, after 72 h of challenge, a spike-based vaccine confers acute protection in the lung, but not in the brain. However, combining a spike-based vaccine with a nucleocapsid-based vaccine confers acute protection in both the lung and brain. These findings suggest that nucleocapsid-specific immunity can improve the distal control of SARS-CoV-2, warranting the inclusion of nucleocapsid in next-generation COVID-19 vaccines. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Dangi, Tanushree AU - Dangi T AD - Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Class, Jacob AU - Class J AD - Department of Microbiology & Immunology, University of Illinois, Chicago College of Medicine, Chicago, IL 60612, USA. FAU - Palacio, Nicole AU - Palacio N AD - Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. FAU - Richner, Justin M AU - Richner JM AD - Department of Microbiology & Immunology, University of Illinois, Chicago College of Medicine, Chicago, IL 60612, USA. Electronic address: richner@uic.edu. FAU - Penaloza MacMaster, Pablo AU - Penaloza MacMaster P AD - Department of Microbiology and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. Electronic address: ppm@northwestern.edu. LA - eng GR - DP2 DA051912/DA/NIDA NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20210817 PL - United States TA - Cell Rep JT - Cell reports JID - 101573691 RN - 0 (COVID-19 Vaccines) RN - 0 (Coronavirus Nucleocapsid Proteins) RN - 0 (Phosphoproteins) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (nucleocapsid phosphoprotein, SARS-CoV-2) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Animals MH - Brain/drug effects/virology MH - COVID-19/prevention & control MH - COVID-19 Vaccines/administration & dosage/*immunology MH - Coronavirus Nucleocapsid Proteins/*immunology MH - Humans MH - Immunogenicity, Vaccine MH - Lung/drug effects/virology MH - Mice MH - Phosphoproteins/immunology MH - SARS-CoV-2/*immunology MH - Spike Glycoprotein, Coronavirus/*immunology MH - Viral Load/drug effects PMC - PMC8367759 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 vaccines OT - nucleocapsid antigen OT - spike antigen COIS- Declaration of interests P.P.M. reports being Task Force Advisor to the Illinois Department of Public Health (IDPH) on SARS-CoV-2 vaccines. P.P.M. is also a member/advisor of the COVID-19 Vaccine Regulatory Science Consortium (CoVAXCEN) at Northwestern University's Institute for Global Health. EDAT- 2021/08/28 06:00 MHDA- 2021/09/16 06:00 PMCR- 2021/08/17 CRDT- 2021/08/27 20:10 PHST- 2021/04/30 00:00 [received] PHST- 2021/07/13 00:00 [revised] PHST- 2021/08/13 00:00 [accepted] PHST- 2021/08/28 06:00 [pubmed] PHST- 2021/09/16 06:00 [medline] PHST- 2021/08/27 20:10 [entrez] PHST- 2021/08/17 00:00 [pmc-release] AID - S2211-1247(21)01108-6 [pii] AID - 109664 [pii] AID - 10.1016/j.celrep.2021.109664 [doi] PST - ppublish SO - Cell Rep. 2021 Sep 7;36(10):109664. doi: 10.1016/j.celrep.2021.109664. Epub 2021 Aug 17. PMID- 34405142 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220302 IS - 2632-1297 (Electronic) IS - 2632-1297 (Linking) VI - 3 IP - 3 DP - 2021 TI - Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study. PG - fcab169 LID - 10.1093/braincomms/fcab169 [doi] LID - fcab169 AB - The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated. Detailed information about the clinical characteristics of this form of headache has not yet been described. The aim of the study is to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA COVID-19 vaccine for the first time. In a multicentre observational cohort study, data on the clinical features and corresponding variables were recorded using a standardized online questionnaire. The questionnaire was circulated to 12 000 residential care homes of the elderly as well as tertiary university hospitals in Germany and the United Arab Emirates. The primary outcomes of this study are the clinical features of headache after vaccination. Comorbidities, treatment with medication and sociodemographic variables are also analysed. A total of 2349 participants reported headaches after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Headaches occur an average of 18.0 +/- 27.0 h after vaccination and last an average duration of 14.2 +/- 21.3 h. Only 9.7% of those affected also report headaches resulting from previous vaccinations. In 66.6% of the participants, headache occurs as a single episode. A bilateral location is indicated by 73.1% of the participants. This is most often found on the forehead (38.0%) and temples (32.1%). A pressing pain character is indicated by 49.2% and 40.7% report a dull pain character. The pain intensity is most often moderate (46.2%), severe (32.1%) or very severe (8.2%). The most common accompanying symptoms are fatigue (38.8%), exhaustion (25.7%) and muscle pain (23.4%). Headaches after COVID-19 vaccination show an extensive complex of symptoms. The constellation of accompanying symptoms together with the temporal and spatial headache characteristics delimit a distinctive headache phenotype. CI - (c) The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. FAU - Gobel, Carl H AU - Gobel CH AUID- ORCID: 0000-0002-4283-6936 AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Heinze, Axel AU - Heinze A AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Karstedt, Sarah AU - Karstedt S AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Morscheck, Mascha AU - Morscheck M AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Tashiro, Lilian AU - Tashiro L AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Cirkel, Anna AU - Cirkel A AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. AD - Kiel Migraine and Headache Centre, Kiel, Germany. FAU - Hamid, Qutayba AU - Hamid Q AD - College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Halwani, Rabih AU - Halwani R AD - College of Medicine, University of Sharjah, Sharjah, United Arab Emirates. FAU - Temsah, Mohamad-Hani AU - Temsah MH AD - College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia. FAU - Ziemann, Malte AU - Ziemann M AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Gorg, Siegfried AU - Gorg S AD - Institute of Transfusion Medicine, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Munte, Thomas AU - Munte T AD - Department of Neurology, University Hospital Schleswig-Holstein, Lubeck, Germany. FAU - Gobel, Hartmut AU - Gobel H AD - Kiel Migraine and Headache Centre, Kiel, Germany. LA - eng PT - Journal Article DEP - 20210723 PL - England TA - Brain Commun JT - Brain communications JID - 101755125 EIN - Brain Commun. 2021 Sep 03;3(3):fcab195. doi: 10.1093/braincomms/fcab195. PMID: 34514399 PMC - PMC8344581 OTO - NOTNLM OT - COVID-19 OT - International Classification of Headache Disorders OT - headache OT - mRNA vaccine OT - side-effects EDAT- 2021/08/19 06:00 MHDA- 2021/08/19 06:01 PMCR- 2021/07/23 CRDT- 2021/08/18 06:33 PHST- 2021/05/30 00:00 [received] PHST- 2021/05/30 00:00 [revised] PHST- 2021/06/02 00:00 [accepted] PHST- 2021/08/18 06:33 [entrez] PHST- 2021/08/19 06:00 [pubmed] PHST- 2021/08/19 06:01 [medline] PHST- 2021/07/23 00:00 [pmc-release] AID - fcab169 [pii] AID - 10.1093/braincomms/fcab169 [doi] PST - epublish SO - Brain Commun. 2021 Jul 23;3(3):fcab169. doi: 10.1093/braincomms/fcab169. eCollection 2021. PMID- 34375861 OWN - NLM STAT- MEDLINE DCOM- 20211019 LR - 20221221 IS - 2211-0356 (Electronic) IS - 2211-0348 (Print) IS - 2211-0348 (Linking) VI - 55 DP - 2021 Oct TI - Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. PG - 103189 LID - S2211-0348(21)00456-9 [pii] LID - 10.1016/j.msard.2021.103189 [doi] AB - BACKGROUND: The COVID-19 vaccines are currently recommended for people with rare neuroimmunological diseases such as neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease (MOGAD), and transverse myelitis. However, the safety profile of the vaccines in this population is uncertain. OBJECTIVE: To report real-world safety data of the COVID-19 vaccines in persons with rare neuroimmunological diseases. METHODS: An anonymous survey was distributed to patients recruited on social media. Participants answered general demographic and disease-related questions, and specific questions about their experiences with the COVID-19 vaccines. RESULTS: 438 participants completed the questionnaire. The median age was 51 (range 18-82 years); 366 were female (83.6%); 102 (23.3%) had associated comorbidities, and 354 (80.1%) were treated with immunotherapies. 242 participants (55.3%) reported a diagnosis of NMOSD; 99 (22.6%) had MOGAD; 79 (18%) had transverse myelitis. 239 participants (66.2%) were younger than 55 years of age. 138 participants (31.5%) reported earlyadverse events. Of these, 93 (67.4%) were < 55 years old, and 45 (32.6%) were > 55 years old (p=0.0086). The most common adverse events were local reactions, including pain, redness, and swelling at the injection site, reported by 155 participants (35.4%). 73 participants (16.7%) reported new or worsening neurological symptoms following the vaccination. Most symptoms occurred within the first week after vaccination and resolved within three days. CONCLUSIONS: This survey indicates an overall favorable safety and tolerability profile of the COVID-19 vaccines among persons with rare neuroimmunological diseases. Longer-term studies are warranted to confirm these data. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Lotan, Itay AU - Lotan I AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. Electronic address: ilotan@mgh.harvard.edu. FAU - Romanow, Gabriela AU - Romanow G AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. FAU - Levy, Michael AU - Levy M AD - Division of Neuroimmunology & Neuroinfectious Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, USA. LA - eng PT - Journal Article DEP - 20210802 PL - Netherlands TA - Mult Scler Relat Disord JT - Multiple sclerosis and related disorders JID - 101580247 RN - 0 (Aquaporin 4) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Aged, 80 and over MH - Aquaporin 4 MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Middle Aged MH - *Neuromyelitis Optica MH - Patient Reported Outcome Measures MH - SARS-CoV-2 MH - Young Adult PMC - PMC8327627 OTO - NOTNLM OT - COVID-19 OT - MOGAD OT - NMOSD OT - Safety OT - Tolerability OT - Vaccine COIS- This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. EDAT- 2021/08/11 06:00 MHDA- 2021/10/21 06:00 PMCR- 2021/08/02 CRDT- 2021/08/10 20:19 PHST- 2021/06/23 00:00 [received] PHST- 2021/07/08 00:00 [revised] PHST- 2021/08/01 00:00 [accepted] PHST- 2021/08/11 06:00 [pubmed] PHST- 2021/10/21 06:00 [medline] PHST- 2021/08/10 20:19 [entrez] PHST- 2021/08/02 00:00 [pmc-release] AID - S2211-0348(21)00456-9 [pii] AID - 103189 [pii] AID - 10.1016/j.msard.2021.103189 [doi] PST - ppublish SO - Mult Scler Relat Disord. 2021 Oct;55:103189. doi: 10.1016/j.msard.2021.103189. Epub 2021 Aug 2. PMID- 34326180 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231227 IS - 1526-632X (Electronic) IS - 0028-3878 (Print) IS - 0028-3878 (Linking) VI - 97 IP - 15 DP - 2021 Oct 12 TI - COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology. PG - 720-728 LID - 10.1212/WNL.0000000000012578 [doi] AB - The COVID-19 pandemic caused by the SARS-CoV-2 virus has left many unanswered questions for patients with neurological disorders and the providers caring for them. Elderly and immunocompromised patients are at increased risk for severe symptoms due to COVID-19, and the virus may increase symptoms of underlying neurological illness, particularly for those with significant bulbar and respiratory weakness or other neurologic disability. Emerging SARS-CoV-2 vaccines offer substantial protection from symptomatic infection, but both patients and providers may have concerns regarding theoretical risks of vaccination, including vaccine safety and efficacy in the context of immunotherapy and the potential for precipitating or exacerbating neurological symptoms. In this statement on behalf of the Quality Committee of the AAN we review the current literature, focusing on COVID-19 infection in adults with neurological disease, in order to elucidate risks and benefits of vaccination in these individuals. Based on existing evidence, neurologists should recommend COVID-19 vaccination to their patients. For those patients being treated with immunotherapies, attention should be paid to timing of vaccination with respect to treatment and the potential for an attenuated immune response. CI - Copyright (c) 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. FAU - Marsh, Elisabeth B AU - Marsh EB AUID- ORCID: 0000-0002-2385-5074 AD - The Johns Hopkins School of Medicine, Baltimore, MD ebmarsh@jhmi.edu. FAU - Kornberg, Michael AU - Kornberg M AUID- ORCID: 0000-0003-2588-7325 AD - The Johns Hopkins School of Medicine, Baltimore, MD. FAU - Kessler, Kevin AU - Kessler K AD - The University of Virginia Medical Center, Charlottesville, VA. FAU - Haq, Ihtsham AU - Haq I AUID- ORCID: 0000-0002-8001-8440 AD - The University of Miami Miller School of Medicine, Miami, FL. FAU - Patel, Anup D AU - Patel AD AUID- ORCID: 0000-0001-9313-1541 AD - Nationwide Children's Hospital, Columbus, OH. FAU - Nath, Avindra AU - Nath A AUID- ORCID: 0000-0003-0927-5855 AD - The National Institutes of Health, Bethesda, MD. FAU - Schierman, Becky AU - Schierman B AD - The American Academy of Neurology, Minneapolis, MN. FAU - Jones, Lyell K Jr AU - Jones LK Jr AUID- ORCID: 0000-0002-5851-8705 AD - The Mayo Clinic, Rochester, MN. CN - Quality Committee of the American Academy of Neurology* LA - eng PT - Journal Article DEP - 20211012 PL - United States TA - Neurology JT - Neurology JID - 0401060 SB - IM PMC - PMC8575134 OTO - NOTNLM OT - COVID-19 vaccine OT - immunosuppression OT - infection OT - neurological disease EDAT- 2021/07/31 06:00 MHDA- 2021/07/31 06:01 PMCR- 2021/10/12 CRDT- 2021/07/30 05:50 PHST- 2021/07/29 00:00 [aheadofprint] PHST- 2021/05/05 00:00 [received] PHST- 2021/07/19 00:00 [accepted] PHST- 2021/07/31 06:01 [medline] PHST- 2021/07/30 05:50 [entrez] PHST- 2021/07/31 06:00 [pubmed] PHST- 2021/10/12 00:00 [pmc-release] AID - WNL.0000000000012578 [pii] AID - NEUROLOGY2021174018 [pii] AID - 10.1212/WNL.0000000000012578 [doi] PST - epublish SO - Neurology. 2021 Oct 12;97(15):720-728. doi: 10.1212/WNL.0000000000012578. PMID- 34324407 OWN - NLM STAT- MEDLINE DCOM- 20220315 LR - 20241207 IS - 2164-554X (Electronic) IS - 2164-5515 (Print) IS - 2164-5515 (Linking) VI - 18 IP - 1 DP - 2022 Dec 31 TI - COVID-19 vaccination in Chinese children: a cross-sectional study on the cognition, psychological anxiety state and the willingness toward vaccination. PG - 1-7 LID - 10.1080/21645515.2021.1949950 [doi] AB - It is important to understand the cognition, willingness, and psychological anxiety state of Chinese guardians toward COVID-19 vaccination for their children to predict the future vaccination rate and to help the design of policies that aim to expand the population with immunity against COVID-19. This study collected data with a professional vaccination registration platform for children named "Xiao Dou Miao" in February 2021. The psychological anxiety state of the guardians was self-evaluated using the psychological anxiety scale. Factors that might influence the willingness of guardians to vaccinate their children were identified using logistic regression analysis. This study included 12,872 questionnaires with 70.9% of guardians showing willingness to vaccinate their children. Guardians who were male, aged 40-49 and from rural area were more willing to vaccinate their children. Fathers, guardians with higher education and income, whose children have a history of adverse vaccine reactions and allergies were less willing to vaccinate their children (p < .001). More than 80% of the guardians expressed a high level of trust for vaccine information released by official and health-related agencies. Guardians who were not vaccinated were more anxious than those who were vaccinated (chi2 = 27.99, p < .001). To protect children from COVID-19, vaccine coverage in children should be expanded rapidly and public awareness on vaccine safety and effectiveness should be improved. FAU - Yang, Jin AU - Yang J AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Ting AU - Zhang T AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Qi, Weiran AU - Qi W AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Zhang, Xingxing AU - Zhang X AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Jia, Mengmeng AU - Jia M AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Leng, Zhiwei AU - Leng Z AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Qing AU - Wang Q AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Yuan AU - Yang Y AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. FAU - Yang, Weizhong AU - Yang W AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Ma, Libing AU - Ma L AUID- ORCID: 0000-0002-7234-2312 AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. AD - Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Guilin Medical University, Guilin, China. FAU - Feng, Luzhao AU - Feng L AD - School of Population Medicine and Public Health, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. AD - Institute of Pharmaceutical and Medical Devices Supervision, National Medical Products Administration-Chinese Academy of Medical Sciences, Beijing, China. FAU - Wang, Chen AU - Wang C AD - Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210729 PL - United States TA - Hum Vaccin Immunother JT - Human vaccines & immunotherapeutics JID - 101572652 RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Anxiety MH - *COVID-19/prevention & control MH - *COVID-19 Vaccines MH - Child MH - China/epidemiology MH - Cognition MH - Cross-Sectional Studies MH - Humans MH - Male MH - Middle Aged MH - SARS-CoV-2 MH - Vaccination/psychology PMC - PMC8920157 OTO - NOTNLM OT - COVID-19 vaccine OT - Guardians OT - children OT - cognition OT - psychological anxiety OT - willingness EDAT- 2021/07/30 06:00 MHDA- 2022/03/16 06:00 PMCR- 2021/07/29 CRDT- 2021/07/29 17:19 PHST- 2021/07/30 06:00 [pubmed] PHST- 2022/03/16 06:00 [medline] PHST- 2021/07/29 17:19 [entrez] PHST- 2021/07/29 00:00 [pmc-release] AID - 1949950 [pii] AID - 10.1080/21645515.2021.1949950 [doi] PST - ppublish SO - Hum Vaccin Immunother. 2022 Dec 31;18(1):1-7. doi: 10.1080/21645515.2021.1949950. Epub 2021 Jul 29. PMID- 34288285 OWN - NLM STAT- MEDLINE DCOM- 20211026 LR - 20260127 IS - 1468-1331 (Electronic) IS - 1351-5101 (Print) IS - 1351-5101 (Linking) VI - 28 IP - 11 DP - 2021 Nov TI - Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. PG - 3742-3748 LID - 10.1111/ene.15028 [doi] AB - BACKGROUND AND PURPOSE: Although the COVID-19 vaccines are currently recommended for people with multiple sclerosis (MS), the fact that they were not specifically tested in people with MS raises uncertainty regarding their safety in this population. The purpose of this study was to report real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. METHODS: An anonymous survey was distributed to 425 MS patients. Participants were asked general demographic and disease-related questions and specific questions regarding the safety profile of the COVID-19 vaccine. RESULTS: Of the 425 MS patients, 262 completed the questionnaire. The median (range) participant age was 42 (22-79) years, 199 participants were women (75.9%), and 66 participants (25.2%) had associated comorbidities. A total of 198 participants (75.6%) were treated with disease-modifying therapies. In all, 239 participants (91.2% of the responders) had received the BNT162b2 COVID-19 vaccine. Of these, 182 (76.1%) were aged <55 years, and 57 (23.9%) were aged >55 years. Adverse events were reported by 136 participants (56.9%; 52.5% of those aged <55 years and 40.3% of those aged >55 years; p = 0.1517) and 36 participants (15.1%) reported new or worsening neurological symptoms following the vaccination, the most frequent being sensory disturbances (21 participants, 58.3%). Most symptoms occurred within the first 24 h after vaccination and resolved within 3 days. A total of 28 participants (77.8%) did not require any medication to treat their symptoms. CONCLUSIONS: This survey indicates an overall favorable safety profile of the BNT162b2 vaccine in people with MS. These data should be confirmed in further prospective, large-scale studies. CI - (c) 2021 European Academy of Neurology. FAU - Lotan, Itay AU - Lotan I AUID- ORCID: 0000-0002-4015-9783 AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Wilf-Yarkoni, Adi AU - Wilf-Yarkoni A AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Friedman, Yitzhak AU - Friedman Y AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Stiebel-Kalish, Hadas AU - Stiebel-Kalish H AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. AD - Department of Ophthalmology and Neuro-Ophthalmology Unit, Rabin Medical Center, Petah Tikva, Israel. FAU - Steiner, Israel AU - Steiner I AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. FAU - Hellmann, Mark A AU - Hellmann MA AD - Department of Neurology, Rabin Medical Center, Petah Tikva, Israel. AD - Neuroimmunology Unit, Rabin Medical Center, Petah Tikva, Israel. AD - Sackler Faculty of Medicine, Tel-Aviv University, Israel. LA - eng PT - Journal Article DEP - 20210802 PL - England TA - Eur J Neurol JT - European journal of neurology JID - 9506311 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Adult MH - Aged MH - BNT162 Vaccine MH - *COVID-19 MH - COVID-19 Vaccines MH - Female MH - Humans MH - Israel MH - Middle Aged MH - *Multiple Sclerosis MH - SARS-CoV-2 PMC - PMC8444776 OTO - NOTNLM OT - COVID-19 OT - adverse events OT - multiple sclerosis OT - safety OT - vaccine COIS- The authors declare that there is no conflict of interest. The authors do not have any specific agreements with the vaccine manufacturer for data delivery or similar. EDAT- 2021/07/22 06:00 MHDA- 2021/10/27 06:00 PMCR- 2021/08/02 CRDT- 2021/07/21 13:35 PHST- 2021/06/19 00:00 [revised] PHST- 2021/05/11 00:00 [received] PHST- 2021/07/16 00:00 [accepted] PHST- 2021/07/22 06:00 [pubmed] PHST- 2021/10/27 06:00 [medline] PHST- 2021/07/21 13:35 [entrez] PHST- 2021/08/02 00:00 [pmc-release] AID - ENE15028 [pii] AID - 10.1111/ene.15028 [doi] PST - ppublish SO - Eur J Neurol. 2021 Nov;28(11):3742-3748. doi: 10.1111/ene.15028. Epub 2021 Aug 2. PMID- 34200720 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20210714 IS - 2076-393X (Print) IS - 2076-393X (Electronic) IS - 2076-393X (Linking) VI - 9 IP - 6 DP - 2021 Jun 10 TI - Specific Treatment Exists for SARS-CoV-2 ARDS. LID - 10.3390/vaccines9060635 [doi] LID - 635 AB - The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to be difficult to overcome. A pandemic of such a scale has not been seen since the 1918 influenza pandemic. Although the predominant clinical presentation is respiratory disease, neurological manifestations and sequelae are increasingly being recognized. We observed a case series of rapid recovery of ARDS within 24 h in the preliminary clinical features of COVID-19 ARDS-associated neurological disease. It was also noted that by 15 April, 2021, there was no SARS-CoV-2 ARDS on Sorok Island in South Korea, where lepers had been living together. We compared each of dapsone's effects on humans and considered those of SARS-CoV-2. Dapsone showed different effects in the brain. The Sorokdo National Hospital reported a relationship between dapsone and the neuroinflammasome of Alzheimer's disease (AD) in Sorok Island from January 2005 to June 2020. AD prevalence was low in the leprosy patient group who took dapsone regularly. The preliminary cross-sectional study of the trial group (22 subjects) and the control group (22 subjects) in the Hunt Regional Hospital reported the following results: The chi-square statistic is 5.1836. The p-value is 0.022801. The result is considered significant at p < 0.05. The results from the medical treatment from 21 December to 29 December 2020 were considered. The mortality rates at the ARDS onset stage were 0% with dapsone administered as a standard COVID-19 treatment and 40% without dapsone administered as a standard COVID-19 treatment, respectively. Based on the respiratory failure and sudden high death rate originating from the involvement of the brainstem, especially the pre-Botzinger complex, dapsone can be used to significantly reduce the incidence of the cases of acute respiratory distress syndrome and other illnesses caused by SARS-CoV-2. FAU - Kanwar, Badar AU - Kanwar B AD - Department of Pulmonary Critical Care Medicine, Hunt Regional Hospital, Greenville, TX 75401, USA. FAU - Lee, Chul Joong AU - Lee CJ AUID- ORCID: 0000-0001-5388-8945 AD - Zein Pain Clinic Seongbuk, Seoul 02830, Korea. FAU - Lee, Jong-Hoon AU - Lee JH AUID- ORCID: 0000-0003-1775-5656 AD - Science & Research Center, Seoul National University College of Medicine, Seoul 03080, Korea. LA - eng PT - Journal Article DEP - 20210610 PL - Switzerland TA - Vaccines (Basel) JT - Vaccines JID - 101629355 PMC - PMC8229893 OTO - NOTNLM OT - brainstem OT - inflammasome OT - oral DNA vaccine COIS- All authors declare no competing interests. EDAT- 2021/07/03 06:00 MHDA- 2021/07/03 06:01 PMCR- 2021/06/10 CRDT- 2021/07/02 01:08 PHST- 2021/05/17 00:00 [received] PHST- 2021/06/04 00:00 [revised] PHST- 2021/06/07 00:00 [accepted] PHST- 2021/07/02 01:08 [entrez] PHST- 2021/07/03 06:00 [pubmed] PHST- 2021/07/03 06:01 [medline] PHST- 2021/06/10 00:00 [pmc-release] AID - vaccines9060635 [pii] AID - vaccines-09-00635 [pii] AID - 10.3390/vaccines9060635 [doi] PST - epublish SO - Vaccines (Basel). 2021 Jun 10;9(6):635. doi: 10.3390/vaccines9060635. PMID- 34022372 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231107 IS - 1090-2139 (Electronic) IS - 0889-1591 (Print) IS - 0889-1591 (Linking) VI - 96 DP - 2021 Aug TI - Pre-pandemic cognitive function and COVID-19 vaccine hesitancy: cohort study. PG - 100-105 LID - S0889-1591(21)00197-5 [pii] LID - 10.1016/j.bbi.2021.05.016 [doi] AB - BACKGROUND: Whereas several predictors of COVID-19 vaccine hesitancy have been reported, the role of cognitive function is largely unknown. Accordingly, our objective was to evaluate the association between scores from an array of cognitive function tests and self-reported vaccine hesitancy after the announcement of the successful testing of the first COVID-19 vaccine (Oxford University/AstraZeneca). METHODS: We used individual-level data from a pandemic-focused study ('COVID Survey'), a prospective cohort study nested within United Kingdom Understanding Society ('Main Survey'). In the week immediately following the announcement of successful testing of the first efficacious inoculation (November/December 2020), data on vaccine intentionality were collected in 11,740 individuals (6702 women) aged 16-95 years. Pre-pandemic scores on general cognitive function, ascertained from a battery of six tests, were captured in 2011/12 wave of the Main Survey. Study members self-reported their intention to take up a vaccination in the COVID-19 Survey. RESULTS: Of the study sample, 17.2% (N = 1842) indicated they were hesitant about having the vaccine. After adjustment for age, sex, and ethnicity, study members with a lower baseline cognition score were markedly more likely to be vaccine hesitant (odds ratio per standard deviation lower score in cognition; 95% confidence interval: 1.76; 1.62, 1.90). Adjustment for mental and physical health plus household shielding status had no impact on these results, whereas controlling for educational attainment led to partial attenuation but the probability of hesitancy was still elevated (1.52; 1.37, 1.67). There was a linear association for vaccine hesitancy across the full range of cognition scores (p for trend: p < 0.0001). CONCLUSIONS: Erroneous social media reports might have complicated personal decision-making, leading to people with lower cognitive ability being vaccine-hesitant. With individuals with lower cognition also experiencing higher rates of COVID-19 in studies conducted prior to vaccine distribution, these new findings are suggestive of a potential additional disease burden. CI - Copyright (c) 2021 The Author(s). Published by Elsevier Inc. All rights reserved. FAU - Batty, G David AU - Batty GD AD - Department of Epidemiology and Public Health, University College London, UK. Electronic address: david.batty@ucl.ac.uk. FAU - Deary, Ian J AU - Deary IJ AD - Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK. FAU - Fawns-Ritchie, Chloe AU - Fawns-Ritchie C AD - Department of Psychology, University of Edinburgh, UK. FAU - Gale, Catharine R AU - Gale CR AD - Lothian Birth Cohorts, Department of Psychology, University of Edinburgh, UK; Medical Research Council Lifecourse Epidemiology Unit, University of Southampton, UK. FAU - Altschul, Drew AU - Altschul D AD - Department of Psychology, University of Edinburgh, UK. LA - eng PT - Journal Article DEP - 20210520 PL - Netherlands TA - Brain Behav Immun JT - Brain, behavior, and immunity JID - 8800478 SB - IM UOF - medRxiv. 2021 Mar 25:2021.03.16.21253634. doi: 10.1101/2021.03.16.21253634. PMID: 33791726 PMC - PMC8133799 OTO - NOTNLM OT - COVID-19 OT - Cognitive ability OT - Cognitive function OT - Cohort OT - IQ OT - Mental ability OT - Vaccine hesitancy COIS- The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2021/05/23 06:00 MHDA- 2021/05/23 06:01 PMCR- 2021/08/01 CRDT- 2021/05/22 20:12 PHST- 2021/05/10 00:00 [received] PHST- 2021/05/17 00:00 [accepted] PHST- 2021/05/23 06:00 [pubmed] PHST- 2021/05/23 06:01 [medline] PHST- 2021/05/22 20:12 [entrez] PHST- 2021/08/01 00:00 [pmc-release] AID - S0889-1591(21)00197-5 [pii] AID - 10.1016/j.bbi.2021.05.016 [doi] PST - ppublish SO - Brain Behav Immun. 2021 Aug;96:100-105. doi: 10.1016/j.bbi.2021.05.016. Epub 2021 May 20. PMID- 33979412 OWN - NLM STAT- MEDLINE DCOM- 20210609 LR - 20230920 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 16 IP - 5 DP - 2021 TI - COVID-19 vaccine rumors and conspiracy theories: The need for cognitive inoculation against misinformation to improve vaccine adherence. PG - e0251605 LID - 10.1371/journal.pone.0251605 [doi] LID - e0251605 AB - INTRODUCTION: Rumors and conspiracy theories, can contribute to vaccine hesitancy. Monitoring online data related to COVID-19 vaccine candidates can track vaccine misinformation in real-time and assist in negating its impact. This study aimed to examine COVID-19 vaccine rumors and conspiracy theories circulating on online platforms, understand their context, and then review interventions to manage this misinformation and increase vaccine acceptance. METHOD: In June 2020, a multi-disciplinary team was formed to review and collect online rumors and conspiracy theories between 31 December 2019-30 November 2020. Sources included Google, Google Fact Check, Facebook, YouTube, Twitter, fact-checking agency websites, and television and newspaper websites. Quantitative data were extracted, entered in an Excel spreadsheet, and analyzed descriptively using the statistical package R version 4.0.3. We conducted a content analysis of the qualitative information from news articles, online reports and blogs and compared with findings from quantitative data. Based on the fact-checking agency ratings, information was categorized as true, false, misleading, or exaggerated. RESULTS: We identified 637 COVID-19 vaccine-related items: 91% were rumors and 9% were conspiracy theories from 52 countries. Of the 578 rumors, 36% were related to vaccine development, availability, and access, 20% related to morbidity and mortality, 8% to safety, efficacy, and acceptance, and the rest were other categories. Of the 637 items, 5% (30/) were true, 83% (528/637) were false, 10% (66/637) were misleading, and 2% (13/637) were exaggerated. CONCLUSIONS: Rumors and conspiracy theories may lead to mistrust contributing to vaccine hesitancy. Tracking COVID-19 vaccine misinformation in real-time and engaging with social media to disseminate correct information could help safeguard the public against misinformation. FAU - Islam, Md Saiful AU - Islam MS AUID- ORCID: 0000-0002-5690-5971 AD - Infectious Diseases Division, Program for Emerging Infections, International Centre for Diarrheal Diseases Research, Dhaka, Bangladesh. AD - School of Population Health, University of New South Wales, Sydney, Australia. FAU - Kamal, Abu-Hena Mostofa AU - Kamal AM AUID- ORCID: 0000-0002-2529-3685 AD - Khulna University of Engineering and Technology, Khulna, Bangladesh. AD - Department of Sociology, University of Saskatchewan, Saskatoon, Canada. FAU - Kabir, Alamgir AU - Kabir A AD - School of Population Health, University of New South Wales, Sydney, Australia. AD - Centre for Primary Health Care and Equity, University of New South Wales, Sydney, Australia. FAU - Southern, Dorothy L AU - Southern DL AD - Independent Scientific Writing Consultant, Mandalay, Myanmar. FAU - Khan, Sazzad Hossain AU - Khan SH AD - Infectious Diseases Division, Program for Emerging Infections, International Centre for Diarrheal Diseases Research, Dhaka, Bangladesh. FAU - Hasan, S M Murshid AU - Hasan SMM AD - Department of Society and Health, Mahidol University, Salaya, Thailand. FAU - Sarkar, Tonmoy AU - Sarkar T AD - Infectious Diseases Division, Program for Emerging Infections, International Centre for Diarrheal Diseases Research, Dhaka, Bangladesh. FAU - Sharmin, Shayla AU - Sharmin S AD - Independent Researcher, Sydney, Australia. FAU - Das, Shiuli AU - Das S AD - Infectious Diseases Division, Program for Emerging Infections, International Centre for Diarrheal Diseases Research, Dhaka, Bangladesh. FAU - Roy, Tuhin AU - Roy T AD - Sociology Discipline, Khulna University, Khulna, Bangladesh. FAU - Harun, Md Golam Dostogir AU - Harun MGD AD - Infectious Diseases Division, Program for Emerging Infections, International Centre for Diarrheal Diseases Research, Dhaka, Bangladesh. FAU - Chughtai, Abrar Ahmad AU - Chughtai AA AD - School of Population Health, University of New South Wales, Sydney, Australia. FAU - Homaira, Nusrat AU - Homaira N AD - School of Women's and Children's Health, University of New South Wales, Sydney, Australia. FAU - Seale, Holly AU - Seale H AD - School of Population Health, University of New South Wales, Sydney, Australia. LA - eng PT - Journal Article DEP - 20210512 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (COVID-19 Vaccines) SB - IM MH - COVID-19/*psychology MH - COVID-19 Vaccines/pharmacology MH - Communication MH - Cross-Sectional Studies MH - Humans MH - Information Dissemination/ethics/*methods MH - Public Health MH - SARS-CoV-2/pathogenicity MH - Social Media MH - Surveys and Questionnaires MH - Vaccination/methods MH - Vaccination Refusal/*psychology PMC - PMC8115834 COIS- Associate Professor Holly Seale has previously received funding from drug companies for investigator-driven research and consulting fees to present at conferences/workshops and develop resources (Seqirus, GSK and Sanofi Pasteur). She has also participated in an advisory board meeting for Sanofi Pasteur. This work has been a voluntary contribution from all authors. The commercial affiliation of the authors did not play a role in our study, and this does not alter our adherence to PLOS ONE policies of sharing data and materials. EDAT- 2021/05/13 06:00 MHDA- 2021/06/10 06:00 PMCR- 2021/05/12 CRDT- 2021/05/12 17:21 PHST- 2021/02/24 00:00 [received] PHST- 2021/04/29 00:00 [accepted] PHST- 2021/05/12 17:21 [entrez] PHST- 2021/05/13 06:00 [pubmed] PHST- 2021/06/10 06:00 [medline] PHST- 2021/05/12 00:00 [pmc-release] AID - PONE-D-21-06301 [pii] AID - 10.1371/journal.pone.0251605 [doi] PST - epublish SO - PLoS One. 2021 May 12;16(5):e0251605. doi: 10.1371/journal.pone.0251605. eCollection 2021. PMID- 33971332 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20240214 IS - 1872-9649 (Electronic) IS - 1568-1637 (Print) IS - 1568-1637 (Linking) VI - 69 DP - 2021 Aug TI - Fostering healthy aging: The interdependency of infections, immunity and frailty. PG - 101351 LID - S1568-1637(21)00098-2 [pii] LID - 10.1016/j.arr.2021.101351 [doi] AB - Untangling the interdependency of infections, immunity and frailty may help to clarify their roles in the maintenance of health in aging individuals, and the recent COVID-19 pandemic has further highlighted such priority. In this scoping review we aimed to systematically collect the evidence on 1) the impact of common infections such as influenza, pneumonia and varicella zoster on frailty development, and 2) the role played by frailty in the response to immunization of older adults. Findings are discussed under a unifying framework to identify knowledge gaps and outline their clinical and public health implications to foster a healthier aging. Twenty-nine studies (113,863 participants) selected to answer the first question provided a moderately strong evidence of an association between infections and physical as well as cognitive decline - two essential dimensions of frailty. Thirteen studies (34,520 participants) investigating the second aim, showed that frailty was associated with an impaired immune response in older ages, likely due to immunosenescence. However, the paucity of studies, the absence of tools to predict vaccine efficacy, and the lack of studies investigating the efficacy of newer vaccines in presence of frailty, strongly limit the formulation of more personalized immunization strategies for older adults. The current evidence suggests that infections and frailty repeatedly cross each other pathophysiological paths and accelerate the aging process in a vicious circle. Such evidence opens to several considerations. First, the prevention of both conditions pass through a life course approach, which includes several individual and societal aspects. Second, the maintenance of a well-functioning immune system may be accomplished by preventing frailty, and vice versa. Third, increasing the adherence to immunization may delay the onset of frailty and maintain the immune system homeostasis, beyond preventing infections. CI - Copyright (c) 2021 The Author(s). Published by Elsevier B.V. All rights reserved. FAU - Vetrano, Davide L AU - Vetrano DL AD - Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Centro Medicina dell'Invecchiamento, Fondazione Policlinico "A- Gemelli" IRCCS and Catholic University of Rome, Italy. Electronic address: davide.vetrano@ki.se. FAU - Triolo, Federico AU - Triolo F AD - Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden. FAU - Maggi, Stefania AU - Maggi S AD - National Research Council, Neuroscience Institute, Padua, Italy. FAU - Malley, Richard AU - Malley R AD - Division of Infectious Diseases, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. FAU - Jackson, Thomas A AU - Jackson TA AD - Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; Department of Geriatrics, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. FAU - Poscia, Andrea AU - Poscia A AD - Vaccination Office of Marche Region, Italy. FAU - Bernabei, Roberto AU - Bernabei R AD - Centro Medicina dell'Invecchiamento, Fondazione Policlinico "A- Gemelli" IRCCS and Catholic University of Rome, Italy. FAU - Ferrucci, Luigi AU - Ferrucci L AD - Longitudinal Studies Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, USA. FAU - Fratiglioni, Laura AU - Fratiglioni L AD - Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Stockholm Gerontology Research Center, Stockholm, Sweden. LA - eng PT - Journal Article PT - Review DEP - 20210507 PL - England TA - Ageing Res Rev JT - Ageing research reviews JID - 101128963 SB - IM MH - Aged MH - *COVID-19 MH - *Frailty/epidemiology MH - *Healthy Aging MH - Humans MH - Middle Aged MH - Pandemics MH - SARS-CoV-2 PMC - PMC9588151 OTO - NOTNLM OT - Frailty OT - Healthy aging OT - Immunosenescence OT - Vaccination COIS- The authors report no declarations of interest. EDAT- 2021/05/11 06:00 MHDA- 2021/06/22 06:00 PMCR- 2021/05/07 CRDT- 2021/05/10 20:15 PHST- 2020/12/16 00:00 [received] PHST- 2021/04/16 00:00 [revised] PHST- 2021/05/03 00:00 [accepted] PHST- 2021/05/11 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2021/05/10 20:15 [entrez] PHST- 2021/05/07 00:00 [pmc-release] AID - S1568-1637(21)00098-2 [pii] AID - 101351 [pii] AID - 10.1016/j.arr.2021.101351 [doi] PST - ppublish SO - Ageing Res Rev. 2021 Aug;69:101351. doi: 10.1016/j.arr.2021.101351. Epub 2021 May 7. PMID- 33938413 OWN - NLM STAT- MEDLINE DCOM- 20220517 LR - 20220719 IS - 1559-6834 (Electronic) IS - 0899-823X (Print) IS - 0899-823X (Linking) VI - 43 IP - 5 DP - 2022 May TI - Factors associated with behavioral intention of free and self-paid severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination based on the social cognitive theory among nurses and doctors in China. PG - 609-615 LID - 10.1017/ice.2021.201 [doi] AB - OBJECTIVE: To examine the associations between factors based on the social cognitive theory (SCT) and behavioral intention among doctors and nurses in China toward free and self-paid (600 RMB or US$91) severe acute respiratory coronavirus virus 2 (SARS-CoV-2) vaccination given 80% effectiveness and rare mild side effects. DESIGN: Cross-sectional study. SETTING: Public hospitals. PARTICIPANTS: The study included 362 doctors and 1,702 nurses in major departments of 5 hospitals of 3 Chinese provinces. METHODS: An anonymous online survey was conducted from October to November 2020, facilitated by hospital administrators through online WeChat/QQ working groups. Data on outcome expectations, self-efficacy, norms, and COVID-19-related work experiences were collected. Multivariate logistic regression models were used for data analyses. RESULTS: The logistic regression analysis showed that physical (eg, protective effect of vaccination) and self-evaluative outcome expectations (eg, anticipated regret), self-efficacy, norms (eg, descriptive norm, subjective norm, professional norm, and moral norm), and job satisfaction were significantly and positively associated with the free and self-paid SARS-CoV-2 vaccination intention outcomes among doctors and nurses, adjusted for background variables. Doctors who had engaged in COVID-19-related work reported higher self-paid vaccination intention. CONCLUSIONS: Health promotion is needed to improve the uptake of SARS-CoV-2 vaccination among healthcare workers. Such interventions may consider modifying the identified factors of vaccination intention, including strengthening perceived efficacy, positive feelings about vaccination, the need to avoid future regret, self-efficacy, and social norms. Future studies should examine the actual behavior patterns of SARS-CoV-2 vaccination, and the efficacy of promotion intervention should be tested in randomized controlled studies. FAU - She, Rui AU - She R AD - Centre for Health Behaviours Research, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. FAU - Chen, Xi AU - Chen X AD - Hunan Provincial Center for Disease Control and Prevention, Changsha, China. FAU - Li, Liping AU - Li L AD - Shantou University Medical College, Shantou, China. FAU - Li, Lijuan AU - Li L AD - School of Public Health, Dali University, Dali, Yunnan, China. FAU - Huang, Zepeng AU - Huang Z AD - The Second Affiliated Hospital of Shantou University Medical College, Shantou, China. FAU - Lau, Joseph T F AU - Lau JTF AUID- ORCID: 0000-0003-2344-7107 AD - Centre for Health Behaviours Research, School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20210503 PL - United States TA - Infect Control Hosp Epidemiol JT - Infection control and hospital epidemiology JID - 8804099 RN - 0 (COVID-19 Vaccines) SB - IM MH - *COVID-19/prevention & control MH - COVID-19 Vaccines MH - China MH - Cross-Sectional Studies MH - Humans MH - Intention MH - Psychological Theory MH - *SARS-CoV-2 MH - Vaccination/psychology PMC - PMC8712960 EDAT- 2021/05/04 06:00 MHDA- 2022/05/18 06:00 PMCR- 2021/05/03 CRDT- 2021/05/03 09:14 PHST- 2021/05/04 06:00 [pubmed] PHST- 2022/05/18 06:00 [medline] PHST- 2021/05/03 09:14 [entrez] PHST- 2021/05/03 00:00 [pmc-release] AID - S0899823X21002014 [pii] AID - 10.1017/ice.2021.201 [doi] PST - ppublish SO - Infect Control Hosp Epidemiol. 2022 May;43(5):609-615. doi: 10.1017/ice.2021.201. Epub 2021 May 3. PMID- 33806624 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20241004 IS - 2076-2607 (Print) IS - 2076-2607 (Electronic) IS - 2076-2607 (Linking) VI - 9 IP - 3 DP - 2021 Mar 4 TI - SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention. LID - 10.3390/microorganisms9030525 [doi] LID - 525 AB - The SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is a high-risk viral agent involved in the recent pandemic stated worldwide by the World Health Organization. The infection is correlated to a severe systemic and respiratory disease in many cases, which is clinically treated with a multi-drug pharmacological approach. The purpose of this investigation was to evaluate through a literature overview the effect of adjuvant therapies and supplements for the SARS-CoV-2 infection. The research has analyzed the advantage of the EK1C4, by also assessing the studies on the resveratrol, vitamin D, and melatonin as adjuvant supplements for long hauler patients' prognosis. The evaluated substances reported important benefits for the improvement of the immune system and as a potential inhibitor molecules against SARS-CoV-2, highlighting the use of sartans as therapy. The adjuvant supplements seem to create an advantage for the healing of the long hauler patients affected by chronic symptoms of constant chest and heart pain, intestinal disorders, headache, difficulty concentrating, memory loss, and tachycardia. FAU - Inchingolo, Alessio Danilo AU - Inchingolo AD AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - Inchingolo, Angelo Michele AU - Inchingolo AM AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - Bordea, Ioana Roxana AU - Bordea IR AUID- ORCID: 0000-0001-7166-9949 AD - Department of Oral Rehabilitation, Faculty of Dentistry, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania. FAU - Malcangi, Giuseppina AU - Malcangi G AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - Xhajanka, Edit AU - Xhajanka E AD - Dental Prosthesis Department, Medical University of Tirana, UMT, Rruga e Dibres, 1001 Tirana, Albania. FAU - Scarano, Antonio AU - Scarano A AUID- ORCID: 0000-0003-1374-6146 AD - Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy. FAU - Lorusso, Felice AU - Lorusso F AUID- ORCID: 0000-0002-2660-9231 AD - Department of Innovative Technologies in Medicine and Dentistry, University of Chieti-Pescara, 66100 Chieti, Italy. FAU - Farronato, Marco AU - Farronato M AUID- ORCID: 0000-0002-6209-9873 AD - Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, UOC Maxillo-Facial Surgery and Dentistry, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, 20100 Milan, Italy. FAU - Tartaglia, Gianluca Martino AU - Tartaglia GM AD - Department of Biomedical, Surgical and Dental Sciences, School of Dentistry, University of Milan, UOC Maxillo-Facial Surgery and Dentistry, Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, 20100 Milan, Italy. FAU - Isacco, Ciro Gargiulo AU - Isacco CG AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. AD - Human Stem Cells Research Center HSC of Ho Chi Minh, Ho Chi Minh 70000, Vietnam. AD - Embryology and Regenerative Medicine and Immunology, Pham Chau Trinh University of Medicine Hoi An, Hoi An 70000, Vietnam. FAU - Marinelli, Grazia AU - Marinelli G AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - D'Oria, Maria Teresa AU - D'Oria MT AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. AD - Department of Medical and Biological Sciences, Via delle Scienze, Universita degli Studi di Udine, 206, 33100 Udine, Italy. FAU - Hazballa, Denisa AU - Hazballa D AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. AD - Kongresi Elbasanit, Rruga: Aqif Pasha, 3001 Elbasan, Albania. FAU - Santacroce, Luigi AU - Santacroce L AUID- ORCID: 0000-0001-5671-8124 AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - Ballini, Andrea AU - Ballini A AUID- ORCID: 0000-0001-8758-1415 AD - Department of Biosciences, Biotechnologies and Biopharmaceutics, Campus Universitario, University of Bari, 70125 Bari, Italy. AD - Department of Precision Medicine, University of Campania, 80138 Naples, Italy. FAU - Contaldo, Maria AU - Contaldo M AUID- ORCID: 0000-0002-4773-6694 AD - Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Via Luigi de Crecchio, 6, 80138 Naples, Italy. FAU - Inchingolo, Francesco AU - Inchingolo F AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. FAU - Dipalma, Gianna AU - Dipalma G AD - Department of Interdisciplinary Medicine, University of Medicine Aldo Moro, 70124 Bari, Italy. LA - eng PT - Journal Article PT - Review DEP - 20210304 PL - Switzerland TA - Microorganisms JT - Microorganisms JID - 101625893 PMC - PMC7999785 OTO - NOTNLM OT - COVID-19 OT - SARS-CoV-2 OT - cytokine storm syndrome OT - endovir stop spray OT - furin OT - microbiome OT - oral mucosa OT - pandemics OT - resveratrol OT - vaccines COIS- The authors declare no conflict of interest. EDAT- 2021/04/04 06:00 MHDA- 2021/04/04 06:01 PMCR- 2021/03/04 CRDT- 2021/04/03 01:24 PHST- 2021/02/08 00:00 [received] PHST- 2021/02/28 00:00 [revised] PHST- 2021/03/01 00:00 [accepted] PHST- 2021/04/03 01:24 [entrez] PHST- 2021/04/04 06:00 [pubmed] PHST- 2021/04/04 06:01 [medline] PHST- 2021/03/04 00:00 [pmc-release] AID - microorganisms9030525 [pii] AID - microorganisms-09-00525 [pii] AID - 10.3390/microorganisms9030525 [doi] PST - epublish SO - Microorganisms. 2021 Mar 4;9(3):525. doi: 10.3390/microorganisms9030525. PMID- 33768521 OWN - NLM STAT- MEDLINE DCOM- 20210615 LR - 20260127 IS - 1532-5415 (Electronic) IS - 0002-8614 (Print) IS - 0002-8614 (Linking) VI - 69 IP - 6 DP - 2021 Jun TI - Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. PG - 1441-1447 LID - 10.1111/jgs.17153 [doi] AB - BACKGROUND/OBJECTIVES: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles. DESIGN: Multicenter longitudinal cohort study. SETTING AND PARTICIPANTS: A total of 134 residents aged >/=65 years with different frailty and disability profiles in five long-term care facilities (LTCFs) in Albacete, Spain. INTERVENTION AND MEASUREMENTS: Residents were administered two vaccine doses as per the label, and antibody levels were determined 21.9 days (SD 9.3) after both the first and second dose. Functional variables were assessed using activities of daily living (Barthel Index), and frailty status was determined with the FRAIL instrument. Cognitive status and comorbidity were also evaluated. RESULTS: Mean age was 82.9 years (range 65-99), and 71.6% were female. The mean antibody titers in residents with and without previous COVID-19 infection were 49,878 AU/ml and 15,274 AU/ml, respectively (mean difference 34,604; 95% confidence interval [CI]: 27,699-41,509). No severe adverse reactions were observed, after either vaccine dose. Those with prevaccination COVID-19 had an increased antibody level after the vaccine (B = 31,337; 95% CI: 22,725-39,950; p < 0.001). Frailty, disability, older age, sex, cognitive impairment, or comorbidities were not associated with different antibody titers. CONCLUSIONS: The BNT162b2 mRNA COVID-19 vaccine in older adults is safe and produces immunogenicity, independently of the frailty and disability profiles. Older adults in LTCFs should receive a COVID-19 vaccine. CI - (c) 2021 The American Geriatrics Society. FAU - Salmeron Rios, Sergio AU - Salmeron Rios S AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Mas Romero, Marta AU - Mas Romero M AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Cortes Zamora, Elisa Belen AU - Cortes Zamora EB AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Tabernero Sahuquillo, Maria Teresa AU - Tabernero Sahuquillo MT AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Romero Rizos, Luis AU - Romero Rizos L AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Jurado, Pedro Manuel AU - Sanchez-Jurado PM AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. FAU - Sanchez-Nievas, Gines AU - Sanchez-Nievas G AD - Department of Rheumatology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Senalada, Jose Joaquin Blas AU - Senalada JJB AD - Department of Microbiology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Garcia Nogueras, Inmaculada AU - Garcia Nogueras I AD - Residencia de Mayores San Vicente de Paul, Diputacion de Albacete, Albacete, Spain. FAU - Estrella Cazalla, Juan de Dios AU - Estrella Cazalla JD AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Diputacion de Albacete, Vasco Nunez de Balboa Facility, Albacete, Spain. FAU - Andres-Pretel, Fernando AU - Andres-Pretel F AD - Department of Statistics, Foundation of the National Paraplegics Hospital of Toledo, Toledo, Spain. FAU - Murillo Romero, Antonio AU - Murillo Romero A AD - Long-Term Care Facilities Coordination, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. FAU - Lauschke, Volker Martin AU - Lauschke VM AD - Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden. FAU - Stebbing, Justin AU - Stebbing J AD - Department of Surgery and Cancer, Imperial College, Hammersmith Hospital, ICTEM building, London, United Kingdom. FAU - Abizanda, Pedro AU - Abizanda P AUID- ORCID: 0000-0002-4707-2963 AD - Department of Geriatrics, Complejo Hospitalario Universitario de Albacete, Albacete, Spain. AD - CIBERFES, Ministerio de Economia y Competitividad, Spain. AD - Facultad de Medicina, Universidad de Castilla-La Mancha, Albacete, Spain. LA - eng GR - CB16/10/00408/Centro de Investigacion Biomedica en Red Fragilidad y Envejecimiento Saludable/ GR - COV20/00004/Instituto de Salud Carlos III/ PT - Journal Article PT - Multicenter Study PT - Research Support, Non-U.S. Gov't DEP - 20210402 PL - United States TA - J Am Geriatr Soc JT - Journal of the American Geriatrics Society JID - 7503062 RN - 0 (BNT162 Vaccine) RN - 0 (COVID-19 Vaccines) SB - IM MH - Activities of Daily Living MH - Aged MH - Aged, 80 and over MH - *Antibody Formation MH - BNT162 Vaccine MH - COVID-19/*prevention & control MH - COVID-19 Serological Testing MH - COVID-19 Vaccines/*immunology/*therapeutic use MH - Comorbidity MH - *Persons with Disabilities MH - Female MH - *Frail Elderly MH - Health Status Indicators MH - Humans MH - Longitudinal Studies MH - Male MH - Nursing Homes MH - SARS-CoV-2 MH - Spain PMC - PMC8250586 OTO - NOTNLM OT - BNT162b2 vaccine OT - COVID-19 OT - disability OT - frailty OT - immunogenicity OT - older adults COIS- All authors declare that there are no conflicts of interest, except. V.M.L. declares no conflict of interest according to the ICMJE Uniform Requirements but discloses the following financial relationship: CEO and shareholder of HepaPredict AB; co-founder and chairman of the board PersoMedix AB; consultancy work for Enginzyme AB. JS declares his conflict at https://www.nature.com/onc/editors, and none are relevant here. EDAT- 2021/03/27 06:00 MHDA- 2021/06/16 06:00 PMCR- 2021/07/02 CRDT- 2021/03/26 07:15 PHST- 2021/03/12 00:00 [revised] PHST- 2021/03/10 00:00 [received] PHST- 2021/03/12 00:00 [accepted] PHST- 2021/03/27 06:00 [pubmed] PHST- 2021/06/16 06:00 [medline] PHST- 2021/03/26 07:15 [entrez] PHST- 2021/07/02 00:00 [pmc-release] AID - JGS17153 [pii] AID - 10.1111/jgs.17153 [doi] PST - ppublish SO - J Am Geriatr Soc. 2021 Jun;69(6):1441-1447. doi: 10.1111/jgs.17153. Epub 2021 Apr 2. PMID- 33715108 OWN - NLM STAT- MEDLINE DCOM- 20210716 LR - 20241021 IS - 1559-1182 (Electronic) IS - 0893-7648 (Print) IS - 0893-7648 (Linking) VI - 58 IP - 7 DP - 2021 Jul TI - Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19. PG - 3417-3434 LID - 10.1007/s12035-021-02318-9 [doi] AB - There are regular reports of extrapulmonary infections and manifestations related to the ongoing COVID-19 pandemic. Coronaviruses are potentially neurotropic, which renders neuronal tissue vulnerable to infection, especially in elderly individuals or in those with neuro-comorbid conditions. Complaints of ageusia, anosmia, myalgia, and headache; reports of diseases such as stroke, encephalopathy, seizure, and encephalitis; and loss of consciousness in patients with COVID-19 confirm the neuropathophysiological aspect of this disease. The brain is linked to pulmonary organs, physiologically through blood circulation, and functionally through the nervous system. The interdependence of these vital organs may further aggravate the pathophysiological aspects of COVID-19. The induction of a cytokine storm in systemic circulation can trigger a neuroinflammatory cascade, which can subsequently compromise the blood-brain barrier and activate microglia- and astrocyte-borne Toll-like receptors, thereby leading to neuronal tissue damage. Hence, a holistic approach should be adopted by healthcare professionals while treating COVID-19 patients with a history of neurodegenerative disorders, neuropsychological complications, or any other neuro-compromised conditions. Imperatively, vaccines are being developed at top priority to contain the spread of the severe acute respiratory syndrome coronavirus 2, and different vaccines are at different stages of development globally. This review discusses the concerns regarding the neuronal complications of COVID-19 and the possible mechanisms of amelioration. FAU - Kumar, Dipak AU - Kumar D AUID- ORCID: 0000-0001-6104-9447 AD - Zoology Department, KKM College, Jamui, Munger University, Munger, India. FAU - Jahan, Sadaf AU - Jahan S AUID- ORCID: 0000-0002-6976-5672 AD - Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Majmaah, 11952, Saudi Arabia, Kingdom of Saudi Arabia. jahan149@gmail.com. FAU - Khan, Andleeb AU - Khan A AUID- ORCID: 0000-0001-6125-3309 AD - Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan, 45142, Saudi Arabia. FAU - Siddiqui, Arif Jamal AU - Siddiqui AJ AUID- ORCID: 0000-0002-6236-0920 AD - Department of Biology, College of Science, University of Hail, Hail, PO Box 2440, Saudi Arabia. FAU - Redhu, Neeru Singh AU - Redhu NS AUID- ORCID: 0000-0002-4438-5147 AD - Department of Molecular Biology, Biotechnology and Bioinformatics, Chaudhary Charan Singh Haryana Agricultural University, Hisar, Haryana 125004, India. FAU - Wahajuddin AU - Wahajuddin AUID- ORCID: 0000-0003-3362-7558 AD - Division of Pharmaceutics & Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, UP, India. FAU - Khan, Johra AU - Khan J AD - Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Majmaah, 11952, Saudi Arabia, Kingdom of Saudi Arabia. FAU - Banwas, Saeed AU - Banwas S AD - Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Majmaah, 11952, Saudi Arabia, Kingdom of Saudi Arabia. AD - Health and Basic Sciences Research Center, Majmaah University, Majmaah, 11952, Saudi Arabia. AD - Departments of Biomedical Sciences, Oregon State University, Corvallis, OR, 97331, USA. FAU - Alshehri, Bader AU - Alshehri B AD - Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Majmaah, 11952, Saudi Arabia, Kingdom of Saudi Arabia. AD - Health and Basic Sciences Research Center, Majmaah University, Majmaah, 11952, Saudi Arabia. FAU - Alaidarous, Mohammed AU - Alaidarous M AD - Department of Medical Laboratories, College of Applied Medical Sciences, Majmaah University, Majmaah, 11952, Saudi Arabia, Kingdom of Saudi Arabia. AD - Health and Basic Sciences Research Center, Majmaah University, Majmaah, 11952, Saudi Arabia. LA - eng PT - Journal Article PT - Review DEP - 20210314 PL - United States TA - Mol Neurobiol JT - Molecular neurobiology JID - 8900963 SB - IM MH - Brain/*virology MH - COVID-19/*complications MH - Cytokine Release Syndrome/*virology MH - Encephalitis/*virology MH - Humans MH - Inflammation/*virology MH - SARS-CoV-2 MH - Stroke/*virology PMC - PMC7955900 OTO - NOTNLM OT - COVID-19 OT - Cytokine storm OT - Neurodegenerative disorders OT - Neuropathophysiology OT - Pandemic OT - Vaccine COIS- The authors of the manuscript declare no conflict of interest/competing interests. All data and materials are available in the manuscript. EDAT- 2021/03/15 06:00 MHDA- 2021/07/17 06:00 PMCR- 2021/03/14 CRDT- 2021/03/14 21:01 PHST- 2020/09/03 00:00 [received] PHST- 2021/02/01 00:00 [accepted] PHST- 2021/03/15 06:00 [pubmed] PHST- 2021/07/17 06:00 [medline] PHST- 2021/03/14 21:01 [entrez] PHST- 2021/03/14 00:00 [pmc-release] AID - 10.1007/s12035-021-02318-9 [pii] AID - 2318 [pii] AID - 10.1007/s12035-021-02318-9 [doi] PST - ppublish SO - Mol Neurobiol. 2021 Jul;58(7):3417-3434. doi: 10.1007/s12035-021-02318-9. Epub 2021 Mar 14. PMID- 33393415 OWN - NLM STAT- MEDLINE DCOM- 20210216 LR - 20210216 IS - 1532-4230 (Electronic) IS - 1532-1819 (Linking) VI - 41 IP - 6 DP - 2020 Nov 1 TI - Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. PG - 960-975 LID - 10.1080/15321819.2020.1865400 [doi] AB - In December 2019, an outbreak of pandemic severe respiratory distress syndrome coronavirus disease 2019 (COVID-19) initially occurred in China, has spread the world resulted in serious threats to human public health. Uncommon neurological manifestations with pathophysiological symptoms were observed in infected patients including headache, seizures, and neuroimmunological disorders. Regardless of whether these neurological symptoms are direct or indirect casual infection relationship, this novel viral infection has a relevant impact on the neuroimmune system that requires a neurologist's careful assessment. Recently, the use of immunotherapy has been emerged in fighting against COVID-19 infection despite the uncertain efficiency in managing COVID-19 related disorders or even its proven failure by increasing its severity. Herein, the author is addressing the first approaches in using immunotherapies in controlling COVID-19 viral impact on the brain by highlighting their role in decreasing or increasing infection risks among subjects. This point of view review article supports the use of immunotherapies in managing COVID-19 neurological disorders but in optimal timing and duration to ensure the maximum therapeutic outcome by reducing morbidity and mortality rate. Based on recently published data, the current review article highlights the beneficial effects and drawbacks of using immunotherapies to combat COVID-19 and its neurological symptoms. FAU - Anwar, Mai M AU - Anwar MM AUID- ORCID: 0000-0002-1991-2945 AD - Department of Biochemistry, National Organization for Drug Control and Research (Nodcar)/egyptian Drug Authority , Cairo, Egypt. LA - eng PT - Journal Article PT - Review DEP - 20210103 PL - England TA - J Immunoassay Immunochem JT - Journal of immunoassay & immunochemistry JID - 100963688 RN - 0 (Cytokines) RN - 0 (Glucocorticoids) RN - 0 (IL6 protein, human) RN - 0 (Immunoglobulins, Intravenous) RN - 0 (Interleukin-6) RN - 47M74X9YT5 (Cladribine) RN - 77238-31-4 (Interferon-beta) SB - IM MH - Brain/pathology MH - COVID-19/complications/*immunology/*therapy MH - Cladribine/therapeutic use MH - Cytokine Release Syndrome/therapy/*virology MH - Cytokines/immunology MH - Glucocorticoids/therapeutic use MH - Headache/virology MH - Humans MH - Immunoglobulins, Intravenous/therapeutic use MH - Immunotherapy/*methods MH - Interferon-beta/immunology MH - Interleukin-6/immunology MH - Nervous System Diseases/*immunology/*therapy/virology MH - Pandemics OTO - NOTNLM OT - COVID-19 OT - cytokines storm OT - immunotherapies OT - inflammation OT - neurological disorders OT - vaccines EDAT- 2021/01/05 06:00 MHDA- 2021/02/17 06:00 CRDT- 2021/01/04 08:50 PHST- 2021/01/05 06:00 [pubmed] PHST- 2021/02/17 06:00 [medline] PHST- 2021/01/04 08:50 [entrez] AID - 10.1080/15321819.2020.1865400 [doi] PST - ppublish SO - J Immunoassay Immunochem. 2020 Nov 1;41(6):960-975. doi: 10.1080/15321819.2020.1865400. Epub 2021 Jan 3. PMID- 33256258 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20231112 IS - 2079-9721 (Print) IS - 2079-9721 (Electronic) IS - 2079-9721 (Linking) VI - 8 IP - 4 DP - 2020 Nov 26 TI - Can Melatonin Be a Potential "Silver Bullet" in Treating COVID-19 Patients? LID - 10.3390/diseases8040044 [doi] LID - 44 AB - The therapeutic potential of melatonin as a chronobiotic cytoprotective agent to counteract the consequences of COVID-19 infections has been advocated. Because of its wide-ranging effects as an antioxidant, anti-inflammatory, and immunomodulatory compound, melatonin could be unique in impairing the consequences of SARS-CoV-2 infection. Moreover, indirect evidence points out to a possible antiviral action of melatonin by interfering with SARS-CoV-2/angiotensin-converting enzyme 2 association. Melatonin is also an effective chronobiotic agent to reverse the circadian disruption of social isolation and to control delirium in severely affected patients. As a cytoprotector, melatonin serves to combat several comorbidities such as diabetes, metabolic syndrome, and ischemic and non-ischemic cardiovascular diseases, which aggravate COVID-19 disease. In view of evidence on the occurrence of neurological sequels in COVID-19-infected patients, another putative application of melatonin emerges based on its neuroprotective properties. Since melatonin is an effective means to control cognitive decay in minimal cognitive impairment, its therapeutic significance for the neurological sequels of SARS-CoV-2 infection should be considered. Finally, yet importantly, exogenous melatonin can be an adjuvant capable of augmenting the efficacy of anti-SARS-CoV-2 vaccines. We discuss in this review the experimental evidence suggesting that melatonin is a potential "silver bullet" in the COVID 19 pandemic. FAU - Cardinali, Daniel P AU - Cardinali DP AD - Faculty of Medical Sciences, Pontificia Universidad Catolica Argentina, Buenos Aires 1007, Argentina. FAU - Brown, Gregory M AU - Brown GM AD - Centre for Addiction and Mental Health, Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada. FAU - Pandi-Perumal, Seithikurippu R AU - Pandi-Perumal SR AUID- ORCID: 0000-0002-8686-7259 AD - Somnogen Canada Inc., College Street, Toronto, ON M6H 1C5, Canada. LA - eng PT - Journal Article PT - Review DEP - 20201126 PL - Switzerland TA - Diseases JT - Diseases (Basel, Switzerland) JID - 101636232 PMC - PMC7709121 OTO - NOTNLM OT - COVID-19 pandemic OT - aging OT - anti-SARS-CoV-2 vaccination OT - chronotherapy OT - cognitive impairment OT - cytoprotection OT - diabetes OT - inflammation OT - melatonin OT - metabolic syndrome OT - neurodegeneration OT - oxidative stress OT - renin-angiotensin system COIS- The authors declare no conflict of interest. EDAT- 2020/12/02 06:00 MHDA- 2020/12/02 06:01 PMCR- 2020/11/26 CRDT- 2020/12/01 01:11 PHST- 2020/11/04 00:00 [received] PHST- 2020/11/24 00:00 [revised] PHST- 2020/11/24 00:00 [accepted] PHST- 2020/12/01 01:11 [entrez] PHST- 2020/12/02 06:00 [pubmed] PHST- 2020/12/02 06:01 [medline] PHST- 2020/11/26 00:00 [pmc-release] AID - diseases8040044 [pii] AID - diseases-08-00044 [pii] AID - 10.3390/diseases8040044 [doi] PST - epublish SO - Diseases. 2020 Nov 26;8(4):44. doi: 10.3390/diseases8040044. PMID- 33072783 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20240329 IS - 2296-858X (Print) IS - 2296-858X (Electronic) IS - 2296-858X (Linking) VI - 7 DP - 2020 TI - Covid-19 Pandemic: Maximizing Future Vaccination Treatments Considering Aging and Frailty. PG - 558835 LID - 10.3389/fmed.2020.558835 [doi] LID - 558835 AB - The COVID-19 pandemic is proving to be a multiplier of inequalities. Especially toward the elderly population. A voiceless scream that comes from geriatrics, nursing homes, hospices from all over Italy. They call it the silent massacre: from North to South, the bulletin of coronavirus positive-or already deceased-elderly people continues to grow exponentially without a chance to counter it. Population aging and chronicity are a question that needs to be addressed. Frailty is the most challenging expression of population aging, with major consequences for public health and clinical practice. It is a geriatric syndrome which consists in a state of higher vulnerability to stressors attributed to a lower homeostatic reserve due to an age-related multisystem physiological change. People over 60, and especially over 80, are particularly vulnerable to severe or fatal infection. Moreover, the age-related dysregulation of the immune system in the elderly (i.e., immunosenescence and inflammaging) results in poorer responses to vaccination. Physical frailty is an effective health indicator and it has previously shown to predict the response to the seasonal flu vaccine. These findings suggest that assessing frailty in the elderly may identify those who are less likely to respond to immunization and be at higher risk for COVID-19 and its complications. Moreover, cognitive frailty and neurocognitive disorders, mental health and reduced awareness of illness negatively impact on adherence to complex medication regimens among elderly patients. A worldwide research and development blueprint have been initiated to accelerate the development of vaccines and therapeutics for the COVID-19 outbreak. Considered the above, I suggest the importance to consider aging in thinking about future Civud-19 vaccination and treatment, focusing on the possible impact of physical and cognitive frailty. CI - Copyright (c) 2020 Palermo. FAU - Palermo, Sara AU - Palermo S AD - Department of Psychology, University of Turin, Turin, Italy. AD - European Innovation Partnership on Active and Healthy Aging, Bruxelles, Belgium. LA - eng PT - Journal Article DEP - 20200918 PL - Switzerland TA - Front Med (Lausanne) JT - Frontiers in medicine JID - 101648047 PMC - PMC7530612 OTO - NOTNLM OT - COVID-19 OT - adherence to treatment OT - ageotype OT - frailty OT - immunology OT - immunosenecence OT - inflammaging OT - vaccination EDAT- 2020/10/20 06:00 MHDA- 2020/10/20 06:01 PMCR- 2020/09/18 CRDT- 2020/10/19 05:59 PHST- 2020/05/18 00:00 [received] PHST- 2020/09/02 00:00 [accepted] PHST- 2020/10/19 05:59 [entrez] PHST- 2020/10/20 06:00 [pubmed] PHST- 2020/10/20 06:01 [medline] PHST- 2020/09/18 00:00 [pmc-release] AID - 10.3389/fmed.2020.558835 [doi] PST - epublish SO - Front Med (Lausanne). 2020 Sep 18;7:558835. doi: 10.3389/fmed.2020.558835. eCollection 2020. PMID- 32463026 OWN - NLM STAT- MEDLINE DCOM- 20200602 LR - 20240328 IS - 1643-3750 (Electronic) IS - 1234-1010 (Print) IS - 1234-1010 (Linking) VI - 26 DP - 2020 May 28 TI - A Novel Vaccine Employing Non-Replicating Rabies Virus Expressing Chimeric SARS-CoV-2 Spike Protein Domains: Functional Inhibition of Viral/Nicotinic Acetylcholine Receptor Complexes. PG - e926016 LID - 10.12659/MSM.926016 [doi] AB - The emergence of the novel ss-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nAChR). By comparison, it has been hypothesized that a similar mechanism exists to explain the multiple neurological effects of SARS-CoV-2 via binding to peripheral nAChRs followed by orthograde or retrograde transport into the CNS. Genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1), Middle East respiratory syndrome (MERS-CoV), Ebolavirus, and hepatitis C virus (HCV) sequences. Accordingly, we present a critical discussion that integrates lessons learned from prior RABV research and vaccine development into a working model of a SARS-CoV-2 vaccine that selectively targets and neutralizes CNS penetration of a tightly bound viral nAChR complex. FAU - Stefano, Michelle L AU - Stefano ML AD - Library of Congress, Washington, DC, USA. FAU - Kream, Richard M AU - Kream RM AD - Department of Psychiatry, First Faculty of Medicine Charles University in Prague and General University Hospital in Prague, Center for Cognitive and Molecular Neuroscience, Prague, Czech Republic. AD - International Scientific Information, Inc., Melville, NY, USA. FAU - Stefano, George B AU - Stefano GB AD - Department of Psychiatry, First Faculty of Medicine Charles University in Prague and General University Hospital in Prague, Center for Cognitive and Molecular Neuroscience, Prague, Czech Republic. AD - International Scientific Information, Inc., Melville, NY, USA. LA - eng PT - Journal Article DEP - 20200528 PL - United States TA - Med Sci Monit JT - Medical science monitor : international medical journal of experimental and clinical research JID - 9609063 RN - 0 (COVID-19 Vaccines) RN - 0 (Receptors, Nicotinic) RN - 0 (Spike Glycoprotein, Coronavirus) RN - 0 (Viral Vaccines) RN - 0 (spike protein, SARS-CoV-2) SB - IM MH - Betacoronavirus/chemistry/*immunology MH - COVID-19 MH - COVID-19 Vaccines MH - Coronavirus Infections/*immunology/metabolism/prevention & control/virology MH - Humans MH - Pandemics MH - Pneumonia, Viral/*immunology/virology MH - Protein Domains MH - Rabies virus/genetics/*physiology MH - Receptors, Nicotinic/*metabolism MH - SARS-CoV-2 MH - Spike Glycoprotein, Coronavirus/chemistry/genetics/*immunology MH - Viral Vaccines/chemistry/*immunology/metabolism MH - *Virus Replication PMC - PMC7278327 COIS- Conflict of interest None. EDAT- 2020/05/29 06:00 MHDA- 2020/06/03 06:00 PMCR- 2020/05/28 CRDT- 2020/05/29 06:00 PHST- 2020/05/29 06:00 [entrez] PHST- 2020/05/29 06:00 [pubmed] PHST- 2020/06/03 06:00 [medline] PHST- 2020/05/28 00:00 [pmc-release] AID - 926016 [pii] AID - 10.12659/MSM.926016 [doi] PST - epublish SO - Med Sci Monit. 2020 May 28;26:e926016. doi: 10.12659/MSM.926016.